%PDF-1.3
%‚„œ”
7 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
1 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
6 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
8 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
15 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
4 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
20 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
5 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
14 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
18 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
19 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
11 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
17 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
3 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
13 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
12 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
10 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
16 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
9 0 obj
<</Subtype/Form/Filter/FlateDecode/Type/XObject/Matrix [1 0 0 1 0 0]/FormType 1/Resources<</ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<</F1 2 0 R>>>>/BBox[0 0 612 792]/Length 133>>stream
xúÕAÇ0Ñ·}O1K]¯Ë{Å≠QN–P)â¶¥§@noŸÃüÃÊ{UıåfRå£§Å<ÑÓ5Ã¨.ØòÉè√ËFÿ¨[MÃâtòRúës&ˇu÷•mŸ-} 5l–Rq[IMËc¬‚“√‡±Ø1¯Ép5?urß{n¡ﬁF˝Èä'0
endstream
endobj
22 0 obj
<</Subtype/XML/Type/Metadata/Length 3424>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta x:xmptk="Adobe XMP Core 4.0-c320 44.284297, Sun Apr 15 2007 17:19:00" xmlns:x="adobe:ns:meta/">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about="" xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about="" xmlns:xap="http://ns.adobe.com/xap/1.0/">
         <xap:CreatorTool>Arbortext Advanced Print Publisher 9.0.114/W</xap:CreatorTool>
         <xap:ModifyDate>2023-02-18T21:11:52-08:00</xap:ModifyDate>
         <xap:CreateDate>2023-02-06T07:01:28+05:30</xap:CreateDate>
      </rdf:Description>
      <rdf:Description rdf:about="" xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">CAN-2022-0267-ver9-Chu_2P 1..19</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about="" xmlns:xapMM="http://ns.adobe.com/xap/1.0/mm/">
         <xapMM:DocumentID>uuid:12125255-bc20-4c4a-9bc2-5a3ce7f75264</xapMM:DocumentID>
         <xapMM:InstanceID>uuid:4f23713a-1838-4d4f-bc32-86fe762a888e</xapMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
                                                                                                   
<?xpacket end="w"?>
endstream
endobj
23 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
24 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih§‡íØ»» Ä~V
endstream
endobj
25 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
26 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi¢‡íØ»» y\'
endstream
endobj
27 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
28 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi®‡íØ»» yA$
endstream
endobj
29 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
30 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih¶‡íØ»» Ä¢Z
endstream
endobj
31 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
32 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi§‡íØ»» yJ%
endstream
endobj
33 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
34 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih®‡íØ»» ÄuU
endstream
endobj
35 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
36 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi¨‡íØ»» yS&
endstream
endobj
37 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
38 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih™‡íØ»» ÄôY
endstream
endobj
39 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
40 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi†‡íØ»» y8#
endstream
endobj
41 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
42 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi™‡íØ»» ye(
endstream
endobj
43 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
44 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi¶‡íØ»» yn)
endstream
endobj
45 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
46 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih¨‡íØ»» ÄáW
endstream
endobj
47 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
48 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi°‡íØ»» yÄ+
endstream
endobj
49 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
50 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih¢‡íØ»» ÄêX
endstream
endobj
51 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
52 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih°‡íØ»» Ä¥\
endstream
endobj
53 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
54 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëih†‡íØ»» ÄlT
endstream
endobj
55 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
56 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëi©‡íØ»» yâ,
endstream
endobj
57 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
58 0 obj
<</Filter/FlateDecode/Length 36>>stream
xúS‰*‰*T0T0 Bôú´†ëiÆ‡íØ»» yw*
endstream
endobj
59 0 obj
<</Filter/FlateDecode/Length 10>>stream
xú+‰  Ó |
endstream
endobj
60 0 obj
<</Filter/FlateDecode/Length 37>>stream
xúS‰*‰*T0T0 Bôú´†ëihÆ‡íØ»» Ä´[
endstream
endobj
62 0 obj
<</Length 15176>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 62.022 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(HAND,)-286.5(the)-282.3(neurocognitive)-286.9(impairments)-287(can)-287.3(cause)-283.6(se-)]TJ
0 -1.1847 TD
[(rious)-423.4(impairments)-421.5(in)-419.9(daily)-418.5(living,)-421(driving,)-423.3(managing)]TJ
0 -1.1795 TD
[(medications,)-235.9(and)-235(employment.)]TJ
8.2191 0 0 7.3052 196.3275 676.8565 Tm
(6Ö8)Tj
10.959 0 0 10.959 211.011 671.981 Tm
[(Therefore,)-236.2(therapeu-)]TJ
-13.5951 -1.1847 TD
[(tic)-330.8(strategies)-331.4(are)-335(needed)-331.8(to)-330.9(develop)-334.3(adjunct)-330(t)-8.4(h)-12.2(e)-8.2(r)-13.6(a)-7.9(p)-7.7(i)-14.2(e)-8.2(s)-8.5(,)]TJ
0 -1.1795 TD
.0084 Tc
[(al)-5.4(on)-4.1(g)-387.2(w)-2.6(ith)-391.8(c).2(o)-3.7(m)-2.1(bin)-4.1(e).2(d)-392.4(a).5(n)-4.1(t)0(ire)-5(t)0(ro)-3.7(vir)-5.2(a).5(l)-393.4(t)0(he)-5(rap)-4.4(y)-387.2(\()-5.6(c).2(ART\),)]TJ
0 -1.1847 TD
.0099 Tc
[(to)-323(further)-319.3(h)-2.3(inder)-324.5(H)4.3(IV-1)-318.1(repl)]TJ
11.9138 0 TD
.0126 Tc
[(ic)4.4(a)4.7(t)-1(i)3.6(o)5.6(n)-320.7(a)4.7(nd)-315.8(HI)4.2(V-)4.5(r)4.1(e)-.8(l)3.9(a)4.7(te)4.4(d)]TJ
-11.9138 -1.1795 TD
.008 Tc
[(n)-4.5(e)-.2(ur)-5.6(oc)-5.4(ogn)-4.5(i)-1(ti)-6.2(ve)-300.2(i)-6.2(m)8(p)-10.2(a).1(ir)-5.6(ment)-5.6(s.)]TJ
.9984 -1.1795 TD
0 Tc
[(The)-254.8(endocannabinoid)-250.5(system)-253.4(\(ECS\))-256(in)-254.3(the)-251.2(brain)-251.8(is)-255.4(a)]TJ
-.9984 -1.1847 TD
[(neuromodulatory)-388.6(system)-387.9(that)-393.8(comprises)-386.4(cannabinoid)]TJ
0 -1.1795 TD
[(receptor)-302.6(type)-306(1)]TJ
8.2191 0 0 7.3052 128.6362 586.2046 Tm
(9)Tj
10.959 0 0 10.959 135.8929 581.329 Tm
[(and)-302.3(type)-306(2)]TJ
8.2191 0 0 7.3052 182.7779 586.2046 Tm
(10)Tj
10.959 0 0 10.959 194.0031 581.329 Tm
[(\(CB1)-303.2(and)-302.3(CB2\),)-302.4(the)-303(two)]TJ
-12.0431 -1.1847 TD
-.0002 Tc
[(major)-348(endocannabinoids,)-354.6(N-arachidonylethanolamine)]TJ
0 -1.1795 TD
0 Tc
(\(AEA\))Tj
8.2191 0 0 7.3052 90.7653 560.2959 Tm
(11)Tj
10.959 0 0 10.959 104.0882 555.4203 Tm
[(and)-493.7(2-arachidonoyl)-492(glycerol)-493.7(\(2-AG\),)]TJ
8.2191 0 0 7.3052 271.3889 560.2959 Tm
(12)Tj
10.959 0 0 10.959 284.7117 555.4203 Tm
(and)Tj
-20.3202 -1.1847 TD
[(their)-279.1(metabolizing)-274.7(enzymes)-275.9(fatty)-279.3(acid)-275.9(amide)-281.3(hydrolase)]TJ
0 -1.1795 TD
(\(FAAH\),)Tj
8.2191 0 0 7.3052 101.0267 534.3873 Tm
(13)Tj
10.959 0 0 10.959 111.9118 529.5117 Tm
[(diacylglycerol)-273.8(lipase,)-276.8(and)-276.4(monoacylglycerol)]TJ
-4.5524 -1.1847 TD
[(lipase)-587.9(\()-81.2(MAGL\).)]TJ
8.2191 0 0 7.3052 134.7023 521.4046 Tm
(14)Tj
10.959 0 0 10.959 148.9889 516.529 Tm
[(Their)-587.8(interactions)-589.2(with)-583.8(neurons,)]TJ
-7.9356 -1.1795 TD
[(astrocytes,)-261.4(and)-260.9(microglia)-262.6(are)-262.5(necessary)-264.3(for)-262.5(endocanna-)]TJ
T*
[(binoid)-414.3(signaling.)]TJ
8.2191 0 0 7.3052 136.3464 495.4959 Tm
(15)Tj
10.959 0 0 10.959 148.8188 490.677 Tm
[(The)-415.2(ECS)-414.3(plays)-417.9(an)-413.6(important)-416.2(role)]TJ
-7.9201 -1.1847 TD
[(in)-430.2(modulating)-428.4(neurotransmitter)-432.4(release)-430.6(and)-431.6(synaptic)]TJ
0 -1.1795 TD
[(plasticity,)-393(which)-388.9(can)-395.9(provide)-391.9(protection)-390.1(against)-392.9(exci-)]TJ
0 -1.1847 TD
-.0001 Tc
[(totoxicity)-412.1(and)-411(neuroinîammation)-409.5(that)-414.6(are)-407.5(two)-409.3(main)]TJ
0 -1.1795 TD
[(trademarks)-528.7(of)-533.4(neurodegenerative)-531.9(disorders,)-533.2(such)-533.3(as)]TJ
0 -1.1847 TD
0 Tc
(HAND.)Tj
8.2191 0 0 7.3052 96.3212 430.7527 Tm
(16)Tj
10.959 0 0 10.959 107.6031 425.877 Tm
[(Drugs)-306.8(can)-308(boost)-306.8(the)-308.1(ECS)-305.7(activity)-309.2(by)-309.4(imitat-)]TJ
-4.1592 -1.1795 TD
[(ing)-318.8(or)-310.3(enhancing)-318.3(its)-315.6(neuroprotective)-316.4(function.)-316.8(Studies)]TJ
0 -1.1847 TD
[(have)-361.8(shown)-361.6(that)-357.6(alterations)-363.9(in)-357.8(the)-365(ECS)-357.4(implicated)-364.6(in)]TJ
0 -1.1795 TD
[(some)-530.8(neurocognitive)-535.2(disorders)-533.8(possibly)-529.4(weaken)-531.4(the)]TJ
0 -1.1847 TD
[(neuroprotection)-309.8(of)-316.1(the)-308.1(ECS)-310.9(in)-316.4(normal)-308.6(state,)-314.8(aggravat-)]TJ
0 -1.1795 TD
[(ing)-298.1(excitotoxicity.)]TJ
.9984 -1.1795 TD
[(Therefore,)-220.7(strategies)-222.8(to)-217.1(preclude)-220(the)-220.2(loss)-218.8(of)-222.9(endocan-)]TJ
-.9984 -1.1847 TD
[(nabinoid)-564.1(signals)-569.6(possibly)-565.6(retain)-561.5(its)-569.1(neuroprotective)]TJ
0 -1.1795 TD
[(function,)-285.8(while)-287.1(drugs)-288.2(that)-285.2(mimic)-285.3(or)-289.6(boost)-286.1(endocanna-)]TJ
0 -1.1847 TD
[(binoid)-435(signaling)-435.1(may)-434.7(rescue)-437.2(for)-433.2(its)-434.6(decreased)-440.3(ability)]TJ
0 -1.1795 TD
[(under)-520.5(neurotoxic)-518.9(or)-522.4(inîammatory)-515.9(conditions,)-518.4(such)]TJ
0 -1.1847 TD
[(as)-399.2(HAND.)-400.3(Cannabis)-397.4(is)-400.3(used)-399.3(more)-401.5(frequently)-401.7(among)]TJ
0 -1.1795 TD
[(PLWH)-355.4(than)-356.6(the)-354.7(general)-356.4(population,)]TJ
8.2191 0 0 7.3052 223.7102 275.3574 Tm
(17,18)Tj
10.959 0 0 10.959 245.1968 270.4818 Tm
[(perhaps)-355.4(as)-357.8(a)]TJ
-16.7145 -1.1847 TD
[(way)-502.5(to)-496.5(cope)-501.8(with)-501(HIV-induced)-498.4(symptoms,)-502.5(such)-502.1(as)]TJ
0 -1.1795 TD
.0102 Tc
[(pain)-416.2(an)2.8(d)-416.5(a)2.3(pp)2.5(etite)-417(l)1.5(o)3.2(s)-3.4(s,)-413.3(alth)3.2(ou)2.5(gh)-410.7(it)-412(has)-412.1(t)-3.4(h)3.2(e)-417(n)2.8(e)2(gativ)2.6(e)]TJ
T*
0 Tc
[(ef)19(f)11.6(e)0(c)19.8(t)0(s)19.3(.)]TJ
8.2191 0 0 7.3052 90.9354 236.4661 Tm
-.0169 Tc
(19)Tj
10.959 0 0 10.959 102.5574 231.6472 Tm
0 Tc
[(M)10.7(o)0(r)20.8(e)-354.8(i)11.7(m)10.2(po)16.4(r)12.2(t)12.3(an)15.8(t)12.3(l)12(y,)-348.3(c)12.5(a)0(n)21(n)0(a)21(b)0(i)20.2(s)0(-)19.6(d)0(e)20.3(r)0(i)18.7(v)0(e)20.4(d)-354.3(ca)20.1(nn)16.3(a)12.8(b)0(i)20.2(-)]TJ
-3.6988 -1.1847 TD
[(no)21.9(id)19.5(s)-412(s)12.2(ho)17.1(w)-404.2(a)-411.4(pr)20.1(om)18.7(i)11.7(s)0(e)-399.5(a)0(s)-399.2(n)0(e)20.7(u)0(r)20.1(o)0(p)16.4(r)12.2(ot)20.8(ec)19.8(ti)18.8(v)13.1(e)-411.7(ag)20.7(en)20.6(ts)-399.7(wi)21.3(th)]TJ
0 -1.1795 TD
[(go)21.6(od)-226.7(p)13(r)0(o)20.8(s)0(p)20.1(e)0(c)19.8(t)0(s)-223.8(f)0(o)20.2(r)-236.1(th)20.8(e)-235.8(t)12.3(re)19.5(at)19.9(m)10.2(e)0(n)20.7(t)-236(o)13.7(f)-236.7(s)12.2(e)0(v)15.2(e)12.5(ra)19.8(l)-236.3(n)13.3(eu)20.3(ro)20.8(de)15.2(g)13.1(e)0(n)20.7(-)]TJ
0 -1.1847 TD
[(er)19.5(at)19.9(i)11.7(v)0(e)-202(d)13(is)18.7(ea)20.1(se)19.5(s,)-199.2(su)20.1(ch)-201.5(a)12.8(s)-210.2(Pa)21.3(rk)20.1(in)19.8(so)20.8(nê)19.2(s)-210.2(d)0(i)19.5(s)12.2(ea)20.1(se)19.5(,)-211.4(A)0(l)21.3(z)0(h)21(e)0(i)19(m)10.2(e)12.5(r)0(ê)18.1(s)]TJ
0 -1.1795 TD
[(di)19.5(se)19.5(as)19.8(e,)-343.7(a)12.8(n)0(d)-340.9(H)0(A)19.2(N)0(D)19.5(,)-351(o)13.7(w)0(i)16.2(n)13.3(g)-354.2(t)12.3(o)-348.4(t)0(h)20.8(e)0(i)19(r)-355.1(a)12.8(n)0(t)20.5(i)0(-)19.1(i)11.7(nî)16.7(a)12.8(m)10.2(m)10.2(a)0(t)19.9(o)0(r)20.8(y)]TJ
0 -1.1847 TD
[(an)21(d)-292.2(a)12.8(nt)20.5(i-)19.1(ex)20.1(ci)19(to)20.8(to)20.8(xi)19.3(c)-292.7(p)13(ro)20.8(pe)20.3(rt)19.3(i)11.7(e)0(s)19.5(.)]TJ
8.2191 0 0 7.3052 196.2141 171.7228 Tm
-.0176 Tc
[(16)-17.6(,20)-17.6(,)3.4(21)]TJ
10.959 0 0 10.959 72.9637 153.9212 Tm
0 Tc
[(Neuroendocrine)-439.8(dysfunction)-439.5(is)-436.5(emerging)-439.4(as)-440.6(a)-437.3(po-)]TJ
-.9984 -1.1847 TD
[(tential)-689.1(contributor)-687(of)-688.5(HAND.)-684.8(It)-689.3(is)-684.8(possible)-690.4(that)]TJ
0 -1.1795 TD
[(HIV)-470.7(infection)-477.1(of)-471.3(the)-473.7(central)-471.1(nervous)-473.8(system)-470.7(\(CNS\))]TJ
0 -1.1847 TD
-.0001 Tc
[(possibly)-369.1(results)-374(in)-373.4(abnormal)-370.1(hypothalamicÖpituitaryÖ)]TJ
0 -1.1795 TD
0 Tc
[(adrenocortical)-671.1(\(HPA\))-667.6(and)-669.6(hypothalamicÖpit)5.2(uitaryÖ)]TJ
T*
.0197 Tc
[(gonadal)-661.5(\().6(HPG\))-661.6(axe)-4(s).9(.)-662.4(H)3.7(owever,)-662.4(E)2.3(CS)-660.7(component)]TJ
0 -1.1847 TD
0 Tc
[(ove)-7.3(rlaps)-248.1(with)-242.4(the)-240.9(HPA)-241.3(and)-245.4(HPG)-241(axe)-8.5(s,)-240.5(and)-240.2(the)-246.1(inte)-7.1(rac-)]TJ
0 -1.1795 TD
[(tions)-340.3(of)-331.6(ECS)-336.7(with)-335.5(HPA)-334.5(and)-333.3(HPG)-334.2(axe)-8.5(s)-329.2(may)-336.4(inî)-7.9(uence)]TJ
22.9068 57.9085 TD
[(the)-277.1(ECS)-279.8(as)-275(a)-271.7(poten)-7.6(tial)-277.1(the)-8.1(rapeu)-8.9(tic)-279.1(targe)-9.5(t.)-271.5(For)-276.6(ins)-9.3(tance)-9(,)]TJ
0 -1.1847 TD
[(end)-7.7(oca)-7.6(nna)-7.1(binoi)-8.3(ds)-440.3(wid)-7(ely)-443.5(dist)-7.7(ribut)-9.5(ed)-440.1(thr)-8.4(oug)-6.7(hout)-443.9(the)]TJ
0 -1.1795 TD
[(hyp)-6.8(oth)-6.9(alamus)-392.6(and)-385(lim)-7.5(bic)-386.3(syst)-7.1(em)-386(regul)-9.6(ate)-386.6(the)-385.7(rele)-7.7(ase)]TJ
0 -1.1847 TD
[(of)-248.8(excit)-10.7(atory)-251.4(and)-245.4(inh)-7.9(ibit)-7.5(ory)-245.5(tr)-6.5(ansmit)-10.3(ters)-7.7(,)-242.4(ìna)-6.7(lly)-247.4(resul)-10.4(t-)]TJ
0 -1.1795 TD
[(ing)-308.5(in)-306.1(being)-308.1(const)-8.4(raine)-9.9(d)-302.5(o)0(f)-300.5(the)-308.1(HPA)-303.4(act)-9(ivity.)]TJ
8.2191 0 0 7.3052 512.844 650.9479 Tm
(22)Tj
10.959 0 0 10.959 324.0566 633.0896 Tm
[(Conversely,)-201.2(glucocorticoids)-203.3(also)-202.7(inhibit)-206.8(the)-204.7(release)-203(of)]TJ
-1.0036 -1.1795 TD
[(endocannabinoids)-315.8(and)-317.8(inhibit)-315.4(the)-313.3(excitatory)-313.9(inputs)-317.6(to)]TJ
T*
[(corticotropin-releasing)-527.6(factor)-530.1(\(CRF\))-529.6(neurons)-525.3(within)]TJ
0 -1.1847 TD
[(the)-308.1(paraventricular)-308.1(nucleus)-304.6(\(PVN\),)-305.4(which)-306.1(can)-308(be)-304.9(hin-)]TJ
0 -1.1795 TD
[(dered)-474.8(by)-469.8(CB1)-470.3(receptor)-473.3(antagonists.)]TJ
8.2191 0 0 7.3052 475.4266 586.2046 Tm
(23)Tj
10.959 0 0 10.959 488.5227 581.329 Tm
[(In)-471(addition,)-466.8(a)]TJ
-16.011 -1.1847 TD
[(la)19.7(rg)20.2(e)-328.9(o)0(v)21.6(e)0(r)19.5(l)0(a)19.7(p)-328.4(ex)20.1(is)18.7(ts)-316.9(be)15.9(t)12.3(w)0(e)22.1(e)0(n)-320.8(t)12.3(he)-320.4(E)13.6(C)0(S)-319.3(a)0(n)21(d)-328.4(re)19.5(ce)19.8(pt)20.1(or)15.6(s)-324(f)0(o)20.2(r)]TJ
0 -1.1795 TD
[(gon)-6.4(ada)-7.9(l)-401.8(s)0(t)-6.5(eroid)-412.8(hor)-6.9(mones,)]TJ
8.2191 0 0 7.3052 433.2471 560.2959 Tm
(24)Tj
10.959 0 0 10.959 445.6062 555.4203 Tm
[(sugge)-8.5(stin)-7.4(g)-405.9(that)-409.3(it)-405.4(cou)-7.3(ld)]TJ
-12.0949 -1.1847 TD
[(be)-268.7(an)-268.7(import)-9.7(ant)-266.8(neu)-7.7(roreg)-8.7(ulat)-6.8(ory)-266.2(sys)-9(tem)-265.1(tha)-7.8(t)-261.9(reg)-8.7(ulat)-6.8(es)]TJ
0 -1.1795 TD
[(gon)-6.4(ada)-7.9(l)-303.5(ster)-7.7(oid)-303(hor)-6.9(mone)-7.2(s.)-302.6(In)-305.5(this)-307.1(regar)-9.6(d,)-307(inte)-7.1(ract)-7.1(ions)]TJ
0 -1.1847 TD
[(of)-248.8(the)-251.2(ECS)-248.8(with)-247.6(the)-251.2(HPA)-246.5(and)-250.5(HPG)-246.2(axe)-8.5(s)-241.3(m)0(a)-8.1(y)-245.6(inîue)-8.2(nce)]TJ
0 -1.1795 TD
[(the)-308.1(ECS)-305.7(as)-300.9(a)-302.8(pot)-7.5(enti)-7.1(al)-301.1(the)-8.1(rapeu)-8.9(ti)-7.1(c)-297.9(t)0(a)-5.9(rget)-306.8(for)-303.8(H)-5.6(AND.)]TJ
1.0036 -1.1795 TD
[(To)-313.8(deepen)-321.5(our)-318(understanding)-315.2(of)-321.2(the)-313.3(role)-316.8(of)-321.2(ECS)-316(in)]TJ
-1.0036 -1.1847 TD
[(HAND,)-245.1(we)-241.7(focused)-247.7(on)-242(reviewing)-242(how)-242.3(neuroHIV)-245.6(alters)]TJ
0 -1.1795 TD
[(ECS)-259.1(and)-260.9(how)-257.8(cannabinoids)-259.8(affect)-257.7(HIV-1)-258.5(infection)-254.6(and)]TJ
0 -1.1847 TD
[(HAND.)-415.8(In)-414.1(this)-410.5(review,)-413.9(we)-412.4(ìrst)-415.2(discuss)-414.9(the)-411.6(potential)]TJ
0 -1.1795 TD
[(pathogenesis)-203.9(of)-207.4(HAND,)-203.7(including)-201.9(HIV-1-induced)-203.4(neu-)]TJ
0 -1.1847 TD
[(roinîammation)-423(indirectly)-424(affecting)-421.4(neurons,)-421.1(and)-426.4(the)]TJ
0 -1.1795 TD
[(sustained)-373.2(release)-368.5(of)-373(neurotoxic)-368.9(HIV)-367.2(proteins)-369.8(that)-373.1(di-)]TJ
0 -1.1847 TD
[(rectly)-261.6(target)-255.9(neurons.)-255.6(Second,)-257.7(we)-257.2(discuss)-259.7(the)-256.4(structural)]TJ
0 -1.1795 TD
[(and)-369.5(functional)-370.3(changes)-365.1(in)-368.1(the)-370.2(ECS)-367.8(that)-368(are)-366(currently)]TJ
0 -1.1847 TD
[(known.)-505.2(Third,)-509(we)-505.5(discuss)-502.9(current)-506.9(clinical)-506.7(and)-504(pre-)]TJ
0 -1.1795 TD
[(clinical)-377.4(ìndings)-370.1(regarding)-372.3(the)-375.4(anti-inîammato)7.7(ry)-373(and)]TJ
T*
[(neuroprotective)-585.4(properties)-583.4(of)-585.1(the)-587.5(ECS.)-584.3(Fourth,)-583.5(we)]TJ
0 -1.1847 TD
[(will)-337.4(discuss)-332.2(the)-334(interactions)-335.7(between)-332.6(the)-334(ECS)-331.6(and)-338.5(the)]TJ
0 -1.1795 TD
[(HPA)-282.7(and)-281.6(HPG)-277.3(axes)-286(under)-277.4(HAND)-282.1(conditions.)-280.5(Finally,)]TJ
0 -1.1847 TD
[(we)-246.9(discuss)-249.4(the)-246.1(signiìcance)-243.5(of)-248.8(further)-243.5(research)-246(to)-248.2(deter-)]TJ
0 -1.1795 TD
[(mine)-231.7(the)-230.5(role)-228.9(of)-233.3(the)-230.5(ECS)-228.1(in)-228.5(HIV-induced)-229.4(neurotoxicity)]TJ
0 -1.1847 TD
[(and)-271.2(hypothesize)-273(that)-269.7(measures)-269.7(to)-268.9(increase)-272.8(endocanna-)]TJ
0 -1.1795 TD
[(binoid)-300.5(signaling)-300.6(may)-300.2(halt)-295.8(cognitive)-300(decline.)]TJ
/F5 1 Tf
10.4607 0 0 10.4607 313.0582 244.5731 Tm
[(The)-301.6(Mechanisms)-297.8(Underlying)-304.6(HAND)]TJ
/F6 1 Tf
10.959 0 0 10.959 313.0582 231.5905 Tm
[(In)-621(PLWH,)-618.5(HAND)-613.1(have)-620.5(been)-615.3(prevalent)-620.8(since)-620.7(the)]TJ
T*
[(epidemic)-472(began.)]TJ
8.2191 0 0 7.3052 386.0786 223.5401 Tm
(25,26)Tj
10.959 0 0 10.959 408.8125 218.6645 Tm
[(The)-466.9(clinical)-470.5(features)-469.9(of)-471.3(HAND)]TJ
-8.7375 -1.1847 TD
[(are)-236.7(predominantly)-235.2(neurocognitive)-230(dysfunction,)-237.1(includ-)]TJ
0 -1.1795 TD
[(ing)-422.3(difìculties)-422.4(paying)-419.6(attention,)-417.9(concentrating,)-423.5(mov-)]TJ
0 -1.1847 TD
[(ing)-463.7(rapidly,)-454.6(learning,)-462.2(and)-457.5(executive)-461.4(function.)]TJ
8.2191 0 0 7.3052 519.3636 184.6488 Tm
(5)Tj
10.959 0 0 10.959 528.3778 179.7732 Tm
(HAD)Tj
-19.6477 -1.1795 TD
[(is)-374.4(characterized)-369.7(by)-366.3(impairment)-371.6(in)-368.1(cognitive)-367.2(function,)]TJ
T*
[(processing)-613.3(information,)-612.8(and)-612.7(focusing)-612.7(or)-610.4(attention.)]TJ
0 -1.1847 TD
[(Even)-356.1(though)-355.1(combined)-354.6(antiretroviral)-352.8(therapy)-355.3(has)-359.6(de-)]TJ
0 -1.1795 TD
[(creased)-305.4(the)-303(incidence)-300.9(of)-300.5(HAD,)]TJ
8.2191 0 0 7.3052 448.5542 132.8882 Tm
(27,28)Tj
10.959 0 0 10.959 469.4172 128.0126 Tm
[(approximately)-298.3(half)]TJ
-14.2676 -1.1847 TD
[(of)-305.7(the)-303(infected-HIV)-307(patients)-303.4(develop)-303.3(a)-302.8(milder)-306(form)-304(of)]TJ
0 -1.1795 TD
(HAND,)Tj
8.2191 0 0 7.3052 347.4141 106.9795 Tm
(1Ö3)Tj
10.959 0 0 10.959 362.8912 102.1039 Tm
[(which)-316.5(can)-313.2(have)-310.1(substantial)-316.8(effects)-313.1(on)-314.4(daily)]TJ
-4.5472 -1.1847 TD
(activities.)Tj
8.2191 0 0 7.3052 353.5369 93.9968 Tm
(6Ö8)Tj
10.959 0 0 10.959 369.0141 89.1212 Tm
[(Even)-304.4(with)-309.6(mild)-304.9(HAND,)-307.2(HIV-infected)-307(in-)]TJ
-5.1059 -1.1795 TD
[(dividuals)-440.9(still)-441.5(maintain)-439.9(low)-440.5(plasma)-439.1(viremia)]TJ
8.2191 0 0 7.3052 510.9731 81.0708 Tm
(29Ö31)Tj
10.959 0 0 10.959 535.7479 76.1953 Tm
(and)Tj
-20.3202 -1.1847 TD
[(signs)-418.5(of)-414.4(innate)-410.4(immunity.)]TJ
8.2191 0 0 7.3052 430.3558 68.0882 Tm
(32Ö34)Tj
10.959 0 0 10.959 454.8471 63.2126 Tm
[(Therefore,)-412.1(developing)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(2)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
70 0 obj
<</Length 18066>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 59.7543 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(ad)15.5(j)12(u)13(nc)15.5(t)-256.7(t)0(h)20.8(e)0(r)19.5(a)0(p)20.7(i)0(e)19(s)0(,)-250.9(a)0(l)19.7(o)13.7(ng)-252.9(wi)21.3(t)12.3(h)-260.5(cA)21.8(RT)17.5(,)-257.9(w)0(i)21.3(l)0(l)-250.1(p)0(r)20.1(e)0(v)20.4(e)0(n)20.7(t)-261.9(HI)22.1(V-)21.5(1)]TJ
0 -1.1847 TD
[(rep)-8.8(lica)-7.9(tion,)-444.9(suppr)-8.9(ess)-439(immun)-8.9(e)-437.6(acti)-7.6(vati)-7(on,)-437.8(and)-442(red)-8.8(uce)]TJ
0 -1.1795 TD
[(neu)-7.7(roinî)-7.8(amm)-8.3(atio)-6.4(n.)]TJ
1.0036 -1.1847 TD
[(The)-492.8(pathogenesis)-493.6(of)-492(HAND)-494.2(mainly)-490.8(involves)-493.2(two)]TJ
-1.0036 -1.1795 TD
[(pathways,)-396.3(the)-390.9(ìrst)-394.5(being)-390.9(HIV-1-caused)-392.3(neuroinîam-)]TJ
0 -1.1847 TD
[(mation)-495.1(that)-492.1(indirectly)-496.4(results)-498.1(in)-492.3(neuronal)-497.2(loss,)-492.3(and)]TJ
0 -1.1795 TD
[(the)-603(second)-600.4(being)-603(sustained)-600.8(release)-601.3(of)-605.8(HIV-related)]TJ
T*
[(neurotoxic)-446.5(proteins)-447.4(that)-450.7(directly)-443.9(target)-447.3(neurons)-447.7(and)]TJ
0 -1.1847 TD
[(damage)-246.4(the)-246.1(neurons.)-250.4(More)-245.7(speciìcally,)-244.1(continued)-246.7(neu-)]TJ
0 -1.1795 TD
[(roinîammation)-500.6(within)-501.9(the)-499.5(CNS)-501.2(seems)-499.1(to)-501.6(outweigh)]TJ
0 -1.1847 TD
[(in)-409.5(HIV-1-related)-406.9(neuronal)-409.2(injury.)]TJ
8.2191 0 0 7.3052 211.9747 573.2219 Tm
(35)Tj
10.959 0 0 10.959 224.3338 568.3463 Tm
[(HIV-1)-408.5(virus)-408.5(can)]TJ
-15.0177 -1.1795 TD
[(enter)-309.6(the)-308.1(macrophages,)-305.5(monocytes,)-304.8(and)-312.6(T)-306.8(cells)-306(within)]TJ
0 -1.1847 TD
[(th)20.8(e)-354.8(b)0(r)20.8(a)0(i)19.3(n)-354(sh)20.7(or)15.6(t)12.3(l)12(y)-354.2(a)0(f)19.3(t)0(e)19.6(r)-355.1(i)11.7(n)0(f)19.8(e)0(c)19.8(t)0(i)18.8(o)0(n)21.9(,)]TJ
8.2191 0 0 7.3052 200.4094 547.3132 Tm
-.0179 Tc
[(36)-17.9(,37)]TJ
10.959 0 0 10.959 221.3858 542.4377 Tm
0 Tc
[(an)21(d)-354.3(t)0(h)20.8(e)-354.8(vi)19.6(ru)20.1(s)-355.1(c)0(a)20.1(n)]TJ
-14.7487 -1.1795 TD
[(al)19.7(so)-175.8(i)11.7(n)0(f)19.8(e)12.5(ct)-177(m)15.3(i)0(c)19(r)0(o)20.8(g)0(l)20(i)0(a)19.3(,)-185.5(e)12.5(n)0(d)21.2(o)0(t)20.8(h)0(e)15.8(l)12(i)11.7(a)0(l)-171.8(c)0(e)19.8(l)0(l)18.9(s)0(,)-173.3(o)0(r)-170.6(a)0(s)19.8(t)0(r)19.4(o)0(c)21(y)0(t)20.2(e)0(s)-171.9(t)0(o)-175.7(e)12.5(s-)]TJ
0 -1.1847 TD
[(ta)19.9(bl)20.6(is)18.7(h)-219.1(a)-214.8(ce)19.8(nt)20.5(ra)19.8(l)-215.6(r)0(e)19.5(s)0(e)19.5(r)0(v)20.2(o)0(i)20.2(r)0(.)]TJ
8.2191 0 0 7.3052 168.9448 521.4046 Tm
[(35)26.8(,3)21(8)16.8(,)0(3)21(9)]TJ
10.959 0 0 10.959 197.8015 516.529 Tm
[(I)12.3(n)0(d)16(i)11.7(re)19.5(ct)19.6(l)12(y)0(,)-208.6(H)0(I)22.1(V)0(-)16.4(1)-214.2(in)19.8(fe)19(c-)]TJ
-12.5967 -1.1795 TD
[(ti)18.8(on)-221.3(c)12.5(a)0(u)20.7(s)0(e)19.5(s)-230.9(ne)20.6(ur)20.1(on)16.7(s)-225.7(t)0(o)-222.3(b)13.7(e)-230.6(i)0(m)21.8(p)0(a)15.5(i)11.7(r)12.2(e)0(d)-222.8(b)0(y)-216.3(t)0(h)20.8(e)-230.6(pr)20.1(od)16.4(u)13(c)0(t)19.6(i)11.7(on)-221.3(of)]TJ
T*
[(ne)15.5(u)13(r)0(o)20.8(t)0(o)20.8(x)0(i)19.3(c)-199.6(m)15.3(e)0(d)15.2(i)11.7(a)12.8(t)0(o)20.8(r)0(s)19.3(,)-201(s)12.2(u)0(c)20.3(h)-198.4(a)12.8(s)-199.9(i)11.7(n)0(î)21.8(a)0(m)17.8(m)10.2(a)12.8(t)12.3(or)15.6(y)-193.8(f)11.6(ac)20.1(to)20.8(rs)19.3(.)]TJ
8.2191 0 0 7.3052 279.3826 495.4959 Tm
-.0168 Tc
[(40)-16.8(Ö)6.5(4)0(2)]TJ
10.959 0 0 10.959 70.7527 477.6943 Tm
0 Tc
[(Indeed,)-460.7(HIV-1)-465.4(has)-463.1(been)-465.3(shown)-459.9(to)-465.4(induce)-462(neuro-)]TJ
-1.0036 -1.1795 TD
[(toxicity)-422.5(via)-422.8(releasing)-425.7(proinîammat)6.5(ory)-426.5(cytokines)-418.5(and)]TJ
0 -1.1847 TD
[(chemokines)-371.3(in)-368.1(the)-365(CNS,)-371.1(triggering)-366.2(the)-370.2(production)-368.1(of)]TJ
0 -1.1795 TD
-.0266 Tc
(TNF-)Tj
/F9 1 Tf
2.1262 0 TD
0 Tc
(a)Tj
/F6 1 Tf
.4708 0 TD
-.0266 Tc
[(,)-243.1(R)-2.3(ANTES/)-4.6(CCL5,)-243.1(a)-3.5(nd)-246.4(MCP-1/CCL2)-246(from)-244.1(infected)]TJ
-2.5969 -1.1847 TD
0 Tc
[(mic)-7.1(rog)-7.5(lia)-377.3(and)-379.9(macr)-9.3(ophage)-9.1(s)]TJ
8.2191 0 0 7.3052 183.6283 430.7527 Tm
[(43)-7.7(,44)]TJ
10.959 0 0 10.959 205.3984 425.877 Tm
[(and)-379.9(IL-8,)-381.9(IL-)-8.1(1)]TJ
/F9 1 Tf
5.8819 0 TD
(b)Tj
/F6 1 Tf
.5484 0 TD
[(,)-376.9(and)]TJ
-19.7201 -1.1795 TD
[(TN)-7.6(F-)]TJ
/F9 1 Tf
2.2348 0 TD
(a)Tj
/F6 1 Tf
.9829 0 TD
[(from)-485.1(infe)-7.8(ct)-6.3(ed)-481.5(ast)-9.2(rocyt)-8.6(es.)]TJ
8.2191 0 0 7.3052 207.6094 417.8267 Tm
[(35)-7.7(,38,)-13.1(39)]TJ
10.959 0 0 10.959 240.2645 412.9511 Tm
[(Fur)-8.3(thermo)-8.2(re,)]TJ
-16.4714 -1.1847 TD
[(H)-5.6(IV-1)-314.9(res)-9.6(ults)-317.7(in)-316.4(HAN)-7.4(D)-310.8(v)0(i)-6.3(a)-313.1(the)-318.5(conti)-8.9(nuou)-9(s)-313.7(rele)-7.7(ase)-319.4(of)]TJ
0 -1.1795 TD
[(neu)-7.7(rotox)-7.7(ic)-420.7(HIV-)-8.1(1)-421.1(prote)-8.7(ins)-423.2(withi)-8.3(n)-416(the)-421.9(CNS)-423.6(that)-424.9(can)]TJ
0 -1.1847 TD
[(ta)19.9(rg)20.2(et)-285.6(n)13.3(e)0(u)20.3(r)0(o)20.8(n)0(s)-284.8(d)0(i)19.5(r)12.2(ec)19.8(tl)19.2(y.)]TJ
8.2191 0 0 7.3052 159.6472 378.9353 Tm
[(3)16.8(4)0(,)21(4)16.8(5Ö)23.3(47)]TJ
10.959 0 0 10.959 191.7354 374.0597 Tm
[(H)15.1(I)0(V)16.1(-)12.6(1-)20.8(as)19.8(so)20.8(ci)19(at)19.9(e)12.5(d)-292.2(ne)15.5(u)13(r)0(o)20.8(-)]TJ
-12.0431 -1.1795 TD
[(toxic)-335.4(prot)9.9(eins)8.3(,)-345.9(such)-336.6(as)-337.1(the)-339.2(tran)9.3(sacti)9.8(vato)10.5(r)-344.7(o)0(f)-336.8(tran)9.3(scrip)9.9(-)]TJ
T*
[(tion)-316.3(\(Tat)9.5(\))-324.3(and)-317.8(the)-318.5(enve)10(lope)-316(glyc)9.3(opro)11.3(tein)-317.5(120)-316.7(\(gp1)10.1(20\),)]TJ
0 -1.1847 TD
[(may)-274.3(be)-268.7(respon)9.7(sible)-268.9(for)-267.6(neuro)7.9(nal)-272.2(heal)9.6(th)-268.9(in)-275(PLWH.)]TJ
8.2191 0 0 7.3052 278.9857 340.1007 Tm
(48Ö50)Tj
10.959 0 0 10.959 70.7527 322.2991 Tm
[(Tat)-462.8(and)-462.6(gp120)-461.3(affect)-464.7(neurons)-463.2(directly)-464.5(by)-464.6(activat-)]TJ
-1.0036 -1.1847 TD
[(ing)-463.7(glutamate)-458.1(NMDA)-457.1(receptors,)-460.3(altering)-458.8(chemokine)]TJ
0 -1.1795 TD
.0191 Tc
[(r)-4.9(ece)-4.6(ptor)-548.1(si)-5.4(gnals,)-554.4(and)-552.4(i)-.3(nter)-4.9(acti)-5.4(ng)-552.4(wit)-4.8(h)-551.8(lipoprotein)]TJ
0 -1.1847 TD
0 Tc
[(re)19.5(ce)19.8(pt)20.2(or)20.8(-a)20.2(ss)19.3(oc)21(ia)19.3(te)19.6(d)-364.6(p)13(ro)20.8(te)19.6(in)19.8(s.)]TJ
8.2191 0 0 7.3052 183.0047 288.2834 Tm
[(51)26.8(,5)21(2)]TJ
10.959 0 0 10.959 204.0944 283.4078 Tm
[(Pr)20.7(ev)20.4(io)20.2(us)-352.4(re)19.5(se)19.5(ar)19.8(ch)-351.5(ha)21.3(s)]TJ
-13.1709 -1.1795 TD
-.0225 Tc
[(d)-4.3(e)-4.8(mon)-4(s)-5.1(tra)-4.5(t)-5(e).3(d)-578.5(t)-5(ha)-4.5(t)-579.2(t)-5(he)-579.1(i)-5.6(n)1.2(î)-3.6(u)-4.3(en)-4(c)-4.8(e).3(s)-579.3(o)-3.6(f)-579.9(T)-3.4(at)-579.2(o)-3.6(n)-578.2(NMDA)]TJ
0 -1.1847 TD
-.0186 Tc
[(re)4.2(cep)4.8(to)5.5(rs)-590.9(in)-589.8(neu)4.8(r)-1.2(on)-589.8(cu)4.8(lture)-595.8(c)-.9(a)4.5(n)-595(e)4.2(n)-.1(ha)4.5(nce)-590.7(g)-.3(lutama)4.5(te)4.2(-)]TJ
0 -1.1795 TD
-.0189 Tc
[(in)4.8(duc)3.9(ed)-207.6(ex)4.2(cita)4.2(to)5.2(ry)-207.5(tox)4.2(i)-2(c)3.9(i)-2(ty,)-204.4(r)-1.5(esulting)-207.5(in)-207.3(increa)4.2(se)3.9(d)-207.6(i)-2(n)4.8(t)-1.4(race)3.9(l-)]TJ
T*
-.0172 Tc
[(lu)6.2(la)5.9(r)-279.2(c).5(a)5.9(l)0(c)5.6(i)-.3(u)6.2(m)-281.2(\()5.1(C)2.5(a)]TJ
8.2191 0 0 7.3052 132.4346 236.4661 Tm
0 Tc
(2)Tj
/F8 1 Tf
.6139 0 TD
(+)Tj
/F6 1 Tf
10.959 0 0 10.959 143.2063 231.6472 Tm
-.0185 Tc
[(\))-280.8(l)3.9(ev)5(els,)-276.4(den)5.2(d)-.3(rit)4.1(e)-280.2(in)5.2(ju)4.9(ry,)-276.4(a)-.5(nd)-279.6(s)4.1(y)-.2(n)5.2(a)-.5(pt)4.1(ic)]TJ
-7.6149 -1.1847 TD
-.0202 Tc
(damage.)Tj
8.2191 0 0 7.3052 94.3937 223.5401 Tm
-.0307 Tc
[(51)-7(,)-5.8(5)-7(3,)-5.8(5)-7(4)]TJ
10.959 0 0 10.959 125.7448 218.6645 Tm
-.0193 Tc
[(Similarly,)-535.9(block)4.1(i)-2.4(n)4.4(g)-539(c)3.5(h)-.4(emo)4.8(k)-1.1(ine)-534.5(r)-1.9(ec)3.5(ep)4.1(tor)]TJ
-6.0216 -1.1795 TD
-.0199 Tc
[(signaling)-622.4(p)-1.7(revents)-623.3(g)-1.6(p120)3.9(-induced)-622.5(neuron)3.8(al)-623.5(apoptosis)]TJ
0 -1.1847 TD
-.0205 Tc
[(when)-271(n)3.2(o)-1.6(nneuronal)-267.1(cells)-266.9(a)-2.5(re)-266.7(absent.)]TJ
8.2191 0 0 7.3052 207.3826 197.6315 Tm
-.0238 Tc
[(55,)8(5)-.1(6)]TJ
10.959 0 0 10.959 227.2251 192.7559 Tm
-.021 Tc
[(Thus,)-304.8(e)-3.3(ven)-307.7(i)1(f)-309.4(t)-3.5(he)]TJ
-15.2815 -1.1795 TD
-.0194 Tc
[(pro)4.7(duction)-735.5(o)4.7(f)-737.2(HIV-1)4.4(-)-1.7(associ)]TJ
11.5413 0 TD
-.0197 Tc
[(ated)-730.9(neurotoxic)-731.5(pro)4.4(t)-2.2(eins)]TJ
-11.5413 -1.1847 TD
-.021 Tc
[(f)-4.2(r)1.6(om)-300.5(i)-4.1(n)2.7(f)-4.2(e)1.8(ct)-3.5(ed)-302.8(cel)-3.8(l)1.4(s)-303.6(c)-3.3(an)-302.5(potent)-3.5(ially)-302.8(i)-4.1(n)-2.5(teract)-303.6(wit)-3.5(h)-302.2(the)-303.4(c)-3.3(ell)-3.8(s)1.6(,)]TJ
0 -1.1795 TD
-.0196 Tc
[(HIV-1)-301.1(i)2.4(tself)-302.8(c)3.2(an)4.1(not)-297(d)-1.4(irectly)-296.2(d)-1.4(ama)3.5(g)-1.3(e)-302(n)4.1(eu)3.8(ral)-297.3(c)-1.9(ells.)]TJ
1.0036 -1.1847 TD
.0111 Tc
[(Ult)-2.5(i)-3.1(mately,)-215.8(i)-3.1(f)-215.2(t)2.7(he)-214.4(vi)-3.1(ral)-214.8(l)-2.7(oad)-213.8(i)-3.1(s)-214.6(n)-1.4(ot)-214.6(cont)-2.5(rol)-2.7(l)2.4(ed,)-215.8(H).3(I)-2.5(V)-.6(-1)]TJ
-1.0036 -1.1795 TD
.0121 Tc
[(can)-352.2(l)-1.7(ea)4.2(d)-357.7(t)-1.5(o)-351.8(n)-.4(eu)4.4(ronal)-353.5(l)3.4(oss.)-354.5(Cog)4.5(n)-.4(itive)-353(i)-2.1(mpairments)-358.5(in)]TJ
0 -1.1847 TD
.0124 Tc
[(HAND)-267.4(ha)4.5(ve)-270(bee)4.2(n)-269.1(demons)3.9(trat)4(e)-1(d)-269.4(t)4(o)-268.7(b).3(e)-270(w)1.4(ell)-270.4(a)-.7(s)3.9(s)-1.2(ociate)4.2(d)]TJ
0 -1.1795 TD
.0123 Tc
[(with)-434.4(synaptic)-435.6(damage)-435.6(than)-439.9(neurodegenerativ)4.7(e)-440.8(d)-.5(eì)5.3(-)]TJ
T*
[(cits,)-307.8(a)-.9(s)-306.7(axonal)-306.8(d)-.6(egeneration,)-307.8(astrocytosis,)-307.8(a)-.9(nd)-305.9(synap-)]TJ
0 -1.1847 TD
.0126 Tc
[(tic)-450.8(l)3.9(oss)-451.1(a)-.5(re)-456(a)4.7(l)-1.2(so)-449.6(ac)4.4(companied)-450.3(b).5(y)-450.2(cell)-446.1(d)-.2(eath)5.6(.)]TJ
8.2191 0 0 7.3052 266.0031 81.0708 Tm
.0172 Tc
[(35,5)6.5(7)]TJ
10.959 0 0 10.959 289.1905 76.1953 Tm
.0084 Tc
(In)Tj
-20.9358 -1.1795 TD
.0122 Tc
[(addition)4.8(,)-354.4(o).1(ther)-353.2(stu)4.5(dies)-353.2(sought)-353.1(t)3.8(o)-351.7(d)-.6(etermine)-353(wh)5.2(ether)]TJ
22.912 57.9085 TD
.012 Tc
[(neuroco)5(g)-.8(nitive)-663.5(impairments)-663.8(s)3.5(till)-664(persist)-663.7(i)-2.2(n)-662.7(H)1.2(IV-)]TJ
0 -1.1847 TD
.0114 Tc
[(infected)-539.4(individuals)-540.3(whose)-540(v)3.8(iral)-540.4(load)-544.6(is)-540.3(well)-540.4(con-)]TJ
0 -1.1795 TD
.0122 Tc
[(trolled.)-468.2(Altho)5.2(ugh)-470.7(some)-471.9(cohort)-467(studies)-472.2(have)-471.9(shown)]TJ
0 -1.1847 TD
.0107 Tc
[(that)-297.7(cognit)-2.9(i)-3.5(v)3.1(e)-297.5(f)-3.5(unct)-2.9(i)-3.5(o)3.7(n)-296.7(h)-1.5(as)-292.6(not)-297.7(b)-1.4(ee)-2.7(n)-296.7(a)-2.4(ff)-3.5(e)-2.7(c)2.5(t)-2.9(e)-2.7(d)-297(i)1.7(n)-296.7(i)-3.5(ndi)-3.5(-)]TJ
0 -1.1795 TD
.0121 Tc
[(viduals)-477.5(with)-476(th)5.1(e)-482.4(a)4.2(bsence)-477.2(of)-478.1(viremia,)]TJ
8.2191 0 0 7.3052 482.7967 650.9479 Tm
.0176 Tc
(58)Tj
10.959 0 0 10.959 496.1762 646.0723 Tm
.0124 Tc
[(others)-477.2(have)]TJ
-16.9111 -1.1847 TD
.0126 Tc
[(r)4.1(e)-.8(vealed)-429.6(that)-430.3(the)-430.1(p)-.2(re)4.4(vale)4.4(nce)-430.1(o).5(f)-436.2(H)1.8(AND)-432.7(i)3.6(s)-435.6(s)4.1(till)-430.6(high)]TJ
0 -1.1795 TD
.0105 Tc
[(in)-302.1(pat)-3.1(i)1.5(ents)-303.2(wi)-3.7(th)-301.7(HI)-3.1(V)-301.3(v)-2.3(ir)-3.1(emi)-3.7(a)2.6(.)]TJ
8.2191 0 0 7.3052 444.8125 625.0392 Tm
.0176 Tc
(59)Tj
10.959 0 0 10.959 321.7889 607.2377 Tm
0 Tc
[(This)-548.6(could)-546.2(be)-548(explained)-548.5(by)-547.4(several)-549(nonexclusive)]TJ
-.9984 -1.1847 TD
[(mechanisms)-225.4(as)-228.5(follows.)-229.8(First,)-227.5(due)-230.5(to)-227.5(irreversible)-229.1(neuro-)]TJ
0 -1.1795 TD
[(nal)-427.4(damage)-432.6(before)-430.7(initiating)-429.6(cART,)-430.8(the)-432.3(HIV-1)-429.2(virus)]TJ
0 -1.1847 TD
[(was)-306.8(not)-307.3(completely)-300.4(inhibited)-310.6(in)-306.1(the)-308.1(CNS)-304.6(since)-305.1(several)]TJ
0 -1.1795 TD
[(antiretroviral)-502.8(drugs)-510.6(do)-506.1(not)-503.8(penetrate)-507.4(into)-507.7(the)-504.7(CNS)]TJ
0 -1.1847 TD
[(and/or)-342.3(viral)-341.7(strains)-342.6(are)-340.1(immune)-343(to)-341.3(them.)]TJ
8.2191 0 0 7.3052 494.8723 547.3132 Tm
(38,49)Tj
10.959 0 0 10.959 516.1888 542.4377 Tm
(Second,)Tj
-18.7372 -1.1795 TD
[(viral)-445.1(replication)-446.8(at)-445.7(even)-450.4(very)-445.7(low)-445.7(levels)-448.1(in)-445.7(the)-447.8(CNS)]TJ
0 -1.1847 TD
[(could)-422(cause)-428.4(neuronal)-424.7(damage)-422.3(or)-424.1(dysfunction)-429.2(due)-421.9(to)]TJ
0 -1.1795 TD
[(prolonged)-426.5(exposure)-425.7(to)-424(neurotoxic)-425.8(viral)-429.6(proteins)-426.7(and)]TJ
T*
[(extensively)-596.6(inîammatory)-598.7(responses.)]TJ
8.2191 0 0 7.3052 475.9369 495.4959 Tm
(32,33,60)Tj
10.959 0 0 10.959 509.7258 490.677 Tm
[(Third,)-602.1(it)]TJ
-18.1475 -1.1847 TD
[(could)-303(be)-304.9(the)-303(neurotoxicity)-306(of)-305.7(antiretroviral)-306.2(drugs,)]TJ
8.2191 0 0 7.3052 529.9652 482.5699 Tm
(61Ö65)Tj
10.959 0 0 10.959 310.8472 464.7684 Tm
[(as)-223.3(well)-222.8(as)-223.3(exposure)-224(to)-222.3(other)-220.1(conditions)-224.3(that)-223.1(could)-220.2(affect)]TJ
T*
[(long-term)-286.4(survivorsê)-289.3(cognitive)-289.6(abilities,)-292.2(such)-290(as)-290.5(an)-289.4(ele-)]TJ
0 -1.1795 TD
[(vated)-262.2(incidence)-259.5(of)-264.3(metabolic)-261.1(abnormalities)-257.9(and)-260.9(related)]TJ
0 -1.1847 TD
[(vascular)-308(pathology)-301.6(or)-305.1(increased)-311.5(deposits)-302.8(of)]TJ
/F4 1 Tf
17.6767 0 TD
(b)Tj
/F6 1 Tf
.5484 0 TD
(-amyloid)Tj
-18.2251 -1.1795 TD
[(protein)-557.9(in)-559.6(the)-556.4(brain.)]TJ
8.2191 0 0 7.3052 408.9259 417.8267 Tm
(66)Tj
10.959 0 0 10.959 422.929 412.9511 Tm
[(HAND)-556.2(persists)-558.6(despite)-559.4(the)]TJ
-10.2274 -1.1847 TD
[(cART)-488.4(era,)-484.3(and)-488.5(this)-488.1(raises)-490.2(questions)-485.7(concerning)-487.4(the)]TJ
0 -1.1795 TD
[(etiology)-487.6(of)-486.8(HAND)-489(and)-488.5(HIV-associated)-487.6(neurocogni-)]TJ
0 -1.1847 TD
[(tive)-359.1(diseases,)-360.6(and)-364.4(the)-359.9(degree)-358.7(to)-362(which)-357.8(HAND)-359.6(can)-359.7(be)]TJ
0 -1.1795 TD
(recovered.)Tj
/F5 1 Tf
10.4607 0 0 10.4607 310.8472 335.2251 Tm
[(The)-296.2(Effects)-302.2(of)-303.6(HIV)-299.3(Infection)-295.9(on)-302.9(the)-299.8(ECS)]TJ
/F6 1 Tf
10.959 0 0 10.959 310.8472 322.2424 Tm
[(The)-435.9(ECS)-435(modulates)-431.4(cognitive)-434.5(and)-436.8(immune)-436.1(function)]TJ
T*
[(and)-307.5(provides)-307.2(a)-307.9(potentially)-306.1(therapeutic)-306.4(target)-307.6(for)-309(treat-)]TJ
0 -1.1847 TD
[(ing)-396.4(the)-390.9(impact)-398.3(of)-393.7(HIV-1)-393(infection)-394.3(on)-397.1(the)-396.1(brain)-391.5(\(i.e.,)]TJ
0 -1.1795 TD
.0207 Tc
[(H)4.7(A)-1(ND)4.8(\))-417.5(b)-1.8(ecause)-416.9(o)3.4(f)-417.7(i)1.3(ts)-412(po)3.4(ten)3(t)2(ial)-417.3(a)2.5(n)3(t)2(i-in)3(îammatory)]TJ
T*
.0192 Tc
[(and)-298.9(n)1.5(e)-4.5(u)1.2(roprotec)-4.5(tive)-304.6(proper)-4.8(ties.)]TJ
.9984 -1.1847 TD
0 Tc
[(Uses)-222.2(of)]TJ
/F10 1 Tf
3.1091 0 TD
[(Cannabis)-226(sativa)]TJ
/F6 1 Tf
6.513 0 TD
[(have)-227.3(been)-222.2(around)-221.9(for)-226.2(centu-)]TJ
-10.6205 -1.1795 TD
[(ries.)-214.5(Today,)-217.3(it)-214(is)-214.1(becoming)-214.9(increasingly)-211.7(legal)-216.9(to)-212(use)-215.7(can-)]TJ
0 -1.1847 TD
[(nabis)-334.6(for)-334.9(therapeutic)-332.3(purposes.)-337.1(Despite)-334.9(its)-331.1(popularity,)]TJ
0 -1.1795 TD
[(it)-219.2(was)-224(not)-219.3(until)-222.2(1964)-220.5(that)-223.1(the)-220.2(major)-218.4(psychoactive)-224.6(ingre-)]TJ
0 -1.1847 TD
[(dient)-495.9(in)]TJ
/F10 1 Tf
3.8281 0 TD
(cannabis)Tj
/F6 1 Tf
3.4971 0 TD
[(,)-495.9(called)]TJ
/F11 1 Tf
11.9551 0 0 11.9551 429.4487 205.6818 Tm
(O)Tj
/F6 1 Tf
10.959 0 0 10.959 442.5448 205.6818 Tm
[(-9-tetrahydroca)5.4(nnabinol)]TJ
-12.0173 -1.1795 TD
(\()Tj
/F11 1 Tf
11.9551 0 0 11.9551 314.5889 192.7559 Tm
(O)Tj
/F6 1 Tf
8.2191 0 0 7.3052 327.6849 197.6315 Tm
(9)Tj
10.959 0 0 10.959 331.5968 192.7559 Tm
[(-THC\),)-490(was)-493(isolated)-489.5(and)-488.5(characterized.)]TJ
8.2191 0 0 7.3052 511.8235 197.6315 Tm
(67)Tj
10.959 0 0 10.959 525.0896 192.7559 Tm
(Later,)Tj
-19.5494 -1.1847 TD
[(its)-196.6(molecular)-199.5(target)-199(was)-203.3(discovered.)-198.7(CB1)]TJ
8.2191 0 0 7.3052 484.1573 184.6488 Tm
(9)Tj
10.959 0 0 10.959 490.2802 179.7732 Tm
[(was)-198.1(identiìed)]TJ
-16.3731 -1.1795 TD
[(in)-238.8(1990,)-240.5(followed)-238(by)-242.2(the)-240.9(cannabinoid)-235.8(receptor)-245.7(\(CB2\).)]TJ
8.2191 0 0 7.3052 542.0408 171.7228 Tm
(10)Tj
10.959 0 0 10.959 310.8472 153.9212 Tm
[(However,)-293.4(their)-294.6(crystallographic)-289.6(structure)-296.4(was)-296.4(only)-294.4(d)23.4(e)17.7(-)]TJ
0 -1.1847 TD
-.0192 Tc
[(scrib)4.9(e)-1.5(d)-244.1(i)-2.3(n)-243.8(201)4.6(6.)]TJ
8.2191 0 0 7.3052 376.4409 145.8141 Tm
-.0238 Tc
[(68,)8(6)-.1(9)]TJ
10.959 0 0 10.959 395.603 140.9385 Tm
-.0187 Tc
[(The)4.1(y)-248.7(bo)5.4(th)-243(are)-249.3(s)3.9(ev)4.8(en-)4.2(t)3.9(ran)5(s)-1.3(me)4.1(mbra)4.4(ne)]TJ
-7.7339 -1.1795 TD
0 Tc
[(G)-212.8(protei)8.2(n-co)10.7(uple)9.2(d)-219.8(rece)8.3(ptor)-207.4(that)-212.8(are)-210.8(expres)7.9(sed)-210.6(throug)10.8(h-)]TJ
0 -1.1847 TD
[(out)-219.6(the)-220.2(CNS)]TJ
8.2191 0 0 7.3052 364.1952 119.9055 Tm
(70)Tj
10.959 0 0 10.959 374.57 115.0299 Tm
[(and)-219.5(in)-223.3(periph)8.9(eral)-219.5(syste)10.6(ms.)]TJ
8.2191 0 0 7.3052 487.5589 119.9055 Tm
(71)Tj
10.959 0 0 10.959 497.9337 115.0299 Tm
[(As)-221.6(canna)7.8(bi-)]TJ
-17.0715 -1.1795 TD
[(noid)-450(recep)-9.7(tors)-446.2(hav)-7(e)-442.7(bee)-7.9(n)-441.9(disco)-9.3(ver)-8.8(ed)-445.2(to)-444.7(mediat)-10.3(e)-442.7(the)]TJ
0 -1.1847 TD
[(effe)-8.6(cts)-361.3(of)-362.6(natur)-8.8(al)-6.2(ly)-357.7(occ)-7.9(urri)-7.8(ng)-361.5(plant)-365.9(can)-7.9(nabin)-7.6(oi)-5.6(ds,)-362(en-)]TJ
0 -1.1795 TD
.0093 Tc
[(dogenous)-464.8(ca)-3.8(nnabi)-4.9(n)1.9(oid)-463.9(l).6(igands)-464.8(have)-464.5(bee)-4.1(n)-463.6(ident)-4.3(i).3(ìe)-4.1(d)]TJ
0 -1.1847 TD
0 Tc
[(\()-8.8(s)-8.5(u)-12.8(m)-10.5(ma)-18.4(r)-8.5(i)-9(z)-13.4(e)-8.2(d)-312.9(i)-9(n)-307.4(T)-12(a)-7.9(b)-12.1(l)-8.7(e)-308.2(1)-12.5(\))-8.8(.)]TJ
8.2191 0 0 7.3052 425.14 68.0882 Tm
.0159 Tc
[(72)5.2(Ö7)5.2(4)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
0 Tc
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23783.5(3)]TJ
ET

endstream
endobj
78 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 315>>stream
hﬁlêAKA«w¨ç±Qa=ºnEbÉuµ≈C“¡ÀË>›!wFfFeèûÖæH!Ë{H—«hW€†YOz∑˜ˇø¸xƒŸ.8Ñê£ñﬂºkﬁú7ÇÈ}ª~Ekóı<.•%íñ˜éﬂAŸΩ]Ω∏…r?˘<X§Ó°S∞†ÛEHïÊR ≠“*¯r+>tO˝Ó‘(•–iúrT–Ós}ÑÎNë6®U‡!Dh°	Qçòt54¬@
£!b1Ù&∞-\≈{c˜ÅBŸ:ﬁ4FNQ≈R†	ô¢¶Ñ40FqìC3nB91–óB£0 ˇ	n$,Àµ≈a∆îb¬ƒ˘11<˝˝ì‚PgãêÇ{‚%œﬁzπÆ<≥›’<Û~ÊÓÍ‚≠ò}Ï$ØÈªÎ˝
0 r|N

endstream
endobj
81 0 obj
<</Length 11790>>stream
/GS1 gs
BT
/F10 1 Tf
10.959 0 0 10.959 72.9637 283.4078 Tm
0 0 0 rg
0 Tc
0 Tw
(N)Tj
/F6 1 Tf
.6984 0 TD
-.0001 Tc
[(-arachidonoylethanolamine)-369.1(is)-364.2(isolated)-365.4(as)-368.2(the)-365.1(ìrst)]TJ
-1.6968 -1.1795 TD
-.0002 Tc
(endocannabinoid.)Tj
8.2191 0 0 7.3052 140.3716 275.3574 Tm
0 Tc
(11)Tj
10.959 0 0 10.959 150.6897 270.4818 Tm
[(Later,)-220.3(another)-225(derivative)-221.7(of)-222.9(arachi-)]TJ
-8.0908 -1.1847 TD
.0198 Tc
[(donic)-257.4(a)-3.6(cid,)-253.7(2-ar)-4.2(achdonoylglycerol,)-258.8(w)3.6(as)-257.7(disc)-3.9(ove)-3.9(r)1(ed.)]TJ
8.2191 0 0 7.3052 293.0456 262.3748 Tm
.0245 Tc
(12)Tj
10.959 0 0 10.959 62.022 244.5731 Tm
.0185 Tc
[(AEA)-546.4(i)-.9(s)-548.7(g).6(e)-5.2(n).8(er)-5.5(ated)-547.9(f)-6.1(r)-.3(om)-545.6(membr)-5.5(a).3(ne)-548.4(p)-4.7(h)1.1(os)-5.5(ph)-4(olip)-4.7(ids)]TJ
T*
.0277 Tc
(by)Tj
/F10 1 Tf
1.8572 0 TD
0 Tc
(N)Tj
/F6 1 Tf
.7242 0 TD
.0289 Tc
[(-acetyl)-5.6(trans)-5.4(f)-.8(eras)-5.4(e)-838(a).3(ction)-837.2(f)-.8(ol)-5.6(lowe)-5.2(d)-837.5(b)1.2(y)-842.6(N)2.3(-)]TJ
-2.5814 -1.1795 TD
-.0274 Tc
[(a)-4.3(c).6(yl)-5(phos)-4.8(phati)-5.4(d)1.1(ylet)-4.8(hanolamine-)-4.5(s).3(pe)-4.6(ci)-5.4(ìc)-325.3(p)-4(h)1.8(osphol)-5(ipa)-4.3(s).3(e)-4.6(D)3.2(,)]TJ
8.2191 0 0 7.3052 293.5558 223.5401 Tm
-.0375 Tc
(75)Tj
10.959 0 0 10.959 62.022 205.6818 Tm
.0092 Tc
[(whe)-4.2(r).7(eas)-692.5(2)1.9(-AG)-695.1(i).2(s)-692.5(p)1.5(r)-4.4(o)2.2(duce)-4.2(d)-691.7(b)-2.9(y)-691.6(t).8(he)-697.4(enz)-4.2(y)1.6(me)-692.2(1,2-)]TJ
T*
.01 Tc
[(diacy)2.4(l)1.3(gly)2.4(c)-3.4(erol)-210.8(lip)2.3(a)-3.1(se)]TJ
/F4 1 Tf
8.3185 0 TD
0 Tc
(a)Tj
/F10 1 Tf
.5639 0 TD
(/)Tj
/F4 1 Tf
.3207 0 TD
(b)Tj
/F6 1 Tf
.7708 0 TD
.0097 Tc
(\(DAGL\).)Tj
8.2191 0 0 7.3052 211.0677 197.6315 Tm
.0176 Tc
(14)Tj
10.959 0 0 10.959 221.4991 192.7559 Tm
.0092 Tc
[(However,)-212.5(alt)-4.4(e)1(rna-)]TJ
-14.5521 -1.1795 TD
[(ti)-4.9(ve)-593.8(pathways)-599.3(of)-599.8(2-AG)-596.7(m)9.3(a)-9.1(y)-593.2(o)-2.8(ccur)-594.1(s)-4.3(ince)-593.8(a)-598.7(s).8(tudy)]TJ
0 -1.1847 TD
.009 Tc
[(showed)-464.3(that)-459.8(DAGL)]TJ
/F12 1 Tf
8.2191 0 0 7.3052 152.9007 171.7228 Tm
0 Tc
()Tj
/F6 1 Tf
.7725 0 TD
(/)Tj
/F12 1 Tf
.3311 0 TD
()Tj
/F6 1 Tf
10.959 0 0 10.959 173.3669 166.8472 Tm
.0118 Tc
[(mice)-456.8(re)3.6(v)4.2(e)-1.6(a)3.9(l)3.1(ed)-456.3(on)4.4(ly)-461.4(a)3.9(n)-461.1(8)4.5(0)-.7(%)]TJ
-10.1601 -1.1795 TD
.0089 Tc
[(decr)-4.7(eas)-4.7(e)-382.1(i)-5.3(n)-386.4(2-AG)-385(conc)-4.5(ent)-4.7(r).4(at)-4.7(ions.)]TJ
8.2191 0 0 7.3052 214.7527 158.7968 Tm
.0176 Tc
(76)Tj
10.959 0 0 10.959 227.1118 153.9212 Tm
.0078 Tc
[(Ear)-5.8(l)-.9(y)-387.8(s)-.7(tu)-5(die)-5.6(s)-388.7(on)]TJ
-15.0643 -1.1847 TD
.0098 Tc
[(endocannabinoids)-334.9(\(i.e)-3.6(.,)-330.9(AEA)-332.7(a)1.9(nd)-328.9(2-AG\))-330.1(h)-2.4(ave)-329.5(s)1.3(hown)]TJ
0 -1.1795 TD
.009 Tc
[(that)-299.4(t)-4.6(h)2(e)-4.4(y)-298.6(ar)-4.6(e)-299.2(o)2(n-demand)-298.7(s)-4.6(y)1.4(nt)-4.6(he)-4.4(size)-4.4(d.)]TJ
.9984 -1.1847 TD
0 Tc
[(Their)-261.9(synthesis)-259.2(takes)-257.9(place)-257.9(locally,)-257.7(rather)-255.4(than)-258.3(being)]TJ
-.9984 -1.1795 TD
(stored.)Tj
8.2191 0 0 7.3052 91.4456 106.9795 Tm
(77)Tj
10.959 0 0 10.959 101.8771 102.1039 Tm
-.0001 Tc
[(Notably,)-227.7(the)-235.8(endocannabinoids)-232.2(stored)-234.5(in)-233.7(lipid)]TJ
-3.6367 -1.1847 TD
0 Tc
[(droplets)-380.1(are)-376.3(a)-380.4(pool)-376.9(of)-383.3(metabolic)-374.9(intermediates)-378.9(rather)]TJ
0 -1.1795 TD
[(than)-351.4(a)-349.3(pool)-351(of)-352.3(biologically)-349.7(active)-349.3(lipids)-350.5(that)-352.4(send)-352.4(sig-)]TJ
T*
(nals.)Tj
8.2191 0 0 7.3052 81.8645 68.0882 Tm
(78,79)Tj
10.959 0 0 10.959 106.526 63.2692 Tm
[(This)-646.9(ìnding)-651.3(does)-646.9(not)-648.7(contradict)-644.5(to)-646.5(the)]TJ
18.8459 20.0874 TD
[(on-demand)-299.4(synthesis)-295.4(theory)-295(that)-290.4(explains)-298(endocanna-)]TJ
0 -1.1795 TD
[(binoid)-486.7(regulation)-483.7(in)-487.1(neuronal)-486.8(synapsis.)-483.3(The)-487.6(actions)]TJ
0 -1.1847 TD
-.0001 Tc
[(of)-507.6(endocannabinoids)-506.4(on)-505.9(their)-501.6(receptors)-507.7(cease)-506.7(upon)]TJ
0 -1.1795 TD
0 Tc
[(degradation)-547.6(by)-547.4(their)-542.9(hydrolyzing)-546.6(enzymes.)-549.3(AEA)-542(is)]TJ
0 -1.1847 TD
[(inactivated)-286.2(by)-283.6(FAAH,)-283.7(mainly)-278.7(located)-283.6(in)-285.4(the)-282.3(cell)-287.2(mem-)]TJ
0 -1.1795 TD
(brane,)Tj
8.2191 0 0 7.3052 340.2141 223.5401 Tm
(80)Tj
10.959 0 0 10.959 351.4393 218.6645 Tm
[(while)-302.6(the)-303(primary)-308(catabolic)-299.8(pathway)-305.8(of)-305.7(2-AG)]TJ
-3.5022 -1.1847 TD
[(is)-229.6(through)-229(MAGL)-225.7(linked)-224.4(to)-227.5(the)-230.5(inner)-226.6(leaf)-230.4(of)-228.1(the)-225.4(plasma)]TJ
0 -1.1795 TD
[(membrane,)-445.1(and,)-446.4(to)-444.7(some)-448.1(extent,)-446.1(by)]TJ
/F9 1 Tf
15.4212 0 TD
(a)Tj
/F6 1 Tf
.5018 0 TD
(/)Tj
/F9 1 Tf
.3207 0 TD
(b)Tj
/F6 1 Tf
.5484 0 TD
(-hydrolase-6)Tj
-16.7921 -1.1795 TD
[(and)-302.3(-12)-296.9(\(ABHD6)-298.9(and)-302.3(ABHD12\).)]TJ
8.2191 0 0 7.3052 459.4959 184.6488 Tm
(81)Tj
10.959 0 0 10.959 324.0566 166.8472 Tm
[(2-AG)-586.2(is)-586.5(also)-590.7(hydrolyzed)-585(by)-588.8(FAAH)-589.6(despite)-585.3(this)]TJ
-1.0036 -1.1795 TD
[(degradation)-340.6(seems)-338.8(to)-341.3(be)-335.9(minor)]TJ
/F10 1 Tf
13.0209 0 TD
[(in)-337.1(vivo)]TJ
/F6 1 Tf
2.7521 0 TD
(.)Tj
8.2191 0 0 7.3052 488.2959 158.7968 Tm
(82)Tj
10.959 0 0 10.959 499.918 153.9212 Tm
[(In)-336.5(addition,)]TJ
-17.0508 -1.1847 TD
[(both)-350.1(AEA)-345.4(and)-348.8(2-AG)-348.3(can)-349.4(be)-346.3(metabolized)-349.4(into)-347.3(arachi-)]TJ
0 -1.1795 TD
[(donic)-711.7(acid)-705.3(under)-706.7(the)-711.6(catalysis)-705.7(cyclooxygenase2.)]TJ
8.2191 0 0 7.3052 544.3085 132.8882 Tm
(83)Tj
10.959 0 0 10.959 313.0582 115.0299 Tm
-.0001 Tc
[(N-palmitoylethanolamine)-238.1(\(PEA\))-239.7(and)-235.1(N-oleoylethano)6.7(l-)]TJ
T*
0 Tc
[(amine)-275.8(\(OE)9.3(A\))-268.5(are)-267.7(part)-260.1(of)-269.5(N-ac)11.2(yleth)11.9(anolam)12.7(ines)-265.8(\(NA)10.1(Es\))]TJ
0 -1.1847 TD
[(family)-358(beside)8.4(s)-365.4(AEA,)-365.4(whic)11.3(h)-369.1(are)-366(stru)8.4(ctur)8.6(ally)-363.9(anal)9.6(ogous)]TJ
0 -1.1795 TD
[(lipid)9.7(s.)]TJ
8.2191 0 0 7.3052 339.1369 81.0708 Tm
(84)Tj
10.959 0 0 10.959 349.5117 76.1953 Tm
[(2-AG)-218.9(and)-224.7(its)-227.6(str)10.9(uctura)8.6(l)-225.9(anal)9.6(og)-226.7(2-ol)10.3(eoyl)9.9(glycer)8.2(ol)]TJ
-3.3264 -1.1795 TD
[(\(2-OG)10.5(\))-567.5(are)-557.4(part)-554.9(of)-564.4(the)-556.4(famil)11.7(y)-566.3(o)0(f)-559.2(2-ac)9.9(ylgly)11.6(cerols)7.9(.)]TJ
8.2191 0 0 7.3052 544.3085 68.0882 Tm
(85)Tj
ET
62.022 692.56 490.167 .22681 re
f
62.022 344.239 490.167 .28345 re
f
62.022 665.915 490.167 .22681 re
f
BT
/F5 1 Tf
8.9663 0 0 8.9663 62.022 699.2502 Tm
[(Table)-306.5(1.)-500.5(Cannabinoid)-301.5(Receptor)-306.6(Agonists)-302.1(and)-302(Antagonists)]TJ
7.9702 0 0 7.9702 62.022 672.151 Tm
[(Category)-15051.8(Ligand)]TJ
/F2 1 Tf
5.9774 0 0 5.3127 238.5637 675.666 Tm
(a)Tj
/F5 1 Tf
7.9702 0 0 7.9702 348.3778 681.1085 Tm
[(Selectivit)7.3(y)-333.6(o)0(f)]TJ
-1.0527 -1.1239 TD
[(receptor)-324.1(binding)]TJ
/F2 1 Tf
5.9774 0 0 5.3127 400.2519 675.666 Tm
(a)Tj
/F5 1 Tf
7.9702 0 0 7.9702 480.9825 681.1085 Tm
[(If)-332.1(the)-332.6(molecule)-328.3(is)]TJ
-1.1452 -1.1239 TD
[(agonist)-330.1(or)-333.4(antagon)11.9(ist)]TJ
/F2 1 Tf
5.9774 0 0 5.3127 549.1841 675.666 Tm
(a)Tj
/F7 1 Tf
7.9702 0 0 7.9702 62.022 655.1998 Tm
[(Endocannabin)13.8(oids)-7648.1(AEA)-16861.2(CB1)]TJ
/F8 1 Tf
36.0351 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
(CB2)Tj
/F8 1 Tf
2.1197 0 TD
(>)Tj
/F7 1 Tf
1.0527 0 TD
[(VR1)-12348.8(Agonist)]TJ
-24.896 -1.1239 TD
[(2-AG)-16497.2(CB1/CB)10.3(2)-16710.9(Agonist)]TJ
T*
[(2-AGE)-16008.2(CB1)-18656.6(Agonist)]TJ
0 -1.131 TD
[(NADA)-16038.2(CB1)-18656.6(Agonist)]TJ
0 -1.1239 TD
[(AG)-17309.2(CB1)]TJ
/F8 1 Tf
20.6779 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-37.0808 -1.1239 TD
[(Phytocannabin)13.5(oids)]TJ
15.3573 -1.1239 TD
[(Palmitoylethan)13.5(olamide)-8932.7(CB2?)-18261.6(Agonist)]TJ
/F4 1 Tf
T*
(D)Tj
/F7 1 Tf
5.9774 0 0 5.3127 189.7511 595.9557 Tm
(9)Tj
7.9702 0 0 7.9702 192.7558 592.4408 Tm
[(-THC)-15504.5(CB1)]TJ
/F8 1 Tf
19.6323 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
/F4 1 Tf
-21.7235 -1.1239 TD
(D)Tj
/F7 1 Tf
5.9774 0 0 5.3127 189.7511 586.9983 Tm
(8)Tj
7.9702 0 0 7.9702 192.7558 583.4833 Tm
[(-THC)-15504.5(CB1)]TJ
/F8 1 Tf
19.6323 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-21.7235 -1.131 TD
[(Cannabinol)-13811.2(CB1)]TJ
/F8 1 Tf
20.6779 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-21.7235 -1.1239 TD
[(Cannabidi)12.1(ol)-13584.3(Low)-324.8(binding)-325.7(affinity)-11792.1(Agonist)]TJ
T*
[(Virodhamine)-13207.2(CB2)-18656.6(Agonist)]TJ
-15.3573 -1.1239 TD
[(Synthetic)-294.4(cannabinoi)12.7(ds)]TJ
15.3573 -1.1239 TD
[(HU-308)-15436.2(CB2)-18656.6(Agonist)]TJ
T*
[(JWH-133)-14874.2(CB2)-18656.6(Agonist)]TJ
T*
[(Dexanabino)14.6(l)-13335.7(N)0(o)-325.2(binding)-325.7(to)-332(CB1/CB2)-10419.7(Agonist)]TJ
0 -1.131 TD
(\(HU-211\))Tj
0 -1.1239 TD
[(HU-210)-15436.2(CB1)]TJ
/F8 1 Tf
20.6779 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-21.7235 -1.1239 TD
[(Nabilone)-14810.2(CB1)]TJ
/F8 1 Tf
20.6779 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-21.7235 -1.1239 TD
[(Levonantr)11.1(adol)-12543.3(CB1)]TJ
/F8 1 Tf
20.6779 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-21.7235 -1.1239 TD
[(CP-55940)-14603.2(CB1)]TJ
/F8 1 Tf
20.6779 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-21.7235 -1.1239 TD
(R\()Tj
/F8 1 Tf
.9745 0 TD
(+)Tj
/F7 1 Tf
.7184 0 TD
[(\)WIN55,212)11.5(-2)-11308.8(CB1)]TJ
/F8 1 Tf
18.985 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Agonist)]TJ
-21.7235 -1.131 TD
[(S\(-\)WIN-552)12(13)-12637.2(Low)-324.8(binding)-325.7(affinity)-11792.1(Agonist)]TJ
0 -1.1239 TD
[(JWH-015)-14874.2(CB2)-18656.6(Agonist)]TJ
T*
[(ACEA)-16289.2(CB1)-18656.6(Agonist)]TJ
T*
[(ACPA)-16247.2(CB1)-18656.6(Agonist)]TJ
T*
(R-\()Tj
/F8 1 Tf
1.2804 0 TD
(+)Tj
/F7 1 Tf
.7113 0 TD
[(\)-methanandam)11.2(ide)-8560.7(CB1)-18656.6(Agonist)]TJ
-1.9917 -1.1239 TD
[(Dronabinol)-287.8(\(Marinol\))-9891.4(CB1)-18656.6(Agonist)]TJ
T*
[(Rimonaban)13.5(t)-304(\(SR-14171)13.1(6A\))-7652.9(CB1)-18656.6(Antago)12.7(nist)]TJ
0 -1.131 TD
[(SR-144528)-14176.2(CB2)-18656.6(Antago)12.7(nist)]TJ
0 -1.1239 TD
[(AM251)-15622.2(CB1)-18656.6(Antago)12.7(nist)]TJ
T*
[(AM281)-15622.2(CB2)-18656.6(Antago)12.7(nist)]TJ
T*
[(AM630)-15622.2(CB1)]TJ
/F8 1 Tf
20.6779 0 TD
(>)Tj
/F7 1 Tf
1.0456 0 TD
[(CB2)-15491.2(Antago)12.7(nist)]TJ
-21.7235 -1.1239 TD
[(Virodhamine)-13207.2(CB1)-18656.6(Antago)12.7(nist)]TJ
T*
[(LY320135)-14499.2(CB1)-18656.6(Antago)12.7(nist)]TJ
5.9774 0 0 5.3127 70.9795 336.0188 Tm
(a)Tj
7.9702 0 0 7.9702 73.8708 332.4471 Tm
[(Summar)11.5(ized)-295(from)-296.3(Patel)-300.6(and)-292(Hillard,)]TJ
5.9774 0 0 5.3127 192.7558 336.0188 Tm
(72)Tj
7.9702 0 0 7.9702 201.2598 332.4471 Tm
(Lo)Tj
.5904 .0356 TD
(¥)Tj
.4197 -.0356 TD
(pez,)Tj
5.9774 0 0 5.3127 222.6897 336.0188 Tm
(73)Tj
7.9702 0 0 7.9702 231.1936 332.4471 Tm
[(and)-292(Croxford.)]TJ
5.9774 0 0 5.3127 276.5479 336.0188 Tm
(74)Tj
7.9702 0 0 7.9702 70.9795 323.4897 Tm
[(2-AG,)-245.8(2-arachidono)10.4(yl)-249(glycerol;)-242.3(2-AGE,)-240.5(2-arachidono)10.4(yl)-249.1(glyceryl)-242(ether;)-238.9(ACEA,)-244.1(arachidonyl-2)]TJ
/F8 1 Tf
36.5829 0 TD
(¢)Tj
/F7 1 Tf
.249 0 TD
[(-chloroethy)10.2(lamide;)-243.1(ACPA,)-244.8(arachidonyl-)12.1(cyclopropyl)7.5(amide;)]TJ
-37.9557 -1.1239 TD
[(AEA,)-325.3(N-arachidonylet)10.5(hanolamine;)-319.9(AG,)-332.3(Noladin)-322.8(ether;)-324.2(CB1,)-328.2(cannabinoid)-321.6(receptor)-325.1(type)-331.7(1;)-331.5(CB2,)-328.2(cannabinoi)12.7(d)-334.3(receptor)-325.1(type)-324.6(2;)-331.5(NADA,)-327.4(N-arachidon)13.7(oyl-)]TJ
T*
(dopamine.)Tj
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(4)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
88 0 obj
<</Length 11642>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 59.7543 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(Intere)7.8(sti)10.3(ngly,)-201.2(t)-13.6(h)-17.4(e)-13.4(r)-13.6(e)-225.5(a)-13.1(r)-18.8(e)-220.3(s)-18.8(o)-12.1(m)-15.7(e)-220.3(m)-15.7(e)-18.5(t)-13.6(a)-13.1(b)-17.3(o)-12.1(l)-13.8(i)-14.2(c)-225.5(s)-13.6(i)-14.2(m)-15.7(i)-14.2(l)-19(a)-13.1(r)-13.6(i)-14.2(t)-18.7(i)-14.2(e)-13.4(s)-225.7(b)-12.1(e)-18.5(-)]TJ
0 -1.1847 TD
.0137 Tc
[(t)-5(w)2.7(e)-4.8(e).3(n)-247.1(P)1.5(EA,)-249.4(O)-2.6(EA,)-244.2(a)-4.5(nd)-247.4(2-OG,)-244.2(b)-3.6(ut)-248.2(none)-248(of)-248.8(them)-245.1(ta)-4.5(rge)-4.8(t)]TJ
0 -1.1795 TD
.0187 Tc
[(th)6.5(e)-294.7(C)2.2(B)6.8(1)-299(o)6.6(r)-300.2(C)7.4(B)1.6(2)6.2(.)]TJ
8.2191 0 0 7.3052 134.759 676.8565 Tm
.0245 Tc
(86)Tj
10.959 0 0 10.959 70.7527 658.9983 Tm
0 Tc
[(Since)-216.6(CB1)-216.8(receptors)-217.9(are)-216(largely)-217.4(placed)-213.9(at)-218(axon)-216.4(termi-)]TJ
-1.0036 -1.1795 TD
[(nals,)-388.6(activation)-386(of)-388.5(the)-385.7(receptors)-388.6(leads)-387.5(to)-387.8(a)-385.5(strong)-388.7(in-)]TJ
0 -1.1847 TD
[(hibition)-384.5(of)-388.5(neurotransmitter)-385.8(release)-389.2(to)-382.7(the)-385.7(synapse.)]TJ
8.2191 0 0 7.3052 291.0046 637.9652 Tm
(77)Tj
10.959 0 0 10.959 59.7543 620.1636 Tm
[(CB1)-392.7(receptors)-393.8(are)-397(primarily)-392.9(observed)-388.5(presynaptically)]TJ
0 -1.1795 TD
[(on)-412.7(neurons,)-415.9(including)-408.8(on)-412.7(GABAergic,)-412.4(glutamatergic)5.3(,)]TJ
0 -1.1847 TD
[(serotonergic,)-343.9(noradrenergic,)-346.3(and)-343.7(dopaminergic)-341.8(termi-)]TJ
0 -1.1795 TD
(nals,)Tj
8.2191 0 0 7.3052 79.5968 586.2046 Tm
(70,87Ö89)Tj
10.959 0 0 10.959 114.1795 581.329 Tm
[(but)-442.1(they)-450.2(also)-445.9(exist)-445.5(in)-450.9(various)-444.1(peripheral)]TJ
-4.9662 -1.1847 TD
[(tissues,)-404.6(and)-395.4(on)-402.3(cells)-399.2(of)-398.8(the)-396.1(immune)-399.9(system,)-397.6(vascular)]TJ
0 -1.1795 TD
[(smooth)-338.1(muscle,)-340.7(and)-343.7(ileum)-339(\(Table)-342.2(2\).)]TJ
8.2191 0 0 7.3052 224.844 560.2959 Tm
(90)Tj
10.959 0 0 10.959 236.4661 555.4203 Tm
[(In)-341.7(addition)-338.2(to)]TJ
-16.1248 -1.1847 TD
[(the)-365(classic)-364.1(CB1)-361.6(and)-364.4(CB2,)-366.1(other)-365(receptors)-362.8(can)-364.9(also)-363.1(be)]TJ
0 -1.1795 TD
[(tr)19.4(ig)19.6(ge)20.4(re)19.5(d)-250.8(b)13.7(y)-250.7(c)12.5(an)21(na)15.8(b)13.7(i)0(n)19.8(o)0(i)20.2(d)0(s)20.1(,)-247.6(in)19.8(cl)19.3(ud)20.9(in)19.8(g)-250.7(G)0(-)22.2(p)0(r)20.1(o)0(t)20.8(e)0(i)19(n)0(-)20.7(c)0(o)21(u)0(p)15.7(l)12(e)12.5(d)]TJ
0 -1.1847 TD
[(rec)-9.4(eptor)-267.3(55)-262.9(\(GPR)-7.8(55\),)]TJ
8.2191 0 0 7.3052 153.5244 521.4046 Tm
(91)Tj
10.959 0 0 10.959 164.296 516.529 Tm
[(G-prot)-9.3(ein-c)-9.9(ouple)-8.1(d)-261.2(recep)-9.7(tor)-267(18)]TJ
-9.5393 -1.1795 TD
[(\(GPR)-7.8(18\))-7.8(,)-211.4(G-pr)-9.5(otei)-6.7(n-c)-8.2(ouple)-8.1(d)-214.6(recep)-9.7(tor)-215.3(119)-218.4(\(GPR119)-9(\),)]TJ
8.2191 0 0 7.3052 291.0046 508.4786 Tm
(92)Tj
10.959 0 0 10.959 59.7543 490.677 Tm
[(tr)-6.5(ansie)-9.9(nt)-305.5(recep)-9.7(tor)-303.2(pot)-7.5(enti)-7.1(al)-301.1(van)-7.3(ill)-5.6(ic)-301.7(aci)-9.6(d)-302.5(1)-297(\(TRP)-8.7(V1\))-7.1(,)]TJ
8.2191 0 0 7.3052 291.0046 495.4959 Tm
(93)Tj
10.959 0 0 10.959 59.7543 477.6943 Tm
-.0205 Tc
[(and)-224.7(p)-2.3(er)-3.1(oxi)-3.6(s)2.1(ome)-225.3(p)-2.3(roli)-3.6(ferator)-3.1(-)2.4(act)-3(i)1.5(vat)-3(e)2.3(d)-229.9(r)2.1(eceptor)-225.6(\()-3.4(P)-1.7(PAR\).)]TJ
8.2191 0 0 7.3052 291.2314 482.5699 Tm
-.0306 Tc
(94)Tj
10.959 0 0 10.959 59.7543 464.7684 Tm
0 Tc
[(Thes)-9.8(e)-396.2(orp)-7.6(han)-399.9(G)-5.9(PRs,)-404.4(espec)-9.7(ially)-403.9(GPR55)-406.8(and)-400.6(GPR11)-8.5(9,)]TJ
0 -1.1847 TD
[(hav)-7(e)-303.1(becom)-9.9(e)-297.9(pot)-7.5(enti)-7.1(al)-306.3(targe)-9.5(ts)-301.4(of)-305.7(cannab)-9.5(inoid)-9(s.)]TJ
8.2191 0 0 7.3052 267.7039 456.6613 Tm
[(92)-7.7(,95)]TJ
10.959 0 0 10.959 70.7527 438.8597 Tm
[(The)-451.4(present)-449.9(study)-453.6(focuses)-455.4(on)-448.9(the)-453(neuroprotective)]TJ
-1.0036 -1.1847 TD
[(role)-275.5(of)-274.7(CB1)-273.7(by)-273.2(preventing)-276.4(glutamate)-271.8(production)-275(at)-274.9(ex-)]TJ
0 -1.1795 TD
[(citatory)-313.3(synapses)-312.5(when)-313(they)-310.6(are)-309.1(activated.)]TJ
8.2191 0 0 7.3052 245.1401 417.8267 Tm
(19)Tj
10.959 0 0 10.959 256.4787 412.9511 Tm
(Endocan-)Tj
-17.9509 -1.1847 TD
[(nabinoids)-334.6(produce)-329(postsynaptic)-328.9(diffusion)-332.9(through)-332.5(the)]TJ
0 -1.1795 TD
[(synaptic)-333.6(cleft)-332.2(to)-325.8(act)-334.9(on)-329.9(presynaptic)-326.9(CB1)-330.6(in)-331.9(this)-327.8(retro-)]TJ
0 -1.1847 TD
[(grade)-396.8(signaling)-393.7(system.)]TJ
8.2191 0 0 7.3052 163.7291 378.9353 Tm
(19)Tj
10.959 0 0 10.959 175.9747 374.0597 Tm
[(Feedback)-393.5(inhibition)-395.7(is)-395.1(pro-)]TJ
-10.605 -1.1795 TD
[(vided)-319.5(by)-314.6(the)-318.5(ECS)-316(at)-321.5(glutamatergic)-315.5(synapses.)-316.9(Once)-319.4(the)]TJ
22.912 30.7286 TD
[(postsynaptic)-230.6(cell)-235.5(is)-229.6(excited,)-238(it)-229.5(synthesizes)-234.3(2-AG)-229.3(that)-233.5(ac-)]TJ
0 -1.1847 TD
[(tivates)-264.9(presynaptic)-264.8(CB1,)-262.6(which)-264.7(inhibits)-261.8(or)-263.8(reduces)-269(glu-)]TJ
0 -1.1795 TD
[(tamate)-237.6(release.)-238.5(Amusingly,)-237.9(in)-233.6(a)-240.7(recent)-240.3(study,)-235.7(astrocytes)]TJ
0 -1.1847 TD
[(generate)-281.6(2-AG)-281(when)-281.9(they)-284.7(activate)-282.9(metabotrop)7.4(ic)-286.2(gluta-)]TJ
0 -1.1795 TD
[(mate)-236.8(receptors,)-237.9(followed)-238(by)-237(activating)-236.5(presynaptic)-233.8(CB1)]TJ
0 -1.1847 TD
[(to)-299.9(produce)-298(a)-297.6(form)-304(of)-295.4(synaptic)-302.6(inhibition.)]TJ
8.2191 0 0 7.3052 491.8676 637.9652 Tm
(96)Tj
10.959 0 0 10.959 321.7889 620.1636 Tm
[(Presynaptic)-202.1(inhibition)-204.3(mediated)-202.1(by)-200.8(CB1)-201.3(provides)-203.7(the)]TJ
-.9984 -1.1795 TD
-.0001 Tc
[(basis)-460(for)-459.1(the)-463.4(neuroprotective)-460.8(properties)-464.5(of)-461(the)-458.3(ECS,)]TJ
0 -1.1847 TD
0 Tc
[(thereby)-463.5(inhibiting)-463.6(glutamate)-463.2(release)-461.6(and)-467.8(dampening)]TJ
0 -1.1795 TD
[(excitotoxicity)-471.2(caused)-477.5(by)-475(overactivation)-474.1(of)-476.4(the)-473.7(gluta-)]TJ
0 -1.1847 TD
[(mate)-464.4(pathway.)-460.3(Neurodegenerative)-465.2(diseases)-464.7(are)-464.3(often)]TJ
0 -1.1795 TD
[(characterized)-457.6(by)-459.5(excitotoxicity,)]TJ
8.2191 0 0 7.3052 450.1983 560.2959 Tm
(97)Tj
10.959 0 0 10.959 463.0676 555.4203 Tm
[(such)-460.7(as)-461.3(HAND,)]TJ
8.2191 0 0 7.3052 536.3148 560.2959 Tm
(7,30)Tj
10.959 0 0 10.959 310.8472 542.4377 Tm
[(wh)23.3(er)19.5(e)-349.6(o)0(v)16.5(e)12.5(re)19.5(xp)20.6(re)19.5(ss)19.3(i)11.7(o)0(n)-345.4(o)13.7(f)-350.5(g)0(l)20(u)0(t)20.2(a)0(m)17.8(a)12.8(te)-342.5(r)12.2(e)0(c)19.8(e)0(p)15.2(t)12.3(or)20.8(s)-349.9(r)0(e)19.5(s)0(u)20.1(l)0(t)19.2(s)-349.9(in)]TJ
T*
[(the)-323.7(loss)-322.3(of)-321.2(cha)-7.6(ract)-7.1(eris)-8.3(ti)-7.1(cs)-321.9(of)-321.2(posts)-8.9(ynapt)-7.9(ic)-322.4(st)-6.5(ructu)-9.4(res.)]TJ
8.2191 0 0 7.3052 542.0408 534.3873 Tm
(97)Tj
10.959 0 0 10.959 310.8472 516.529 Tm
[(Theref)-11.5(ore,)-323(pre)-8.8(venti)-9.5(ng)-320.2(CB1)-320.2(may)-320.9(sl)-6.8(ow)-318.1(down)-322.7(the)-323.7(devel)-9.3(-)]TJ
T*
[(opme)-7.5(nt)-476.2(of)-481.6(disea)-10.2(se)-477.1(and)-483.3(atte)-7(nua)-7.4(te)-477(rela)-7.4(te)-6.2(d)-478.4(sympto)-8.3(ms.)]TJ
T*
[(Conv)-7.4(inci)-7.7(ng)-278.8(evi)-9.3(dence)-288(that)-285.2(CB1)-284(prote)-8.7(cts)-283.7(again)-8.7(st)-280.7(exc)-8.8(ito-)]TJ
0 -1.1847 TD
[(toxi)-6.4(city)-297(was)-296.4(pro)-7.6(vided)-298.8(by)-293.9(Marsic)-10.6(ano)-296.4(et)-290.8(al)-295.9(who)-294(demo)-7.5(n-)]TJ
0 -1.1795 TD
[(stra)-7.4(ted)-376(in)-378.5(a)-375.2(mode)-7.5(l)-370.8(o)0(f)-378.1(kaini)-9.9(c)-375.5(acid-)-9.9(induc)-8.9(ed)-378(excit)-10.7(otoxi)-8.3(c)]TJ
0 -1.1847 TD
[(seiz)-8(ures)-550.1(tha)-7.8(t)-541.2(mic)-7.1(e)-546.2(exper)-9.5(ience)-553.1(more)-546.3(sev)-8.7(ere)-547.4(sei)-10.2(zures)]TJ
0 -1.1795 TD
[(when)-364.7(thei)-6.8(r)-360.2(CB1)-366.8(in)-363(all)-361.5(for)-9(ebrai)-9.5(n)-359.1(prim)-9.8(ary)-365.4(neuron)-9.8(s)-360.2(ex-)]TJ
0 -1.1847 TD
[(cept)-306.7(astr)-7.4(ocy)-7.2(tes)-304.4(are)-303.9(kno)-6.4(cke)-8.5(d)-302.5(out.)]TJ
8.2191 0 0 7.3052 452.8629 430.7527 Tm
(98)Tj
10.959 0 0 10.959 321.7889 412.9511 Tm
.2097 Tc
[(M)230.8(o)228.6(r)232.3(e)227.4(o)228.6(v)233.2(e)227.4(r)232.3(,as)227.1(t)232.3(u)227.9(d)233.1(yb)228.6(yM)230.8(o)228.6(n)228.2(o)233.8(r)]TJ
10.9464 0 TD
-.0189 Tc
[(y)-228.2(e)3.9(t)-229(a)-.9(l)-229.3(s)3.7(how)6.3(ed)-228.3(th)5.1(at)-229(hippo-)]TJ
-11.9449 -1.1847 TD
-.021 Tc
[(campal)-236.6(glutamat)-3.5(er)-3.6(gic)-236.1(n)-2.5(eur)-3.6(o)3.1(ns)-236.4(e)-3.3(x)2.1(pre)-3.3(s)-3.6(s)-236.4(C)3.9(B1,)-237.5(w)-1(hi)-4.1(ch)-234.9(i)-4.1(s)-236.4(c)-3.3(r)1.6(it)-3.5(-)]TJ
0 -1.1795 TD
-.0204 Tc
[(ical)-179.1(for)-178.9(c)2.4(annabinoid-medi)-3.5(a)2.7(ted)-178.1(s)]TJ
11.8414 0 TD
-.0174 Tc
[(e)5.4(c).3(ur)5.2(it)5.2(y)-175(a).6(g)6.1(a).6(i)4.6(n)1.1(s)5.2(t)-175.8(ka)5.7(in)6.3(ic)-175.6(a)5.8(c).3(i)4.6(d).8(-)]TJ
-11.8414 -1.1847 TD
-.0198 Tc
[(indu)3.6(ce)3(d)-358.5(a)-1.8(c)3(u)-1.6(te)-359.1(e)3(x)-1.9(citoto)4.3(xic)-359.1(s)2.8(eizures.)]TJ
8.2191 0 0 7.3052 457.2849 378.9353 Tm
-.0306 Tc
(99)Tj
10.959 0 0 10.959 469.077 374.0597 Tm
-.019 Tc
[(Sub)5.1(s)-1.6(eq)4.7(uen)4.7(t)-394.7(studies)]TJ
-14.4383 -1.1795 TD
-.0187 Tc
[(fur)3.9(t)-1.2(he)4.1(r)-394.5(e)-1(lab)5.4(o).2(ra)4.4(te)4.1(d)-393.7(t)-1.2(he)4.1(se)-394.2(ìn)5(dings)3.9(,)-395.6(su)4.7(gge)4.1(st)3.9(ing)-393.6(t)-1.2(h)5.3(a)-.7(t)-394.4(v)-.4(iru)4.7(s)-1.3(-)]TJ
ET
59.754 328.592 490.167 .28348 re
f
59.754 75.969 490.167 .22675 re
f
59.754 310.904 490.167 .28348 re
f
BT
/F5 1 Tf
8.9663 0 0 8.9663 59.7543 335.2818 Tm
0 Tc
[(Table)-306.5(2.)-500.5(Locations)-306.5(and)-295.7(Functions)-309.4(of)-302.7(Cannabinoid)-301.5(Receptors)]TJ
7.9702 0 0 7.9702 59.7543 317.1401 Tm
[(Receptors)-13253.8(Cell)-331.6(types)-328.8(vs.)-332.3(tissues/o)10.1(rgans)-17905.4(Function)]TJ
/F7 1 Tf
0 -2.1268 TD
(CB1)Tj
1.003 -1.1239 TD
[(Mainly)-292.5(in)-293.1(CNS)-11669.9(Hippocampu)9.2(s)-14507(Memory)-332.4(storage)]TJ
17.5125 -1.1239 TD
[(Hypothalam)9.9(us)-14257.7(Neuroendocrin)12.5(e)-332.2(release,)-327.9(thermal)-326.7(regulation,)-330.3(appetite)]TJ
T*
[(Cerebellum)-15505.8(Coordination)-326.8(of)-334.6(motor)-328.9(function)10.9(,)-336.5(posture,)-326(and)-334.7(balance)]TJ
T*
[(Cortex)-17578.8(Emesis)]TJ
T*
[(Basal)-295.5(ganglia)-14803.3(Movement)-322.2(control)]TJ
0 -1.131 TD
[(Spinal)-291(cord)-15590.8(Nociception)]TJ
-17.5125 -1.1239 TD
(Periphery)Tj
17.5125 -1.5009 TD
[(Immune)-324.7(cells)-14681.1(Anti-inflammat)10.6(ory)-333.5(effects)]TJ
0 -1.1239 TD
[(Cardiac)-295.9(cells)]TJ
T*
[(Testicular)-293.6(cells)]TJ
T*
[(Lung)-298.4(smooth)-294.3(muscle)-291.5(cells)-9367.6(Bronchodilation)]TJ
T*
[(Eye)-299.9(ciliary)-292.9(body)-13708(Intraocular)-331.3(pressure)]TJ
-18.5155 -1.1239 TD
(CB2)Tj
1.003 -1.131 TD
[(Mainly)-292.5(in)-293.1(periphery)-9369.9(Lymphoi)11.1(d)-334.3(tissues)-12978.6(Cell-mediated)-326.8(and)-327.6(innate)-325.1(immunity)]TJ
17.5125 -1.1239 TD
[(Macrophag)12.9(es)-14675.7(Anti-inflammat)10.6(ory)-333.5(effects)]TJ
T*
[(Splenocy)10.9(tes)]TJ
T*
(Microglia)Tj
T*
[(Monocyte)11.8(s)]TJ
T*
(Thymus)Tj
T*
(Spleen)Tj
0 -1.131 TD
[(Bone)-291.6(marrow)]TJ
0 -1.1239 TD
(Tonsils)Tj
-17.5125 -1.1239 TD
[(CNS)-15795.5(Microglia)-16463.8(Mediated)-326.1(anti-inflamma)11.8(tory)-331.6(activity)]TJ
17.5125 -1.1239 TD
[(Astrocyte)8.8(s)]TJ
-17.3845 -2.2406 TD
[(CNS,)-291.1(central)-300.1(nervous)-290.6(system.)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23783.5(5)]TJ
ET

endstream
endobj
92 0 obj
<</Length 20702>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 62.022 697.8896 Tm
0 0 0 rg
-.0181 Tc
0 Tw
[(med)5.3(i)-1.2(a)5(t)-.6(e)4.7(d)-253.4(CB)6.2(1)-253(o).8(v)5.4(e)-.4(r)4.5(e)-.4(xp)5.3(re)4.7(ss)4.5(io)]TJ
10.8326 0 TD
-.0213 Tc
[(n)-256.3(o)-2.4(n)-251.1(t)-3.8(he)-257.1(major)-257.4(h)-2.4(ippocampal)]TJ
-10.8326 -1.1847 TD
-.0191 Tc
[(ne)3.7(uro)5(n)-.6(s)-488(p)-.9(re)3.7(ve)3.7(nts)-493.2(s)3.5(eizure-)3.8(i)-2.2(n)4.6(duc)3.7(ed)-487.2(exc)3.7(i)-2.2(totox)4(i)-2.2(c)3.7(i)-2.2(ty)]TJ
8.2191 0 0 7.3052 268.611 689.7825 Tm
-.0237 Tc
[(10)7(0)]TJ
10.959 0 0 10.959 285.1653 684.9069 Tm
-.0208 Tc
(and)Tj
-20.3616 -1.1795 TD
-.0191 Tc
[(th)4.9(at)-224.1(2-)3.8(AG)-226.8(is)-224.1(a)-228.7(k)4.3(ey)-223.3(activator)-224.1(o)-.2(f)-224.7(C).6(B1,)-225.3(w).9(h)4.9(i)-2.2(c)3.7(h)-227.9(ev)4.4(entua)4(l)-1.9(ly)-228.4(me)3.7(-)]TJ
0 -1.1847 TD
-.0194 Tc
[(diates)-364.1(sei)-2.5(z)3.4(ure)-363.9(i)2.6(nhibition.)]TJ
8.2191 0 0 7.3052 165.9401 663.8738 Tm
-.0238 Tc
[(10)6.8(1)]TJ
10.959 0 0 10.959 181.1338 658.9983 Tm
-.0214 Tc
[(CB1)-370.1(a)1.7(goni)-4.5(st)-3.9(s)-366.1(h)-2.5(ave)-371(p)2(otenti)-4.5(al)]TJ
-10.8688 -1.1795 TD
-.0202 Tc
[(protection)-503.5(p)-2(roper)-2.8(t)2.4(ies,)-505.8(such)-498(as)-504.6(const)-2.7(r)2.4(aining)-503.7(exci)-3.3(totoxic)]TJ
0 -1.1847 TD
-.0198 Tc
[(neuro)4.3(t)-2.3(ransmission)-446.2(v)3.7(ia)-446.7(re)]TJ
9.8394 0 TD
-.0188 Tc
[(du)4.6(cing)-445.4(in)4.9(trac)4(ellular)-446.3(C)6.1(a)]TJ
8.2191 0 0 7.3052 269.4613 637.9652 Tm
0 Tc
(2)Tj
/F8 1 Tf
.6208 0 TD
(+)Tj
/F6 1 Tf
10.959 0 0 10.959 285.1653 633.0896 Tm
-.0208 Tc
(and)Tj
-20.3616 -1.1795 TD
[(decreasi)-4(ng)-302.7(presynapti)-4(c)-298.1(g)-2.6(lutamat)-3.4(e)-303.3(releas)-3.5(e.)]TJ
8.2191 0 0 7.3052 234.5952 625.0392 Tm
-.0306 Tc
(90)Tj
10.959 0 0 10.959 72.9637 607.2377 Tm
0 Tc
[(Ho)18.4(we)22.1(ve)20.4(r,)-147.4(d)13(i)0(r)18.7(e)0(c)19.8(t)-153.2(tr)19.4(ea)20.1(t)12.3(m)10.2(en)15.5(t)-153.2(w)14.8(it)18.8(h)-151.9(C)0(B)18.1(1)-152.1(ag)20.7(on)21.9(is)18.7(ts)-146.2(i)11.7(s)-153.3(li)18.5(m)10.2(i)11.7(te)19.6(d)]TJ
-.9984 -1.1847 TD
[(be)21(ca)20.1(us)20.1(e)-163.4(o)13.7(f)-159.1(t)0(h)20.8(e)-163.4(p)13(s)0(y)20.2(c)0(h)21(o)0(a)21.3(c)0(t)19.6(i)0(v)19.6(e)-163.4(s)12.2(i)11.7(de)-150.4(ef)19(f)11.6(e)0(c)19.8(t)0(s)-151.4(i)11.7(m)10.2(p)0(l)19.9(i)0(c)19(a)0(t)19.9(e)0(d)-150.4(i)11.7(n)-162.6(C)14.5(B1)]TJ
0 -1.1795 TD
[(ac)20.1(ti)18.8(v)13.1(a)0(t)19.9(i)0(o)20.2(n)0(,)-348.1(i)11.7(nc)20.6(lu)19.9(di)19.5(ng)-346(s)12.2(e)0(n)20.6(s)0(o)15.6(r)12.2(i)11.7(m)10.2(ot)20.8(or)20.8(,)-356.2(a)0(n)21(d)-354.3(ne)15.5(u)13(r)0(o)20.8(c)0(o)21(g)0(n)16.1(i)11.7(t)12.3(i)0(v)19.6(e)]TJ
0 -1.1847 TD
[(i)11.7(m)10.2(ba)21.3(la)19.7(nc)15.5(e)12.5(s)12.2(.)]TJ
8.2191 0 0 7.3052 111.7984 573.2219 Tm
-.0169 Tc
(85)Tj
10.959 0 0 10.959 123.7039 568.3463 Tm
0 Tc
[(Th)17.2(e)-375.5(p)0(r)20.1(o)0(t)20.8(e)0(c)19.8(t)0(i)18.8(v)0(e)-372.7(e)12.5(f)11.7(f)0(e)19(c)0(t)-373.5(o)13.7(f)-381.5(C)0(B)23.3(1)-379.7(ag)20.7(on)16.7(i)11.7(s)12.2(ts)-373.8(i)11.7(n)]TJ
-5.6284 -1.1795 TD
[(t)12.3(h)0(e)-211.8(m)10.2(o)13.7(d)0(e)20.3(l)0(s)-208.5(o)0(f)-207.4(n)0(e)20.6(u)0(r)20.1(o)0(d)21.6(e)0(g)15.2(e)12.5(ne)20.6(ra)19.8(ti)18.8(on)-205.7(su)20.1(gg)21(es)19.5(ts)-208.3(th)20.8(e)-220.3(p)13(os)20.8(si)18.7(bi)20.2(l)12(i)0(t)18.8(y)]TJ
0 -1.1847 TD
[(of)-197.1(a)-209.6(p)0(r)20.1(o)0(t)20.8(e)0(c)19.8(t)0(i)18.8(v)0(e)-196.9(e)0(f)19(f)0(e)19(c)0(t)-197.7(a)0(g)20.7(a)0(i)19.3(n)0(s)20.4(t)-210.1(HA)19.2(ND)24.7(.)-211.4(A)0(s)-200.9(a)-209.6(r)12.2(e)12.5(su)14.9(l)12(t)12.3(,)-211.4(C)0(B)23.3(1)-209(ac)20.1(-)]TJ
0 -1.1795 TD
-.0199 Tc
[(t)-7.6(i)-19.9(va)-19.9(ti)-19.9(on)-368.7(r)-7.7(e)-19.9(gu)-19.9(la)-19.9(te)-19.9(s)-357.3(H)-19.9(IV)-367.9(T)-6(a)-19.9(t)-356.9(p)-19.9(ro)-19.9(te)-19.9(in)-19.9(-i)-19.9(nd)-19.9(uc)-19.9(ed)-369(c)-7.4(h)-19.9(an)-6.6(g)-19.9(e).5(s)-369.8(i)-8.2(n)]TJ
0 -1.1847 TD
0 Tc
[(ne)20.6(tw)22(or)20.8(k)-219.7(e)0(x)20.1(c)0(i)19(t)0(a)19.9(b)0(i)20.2(l)12(it)18.8(y.)-208.6(In)-212.4(a)12.8(n)]TJ
/F10 1 Tf
10.3619 0 TD
[(in)-212.9(v)12.8(i)11.3(tr)19.3(o)]TJ
/F6 1 Tf
3.0315 0 TD
[(st)19.4(ud)20.9(y,)-208.6(HI)17(V)-218.7(n)0(e)20.6(u)0(r)20.1(o)0(t)20.8(o)0(x)21.3(-)]TJ
-13.3933 -1.1795 TD
[(i)11.7(c)0(i)19(t)0(y)-362.6(m)10.2(o)13.7(d)0(e)20.3(l)-370.8(de)20.3(m)10.2(o)0(n)21.9(s)0(t)19.3(r)0(a)19.8(t)0(e)19.6(d)-369.8(t)12.3(h)0(a)16.1(t)-365.3(AE)17.8(A)-368.3(a)0(n)21(d)-369.8(2-)20.8(AG)-358.7(re)19.5(du)15.7(c)12.5(e)]TJ
T*
[(Ta)21.5(t-)19.7(in)19.8(du)20.9(ce)19.8(d)-468.1(i)11.7(nt)20.5(ra)19.8(ce)19.8(l)12(l)0(u)19.9(l)0(a)19.7(r)-463.7(Ca)]TJ
8.2191 0 0 7.3052 187.937 495.4959 Tm
(2)Tj
/F8 1 Tf
.6277 0 TD
(+)Tj
/F6 1 Tf
10.959 0 0 10.959 204.0944 490.677 Tm
[(le)19.4(ve)20.4(ls)-456.8(a)12.8(n)0(d)-454.7(a)0(u)20.7(g)0(m)18.1(e)12.5(nt)20.5(ed)]TJ
-12.964 -1.1847 TD
[(ne)20.6(ur)20.1(on)16.7(a)12.8(l)-262.1(s)12.2(u)0(r)20.1(v)0(i)19.6(v)0(a)20.7(l)0(;)-251.1(t)0(h)20.8(e)-261.7(CB)18.1(1)-260.8(i)11.7(nv)21.3(er)19.5(se)-254.6(a)12.8(g)0(o)21.7(n)0(i)19.8(s)0(t)19.4(,)-263.1(r)12.2(i)0(m)21.8(o)0(n)16.7(a)12.8(ba)21.3(nt)20.5(,)]TJ
0 -1.1795 TD
[(pr)20.1(oh)22.2(ib)20.2(it)18.8(s)-230.9(t)0(h)20.8(e)-230.6(ca)20.1(nn)16.3(a)12.8(b)0(i)20.2(n)0(o)21.9(i)0(d)19.5(-)0(m)17.6(e)12.5(di)19.5(at)19.9(ed)-222.8(n)13.3(e)0(u)15.2(r)12.2(op)21.6(ro)20.8(te)19.6(ct)19.6(i)11.7(o)0(n)16.7(.)]TJ
8.2191 0 0 7.3052 289.5306 469.644 Tm
[(10)26.8(2)]TJ
10.959 0 0 10.959 62.022 451.7857 Tm
[(Al)21.3(th)20.8(ou)21.6(gh)-485.4(t)12.3(h)0(i)20.2(s)-494.7(CB)23.3(1-)20.8(m)10.2(e)0(d)20.3(i)0(a)19.3(t)0(e)19.6(d)-493.9(ne)20.6(ur)20.1(op)21.6(ro)15.6(t)12.3(e)12.5(ct)19.6(iv)19.6(e)-494.5(m)10.2(e)12.5(c)0(h)15.8(a)12.8(-)]TJ
T*
[(ni)19.8(sm)-329.4(i)11.7(s)-344.7(u)13(n)0(k)21.2(n)0(o)16.7(w)14.8(n,)-332.5(t)12.3(h)0(i)20.2(s)-339.6(st)19.3(ud)15.7(y)-338.7(s)12.2(ug)21(ge)20.4(st)19.3(s)-339.6(t)0(h)20.8(a)0(t)-331.9(a)12.8(ug)15.8(m)15.3(e)0(n)15.5(t)12.3(i)11.7(n)0(g)]TJ
0 -1.1847 TD
[(ca)20.1(nn)21.5(ab)16.2(i)11.7(n)0(o)21.9(i)11.7(d)-292.2(s)0(i)18.7(g)13.1(na)15.8(l)12(i)11.7(ng)-278.8(m)10.2(a)0(y)-279.3(b)0(e)-284.2(b)13.7(en)20.6(eì)21(ci)19(al)-280.4(to)-279.2(HA)19.2(ND)24.7(.)]TJ
.9984 -1.1795 TD
-.013 Tc
[(T)-13(a)8.5(rgeting)-268.9(C)1.5(B)-13(1)-254.6(for)-269.8(t)-.7(he)-264.3(tr)-13(e)6.5(a)-.2(tmen)-13(t)-256.4(o).7(f)-270.4(H)2.1(AN)-13(D)-257.3(a)-.2(nd)-269(other)]TJ
-.9984 -1.1847 TD
-.0125 Tc
[(neu)-12.5(r)7.6(odeg)-12.5(e)7.9(n).8(erative)-682.9(d).5(isord)-12.5(e)7.8(rs)-678(in)-12.5(v)8.8(o)1.2(lves)-683.1(several)-683.3(c)0(ritical)]TJ
0 -1.1795 TD
0 Tc
[(c)12.5(o)13.7(ns)20.4(i)11.7(d)13(e)12.5(r)12.2(a)12.8(t)12.3(i)11.7(o)13.7(ns)20.4(.)-661.4(A)-663.2(CB)23.3(1)-664.3(a)12.8(g)13.1(o)13.7(ni)19.8(s)12.2(t)12.3(ê)11.1(s)-660.3(t)12.3(h)0(e)21(r)12.2(a)12.8(p)13(e)12.5(u)0(t)20.2(i)11.7(c)-660(p)0(o)21.6(t)12.3(e)12.5(n)13.3(-)]TJ
0 -1.1847 TD
-.0123 Tc
[(tial)-305.5(is)-300.1(limited)-304.5(t)0(o)-303.8(i)4.6(ts)-305.3(ad)-12.3(v)8.7(e).2(rse)-305(effects,)-306.4(such)-303.8(as)-305.3(moto)-12.3(r)-291.6(s)-.1(lo)-12.3(w)11.1(-)]TJ
0 -1.1795 TD
-.0128 Tc
(ing,)Tj
8.2191 0 0 7.3052 77.6693 366.0094 Tm
0 Tc
[(16)26.8(,)18(1)16.9(9,)27.9(1)16.9(0)16.9(3)]TJ
10.959 0 0 10.959 111.2315 361.1338 Tm
-.0126 Tc
[(due)-320.8(to)-319.6(C)-12.6(B)10.7(1)-319.9(a).2(c)-12.6(t)7(ivation)-320(m)-2.4(ostly)-320.2(m)-2.4(ediating)-325.4(the)]TJ
-4.4903 -1.1795 TD
0 Tc
[(p)13(s)12.2(yc)20.4(h)13.7(o)13.7(a)12.8(c)12.5(t)12.3(i)11.7(v)0(e)-662.4(p)0(r)20.1(o)13.7(p)13(e)12.5(r)12.2(t)12.3(i)11.7(e)12.5(s)-675.8(o)13.7(f)-676.4(e)12.5(x)12.8(o)0(g)21.6(e)12.5(n)13.3(o)13.7(us)-662.8(ca)20.1(n)13.3(n)13.3(a)12.8(bi)25.4(no)21.9(i)11.7(d)13(s)12.2(.)]TJ
0 -1.1847 TD
[(M)10.7(o)13.7(r)12.2(e)12.5(o)13.7(v)13.1(er)19.5(,)-402.8(c)12.5(a)12.8(n)0(n)21.5(a)12.8(b)13.7(i)11.7(no)21.9(i)11.7(d)13(s)-406.8(h)13.7(a)12.8(v)13.1(e)-406.5(b)13.7(e)12.5(e)12.5(n)-405.7(s)12.2(h)13.7(ow)23.4(n)-405.7(t)12.3(o)-405.3(d)13(a)12.8(m)10.2(p)13(e)12.5(n)]TJ
0 -1.1795 TD
-.0126 Tc
[(cog)-12.6(n)8.7(itive)-977.8(f)-1(unction)-12.6(s)7.8(,)-974.1(p)-12.6(a)8(r)-.4(ticularly)-977.2(i)-.9(nhib)-12.6(i)7.6(t)-.3(ing)-977.2(s)-.4(hort-)]TJ
0 -1.1847 TD
-.0121 Tc
[(term)-353.7(memory,)]TJ
8.2191 0 0 7.3052 124.4409 314.192 Tm
-.0169 Tc
(104)Tj
10.959 0 0 10.959 139.748 309.3164 Tm
-.0131 Tc
[(wh)-13.1(i)7.1(c)-.6(h)-351.2(i)-1.4(s)-357.8(a)-.3(n)-356.7(i)-1.4(mpe)-13.1(r)6.4(ative)-357.6(c)-.6(onside)-13.1(r)6.4(a)-.3(tion)]TJ
-7.0924 -1.1795 TD
-.0127 Tc
[(wh)-12.7(e)8.3(n)-206.3(the)-202(t)-.4(h)-12.7(e)8.3(rapeutic)-207.1(aims)-202.2(to)-205.9(avoid)-206.6(c)-.2(ogn)-12.7(i)7.1(tive)-202(slow)-12.7(.)-193.7(I)-.4(n)-206.3(a).1(d-)]TJ
0 -1.1847 TD
0 Tc
[(d)13(i)11.7(t)12.3(i)11.7(o)13.7(n)0(,)-353.2(c)12.5(h)13.7(r)12.2(on)21.9(i)11.7(c)12.5(a)12.8(l)12(l)12(y)-359.4(t)12.3(a)12.8(ki)19.6(n)13.3(g)-359.4(c)12.5(a)0(n)21(n)13.3(a)12.8(b)13.7(i)11.7(s)-365.4(c)12.5(o)13.7(u)13(l)12(d)-364.6(a)12.8(l)12(s)12.2(o)-358.7(r)12.2(es)19.5(u)13(l)12(t)-360.2(i)11.7(n)]TJ
0 -1.1795 TD
[(d)13(e)12.5(pe)20.3(n)13.3(d)13(e)12.5(n)0(c)20.6(e)12.5(.)]TJ
8.2191 0 0 7.3052 114.7464 275.3574 Tm
-.0169 Tc
[(105Ö)-16.9(1)13.3(0)0(7)]TJ
10.959 0 0 10.959 147.9118 270.4818 Tm
0 Tc
[(Th)22.4(e)12.5(r)12.2(e)12.5(f)11.7(o)13.7(r)12.2(e,)-550.7(a)12.8(l)12(t)12.3(h)13.7(ou)21.6(g)13.1(h)-560.5(C)14.5(B)0(1)-546.9(a)12.8(go)21.7(n)13.3(i)11.7(s)12.2(t)12.3(s)]TJ
-7.8374 -1.1847 TD
-.0126 Tc
[(hav)-12.6(e)-312.9(ne)-12.6(u)7.7(r)-.4(opro)-12.6(t)8.2(ective)-326(e)-.1(ffects)-321.1(a)-12.6(n)8.4(d)-325.5(can)-325.2(d).4(ecrease)-326(neu)-12.6(r)7.5(onal)]TJ
0 -1.1795 TD
[(injur)-12.5(y)-401(in)-407.8(n)-12.5(e)8.1(urode)-12.5(g)7.9(enerativ)-12.5(e)-400.8(d).5(isease)-12.5(s)-401.6(r)-.3(elated)-413.3(to)-407.5(an)-12.5(i)12.5(m)-2.3(al)]TJ
T*
[(model,)-363.5(th)-12.5(e)8.5(i)-.8(r)-362.4(a).3(dve)-12.5(r)7(se)-362.1(effects)-367.6(h)1.2(ave)-367.3(s)-.3(timulate)-12.5(d)-354.3(i)-.8(ntere)-12.5(s)7(t)-362.3(i)-.8(n)]TJ
0 -1.1847 TD
[(oth)-12.7(e)8.3(r)-471.2(E).9(CS)-470.7(co)-12.7(m)11.2(p).3(o)-12.7(n)9.2(ents.)-472.4(A)-12.7(l)8.6(t)-.4(ernatively,)-472.4(r)-.5(eg)-12.7(u)8.3(l)-.7(ating)-470.4(C)-12.7(B)10.6(2)]TJ
0 -1.1795 TD
-.0134 Tc
[(and)-491.8(s)-1.2(lacken)-13.4(i)6.4(n)-.1(g)-486.6(e)-.9(n)-13.4(d)7.8(ocan)-13.4(n)8.1(a)-.6(bino)-13.4(i)6.8(d)-486.6(me)-13.4(t)6.2(a)-.6(bol)-13.4(ism)-489.5(m)-3.2(a)-13.4(y)-478.9(b)-13.4(e)]TJ
0 -1.1847 TD
0 Tc
[(pr)20.1(om)18.7(i)11.7(s)12.2(in)19.8(g)-292.1(t)12.3(re)19.5(at)19.9(m)10.2(e)0(n)20.6(t)0(s)-280.7(w)0(i)21.3(t)0(h)-279.2(d)0(e)20.3(c)0(r)19.5(e)0(a)20.1(s)0(e)19.5(d)-292.2(s)12.2(i)0(d)19.5(e)-292.7(e)12.5(f)0(f)18.1(e)0(c)19.8(t)0(s)19.4(.)]TJ
.9984 -1.1795 TD
[(CB)18.1(2)-183.2(r)0(e)19.5(c)0(e)19.8(p)0(t)20.2(o)0(r)20.8(s)-189.5(a)12.8(r)12.2(e)-189.3(m)10.2(o)13.7(s)0(t)19.3(l)0(y)-176.6(l)12(oc)21(at)19.9(ed)-176.2(i)11.7(n)-188.4(i)11.7(m)10.2(m)10.2(u)0(n)21.2(e)-189.3(c)12.5(e)0(l)19.3(l)12(s)-189.5(a)12.8(nd)21.2(,)]TJ
-.9984 -1.1847 TD
[(on)21.9(ce)-352.7(ac)20.1(ti)18.8(v)13.1(a)0(t)19.9(e)0(d)20.3(,)-366.6(t)12.3(h)0(e)21(y)-359.4(ca)20.1(n)-364.3(r)12.2(eg)20.4(ul)19.9(at)19.9(e)-360(t)0(h)20.8(e)-365.1(m)10.2(i)11.7(gr)20.2(a)12.8(t)0(i)18.8(o)0(n)-350.6(o)0(f)-352.3(i)11.7(m)10.2(-)]TJ
0 -1.1795 TD
[(m)10.2(u)0(n)21.2(e)-173.7(c)12.5(e)0(l)19.3(l)12(s)-174(a)12.8(nd)-165(t)12.3(h)0(e)-160.1(r)12.2(el)19.3(ea)20.1(se)-161.5(of)-160.9(cy)20.4(to)20.8(ki)19.6(ne)20.6(s)-174(i)11.7(ns)20.4(i)11.7(d)0(e)-160.7(a)0(n)15.8(d)-168(ou)21.6(ts)19.4(id)19.5(e)]TJ
0 -1.1847 TD
[(t)12.3(h)0(e)-423.9(b)0(r)20.8(a)0(i)19.3(n)-431.6(\(T)20.7(ab)21.3(le)-425.5(2)13.4(\))0(.)]TJ
8.2191 0 0 7.3052 150.8598 145.8141 Tm
(90)Tj
10.959 0 0 10.959 163.7858 140.9385 Tm
[(Ev)16.4(i)11.7(d)0(e)20.3(n)0(c)20.6(e)-473.8(ha)21.3(s)-474.1(s)12.2(ho)17(w)14.8(n)-472.9(th)20.8(at)-461.2(CB)18.1(2)]TJ
-9.2858 -1.1795 TD
[(co)21(ul)19.9(d)-281.8(b)0(e)-273.8(e)0(x)20.1(p)0(r)20.1(e)0(s)19.5(s)0(e)19.5(d)-287(b)13.7(y)-281.8(so)20.8(m)10.2(e)-287.6(n)13.3(e)0(u)20.3(r)0(o)20.8(n)0(s)20.4(,)-283.8(bu)16.4(t)-282.6(i)11.7(t)12.3(s)-287.8(p)13(h)0(y)21.6(s)0(i)18.7(o)0(l)20.6(o)0(g)21.6(-)]TJ
0 -1.1847 TD
[(i)11.7(c)0(a)20.1(l)-319(m)10.2(e)12.5(ch)21(an)15.8(i)11.7(s)12.2(m)-315.8(r)0(e)19.5(m)10.2(ai)19.3(ns)-305.5(ob)22.3(sc)19.5(ur)20.1(e.)]TJ
8.2191 0 0 7.3052 206.022 119.9055 Tm
(83)Tj
10.959 0 0 10.959 217.2472 115.0299 Tm
[(It)-306.5(is)-307.2(co)21(m)10.2(m)10.2(o)0(n)21.9(l)0(y)-305.9(b)0(e)21(-)]TJ
-14.1641 -1.1795 TD
[(l)12(i)0(e)19(v)0(e)20.4(d)-375(th)20.8(at)-362.9(CB)18.1(2)-374.6(a)12.8(ct)19.6(i)11.7(v)0(a)20.7(t)0(i)18.8(o)0(n)-366.1(a)12.8(ff)18.1(e)12.5(c)0(t)19.6(s)-375.8(t)12.3(h)0(e)-367(i)11.7(m)10.2(m)10.2(u)0(n)21.2(e)-375.5(s)12.2(y)0(s)20.2(t)0(e)19.6(m)10.2(,)]TJ
T*
[(bu)21.6(t)-189.5(C)0(B)18.1(2)-188.3(a)12.8(c)0(t)19.6(i)0(v)19.6(a)0(t)19.9(i)0(o)20.2(n)-188.4(do)16.4(e)12.5(s)-189.5(no)21.9(t)-189.5(p)0(r)14.9(o)13.7(du)20.9(ce)-181.9(s)12.2(t)0(r)19.4(o)0(n)16.7(g)-188.6(p)13(s)0(y)20.2(c)0(h)21(o)0(a)16.2(c)12.5(t)12.3(i)0(v)19.6(-)]TJ
0 -1.1847 TD
[(i)11.7(t)0(y)-181.5(b)0(e)21(c)0(a)20.1(u)0(s)14.9(e)-189.3(t)12.3(h)0(e)-180.8(e)0(x)20.1(p)0(r)14.9(e)12.5(ss)19.3(i)11.7(o)0(n)-179.9(o)0(f)-181.6(C)0(B)18.1(2)-188.3(in)-181.9(ne)20.6(ur)20.1(on)16.7(s)-189.5(i)11.7(s)-194.7(l)12(im)21.8(it)18.8(ed)20.3(.)]TJ
8.2191 0 0 7.3052 293.3857 81.0708 Tm
-.0168 Tc
(89)Tj
10.959 0 0 10.959 62.022 63.2692 Tm
0 Tc
[(CB)18.1(2)-209(a)0(g)15.6(o)13.7(ni)19.8(st)19.4(s)-215.4(a)12.8(re)-208.1(p)13(r)0(e)19.5(f)0(e)19(r)12.2(en)15.5(t)12.3(i)11.7(al)19.7(ly)-202.5(ef)19(fe)19(ct)19.6(i)11.7(v)0(e)-207.2(i)11.7(n)-214.3(i)0(n)19.8(î)0(a)21.3(m)10.2(m)10.2(a)0(t)19.9(o)0(r)20.8(y)]TJ
22.9068 57.9085 TD
[(st)19.3(at)19.9(es)-316.7(s)12.2(i)0(n)19.8(c)0(e)-316.4(r)0(e)19.5(c)0(e)19.8(p)0(t)20.1(o)0(r)-315.5(e)0(x)20.1(p)0(r)20.1(e)0(s)19.5(s)0(i)18.7(o)0(n)-314.4(i)11.7(s)-329.2(i)11.7(m)10.2(m)10.2(u)13(ne)-315.6(ce)19.8(ll)18.9(-)12.6(s)0(p)14.9(e)12.5(ci)19(ìc)]TJ
0 -1.1847 TD
-.0196 Tc
[(a)-19.6(n)-3.8(d)-265.2(s)-19.6(ta)-19.6(te)-19.6(-d)-19.6(ep)-19.6(en)-19.6(de)-7.1(n)-19.6(t).9(,)-267.2(C)-19.6(B2)-270(c)-7.1(a)-19.6(n)-257.3(i)-19.6(nh)-19.6(ib)-19.6(it)-271.1(t)-7.3(h)-19.6(e)-257.3(d)-19.6(el)-19.6(et)-19.6(er)-19.6(io)-19.6(us)-271.2(e)-7.1(f)-19.6(-)]TJ
0 -1.1795 TD
0 Tc
[(fe)19(ct)19.6(s)-293(o)13.7(f)-293.6(i)11.7(m)10.2(m)10.2(u)13(ne)-284.6(a)12.8(c)0(t)19.6(i)11.7(va)20.7(ti)18.8(on)-278.2(in)-280.2(th)20.8(e)-292.7(C)0(N)18.9(S)12.8(.)]TJ
1.0036 -1.1847 TD
-.0201 Tc
[(C)-20.1(h)2.9(ro)4(nic)-193.8(i)1.9(nîammatio)4(n)-193(is)-188.9(associated)-193.3(with)-192.7(increasing)-188.1(nu-)]TJ
-1.0036 -1.1795 TD
-.0189 Tc
[(mero)5.2(us)-342.9(neurodegen)4.8(erativ)4.6(e)-342.7(d)-.7(is)]TJ
11.6345 0 TD
-.0202 Tc
[(orders.)-340.2(F)-2(or)-344.2(instance,)-345.4(r)-2.8(eac-)]TJ
-11.6345 -1.1847 TD
-.0182 Tc
[(tive)-460.9(oxy)5.3(g).1(e)4.6(n)-465.3(sp)5.2(ec)4.6(ie)4.6(s)-466.4(\()4.1(ROS\))]TJ
10.962 0 TD
-.0204 Tc
[(produced)-467.8(by)-462.5(microglia)-462.8(c)-2.7(an)]TJ
-10.962 -1.1795 TD
-.0193 Tc
[(damage)-327.5(n)4.4(e)-1.6(urons)-322.6(i)-2.4(n)-326.7(A).4(lzheimerês)-322.6(disease)-322.4(a)-1.3(nd)-327(P)4.7(a)-1.3(rkin)4.4(so)4.8(nês)]TJ
T*
-.0202 Tc
(disease.)Tj
8.2191 0 0 7.3052 344.1826 612.0565 Tm
-.0307 Tc
[(10)-7(8)]TJ
10.959 0 0 10.959 360.0566 607.2377 Tm
-.0196 Tc
[(Proinî)4.4(ammatory)-430.7(cy)3.9(to)4.5(kines)-426.4(c)-1.9(an)-425.3(also)-430.1(d)3.8(i)-2.7(rectly)]TJ
-4.2886 -1.1847 TD
-.0193 Tc
[(damage)-332.7(n)4.4(e)-1.6(urons)-327.8(a)-1.3(nd)-332.2(syn)4.4(a)-1.3(ptic)]TJ
11.9707 0 TD
-.02 Tc
[(dendrites)-333.7(t)2.6(hrough)-332.2(excito-)]TJ
-11.9707 -1.1795 TD
-.0182 Tc
[(tox)4.9(i)-1.3(c)4.6(i)-1.3(t)4.4(y)]TJ
8.2191 0 0 7.3052 343.8424 586.2046 Tm
-.0306 Tc
[(10)-6.8(9)]TJ
10.959 0 0 10.959 359.8298 581.329 Tm
-.0215 Tc
[(or)-443.8(i)-4.6(n)2.2(dir)-4.1(e)-3.8(ct)-4(ly)-442.9(acti)-4.6(vat)-4(e)-438.4(i)-4.6(mmune)-443.6(cel)-4.3(l).9(s.)]TJ
8.2191 0 0 7.3052 514.0912 586.2046 Tm
-.0306 Tc
[(11)-6.8(0)-6.9(,)-5.7(11)-6.9(1)]TJ
10.959 0 0 10.959 542.8345 581.329 Tm
-.0226 Tc
(In)Tj
-20.9669 -1.1847 TD
-.0194 Tc
[(some)-581.1(d)4(i)-2.5(sease)-581.1(m)1.1(odels,)-582.5(CB)4.9(2)-585.4(a)3.7(ctiv)4.1(atio)4.7(n)-585.5(c)3.4(an)-580.3(co)4.7(unteract)]TJ
0 -1.1795 TD
-.0198 Tc
[(neuroinî)4.2(ammation.)-200.1(C)-.1(B2)-197.8(activation)-197.9(represents)-204.2(an)-203(enco)4.3(ur-)]TJ
0 -1.1847 TD
-.0189 Tc
[(aging)-321.4(t)-1.4(h)5.1(e)-1.2(rape)3.9(utic)-322(ta)4.3(rg)4.6(et)-322.2(th)5.1(at)-322.2(is)-327.4(inv)4.6(o)0(lved)-321.4(in)-321.1(ne)3.9(uroprotec-)]TJ
0 -1.1795 TD
-.0204 Tc
[(tion)-586.5(mechanisms,)-588.7(s)2.2(uch)-586.1(a)-2.4(s)-582.4(r)-3(educing)-586.7(p)-2.2(roinîammatory)]TJ
0 -1.1847 TD
-.0191 Tc
[(cytok)4.3(i)-2.2(ne)3.7(s)]TJ
8.2191 0 0 7.3052 352.1763 521.4046 Tm
-.0306 Tc
[(11)-6.9(2)]TJ
10.959 0 0 10.959 368.5605 516.529 Tm
-.018 Tc
[(an)5.7(d)-480.9(R)1.1(O)7.1(S)-.1(,)]TJ
8.2191 0 0 7.3052 411.0235 521.4046 Tm
-.0238 Tc
(113)Tj
10.959 0 0 10.959 427.4644 516.529 Tm
-.0196 Tc
[(increa)3.5(sing)-477.2(an)4.1(ti-inîa)3.6(mmatory)]TJ
-10.4395 -1.1795 TD
-.0187 Tc
[(cytok)4.7(i)-1.8(ne)4.1(s,)]TJ
8.2191 0 0 7.3052 354.3306 508.4786 Tm
-.0238 Tc
(90)Tj
10.959 0 0 10.959 364.3085 503.603 Tm
-.0209 Tc
[(impedi)-4(ng)-235.4(chemotaxis)-236.3(to)-234.8(vari)-4(ous)-231.1(c)-3.2(hemokines,)]TJ
-4.6765 -1.1795 TD
-.0203 Tc
[(and)-297(t)-2.8(ransf)-3.5(o)3.8(rming)-302.1(m).2(icrogl)]TJ
9.9532 0 TD
-.0211 Tc
[(ia)-303.2(from)-300.6(proi)-4.2(nîammatory.)]TJ
8.2191 0 0 7.3052 530.5889 495.4959 Tm
-.0306 Tc
[(11)-6.9(4)]TJ
10.959 0 0 10.959 324.0566 477.6943 Tm
0 Tc
[(This)-274.4(extensive)-280.3(effect)-278.7(of)-279.9(CB2)-278.9(agonists)-276.3(can)-276.9(well)-279.7(coun-)]TJ
-1.0036 -1.1795 TD
[(teract)-391(a)-385.5(major)-384(source)-389.4(of)-383.3(neuroinîammatory)-389.1(damage.)]TJ
0 -1.1847 TD
[(Indeed,)-398.6(CB2)-392.7(agonists)-390.1(can)-395.9(decrease)-396.4(neurotoxicity)-388.7(and)]TJ
0 -1.1795 TD
[(cognitive)-662.1(impairment)-656.2(in)-657.8(Alzheimerês)-656.5(disease,)]TJ
8.2191 0 0 7.3052 526.7338 443.7353 Tm
(115,116)Tj
10.959 0 0 10.959 313.0582 425.877 Tm
[(Parkinsonês)-414.2(disease,)]TJ
8.2191 0 0 7.3052 401.2723 430.7527 Tm
(115,117)Tj
10.959 0 0 10.959 431.2629 425.877 Tm
[(Huntingtonês)-409.4(disease,)]TJ
8.2191 0 0 7.3052 526.7338 430.7527 Tm
(115,118)Tj
10.959 0 0 10.959 313.0582 412.9511 Tm
-.0197 Tc
[(and)-327.4(m).8(ultiple)-333.1(s)2.9(clero)4.4(s)-2.3(is)]TJ
8.2191 0 0 7.3052 405.0141 417.8267 Tm
-.0238 Tc
[(1)6.8(15,)8(119)]TJ
/F10 1 Tf
10.959 0 0 10.959 432.5101 412.9511 Tm
-.0173 Tc
[(in)-324.4(vi)4.4(tr)5.3(o)]TJ
/F6 1 Tf
3.166 0 TD
-.0209 Tc
(and)Tj
/F10 1 Tf
1.7692 0 TD
[(in)-333.1(vi)-4.4(vo)]TJ
/F6 1 Tf
2.9539 0 TD
-.017 Tc
[(\(F)6.4(ig)6.5(.)-331.8(1)6.8(\).)]TJ
-18.789 -1.1847 TD
0 Tc
[(T)-6.8(hus,)-576(CB2)-568.6(ago)-6.9(nist)-7.4(s)-572.3(could)-577.2(poten)-7.6(tial)-8.1(ly)-569.8(tr)-6.5(eat)-572.9(a)-571.8(wide)]TJ
0 -1.1795 TD
[(ran)-8.2(ge)-755.6(of)-750.6(neu)-7.7(rodeg)-7.9(ene)-8.2(rati)-7.9(ve)-750.4(dis)-9.6(eases)-755.1(by)-754.3(ta)-5.9(rgeting)]TJ
ET
1 i 
q 1 0 0 1 313.058 365.329 cm 0 0 m
.113 1.02 l
.671 3.657 2.352 5.338 4.989 5.896 c
6.009 5.953 l
6.009 4.989 l
5.159 4.932 l
3.117 4.572 1.438 2.893 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 546.236 371.282 cm 0 0 m
1.02 -.057 l
3.385 -.504 5.556 -2.479 5.839 -4.932 c
5.953 -5.953 l
4.932 -5.953 l
4.876 -5.102 l
4.613 -3.125 2.783 -1.327 .85 -1.02 c
0 -.964 l
f*
Q
319.068 370.318 227.168 .96378 re
f
q 1 0 0 1 319.068 63.213 cm 0 0 m
-1.02 .113 l
-3.628 .575 -5.318 2.396 -5.896 4.932 c
-6.009 6.009 l
-4.989 6.009 l
-4.932 5.159 l
-4.572 3.117 -2.893 1.438 -.85 1.077 c
0 1.02 l
f*
Q
q 1 0 0 1 552.189 69.222 cm 0 0 m
-.113 -1.077 l
-.441 -3.505 -2.579 -5.451 -4.932 -5.896 c
-5.953 -6.009 l
-5.953 -4.989 l
-5.102 -4.932 l
-2.979 -4.46 -1.462 -3.042 -1.077 -.85 c
-1.02 0 l
f*
Q
319.068 63.213 227.168 1.0205 re
f
313.058 69.222 1.0205 296.107 re
f
551.168 69.222 1.0204 296.107 re
f
q
213.077 0 0 197.461 330.009 163.899 cm
/Im2 Do
Q
BT
/F5 1 Tf
9.9626 0 0 9.9626 330.0093 145.9275 Tm
[(FIG)-7.2(.)-330.4(1)0(.)]TJ
/F7 1 Tf
3.8753 0 TD
[(Alterations)-313.5(in)-300.2(the)-304.7(ECS)-305.1(elements)-306(in)]TJ
-3.8753 -1.2974 TD
[(neur)-8.4(ocognitiv)-11.7(e)-296.7(dise)-9.8(ases.)-304.5(Main)-305.2(ìndings)]TJ
0 -1.3031 TD
[(con)-7.8(cerning)-305.8(in)-300.2(mem)-7.8(bers)-303.7(of)-306.1(the)-299(EC)-8.8(S)-296.3(i)0(n)-305.9(HIV-)]TJ
0 -1.2974 TD
[(associ)-12.1(ated)-305.1(neuroco)-10.1(gnitive)-306.6(disorders)-13.1(,)-298.1(Alzhei)-8.3(merês)]TJ
0 -1.3031 TD
[(disea)-8.8(se,)-302.2(Huntin)-9.9(gtonês)-309(disease,)-305.2(and)-307.6(Parkin)-8.2(sonês)]TJ
0 -1.2974 TD
[(disea)-8.8(se.)-302.2(ECS,)-307.3(endoca)-8.9(nnabinoi)-8.5(d)-303(system.)]TJ
/F5 1 Tf
-26.8992 67.5696 TD
(6)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
94 0 obj
<</ColorSpace/DeviceGray/Subtype/Image/Height 412/Filter/DCTDecode/Type/XObject/Width 444/Length 34378/BitsPerComponent 8>>stream
ˇÿˇÓ Adobe dÄ    ˇ€ C 		



ˇ¿ úº ˇƒ “            	
 s !1AQa"qÅ2ë°±B#¡R—·3b$rÇÒ%C4Sí¢≤cs¬5D'ì£≥6Tdt√“‚&É	
ÑîEF§¥V”U(Ú„Ûƒ‘‰ÙeuÖï•µ≈’ÂıfvÜñ¶∂∆÷Êˆ7GWgwáóß∑«◊Á˜8HXhxàò®∏»ÿË¯)9IYiyâô©π…ŸÈ˘*:JZjzäö™∫ ⁄Í˙ˇ⁄   ? ıNlŸ≥f»ÊÊÖüî¨˛´k∆„^∏Z€€ìUçNﬁ¨¥Ì¸£ˆæYÀº´˘ÌÊ´-U_^õÙñô3§"∆â,`˛‘\÷ü zÁ†tçgM÷4¯u6uπ≥∏^QJác‚ÍËAÈÉsfÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6kﬁ`“4-.}SV∫K;e-5ƒáa‡ ≥ 79Ê/8ˇ ŒQ˘¬ÎX®ãN“!jCıàViß ˝π9lÄˇ *Ó<s¥˛N~mY˘˚Fs0K}~Àà‘¨íºh∆ã4\â%˛Ì·ù6lŸ≥fÕõ6lÑ˛e~eXyCO·ùfÂO‘ÏÎ”∑´-: ¸zÛ°{®_O}}3OwrÊIÊ}À1˛∂…wÂÁÊ.ß‰ÌD≤s•\o,kJˆı#ÆÀ Cûú–5˝/^”!‘Ù…÷{I«¬√b¨>“:ıV^‡·élŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≤1ÁﬂÃ/.˘'FmKYûå’[K4ﬁkâ Ø◊ı±ÿwœ˛c˛gyèœzØ÷u'Ù, bl4∏ÕaÑ™zsê˜sÙPdG|≠Ê}c ˙ÌÆ∑§KÈ^⁄5Vª§àvx‰—∆«ÔÎûﬂ¸ºÛÓçÁo.¡¨i≠ƒüÇÚ—à2[Ã>‘oOΩOqæIÛfÕõ6lŸ≤%˘á˘á¶y?Lı$§˙ú‡˝Fƒ#ˆﬂ˘c^ÁËÁóu}[Q’ı;çOQîÕyt¸Âì†ˆUïF¿`<Ÿ≤O‰??j˛P‘Õ≈ØÔÏg#Î∂h≤˚JfEÏﬂAœN˘_ÕOô4òµ=2_V	6emû7j9≥7Õõ6lŸ≥fÕõ›j˙e≠~±ud~…a_∏oÖWy–‚Ø¶ÚO·È°Ôn8_7Êch,ôº∏Ä…˘Ö™˙v–ßÖy7ÒºıØ∞†0°Òâ8œÒøòﬂ±ˇ »±òyﬂÃ ˇ yò≈”œ⁄–5h‡q·≈á¸mÇ"¸√ªı¨„otbø¨6áÛN?ﬂ[Õ∫Òq˙◊Ìº›†\P-–çèiO÷)ÜêœÀ )E˛e!á·äfÕõ6lŸ≥fÕú„Û_ÛüCÚ%Ø’≈/º¡*Ú∂”©ƒ“YÿWÇ{unﬁ9‰4yß^ÛF±.ØÆ]ªÈvÂˆQté4"è˙´6ló~X~djæBÛÍVº¶∞ûëÍv –MÈJÙë+T?GCû‹Ú˛Ω•Î⁄EÆ≠•\-’Ö⁄	 ôz–Ç;2ùòv8cõ6lŸ≥d_œæ|“º£§}jÎ˜◊SUl¨î—Âp?·QiøéywÃ˛ßØÍ”Í∫úæ≠‘ÁzlàÉÏ∆É≤Øl	ggu{u•úM=‘Ì¬PUôè`1&VRUÅVRUîÏAAÔïõ6H<ôÁmg Zß◊tˆÁî[ª7'“ôc¸¨?eªgß¸£Ê˝#Ã˙Dzñõ'¿hì@‘ı"ì∫H<Õõ6lŸ™0ßRÛ>è`J…8yX¢¯€È¶√È»›˜ÊÀ’l≠÷!⁄IO&ˇ ÅEyÆÍ˜ï›9S˚
xØ‹¥6lŸ≥õ6lŸ±–À,.'	S¯aÕüú5ÀbJ.P~Ã¬ß˛P‰Ü√œˆê∑êΩ≥:˛Ò?ã…•ıù‹BKiíd=–◊Ô≈Îõ6lŸ≥qŒ_˘»;?.ôÙ+ºwö˙’./6x-lE“K˛OEÔ·ûWººªΩªöˆÚgπªπs%≈ƒ¨Y›ÿ‘≥âfÕá˙gê<Î™iX”Ùkãù7‚):˚¿ül¬Ñáóè~
ië¸Íëˇ õ“˘#W:~ß#?ñ5YSV˙¨ßaq¯˜`F˝F˛»∑ö9°I£uí) x›MUïÖC:Ç1LŸ≥f»˜ù|Á•ySG}B˝ârxZ⁄©Áíï‡æ˘õ∞œ-˘£Ã˙∑ôµâu]N@”?√K˝‹QÉ∆É¿~=p†êNJ5ÀÔ3iÙö–G©„ä·üNì’ñ%ëDàÌ“UÍ`¥˜¡∫æßÂ˝wD∂ä+ynº˜}-ºWSàJÏ•ñïÂFë˘(f†Â@HÆEı}T—Ôö√S∑6◊à<, ƒÈRÖá„ÄÛf√ü)˘∑ZÚæ®∫Üó/4[ãw©äd± ˝G®œPy#Œ⁄GõtÖø±n3%Ó—àı!íüeºA˝ñÔí,Ÿ≤ô’T≥(‹ì∞#ö∑ùÙÀRcµÓa›M#›ª˝‘ºÀ¨jñYåpü˜L_
”ﬁõüß
ÛfÕõ6lŸélŸ≥fÕõ6)ƒˆÚ	 ï¢êtd%O·íM/œw–êóÒãò«˚±h≤¯’≤a¶kzn§ïµò3VåÏ„ÊßfÕåöx†âÊïÇE-$åB™®,ƒÏ Ê_ŒO˘»©uüÀ˛Lú«d’é˜ZZ´Ã§P•∑Bã„'S˚4Îú ÂÊ $S∞√{(˘üP”nuKM"Í„L≥åÕst±≤¬#Mÿ˙Ñ vÎ∆π0ÛRkﬁbÛŒô¨yRc}—Ñ˘v⁄“UY¨Ÿ∂Ô<≠Ñ|N@B>*ö‚ôL˙ù÷©™√{≈˝≠Á2ÈˆÒºQY\^ì,?WÊñ∫züÃ6ÿåÁ˘ﬂ?Áø9?GKí¸√qM>S√EªêÌåI˙ª±;#∞{∫OO©y≥a'õ¸Ÿ•˘cFóS‘_˜k√
ˇ y,ßÏ∆Éƒ˛|Ú◊õ¸ﬂ´yßW}GQjlR⁄ŸIÙ·éµ‡øÒ≥w8I–W&˙á¢]yIÓbö"†óÛ5¸äÊ ÿb¥Ä˝Ø\ÌÍÉ◊cAïsÊF«…ötp3ÿj≤ø•kt†-›Œîéœ ıTÚçcö¢õs•@¿ÊìÊ˙~[ÿÔÁ´‹_ƒ¬q˙—Ã3ì˚j~ÜÌÄız€V“‘Íq≥Î–≤¨öqˇ HÉ°K†~”«˚7#cÜ7ûP“£ÚMÆ∑e{%Ó™Ò§˜ˆzEmagdÁ"ÉÍq™“ΩèZë<Ÿ∞œÀæd÷<ª©«©iSòn·u;«"V•$_⁄S˛÷zÉ»^~“|›•ãõb!ºÑΩ±cWâœq¸»ﬂ≤ﬂ«%·.µÊ≠;L2}{Æ–!È˛±˝úÇÍæa’56"y8A⁄›6Oß˘æú-Õõ6lŸ≥fÕõ6lŸ≥fÕõ6ltrIã$lRE›]I}#%:7ûÆ!+§æ¥}>∞£„Îçì[K€k∏{yXõ£)Ø–p&ΩÊ#A“ß’5{®ÏÏ-á)gê–
Ï K∞sûF¸›¸Ú’¸Ì,öfú$”º≤≠µµi5œè9Sˆ|#È„Sú∑/+%^MÚœóÔÙ«öµE“¸∑¬A(ã˜óó3EIWUT5y†*p˜^∫µ≥◊öÔ ˙$6öÓî”[›X⁄B5]=¨’[ﬂ£»$Uì”#ëa◊‚ÿ‘d•Ô¸¡Á_,Ÿ•Ω &∑Ø[$^c’§π„ßi˙uº≈#.õGm-„™˙ë&ÌƒPXC<:'ì_T].k´Õ‡Õ⁄}¿KMNTñKãr	˝‹•K ‹~√ÏA≈Ónıˇ 4À•Èvv◊6ﬁ@”-,ÁΩüYuÜ9Ì-Y”ÎWw1fÂÒ$håN‘QúÎÃÀÂÂ◊Øáó^y4A)˙É‹é2òˇ  ˆ≠i]È◊|+"¢á°œUŒ=˛rù~÷?*ÎÛW\µéñ7R‹(>œº±éøÃ7Î\Ó@É”6yõÃzgótyµ]J_NﬁÄªπ˚1†ÓÕ€<µÁo;Í˛m’çÌÈÙÌ„™ŸY)™Báıª~”èaœìı’–|…e©»º†âä\é!è£*ò‰*…UπñLµùON–5¥µµ±˙«öcéáP”Íˆ∑&‚Ü(d≥*Òœë2Û(§¸=+é“4ï∫ñÛQ◊≠≠Ôu(•y<”ox‘≤∞D¯>ßG‚,>À˝Ÿ¢–npö÷Ó«…”[Í6Æ⁄ÆèÆX…$z}‰k±ãÎP±ê:#Ø%e;ˆ=qo/X›¥≤y∂Í{K›dî˘ï^5¨|€‚∂Ù>Wó·Ù^:}éﬂ≠¶ã®YÎZ‘y¡q KxﬁüZ∑ —‡∫èuaΩ+ˆ\aé^GëÄÿ±
®$◊`6ÿcsf√.Ízﬁõ¨[]híI§≠˚°-œπF^åá∏;g†Æ<Û¨ﬁÈ∞!Öl.û57ûìs§Ñ|K/„Ñ$íjw'©9≥fÕõ6lVﬁ÷Ê‡“^S˛Bñ˝Xeîı˘∫ZòÎ˛¸e_¬µ¡ÒyWoÔ&Ü>õUò˛G˘w-y| Ì∆2[cˇ Â]˘o?Ú+˛nÃ.≈?ﬁÛ^ﬂªˇ õ±¸ºΩ‡ºçè~J√ıWÕ‰}v?∞"ó˝W°ˇ ÜÆtf⁄¶k9Bé¨´»}Î\ ¿©‚¬á∏;Ÿ≥fÕõ6
”µ;Ì:oZ“Rç˚K’[Ÿóær/˘»)¸Ì¨Í´™\ÚìÀ6Ëãkofé›¯—ﬁd˛gj—œj
Áy≥`≠*ˆB+πl≠ı‚$µ•ÿfÖˆË·nΩs∞è9ÎSy≠	ÌuΩr9¥õ-IâRÕcçÄπ‘bÇ‹zÅùHÑzï£re9∑–¸…ÂO/MkÊÀ æU◊Ê˙¥ˆXàOo{sÜÁ”C#F—∂•wMà˚9#—¸£‰Õe≠uç_ZπÛ|ımfÓ
X[ÿ⁄YCÕZoQM‘™Ò©HòÊ€ú‚˚Õ˜í˘~ÁÀPr]7∆ˇ N∂ôãImˆÄ@¿Äy+@Éæ‚Üπ)—¥ø%˘gIª≤ÛÕ¥7ﬁ•íX⁄ß®◊svhÂ·~+Î9ZCBG⁄b:g7ZÒÎMÒkKÀª+∏o,Ê{{ªgYmÓ#<]$SUe#∏œg~J˛l⁄˘ÔD1\ïáÃV
£Q∂]Ééãq˛W=GÏùº3§gõ?>5]^„ŒÚÈ˜LÀaeMcD"DÂßrZ´_lÊ˘≥dá Zº0Î…&©v§ñíÿC®ªZ˙êò°êw„i∑AÉÏt=C Ø6≠-¸_"˙z"ÿ\«p˜3»¿„z¡¬ºƒÄr®q{}SÃ?û¢øÛu´€µ‡kYÕ‘
céó”`—qábv†#Î:∆ãÂmN{k{PûaÜ™lG&Âú‘¡-§¸πG¡Å.ÑoˆG|ÁDÇ≈®§û+–W∞ˆY≥`˝Dø’Ó˛≠hï•”7ÿçOv?®u9‘t.i˙,`^w)5ÀçΩáÚØ∂ÊÕõ6nò.√J‘o⁄ñê<£°p(£Ê«líX~_Ã‘k˚éºq
ü¯#∑·í/*Ëvî)l$q˚s|gÒ€√dDE
Ä*éÄ
√/6lŸ≥fÕÅÓÙÎµ„srèÚî˜ı¬+Ô"i÷ÂÌü∑…‡[˙‰wPÚ^≥k…¢QuËc˚_ª]£©G_¥¨#ÊVlŸ≥e0•X¨( EA® ıŒMÁˇ  I5O,≈∏¯Æ4•¸Zﬂ¯ß¸ÜrB¨ –É±lA≥f√Ô+˘€Õû^í8¥]^]:ù&ñ>G–,+2 yG«ÌØq⁄π‘µ,höæß≤Bë˘kO∂∏õ ^Tµî√w¨µ}kõ®ãñtäg$©oç—B¶sª(|√c£¡§Àh4Ω#ŒWpw!+€A7úùÅ´…ŒÆ"µ≠0ùÙ-…Q‹y~MgWæ^Rk2qh-Ì˝C¡,—I¨¨˜í∑Nä;‰íI$íORw9≤∞”Àf÷<≥ÆZÎZDﬁçÌ´Uk^ßÌG ‰é6#=áˇ +ìBˇ ïO˛=Ù_“·È˝Gˆ˛πÀ“Ù+·Í˛◊ÚÔá~~¸Ω—¸ﬂß˙W#–øà©ﬂ†¯„'±˛d'™ˇ Úˇ ò<ø™˘VõK’"ÙÆ°‹^'Ï…~“∂fÕíﬂ-yVœUÚÌ‘ˆ≠ﬂ	‘¶òî˝gı †!•g„∆´^=)S\;’<ÙÀÂ{KÎBóózúøV÷ Ω§ˆ¸Ï‘RD≥í°M“2¥è„∑\Äj:çﬁ£v˜wOŒW
¢õDP®äh®†*˚`lŸ∞€Àﬁ[æ÷Ó
≈˚´X»Dlµ˝ï˛fˆ˚Û™È⁄eéõhñ∂Q°]œvfËYœv8+6lŸ∞~ó°ÍZõÅmÓˇ jf¯P}=˛åôi^G”mx…v~∑7Z6—É˛Øß$q«h5É¢®†@«fÕõ6lŸ≥fÕõ6l®h˙u¸en†YgË„‰√|àÍﬁDπÑtÁı”˝ÚÙ>G£dZX•ÜFäT1»¶åå ˚ÉçÕõ6lÁﬂòøñkà˙¶åâ≤*”E≤•»˜Ï≤x7~˛9√¶Çh&í	—¢û&),n8≤∞ÿÇB1ô≥aÔîº¡a°Í£VΩ±mNÚÕiºÃê≈rårJ„tè™¢ê+◊lñyoBãŒ∑◊>b¸√’nl≠ı9~¨“C÷.SÌCR#V(◊´/Nï©Œk≈êÇãSNü√/6l:Úáìº¡Ê›e4ùÿœrG)§?P«Z%~ä£Ô=≥÷_Ú•4ˇ ˘Sˇ ‡Æ∑´˛Ù~í‚iıøS÷ı=:˝é_˝ü|È˘Û∑ëÙ_6iÜ“˛>3∆	¥º@=X\˜S‹⁄S±œ/yß ⁄øñuy4ÕR>Ø≈À_Nh˚<dı#®¬åÿ3H÷5QáQ”¶0]B~ÜSˆë‘Ï √b!yp.nÊπÙ£ÄÃÏ˛å+¬4‰k≈z(Ï1,Ÿ∞ﬂÀ~^∏÷ØΩ&;XË◊7 }ë¸£¸¶Ìù^  “ ÷;[XƒPD(à?Or{ú_6lÿ¯`ûyVci%sEE'&öë¢@≥Íá‘~¢ŸO¿?÷?µíÿ‚H–"(TQEU {éÕõ(∞áª‘,l¢2ﬁ\Emˇ vLÍã˜±‘ø9?/tÚUıTπê~≈¢<ˇ  8˛9Ωˇ úçÚ‘fñz]Ì»Ø⁄N!J{≥∏a‰ŒEÛoòNêt≥c˚â'YLﬁ≠LeGJlŸ“≤;Áˇ 5∑ï<ü™yÅm≈”iÒ	‹±@Ï]P¿nﬁ∆ÌÁ/¨wÂâ—v°ÜÍ7>ıë‰óKˇ ú¶¸≥ª!n≈ˆúƒ“≥¡ÕÙ-'Í…ŒÉ˘ü‰yÇÈzıîÓ›!2àÂﬂ˛+ìÉ~'Ê65ÿÙ9y≥f¶ ’tM?Sèç‘`∏IWg_ë˛ :ÁïØÙ¬e◊≥Ì2ç◊˝uÌÛÈÑŸ≥fÕêOÃøÀ∏º¡l⁄ñùMrË( /Ï7˘cˆ[Ë9¡ù$éFéE)"Æåe`hA°Y≤∞^£™ÍZìB◊˜2\õxíﬁUπ·åQcA—Tõ6M,ø*<≈ÁÌGÖò6∫D∆˚Vu¨q˜·€‘ì¸ë”æ{…^CÚÔìtt“¥H=(k yõ‚öi;ºØ˚G≤A«jeÊ¬?7y?GÛNí˙v£5´Ap¥ı!íî=¸GCﬂ<ªÁ'kU’Z√Qé®I6∑j•2⁄S„¸À‘alŸ≥`ÌG∫’µ¥∂'‚ñSˆcè°s¸sùwK”-4À(¨Ìå1ßÌ3Æﬁ$‡¨Ÿ≥`˝Eæ’n=+u§k˝ÏÌˆTÌùG–lt∏x@º•?ﬁNﬂiø†ˆ√,Ÿ±ìO(“J¬8–U›à
â'aúÛÃˇ û~O“·±v’Ó◊n6‘É˛TÕˇ ¿◊9gò?<ºÒ™ñKIc“mŒ¡-V≤”ﬁW©ˇ Å w∑◊∑”ÔÆ%∫òÓdù⁄F˚ÿúG6Oˇ "Êhˇ 1Ï’@"h.Q´‡#Á∑“ôÈÃÊüÛë7/o˘G≠ ˙ˇ WÖ´Ÿ^‚0HœeÂQZtÆI<∑˘ìÁø-∫ùZπ∑âN÷Œ˛¥Áº”Œ¡Â/˘À-B2êyØJY„ÿ5ˆü?Õ°êï?ÏX|≥∏˘GÛ'…ænÄI†Íq\ d¥o›‹'˙–ΩÈô'£6l¶U`C
É±¶C¸≈‰•nWZZÒ~Økÿˇ ©‡}≤  ≈Xe4e;| Õõ6s?ÕÀ”®≈/ò4®Î®ƒµæ∑_˜th?ºQ˛¸@7˛aÔúT{Éõ/6l¨Îìˇ ê˙óúc[X˘f°£Í≥^⁄/‰è≈˚˛œéz”G—¥ΩM∑”tªhÏÏmê$Ò*™?YÒ'sÉsfÕõ
|ÀÂù'ÃZT∫nß´o ™ë≥£˛Ãë∑Ï∞œ/y„»zœîu#ox¶[9I˙ï˙ä$´÷á˘\´˜mëºŸ±A5ƒÒ¡&ïÇFÉ©c–g\ÚﬁÉçßèq'≈u0˝ß‰ØA˜·∂lŸ∞„Àﬁ\π’fÊ¿«dá˜í˜$~ {˛¨ËˆVV÷vÈomé$˚*?Y=Œ/õ7!ZW|Áx¸ÍÚˆÄÚYiÙ’µD®1ƒ‘Ü6ˇ ã%Ø˙´SÚŒÊü>y£ÃÚ“∑å÷ı™YE˚ªuˇ `>◊Õ™r><3fÕõ%ﬂîì1¥6/¿4œ|y¬‡§Á´¶rO˘ û? πï_àö˙’0ÊZüz◊<Ü>_–5MWÉJ”"ınÁ©‹ÖDEydc≤".Ï«˘£ 7˙ôÂÚï5+•Ù}	l√:Ã.#YcÙ‘éF™„	YIVYMà#®#6>ﬁ‚{i„∏∑ï·∏àÚähò£©’îÇ3≥y˛roÕ3EgÊÑmsN_≠
%Ïc«ñÀ/˚*|ÙüîºÔÂØ6i¬ˇ BæéÓA*∆Xò˛Ã±µÃa˛lŸÛ/ï°‘ïÆ-¿é¯õ¢Ω;7øÅŒ{<¡3√*ÂCGFÿÉåÕõ5H5Ÿƒ7<Ü4ªìØi±”N∫z]ƒ£hfcˆáÇH~„∑qú‹fÀÃ$(± *ç…'` œD˛Mˇ Œ93˙>`Û≈πUíÀB}çA®{Ø·¸Üz>(í8’B¢ ™†    «ÊÕõ6lÿ]ØË:fª¶M¶ÍP	Ì.Nƒ—î˛À)‹ûaÛˇ Â÷ØÂÍJ∆ï3≥øc‹$Ä}ô ˙lâÊŒâ˘Âœ´¡˙bÂiq:“—OÏDzøÕ˚{|ÚbsfÕá\ÚÙ⁄µ¿f™YF}'s˛B˚˛¨ÈVˆ€¬ê¬Å"åqD^ÄS6kû`“4=:]GTπ[kHæ”∑R{*®›òˆ<ÛÁˇ ŒMkÃFK-7ûõ£ö©U4ûuˇ ã}ï?»øI9Œ¿∂+N“ıJÁÍ÷04” ]îQB®ÍŒÃUTo‘úñi>Tˇ q√Jº∂òj˙„Më1®K[À™≈+üåîûCÏÒemÚ  ≈Xu$2û†çà?,¨ÿ7O—5mGë≤µyÇ/6aEZÒ£1PKq<@‹”l2¸øü–ÛŒÅ59}ß˙Ì√˛6œ]®†¶q˘À9„_"iêñ§íÍhQ|BA%^yS':?û|ØÂˇ +ù&◊F:§∫ºæhªûY-'eÂTµ¥í%"P91#„=Vô4◊ö€JÛóò¸˘§6ùß[Ë
Ãñ•{av„ês\§jw!⁄ØÂ∫G‰¡Ê•π∏“ŸU=m;\E∑ûÍFñ¶≥´Ë»π»Ôö¸≠wÂõ€[ÈQØÊ¥äÓÍŸC∂iá!ÑÏ]Sâjt≠0ì/40Î~_‘„‘Ù[…,o‚˚3DiQ¸Æß·u=’Ö3‘øîøÛê˙WöÃ^ûóØµ)√kti˚èÓ‰?»«~«∂v`j3f¬/3yj=RV%ÙC˜nv?ëèÍŒq4RC+≈*ëFÿÇ;csfƒo,Ìom&≥ªåMkpÜ9¢nå¨(Fy≥Œ~VπÚŒª6ù)2[üﬁŸ\˜d,v?Î/Ÿo|#¡nõ®jói⁄m¥óó◊-¬ﬁ⁄…›ΩáÎ=≥’ﬂìüêZwïVk_ﬂ˘åéQ®¯†¥®È#‚îwì˛«;(Õõ6lŸ≥fÕÄµçO’Ù˘Ù˝B∏≥∏RìB√b<GÅA3ÃﬂòﬂñZüî.Ωd-u¢L¸mØ)Ò!=#öù¿ÙoûÿKÂ=Î¢«(ˇ C∑§óg≈kß˚3¯W:» l †††y≥`˝GüUΩ[x˛«≈4¥Ø˛ß∂u++{;hÌ≠”ÑQä(˝d˚ú_6GºÎÁ]# öCﬂ_∑'`V÷’Hı&ì˘Tx3tÊ/7yÀ[ÛV§ou)(äO’l–üF=ê˛,w8DM'Ùø*«qxÒ_‹˙v¬û∂
Ì<rêôLIÈ≈≈åÆMâ…f°™€h“˙öÄ∂ñ·-#≥x„å“6lR[-B›§édıìÄÊ&€aê˝SÕzùÕ≈…≥∏π¥¥πEäx=vfú"Òı.qH„Ì{t¬MÜI¥_+≠ΩÿªÛBõŸaíÒ$WiåwL—≈H„<–’K|T•:·ıüì4[m6k{ıIo!ñÓ⁄˙Ï1SlÒév∑ÊEH·hàp='2«l?ücmbkÁíkõ[˚{I%µDÄ§0†Wç#∫äd
>0•@†l!”µ'ú-5bK5ìQäx·èÏDpx≠{(9Ï%Ë~g<ˇ ˇ 9yrCÚ›ØônÁî7Äé ¥˙}LÛ&l8ÚÔõ5ﬂ/^⁄›È≥Äm&˙Ã6Û(öﬂ÷(c.aáóWóQÿ‰≤/:˘7UÛmøöıÀàµ8Êª∏¥y‰ºµººåi~Ø)`å…Ò:≥ï††…:i^cÛ«ótç]‘÷}sZ∏óÃ2Í7Ñ2izPäÄj8˝jV#≠:t»ù<Üﬁ]Ç÷ÚﬁyÓ,Óßû»«wjˆwq][q/ê1}ôdVFV åèÍ˙]÷ì©Mß›4Oqn@ë†ï'é¨°æïmõ∂ =7ÈûÅ¸îˇ úáûŒK-˘ s-£éµ+U‚ÆÀ…?i;	:è⁄€qÈò›]C)N‡ÉPAﬂ∂;1»œõ¸¥/a7∂´˛ô¯‘ªvˇ XvŒõ6lã~cy@yõ@x°Pu;:œ`ﬁ&üUêæô√º°‰ø1˘∑ZM#E¥iÆâw`V+t≠Œﬂ∞ﬁzˆÂw‰ˇ óºáßÉ ö‹ËÓ©"ég≈"Ó∏Î€øz‰Ù(y≥fÕõ6lŸ≥`]N√Oø∞ûœPâ'≤ù
\E ™≤ëΩÆq´=F—⁄‚€HWo3:<≠…»Ë*‘ t¡9≥c·ÜYÊHaBÚ»B¢é‰ÁP–4htªÅwôæ)‰˛g˛É∂Ê»˜ù<È•ySI{˚ˆ‰Ê©kjøﬁM%*„fÏ3À>eÛ.ØÊ=Z]SSóúÚmbæúQˆé0z(¸zú+˘ˆ…góº∏∂˜bÁPö“∞[â≠%Â+⁄â£ˇ Gπû4x—›‘TXS}Ê[ù*Ì"ûﬁÎS,œ=∑•%≠≥N≈%Ü©ÈIÒP…!˜◊"ÛO{®^¥≤≥‹ﬁ\µXÄYŸΩÇè¿4—|´u©‹Y†ôb∑∫3,ìj«%∫óx(˛òiô *º∑Ø\ìi˙EûãAq˙8¨∑ÖØT˙π˙ŒóAz,è8GéEê2F‹Î«µ7π‘>≥`Åã[˝BÙ›¢O‰πœ,N)ÃD© ø¥+Ñöû•}™^…}®Ln.Âß9^ï¢Ï£` 
6 tê7&É∂$ éä“er#çÅ?fπÌ;w
H:8+÷ÑW<Èˇ 9t◊rÀÂò#âû[…]ï∏öƒªê3ŒEîW‚Ô˜fy∞„ ˛fõB∫πcm˛ü®[=ñ•ßŒXG=ºÑ1NHC!°ïó°ŒïÂÔ7À≠Kl˙J◊m+¶y#Àì\Kv∂,_È:•ƒÛéë∆øMÇh\˛\yW\“ı‰˚âÊ‘|æ–€]jWrCé≠w;êÎlÚ:znxé¥ÔπÊó÷∫}Ïˆ7–ΩΩÂ´¥WH8∫:öaàfŒÌ˘	˘Ë⁄#¡Â_4\£πÈ∫ÑÑìlƒÌ§ˇ ∫èÏüŸˇ Wß©T’AÎ^˘yàÆ@ºÎ†}Zo“6ÀH&?øQ—\˛◊…ø^E≥fÕ\ò~Z¡£Z⁄ﬁ[YY√iw$≠qvÒ(Vù§5ı˜ öd€6lŸ≥fÕõ6lŸ≤9Ám[Íöo’£4öÓ©QŸ€?√9ÊlŸ≤m‰mÑgTù~7™€Ÿ{ø”–d√6Î∫Œü£iW:û°0Ü“’9»›˝ïGvc∞Â/:y«SÛ^π&•xJD*ñVï™¡eÂ¨{ú!Èøá\òh>]ä¡Êì[¥2TçQ'äﬁW‹√reh‡ÇWV^ÏxwZ‡0Î¬	e”¥ˇ Fd[hÏ€S4ñÎ—(æ•©∏N à~ é•E+Lã–í íh ‹ì‡2U‰€…§¥ø—t˘MÜ∑y≈Ù˚¯è	•hÅÂbd˚H%ÍºH¯≈\Ê0\Y√•éÎZö—SZï¯]€ Z wpZÊ(˛:‘|-Ωr)™j◊∫îÀ=Ïä∆5„"$QFµ&âaQMvyÂüÀ8˘å,ö}É%£«ÌœÓaßäñü˝à9*¥¸∑ÚVô{5Æπ®ÍΩÕë§¢—¨Áñﬁ‘êåÛFí∞n,®£Szd 'y3ÎZìÂ[Kh∆µ◊rÎaE‹©el≥@”âS‘íIc@ƒ|"¶ï¶ﬁÈ2y"]2˚Lø∫üOπΩµ”ÔÙ€Ÿ}ueªêB≥@Œ9«*»·àS≈ñøhs†Ä €1 Ç®;ÖØîºØ™#.£§Yﬁ&kx‹“îÍEzÅkˇ Ûçøï⁄™±∑±óHù∫Kc+"Éˇ §ı#¸3ì˘≥˛qWÕñÁÚÂÙ:Ã+ø’ÂVπßÄ©11ˇ dπ«5}X—ØZ«W≤üOº^∞\F—±"øh{ç∞>9eâ√ƒÌÄ@d%M°‹xÉLöË>n—g∂”l¸…çÀ5Œü†Z£©j˚5ƒç Ö´Yø`q\úÎˇ ïQkw∑sﬂj7˛pªiÂ’ÔmGN∞æK¨≠ïÃ_ﬂ"4CäM^;S8jµEF^b+µ6=s“ˇ Ûéúr^¨^KÛ¡{»◊éãy+o*(ˇ yúü€@>‹m‘g°kõ∫∂ÜÊﬁH&PÒ»•]OÅŒU´ÈíÈ∑Ú⁄IøXﬂ˘êÙ86l£Í/ßjP›x)„(—∂aùb7GEd<ïÄ*GpzeÊÕõ6lŸ≥fÕîvŒaÊ}OÙÜ±3ÉXb>î?%Í~ìÖ9≥`ÌL}ORä’~¡<•o∑ÙŒ´IIk≈B™éÄ@1˘MZm◊<◊˘Õ˘Äﬁa÷Dÿ…]Mr•óÏœrª3˚™}ï˙Nsúêy6«Lºæí;ªS}1*∞Yë'RÆÚ—£*}^Òâ+ªÙ¶Û^Ωs‹i‹Õw¶ê…=‹è,ÒFxJ÷l¬}'P≠"†f¶F`µûtù·^b›=YÀçhJ≠y5:û#aøLô˘~√J–µP◊s‹ºßL˙›Âƒ
"[xn7I≠•W2IB‚7(†–∑∆˘øU≤‘µqyh¡Áh◊Îóq£C∑âÁly™™ÒP[‚4‰w8óñ<•Æ˘ñˇ ÍZ=±ô≈”7√@˛‘è–|∫üÔ~J¸íÚÊÑ#∫‘‘j⁄¢ÔÍJ£–çø‚∏çAßÛ=OÀ:2ÒPÜ‘ ﬁVª_,ﬂKÂùX</}}wu•jç˝ÕÁ÷ßy˝&ì`∑)ÃØ˚J*µ‹	çÂ,h˙ÖÊ£•ÈÒZﬁ_neN[ÚnlU?ƒ¡ Ów¬kœ˜9˘áofˇ üÂò˙H˚5˝Á8Ì˘∆FÓlô(†Õõ6b@¬1y[Àﬁd”ﬁ«[∞áPµj—&Zï'∫?⁄F˜R3Õˇ ô_ÛåöÆñíÍ~My5;´I•…Ω‹c˛*a¥√€f˘Átx›£ëJ:Æåee4*¿Ó €æ‡ıŒâ°˛a˛íëÌ¸Õvöu≥[p’ı]>MWTÇñ2Lç¿˙ÉbÓ£aZ◊	¸ÁÁ´O2⁄[€ßóÏ4ü®?>{0»ÒŸ*—-§ﬂåîoè‘;◊	ÔºØÊ?G±÷o¥˘≠¥ΩH≤ÿ›HºVRÇ¶ïﬁÑn§˝°”1O=ºÒ\[»–‹BÎ,3!‚ËËy+)"£=≠˘/˘ôû|¨ì‹2ÆπbVZ⁄ØOÜe…(ˆ5≥°f»Áù4qyßõ®÷∑†∞ßSÌ£ÆsÃŸ≥gCÚ>ßı≠+ÍÓk5©·ÛC∫·í<Ÿ≥fÕõ6lŸ∞ØÃöÅ∞“.&SI}8ø÷}øπÀsfÕù»⁄W’ÙÛy §∑g·ØQÙ˚Œ˘&ÕúÎÛ£œÂˇ -˝JŒN∂´ 
üä8©˚Ÿ~ÄxØπˆœ4ÅAA–t√ΩŒ{IÌoÖ›µ≠Ë>§V7‚HVxiQ#ß¢…*ñ_¥2¸«∫kÆôm0˝+B⁄$x‰e2Ø≤…nm
Ø≈”qˆ∞öﬁﬁ{â„∂∑Fíyò$1 ,ÃÏhÅ‘ìù∆›t›&X&∑m*{)≈À‹Á®i2?N]¡kõ¯¸lù*GŒ-Ê/4\ﬁ<÷6SºZ>√Íëñ[vp‹ù¢çá8¢w¯ƒU¢ú8¸∏¸Æ‘º€t∑3ó≥–„$Kv≈#˜\5Í|[†˘Á§ÙMI–ÙËÙ˝.Ÿ-≠bËà7'ª1;≥‰‡ˆ4\Áˆ_”<€™Î∑^bWºóN‘•±≤≥2ÀV∞¬à—≤$lüºîIÍ˚Ä(–u?,jˇ ßˇ /u›JNm.‚H‚éyÅ∏k%XÂâÃï‰e∂g‡dØ0 	ﬂ|)¸∏¸Ï”Ôı;è,ÍÚI √◊[O2]Üÿ≠‹™≥◊àIY74®j∑LÇ˛X~{]EÁ›yº€,ie´3HØl˛î÷†Eq©1òTˆÍ+ﬂ:õ~˘]î« Ï‚‹–¸™¿‚ˆøûˇ ós˝ªôÌ˜†ı≠‰MP>Ÿ"“ø0<ô´2≠Ü±k,ç“# çˇ ‡$‚ﬂÜÛ®‹≈;Á0æ¸÷”<ÀÊ±‰o)Í-o™oµoMZ8°∑ß[RıYf4‚ßè›∑•0—Ìu?+k˙pÎöñõ≠\5Ö’é°(∏ëeÙd∏ÜR¿â'Ÿ£TRõ∫M4˘õ[èYñitÌ"H-tÎgöﬁ5w∑I‰ù˝çûBe
µ4P6‹úÊﬁq¸ô“¸«gÊKıÉY–.Ã6∫’€[òZﬁ9÷ﬁ˙V ;ƒeÙƒﬂjîÂÀ<Ÿwk5ù‹÷sÒÏRUGY‡ËYXxqü˛UÈö-»’Ô>†5œ4È∞ã≠@ükkÄÑd*7ô·£˚C«±∆õwÊÎﬂ-˘«^Û”Ã4Bœ”Öoó“2ÍhG‘ÖåLá£ø.ƒ&«9çˆù®X<Qﬂ[Im$—%ƒK*-£îr eáCÅÚ]˘WÁÎü#˘∆”WR«OÙ}V˚vŒ~#OÊå¸kÚß|˜E•‘7VÒ\@Î,"…®j¨é*¨Å∏ÆQPE‡ıÀ|√¶~é’¶ÅE!oﬁC˛£v˙:aflÿuÂCÍz‹J∆ë\~È¸*~…ˇ ÇŒôõ6lŸ≥fÕõ6Aˇ 0o˘Õmbßh¡ñJxùóÆD2Û`ù6…ÔØ‡¥O˜sÖ$v^¨~Åùní(ñ4Q U 
v2i8⁄G`®£ì±Ë ‹ìÚœ%~ay©¸—ÊªÕMI˙¢üB¡Oh#$)ˇ fjÁÁÑ˙nü}{3˝N—ØZŸ}y≠“•ö4#ó¬§;”%∫•∆çam-á®í«,óûZºgqo<†]:ıAux…—©‡yS Ù†…øì¥ª{o—w±NLÍû∑Ë·$AÙˆDÁ÷” 8§êÒØ˜bÑı¬?2‹Õ”Ëë¨XÈ“2€Z›í{~`zê,ÈRÒ›w°˚TÆ~X~\\˘ªS3\âf¿ﬁK∏2∑_F3‚h˛»˜¶zvŒ ÷ ⁄+[Xñh$0†QTP /îˇ g<©Ê;kûHˇ úÜ‘Øı©ﬂM{•7v»ƒ§ñS@´#®Bch|WÆÈ⁄öÈ⁄◊ö`“t˘5+âÆ'iÆ˘K2›JãwÈ≈É“(…'“ºõg&üYE7ôtÿ£ºf‘-,/“m„ksm6ü{√#˝X$&{eò9+Nvﬂs¡|≈†«Âœ6ÈçzÓt˚‰µ‘}U¯_Í◊∆Bµ®®‚€Áß ˇ ú~ÚBçÎ_IQQ'Æ£êÒ†JbüÛé˛Qp~´y}niAWéA_2¯‰kYˇ úr’cV}+UÜ‰ë]Fbo¯42/·ú◊Õ~d¸¬ÚÕÂ√®œcqq	ı I÷dX$y•f˝í(G\˘æ_ı|∆4¡q©‹C*È3MÎ4p€F)=«£o“ï‰B≥û*¿÷π”|Å™˘í€Õ:é£˘°®Y§ñVäﬁ^ø/6ûÑÃÕrˆÙ
çP#ƒÚ„A”'_ó7qj±k~`Ça=ñ±™M%å™AG∑∂D¥ç“ÄlÊaÛ√ﬂ ˘F˜W:ΩÊù≈„2»¬RœHã≈ekr}ëTqSï;Á2¸˘¸∞—¸«˙◊E∂∑¥ÛeÕÀGo"†èù¨pºìz‹ ˝⁄J10ÛÀÖÖÓù}qa}[ﬁZH–‹A £#°°msskqÕ¨ØÃ,¢béå:2≤êAŒ©Â]bÎYäﬂRıf◊¸”ñˆ˜:◊ò$YltÅ{qıxMµ¥ÆﬂXïè≈»Ï?ólä~a˘IÙ+∏nQóTµπñÍ–Oq[Õ≈Ñæå¥LŒ©*Sâ„ƒˆÈë,ŸÍœ˘≈ﬂ>~ñÚƒﬁXºí∑˙V,j^ C»¶™|∏ÁoÕë=Èæ∂úóà?yj~3ˇ ∂«Ó4»lŸjÃ¨MMT˚ç∆u≠.Ìo4˚{°˛Ó@Õ˛∑q˜‡ºŸ≥fÕõ6l«9Oò/>∑≠]ÃWôDˇ U>˙∞ø6lñ˘√ù‘˜Ã6â}8ˇ ÷mœ·ìúŸŒˇ ;¸Œ⁄7íÂ¥Ö ^jÌıHà;à»¨Õˇ ˝9ÊçæåtRKâ4.—KéD%YXt*√pp^´¨^j≤G5ËâÓî-“FY™jb¥„ß*T˜Æ˘ONà^[Í∫Ç∆t®ÁÙ(¸]‰ôñâÈ[ä„“y›l6’¸”wß[€ZGyi{{Œt’‚≥éH,Æ!†HñÊ[`en*>ÆhzFØÁ/4•§lÓ˙C%Õ¿P(«€~+∞T]î|Üz∑À˙ô°Ëˆ⁄^ùé÷Ÿ8ØÛ1?iÿ˜f;ìÜ9L|3ó~g˛pA†4ç≠∆µB&òê—[¨?jOÚ{wœ5~`È>fñ+O4j©;≈´óÜ;Îäñï„Åﬂè¯OM∂Œ•}Êão'˘C ˛mãLèZµ’`â-gñGék[àa‚#òéQÕ√„X‹®p£çzf¸¿ø¸∆‘?+4è1Ë≤˙ZN≠	˝'aen kh¶¯P,]ëòïfZá°√oÕœ ≠cÃó˙µu,vöÁót±± xñ4iB rãã0‚£Æw÷;=O¥éssΩ¥1%…Î"§aCö0¡ÿU‘l4€	ØÔÊK{;eı&ôÕTû√æy√D¸†’Ô¸ﬂÁﬂÃG˘j6ìWtπaÎÕ&Hcûã“X„Œ3·¿aøê<≈•Î∫MÃæYö5’aÜX'–/0n`äY§∂â˝⁄∞∏"N é€u∆}I°”uM7S0ÍXPã~í«wvJôÍ;hM…Ü^D€ƒQU8Ø.ÄamáÁÖ˘a‰çBÚ¸#Z‘$3]ÍK4• ÚµR®é‘¯W†≠s∞i∫7ô|Õck™k∫≈Œü‹Q‹E¢ÈLm%ëCö‰è¨»‡ãâA˛NËMÚÓÖ,≥È∂ú.gPì›À$ó´∏VöfíB+Ω+L‰_ÛíïI™È“y«Iá˝ ÈÈ˛Â"Eﬁ{Uˇ vm’·z¸Üyo∂ÿwÂ6OÂ˘.πY¡©È◊®Ç˚N∫Ê#ì–R'Wå´£∆‚™ |G|ÎöøëÙ2ÍW˙≠ı˝ˇ õÆ.„ô±‡∫~ï6ß πÜE∑pœ%≥0·,°¡®Æp¶R¨ H%IRT’Iõ„+%üï^p)yÛK’Àï≥2}[P°∂úÑzˇ ©≥˝Ó‰ee™öÉ–ç≈2Ò+´hÓm•ÇATï
7…Ö3ë\@ˆÛÀõ<LQæjiâÊÕìÔ ﬁz∫dñƒ’≠‰4‰æ„ÒÆJ3fÕõ6lŸ∞6ßr-¥Îõè˜‘l√Êﬂér"I‹ı;úŸ≥gMÚÖü’t+zä<’ôˇ ŸÙˇ Ö¶Ê=yØÛﬂÃRÛ©∞F≠æì¡A”’ê	$?äØ—ú„6>^yí%≠XÄXxØÌ1≤çœ∂Oµ[mIæ∑˝$∂˙e‰f“ Z‰êÒ[õ9`ÙJóÜh˘:2P◊lÅﬁ]Owu=›À˙ì‹HÚÕ!€ìªc˜úÙW‰íøCytj˜IMKV%°é€¨I˛ÀÌü£√:fbh3ó˛p~f∑ó≠ˇ CiR”W)…Â˝Z&Áˇ ˆ|:¯dGÚìÚòÍﬁóô<√©ßπ2YŸ…π∏$◊’ñΩRΩÌu;uÍ?òüó⁄?ù<≤˙%hΩ#ÍÿMaù¨dmN?
”¶Úñ<∑w˘W¢È2i—À¶McKg=&Y)Z≠_ã‘f!áNÿ¡‰8K§'ñnıªy<≥in]-Y5)mê–BÚ˙¶< C"«R7†;‰‚Ê⁄+õym¶NpŒç®zpUá‹r=˘h◊‡≠:ﬁ·˝Il=m<…πÊ,g{Ujê>“ƒI»®»ÚîÜ®∫£X	ØV∏âßíYë&f‰dé)¢FÆ‡™ävƒø2bøì»öÏVˇ [∫íŒTKræß5aI(înLí´MŒrO9h^TÚ◊Â‘6ñ6È´ÎW1‹YÕµÂ˘éZKàMZEÙî=Ú5‹·nª®˘õJ¸∂O0˘ÍÒ¨<¡zíŸÈ:m§Ik{2H¥ÓQSÈè∂ËPw‰sëy4∂◊Ï5›V»_X[N'6“Ç©p—µƒ#}9ÓY”µù6KOòMirÅ„~Üá®aÿÉ±?$i"u§ wà Áàø:/ˇ ¡~vû“›
È‡›Èg≤∆«„ÜøÒSÌÚ¶@èáPzÁPÚf≥®k>\‘X◊/,¨Ù»≠¥ø¨iñ—=‡¥º&0o%fíŒ©Zí* #
ø3|óó”LπK“&Ωkòg“⁄spïµuTª∂w˝·∑∏V™ÛÓAràz≥€ﬂëûi>c¸µ“n•~wñàlos%∑¿	ˇ Y8∑”ìÏ«¶s:Ÿ˝_\y ¢\¢ >eøVÊÕí_!]zZƒê‹Di˛≤˛™ÁAÕõ6lŸ≥f¬;\ºø2é≥2G˜öü¿g7ÕõM4—¬øjVT64Œ√KKä*(QÚQL~'uqµ¥∑öE
4é|O‡3∆:û£.•©]Í2ö…{4óÛëãõ%LSgp.¶+n5{Wº∑ë¨no›Õ\DC¬ÊºC(4ÔÖ~adãPí¬2ZY±â-%∏˙“E"û2,R(U)»|'ç|poÂˇ ñœò¸€ßÈl+nœÍﬁ∆æ'ˇ Ç˚?Nz‚4TP®®ŸTl  1ÿGÁO4Ÿ˘gÀ◊z≠≈ƒ¥∑äª…3môÎÌúÚ„ wæ{ÛeŒØ≠3MeüX‘d=&ïçRÌ∂˛
)ûñä4âB® *®† 
  Ûù®j:Lˆ6ø£Êπ7ªTÊÈHb I¬º‘Ω“Ù€M/N∂”¨–EigAo˝ò„P™>·Ç∞´ÃìÎêÈØ˙›.5)Hä3Ñä.{zÚweèÌ]€†ÀÚæáÖ†YÈ0;J∂©≈Á}ûIóíVßÌI#3ûf eÆZy{A∞Ωû˙ÀMµ∂ΩªØ÷n°Ü8Âí¶ßõ®™wﬂ9oùˇ /m?6ıÙô/^√DÚÒí…o‚A#^NŒ C»ÖTÑ†OSzø!Oáy7õ+t]K…êh:d	j˙Tt—ò∞ >√§K˚D˜¯∫Á5¸ïÛçŒÉÊ<±©ñÜ÷ˆSG&ﬁç‚û<wÈÍSâ˜¶zMF^rü˘»ﬂ%à?/ßøÅ9jÿc∏O¯ãÊπ„ú;Úfø´h~bµº“Ôˇ F\J~®˜‹U˝(ÆHéG£><áÖ3ßkﬁQ–a”57Û3˛êª∫÷í-{YπëoÅ”cçÏå*Hédüù
ÅΩ~ô≈Öh*(rÛ–ﬂÛà˛`+uØyu€i-B›}«Óeß¸&zTtÕëÃ+^V∂∑@oòÿ˚8®¸W!≥aáóÁÙ5ª):T)>œü◊ùXfÕõ6lŸ≥à~aNE≠ú?œ#==ïiˇ d#6l4ÚƒæΩf¥®Wıˇ PŒ¢^D?6u6”ø/µôï∏…,?Wå÷Ü≥∞èı1œ)ç∂Õä¡gypì=ºŒ∞/9åHœ¡Iß&‚|s°ﬂMc†Ë/sÂ€Òjè{[ãkµóÎeEçg∂ë§§‹í3*/ß≠vŒpIbKXíK…'rNvˇ ˘«=}[]ëwëñ ›ø…JI->d®˙3µÅLŸÁØœø2À©yé◊À÷§…úI˛’‘„aÓUI…-‹∑FÚﬁùÂù1ƒ7Ô÷u;•íNºcQJ¯ë€8k∂∑éˆö¨í‹¡FöﬁILÀøƒë±4lÓ>\’‚÷4K=J5‡∑)»°˝ñÜ_°Å√Ÿ≥f¬?7yÆ”Àzjﬁ‹F”$XbÖ(;~” I8FÛt⁄ÔñõX—¨å◊ ºb¬y'’ç∏∫@un0Í˘ˇ ]`÷–˘wMîqªΩKÅs|»~“[**«∑®ÃHÏµﬂÌÌt›IÜ÷Œ%∑±≥âbÇAEQ„ú˚Õ~s’-µH¥6ÒGπW∏+¨KÅr¿•Qî%Y‰ØQÁ;¸Ÿ—•KÀO3[´D∫àA;çônG$~—^ß≈kùœÚÔÃÀÊ?(ÿjLAπdÙÆ¿Ì<_üyæúíbw0Eqo$ íî«*åå(¿¸¡œüﬁn–dÚ˜öum˙È˜R¿Ñ˜çZ±ü•8Sùá…6Qj~V”M)|…©ﬁGkk™º∑V÷7v‘{-=cg	
‹"üàëR¬ù3ûyÓÀH±Ûn£i§˙keßÓ°êÕRò‘œrüÔ)ã"∑p0á:/¸„Ê≤tøÕç≠∆;ˇ Z∆MË≠(?‰b.{XtÕÑæqÉ’Úı÷’1Òê±a_√9ûlŸqπéDêuF˜ÁcçÉ¢∏Ë¿ÙåvlŸ≥fÕòÙ»/ÊüÈ∂qWÏƒÃG˙Ã¸kë<Ÿ≤E‰8πÎÖËi.~Úø:&lÂüÛê˜æèìm-A°ªæåZ±£π€∏®Á|Ÿ(Ús˘f ◊öç’éÆé~™©+⁄[2”nw0§“©Øn {‚v’ÆuN1ugao<	Ω≈É,∆up
º∑
[’4ÓwÒ»ˆz´ÚãJwÂˆéÖx…<FÊOvùåüÒ2cà›\«mo-ƒ¶ëBç$á¡TT˛<Ÿ˘gk'õ?4Üßv=DIf’'Æ˚Ü˝–˙óÓ…áÊ^°iqÊy}"JŸƒ∞Œ›~4%öÄ~‘>˘À¥Ò´w6˛úêÃ◊ELìPΩ>	âVE~údOc∑£ø,/mgÚ}îP^€úS©˝ô9?AQí√”8∑óu_Œf¸‚∏¥‘·π_-˙≥˙’ç~¢-hˇ Whd†<…–÷µÂùô‰TFw`Wì14 §ìÅ4≠oH’†7]Ï–(“€»≤®a’IRwŒ]ÊO5˘„EÛÀ‹^ò¸Ω¬Ç ÷Øfh§ß˜¶Ω9rÂ˛Nﬂyí5iNçÂÎ;˝)ò…© dh«*±Ç9V7Zˆ}≤¥ˇ :€ykK≥â¥{K◊‘µ6ZÑs3£∆H“TÑÕ^u%Xì_|:ª¸œÚù≠Âµª›<ãr±8∏çDã?˜e€ˆ}ˆ€æ˘âüÍ–/Ug´|¿€9v•¨›]˘äÛDMq4´yU≠}&˙πõü¶ïdI,æµπµX.˘ßÀ…≠˘#^âWî∞∆í⁄ìøÔ-Aìor	_ß#ÛéZ„z∫∂àÕïK€u˜˛ÓJ¬gs3ô‰˘…˝l3>∫Çâ™Ÿ√94†/ao¡9=..#éH„ï“9iÍ¢≥*øU‰°°È\f‘†Èõ|•®∂ôÊÕQV‚m/Ì•-^"ã2Ú©Ï)\˙)M∫f¿öº^Æów	ÂÄZÒ9…LŸ≤èCùsHó’“Ï‰≠yC'ƒÒ¡y≥fÕõ6lÁﬁ~ìñ≥$O•ò‰k6lñ~^†7˜è]÷%Z¨’ˇ çruõ	|Õ‰ˇ /˘ö`÷≠~µª3¡Ò∫fI
ˆ»åˇ ê_óÚï·‹ÎÈ‹±Øœò|+πˇ úrÚ€ı}Rˆ#Zûb)<> ·]œ¸„tü’uÌÎ	≠ª{ïìØ—Öó?Ûé~iå9∂‘Ï¶Ï∆X˚Ï‡aUﬂ‰/Ê\ÑP⁄‹;4w o‡™Á£4k#c§ŸYm˛ão&ÄX–/AÚ¡ô¸–æ6^@◊'émö%5¶Û¸múÚÔSπ”,ıI,‰0›]zVÊe4eÖjÏˆ‰‹wÕ}Ó.?—c∑{Ö⁄{©8˙ÀBJÖhã!îù⁄ÄûÇ†‡ãPX–¸1ª3€¡…ÿG≈?xáç()Zôÿ?'4˚ò4õπCºüî
vcPºá˙∆øv)˘À•˘«QÚdê˘Uú^¨®˜1≈/°$ñ ö#’7ØNB†d;ÚÔŒ^t±Ú¨ö≈Âó◊-,Â‘πﬂ4◊'NW!$oFÇäoâòä}&>lÛø´˘V{∂∂Ük˝«[†äÓ∆ÍIgZ†áÎï?lnÖÜ¸äÚ~Y—Æı‘øIp≈*∫DaTXÉ(RåÃﬁß&`ı;Rô#¸ƒ∑úÈñw´l.ÌÙÎü^Ó‹©u1¥2C…î,®e‘Rx÷É!pÈ˜∫áóÆ’5[k{›T∑÷Æmn#∏∂ê\pIfU1∆¡£Ö}8ìï ë;·mÊã®h˙lë√´ÿà≈µ∆ùk9)E”ãòΩ8w)'-†´Ò'‰´Àøïz=Âµñ≠¨€M†“Iq-àê§TiöXRhÍ€∆TÏkLïyÖˇ ymm‘3:¯É@ÎŒkaØj:ñ∑È5Å∏Sµ≥ﬁ ä[h—ßvfn2±VXbà#Ø"Ÿ‘Ù+xçÒ⁄xÎ Ò/ˆ≥œﬂïLtèÕ®ÏkD2^XµM6P‹z˚∆3“À–fjÒ4Œˇ 9+˘uÊü3‹h~_”PöŸn!∫zj ¨Qê±v]´À9=Ø¸„èÊÏÌF“b∑ÂŒ[® ˘|,ÊøFZŒ+˛fMÈôÊ”≠É8i‰r£«‡åÉÙ8∑ˇ úFÛC˙œò,b5¯DpÕ #ﬁ¶:aÕ∑¸‚†`nºÕ3•7Z¢û_6ëˆ˙0ﬁ«˛q7…PòöÎU‘Æ6¸L1+P‘
b>¸Ó(ºTºdÀ '^Ã§§g"ÑØ`HÕõ6u?,…Íh6,E?t¸G√<Ÿ≥fÕõ6sø>«u„
~∂»ÓlŸ.¸ºˇ zÔ„~≥ìåŸ≥fÕõ6lŸ¸Ìˇ …q™≠oˇ '”9ÂøïÔ5ø%ÍXÄ˜∂wƒ¨Öı°NJ	€ñ’≈@Û,Û˝R*ËOR§<L†x¸D˙kùB¸ü”"Hg’Ê{õÄMl§,<∫Ò®òòÆt8aéí(‘$h¢(¢Ä: lKP∂[ªãF%V‚'âòu‘≠‚W_∑ÖÆb÷ı9¥Ωp«%§´$mıFµk3d
R¥ê0}õÌ(9W—h7Vñ÷ó∫‚K<qÀo•ŸÈIí\Õ√ãïÊ.√”r o∏Œπ‰›6ˇ NÚ›•∂¢PÍ‘öÛ“⁄14Ú¥“*ıŸZBÕÃDÂ /ƒÒ–M™sèy◊Y’|◊}ò¥(^ﬂ“vª{õQb∏$RzkŒøvÿ\_Œ˛j≥ÚwòaÉL–4ËŸaIísn±…)w «FÑqß}œLÎ§¥
ƒ,*TıÔLçyÇNπµ1->`µ Ìæsü'%◊È´´U[´-ÌbékBhe∫
P*¬å*∑ƒ%pyœnßÂÌMZÀ“∏*¶XUâ
≥◊æp}6øÚæ∑ˇ ´‘ˇ ≠Û“£¶lŸ≥fÕõ6lß˚'8€˝∂˘ü◊ïõ6u* ?eˇ ˇ „cÜŸ≥fÕõ6lÁ~|ˇ é‚ˇ ∆˝g#π≥dªÚÛ˝ÎΩˇ åi˙ŒN3b∂∂‰zÛG/≥Í0J”√ëUsÁØ%€+µ∆ΩßD#Ÿ˘]C±È∏Â\*ª¸‚¸Ø¥eYºœß’∑^	?‚©ÖW?Ûêüî∞+ëÆ,∆?Ÿäá-˛Ø¡CÖWÛîï±KÎäı1⁄∞ßœ‘)¯aMﬂ¸ÂóíêIı]'QòØ˜lÀ
+|Î!#;e¨‚{x¶	Q\≤≈r˘ÕM˘q¨q41¨Rö˜	2ë?˘«ÖmZ∂˝®Ó£ìﬁè?„LÏTÕõ9ÔÁvëÊÕW…omÂïí[°:=’¥/È…-∏Väjºæ"§≠w¶¸°“¸€¶˘∆”Õ/!‘ê Drø©$p˝‘r8-VU˜>¸Ô¸©Ûáúı}2ÔCû0õy“ÊFOH˙úƒ…EmËw¶˚Î∫mª€iˆˆ“H”<§o4õªîP•ÿ¯µ*pNW|Jk+iû7ñ4wÑÚâŸUä$l~X™ä
u»Áù¥õã›Ó[(‚óPé=Æ,Tníï¯ÇülÄ˘/Kπ”¢ö„QéhØÂUÜ‰Mhµ$¥ãõ4j6ÂÀÆŸ'“¨ÓÆÓU#F13$î<T¯®O√^Ÿ»¸Æ«Q¸ÚI“Ä>©u0Ó8ß®{x”=.:ƒ–W	µœ5È:!Äj2≈¡aTg˚4©<zu¿â˘ã‰ÁØ˚íç)¸Î"˝’\õ<ª/˜zù£TVû™O§å•c0SƒR˚%Zø*Ç–‘e3”Áñ¶™^S˝ìÚŒ6ˇ iægıÂfÕùC É˛u˚/¯«ˇ 6Õõ6lŸ≥ô¸¡B5;g¶Õ˜ÆE≥f…GÂÛÒ’Æü∑Ía˝r}õ8/¸Âµó©Â≠
Ï™ëÙë‘˝™K	;{~Ô|ÛH¡®Pç_À5Täıﬁï˜Õ∂S
© èø=Â˘k™G™yÀ◊…˛Ì”Ì˘¨ëÑo⁄Sí\)ÛNõ˙SÀ∫ûú7kªYb_ıô«8¸„Œ™-|’{¶Jxõ˚j™ˇ ≈ñÌZ¿≥g°≥fÕLŸ©õ6lŸ≤ôîÇ*Gœ"Ô‰˘Õ…·2≠±5©êßµK´mÀ◊w`Ü¬⁄IhOtRF˛$Áˇ ú”‰ΩÛµŒ•%H≥µëŸø‚ÀÜ˙πg¢∆c–Á#¸ﬂ∏V÷¨≠Ö£n\˚˙&@Úà®0 t˜b—]]B)ÚF+Z#≤ä˝ŸyÉÃkspÍóJ“∫%LÆ√‚`;ì„ûÇåq@<1ÿçÎàÏÁê÷â∂›vRsèôy≥vŒØ†!M…H°•GÃWÊÕõ6lŸèLÖ~bEΩå‘ˇ ~!?qÕõ¸õ7•Ê7†ë]:ı™‘~¨È`ÊŒYˇ 9)¶ﬂ ´ÈîU¨.-ÓæÅ çªŸì<yÇ4Ûf/ÌMÚ≥Xâ£7kŒa=@æ¸+ùß]º“üGºík˝)ÙÀã[Î8t-/“ïÓË∆Mx-‚R…
…I]¯ê÷µŒ+MÛW=oˇ 8øØçCÚËÈÆıõG∫ñ=ƒSZ?£„aÙg_Õ∂yãÕM‰OÕc}ëm ﬂ¿¡≠Á$»ÉÔuœKŸ‹¡smÃ—dâ∆‡´ÄT˝«5Â‘V∂≥\Ãx≈
4í7Ç®©Œ#ÊèÃÌiÖ≈ˇ ◊€J”`¯ñ8ÈP£ß6°gs‡>Xq†~mjñÂ5®^¯V∑∏à*Hk⁄@hΩ2qÂü>h`î¡k#Eto´N9©ZË9$Õõ)‰ç≥∞Uñ&ÄßKÎ)YR;àùòrUWRHÒ é?öomÔ$7°¥I
HÇ¢X‘6‰6€”√%∫ºjÍC+ A"∏ÏÂ_ü˛fK/,√¢¬Ùπ’d¨™‚ﬁ´˛≥Ò~/˘	Â√ß˘Eµ9Wå˙º¶eØ_F?Ç?ø‚oß:pÈîﬂdÁÛŒ¢/¸◊®L¶±∆‚œjD8˛∫·i^^µ’mœ’5é˛(⁄[õ[îh£USJ¨ﬂSq÷òS—ı1„K»∏z†¥2++£®ÿîd$Ä€ V¶ÎÃ˙\4®7ÌÚè„?ÒÙ
˝ëóÖæeõ—–o_ø§ToM€·˛9 ¸3f 5°©€;î^ï§1Rú#Eß…@≈≥fÕõ6lŸÛ¸ÙxÂbôO–¿åÄfÕÇ¥´ü´jvó£ï	˘VáŒ∏3aùÙ?”æR÷4Ç*olÊÖ˘láá¸53¿°X
8£çôOPFƒf¶tø+k∫è‰õõÌ3P∂“º≈˙:‚¬Gè‘]QÔfæäH•ÜÄ´«ıe„±°ÆG2,ÓÃ˜õXOae¨1ª”÷Ê!o$±Ïè?£˛Îı$V~>˘¶uÔ˘∆o6~àÛ€È?mvEjv˙ƒ5xæñ^kû∏≥ó~z˘9ıo/&±i+› 3∏ó∂oÔ˚}¯Úœ	y¶7ñodˇ K±Rˆè€∑'tÒü¯SÌùKWµ˙ÓówfÅ∏Ö‚{Rœ8˘ãÀ“<Ü ˘€V™W™öäï
—‘qƒ¸$”¥˚À›2Ë¡©3≥NZÊÚÚÊFí£Ï"€¢Ú}B®´ˆöµ„á÷öàÇÊ◊T∞íèû§nZ4mB ‹Fz^'Áµ)»OòÆ;)öä~YŒ¸”≠´áq,M1èO∂íh·[âÌp2¨Á~>ŸÚ˚jó‹K3s¥IdX“uÙØÌYXqä·p$èâYN¬ükÌdñÁW∏ªÜ8Ó3≈ ûøï"ú≈?d/ZÔì}óËk/¯¬îÎ“õuﬂ¶Ωº∑≥¥öÍ‚AºdöVŸUUâ˙3Ã∑≥Íôﬂò ±ÜKY‹$ÒEîGv>‰o˛±œMŸZAgi•∫‡Å8êtÄ*è∏bÿYÊM^='CºøcFÜ3È»?‡àœ=f%ò’ÿíÃzíw'iˆ_›•¥L®X3ºí"")gv#≤Åáñ÷k§«©Ÿj,¬¬˛(aèUµ_V0XãàËVEÍ0≥\æµπûlÉ⁄◊òò-Y‰eªL.…üÂ=áØÊW∫"´g îá,Ï£¶lç˘ÚÎ”—D@¸S ´Oe¯èÍŒ{õ6”°ııXﬂí¢˝Ï3Øˆ≥fÕõ6lŸ∞≥Ã÷ﬂX–Ø#§F]~iÒÂô≥fŒ≥£^Ω.÷‚µ/Úˇ X
7‚0nc–ÁÜ?7<∏|Ω˘ç≠ÈÍú-ﬁswj:FÁ˜´OëbøFD2[˘iÊ][πöKò¥€ÀõI ”u©·˙¬X›WIö>/∞S0®j‰ØÕsÀÊˇ /›6ëßÍ∫Ω˚^6•%ÃÉ’¥¥é4hØü+±ökye*¸xém\‰ı˛ÃZ∆ˆÍ∆ˆﬁˆ—ÃWV≤$÷Ú´$lOﬁ3ﬁDÛuóõ<´ßÎ∂§RÓ1ÎDÒÃø±üı\£$Ÿ^6F ´
0"†É‘ûk¸ƒÚéß‰/5C¨Ë•¢”‰õ÷”ÁPHÜN≠˚u†=WlÌæ@Û∆ùÊÌ^CHØ"¢_YìVçÈ‘x£uS¸p◊]Úˆü≠XIiu’îàÊ‚∆ﬂ≤»{PÁûıM,À#ƒ%Ùn≠•dKïPH+Œ2xí;;æ«|¶,êzWw\›£îzˆÚtõrnî“nÃ„fÆ‘Í8ÿ:+è≤¿=é;#>oøé∏‹J!∞ä'∏ªf$/Ø⁄? íFs-mı=zÈÙ(≠-~Ø4bÎOûFh•∂+	B=diW◊‚Ò(ı-∫nõ`-maé÷ÿUbÇ%Äû¿eiöEﬁ•(H—íﬂoV‡Ç.’
OV#¶t8ñ8‚H–UP™£† PúÛõÛ$Í˜Â}ÃñQ»˙h˛/¨J„S™´u˛cìﬂ ÀÔ∆é◊7»?Mj
≠s]˝(∆Î>›[ﬂÂù
fŒU˘µÊöÊ™√˚Î∫tÊGÓ‘¸Üˇ NsœûyMi4ÔñR\ Ü‹i˜•„ı£êQƒrÇXÙ‹‚˛k’UΩK—≥i∑.µ‰S…ŒÇﬁ?JàP|Mkﬂ#Y≥Æ~Ri^éÉ5˚
=Ïƒ°ˇ ä‚¯G¸7,ûŸ¸¡ªÁ{mj—!ëáªö¡r)õ6y:€◊◊‡4®Ñ4ßËâŒòlŸ≥fÕõ66D!F›XG±ŒCyn÷◊s€∑X]ìÓ4ƒsf…Áê/Ñö|÷l~8íèÚ_˚A…VlÛ∑¸ÂîÀE§˘Æ©àù>˝áeb^?Ïπ/“3Œ[f=6=év}œRæ¥—ö˙Êˆ{Ì)¥˜—<ΩkY"æ¥QnÒ≈r)∂º<NT`ŸŒºÁÂ-oAøiµ∂hÔ&üå÷2¨ˆÎ2H}k~kˆdÖõã)˝Y€;¸„óÊJ˘wÃ-Â›J`ö>≥ ÙdcEÜÚÅPÔ–J(áﬁôÎUÈõıÌL÷Ùπ¥ÕJ=§‚éá®#£)˝ñS∏9Á{@ÛgÂáôV˚Nô˛™ƒãKµäT&æåÎˆyxè•s≥˘ÛKDÛ\+ ae´®¨⁄|ÑT”´B∆ú◊ÒüŒóöå∫åöÜêÇu∫bÛ€rUevÍÀ»ÄC˝∞ó?,ıãçJ)µàÖ≠ïªá1VíVSP¥RBØâŒ∏Ω2ü^“§ªTñ≠,aï¢≤Ò∑⁄Ì]∂ØÀ"⁄OñøF£€Èˆ3Cí<ë€HbvﬁOJªFÆ«ë “Ω2U•Ë–9∏∏k£N,wèØOüSÉÓÓÌlm§π∫ô`∂âKK4åUGRIŒ˘ì˘À>Æ_DÚªHñR1ékÂKqÀnÄ9*ü≠í ? 1¶˙:ˇ ò!ˇ r$r≤±o¯˜wÔœ˚?>ùx(2£Ãﬁa∑–ÙôØ•£2¸0E›‰?eGÎ>Ÿ¿ÓÆÆ.Æf∫∏R‚wi%cSïm\Në¸r∞%Qi€à&ä79-K(‹h≤õãòÓ'∞yaë∞ÖõÄy£óä 9u+æGº¡)üWûssŸò´â≠É,t*®V›JÅB0øoo-ÃÒ[B9M;¨q®ÓŒ@Ø=§XEßÈ∂÷1m¥kˇ ±'È;‡Ã«¶rçv˚Î⁄Ω’¿5BÂcˇ U~˙∞lŸ2¸ª¥¯Ø.»˛Xêˇ √7…¶lŸ≥fÕõ6cú„Œ÷FﬂZ2ÅDπ@‡ˇ î>¬Ÿ∞Á :á‘ı∏yGq˚óˇ eˆ·≥¶Ê¬?;yb◊ÕU‘¥ùí˛ç$Óíä7ˇ b‡e˝çﬁü}qayäÓ“WÇ‚#’dçä∞˚∆!í?$˘öÀC∫æèPYˇ GjñﬂT∫öÃ¢‹√∆Tö9b/Ø‰≠ˆÜM|¸¢Ú ˛„[#E˝'{q¨h~Z∂åO©Õ5ÃhÇ{ÍE≈+OµÒl3î2≤í¿—îÏA Âg¨? 7áô¥‰ÚÓ≥=|≈aÓ•¯˚∑J ıÔ*~ÿÔˆºs≥Tf¿ö¶óa©ÿÀc}nó6≥ØaëC)‘v9¬|Î˘´Ès6£ÂfíÓ⁄3Í-ß".¢#›0ß©NﬂµÛ¿˛W¸ÛÛ.å‚√Ã6Ì©C	‡Ãˇ ∫ºJvb¬è˛»Ôù[@¸ŸÚ&≥ƒE®••√«ΩÁÓæ≈æÙ6L!ñP<N≤!Ë»CÙå~méj⁄˛Ö§ƒd‘ØÌÏ‘ø§T?@&ß9œô??¸≥d≠âö•»®ö√n˙Ã9∑–øNsYØ?23ØƒJØ=≤6—%a±á›â®,=˘6uˇ Àˇ  À;Î¶Üµ@~∞À˚∏èÑ*z¨w˘gB†ÕQà]›¡k∑»#Ç/#ì@
ísÜyÀÕ2˘ÉSıV©aV“÷á´∞˛f¸v√Ìõ,3_=÷ï=“´È⁄¨[∆∂!”ˆ—økzèWÃ^å7ó6óëGc©«X÷˜Dïh√ƒ÷úè—∂GsdﬂÚ´B7∫ƒöúÉ˜ë{Ã‚É˛w˚≥∞ †À¬Ø3j?P—ÁïM$qÈ≈˛≥Ì¯ÛófÕõ:wîÏ~©°€)$† „›˜Ö0„6lŸ≥fÕõ6Fº˘aÎÈIr¢Øj¸è˙ç≥ÁŸ≥f©®4a∏>’tMu*ä˛é2è]õ˙·éc”<Ωˇ 9?˘~⁄~±ú,¢•¶§Dü≤‹®§røPP˚è|·U¡z^´}•_«}c äÍ ‚9
#ÅÕ
7¬·î¸,{g@MS^ÚÁì|∂|†≤G©y°emGZ∑[Ÿ.aòƒ∂=£∆∏ÆÌ_GÛF$]7Jo0\ƒﬂòâXıòm∏πk`+_: ÇÌ~À≠WÌoúÎ±æº∞ºÇˆ w∂º∂q-ΩƒGã£ØFSû∏¸ò¸Í±ÛïöÈö´«kÊ{u˝‰[*](ﬁ¬?õ˘”∑m≥´S”/6G¸…‰O+yçÈ]>9ß•Âw2¸§Z7ﬂúÀ[ˇ úqYÙMWà=-ÔSê˘zë”Ò\ã…˘?˘©§?+,’^ ÔÜ‡ÏBìÔ·ï˙3Û‚Ãî_”ÓxLexf >N¸Ó‘ÄI◊Rdî‘˙˜|£q»0nõˇ 8˚ÁK…=MJÍ÷ ª≥3µƒø†¯lüy{Ú s,∫ãK´Nª“cÈ√_¯∆ùŸ1Œãgekenñˆ∞§F)1(DQ‡h1|ÿ˙Í⁄÷›Æ.dX†åryÖP<I9∆|ÔÁyıŸÕ≠©1ÈQÖ:4ÃΩ«áÚÆEp”ÀvV◊zèÄé©è2…Ë«4™>öCN ı;ˆ√€˘Á—Ïdπ±û	≠d∏TìNkví≈e‚[ù´LI~~&oëâÊ∏ûKâ‹…4Ã^W=Yò‘úf:(•öTÜ/4¨$Yò–ÙÁ}Úûáã£¡bÑy\8˝©[w?~√€sdœöüØ}ä•∞Â%?ﬂç˝EÛf¡:eìﬂj6ˆä+Í∏Ï£v?vu¥EE
¢ä¢Ä{vlŸ≥fÕõ6lNÊÓ-‰ÇAXÂRå=òS9Â¨∂ós[Iˆ·bßﬁù”àÊÕí_#ÍﬂVøk)ÓÆæ≈z	O¯!∂t”6˘ßÀöwô4ÕR^vw±4Rx©;´ØÉ#  |s¬˛nÚ∂©Âo0ﬁËZí“ÊÕË$ã,mºrß˘.ª˛∞ûô!ÚÁüº’ÂÕ:˜O—Ô¥ƒ3∞P“D¸J4ñÏ∫wåîf]ÈéÚgñ"Û˝Ï⁄Ö·≤“4´w‘uõ–≥ÄoM7/#≥ +Û8Ô0hB]2_5ÿX.çÂ©Ó”I∂∏úºÛÒZ<âœy)∆≤≤¸!çFΩ˚x‚ñ˜€\Gqo+C<,$Üh…WGSP √pFz7Ú´˛rRﬁEáHÛ√Æ √ÆHﬂ∞˙ è∞ﬂÂçèzg† πÇxRx]eÜ@9c`» za±®5Õõ(äÊ‚3qÀÕõ(µ0£Ã^i“4;R˙ZH¬±[•Ø˛™ˇ ∂qﬂ4˘«SÛ¸f>Öåf∞⁄!™ès˚M˛cpEÜùu®Œm≠8µ¡Fh„f
ŒTWÇW´û√&ë‹3IãõfÚá†"º”¶dWÉÑ|]-˚œ\I∏eúÑOww:∆ìM$±¿º-÷F,;*É∞˙1,Ÿ–ˇ *º¨füÙı“˛Í"…b§u~è/—ˆWÈŒ®óÅ5mB=>¬k∑ﬂ”_Ö|XÏ£È9…ÊöIÊy•nRH≈ùèrMqô≥døÚˇ N-,˙ãçêz1|ŒÏ~Ì≤oõ6lŸ≥fÕõ6lÉ˘˚K)q°¸R9à˛aˆO“6»élŸaôX2í¨¶™GPGCùGÀ∫¬ÍörLHı”‡ùGg˛GÆf Âûˇ ï#ŒZ‘4»«¯ãKBm)±∏á´€±Ò=cˇ +n˘„ÊGGdëJ:Æåe`hA°ÆV–µ›SB‘£‘t…Ã1’N¿§ë∑€äD;<n6e;Í>≥Êˇ 2Ëó~`—,!÷|Á5±hΩ¶]/MÖlÌeÂq»‰´IM©øZ·ü<ßms>π≠irŸ§z$6Ê≠jñÕ®‹Ç∑S ¯¨î™Ò+∞»~£Âè2iñ6˜˙ñïwgcwCks</rTTqf‹n0≥&D¸◊Ûóí•§›˙∫}k&ósY-õƒ™‘œ∫ÙÁ°|ôˇ 93‰çec∑÷√Ëƒ Lˇ ºµfˇ &u˚5<Î:Öï˝∫\Ÿ\Guo&È4≤!Ã§åõ6lŸL‘¬ù[ÕZí§ﬂﬁGˆàRí-[9ˇ ò?6Ø'ç’–‘}j`ü5M’~ö‰
‚‚‚ÊwûÊVöw5yd%ôæd‚x">˛k9ÔaÅﬁŒÿÅ<‡|X–T‡˚≠&Í≈,/œ‘. %ÏıhP≥-O"ì"QòWua∏ƒ¸À™A™j¶‚(«EåNWåìp3J:scÖô∞Î ^X∏Û®∂ÀT¥äèy0˝îØŸ˘ü∑ﬂù‚““ﬁ“ﬁ;{t¡Ñé1–*ä 1lƒÁ?Û∂≤.Ôå-X-è∆GÌI–ˇ ¿Ù»ŒlÿË„ycA G!UGRN¿gW—Ù‰”¥Ë-W¨kÒ∑ãùÿ˝¯76lŸ≥fÕõ6lÿT∞ä˛¬kY:J¥‡√u?AŒO<€œ$é2F≈}∆ÿÃŸ∞”À∫ÀiZÇ ƒ˝ZZ%¬èÂ˛oöÁPç÷DWC…¨7áòÄzåÛœ¸‰7‰…üÎtÚÙùG=gOâwëG[ò¬˛–ﬁ„‚ÎZ˘æ†äç¡Ësb÷rπé≥=ºl¡&ö:ñX…˛*[oŸÆ˘Ÿ4Ìc æbøñ.Èˇ Ó ÷Új7ìx}WRƒ‹≤)fuD£À qQJ‚˙„yØ\“˝F“÷«Õg≥πõÃ0ŒeÜﬁ◊M≤xÂ∂‘.!fqo5Q£CM‘ÙÆp˛.9RÎ¡à u°Ôï\ÿ?G◊ı›_G‘ntÈ{µ¥Ø~aM“3†ËﬂÛí?özrÑöÚﬂSçE ºÅym˛\&&?NL¥Ø˘Àni‡∑πÚ‹À4ëƒΩÀØ€`ª+#ÔS∂˘È5≠7‹‰CŒæ|.›Amü÷^xÃºÃú ‹i≤±ÆDnˇ 7µ˘k[{q¸ÕŒS˙–~‘<ÈÊõE∆•0B(—≈Hîèí¬SZíMI‹ìπ9≥Vò:ﬂD‘n ∫tå§÷–ãÅo"≤…$]H¡NßımOR“Ô¥€ç5}MKh≈ç™)kyë‘	‚u ÚvzÚØ≈Ög“Ì¥ÌHEoTIcYÕ£êe∂.*añõU{{aNl£È∫æ£çöÚñMŸœŸDÓÔÏ3∫˘sÀˆZõï®‰≈4ƒQ§êıvß˘å7ÕÑûj◊WL±„•Œ
¬ÏéÔÙv˜ŒhI©'©‹úŸ≥dõ»⁄O÷oö˛A˚´]£ØC!Ò®ŒÅõ6lŸ≥fÕõ6lÿŸ%é4gëÇ"ÃÃh íIËq[Û3…>aÛ¨⁄Nç3Õsm Ù”ºiaj’äØzP”j‡¨Ÿ≥dø…^aÀ•›5üÙW=â˝èÈìzÊÃzgöˇ < ÊÇI¸œ‰˚BˆÔY5="∫≠5∫é™iN´·û}Ì\‘«√4JìA#√4d4r∆≈Xt* AÂì_)yèDπ“5è/yãP∫”§◊Óm$πÛkıß1@O(nC∞s-Œ™N„prK≠#Q“-û<‹Xﬁ∞Úˇ Â÷àƒâBU˙ﬁ®ÙßÔe}ïèÌˆÛóí≠¥€›zÔC∏˙◊ñÙ{ËÙıºù‘;‹H•öË ó“*‹ôi∂˘í)bs®—»øiaﬂpw‹‘√ü%Zµ◊úte`ç.£h°é‡~˝{Ùg*¸„çˆñÙ£¥RÉÚWR?‚Yœ3f««Ú””çò3¨a®xÛcER›9+”ºΩåØ©¿Ô~˙,ÖÔ†h}8$ÙÍ$Ú±<⁄/µ∫ˆ«j:ùúPÍ0\K˙B'It…eº˙‹ÌÃ÷uö%¯"N;ÍNÿK˛ ø¥v:M‰÷p‹˛ˆ{XwR±<ñ0K¸#≥u¬íX±f$≥≥I$ı$úÿ7G—ı^ılÏ"2Jwf;"/Û9Ï3∂y[ ñZÄÇŒ·ËnnH£Hﬂ¡Gaá„¶l®Í÷í\‹7–tÓ«≤èsú∑S‘Æ5Ÿ.ß˚M≤(Ë™:(¿π≥c&ë"â‰sEAR~Y–|ãØhw˙R[ÿ1Im«Ô‡ñÇ^G´ê	‹d¢£6lŸ≥fÕõ6lÿ˛˛Œ¬“kÀ…íﬁ÷›ìœ#DE‹≥1Ë3 _úøü7ûkit?/<ñûZßâH„-·ØÌwH…Íﬂµ·úí“ÚÊ ÓÀW1\€∫…ÉˆYMAœH˘KÃ÷æc–‡‘°¢ ww Î %˘´Ìá9≥fÇ4#°gAÚüôEÚ;¶ˇ Lç~'˚’ˇ ÷ÚKõ1¬ˇ 8Ámµ¶ü^ÚíGi¨π/s¶Ïê\û•êÙéSˇ ›Ëwœ2_Y^ÿ^Me}ñ∑ñÏR{yT££°î‚Ãw…Øïˇ 3Ø4NÛVKyoÂ±é∆∆8—aµÄ•÷1†‰d‚Í KI√o-Í˛B‘tO.Ÿk⁄ÉÈˆﬁ[kªÎ˝ ¿Œöï√7™¨ì©†yV"Æ:∫·Ì∫Xj⁄éÉaØËñ˙«ò¸Òt˙Œ≠<“Iö~ü(+
√$EJp∑ç§¯™†∂sçc –Ÿy~?0Cw ∆ˇ Rª≤“≠›O´-µ≠?“Kl)VJu¬õ˝+Q”÷’Ømﬁ›o†[´BÙ˝‰HYˆ[â•rG˘Gl∑?ô˛Xâì‘_Ø∆ÂG¸WWØ—∆πÓu5Psö~rß¡•IO⁄úWËCLÊ{‡ÀMWª∑kã[9fÅjàªUwj5;”Ì|•,∫\QCuyqs ∏Ñ€∆èn§ì∆)2ª«‚„”ﬂÂö÷ÁG2€…ı]&˙€Í˜qrE∑±(yHâ.rM$´öl|éOÊªπÏ“6∂â/Eπ¥7ÄΩD( ëW“Fa≥0·/6˘c Zßò.€Ø•f¶ì^8¯ƒ/Û7∑ﬂùõ@ÚŒõ¢Y-≠í ≥6ÚH√ˆúˇ ù0‹
fƒÓ'ä^iú$QéNÌ∞ g3Ûø6≠uµR“"D1ˇ Â7π¬úŸ≥aπ{Õ≈¨g·å÷S‚›á—ÄlØØ,.„ª≥ï†πà÷9µz◊ƒùã…û{¥◊c◊ A™"ÇÒVã Z/‚Ω≤\≠\ºŸ≥fÕõ6c”
¸≈Ê=#À⁄E∆≠´›%•ç∞¨≤ΩNÁ¢™çŸòÏ ‹Áêˇ 6ø95ü=ﬁHÉYyrﬁB÷∂ ¸rë≤ÀqN≠‡ΩÁæsöe”$ﬁ@ÛÑæY÷D≤U¥€öGﬂ·fEÃï˙EFz)°ö$öYaïC≈"ö´+
ÇÅ«ÊÕéçﬁ7WçäHÑuÿÇ;ÉùÀièQAkrB_ ˘	ä˚¯åëfÃ@?FB1?)¸ßÁ{ZjPò5(÷ñ⁄§Y„≥ß˘-ÙS<±˘Ö˘;Á$ ÚﬁAı›øª’≠î¥@vıóvàˇ ≠∑Å»6›zÉ·öô©É¥ÕwW“§∏óO∏0Àqm-îè@ÕËLº]∞%j6™Ôù1uﬂ-Îöﬂó<Åg¢⁄k⁄⁄È÷zÅiÌ.ñiÄ{…¢ôH!}Fc≈–˝úÜ~ek∂⁄◊úıã-¥ÀV[-E¥≥Q@|¯r˙p˜˛q˙’Æ?6Ù ¨—˙ƒ∆Ω¬[…∑„û“3û~q+6ì`‡|)r¿ü
∆i˙≥ïdõE’t¥µ±ñ‚h‚‘t◊§opíH´.`€G2‘ê}Oøc◊EΩÂ≈Õµú£‹=≈§“©2@Yâh¡6Î∏"∏Vƒªc…ÿíÃzíw$ÊÕèÜßô Ç6ñi$ôè∞–ºØ˘W4Ö.µÚQ:≠Ñg‚?Òï«¸E~¸È∂∂V÷ê§Ë"Ü1Dç UP; 1lÿú˜€ƒÛL‚8êU›∂ g8Û'ô&’¶Ù„¨v1ü›«–π¥ﬂ¿a&lŸ∞©~- ‚ß˝!ˆèÿwo£#U'z‘úŸi$ëHíD≈$åÜç‘—ïÜ‡É„ùc»ﬂò±Í=7VeèPÈ«ŸIΩèe◊ìÂbrÛfÕõ6léyﬂœ~_Úvå˙¶≥8çhEµ≤êfû@6é%Ó|OAﬂ<u˘è˘õÊ=Í∆ÎPsÑG˝KF&(GJûú‰=‹˝Õõ2œ4pB•ÊïÇFÉ´3(3ùg»ZÓ∑Â[ÿ|©Ê€Y¥ËÓ@óL{°¿ß2@ZìC∞<Of˘ÁT?vlŸ≤’ôX2í¨¶™√bÓN<∑ÁüÖ¶¢¡'ŸcúÏØÏﬁí‹Ÿ®1≤Eà—»Å—¡VF ÇPAÌúáœ?ÛçﬁM◊ƒóz?˚Ä‘⁄¨~Æº≠]øÀÇ£èÕŒÁ…èÃ*¥í]ÈÕ{a˝,,k<TÒe‘OˆKêjÉZ”cÏscíI#ux›ë‘’]IÓ‹cI$‘ÁVˇ úe∑˛i√!BﬂW±∫ë[˘I
ï?Cëû¿¸›à∑ó!q∞éÈ{ÚV»r≤Ûb∂∂óWs-!í‚fÈJ\˛2k°˛Tj◊Ee’%0u0•$òè¯Ç˛9—Ù,h∫,%lmï$;<ÌÒJ√¸ß;·∑ÀÕÅuJ”O∂kã© Ë:≥Œsù{ÃWZº¥?ª¥CX·Ò&Ò8Sõ6lFÍÍXi	ØÏØr|EÆ'í‚VñB7‹Ä˘`´}*{´.≠XO$õãU’HáIi˚I]â_≥ﬂ É]ÚÚ≥£yÛ!¢·¶kí÷=í⁄˘∫é¡e?Ò∑ﬂùF6µÏzc≥fÕòê:‰+Û7ÛSÀ˛C“÷k√ıùN‡c¶F@íB?iøí1›è—Sû:Ûáúıˇ 7Î/´kw¥‰Ç%¯bÇ:‘GˆQ˜û¯Iöπ≤C°˘'UøTΩæˇ q: çn.µªï"ÅŸëL`o,é» ëÆ‰é√|CAæÚ÷ùuww®Z>´$ ˛à≥ê∂íND	n¿n|Qhﬁí˝£±4Î'é€[¸¡∂üZÛ^µo¶⁄Ëvë@ór€ª;%ƒÏ!c"æÄë ô@‚ÄRõdÀ…^læ≥‘ÁÚ_öúGÆÈÚx',f
>Á›∏–°˝°Ôì fÕõ6H¥8]X∑º≠≈†ÿ≤ ˆØQÌìÀ+Î[ÿ{iVX€∫ˆ>v8#6l¶»wö(ˇ /¸Œœ&©£¬nü≠Ìø˙<ıÒ/_Ï´úØÃÛâvÆÕ'óµŸ!Î∆ﬁ˛1(ˆ¨\ÔSú˚Xˇ úq¸’”Àl ‘¢^èg:ÿKÈ6CıÀˇ =iÑ˝À˙ÑEKih+…Í_Ûä˙}‹^z’‰û'Ö†”x4r£#VI“õ0…û•^ô¸‘è‘Úî≠]„ößè««˛6Œ;ù‰‰-Âî∂√Ñn’ß»5¥Ú_öÓÈËÈì z4ÄF7ˇ \ÆX˛Qyäjπ‡¥^‡+}√ä˛9'“ˇ )ºølUÔkÁÒr#éøÍßÒ9/±”,l#Y€«o˝àî(˙iÇ≥fÕQÑzÔöÏt–—!ﬁvâNÀ˛πÌÚŒ®ÍwöÖ¡ûÈ˘∑EQ≤®Q€ÊÕõ4—√íF
´‘üaëã˚ÈnÊÊ€FµGŸGı8;ÀZo◊Æ.[ã≥gÆ∂Ãß)ç2êUôk¬ù∆HK%ûÖg©Ë˜PÀü7≤πU3Gƒ∫£}ñ™5G%?ıÈëõÀkãÿg÷°ä∑íVıÌ≠´˛è_≥…:™7fÈÖŸ≥dœ…_ò7AèO‘ô•“ÎDóvx+·›ì€∑lÎˆ∑v◊ÒÕo"Àä9ue=8∂lƒ”9ÁÁVó‰õcae¬ÛÃ” hlçJB≠“[ät ù[Âæy\÷ı]wU∏’µkñª‘.õî”ø_eP6UQ≤®ÿ`f¶jdõ»HóÕ˙º∫zﬁ.ù1z≤ﬂÀíÍ¡e`»õ5}Œ¿a•∆∑Êalˇ -ıKOM#Iº{kMNÊ5Ö`[vui=]õã(?	‹Ï0˜QÚ^ë≠hZtKíœ¸/`fõ_ÛU¯\«s£†~(·h¯ò#éº´‚0¶5i:zi∂~eÚ›’Óª†@∂v6∆vÇ“xKõãawlPª—§êR£%^x¸∫÷uM+˘Z1Y\IuÊ≠V˙ñ0Ω≈‚,´µ”ë•†A›[ß|ØÀOÃ°™àÙmfQ˙M~[≤Gä~À∑©ˇ ˘ÁFˆÕõ6lc®ﬂXL&¥îƒˇ ¥:´M¥o<Ÿ\R-@}Zc∑©÷#Ùı_ß$…":B[u`A{éÕõ6b*)ç··∂nµ†Øè|v4∆≠‘=Ûp PPñ®¥Ôóõ6lÿQ÷4˝:.wrÑ˛TÍÌÚQæBuü;_^ÜÃ[s±z˛ıáÃ}ü£#grOs‘ÊÕõ62ycÇ'ñV‚ä>◊øÄ˜»Õ˝¸∑íÇj±Æ»ûÁﬂizuº÷“ﬂ^	^÷'Hq˚Ÿ¶í•P(¢ÓiÏ2AqØÑ∞µΩAı€πQ$3RÀ{àá$˝Ï<VAƒ|, |0ûãq´Î_≤H,†ösq¥é≠"ƒ§±dàÄe^J@ﬂl%ÃZ>©ı´`tÌ7S-q$íƒ}oJ2}[MÅU‰˛=AA¨iwvÎ°%¢ŸZÍÔklíà!Mw0"Ω∞∑6lë˘CŒó⁄¬&≠∆òÏ∂’›7›‚ØC‚:ÌZf≠a©⁄Gwc(öﬁ_≤Î‚:Ç:Ç<Œ7˘„˘ﬁ|§[À∫yäX√Àp€•¢H>°˚rë∫ØA‘¯gîÆÆÓÆÓe∫∫ôÓ.gbÛO+ë‹ıfcπ8ïsW5pvâ£ﬁÎZµÆïcÈõÀ«[¨Æ±+9ËºõjûŸ ‘-|›•e˘q8Ü k[ƒ∑6–2§r]Œ‡§◊ß˜¨¢@èŸ2AkÂØ'Í:5Óëofˇ •t[ÎΩ{ÃO$üË◊ˆé¡bp@ÖÌÁ·∆0?ySSﬂ‰À©Øµm3À>kí◊DÚ˜ó#}J}6Ë$ª∏EDnç	ë‰.ªê~
–aáò¨|±ÊÎ›W[—ØÓn<”ßŸçSW’m—†“R[AB–¨Ä‹Úò™Ñ• #óJ‡/!ÍÔôÆu≠V·[Õ^s≥ä˝Ü†‚tS4‹'πHd"66ÍTÖË+ õawÊuÊíNùm%ƒ˛qµ˙W”“8mâ¨pTíXzT˚~_~k#¨ZOòÂ„'Ÿ∂’Ï›ÇN{˚¸s™úŸ≥fÕÉt›kR”ö∂≥ïNÒ7ƒá˝â…fõÁ˚Y(óÒ_º±’ìÓ˚CÒ…%¶£cxúÌgIá˘>c®¡ ◊6lŸ≥fÕõ6l¢¿u¬≠GÕ:5çUÁH?›Q|mÙ”aÙúäÍûz‘.*ñH-c?∑ˆ§˚˙çÀ$≤»dï⁄IÌ;I˙N76lŸ±õ∏mcıejäÂèÄΩæöÓNO¢˝à¡ÿoæ2–Zò≈Ÿql)Ω!W*7†ØJˆ…û≥–úX<z§bh£Ùèy‚·éB’·*Å…ﬂÁÅ≠RB≈†Ü7¥“ÏGØrc„qr“8„Î:dNü¯Gœu6ÎÀ¶->‚àtî€]z¥ùƒá˝!'‚…πÅv€ﬂ	·è[’-mﬁk—%•µ¬¿≠s-VÎ»;Ú≠¶˝iL/4ÀÎy-uMF@aΩíÈn}&¨G"Öp™7F<∂ﬂ
o·eïnπ∑∂ºÂ5§u‰\ Äˇ fî¿Ÿ≥aøñ¸œ©hûΩ´sÅœ˙E£$ÄmÙ0ÏŸÿ∆zO¯[¸AV˙≠)ÈS˜û•x˙T≠9r€<˚ˇ 93˘s©ZÎ≥y⁄‘ÙÀﬂJ-@
ñ∑ôFå‚∑UΩõÁú.ô©öò+K“u=V˛?N∂íÍˆÈ∏€¡´9hN¿§ùá|;É]õÀVöÜó¶≈
ÎR ]kJ&anõ®0Êº‰SV
ë⁄y'WÛîÓ5˘Yı:jè÷ëdè∆È¥˚6Õrë®…~*£cE,+É¸≥Æ˘ó^ÛCh~{’£≥”4nw⁄ïÖÒÜ…nÆ-@Ù¢πtU3'≈πTÓp∑Û.'Í¬Á_≤ûÔQ◊Ó$∑MV˙÷Mn∏üS”i«≠YU*´∞€m∂¡üóût“Ù_*Iô§__kvW´Í“C:√l–CH£ıÇVi°âe%°§∂›˘€@’≠÷O7•ﬁï§È≤∆ë˘wÙJ5õ_¡*¸FîäR9
 “üÚkú‡
PÄË3S'~F¸–æ–Ñz~•Œ˜G
P÷h˘˝•ˇ $˝⁄Ù›SN’,„Ω”ÓÊ÷QTï~‡é†é‡‡¨Ÿ≥fÕñéÒ∞xÿ£éå§Ç>ëá^o◊≠h=q:Ÿòrˇ ÜŸø:µ¸√]Ö’ô-T}Õ˝p÷:Ë”îÕ	=§C˙≈Fã^—Êß•y€ò>t¡+{j¬´4lBOÒ≈U’ÖA{cO}ßU˘ê1)5+ÎÍ\ƒ¥‹’‘SÒ¿r˘ß@äºØcjvJø¸D.πÛˆêÄ˙Õ3v†>ˆ5¸0¢Ôœ˙åÄ≠¥	˛f´∑G{≠j∑µ˙ÕÃéß™≈‡VÉfÕõ6lÿˇ UÜ“®?yqJÑzr9∏ûkâL≥1g=˙ < ∆aÂáò¢]hWq≤ÿHÓ“‹ƒz•ò m…Vüûæÿ4kÎô.ñ¡Ï6¶í\ƒßƒ◊ã¸\HùÔHõOh¶’4ò˛ØØ⁄BJŸç)I.!Êjƒ/˚®ûªÔÄ>≠o©L∫§…k¶ZTó‘isN7ì“TVuSZ∑óL∫Ötõ•}2ŒÊ&kï_Ù∏.VAXßéu˝ÁÓ»¯Z˝pãHÚÎ›B◊R£KnCò`Ö’.•TŸ¶ä7ö°Í;ˆÈÜ7œ¢^y}‡¥ªÖa”ëf∞ÜUhÆπ±§Î%jØÍWê‚v##oqk,ê»ëI˝‹åå™ﬂ&"áõ∂∂∏∫∏ä⁄›≥Ã¡"çzñ9◊ˇ ¿íÄAzÎı∫˝c’ﬂ”ıπÛ„„«ˆóﬁY€^⁄ÀkuÕm:4sB‡2∫0£+‘û8¸Ê¸¢ºÚ6™.¨ñIºµz«ÍósíO’Â?Ò˝°Ó3õdÉ…J‘º·¨'Oû{êû†í‡KÈR†Qû4ê']ãPùpÈ<ﬂ}ßyfÁ»Qi‘’°∏û∆=Z“b≥7´q˚€n<*—HÀJ∂ØÜ±¸∑”-◊T“<√Æh˙n¨ëÚµê_Ü{{à™Z⁄x’}>2≈ànH¿u‹b⁄'ö|ˇ Ê[_—ﬂHñ˙Mº	>â•Ñ≥øΩ≥ÄëbdZÀ$QÔ¿ûõÖÎá>rÚEìÈ?°¯‘<ÕÂ˚yØÖÀ/£ıM‘éﬂRoà}d3ÒçWqZLà˛]ÈjñöÙRﬂ_E•GmÍ:^ô∏ªºWùV0ê±˚∑!ôˇ d|gò¸€Â´[çQÚ°‘mºÕ£ü´‹ﬁ^A"xc_MVx‚fVëW˜o¸kˆ∑»üò¸À≠yèT}KW∏3‹∞·Ä8£f(P|(ãÿ,ÕãYŸ›ﬁ›Cig‹›N¬8-‚RÓÏz*®‹Á∞?()€À~G:n∫ı+Ÿ⁄Ú·c?‹3¢¢∆è‹™†‰zãk^R‘4ÓRƒÕ®ˇ v(¯îîøƒalŸ≥fÕõ6jePxb±3n≤›œÜ&wÎøœ|™ºŸ≥fÕõ6lV÷÷ÊÍa¥m,≠—T¸ŒLÙ?#≈çLâ•Í∂„Ï˛Q˝Ø’ê_Ã_,_XÍÛÍäÜM>Òπ˙ä?∫r (˛oÑÙ»~lÿ;N÷ØÙË¶é’îG9C<n°’¬W‡`v*Cås€⁄jZàM61hf^Ko;ÄÇ_˜‹N{7ÏÚßÜ,ó”Gbtª€H√ƒÔΩ›¬=mΩF¨À@>#ﬂ•W∂	í¬ÔUK=ﬁK€=8È«gëÃ≤ﬁ±≈·^ﬁ¯+Q∏éÀZ6ó
^"¶ï™±fKHîîê"“§≈∫ØÄﬂæg∂èW’Uäñ"≠•¨‘âıÜû© |*Ôﬂ±?\nã}¨M{&®Ú>îÀ"Îq_M S≈U[eïZúÔÙd\t«*≥∫¢)grEIc∞ xúÏüóæJ]ﬂÎ◊©]V·h hD(w‡øÂ⁄?FLÛawò4/_“.¥çVπ∞ºONhõjé†Ç7ßpGCû-¸”¸¥’<áÊ≤∏¨˙]…g“ØªI?aÈ“D®‰>ëÖ1˘≥XM◊B“‘X¿≥$Ûõ0‚‚ÓÈ±I+Ç]å{zh¥Pw∏kÆyV/È¿ÎWsIÁ´È"û◊J∂<ﬁ–;s/z˚∑Ø%~◊‚NJºâ©øôuˆ‘5}-WÕ:¡5éìk6^3ÕKªãûK˚˘a_ãSπÒ¡>q”ﬂY÷`≤–µ»uü=h≥»n5Ò46(i∂≥áqıõòœÌ©€ÏÔ∂y?œﬁ[Úßó•éÍNo4Õ®<˙º*RÓ …µ‘“â≈Vc"p´7\Öjûhyıxı- -¥#Ç-)•ãääÓ“.Ãkªw¬VvvgrYÿñfbI$ÓI'© €6ÿc†yWÛ≠o§hˆÕw®\ü›¬ªP¥Ó«eEXÁÆø(ø&4è#ŸãÀé7æd∏å´ÔÿàÃV‡˝ïÒn≠¯gKÃFkN”o…ñ!ı[É˚h>?Â/Ù»^´Â›WM$ÕxG˚æ?â>û„È¬ÃŸ≥fÕõ6l|C‚?Í∑¸D„3fÕõ6lŸ±—≈,≤,q#I#l®†±?@…6ë‰[Àé2Íıx∫˙KºáÁŸrga•XÿCÈZƒ±ØÌ0›õ˝f;úàœk…®≤E"ïx‹UYOPAŒGÁÀ…¥ì&°¶)óMÎ,"¨◊ø˘I˙≤3f "£uo2Õ©XŸŸInâ£s2fñSƒ!ÊÌ]¯ää&èuÈM¨hW,≠—§ï˘òÓ „O›…«Ìã·#fpÍ“j¬µªî˙çìò"*\LœE‡•@‰ÕAV=ÁJ-;Rº”Êµ&◊K7X_™g≥Y·jUaÕ∂Æı;'◊ıXµ®⁄ ≈!ç"˙ƒ‘ıÁ(?Ωöõr¨ûÁßRs©˛\y#Í öŒ•˙”Ä÷p∏ﬁ5?∂√˘»È‡=Û£ LŸ≥aùºô£yø@∏—µXπ√0¨3 =He‡ñ2z2˛=x£ŒûO◊<ëÊit´‚VxKg{$Y£≠Rhõ®>;’NO+µ◊µ9µõ≤u:YIqKqu£A¶òö)ØëŸxM4™Lï PÔâyû¬œÕñ÷˛Y÷`‘<À¢©¥ü[ππ˙•˛±)R»-¢íziTY˘?Mˆ¬ò5ˇ Àôn4≠wTÇÛÙÆèimn<π≈m5≈ê„çt2£0"îÂZä‰U‘nu=NÛR∫ß÷oßíÊ~"ãŒW.‘86l>Ú_í<¡Áj=+EÉ‘ìfπ∏m°∑åözí∑a‡:ûŸÏ_Ào ˝»öW’lØ>˜⁄îä≥7Üﬂf1˚(?ì ¥ÀÕõ1 ÷ªÉÑzóìÙ{ŒN©ıièÌ≈@	˜^á"∑˛I÷-π4n„…≥ˇ ¿ü‡pÜX¶ÖÃsF—»?aÅS¯„sfÕõ6>Voı˛"qô≥fÕõ+ÿË˙•Ò•≠ª»?úé+ˇ h2K¶˘â®œ∑xa˛.Ä…UÜïßÿ'HV!˚Lƒ~lw8.ô≥f=2ä(zg2ÛœÂø˙ñÖ?iÓlWÔ-˝k˜g5ˇ 3õ6lß©EfˆQ]JñídÅXÑbz‘∏`ö
jvÔy§"Ü7{ÎyO«o¡KT8=>‘èé!}Ê€€väH·ç¶‡nÁâ8…9åQ≠]È◊joÖπ–?.|én⁄=kRåãt!¨†a¥ÑtïÅ˝ë˚>=s´*
éÕõ6lÜ˛f~[Èy–Nº§7p÷]:˘E^©O•£Øûx≥Ã≥Â›^ÎG’°kK˚bcô;a@ √ÌFÎ–˜9>}ÚZjÈÁ!cysÊÿ‚Ñ[i≤˙K¶[]Aƒó
Ë}GE‡"*({Á8öiföI•rÚ ÃÚπÍŒ«ì§úesW6˘1¸µ¸∞◊¸˘´}Z»m:[ÌQ‘ò‚ øœ!Ï£Êvœb˘/»ﬁ]Úééö^çl!ÑQ¶òÔ,“RÜI[ˆò˝√∂H ≥fÕõ6lF‚Œ÷Â
\BíØÉÄﬂØØ<ç£NIÑ=´‰jØ¸W	nø/ıÍmÆcòvW¸l0Æ„ ⁄¸ÂfŒx»qˇ 
kÖÚ⁄‹ƒi,2F{ÚV¨bU3bê}∂ˇ Qˇ ‚' ®ÀZ∂ Úw¡Pi:§‰m&z˜‡i˜ö3∂ÚVΩ1„H˜ë≈~ÂÂáøóëÄ›Ÿoâx˛-_’áñW–ÏËc∂Wêª$¯€Ò€Ä( Ë2ÛfÕõ6l¢†ı»û.‚‘åöéíÇ-G¨ê
*Mˇ 4øøCﬂ94±KØ»cñ2VHÿQïÜƒqπ≥b—^ﬁCêE<ë¡)¨±#ïW S‚ Ô∂#–dø»J:Â»æΩ_˜n‘d5ªèÿ‰è⁄?Fvx„D@à°QEF¿–éÕõ6lŸ≥õ˛r˛R⁄yÎF2⁄*AÊK%ˇ q˜M∞uÍmÂ#ˆ±˝ìøéx‚˙∆Ó¬ˆ{ÿZ⁄Ó÷FÜ‚	N!õ6tè ?…ùcœWI}pœÀ0…∆ÊÙlÛ˚Q€‘û≈˙/πœ^˘À˙FÅ§€È:M≤ZÿZØaNﬁ$ìª1;íw8cõ6lŸ≥fÕõ6lŸàÆ¯Ñö}åøﬁ[ƒ˝˛$Sø“03yEf,÷0{√Â≠
µ1”e¶«ØLµÚÊÑ:XCÙ†?ØèF“cK8T∆5˛#G1ˇ wßèÍ«ÊÕõ6lŸ≥fÕõ6là˘À»ñöÏF‚
A©†<&¶“m≤…O¿ı«/Ï/t˚©-/ah.bŸ‚~Ñ‡ˆ#Õõ$MÚçœòo¯∞hÙËnÆﬁ˛öÊo¿gq≤¥Ç“ﬁ;{x÷(bPë∆¢ÄãÊÕõ6lŸ≥QúoÛ„Úi|”du˝ æc≥å˙∞®Èë/Ï¯µ`˜˚>‰ÁGGdu(ËJ∫0!îÉB;Ç2º||Ïìê∑~hhµœ2$ñû^ŸÌ≠æƒ∑É≠|R~≠€mÛ’ñVVñ6±Z⁄Bñˆ–®H°âB¢*ÏTl/õ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6l ÛWîtÔ0Zpúzwh?—Ó‘Uìÿˇ 2û„8Æ∑°j:-ÛŸﬂG≈ÖLR
ëô	Í?V √O-˘z˜^‘í ◊‡QÒ\NG√WØÃˆ›tm”I±ä Œ1árOVc›è|õ6lŸ≥fÕõ¸{Áôˇ 8?ÂCˇ éØøI˛ï˝/E˝'˙'—Ù=joœ‘ˇ v“ú¯˝;◊	ºóˇ B›˛%≤˙«Èn˛“˛è‘}J|∑ßΩ+“øzÌûÆ∑Ù}5ÙiÈÒ)Jq¶‘¶‘ßJbπ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕò“õ‰sŒˇ ·è–œ˙{˚ç˝?ﬂzîˇ uwÂ¯xÁ1ˇ êkˇ k_˘#ù'»?·Ø–ÉÙ?K‘>ø≠«÷ı?‚ {tÌLîfÕõ6lˇŸ

endstream
endobj
97 0 obj
<</Length 17710>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 59.7543 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(neu)-7.7(roinî)-7.8(amm)-8.3(atio)-6.4(n.)-249.8(When)-254.8(HIV)-253.4(or)-248.2(sim)-7.3(ian)-251.9(immun)-8.9(ode)-7.3(-)]TJ
0 -1.1847 TD
[(ìci)-8.7(ency)-471.1(vi)-6.3(rus)-469.5(\(SIV\))-475(is)-467.5(inf)-9.9(ected)-9.6(,)-464.9(CB2)-470.3(is)-467.5(upr)-8.3(egu)-7.9(late)-7.3(d,)]TJ
0 -1.1795 TD
[(cau)-8.2(sing)-751.5(poten)-7.6(tial)-8.1(ly)-745.7(har)-7.9(mful)-749.8(neuroi)-11.5(nîamma)-9.9(tion,)]TJ
8.2191 0 0 7.3052 287.0361 676.8565 Tm
(120)Tj
10.959 0 0 10.959 59.7543 658.9983 Tm
[(whi)-6.4(ch)-615.3(makes)-617(CB2)-615.1(an)-610.2(at)-5.9(trac)-7.1(tive)-617.8(thera)-8.9(peuti)-9.9(c)-608.3(t)0(a)-5.9(rget)]TJ
T*
[(aga)-7.9(inst)-307.4(HAND)-7.9(.)]TJ
1.0036 -1.1847 TD
[(In)-253.8(fact,)-260.4(in)-254.3(two)]TJ
/F10 1 Tf
5.8405 0 TD
[(in)-259.5(vitro)]TJ
/F6 1 Tf
3.1556 0 TD
[(experiments,)-257.3(the)-256.4(activation)-256.6(of)]TJ
-9.9997 -1.1795 TD
[(CB2)-325.4(by)-319.8(reducing)-322.8(the)-323.7(proinîammatory)-321.8(cytokine)-322(IL-1)]TJ
/F4 1 Tf
21.2669 0 TD
(b)Tj
/F6 1 Tf
-21.2669 -1.1795 TD
[(prevents)-586.9(the)-582.3(synaptic)-587.1(loss)-580.9(caused)-586.1(by)-583.6(HIV)-584.5(protein)]TJ
0 -1.1847 TD
[(gp120)-394.1(in)-394(primary)-390.7(cultures.)]TJ
8.2191 0 0 7.3052 180.1133 599.1306 Tm
(121,122)Tj
10.959 0 0 10.959 209.8771 594.2549 Tm
[(CB2)-392.7(activation)-391.1(may)]TJ
-13.6986 -1.1795 TD
[(not)-415.9(only)-418.6(prevent)-412.9(the)-416.8(production)-414.7(of)-419.5(neurotoxic)-415.5(cyto-)]TJ
0 -1.1847 TD
[(kines)-335.6(and)-333.3(ROS)-336.2(but)-333.4(also)-332(possibly)-332.8(lessen)-333.9(HIV)-336.2(infection)]TJ
0 -1.1795 TD
[(in)-228.5(the)-230.5(CNS.)]TJ
/F4 1 Tf
4.8162 0 TD
(D)Tj
/F6 1 Tf
8.2191 0 0 7.3052 119.8488 560.2959 Tm
(9)Tj
10.959 0 0 10.959 123.7606 555.4203 Tm
[(-THC)-228.5(acts)-229.5(via)-226.2(CB2)-227.1(to)-227.5(inhibit)-227.5(the)-230.5(expres-)]TJ
-5.8405 -1.1847 TD
[(sions)-412.8(of)-414.4(CD4,)-411.5(CXCR4,)-410.2(and)-410.9(CCR5)-409.2(receptors)-414.5(that)-409.3(are)]TJ
0 -1.1795 TD
[(necessary)-253.9(for)-246.9(HIV)-253.4(infection)-249.5(in)-249.2(monocyte-deriv)5.6(ed)-253.8(mac-)]TJ
0 -1.1847 TD
(rophages.)Tj
8.2191 0 0 7.3052 101.4803 521.4046 Tm
(123)Tj
10.959 0 0 10.959 118.3181 516.529 Tm
[(In)-450.3(addition,)-456.4(the)-453(activation)-453.2(of)-455.7(CB2)-449.6(pre-)]TJ
-5.3439 -1.1795 TD
[(cludes)-374.8(the)-375.4(production)-373.3(and)-374.7(infection)-368.4(of)-378.1(CD4)]TJ
/F8 1 Tf
8.2191 0 0 7.3052 259.4834 508.4786 Tm
(+)Tj
/F6 1 Tf
10.959 0 0 10.959 269.4613 503.603 Tm
[(T)-374.1(cells)]TJ
-19.1356 -1.1795 TD
[(by)-247.4(hindering)-247.6(the)-246.1(rearrangement)-246.8(of)-248.8(the)-246.1(cytoskeleton)-245.1(re-)]TJ
0 -1.1847 TD
[(quired)-239.8(for)-231.4(virus)-237.8(fusion.)]TJ
8.2191 0 0 7.3052 159.5905 482.5699 Tm
(124)Tj
10.959 0 0 10.959 173.9905 477.6943 Tm
[(Direct)-234.1(activation)-235.9(of)-233.3(CB2)-232.3(also)]TJ
-10.4239 -1.1795 TD
[(reduces)-398.3(the)-390.9(ability)-393.8(of)-393.7(monocytes)-393.5(to)-393(cross)-392.4(the)-396.1(bloodÖ)]TJ
0 -1.1847 TD
[(brain)-303.5(barrier)-295.5(triggered)-301.2(by)-299.1(HIV.)]TJ
8.2191 0 0 7.3052 197.0645 456.6613 Tm
(125)Tj
10.959 0 0 10.959 70.7527 438.8597 Tm
[(By)-304(activating)-303.8(CB2,)-309.2(HIV)-305.1(infection)-306.4(can)-302.8(slowly)-304.9(spread)]TJ
-1.0036 -1.1847 TD
[(into)-383.5(microglia,)-386(and)-379.9(immune)-384.4(cells)-383.6(that)-383.5(possibly)-379.4(result)]TJ
0 -1.1795 TD
-.0002 Tc
[(in)-337.3(neuroinîammation.)-336.4(Although)]TJ
/F10 1 Tf
13.5744 0 TD
0 Tc
[(in)-337.1(vitro)]TJ
/F6 1 Tf
3.3108 0 TD
[(study)-334.7(shows)]TJ
-16.8852 -1.1847 TD
[(that)-207.6(the)-209.8(CB2)-206.4(activation)-210.1(provides)-203.7(on-demand)-211.5(neuropro-)]TJ
0 -1.1795 TD
[(tection)-325.5(in)-326.8(the)-323.7(presence)-323.5(of)-326.4(HIV,)-325.1(no)-319.6(study)-329.5(has)-323.4(yet)-324.2(used)]TJ
0 -1.1847 TD
[(CB2)-496.1(selective)-499.2(agonists)-498.7(in)-497.5(the)-499.5(HAND)-494.2(model,)-496.6(which)]TJ
0 -1.1795 TD
[(makes)-358.3(it)-358.8(challenging)-361.7(to)-356.8(explain)-356.8(the)-359.9(inîuence)-357.9(of)-362.6(CB2.)]TJ
T*
[(Although)-209.6(these)-211(therapeutic)-213.3(strategies)-212.4(have)-206.6(not)-214.1(been)-211.8(ap-)]TJ
0 -1.1847 TD
[(plied)-470.6(to)-470.6(human)-469.9(beings,)-471.1(evidence)-468(has)-468.3(suggested)-470.6(that)]TJ
0 -1.1795 TD
[(cannabinoid)-328.9(agonists)-328(are)-329.8(well)-326.3(tolerated.)-325.6(Many)-327.7(PLWH)]TJ
0 -1.1847 TD
[(use)-215.8(cannabis)-218.4(either)-214.8(as)-212.9(an)-217(appetite)-215.5(stimulant)-210.9(or)-217.2(in)-212.9(enter-)]TJ
0 -1.1795 TD
[(tainment)-434.5(or)-434.5(medicine,)-429.6(but)-436.9(it)-431.3(has)-432.1(no)-433.4(serious)-434.9(adverse)]TJ
0 -1.1847 TD
[(effect)-304.6(on)-298.9(overall)-299.6(immune)-296.5(function.)]TJ
8.2191 0 0 7.3052 213.1653 288.2834 Tm
(126)Tj
10.959 0 0 10.959 70.7527 270.4818 Tm
[(Ho)23.6(we)22.1(ve)15.2(r)12.2(,)-408(no)-397.1(st)19.3(ud)20.9(ie)19(s)-406.8(h)0(a)16.1(v)13.1(e)-406.5(y)0(e)15.2(t)-406.7(s)12.2(h)0(o)22.2(w)0(n)-401.2(t)12.3(ha)21.3(t)-411.9(c)12.5(an)21(na)21(bi)20.2(s)]TJ
-1.0036 -1.1847 TD
[(us)20.1(er)19.5(s)-572.3(a)0(r)19.8(e)-572.1(le)19.3(ss)-565.3(v)13.1(u)0(l)19.9(n)0(e)20.6(r)0(a)19.8(b)0(l)20.6(e)-572.1(to)-563.7(HA)24.4(ND)-565.1(t)12.3(h)0(a)21.3(n)-571.2(no)16.7(n)13.3(u)0(s)20.1(e)0(r)19.5(s)0(.)]TJ
0 -1.1795 TD
[(In)20.4(de)15.2(e)12.5(d)0(,)-182.8(i)11.7(t)-189.5(i)11.7(s)-189.5(p)0(o)16.4(s)12.2(si)18.7(b)13.7(l)0(e)-182.4(t)12.3(ha)21.3(t)]TJ
/F4 1 Tf
9.6687 0 TD
(D)Tj
/F6 1 Tf
8.2191 0 0 7.3052 172.8566 249.4488 Tm
(9)Tj
10.959 0 0 10.959 176.7118 244.5731 Tm
[(-)12.6(T)0(H)18.6(C)-187.2(it)18.8(s)12.2(e)0(l)19.3(f)-190.1(ca)20.1(n)-193.6(d)13(am)17.8(a)12.8(g)0(e)-181.3(n)0(e)20.6(u)0(-)]TJ
-10.6723 -1.1795 TD
[(ro)20.8(co)15.9(g)13.1(n)0(i)19.8(t)12.3(iv)19.6(e)-675.5(f)11.6(un)16(c)12.5(t)0(i)18.8(o)0(n)-661(i)0(n)-668.2(b)13.7(ot)20.8(h)-674.3(h)0(e)21(a)0(l)19.7(t)12.3(hy)-666.4(c)12.5(o)0(n)16.7(t)12.3(r)12.2(o)0(l)20.6(s)-675.8(an)21(d)]TJ
0 -1.1847 TD
[(PL)17(W)11(H)0(,)-258.4(w)0(h)23.3(i)0(c)19(h)-270.8(m)15.3(a)0(y)-258.6(b)0(e)-258.3(a)-271.7(r)12.2(e)0(s)19.5(u)0(l)19.9(t)-267(of)]TJ
/F4 1 Tf
13.2278 0 TD
(D)Tj
/F6 1 Tf
8.2191 0 0 7.3052 211.918 223.5401 Tm
(9)Tj
10.959 0 0 10.959 215.7732 218.6645 Tm
[(-)12.6(T)0(H)18.6(C)-264.8(of)-259.2(ps)20.1(yc)20.4(ho)17(a)12.8(c)0(-)]TJ
-14.2366 -1.1795 TD
[(ti)18.8(ve)-305.5(ef)19(fe)19(ct)19.6(s)-318.9(r)12.2(at)19.9(he)21(r)-318.9(t)12.3(ha)21.3(n)-317.7(C)0(B)18.1(2)13.4(-m)17.5(e)12.5(d)0(i)19.5(a)0(t)19.9(e)0(d)-305.6(e)0(f)19(f)0(e)19(c)0(t)19.6(.)]TJ
8.2191 0 0 7.3052 251.4897 210.6141 Tm
[(12)19.9(7)]TJ
10.959 0 0 10.959 266.57 205.7385 Tm
[(De)17.2(s)12.2(p)0(i)19.5(t)12.3(e)]TJ
-18.8717 -1.1847 TD
[(th)20.8(e)-473.8(a)12.8(bo)17.1(v)13.1(e)-468.6(li)18.5(m)10.2(i)11.7(ta)19.9(ti)18.8(on)21.9(s,)-463(s)12.2(e)0(l)19.3(e)0(c)19.8(t)0(i)18.8(v)0(e)-460.7(a)12.8(ct)19.6(iv)19.6(at)19.9(io)20.2(n)-472.9(o)13.7(f)-474.6(C)14.5(B2)-458.9(re)19.5(-)]TJ
0 -1.1795 TD
[(m)10.2(a)0(i)19.3(n)0(s)-248.6(a)-256.2(p)13(o)0(t)20.8(e)0(n)15.5(t)12.3(i)11.7(a)0(l)-249.3(t)12.3(he)21(ra)19.8(pe)20.3(ut)20.2(ic)-250(a)12.8(p)0(p)15.7(r)12.2(oa)21.3(ch)-248(f)11.7(o)0(r)-248.2(t)12.3(wo)-245.6(re)19.5(as)19.8(on)21.9(s.)]TJ
0 -1.1847 TD
[(Fi)19.5(rs)19.3(t,)-240.5(si)18.7(n)13.3(c)0(e)-244(C)14.5(B2)-241.6(a)12.8(g)0(o)21.6(n)0(i)19.8(s)0(t)-239.3(m)10.2(ai)19.3(nl)20.2(y)-250.7(t)12.3(ar)19.8(ge)20.4(ts)-239.3(im)16.7(m)15.3(u)0(n)16(e)-246.2(ce)19.8(ll)18.9(s)-251.6(i)11.7(n-)]TJ
0 -1.1795 TD
[(st)19.4(ea)20.1(d)-343.9(o)0(f)-331.6(n)0(e)20.6(r)0(v)20.2(e)-344.5(ce)19.8(ll)18.9(s)12.2(,)-345.9(i)11.7(t)-344.6(ha)21.3(s)-344.7(a)-344.1(l)12(o)13.7(we)17(r)-339.6(a)0(b)16.2(u)13(se)-332.2(po)16.4(t)12.3(e)0(n)20.6(t)0(i)18.8(a)12.8(l)-344.9(a)0(n)21(d)]TJ
0 -1.1847 TD
[(fe)19(we)17(r)-355.1(p)13(sy)20.2(ch)15.8(o)13.7(a)0(c)20.1(t)0(i)18.8(v)0(e)-346.9(e)12.5(ff)18.1(ec)19.8(ts)-347.9(c)12.5(o)0(m)18.7(p)0(a)20.6(r)0(e)19.5(d)-359.4(w)14.8(i)0(t)18.8(h)-358.8(C)14.5(B)0(1)-345.1(a)0(g)15.6(o)13.7(ni)19.8(st)]TJ
0 -1.1795 TD
[(or)-465.5(ot)20.8(he)21(r)-474.1(m)10.2(ix)19.3(ed)-465.9(a)12.8(g)0(o)16.5(n)13.3(is)18.7(t)12.3(.)-475.2(Se)20.1(co)15.9(n)13.3(d)0(,)-467.4(C)14.5(B2)-464.1(ag)20.7(on)16.7(i)11.7(s)12.2(t)-479.1(i)11.7(s)-474.1(a)0(l)19.7(s)12.2(o)]TJ
0 -1.1847 TD
[(m)10.2(o)0(s)20.8(t)-370.5(e)12.5(f)11.7(fe)19(ct)19.6(iv)19.6(e)-370.3(w)14.8(he)21(n)-369.5(n)0(e)20.6(u)0(r)20.1(o)0(p)21.6(r)0(o)20.8(t)0(e)19.6(c)0(t)19.6(i)0(o)20.2(n)-369.5(i)11.7(s)-365.4(m)10.2(o)0(s)20.8(t)0(l)19.2(y)-364.5(ne)15.5(e)12.5(d)0(e)20.3(d)]TJ
0 -1.1795 TD
[(du)15.7(r)12.2(i)11.7(ng)-237.4(HI)17(V)-244.5(i)0(n)19.8(f)0(e)19(c)0(t)19.6(i)11.7(on)-236.8(si)18.7(nc)20.6(e)-251.3(C)14.5(B2)-241.6(e)12.5(x)0(p)20.6(r)0(e)19.5(s)0(s)19.3(i)11.7(on)-236.8(is)-239.9(i)11.7(n)0(c)15.5(r)12.2(ea)20.1(se)19.5(d.)]TJ
1.0036 -1.1795 TD
[(As)-402.7(previously)-401.1(described,)-408.4(several)-404.1(putative)-401.1(endocan-)]TJ
-1.0036 -1.1847 TD
[(nabinoids)-577.7(have)-573.9(been)-573.9(discovered.)]TJ
8.2191 0 0 7.3052 211.181 81.0708 Tm
(19,76Ö79,83)Tj
10.959 0 0 10.959 256.7621 76.1953 Tm
[(Here,)-578.2(we)]TJ
-17.9768 -1.1795 TD
[(mainly)-294.2(focus)-288.7(on)-293.7(two)-290.2(of)-290.2(the)-292.6(most)-287.9(well-characterized)-290.2(li-)]TJ
22.912 57.9085 TD
[(gands,)-333.1(AEA)-335(and)-338.5(2-AG.)-337.2(AEA)-335(generates)-331.5(signaling)-336.8(both)]TJ
0 -1.1847 TD
[(retrograde)-473.5(and)-478.2(nonretrograde,)-479(and)-473(its)-481.1(functions)-476(are)]TJ
0 -1.1795 TD
[(relatively)-331(slow.)]TJ
8.2191 0 0 7.3052 376.044 676.8565 Tm
(82)Tj
10.959 0 0 10.959 387.6093 671.981 Tm
[(2-AG)-332.7(is)-333(the)-334(most)-334.4(famous)-335.1(retrograde)]TJ
-7.0045 -1.1847 TD
[(messenger)-525.6(in)-528.5(the)-530.6(CNS)-527(and)-529.9(plays)-526.6(a)-525.2(critical)-528.3(role)-528.9(in)]TJ
0 -1.1795 TD
[(time-dependent)-378.9(plasticity)-383.4(and)-385.1(long-term)-379.5(inhibition.)]TJ
8.2191 0 0 7.3052 542.0408 650.9479 Tm
(85)Tj
10.959 0 0 10.959 310.8472 633.0896 Tm
[(The)-296.2(concentrations)-297.5(of)-295.4(AEA)-298.8(and)-297.1(2-AG)-296.5(can)-297.6(be)-299.7(elevated)]TJ
T*
[(by)-449.1(preventing)-447.2(their)-449.8(degradative)-450.7(enzymes.)-451(Numerous)]TJ
T*
-.0001 Tc
[(selective)-494.1(inhibitions)-492.2(on)-495.5(endocannabinoids)-496(metabolic)]TJ
0 -1.1847 TD
0 Tc
[(activities)-394.6(have)-392.8(been)-398(developed)-396.8(and)-395.4(extensively)-394.9(inves-)]TJ
0 -1.1795 TD
[(tigated)-279.6(in)-280.2(models)-278.2(of)-279.9(neuropsych)5.1(iatry)-279.3(and)-281.6(neurodegen-)]TJ
0 -1.1847 TD
(eration.)Tj
8.2191 0 0 7.3052 344.1259 573.2219 Tm
(128)Tj
10.959 0 0 10.959 321.7889 555.4203 Tm
[(Unlike)-553.4(the)-551.3(extensive)-554.5(and)-550.6(sustained)-554.3(activation)-551.5(of)]TJ
-.9984 -1.1847 TD
[(CB1)-216.8(or)-217.2(CB2)-211.6(released)-221(by)-216.3(agonists,)-218.7(increasing)-216.1(the)-215(activity)]TJ
0 -1.1795 TD
-.0001 Tc
[(of)-238.6(endocannabinoids)-237.4(by)-237.1(preventing)-240.3(metabolic)-235.3(enzymes)]TJ
0 -1.1847 TD
0 Tc
[(can)-380.4(enhance)-375(endocannabinoidsê)-377.2(signaling)-378.2(and)-379.9(reduce)]TJ
0 -1.1795 TD
[(side)-380(effects)-385.5(of)-378.1(CB1)-382.3(and)-379.9(CB2)-377.2(agonists.)]TJ
8.2191 0 0 7.3052 480.8125 508.4786 Tm
(70,102)Tj
10.959 0 0 10.959 506.4943 503.603 Tm
(Metabolic)Tj
-17.8526 -1.1795 TD
[(enzyme)-365.7(inhibitors)-365.2(also)-368.3(prevent)-366.3(the)-370.2(rapid)-366.6(degradation)]TJ
0 -1.1847 TD
[(of)-326.4(2-AG)-332.7(and)-328.1(AEA)-329.9(when)-328.5(administered)-328.5(directly.)]TJ
8.2191 0 0 7.3052 519.1369 482.5699 Tm
(19)Tj
10.959 0 0 10.959 530.6455 477.6943 Tm
(Col-)Tj
-20.0564 -1.1795 TD
[(lectively,)-301.4(the)-303(targeting)-300.5(of)-305.7(the)-297.8(ECS)-305.7(may)-300.2(be)-304.9(a)-302.8(promising)]TJ
0 -1.1847 TD
[(strategy)-277.1(for)-283.2(alleviating)-281.7(the)-277.1(inîammation)-283.4(and)-276.4(neurode-)]TJ
0 -1.1795 TD
[(generation)-296.7(caused)-301.6(by)-299.1(HIV-1)-299.9(infection.)]TJ
/F5 1 Tf
10.4607 0 0 10.4607 310.8472 412.9511 Tm
[(Pre-clinical)-303.4(and)-298.4(Clinical)-305.1(Evidences)]TJ
0 -1.2411 TD
[(of)-298.1(Cannabinoids)-304.3(as)-299.5(Therapeutic)]TJ
0 -1.2357 TD
[(Agents)-297.7(in)-301.4(HAND)]TJ
/F6 1 Tf
10.959 0 0 10.959 310.8472 374.0597 Tm
[(Pre-clinical)-512.7(evidence)-514.5(accumulated)-510.1(over)-512.4(the)-515.1(last)-514.5(few)]TJ
0 -1.1795 TD
[(years)-314.8(shows)-311(cannabinoids)-316.7(against)-315.3(HAND.)-312.4(A)-316.6(study)-314(on)]TJ
0 -1.1847 TD
[(rat)-231.7(C6)-230.7(glioma)-236.9(cells)-233.6(demonstrated)-227.6(that)-233.5(cannabinoids)-233.9(in-)]TJ
0 -1.1795 TD
[(hibit)-443.9(Tat-induced)-449.1(cytotoxicity)6.8(.)]TJ
8.2191 0 0 7.3052 447.8739 340.1007 Tm
(128)Tj
10.959 0 0 10.959 464.5416 335.2251 Tm
[(It)-446.2(has)-447.6(been)-449.8(shown)]TJ
-14.0245 -1.1847 TD
[(that)-481.8(treatment)-484.6(of)-486.8(C6)-484.2(cells)-481.9(with)-485.5(Tat)-483.5(combined)-484(with)]TJ
0 -1.1795 TD
[(IFN-1)-497.9(inhibits)-505(iNOS)-499.6(expression)-505(and)-504(NO)-498.2(release)-503(in)]TJ
0 -1.1847 TD
[(these)-319.6(cells.)-320.8(Stimulating)-320.1(CB1)-320.2(also)-321.7(hindered)-322.3(Tat)]TJ
/F8 1 Tf
18.8303 0 TD
(+)Tj
/F6 1 Tf
1.0398 0 TD
(IFN-)Tj
/F9 1 Tf
-19.8702 -1.1795 TD
(c)Tj
/F6 1 Tf
.4345 0 TD
[(-caused)-325.3(and)-328.1(NO-mediated)-320.4(cell)-323.4(toxicity.)-328.6(Additionally,)]TJ
-.4345 -1.1795 TD
[(treating)-225.7(C6)-230.7(cells)-228.4(with)-226.9(Tat)]TJ
/F8 1 Tf
10.1135 0 TD
(+)Tj
/F6 1 Tf
.9467 0 TD
(IFN-)Tj
/F9 1 Tf
1.9451 0 TD
(c)Tj
/F6 1 Tf
.6673 0 TD
[(generated)-227.2(a)-230.3(substan-)]TJ
-13.6727 -1.1847 TD
[(tial)-349.5(inhibition)-349.1(of)-352.3(CB1)-351.3(rather)-348.5(than)-351.4(CB2.)]TJ
8.2191 0 0 7.3052 485.9149 262.3748 Tm
(128)Tj
10.959 0 0 10.959 501.562 257.4991 Tm
(Eventually,)Tj
-17.4025 -1.1795 TD
[(treatment)-350.1(with)-356.2(Tat)]TJ
/F8 1 Tf
7.8839 0 TD
(+)Tj
/F6 1 Tf
1.0708 0 TD
(IFN-)Tj
/F9 1 Tf
1.9451 0 TD
(c)Tj
/F6 1 Tf
.7915 0 TD
[(also)-352.7(resulted)-355.4(in)-352.6(a)-354.5(signiì-)]TJ
-11.6914 -1.1847 TD
[(cant)-476.8(inhibition)-478.5(of)-476.4(AEA)-479.9(uptake)-476.8(of)-481.6(C6)-473.9(cells,)-481.2(without)]TJ
0 -1.1795 TD
[(inîuencing)-296.1(FAAH)-299.9(hydrolysis)-302.4(of)-295.4(AEA.)]TJ
.9984 -1.1847 TD
[(Ov)22.7(er)19.5(al)19.7(l,)-189(th)20.8(es)19.5(e)-199.6(d)0(a)20.6(t)0(a)-187(d)0(e)15.2(m)15.3(on)16.7(s)12.2(t)0(r)19.4(a)0(t)19.9(e)12.5(d)-199.1(t)0(h)20.8(a)0(t)-192.2(t)12.3(he)-185.9(EC)17.8(S)-199.3(v)13.1(ia)-187.6(re)19.5(g-)]TJ
-.9984 -1.1795 TD
[(u)13(l)0(a)19.7(t)0(i)18.8(o)0(n)-386.8(o)0(f)-393.7(N)0(O)-389.5(s)12.2(yn)21.3(th)20.8(es)19.5(is)-389.9(de)20.3(cr)19.5(ea)20.1(se)19.5(d)-400.8(H)0(I)17(V)14.1(-1)-393(c)12.5(y)0(t)20.2(o)0(t)20.8(o)0(x)21.3(i)11.7(ci)19(ty)]TJ
0 -1.1847 TD
[(c)12.5(a)0(u)20.7(s)0(e)19.5(d)-302.5(by)-293.9(Ta)21.5(t.)]TJ
8.2191 0 0 7.3052 373.3794 184.6488 Tm
[(12)26.8(8)]TJ
10.959 0 0 10.959 388.2896 179.7732 Tm
[(La)21.3(te)19.6(r,)-292.3(in)-295.7(a)12.8(n)]TJ
/F10 1 Tf
4.8886 0 TD
-.0121 Tc
[(in)-314(v)-12.1(i)6.9(vo)]TJ
/F6 1 Tf
2.9746 0 TD
0 Tc
[(st)19.3(ud)20.9(y,)-296.6(t)12.3(h)0(e)-294.6(g)13.1(p1)16.1(2)13.4(0)0(-)]TJ
-14.9298 -1.1795 TD
[(i)11.7(n)0(d)21.2(u)0(c)20.3(e)0(d)-481.5(n)0(e)20.7(u)0(r)20.1(o)0(n)21.9(a)0(l)-482.1(a)12.8(po)21.6(pt)20.1(os)20.8(is)-483.1(i)11.7(n)-488.5(t)12.3(h)0(e)-480.8(n)0(e)20.6(o)0(c)21(o)0(r)20.8(t)0(e)19.6(x)-489(of)-476.4(ra)19.9(ts)]TJ
T*
[(r)12.2(e)0(s)19.5(u)0(l)19.9(t)0(e)19.6(d)-421.5(in)-414.7(a)-421.7(t)0(i)18.8(m)10.2(e)12.5(-)0(d)20.4(e)0(p)15.2(e)12.5(nd)21.2(en)15.5(t)-422.2(e)12.5(l)12(e)0(v)20.4(a)0(t)19.9(i)0(o)20.2(n)-426.4(i)11.7(n)-421.2(th)20.8(e)-427.2(a)12.8(ct)19.6(i)11.7(v)0(i)19.6(t)0(y)]TJ
0 -1.1847 TD
[(a)12.8(n)0(d)-330.6(i)11.7(m)10.2(m)10.2(u)13(no)16.7(r)12.2(e)0(a)20.1(c)0(t)19.6(i)11.7(vi)19.6(ty)-326.4(of)-326.4(FA)22.3(AH)-327.4(\()11.9(a)0(p)15.5(p)13(ro)20.8(xi)19.3(m)10.2(a)0(t)19.9(e)0(l)19.3(y)-333.5(th)20.8(re)19.5(e-)]TJ
0 -1.1795 TD
[(f)11.7(o)0(l)20.6(d)-338.7(vs)20.2(.)-340.7(t)12.3(he)-330.8(c)12.5(o)0(n)16.7(t)12.3(r)12.2(o)0(l)20.6(\))0(,)-328.8(p)0(a)15.5(r)12.2(al)19.7(l)12(e)0(l)19.3(e)0(d)-331.4(b)13.7(y)-338.7(i)0(n)19.8(c)0(r)19.5(e)0(a)20.1(s)0(e)19.5(d)-338.7(ac)20.1(ti)18.8(vi)19.6(t)12.3(y)-338.7(of)]TJ
0 -1.1847 TD
[(t)12.3(h)0(e)-268.7(A)0(E)22.9(A)-280.4(m)15.3(e)0(m)17.5(b)13.7(ra)19.8(ne)-269.1(t)12.3(r)0(a)19.8(n)0(s)15.2(p)13(or)20.8(te)19.6(r)-277.5(a)0(n)21(d)-276.7(de)20.3(cr)19.5(ea)20.1(se)19.5(d)-281.8(e)12.5(nd)21.2(og)21.6(e-)]TJ
0 -1.1795 TD
[(n)13.3(o)0(u)16.4(s)-287.8(l)12(e)0(v)20.4(e)0(l)19.4(s)-293(o)13.7(f)-293.6(AE)22.9(A)-290.7(\()11.9(ap)15.5(p)13(r)0(o)20.8(x)0(i)19.3(m)10.2(at)19.9(e)12.5(l)0(y)-280.1(h)0(a)21.3(l)0(f)-64.3(\))0(.)]TJ
8.2191 0 0 7.3052 488.2959 106.9795 Tm
[(12)26.8(9)]TJ
10.959 0 0 10.959 321.7889 89.1212 Tm
[(Ad)22.3(di)19.5(ti)18.8(on)21.9(al)19.7(ly)20(,)-195.9(t)0(h)20.8(e)-199.6(F)13(A)0(A)18.6(H)-197(i)11.7(n)0(h)21.8(i)0(b)20.2(i)0(t)18.8(o)0(r)-186.2(m)10.2(e)12.5(t)0(h)20.8(y)0(l)20(-)0(a)20.2(r)0(a)19.8(c)0(h)21(i)0(d)19.5(o)0(n)21.9(y)0(l)]TJ
-.9984 -1.1795 TD
[(î)13.7(u)0(o)16.4(r)12.2(op)21.6(ho)17.1(s)12.2(p)0(h)21.5(a)0(t)19.9(e)-458.3(co)21(ns)15.2(i)11.7(d)0(e)20.3(r)12.2(ab)16.2(l)12(y)-457.6(de)20.3(cr)19.5(ea)20.1(se)19.5(d)-462.9(g)13.1(p1)21.3(20)16.5(-)12.6(c)0(a)20.1(u)0(s)20.1(e)0(d)]TJ
0 -1.1847 TD
[(neocor)-10(tex)-469.4(apo)-7(ptosi)-9.5(s)-463.7(i)0(n)-471.6(the)-468.5(bra)-7.8(in)-466.4(of)-471.3(rat,)-468.9(w)-5.9(hile)-467.4(A)-6.2(E)0(A)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23783.5(7)]TJ
ET

endstream
endobj
101 0 obj
<</Length 16819>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 62.022 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(membr)17.3(an)15.8(e)-458.3(t)12.3(r)12.2(a)0(n)15.8(s)12.2(po)21.6(rt)19.3(er)19.5(s)-458.5(\()11.9(i.)17.6(e.)18.4(,)-459.7(V)0(R)22.9(1)-457.3(re)19.5(ce)19.8(pt)20.2(or)20.8(s\))-451.8(o)13.7(r)-458.5(AE)17.8(A)]TJ
0 -1.1847 TD
[(bi)20.2(nd)21.2(in)19.8(g)-364.5(r)0(e)19.5(c)0(e)19.8(p)0(t)20.2(o)0(r)-356.9(\()11.9(i.)17.6(e)12.5(.)0(,)-360.7(C)14.5(B1)-355.5(an)21(d)-364.6(C)0(B)18.1(2)13.4(\))-365.7(s)0(e)19.5(l)0(e)19.4(c)0(t)19.6(i)11.7(ve)-357.2(a)12.8(n)0(t)20.5(a)0(g)20.7(o)0(-)]TJ
0 -1.1795 TD
[(ni)19.8(st)19.3(s)12.2(,)-232.1(s)12.2(u)0(c)20.3(h)-229.5(as)-218.1(SR)21.5(14)16.5(1)13.4(7)0(1)21.6(6)0(,)-218.7(S)0(R)21.5(1)0(4)16.5(4)13.4(52)21.6(8,)-218.7(an)21(d)-230.1(c)0(a)20.1(p)0(s)20.1(a)0(z)20.1(e)0(p)20.3(i)0(n)19.8(e)0(,)-219.6(r)0(e)19.5(-)]TJ
0 -1.1847 TD
[(sp)20.1(ec)19.8(ti)18.8(v)13.1(e)0(l)19.3(y)0(,)-1005.3(w)0(e)22.1(r)0(e)-1004.7(i)0(n)19.8(e)0(f)19(f)0(e)19(c)0(t)19.6(i)11.7(ve)20.4(.)]TJ
8.2191 0 0 7.3052 193.7196 663.8738 Tm
-.0168 Tc
[(12)-16.8(9)]TJ
10.959 0 0 10.959 216.3968 658.9983 Tm
0 Tc
[(Co)17.9(l)12(l)12(e)0(c)19.8(t)0(i)18.8(v)0(e)20.4(l)12(y,)-1005.3(th)20.8(es)19.5(e)]TJ
-14.0865 -1.1795 TD
[(ìn)21.8(di)19.5(ng)16.1(s)-391.3(s)0(u)20.1(g)0(g)21(e)0(s)19.5(t)-396.4(t)12.3(h)0(a)16.1(t)-391.2(gp)21(12)16.5(0)-390.1(r)0(e)19.5(d)0(u)15.7(c)12.5(es)-384(en)20.7(do)16.4(g)13.1(e)0(n)20.7(o)0(u)16.4(s)-391.3(AE)17.8(A)]TJ
0 -1.1847 TD
[(l)12(e)0(v)20.4(e)0(l)19.3(s)-205(by)-195.6(a)12.8(c)0(t)19.6(i)0(v)19.6(a)0(t)19.9(i)0(n)19.8(g)-204.2(FA)17.2(A)14.5(H)0(.)-196.3(R)0(e)21.2(c)0(e)19.8(n)0(t)20.5(l)0(y)20(,)-206.2(hu)21.5(m)10.2(a)0(n)-196.3(U)0(8)23.3(7)0(M)19(G)-202.5(as)19.8(-)]TJ
0 -1.1795 TD
[(t)12.3(r)0(o)15.6(c)12.5(yt)20.2(om)23.9(a)-271.7(c)12.5(el)19.3(ls)-260.3(t)12.3(r)0(e)19.5(a)0(t)19.9(e)0(d)-259(w)0(i)21.3(t)0(h)-258.5(g)0(p)21(1)0(2)16.5(0)-265.9(sh)20.7(ow)18.2(e)12.5(d)-271.5(a)-266.6(s)12.2(im)16.7(i)11.7(l)12(ar)-259.5(re)19.5(-)]TJ
T*
[(du)20.9(ct)19.6(io)20.2(n)-648.8(i)11.7(n)-648.8(A)0(E)17.8(A)-647.7(t)12.3(o)0(n)21.9(e)-649.7(c)12.5(a)0(u)15.5(s)12.2(ed)-636.6(by)-640.5(i)11.7(n)0(c)20.6(r)0(e)19.5(a)0(s)19.8(e)0(d)-636.7(F)0(A)17.2(A)0(H)]TJ
0 -1.1847 TD
[(ac)20.1(ti)18.8(v)13.1(i)0(t)18.8(y)0(.)]TJ
8.2191 0 0 7.3052 95.1307 599.1306 Tm
[(13)26.8(0)]TJ
10.959 0 0 10.959 110.0409 594.2549 Tm
[(A)-295.9(r)0(e)19.5(c)0(e)19.8(n)0(t)-289.9(s)0(t)19.4(u)0(d)15.7(y)-297.3(f)11.7(o)0(u)16.4(n)13.3(d)-302.5(t)12.3(ha)21.3(t)-303.3(T)13.9(at)-290.5(ex)20.1(pr)14.9(e)12.5(s)12.2(si)18.7(on)-288.5(in)]TJ
-4.3817 -1.1795 TD
[(t)12.3(r)0(a)19.8(n)0(s)15.2(g)13.1(en)20.6(ic)-198.3(m)10.2(i)11.7(ce)-197.5(wa)17.3(s)-205(s)0(e)19.5(x)0(-)20.2(d)0(e)20.3(p)0(e)20.3(n)0(d)16(e)12.5(nt)-196.8(on)-200.6(i)11.7(n)0(h)21.8(i)11.7(bi)20.2(to)20.8(ry)-197.1(ne)15.5(u)13(r)0(o)20.8(-)]TJ
0 -1.1847 TD
[(t)12.3(r)0(a)19.8(n)0(s)15.2(m)15.3(is)18.7(si)18.7(on)-293.7(an)15.8(d)-302.5(w)0(a)22.5(s)-308.5(i)11.7(n)0(h)16.7(i)11.7(b)13.7(i)0(t)18.8(e)0(d)-295.2(b)0(y)-293.9(t)0(h)20.8(e)-308.2(FA)22.3(AH)-296.4(i)11.7(n)0(h)16.7(i)11.7(bi)20.2(t)12.3(o)0(r)]TJ
0 -1.1795 TD
[(PF)21.5(38)16.5(4)13.4(5)-291.8(t)12.3(h)0(r)20.7(o)0(u)21.6(g)0(h)-283.6(a)-287.2(CB)23.3(1)-291.8(m)10.2(e)12.5(c)0(h)15.8(a)12.8(ni)19.8(sm)17.2(.)]TJ
8.2191 0 0 7.3052 216.4535 560.2959 Tm
-.0169 Tc
[(13)-16.9(1)]TJ
10.959 0 0 10.959 72.9637 542.4377 Tm
0 Tc
[(The)-301.4(therapeutic)-301.2(potential)-300.2(of)-305.7(cannabinoids)-301.1(for)-298.7(treat-)]TJ
-.9984 -1.1795 TD
[(ing)-220.5(CNS)-221.8(disorders,)-222.7(including)-217.4(neurodegenerative)-223.5(condi-)]TJ
0 -1.1847 TD
(tions,)Tj
8.2191 0 0 7.3052 85.9464 521.4046 Tm
(132)Tj
10.959 0 0 10.959 101.537 516.529 Tm
[(cognitive)-341.3(decline,)]TJ
8.2191 0 0 7.3052 178.1291 521.4046 Tm
(133)Tj
10.959 0 0 10.959 193.7196 516.529 Tm
[(and)-338.5(appetite)-344.8(loss,)]TJ
8.2191 0 0 7.3052 270.9354 521.4046 Tm
(134)Tj
10.959 0 0 10.959 286.5259 516.529 Tm
(has)Tj
-20.4858 -1.1795 TD
[(been)-330.8(demonstrated.)-330.3(Despite)-329.7(extensive)-332(research)-334(on)-329.9(the)]TJ
T*
[(cognitive)-305.1(effects)-307.9(of)-305.7(cannabis)-311.5(use)-303.7(in)-311.2(PLWH,)-302.9(the)-308.1(results)]TJ
0 -1.1847 TD
[(are)-448.8(contrary,)-445.5(mainly)-449.4(owing)-445.5(to)-444.7(differences)-448.9(in)-445.7(disease)]TJ
0 -1.1795 TD
[(progression)-211.8(and)-209.2(methodologies,)-207.4(such)-207.2(as)-212.9(cognitive)-206.8(func-)]TJ
0 -1.1847 TD
[(tioning)-505.8(assessed)-500.4(and)-504(the)-504.7(amount)-504.1(of)-502.3(cannabis)-502.9(used.)]TJ
0 -1.1795 TD
[(A)-326.9(well-documente)6.2(d)-328.4(and)-323(established)-321.8(effect)-325.3(of)-326.4(cannabis)]TJ
0 -1.1847 TD
[(use)-443.4(on)-438.5(HIV-negative)-439.6(individuals)-441.8(is)-436.5(memory)-440.3(deìcits,)]TJ
0 -1.1795 TD
[(but)-348.9(its)-346.6(long-term)-343.3(effects)-349.3(are)-345.3(still)-348.4(unknown.)]TJ
8.2191 0 0 7.3052 253.7007 417.8267 Tm
(135,136)Tj
10.959 0 0 10.959 282.9543 412.9511 Tm
[(In)-346.9(a)]TJ
-20.1599 -1.1847 TD
[(meta-analysis)-372.4(of)-373(cannabisês)-371(nonacute)-372.5(effects,)-374.4(learning)]TJ
0 -1.1795 TD
[(and)-426.4(memory)-419.6(were)-423.9(found)-426.7(to)-418.9(be)-423.9(only)-423.7(mildly)-424.6(affected,)]TJ
0 -1.1847 TD
[(and)-302.3(no)-298.9(other)-297.7(negative)-297(effects)-302.7(were)-299.8(noted.)]TJ
8.2191 0 0 7.3052 244.0062 378.9353 Tm
(137)Tj
10.959 0 0 10.959 72.9637 361.1338 Tm
[(The)-410(authors)-406.7(pointed)-412.2(out,)-405.1(however,)-408.6(that)-409.3(numerous)]TJ
-.9984 -1.1795 TD
[(studies)-502.8(had)-498.5(methodological)-500.8(limitations)-497.2(and)-504(did)-500.3(not)]TJ
0 -1.1847 TD
[(take)-389.1(into)-388.7(account)-385.8(confounding)-385.3(factors,)-387.8(such)-388.3(as)-388.8(other)]TJ
0 -1.1795 TD
[(disorders)-228.6(and)-229.9(medications.)-230.7(It)-228.9(has)-225.1(been)-232.5(shown)-227.1(that)-228.3(can-)]TJ
0 -1.1847 TD
[(nabis)-360.5(use)-355.4(has)-359.6(varying)-355.6(effects)-359.6(on)-360.9(PLWH)-355.4(based)-360(on)-355.8(the)]TJ
0 -1.1795 TD
[(stage)-232(of)-228.1(the)-230.5(disease.)]TJ
8.2191 0 0 7.3052 146.4377 301.2661 Tm
(138)Tj
10.959 0 0 10.959 160.7811 296.3904 Tm
[(Cannabis)-226.7(use)-231.3(led)-226.3(to)-232.6(neurocogni-)]TJ
-9.0117 -1.1847 TD
[(tive)-550.5(dysfunction)-548.2(in)-544(PLWH)-546.8(who)-547.5(were)-548.1(symptomatic)]TJ
0 -1.1795 TD
[(phase,)-447.2(while)-442.3(such)-450.4(symptoms)-441.1(were)-444.6(found)-447.4(in)-445.7(persons)]TJ
0 -1.1847 TD
[(who)-371.6(were)-372.2(not)-369.3(infected)-371.3(or)-372.4(PLWH)-370.9(who)-371.6(were)-372.2(cannabis)]TJ
0 -1.1795 TD
[(users)-501.7(or)-501.7(with)-501(no)-500.6(symptomatic)-497.2(stage.)]TJ
8.2191 0 0 7.3052 232.781 249.4488 Tm
(139,140)Tj
10.959 0 0 10.959 263.7354 244.5731 Tm
(Sympto-)Tj
-18.4061 -1.1795 TD
[(matic)-639(PLWH)-639.9(with)-635.5(frequent)-644.1(cannabis)-637.4(use)-640(showed)]TJ
0 -1.1847 TD
[(greater)-641.8(cognitive)-641.4(impairment,)-645.1(especially)-641.3(related)-647.2(to)]TJ
0 -1.1795 TD
[(memory)-300.6(performance.)]TJ
.9984 -1.1847 TD
[(Considering)-324.3(that)-316.2(HIV-1)-320.6(infection)-321.9(and)-317.8(cannabis)-321.8(use)]TJ
-.9984 -1.1795 TD
[(affect)-547.4(the)-540.9(immune)-544.8(system,)-547.6(the)-540.9(interaction)-544.5(between)]TJ
0 -1.1847 TD
[(them)-396.3(are)-391.9(likely)-391.2(to)-398.2(be)-392.8(aggravated)-394.8(in)-394(patients)-391.3(who)-392.3(are)]TJ
0 -1.1795 TD
-.0002 Tc
[(more)-608.6(immunosuppressed.)]TJ
8.2191 0 0 7.3052 179.6031 158.7968 Tm
0 Tc
(141,142)Tj
10.959 0 0 10.959 211.748 153.9212 Tm
[(Other)-607.1(studies)-611.4(have)]TJ
-13.6623 -1.1847 TD
[(shown)-201.2(that)-202.4(cannabis)-202.9(has)-204.4(adverse)-206.5(effects)-204.4(on)-200.6(neurocogni-)]TJ
0 -1.1795 TD
[(tive)-353.9(function)-353.7(in)-357.8(people)-352.6(who)-356.1(use)-355.4(it)-353.7(frequently.)-354.4(For)-354.2(in-)]TJ
0 -1.1847 TD
[(stance,)-394.4(cannabis)-389.1(use)-391.6(has)-390.7(been)-392.9(found)-390.5(to)-393(have)-387.7(adverse)]TJ
0 -1.1795 TD
[(effects)-607.9(on)-604.1(HIV-1)-605.1(symptoms,)-606(whereas)-602.5(noncannabis)]TJ
T*
[(use)-345.1(or)-341.4(nondependence)-343.6(had)-343.3(no)-345.4(effects)-344.1(on)-340.2(these)-345.5(symp-)]TJ
0 -1.1847 TD
(toms.)Tj
8.2191 0 0 7.3052 86.0598 81.0708 Tm
(135,137)Tj
10.959 0 0 10.959 117.2976 76.1953 Tm
[(Similarly,)-527.1(moderate-to-heavy)-524.3(users)-532.7(con-)]TJ
-5.0438 -1.1795 TD
[(stantly)-470.6(behaved)-472.6(worse)-472.5(on)-474.7(cognitive)-470.7(tasks)-470.2(than)-475.6(mild)]TJ
22.9068 57.9085 TD
[(users,)-495.8(regardless)-496(of)-492(HIV-1)-491.3(status.)]TJ
8.2191 0 0 7.3052 467.4896 702.7651 Tm
(141)Tj
10.959 0 0 10.959 484.7243 697.8896 Tm
[(In)-491.7(a)-494.2(follow-up)]TJ
-15.6644 -1.1847 TD
[(study,)-344.3(a)-339(signiìcant)-344.2(effect)-340.8(of)-336.8(cannabis)-342.5(use)-339.9(on)-340.2(PLWHês)]TJ
0 -1.1795 TD
[(global)-300.3(cognition)-298.5(had)-301.9(not)-296.9(been)-299.8(conìrmed.)]TJ
8.2191 0 0 7.3052 495.9495 676.8565 Tm
(139)Tj
/F5 1 Tf
10.4607 0 0 10.4607 313.0582 647.036 Tm
[(Reciprocal)-269.8(Interactions)-270.7(of)-265.6(the)-267.3(ECS)-268.9(with)-265.9(the)-267.3(HPA)]TJ
0 -1.2357 TD
[(and)-303.8(HPG)-296.9(Axes)-298.9(Inîuencing)-300.7(Therapeutic)-304.2(Targets)]TJ
/F6 1 Tf
10.959 0 0 10.959 313.0582 621.1274 Tm
[(The)-327.2(viral)-326.2(reservoir)-322.2(resides)-327.5(in)-321.6(the)-323.7(CNS)-325.3(and)-328.1(serves)-323.6(as)-321.6(a)]TJ
0 -1.1795 TD
[(source)-213.5(of)-212.6(HIV)-212(viral)-207.2(toxin,)-214.8(destroying)-209.1(mitochondria)-206.2(and)]TJ
T*
[(promoting)-404.1(neurotoxicity.)-408.7(Evidence)-404.7(has)-406.2(demonstrated)]TJ
0 -1.1847 TD
[(that)-321.4(HIV-1)-315.4(virus)-320.6(or)-315.5(the)-318.5(HIV-1-related)-313.8(neurotoxic)-317.2(Tat)]TJ
0 -1.1795 TD
[(can)-261.4(deregulate)-262(the)-261.6(production)-259.5(of)-259.2(neurosteroids,)-258.8(poten-)]TJ
0 -1.1847 TD
-.0001 Tc
[(tially)-288.3(resulting)-286(in)-285.5(dysfunction)-289.6(of)-285.1(neuroendocrine,)-289.1(such)]TJ
0 -1.1795 TD
0 Tc
[(as)-202.6(HPA)-205.1(and)-198.8(HPG)-204.8(axes.)-202.5(However,)-200.3(HIV-endocrine)-203.7(inter-)]TJ
0 -1.1847 TD
[(actions)-475.3(are)-474.6(becoming)-473.6(dynamic.)-476.6(Speciìcally,)-476.3(endoge-)]TJ
0 -1.1795 TD
[(nous)-413.3(steroids)-407.1(or)-408.6(gonadal)-405.8(hormones)-410.6(affect)-407.8(HIV)-408.6(virus)]TJ
0 -1.1847 TD
[(replication)-529.6(and,)-524(in)-528.5(turn,)-527.8(HIV-1-related)-525.9(neurotoxins)]TJ
0 -1.1795 TD
[(can)-375.2(affect)-376.7(the)-375.4(release)-373.7(of)-373(these)-376.5(hormones.)-373.7(As)-371.6(a)-375.2(result,)]TJ
0 -1.1847 TD
[(the)-406.4(relationship)-407.5(between)-405(the)-406.4(functions)-403.6(of)-404(the)-406.4(neuro-)]TJ
0 -1.1795 TD
[(endocrine)-480.2(systems)-474(and)-478.2(HAND)-473.5(is)-477.9(mutual.)-479.5(However,)]TJ
T*
[(within)-413.9(the)-411.6(PVN,)-412(glucocorticoids)-410.2(cause)-412.9(the)-411.6(release)-409.9(of)]TJ
0 -1.1847 TD
[(endocannabinoids)-315.8(and)-317.8(inhibit)-315.4(the)-313.3(excitatory)-313.9(inputs)-317.6(to)]TJ
0 -1.1795 TD
[(CRF)-222.4(neurons)-220.1(as)-223.3(shown)-216.8(by)-221.5(being)-220.2(blocked)-219.9(by)-221.5(CB1)-216.8(recep-)]TJ
0 -1.1847 TD
[(tor)-303.2(antagonists.)]TJ
8.2191 0 0 7.3052 380.9196 418.7904 Tm
(23)Tj
10.959 0 0 10.959 324.0566 400.9889 Tm
[(B)14(e)0(c)19.8(a)0(u)15.5(s)12.2(e)-654.9(e)0(n)15.5(d)13(oc)21(an)15.8(n)13.3(a)0(b)21.3(i)0(n)19.8(o)0(i)20.2(d)0(s)-647.3(a)0(r)19.8(e)-660(w)14.8(i)0(d)19.5(e)0(l)19.4(y)-659.4(d)13(i)0(s)18.7(t)12.3(ri)18.7(bu)21.6(te)19.6(d)]TJ
-1.0036 -1.1847 TD
[(th)15.6(r)12.2(o)0(u)21.6(g)0(h)21.6(o)0(u)16.4(t)-401.6(t)12.3(h)0(e)-392.9(h)13.7(yp)21(ot)20.8(ha)16.1(l)12(a)12.8(m)10.2(u)0(s)-393.8(a)0(n)21(d)-400.8(th)20.8(e)-401.4(l)0(i)18.5(m)10.2(bi)20.2(c)-401.4(c)0(i)19(r)12.2(cu)15.2(i)11.7(t)12.3(s,)]TJ
0 -1.1795 TD
[(th)15.6(e)12.5(y)-235.2(oc)21(cu)15.2(p)13(y)-235.2(a)-240.7(u)13(ni)19.8(qu)16(e)-235.8(n)13.3(ic)19(he)-227.3(to)-227.5(r)12.2(e)0(g)20.4(u)0(l)19.9(a)0(t)19.9(e)-241(t)12.3(h)0(e)-227.3(r)12.2(el)19.3(ea)20.1(se)-228.8(o)13.7(f)-241.8(e)12.5(x)0(-)]TJ
0 -1.1847 TD
[(ci)19(ta)19.9(to)20.8(ry)-269.5(an)15.8(d)-276.7(i)0(n)19.8(h)0(i)20.2(b)0(i)20.2(t)0(o)20.8(r)0(y)-269.5(t)0(r)19.3(a)0(n)21(s)0(m)17.2(i)11.7(t)12.3(t)0(e)19.6(r)0(s)19.3(,)-283.8(a)12.8(n)0(d)-268.5(t)0(h)20.8(e)-282.4(ìn)21.8(al)-270(re)19.5(su)20.1(lt)]TJ
0 -1.1795 TD
[(is)-198.5(to)-196.4(c)12.5(o)0(n)16.7(s)12.2(tr)19.3(ai)19.3(n)-203.9(t)0(h)20.8(e)-210(HP)23.5(A)-208(a)12.8(ct)19.6(iv)19.6(it)18.8(y)13.1(.)]TJ
8.2191 0 0 7.3052 448.1006 354.0471 Tm
-.0168 Tc
(22)Tj
10.959 0 0 10.959 458.1353 349.1716 Tm
0 Tc
[(T)13.9(h)0(e)-196.3(E)0(C)17.8(S)-204.5(al)19.7(so)-196.5(ov)21.6(er)19.5(l)12(a)0(p)15.5(s)]TJ
-13.2381 -1.1795 TD
[(co)15.9(n)13.3(s)0(i)18.7(d)0(e)20.3(r)0(a)19.8(b)0(l)20.6(y)-411.1(wi)21.3(th)-403.4(r)12.2(e)0(c)19.8(e)0(p)20.3(t)0(o)20.8(r)0(s)-404.9(f)11.7(or)-403.4(g)13.1(o)0(n)16.7(a)12.8(da)20.6(l)-412.2(s)0(t)19.3(e)12.5(ro)15.6(i)11.7(d)13(s,)-406.1(s)12.2(u)0(g)21(-)]TJ
0 -1.1847 TD
[(ge)15.2(s)12.2(t)12.3(in)19.8(g)-266.2(t)12.3(ha)21.3(t)-261.9(t)0(h)20.8(e)-261.7(EC)17.8(S)-261.4(m)10.2(a)12.8(y)-266.2(b)13.7(e)-261.7(an)-253.2(im)16.7(p)13(o)0(r)20.8(t)0(a)19.9(n)0(t)-253.7(n)13.3(eu)15.2(r)12.2(o)0(r)20.8(e)0(g)20.4(u)0(l)19.9(a)0(-)]TJ
0 -1.1795 TD
[(to)20.8(ry)-471.3(s)12.2(y)0(s)20.2(t)12.3(em)-468.8(t)12.3(h)0(a)16.1(t)-474(ca)20.1(n)-478.1(b)0(e)-465.2(u)0(s)20.1(e)0(d)-471.1(f)11.7(or)-465.5(re)19.5(gu)21(la)19.7(t)12.3(i)0(n)19.8(g)-478.3(go)21.6(na)21(da)15.5(l)]TJ
0 -1.1847 TD
[(st)19.3(er)19.5(oi)20.2(ds)20.1(.)-413.1(I)0(n)-403.8(t)12.3(hi)20.2(s)-417.2(r)12.2(e)12.5(g)0(a)15.6(r)12.2(d,)-405.3(i)11.7(n)0(t)20.5(e)0(r)19.5(a)12.8(ct)19.6(io)20.2(ns)-403.8(be)21(tw)22(ee)19.8(n)-416(t)12.3(he)-403.2(EC)23(S)]TJ
0 -1.1795 TD
[(an)15.8(d)-302.5(t)12.3(he)-294.6(HP)18.3(A)-301.1(a)0(n)21(d)-307.7(H)15.1(P)0(G)-297.5(a)12.8(xe)20.1(s)-303.3(m)10.2(ay)-294.8(i)11.7(n)0(î)16.7(u)13(en)20.7(ce)-295.8(t)12.3(h)0(e)-294.6(E)0(C)17.8(S)-302.8(a)12.8(s)]TJ
0 -1.1847 TD
[(a)-375.2(p)13(ot)20.8(en)20.7(ti)18.8(al)-358(th)20.8(er)19.5(ap)15.5(e)12.5(u)0(t)20.1(i)11.7(c)-370.3(t)0(a)19.9(r)0(g)20.2(e)0(t)-363.2(f)11.6(or)-362(HA)24.4(ND)19.5(.)-371.7(A)0(s)-361.3(s)12.2(uc)20.3(h,)-363.2(w)14.8(e)]TJ
0 -1.1795 TD
[(ìr)15.6(s)12.2(t)-298.1(re)19.5(vi)19.6(e)12.5(w)-300.7(t)12.3(h)0(e)-289.4(c)0(l)19.3(i)11.7(ni)19.8(ca)20.1(l)-298.4(a)0(n)21(d)-302.5(p)13(r)0(e)19.5(-)0(c)19.9(l)12(in)19.8(ic)19(al)-290.7(ì)13.7(n)0(d)16(i)11.7(ng)21.3(s)-298.2(f)0(o)20.2(r)-298.2(th)20.8(e)]TJ
0 -1.1847 TD
[(HP)18.3(A)-223.5(a)0(n)15.8(d)-224.9(HP)23.5(G)-228.3(a)12.8(xe)20.1(s)-230.9(i)11.7(n)-224.6(H)0(I)22.1(V)0(,)-217.9(a)0(n)21(d)-230.1(t)12.3(h)0(e)21(n)0(,)-218.7(w)0(e)-215.8(r)12.2(ev)20.4(ie)19(w)-228.3(t)12.3(he)-217(i)11.7(n)0(-)]TJ
0 -1.1795 TD
[(te)19.6(ra)19.8(ct)19.6(io)20.2(ns)-259(of)-259.2(EC)17.8(S)-266.6(w)0(i)21.3(t)0(h)-263.7(t)12.3(he)-258.4(HP)18.3(A)-264.9(a)0(n)15.8(d)-266.3(HP)18.3(G)-269.7(a)12.8(xe)20.1(s)-272.3(i)11.7(n)-271.2(H)0(I)22.1(V)0(.)]TJ
/F7 1 Tf
10.4607 0 0 10.4607 313.0582 205.6818 Tm
[(The)-301.7(dysregulation)-302(of)-300.7(HPA)-295.7(axis)-303.3(in)-297.5(PLWH)]TJ
/F6 1 Tf
10.959 0 0 10.959 313.0582 192.7559 Tm
[(In)-377.9(the)-375.4(precART)-378.3(era,)-375.6(HIV-related)-376(pathogenesis)-374.6(of)-378.1(the)]TJ
0 -1.1847 TD
[(HPA)-256.9(axis)-260.9(was)-255(primary)-261.4(and)-255.7(related)-259.3(to)-253.3(opportunistic)-259.5(in-)]TJ
0 -1.1795 TD
[(fection)-357.2(that)-352.4(promoted)-354.6(adrenal)-356.2(atrophy)-354.1(and)-359.2(the)-354.7(direct)]TJ
T*
[(invasion)-317.2(of)-310.9(tumors)-314.4(or)-315.5(invasive)-313.4(disease.)]TJ
8.2191 0 0 7.3052 484.4408 158.7401 Tm
(143)Tj
10.959 0 0 10.959 499.6912 153.9212 Tm
[(In)-315.8(the)-313.3(post-)]TJ
-17.0301 -1.1847 TD
[(cART)-384.9(era,)-386(a)-385.5(dysfunction)-387.8(of)-383.3(the)-385.7(HPA)-381(axis)-385.1(is)-389.9(believed)]TJ
0 -1.1795 TD
[(to)-299.9(be)-294.5(secondary)-298.5(to)-299.9(hypothalamic)-293.5(or)-294.8(pituitary)-296.6(dysfunc-)]TJ
0 -1.1847 TD
[(tion.)-346.6(Estimates)-340.3(vary,)-346.4(but)]TJ
/F4 1 Tf
10.2739 0 TD
(*)Tj
/F6 1 Tf
.9984 0 TD
[(14Ö46%)-336.6(of)-347.1(PLWH)-339.8(exhibit)]TJ
-11.2723 -1.1795 TD
[(abnormal)-251(of)-248.8(the)-251.2(HPA)-246.5(axis)-250.6(function,)-249.5(which)-249.2(is)-250.3(described)]TJ
0 -1.1847 TD
[(by)-247.4(increased)-244.2(basal)-241.7(concentration)-242.5(of)-243.6(serum)-245.1(cortisol)-241.1(\(i.e.,)]TJ
0 -1.1795 TD
[(hypercortisolmina\))-261.5(but)-261(abnormal)-256.2(adrenal)-263.1(insufìciency)]TJ
0 -1.1847 TD
[(when)-416.4(exposed)-417.3(to)-413.7(stressors.)]TJ
8.2191 0 0 7.3052 434.0408 68.0882 Tm
(143,144)Tj
10.959 0 0 10.959 464.0314 63.2126 Tm
[(Many)-415.6(HIV-infected)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(8)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
105 0 obj
<</Length 14700>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 59.7543 697.8896 Tm
0 0 0 rg
-.0001 Tc
0 Tw
[(PLWH)-319.2(develop)-313.7(hypercortisonemia)-318.4(early)-315.1(or)-320.8(late)-312.6(in)-316.5(the)]TJ
0 -1.1847 TD
0 Tc
[(disease)-301.1(course.)]TJ
8.2191 0 0 7.3052 124.1574 689.7825 Tm
(145)Tj
10.959 0 0 10.959 70.7527 671.981 Tm
[(HIV)-263.8(can)-266.6(have)-263.5(a)-266.6(profound)-263.6(impact)-263.8(on)-267.8(the)-261.6(production)]TJ
-1.0036 -1.1847 TD
[(of)-238.5(circulating)-235.3(steroids.)-235.7(These)-235.3(effects)-235.5(can)-235.6(reduce)-234.7(the)-235.7(lev-)]TJ
0 -1.1795 TD
[(els)-325.4(of)-321.2(steroids)-319.2(in)-321.6(the)-323.7(circulation)-317.5(through)-322.1(the)-318.5(action)-322(of)]TJ
0 -1.1847 TD
[(endocrine)-309.4(glands,)-310.8(including)-310.5(adrenal)-304.5(glands)-311.5(or)-310.3(gonads,)]TJ
0 -1.1795 TD
-.0001 Tc
[(or)-315.6(by)-314.7(targeting)-311(the)-313.4(source)-311.9(of)-316.2(adrenocorticotropic)-316.5(hor-)]TJ
T*
0 Tc
[(mone)-250.4(\(ACTH\))-249.3(and)-250.5(gonadotropin)-247.6(in)-249.2(the)-251.2(hypothalamus)]TJ
0 -1.1847 TD
[(and)-317.8(pituitary.)]TJ
8.2191 0 0 7.3052 119.5653 599.1306 Tm
(144,146)Tj
10.959 0 0 10.959 148.4787 594.2549 Tm
[(As)-314.7(such,)-320.3(PLWH)-314(are)-314.3(usually)-315.3(inîu-)]TJ
-8.096 -1.1795 TD
[(enced)-401.8(by)-402.6(dysfunction)-398.2(of)-404(the)-401.3(HPA)-396.5(axis.)-405.1(It)-399.6(is)-400.3(possible)]TJ
0 -1.1847 TD
[(that)-259.3(this)-260.5(dysfunction)-263.7(contributes)-258.9(to)-258.5(the)-261.6(neuropsych)5.1(iat-)]TJ
0 -1.1795 TD
[(ric)-211.9(components)-204.3(of)-207.4(HAND,)-208.9(which)-207.8(are)-205.6(to)-206.8(a)-209.6(greater)-207.3(extent)]TJ
0 -1.1847 TD
[(in)-280.2(PLWH.)-282.2(One)-280.2(possible)-276.5(mechanism)-279(could)-277.1(be)-279(an)-284.3(enzy-)]TJ
0 -1.1795 TD
[(matic)-333.7(conversion)-326.9(of)-331.6(adrenal)-330.4(androgen)-330.5(to)-330.9(cortisol)-329(or)-325.8(a)]TJ
0 -1.1847 TD
[(compensatory)-360.6(increase)-360.7(in)-363(production)-357.8(of)-362.6(steroid,)-361.7(such)]TJ
0 -1.1795 TD
-.0001 Tc
[(as)-301(dehydroepiandrosterone)-300.2(\(DHEA\).)]TJ
8.2191 0 0 7.3052 222.0661 508.4786 Tm
0 Tc
(144,147)Tj
10.959 0 0 10.959 70.7527 490.677 Tm
[(More)-328.5(speciìcally,)-326.8(the)-328.8(compensatory)-329.6(increase)-329.7(in)-326.8(the)]TJ
-1.0036 -1.1847 TD
[(increase)-526.2(of)-528.2(corticosteroid-bin)5.1(ding)-528.3(globulin)-523.3(occurred)]TJ
0 -1.1795 TD
[(during)-285.7(the)-277.1(transition)-283.1(to)-279.2(AIDS)-281.7(and/or)-280.3(decreased)-279.9(gluco-)]TJ
0 -1.1847 TD
[(corticoid)-233.3(receptor)-230.1(\(GR\))-232(sensitivity)-231.2(to)-227.5(their)-232.5(homologous)]TJ
0 -1.1795 TD
(ligands.)Tj
8.2191 0 0 7.3052 93.2031 443.7353 Tm
(144)Tj
10.959 0 0 10.959 109.0771 438.8597 Tm
[(An)-375.7(increase)-371(in)-373.3(proinîammatory)-373.5(cytokines)]TJ
-4.5007 -1.1847 TD
[(elevates)-220.8(the)-215(ratio)-221.8(of)-217.8(GR)]TJ
/F4 1 Tf
9.1565 0 TD
(a)Tj
/F6 1 Tf
.7708 0 TD
[(to)-217.1(GR)]TJ
/F4 1 Tf
2.3434 0 TD
(b)Tj
/F6 1 Tf
.7656 0 TD
(\(GR)Tj
/F4 1 Tf
1.6658 0 TD
(b)Tj
/F6 1 Tf
.7708 0 TD
[(is)-219.2(the)-220.2(main)-215.9(neg-)]TJ
-15.473 -1.1795 TD
[(ative)-413.6(inhibitor)-413.7(of)-409.2(bioactive)-413.7(GR)]TJ
/F4 1 Tf
12.7001 0 TD
(a)Tj
/F6 1 Tf
.5535 0 TD
[(\),)-411.6(thereby)-411.8(decreasing)]TJ
-13.2537 -1.1847 TD
[(GR-mediated)-357.4(negative)-354(feedback)-358.7(loop)-356.2(inhibition.)]TJ
8.2191 0 0 7.3052 273.4298 404.844 Tm
(148,149)Tj
10.959 0 0 10.959 59.7543 387.0424 Tm
-.0124 Tc
[(H)-12.4(I)9.7(V-in)-12.4(f)7.4(ected)-252.9(cells)-253.7(may)-252.8(s)-.2(ecrete)-253.4(s)-.2(e)-12.4(v)8(eral)-253.9(viroto)-12.4(x)8.9(i)-.7(c)-253.4(p).6(rotein)-12.4(s)]TJ
T*
-.0128 Tc
[(th)-12.8(a)8.5(t)-362.6(may)-361.8(c)-.3(o)-12.8(n)9.1(tribute)-367.6(t)-.5(o)-361.2(a)0(n)-366.8(i)-1.1(mb)-12.8(a)8.5(l)-.8(ance)-367.6(in)-361.6(the)-367.6(H)2.3(PA)-365.6(ax)-12.8(i)11.6(s)-12.8(.)]TJ
0 -1.1795 TD
0 Tc
[(Fo)21.6(r)-349.9(i)11.7(ns)20.4(t)12.3(a)12.8(n)13.3(c)12.5(e)12.5(,)-356.2(H)15.1(I)12.3(V-)21.5(1)-348.7(T)0(a)21.5(t)-349.8(pr)20.1(o)13.7(t)12.3(e)12.5(i)11.7(n)-354(c)12.5(a)12.8(n)-354(a)12.8(l)12(s)12.2(o)-353.6(b)13.7(e)-349.6(us)20.1(e)12.5(d)-354.3(a)12.8(s)-349.9(a)]TJ
T*
[(co)21(a)12.8(c)12.5(t)12.3(i)11.7(v)13.1(a)12.8(t)12.3(o)13.7(r)-236.1(o)13.7(f)-236.7(G)14.8(R)-234.4(t)12.3(o)-229.4(e)12.5(nh)21.8(a)12.8(n)13.3(c)12.5(e)-235.8(t)12.3(h)13.7(e)-235.8(r)12.2(o)13.7(l)12(e)-230.6(o)0(f)-222.9(g)13.1(l)12(u)13(c)12.5(o)0(c)21(o)13.7(r)12.2(t)12.3(i)11.7(c)12.5(o)13.7(i)11.7(ds)20.1(,)]TJ
0 -1.1847 TD
-.0125 Tc
[(w)-12.5(h)10.8(ich)-298.9(m)-2.3(ay)-299.4(pro)-12.5(m)11.4(ote)-305.2(g).6(lucoco)-12.5(r)8.3(t)-.2(icoid)-299.5(r)-.3(esista)-12.5(n)8.5(ce.)]TJ
8.2191 0 0 7.3052 257.3858 340.1007 Tm
-.0169 Tc
(150)Tj
10.959 0 0 10.959 70.7527 322.2991 Tm
0 Tc
[(Evidence)-244.4(has)-245.8(shown)-242.6(that)-243.8(Tat)-245.5(protein)-247.5(may)-243.3(also)-249.3(inter-)]TJ
-1.0036 -1.1847 TD
[(act)-345.2(with)-340.7(these)-345.5(viral)-341.7(toxins,)-342.3(such)-346.9(as)-342.3(Nef)-343.9(and)-343.7(gp120,)-341.6(to)]TJ
0 -1.1795 TD
[(affect)-444(the)-442.6(HPA)-437.9(function)-441.7(and)-442(has)-437.2(a)-442.4(signiìcant)-442.4(effect)]TJ
0 -1.1847 TD
[(on)-500.6(reproducing)-496(clinical)-496.4(phenotypes)-496.6(when)-499.2(expressed)]TJ
0 -1.1795 TD
[(in)-430.2(mice.)]TJ
8.2191 0 0 7.3052 96.4913 275.3574 Tm
(145)Tj
10.959 0 0 10.959 112.9889 270.4818 Tm
[(Indeed,)-424.5(the)-427.1(HIV)-424.1(envelope)-425(protein)-423.4(gp120)]TJ
-4.8576 -1.1847 TD
[(increases)-436.4(ACTH)-428.3(and)-431.6(corticosterone)-433.1(levels)-427.4(in)-435.4(plasma)]TJ
0 -1.1795 TD
[(and)-540.2(similarly)-533.6(increases)-539.9(pituitary)-534.5(ACTH)-537(levels)-536.1(in)-533.7(a)]TJ
T*
[(transgenic)-546.6(mouse.)]TJ
8.2191 0 0 7.3052 141.6756 236.4661 Tm
(151)Tj
10.959 0 0 10.959 159.4204 231.6472 Tm
[(Gp120)-542.4(increased)-539.1(corticotropin)]TJ
-9.0944 -1.1847 TD
[(releasing)-441.2(hormone)-443.5(\(CRH\))-439.7(messenger)-442.8(RNA)-438(\(mRNA\))]TJ
0 -1.1795 TD
[(expression)-349.8(and)-354(CRH)-344.5(levels)-349.8(in)-347.4(hypothalamus)-349.3(tissue)-350.3(of)]TJ
0 -1.1847 TD
[(mouse)-228.1(or)-227.5(rat.)]TJ
8.2191 0 0 7.3052 117.2976 197.6315 Tm
(152)Tj
10.959 0 0 10.959 131.5842 192.7559 Tm
[(Taken)-229.3(together,)-222.9(HIV-related)-225.9(viral)-227.9(pro-)]TJ
-6.5544 -1.1795 TD
[(teins,)-268.3(such)-269.3(as)-269.9(Tat)-266.2(and)-271.2(gp120,)-264(may)-269.2(promote)-264.2(glucocorti-)]TJ
0 -1.1847 TD
[(coid)-223.3(resistance)-227.5(alone)-220.2(or)-227.5(in)-223.3(combination.)-222.5(Since)-221.8(the)-225.4(HPA)]TJ
0 -1.1795 TD
[(axis)-364.4(has)-364.8(a)-359.7(vital)-362.3(role)-363.4(in)-363(overcoming)-360.3(psychological)-361.6(and)]TJ
0 -1.1847 TD
[(physiological)-212.4(challenges,)-214.1(its)-212.1(destruction)-213(may)-212.3(contribute)]TJ
0 -1.1795 TD
[(to)-299.9(the)-303(observed)-295.4(neuro-HIV-like)-300.5(symptoms.)]TJ
/F7 1 Tf
10.4607 0 0 10.4607 59.7543 102.1039 Tm
[(The)-301.7(dysregulation)-296.6(of)-300.7(HPG)-303.5(axis)-297.9(in)-297.5(PLWH)]TJ
/F6 1 Tf
10.959 0 0 10.959 59.7543 89.1212 Tm
[(In)-202(line)-204(with)-195.8(the)-199.5(neuroendocrine)-203.3(dysfunction)-201.6(\(i.e.,)-199.7(HPA\))]TJ
T*
[(in)-290.5(the)-292.6(postcART)-287.1(era,)]TJ
/F4 1 Tf
8.6651 0 TD
(*)Tj
/F6 1 Tf
.9984 0 TD
[(10Ö50%)-284.9(of)-290.2(PLWH)-288.1(suffer)-294.1(from)]TJ
-9.6635 -1.1847 TD
[(hypogonadism,)-357.9(which)-352.7(is)-353.7(characterized)-359.3(by)-356(a)-354.5(reduction)]TJ
22.912 57.9137 TD
[(in)-212.9(testosterone)-210.3(levels)-210.2(in)-212.9(men)-212.3(and)-209.2(an)-217(imbalance)-209.3(between)]TJ
0 -1.1847 TD
[(estradiol)-229(and)-235(progesterone)-229.5(levels)-230.9(in)-233.6(women.)]TJ
8.2191 0 0 7.3052 500.9951 689.7825 Tm
(153,154)Tj
10.959 0 0 10.959 528.9447 684.9069 Tm
(Both)Tj
-19.9012 -1.1795 TD
[(men)-243.4(and)-245.4(women)-240.7(living)-245.8(with)-242.4(HIV)-243.1(who)-242.3(experience)-247(early)]TJ
0 -1.1847 TD
[(menopausal)-262.4(attacks)-269(show)-266.3(hormonal)-260.5(deìciencies.)-269.9(More)]TJ
0 -1.1795 TD
[(speciìcally,)-383.7(after)-383.4(the)-380.6(age)-380.6(of)-383.3(50)-381.9(for)-386.6(men,)-382.3(the)-380.6(levels)-380.9(of)]TJ
0 -1.1847 TD
[(androgens,)-307.3(especially)-305(testosterone)-303.5(levels,)-307.7(gradually)-304.9(de-)]TJ
0 -1.1795 TD
[(crease)-313.3(while)-307.8(the)-313.3(physical)-312.8(and)-312.6(mental)-309.7(disorders)-311.4(caused)]TJ
T*
[(by)-361.2(changes)-365.1(in)-363(hormone)-365.9(secretion)-363(in)-363(the)-365(body)-360.3(are)-366(re-)]TJ
0 -1.1847 TD
(duced.)Tj
8.2191 0 0 7.3052 339.4771 599.1306 Tm
(155)Tj
10.959 0 0 10.959 355.6345 594.2549 Tm
[(Menopause)-398.3(is)-395.1(a)-395.9(process)-397.9(in)-399.2(which)-394.1(womenês)]TJ
-4.0868 -1.1795 TD
[(hormone)-593.6(levels)-598.2(gradually)-599.8(decrease,)-597.5(or)-600(even)-600.4(disap-)]TJ
0 -1.1847 TD
[(pear,)-305.7(which)-300.9(are)-303.9(due)-302.9(to)-305.1(the)-303(decline)-305.6(in)-306.1(ovarian)-303.5(function)]TJ
0 -1.1795 TD
[(when)-297.5(they)-300.2(reach)-298.5(45)-299.1(years)-299.3(of)-300.5(age)-297.9(or)-300(older.)]TJ
8.2191 0 0 7.3052 493.455 560.2959 Tm
(156)Tj
10.959 0 0 10.959 321.7889 542.4377 Tm
[(Therefore,)-246.6(the)-246.1(beneìts)-246(of)-243.6(gonadal)-245.5(hormonal)-245(therapy)]TJ
-.9984 -1.1795 TD
[(for)-278(the)-282.3(HIV)-279.3(population)-280(may)-279.5(be)-284.2(particularly)-279.7(signiìcant)]TJ
0 -1.1847 TD
[(if)-214.6(initiated)-219.8(early.)-216(Among)-214.6(men)-217.5(living)-219.9(with)-216.5(HIV,)-216.5(hypogo-)]TJ
0 -1.1795 TD
[(nadism)-247.5(is)-250.3(primarily)-248(secondary,)-246(occurring)-247.9(in)]TJ
/F4 1 Tf
17.6457 0 TD
(*)Tj
/F6 1 Tf
.9984 0 TD
(12Ö28%)Tj
-18.6441 -1.1795 TD
[(of)-398.8(young)-394.1(or)-398.3(middle-aged)-401.6(individuals.)]TJ
8.2191 0 0 7.3052 478.4314 495.4959 Tm
(157)Tj
10.959 0 0 10.959 494.6455 490.677 Tm
(Hypogonad-)Tj
-16.7714 -1.1847 TD
[(ism)-359.1(is)-364.1(associated)-360.6(with)-356.2(increasing)-366.1(age,)-359.2(prolonged)-359.3(HIV)]TJ
0 -1.1795 TD
[(infection,)-486.7(and)-493.7(decreased)-486.9(CD4)]TJ
/F8 1 Tf
8.2191 0 0 7.3052 448.5542 469.644 Tm
(+)Tj
/F6 1 Tf
10.959 0 0 10.959 459.8361 464.7684 Tm
[(T)-487.9(cell)-489(counts)-492(when)]TJ
-13.5951 -1.1847 TD
[(hypogonadism)-250(occurs.)]TJ
8.2191 0 0 7.3052 408.9259 456.6613 Tm
(158,159)Tj
10.959 0 0 10.959 437.1022 451.7857 Tm
[(HIV-positive)-254.5(men)-248.6(experi-)]TJ
-11.5207 -1.1795 TD
[(ence)-342.4(an)-341.2(early)-340.9(transition)-340(to)-341.3(male)-345.7(menopause)-336.8(linked)-343.4(to)]TJ
0 -1.1847 TD
[(low)-631.9(testosterone)-634.6(levels,)-638.8(normal)-634.5(or)-636.2(low)-637.1(luteinizing)]TJ
0 -1.1795 TD
[(hormone)-402.2(\(LH\))-407.9(levels,)-406(and)-405.7(a)-406.2(higher)-404.3(ratio)-402.9(of)-409.2(estradiol)]TJ
0 -1.1847 TD
[(to)-372.3(testosterone,)]TJ
8.2191 0 0 7.3052 378.5385 404.844 Tm
(160,161)Tj
10.959 0 0 10.959 408.0755 399.9684 Tm
[(which)-373.4(increases)-369.2(the)-375.4(risk)-375(of)-373(car-)]TJ
-8.872 -1.1795 TD
[(diovascular)-435.1(disease)-440.7(and)-442(frailty.)]TJ
8.2191 0 0 7.3052 449.9715 391.918 Tm
(158,162)Tj
10.959 0 0 10.959 480.2455 387.0424 Tm
[(Similarly,)-439.2(HIV-)]TJ
-15.4574 -1.1847 TD
[(p)13(o)0(s)20.8(i)0(t)18.8(i)0(v)19.6(e)-210(wo)23.4(m)10.2(e)0(n)-201.8(e)12.5(xh)21.3(ib)20.2(it)-198.5(ac)20.1(ce)19.8(le)19.4(ra)19.8(te)19.6(d)-209.4(o)0(v)21.6(a)0(r)19.8(i)0(a)19.3(n)-209.1(ag)20.7(in)19.8(g)-209.3(s)0(o)20.8(o)0(n)21.9(e)0(r)]TJ
0 -1.1795 TD
[(than)-289.3(the)-8.1(ir)-286.5(con)-7(trol)-291.2(count)-7.6(erp)-8.8(arts)-7.4(,)-283.8(wit)-7.8(h)-286.4(lower)-291.7(circ)-8(ula)-8.7(ting)]TJ
T*
[(level)-10.3(s)-298.2(o)0(f)-305.7(and)-7.4(rogen)-7.6(s)-303.3(and)-302.3(17)]TJ
/F4 1 Tf
10.7809 0 TD
(b)Tj
/F6 1 Tf
.5535 0 TD
[(-es)-9.3(tradiol)-10.5(.)]TJ
8.2191 0 0 7.3052 478.9983 353.0267 Tm
[(163,1)-11.2(64)]TJ
10.959 0 0 10.959 321.7889 335.2251 Tm
[(Animal)-613.6(models)-614.4(are)-614.3(beginning)-618.8(to)-610.3(shed)-615.9(light)-614.9(on)]TJ
-.9984 -1.1795 TD
[(HIV-induced)-808.8(neuroendocrine)-813.7(dysfunction,)-811.3(despite)]TJ
0 -1.1847 TD
[(the)-437.5(fact)-442.2(that)-440.4(the)-437.5(mechanism)-439.4(is)-441.7(still)-441.5(unclear.)-438.6(For)-442.1(in-)]TJ
0 -1.1795 TD
[(stance,)-378.9(male)-381.9(mice)-377.4(with)-382.1(long-term)-379.6(HIV-1)-377.5(Tat)-380(expres-)]TJ
0 -1.1847 TD
[(sion)-306(have)-310.1(short-term)-305.5(and)-307.5(long-term)-307.1(memory)-311(damage,)]TJ
0 -1.1795 TD
[(while)-250.9(female)-254.3(mice)-253.2(have)-258.3(only)-253(short-term)-248.6(memory)-254.1(dam-)]TJ
0 -1.1847 TD
[(age,)-493.7(and)-493.7(males)-488.7(and)-493.7(females)-495.6(are)-490.2(impaired)-492.7(in)-497.5(motor)]TJ
0 -1.1795 TD
[(coordination)-275.4(and)-276.4(balance)-277.7(abilities.)]TJ
8.2191 0 0 7.3052 461.3101 249.4488 Tm
(5,30,32)Tj
10.959 0 0 10.959 487.6723 244.5731 Tm
[(Subtle)-275.5(sex)-278.1(dif-)]TJ
-16.1351 -1.1795 TD
[(ferences)-247.2(were)-248(observed)-243.6(in)-244(neuropathology,)-246.4(with)-247.6(HIV-1)]TJ
0 -1.1847 TD
[(Tat)-271.4(inducing)-270.8(a)-266.5(higher)-269.8(density)-274(of)-269.5(presynaptic)-270(and)-271.2(post-)]TJ
0 -1.1795 TD
[(synaptic)-292.2(markers)-287.3(in)-295.7(the)-287.4(female)-290.5(cortex)-291.3(and)-291.9(a)-292.4(decreased)]TJ
0 -1.1847 TD
[(density)-625.8(of)-626.5(presynaptic)-627(markers)-628.7(in)-626.8(the)-628.9(male)-625.1(cere-)]TJ
0 -1.1795 TD
(bellum.)Tj
8.2191 0 0 7.3052 343.3322 184.7054 Tm
(153)Tj
10.959 0 0 10.959 359.6598 179.8298 Tm
[(In)-409(addition,)-409.9(the)-406.4(overall)-413.4(DNA)-405.7(methylation)]TJ
-4.4541 -1.1847 TD
[(level)-300(is)-296.8(higher)-300.8(in)-300.9(Tat-exposed)-298.4(females.)]TJ
8.2191 0 0 7.3052 479.4518 171.7228 Tm
(165)Tj
/F7 1 Tf
10.4607 0 0 10.4607 310.8472 140.9385 Tm
[(Interactions)-301.9(between)-296.7(the)-300.7(ECS)-298.1(and)-298.4(HPA)]TJ
0 -1.2357 TD
[(and)-298.4(HPG)-298.1(axes)]TJ
/F6 1 Tf
10.959 0 0 10.959 310.8472 115.0299 Tm
[(As)-356.1(described)-362.6(previously,)-359(HIV-1)-356.8(virus)-362(ìrst)-358.3(attacks)-362.1(the)]TJ
0 -1.1795 TD
[(immune)-374.1(system,)-371.7(causing)-371.8(a)-375.2(severe)-375.1(depletion)-372.2(of)-373(CD4)]TJ
/F8 1 Tf
8.2191 0 0 7.3052 544.025 106.9795 Tm
(+)Tj
/F6 1 Tf
10.959 0 0 10.959 310.8472 89.1212 Tm
[(T)-446.5(lymphocytes)-446.3(and)-447.1(an)-444.6(increase)-448.6(in)-450.9(viral)-445.1(load,)-449.5(which)]TJ
T*
[(in)-632(turn)-632(causes)-628.3(signiìcant)-633.9(physiological)-626.2(stress)-635.1(and)]TJ
0 -1.1847 TD
[(thereby)-722.2(results)-725.7(in)-730.3(dysfunction)-724.1(of)-724.7(neuroendocrine)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23783.5(9)]TJ
ET

endstream
endobj
109 0 obj
<</Length 16771>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 62.022 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(systems,)-276.7(including)-269.1(the)-277.1(HPA)]TJ
8.2191 0 0 7.3052 184.1385 702.7651 Tm
(143,145,154)Tj
10.959 0 0 10.959 226.2047 697.8896 Tm
[(and)-271.2(HPG)-272.1(axes)]TJ
8.2191 0 0 7.3052 289.3039 702.7651 Tm
(154)Tj
10.959 0 0 10.959 62.022 684.9069 Tm
.0082 Tc
[(and)-563.3(E)-4(CS)-4.9(.)]TJ
8.2191 0 0 7.3052 106.2425 689.7825 Tm
.0107 Tc
[(13)-6.9(2)]TJ
10.959 0 0 10.959 124.5543 684.9069 Tm
.009 Tc
[(There)-563.1(i)-5.2(s)-563.3(g)1.4(rowi)-5.2(ng)-562.5(evidenc)-4.4(e)-563.1(that)-563.3(HIV)]TJ
-5.706 -1.1795 TD
.0086 Tc
[(enve)-4.8(lop)-4.2(e)-216.9(pr)-5(ote)-4.8(i)-.4(ns)-217.1(gp)-4.2(120)-216(a).7(nd)-216.3(Ta)-4.5(t)-211.9(m)-1.9(ig)-4.2(ht)-217.1(indu)-4.2(ce)-216.9(the)-211.7(h)-3.6(y-)]TJ
0 -1.1847 TD
.0092 Tc
[(peractivity)-339.8(o)2.2(f)-336.1(t)-4.4(he)-340.4(HPA)-333.3(a)-3.9(xis)]TJ
8.2191 0 0 7.3052 186.3495 663.8738 Tm
.0103 Tc
[(21)-7.3(,1)-7.3(45)]TJ
10.959 0 0 10.959 212.2015 658.9983 Tm
.0095 Tc
[(and)-339.6(E)2.5(CS)-3.6(.)]TJ
8.2191 0 0 7.3052 253.9275 663.8738 Tm
.0107 Tc
[(12)-6.9(8,)-5.8(166)]TJ
10.959 0 0 10.959 283.8046 658.9983 Tm
.0068 Tc
[(Th)-5.4(e)]TJ
-20.2374 -1.1795 TD
.0088 Tc
[(ac)-4.6(tivati)-5.4(on)-386.5(of)-388.2(the)-382.2(H)-2(PA)-385.4(axi)-5.4(s)-382.5(a)-4.3(nd)-386.8(ECS)-387.1(i)-.2(n)-386.5(P)1.8(LWH)-384.8(m)-1.7(ay)]TJ
0 -1.1847 TD
.0092 Tc
[(play)-417.4(a)-417.7(k)-3.6(ey)-417.4(role)-418(in)-417.2(t)-4.4(h)2.2(e)-418(p)-3.6(rocess)-418.3(of)-418.9(inf)-5(ect)-4.4(ion)-417.2(p)-3.6(rogres-)]TJ
0 -1.1795 TD
.0087 Tc
[(si)-5.5(on)-303.9(to)-298.3(disease)-304.7(m)-1.8(ani)-5.5(f)-.3(es)-4.9(tati)-5.5(on.)]TJ
8.2191 0 0 7.3052 194.57 625.0392 Tm
.0107 Tc
[(14)-6.9(5,)-5.8(16)-6.9(7)]TJ
10.959 0 0 10.959 224.0503 620.1636 Tm
.0097 Tc
[(This)-304(is)-298.8(partly)-297.9(be-)]TJ
-14.7849 -1.1795 TD
[(caus)-4(e)-391.8(g)2(lucocortic)-3.8(oids)-392(se)]TJ
9.9842 0 TD
.0088 Tc
[(cre)-4.6(t).4(ed)-397.2(by)-391.9(the)-392.6(H)-2(PA)-395.7(axis)-392.8(and)]TJ
-9.9842 -1.1847 TD
[(endoge)-4.5(nous)-403.1(ca)-4.2(nnabi)-5.3(n)1.5(oids)-403.1(re)-4.5(lea)-4.2(s).4(ed)-402.3(by)-397(ECS)-402.5(h)-3.3(av)-3.9(e)-397.6(t)-4.7(he)]TJ
0 -1.1795 TD
.0095 Tc
[(immunomodulatory)-655.1(e)1.3(ffect)-655.9(of)-656.5(transferring)-655.1(Th1)-654.8(t)1.1(o)]TJ
0 -1.1847 TD
.0093 Tc
[(Th2)-230.8(i)-4.9(m)9.3(m)-6.6(unit)-4.3(y,)-233.1(which)-230.5(i).3(s)-232(a)-231.4(hallmark)-231.1(o)-2.8(f)-232.5(t).9(he)-231.7(progressi)-4.9(on)]TJ
0 -1.1795 TD
.0104 Tc
[(of)-298.7(HIV)-296.2(i)-3.8(nfectio)3.4(n)-2.1(.)]TJ
.9984 -1.1847 TD
0 Tc
[(In)-377.9(contrast,)-373.8(after)-378.3(using)-376.4(antiretroviral)-373.5(therapy,)-375.3(HIV)]TJ
-.9984 -1.1795 TD
[(viral)-284.8(load)-279.5(will)-285.7(decrease,)-281.9(which)-285.4(will)-280.5(inîuence)-285.5(the)-282.3(endo-)]TJ
0 -1.1847 TD
[(crine)-248.2(system.)-247.5(However,)-246.8(it)-250.2(is)-250.3(unclear)-247.9(whether)-244.6(endocrine)]TJ
0 -1.1795 TD
[(indictors)-332.2(could)-334.1(be)-335.9(used)-337.2(to)-330.9(reîect)-333(the)-334(functional)-334.1(alter-)]TJ
T*
[(ation)-412.1(of)-414.4(neuroendocrine)-415.4(systems)-417.1(affected)-413.3(by)-412.9(HIV.)-418.2(It)]TJ
0 -1.1847 TD
[(is)-534.8(therefore)-528.2(of)-533.3(increasing)-531.7(interest)-532.1(to)-532.7(researchers)-535(to)]TJ
0 -1.1795 TD
[(study)-236.4(the)-240.9(possible)-235.2(correlations)-236.8(between)-234.3(virological)-239.1(out-)]TJ
0 -1.1847 TD
[(comes)-301.1(and)-297.1(endocrine)-304.3(systems)-298.1(among)-299(PLWH,)-297.7(particu-)]TJ
0 -1.1795 TD
[(larly)-320.6(abnormalities)-320(in)-326.8(hormonal)-317.4(secretion)-321.6(of)-326.4(the)-318.5(HPA)]TJ
0 -1.1847 TD
[(and)-302.3(HPG)-297.9(axes)-301.5(and)-297.1(ECS.)]TJ
.9984 -1.1795 TD
[(Glucocorticoids,)-423.3(gonadal)-421.4(hormones,)-425.4(and)-421.3(endocan-)]TJ
-.9984 -1.1847 TD
[(nabinoids)-469.1(secreted)-469.3(by)-469.8(the)-468.5(HPA)-469(and)-467.8(HPG)-468.7(axes)-472.2(and)]TJ
0 -1.1795 TD
[(ECS)-357.4(regulate)-354.8(the)-354.7(bodyês)-357.7(adaptation)-353.3(to)-356.8(stress)-355.7(by)-356(alter-)]TJ
0 -1.1847 TD
-.0001 Tc
[(ing)-334.5(the)-328.9(basal)-329.7(levels)-334.4(of)-331.7(these)-330.1(neuroendocrine)-336.4(biomark-)]TJ
0 -1.1795 TD
0 Tc
[(ers)-428.7(and)-426.4(maintaining)-422.5(stress-related)-431.7(homeostasis.)]TJ
8.2191 0 0 7.3052 275.6976 366.0094 Tm
(168,169)Tj
10.959 0 0 10.959 62.022 348.2078 Tm
[(HIV-related)-551.9(infections)-552.8(result)-551.7(in)-549.2(dysfunction)-553.4(of)-548.9(the)]TJ
0 -1.1847 TD
[(HPA)-287.9(and)-286.8(HPG)-282.4(axes)-286(and)-286.8(ECS)-290.2(and)-286.8(thus)-285(lead)-285.9(to)-284.4(a)-287.2(series)]TJ
0 -1.1795 TD
[(of)-378.1(adverse)-382.4(effects)-380.3(of)-378.1(the)-380.6(physiological)-377.9(response.)]TJ
8.2191 0 0 7.3052 275.5842 327.1747 Tm
(145)Tj
10.959 0 0 10.959 291.5716 322.2991 Tm
(In)Tj
-20.9462 -1.1847 TD
[(addition,)-440.9(HIV-infected)-441.5(individuals)-441.8(have)-439.4(also)-440.7(chroni-)]TJ
0 -1.1795 TD
[(cally)-398(suffered)-397.9(from)-397.2(great)-397.5(immune,)-394(physiological,)-397.9(and)]TJ
0 -1.1847 TD
[(psychosocial)-369.3(stress.)-375.7(As)-371.6(a)-370(result)-370.6(of)-373(constant)-368.3(activation)]TJ
0 -1.1795 TD
[(of)-435(the)-432.3(three)-428.3(endocrine)-433.6(systems,)-431.9(imbalances)-435(occur)-432.7(in)]TJ
0 -1.1847 TD
[(the)-535.8(stress)-536.8(response)-534.6(pathway,)-537.9(resulting)-534.3(in)-533.7(abnormal)]TJ
0 -1.1795 TD
[(glucocorticoids,)-300.8(gonadal)-302.4(hormones,)-301.3(and)-302.3(endocannabi-)]TJ
T*
[(noids)-298.1(being)-303(secreted.)]TJ
.9984 -1.1847 TD
[(Re)16.1(s)12.2(e)0(a)20.1(r)0(c)19.5(h)-338.1(h)13.7(a)0(s)-331.9(b)13.7(ee)19.8(n)-338.4(c)0(o)21(n)0(d)21.2(u)0(c)20.3(t)0(e)19.6(d)-338.7(to)-325.8(in)19.8(ve)20.4(st)19.3(i)11.7(g)0(a)15.6(t)12.3(e)-339.3(w)14.8(he)21(th)15.6(e)12.5(r)]TJ
-.9984 -1.1795 TD
[(t)12.3(h)0(e)-341.1(t)12.3(hr)20.7(ee)-342.3(s)12.2(y)0(s)20.2(t)12.3(em)-339.5(fu)19.5(nc)20.6(ti)18.8(on)21.9(s)-349.9(a)0(r)19.8(e)-349.6(a)12.8(b)0(n)16.7(o)13.7(rm)22.4(al)-342.5(i)11.7(n)-348.8(PL)22.1(W)11(H)-347.1(by)]TJ
0 -1.1847 TD
[(se)19.5(pa)20.6(ra)19.8(te)19.6(l)12(y)-395.6(d)13(e)0(t)19.6(e)0(r)19.5(m)10.2(in)19.8(in)19.8(g)-395.6(t)12.3(he)-382.5(l)12(e)0(v)20.4(e)0(l)19.3(s)-391.3(of)-383.3(co)21(rt)19.3(i)11.7(s)0(o)15.6(l)12(,)-392.4(t)12.3(es)19.5(to)20.8(st)19.3(er)19.5(-)]TJ
0 -1.1795 TD
[(on)21.9(e,)-535.1(A)14.5(E)0(A)17.8(,)-542.5(a)12.8(n)0(d)-532.3(2)0(-)20.8(A)0(G)-529.4(f)11.7(ro)15.6(m)-538.2(t)12.3(he)-532.5(en)20.7(d-)20.4(pr)20.1(od)21.6(uc)15.2(t)-536.1(o)0(f)-533.3(t)12.3(he)]TJ
0 -1.1847 TD
[(HP)18.4(A)-197.6(a)12.8(nd)-190.9(HP)23.5(G)-202.5(a)12.8(xe)20.1(s)-199.9(a)0(n)21(d)-199.1(EC)17.8(S)12.8(.)-201(Th)22.4(er)19.5(e)-199.6(a)0(r)19.8(e)-199.6(c)12.5(o)0(n)16.7(î)13.7(ic)19(t)12.3(i)0(n)19.8(g)-199(ìn)16.7(d)13(-)]TJ
0 -1.1795 TD
[(i)11.7(n)0(g)16.1(s)-448.2(co)21(nc)20.6(er)19.5(ni)19.8(ng)-439.1(th)20.8(e)-453.1(H)0(P)23.5(A)-451.1(ax)20.4(i)11.7(s)-453.4(i)11.7(n)-452.2(s)12.2(t)0(u)20.2(d)0(i)19.5(e)0(s)19.5(,)-449.3(wi)21.3(th)-439.6(s)-13.6(o)-7(m)-10.5(e)]TJ
0 -1.1847 TD
.009 Tc
[(ìnding)-531.4(ele)-4.4(v)1.4(at)-4.6(ed)-526.3(c)-4.4(o)2(r)-4.6(t).6(isol)-527.3(le)-4.4(vel)-4.8(s)]TJ
8.2191 0 0 7.3052 204.8881 145.8141 Tm
.0107 Tc
[(14)-6.9(7,)-5.8(17)-6.9(0,)-5.8(17)-6.9(1)]TJ
10.959 0 0 10.959 250.9228 140.9385 Tm
.0096 Tc
[(and)-525.7(o)-2.5(thers)]TJ
-17.237 -1.1795 TD
.0098 Tc
[(ìnding)-437.5(th)2.8(e)-438.1(o)2.8(ppo)2.8(s)-3.8(ite.)]TJ
8.2191 0 0 7.3052 157.8897 132.8882 Tm
.0107 Tc
[(16)-6.9(8,)-5.8(172)-6.9(,)-5.8(173)]TJ
10.959 0 0 10.959 202.9039 128.0126 Tm
.0092 Tc
[(Gi)-5(ven)-437.9(t).8(he)-433.5(limitations)]TJ
-12.8553 -1.1847 TD
.0106 Tc
[(of)-200.2(using)-198.7(a)-204.2(single)-204.5(gluco)3.6(c)2.4(ortico)3.6(id)-198.8(co)3.6(ncentration)-203.7(a)2.7(s)-199.6(a)-204.2(bio)3.6(-)]TJ
0 -1.1795 TD
.0094 Tc
[(mar)-4.2(k)1.8(er)-206(to)-204.5(assess)-206(the)-205.7(a)1.5(ctivity)-205.1(o)2.4(f)-206.6(t)1(he)-200.6(HPA)-203.7(axi)-4.8(s,)-202(i)-4.8(n)2(cons)-4.2(is-)]TJ
T*
0 Tc
[(t)-8.4(e)-13.4(n)-7.4(t)-241.2(ì)-7(n)-12.5(d)-7.7(i)-14.2(n)-7.4(g)-12.8(s)-236.1(s)-13.6(h)-7(o)-12.1(u)-7.7(l)-8.7(d)-240.5(n)-12.5(o)-7(t)-241.2(b)-12.1(e)-241(s)-8.5(u)-7.7(r)-13.6(p)-7.7(r)-8.5(i)-14.2(s)-8.5(i)-9(n)-12.5(g)-7.6(.)-242.4(That)-231.8(is,)-234(a)-230.3(single)]TJ
0 -1.1847 TD
[(glucoco)-7.7(rticoid)-383.6(conce)-7.9(ntration)-384.6(does)-383.1(not)-384.9(accurately)-391.6(and)]TJ
0 -1.1795 TD
[(fully)-305.5(reîect)-307.2(the)-297.8(acti)-7.6(vity)-301.6(of)-300.5(the)-303(HPA)-303.4(axis.)]TJ
23.9104 57.9085 TD
[(Cortisol)-352.8(is)-358.9(converted)-355.6(to)-356.8(inactive)-355.4(cortisone)-356.6(with)-351(the)]TJ
-1.0036 -1.1847 TD
[(aid)-428.1(of)-429.9(the)-427.1(11)]TJ
/F4 1 Tf
5.4991 0 TD
(b)Tj
/F6 1 Tf
.5484 0 TD
[(-hydroxysteroid)-423.8(dehydrogenase)-427.3(type)-425(2)]TJ
-6.0474 -1.1795 TD
(\(11)Tj
/F4 1 Tf
1.3036 0 TD
(b)Tj
/F6 1 Tf
.5484 0 TD
[(-HSD)-389.4(2\),)]TJ
8.2191 0 0 7.3052 374.3432 676.8565 Tm
(174)Tj
10.959 0 0 10.959 390.444 671.981 Tm
[(which)-388.9(is)-389.9(modulated)-389.3(by)-392.2(the)-385.7(negative)]TJ
-7.0614 -1.1847 TD
[(feedback)-260.4(circuit)-260.7(of)-254(the)-256.4(HPA)-256.9(axis.)-260.2(The)-254.8(controversial)-259.9(ca-)]TJ
0 -1.1795 TD
[(veat)-430.4(can)-427(be)-429(resolved)-426.4(by)-428.4(evaluating)-426.9(the)-427.1(HPA)-427.6(activity)]TJ
0 -1.1847 TD
[(comprehensively)-370.5(with)-366.5(multiple)-368.9(biomarkers.)-366.5(A)-368.3(similar)]TJ
0 -1.1795 TD
[(situation)-456(might)-451.2(be)-454.9(true)-456.9(for)-453.9(the)-453(HPG)-453.1(axis)-452.3(and)-457.5(ECS.)]TJ
T*
[(Indeed,)-284.8(multiple)-275.7(steroid)-279.6(concentrations)-276.9(would)-280(provide)]TJ
0 -1.1847 TD
[(a)-411.4(comprehensive)-411.2(analysis)-406.8(of)-409.2(the)-411.6(activity)-407.5(of)-409.2(the)-411.6(HPA)]TJ
0 -1.1795 TD
[(axis)-343.7(and)-343.7(other)-339.1(neuroendocrine)-343(systems,)-344(including)-341.5(the)]TJ
0 -1.1847 TD
[(HPG)-313.5(axis)-307.5(and)-312.6(the)-313.3(ECS.)]TJ
8.2191 0 0 7.3052 416.6928 573.2219 Tm
(175Ö177)Tj
10.959 0 0 10.959 447.9306 568.3463 Tm
[(In)-310.7(addition)-307.1(to)-310.2(the)-313.3(HPA)]TJ
-12.307 -1.1795 TD
-.0001 Tc
[(axis,)-431(ECS)-424.8(and)-421.4(the)-427.2(HPG)-422.2(axis)-426.6(are)-428.2(also)-425.3(stress-sensitive)]TJ
0 -1.1847 TD
-.0149 Tc
[(neuro)4(e)-2.4(ndocrine)-323.1(systems)-323.4(i)2(n)-327.5(h)3.9(uman)-327.5(b)4(e)-2.4(ings.)]TJ
8.2191 0 0 7.3052 494.5889 547.3132 Tm
-.0171 Tc
[(175)6.7(,).9(17)6.6(8,1)6.6(7)-.2(9)]TJ
10.959 0 0 10.959 535.4077 542.4377 Tm
-.0138 Tc
(The)Tj
-20.2892 -1.1795 TD
0 Tc
[(st)-6.5(eroid)-9.3(s)-401.6(and)-405.7(end)-7.7(oca)-7.6(nnabi)-7.6(noids)-406.8(sec)-9.4(rete)-7.4(d)-400.8(b)0(y)-402.6(the)-406.4(thr)-8.4(ee)]TJ
0 -1.1847 TD
[(sys)-9(tem)-6.4(s)-541.3(have)-548(tradit)-8.5(io)-5.6(nall)-6.7(y)-540.4(bee)-7.9(n)-540.2(used)-549.3(as)-544(the)-540.9(cor)-8.1(re-)]TJ
0 -1.1795 TD
[(spo)-7.6(ndi)-8.5(ng)-521.9(bi)-5.6(omar)-8(kers)-529.4(to)-522.3(asses)-10.5(s)-525.8(the)-525.4(acti)-7.6(viti)-8.1(es)-523.6(of)-528.2(the)]TJ
T*
[(thr)-8.4(ee)-306.1(neuroe)-10.7(ndocri)-11.5(ne)-305.3(syst)-7.1(ems.)]TJ
8.2191 0 0 7.3052 447.8172 495.4959 Tm
[(17)-7.7(5,1)-10.4(78)]TJ
10.959 0 0 10.959 324.0566 477.6943 Tm
[(More)-256.1(importantly,)-261(among)-257.6(these)-262.7(three)-257.6(systems,)-261.2(there)]TJ
-1.0036 -1.1795 TD
[(are)-226.3(close)-221.6(interactions)-221.9(\(Fig.)-223.7(2\).)-222.3(It)-223.8(has)-220(been)-222.2(demonstrated)]TJ
0 -1.1847 TD
-.0001 Tc
[(that)-476.7(endocannabinoid)-477.2(signaling)-476.6(modulates)-472.9(the)-473.8(HPA)]TJ
0 -1.1795 TD
0 Tc
[(axis)-498.9(in)-497.5(response)-493.2(to)-496.5(stress,)]TJ
8.2191 0 0 7.3052 433.5873 443.7353 Tm
(180)Tj
10.959 0 0 10.959 450.8219 438.8597 Tm
[(and)-493.7(the)-499.5(CB1)-491(receptor)]TJ
-12.5708 -1.1847 TD
[(modulates)-322.8(the)-323.7(activity)-319.6(of)-321.2(the)-318.5(HPA)-324.1(axis.)]TJ
8.2191 0 0 7.3052 488.2959 430.7527 Tm
(181)Tj
10.959 0 0 10.959 503.603 425.877 Tm
[(Within)-319.5(the)]TJ
-17.387 -1.1795 TD
[(PVN,)-210.2(glucocorticoids)-203.3(cause)-206(the)-209.8(release)-203(of)-207.4(endocannabi-)]TJ
0 -1.1847 TD
[(noids)-220.6(and)-219.5(inhibit)-217.1(the)-220.2(excitatory)-215.6(inputs)-219.3(to)-217.1(CRF)-217.2(neurons,)]TJ
0 -1.1795 TD
[(as)-399.2(shown)-397.8(by)-397.4(being)-396.1(blocked)-400.9(by)-397.4(CB1)-392.7(receptor)-400.9(antago-)]TJ
0 -1.1847 TD
(nists.)Tj
8.2191 0 0 7.3052 335.5653 378.9353 Tm
(23)Tj
10.959 0 0 10.959 347.5275 374.0597 Tm
-.0001 Tc
[(Because)-381.4(endocannabinoids)-377(are)-376.4(widely)-378.2(distrib-)]TJ
-3.1453 -1.1795 TD
0 Tc
[(uted)-564.8(throughout)-562.5(the)-561.6(hypothalamus)-561.4(and)-566.1(the)-561.6(limbic)]TJ
T*
[(circuits,)-273.6(they)-274.3(occupy)-268.8(a)-271.7(unique)-274.9(niche)-272.6(to)-268.9(regulate)-272(the)-271.9(re-)]TJ
0 -1.1847 TD
[(lease)-284.6(of)-274.7(excitatory)-282.8(and)-276.4(inhibitory)-281.6(transmitters,)-277.3(and)-281.6(the)]TJ
0 -1.1795 TD
[(ìnal)-299.9(result)-303.4(is)-296.8(to)-299.9(constrain)-299.8(the)-297.8(HPA)-298.3(activity.)]TJ
8.2191 0 0 7.3052 505.8707 327.1747 Tm
(22)Tj
10.959 0 0 10.959 324.0566 309.3164 Tm
[(A)-233.8(study)-236.4(found)-235.3(that)-233.5(administration)-235.5(of)-233.3(the)-235.7(CB1)-232.3(recep-)]TJ
-1.0036 -1.1795 TD
[(tor)-246.3(antagonist)-250.1(SR141716)-244.7(to)-243(male)-247.4(mice)-248.1(increased)-244.2(serum)]TJ
0 -1.1847 TD
[(corticosterone)-402(levels)-401.6(in)-404.4(a)-401.1(dose-dependent)-405.1(manner.)]TJ
8.2191 0 0 7.3052 540.34 288.2834 Tm
(182)Tj
10.959 0 0 10.959 313.0582 270.4818 Tm
[(Glucocorticoid)-720.8(concentration)5.8(s)-722.4(are)-717.8(increased)-715(when)]TJ
T*
[(CB1)-315.1(is)-317.5(directly)-314.5(activated,)-315.7(especially)-315.4(with)-314.8(high)-315.2(concen-)]TJ
0 -1.1795 TD
[(tr)19.3(at)19.9(io)20.2(ns)-186.5(o)13.7(f)-195.3(d)13(i)0(r)18.7(e)0(c)19.8(t)-194.6(a)12.8(g)0(o)21.7(n)0(i)19.8(s)0(t)19.3(s)0(.)]TJ
8.2191 0 0 7.3052 422.0219 249.4488 Tm
[(23)26.8(,1)21(8)16.9(3)]TJ
10.959 0 0 10.959 445.0959 244.5731 Tm
[(Ha)22.7(ll)18.9(er)-182.2(et)-182.1(al)-182.1(de)15.2(m)10.2(o)13.7(ns)20.4(tr)19.3(at)19.9(e)12.5(d)]TJ
-12.0483 -1.1795 TD
[(tha)-7.8(t)-422.2(inhib)-8.3(itio)-7.5(n)-421.2(o)0(f)-424.7(MAGL)-427.4(with)-423.4(JZL)-7.7(184)-425.4(promot)-7.7(es)-425.4(the)]TJ
0 -1.1847 TD
[(H)-5.6(P)0(A)-432.3(act)-9(ivity)-439.9(in)-435.4(mic)-7.1(e.)]TJ
8.2191 0 0 7.3052 413.4046 223.5401 Tm
[(18)-7.7(4)]TJ
10.959 0 0 10.959 430.0156 218.6645 Tm
[(Conv)-7.4(ersel)-11(y,)-436.2(ECS)-435(act)-9(ivat)-7(ion)]TJ
-10.6723 -1.1795 TD
[(dam)-10.6(pens)-368(the)-365(HPA)-365.5(acti)-7.6(vi)-6.3(ty)-362.6(in)-363(res)-9.6(ponse)-369.8(to)-362(st)-6.5(ress)-7.8(,)]TJ
8.2191 0 0 7.3052 530.5889 210.6141 Tm
[(22,)-10.4(185)]TJ
10.959 0 0 10.959 313.0582 192.7559 Tm
[(mo)-7.2(st)-291(like)-7.6(ly)-290.4(by)-288.7(act)-9(ing)-293(on)-288.5(the)-292.6(hyp)-6.8(oth)-6.9(alamus)-294.3(and)-297.1(amyg)-7.8(-)]TJ
T*
[(dal)-8.7(a.)]TJ
8.2191 0 0 7.3052 333.581 184.7054 Tm
(22)Tj
10.959 0 0 10.959 345.5432 179.8298 Tm
[(The)-373.8(ECS)-372.9(is)-369.3(al)-6.2(so)-372.4(impli)-8.7(cated)-376.6(in)-368.1(the)-375.4(recov)-8.4(ery)-376(of)]TJ
-2.9642 -1.1847 TD
[(the)-421.9(HPA)-422.4(axis)-421.3(to)-418.9(bas)-7.8(elin)-7.4(e,)-421.3(which)-425.1(may)-419.2(be)-418.7(an)-418.8(ef)-6.9(fect)-8(or)]TJ
0 -1.1795 TD
[(in)-295.7(the)-292.6(lo)-5.3(ng-)-7.6(term)-294.3(fe)-6.9(edbac)-7.9(k)-292.2(circ)-8(uit)-294.1(init)-7.9(iate)-7.6(d)-292.2(b)0(y)-293.9(G)0(R)-292(acti)-7.6(-)]TJ
0 -1.1847 TD
[(vat)-8.4(ion)-245.8(in)-249.2(the)-246.1(hip)-8.2(pocampu)-10.1(s)]TJ
8.2191 0 0 7.3052 430.5259 145.8141 Tm
[(18)-7.7(6)]TJ
10.959 0 0 10.959 445.0959 140.9385 Tm
[(and)-245.4(pre)-8.8(front)-9.2(al)-244.2(cor)-8.1(tex.)]TJ
8.2191 0 0 7.3052 540.34 145.8141 Tm
[(18)-7.7(7)]TJ
10.959 0 0 10.959 324.0566 128.0126 Tm
[(In)-357.2(particular,)]TJ
/F10 1 Tf
5.675 0 TD
[(in)-363(vivo)]TJ
/F6 1 Tf
3.1349 0 TD
[(studies)-357.9(in)-357.8(Robertsê)-353.6(laboratory)]TJ
-9.8135 -1.1847 TD
[(showed)-478.8(that)-476.6(CB1)-470.3(blockade)-476.1(in)-476.8(the)-478.9(PFC)-476.1(of)-471.3(male)-480.2(ro-)]TJ
0 -1.1795 TD
[(dents)-314.3(prolonged)-307.6(the)-313.3(recovery)-306.9(time)-310.3(of)-310.9(the)-313.3(HPA)-308.6(axis)-312.7(to)]TJ
T*
[(baseline)-245.9(after)-238.6(stress)-241.9(response.)]TJ
8.2191 0 0 7.3052 440.1637 93.9968 Tm
(188)Tj
10.959 0 0 10.959 454.6771 89.1779 Tm
[(Cortisol)-239(and)-240.2(endocan-)]TJ
-12.9226 -1.1847 TD
[(nabinoids)-355.3(are)-355.7(believed)-354.2(to)-351.6(be)-351.4(interconnected,)-354.5(and)-354(glu-)]TJ
0 -1.1795 TD
[(cocorticoids)-479.4(inhibit)-475.8(the)-473.7(HPA)-479.3(axis)-478.2(by)-475(activating)-474.5(fast)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(10)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
113 0 obj
<</Length 9646>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 59.7543 387.0991 Tm
0 0 0 rg
0 Tc
0 Tw
[(negative)-436.7(feedback.)]TJ
8.2191 0 0 7.3052 141.1653 391.9747 Tm
(23)Tj
10.959 0 0 10.959 153.8645 387.0991 Tm
[(Endocannabino)5.3(ids)-439(derived)-439.6(from)]TJ
-8.5875 -1.1795 TD
[(the)-463.3(ECS,)-465.3(such)-460.7(as)-466.4(AEA)-459.2(and)-462.6(2-AG,)-461.4(and)-467.8(cannabinoid)]TJ
0 -1.1847 TD
[(receptors)-259.3(\(CB1)-261.8(and)-255.7(CB2\))-261.8(also)-254.5(suppress)-261.7(the)-256.4(HPA)-262(activ-)]TJ
0 -1.1795 TD
(ity.)Tj
8.2191 0 0 7.3052 73.3606 353.1401 Tm
(189Ö191)Tj
10.959 0 0 10.959 106.9228 348.2645 Tm
[(In)-517.6(addition,)-523.7(direct)-520.7(stimulation)-521.8(of)-523(agonist)]TJ
-4.3041 -1.1847 TD
[(on)-257.5(CB1)-253(increases)-255.4(the)-256.4(levels)-251.6(of)-254(the)-256.4(circulating)-256(glucocor-)]TJ
0 -1.1795 TD
[(ticoids,)-460.5(especially)-460.2(when)-457.8(the)-463.3(agonist)-454(concentration)-459.8(is)]TJ
T*
(high.)Tj
8.2191 0 0 7.3052 81.6378 314.2487 Tm
(15,192)Tj
10.959 0 0 10.959 70.7527 296.4472 Tm
[(Particularly)-392.9(important,)-389.6(the)-396.1(ECS)-388.5(overlaps)-395(consider-)]TJ
-1.0036 -1.1795 TD
[(ably)-398.4(with)-402.8(receptors)-399(for)-397(gonadal)-400.7(steroid)-398.6(hormones,)]TJ
8.2191 0 0 7.3052 287.0361 288.3968 Tm
(180)Tj
10.959 0 0 10.959 59.7543 270.5385 Tm
[(suggesting)-235.6(that)-233.5(ECS)-238.4(may)-233(be)-232.5(an)-237.7(important)-235.1(neuroregula-)]TJ
T*
[(tory)-228(system)-227.6(that)-223.1(can)-230.4(be)-222.1(used)-228.6(for)-226.2(regulating)-225.7(gonadal)-224.8(ste-)]TJ
0 -1.1847 TD
[(roid)-342.5(hormones.)-332.3(The)-337.6(ECS)-341.9(has)-333.8(considerable)-339.3(interaction)]TJ
0 -1.1795 TD
[(with)-418.3(the)-416.8(HPG)-411.8(axis)-416.1(based)-416.9(on)-417.8(the)-416.8(following)-411.6(evidence,)]TJ
0 -1.1847 TD
[(such)-491.8(as)-492.3(the)-489.2(regulation)-488.9(of)-492(ECS)-486.7(on)-490.3(gonadal)-488.6(steroids,)]TJ
0 -1.1795 TD
[(the)-458.2(localization)-454.2(of)-455.7(receptors)-455.9(and)-457.5(metabolic)-452.5(enzymes)]TJ
0 -1.1847 TD
[(of)-238.5(ECS)-233.3(in)-238.8(the)-230.5(HPG)-235.9(axis,)-239.5(and)-235(the)-235.7(alteration)-231.3(of)-238.5(the)-230.5(endo-)]TJ
0 -1.1795 TD
[(cannabinoid)-308.2(signaling)-300.6(elicited)-305.3(by)-304.3(the)-303(changes)-308.2(in)-306.1(levels)]TJ
T*
[(of)-321.2(gonadal)-312.7(hormones)-317.5([180].)-318(Indeed,)-315.8(ECS-deprived)-321.4(re-)]TJ
0 -1.1847 TD
[(ceptors)-428.9(and)-431.6(enzymes)-431.1(on)-428.2(structures)-429(in)-430.2(the)-427.1(HPG)-427.3(axis)]TJ
0 -1.1795 TD
[(and)-245.4(the)-240.9(altered)-243.7(endocannabinoid)-240.1(signaling)-243.7(are)-247(induced)]TJ
0 -1.1847 TD
[(by)-299.1(gonadal)-302.4(hormone)-298.7(îuctuation.)]TJ
8.2191 0 0 7.3052 204.4913 132.9448 Tm
(180)Tj
10.959 0 0 10.959 70.7527 115.1433 Tm
[(It)-322(is)-317.5(typically)-322(thought)-316.9(that)-321.4(the)-323.7(HPG)-318.6(activity)-319.6(is)-322.7(con-)]TJ
-1.0036 -1.1847 TD
[(strained)-541.4(or)-532.8(restricted)-538.7(by)-537.1(cannabinoids)-533.9(and)-535.1(that)-538.7(its)]TJ
0 -1.1795 TD
[(hormonal)-260.5(products)-260.1(are)-262.5(suppressed.)-261.3(Both)-256.8(males)-261.1(and)-260.9(fe-)]TJ
0 -1.1847 TD
-.0001 Tc
[(males)-271.5(are)-273(inhibited)-269.3(by)-268.1(acute)-273.3(administration)-271.3(o)-.1(f)-274.8(THC)-267(in)]TJ
0 -1.1795 TD
0 Tc
[(terms)-411.4(of)-409.2(LH)-405.8(and)-405.7(prolactin)-408.9(that)-409.3(are)-407.4(the)-406.4(HPG-related)]TJ
22.912 29.544 TD
(hormones.)Tj
8.2191 0 0 7.3052 357.3353 391.9747 Tm
(24,193,194)Tj
10.959 0 0 10.959 396.2267 387.0991 Tm
[(In)-346.9(women,)-343.5(high)-346.2(doses)-345(of)-341.9(THC)-344.5(in-)]TJ
-7.7908 -1.1795 TD
[(terfere)-467.7(with)-459.7(the)-468.5(timing)-465.8(of)-466.1(estrus)-463.5(and)-467.8(the)-463.3(menstrual)]TJ
0 -1.1847 TD
[(cycle,)-485(thereby)-489.4(delaying)-483(and)-488.5(preventing)-488.6(them.)-488.7(There)]TJ
0 -1.1795 TD
[(are)-505.7(also)-507.9(studies)-508(suggest)-506.5(that)-507.6(cannabis)-502.9(use)-510.6(may)-507.1(de-)]TJ
0 -1.1847 TD
[(crease)-282.2(serum)-286.5(LH)-281.7(and)-281.6(testosterone)-282.8(in)-285.4(men)-284.8(and)-281.6(shorten)]TJ
0 -1.1795 TD
[(reproductive)-298.3(cycles)-302.8(in)-300.9(women.)]TJ
8.2191 0 0 7.3052 444.9825 327.2314 Tm
(195,196)Tj
10.959 0 0 10.959 473.7258 322.3558 Tm
[(The)-296.2(result)-303.4(on)-298.9(ex-)]TJ
-14.8625 -1.1795 TD
[(ogenous)-446.4(cannabinoid)-447.9(inhibits)-442.9(the)-447.8(HPG)-448(activity)-443.7(sug-)]TJ
0 -1.1847 TD
-.0001 Tc
[(gesting)-387.8(that)-383.6(endocannabinoids)-391.4(possibly)-384.7(modulate)-386.9(the)]TJ
0 -1.1795 TD
0 Tc
[(HPG)-297.9(axis)-297.1(under)-303.2(normal)-298.2(conditions.)]TJ
.9984 -1.1847 TD
-.0001 Tc
[(For)-276.7(instance,)-281.6(intracerebroventricular)-279(administration)]TJ
-.9984 -1.1795 TD
0 Tc
[(of)-414.4(AEA)-417.8(decreased)-419.6(both)-417.4(prolactin)-419.3(and)-416.1(gonadotropin-)]TJ
0 -1.1847 TD
[(releasing)-606.7(hormone)-603.9(production)-606.1(by)-609.5(both)-603.6(males)-607.7(and)]TJ
0 -1.1795 TD
[(ovariectomized)-322.3(\(OVX\))-326.6(females,)-324.1(consistent)-324(with)-325.2(previ-)]TJ
0 -1.1847 TD
[(ous)-519.7(ìndings)-520.1(that)-518(THC)-520.4(has)-520(an)-517.1(inhibitory)-519.5(effect)-521.9(on)]TJ
0 -1.1795 TD
[(HPG)-525.6(axis.)]TJ
8.2191 0 0 7.3052 358.0156 210.6708 Tm
(197,198)Tj
10.959 0 0 10.959 389.3101 205.7952 Tm
[(Nevertheless,)-529.7(AEA)-526.4(elevates)-531.2(plasma)]TJ
-7.1597 -1.1847 TD
[(levels)-479.2(of)-481.6(LH)-478.2(and)-483.3(prolactin)-481.3(after)-481.7(the)-478.9(estradiol)-482.4(treat-)]TJ
0 -1.1795 TD
(ment.)Tj
8.2191 0 0 7.3052 335.9054 184.7622 Tm
(199)Tj
10.959 0 0 10.959 353.2534 179.8866 Tm
[(Similar)-506.4(ìndings)-504.6(were)-501.5(observed)-502.3(in)]TJ
/F10 1 Tf
14.8004 0 TD
[(in)-502.6(vitro)]TJ
/F6 1 Tf
-18.67 -1.1795 TD
[(studies)-430.4(of)-424.7(medial)-429.6(hypothalamic)-428(basal)-427.9(neurons.)]TJ
8.2191 0 0 7.3052 522.0849 171.7795 Tm
(200Ö202)Tj
10.959 0 0 10.959 310.8472 153.9779 Tm
[(These)-240.4(ìndings)-235.5(suggest)-242.6(that)-238.6(the)-235.7(inhibitory)-240.2(effect)-237.3(of)-238.5(can-)]TJ
T*
[(nabinoids)-298.4(on)-298.9(the)-297.8(HPG)-297.9(can)-302.8(be)-299.7(reversed)-298.1(by)-299.1(estrogen.)]TJ
.9984 -1.1847 TD
[(The)-203.1(HPG)-199.7(axis)-198.9(also)-202.7(regulates)-202.9(the)-199.5(function)-203.7(and)-198.8(activity)]TJ
-.9984 -1.1795 TD
[(of)-254(ECS.)-253.2(More)-250.9(speciìcally,)-254.4(sex)-257.4(hormones)-250.3(possibly)-255.2(affect)]TJ
0 -1.1847 TD
[(the)-297.8(functional)-297.9(activity)-298.9(of)-300.5(ECS)-295.3(in)-300.9(three)-299(ways,)-298.1(including)]TJ
0 -1.1795 TD
[(inîuencing)-337.5(cannabinoid)-334(receptor)-338.8(expression,)-338.7(the)-334(syn-)]TJ
0 -1.1847 TD
-.0001 Tc
[(thesis)-479(or)-476(degradation)-480.4(of)-476.5(endocannabinoids,)-483.8(and)-478.3(de-)]TJ
0 -1.1795 TD
0 Tc
[(graded)-337.2(enzyme)-339.8(activity.)-334.4(First,)-341.3(gonadal)-338.6(hormones)-333(may)]TJ
ET
1 i 
q 1 0 0 1 59.754 699.364 cm 0 0 m
.113 1.02 l
.602 3.474 2.462 5.394 4.932 5.896 c
6.009 5.953 l
6.009 4.989 l
5.159 4.876 l
3.116 4.586 1.44 2.856 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 543.968 705.316 cm 0 0 m
1.02 -.057 l
3.505 -.503 5.415 -2.482 5.896 -4.932 c
5.953 -5.953 l
4.989 -5.953 l
4.876 -5.102 l
4.573 -3.084 2.869 -1.38 .85 -1.077 c
0 -.964 l
f*
Q
65.764 704.353 478.205 .96381 re
f
q 1 0 0 1 65.764 410.683 cm 0 0 m
-1.02 .113 l
-3.628 .575 -5.318 2.396 -5.896 4.932 c
-6.009 6.009 l
-4.989 6.009 l
-4.932 5.159 l
-4.494 3.027 -3.008 1.491 -.85 1.077 c
0 1.02 l
f*
Q
q 1 0 0 1 549.921 416.693 cm 0 0 m
-.057 -1.077 l
-.635 -3.613 -2.325 -5.435 -4.932 -5.896 c
-5.953 -6.009 l
-5.953 -4.989 l
-5.102 -4.932 l
-2.985 -4.511 -1.451 -3.001 -1.077 -.85 c
-.964 0 l
f*
Q
65.764 410.683 478.205 1.0205 re
f
59.754 416.693 1.0205 282.671 re
f
548.957 416.693 .96381 282.671 re
f
q
154.602 695.338 m
455.074 695.338 l
455.074 511.37 l
154.602 511.37 l
W n
q
300.931 0 0 183.968 154.602 511.37 cm
/Im3 Do
Q
Q
BT
/F5 1 Tf
9.9626 0 0 9.9626 76.7055 493.3983 Tm
[(FIG)-7.2(.)-330.4(2)0(.)]TJ
/F7 1 Tf
3.8696 0 TD
[(Sc)-8.6(hematic)-308.4(presenta)-9.9(tion)-302.2(of)-306.1(the)-299(inte)-7.4(ractio)-10.2(ns)-299.2(amo)-7.8(ng)-301.6(the)-304.7(ECS)-305.1(and)-301.9(HPA)-302.7(and)-307.6(HPG)-301.6(axes.)-309.8(AA,)-302.2(arach)-8.6(idonic)]TJ
-3.8696 -1.2974 TD
[(acid;)-305.3(Ca)]TJ
7.4718 0 0 6.641 109.3606 484.8943 Tm
(2)Tj
/F8 1 Tf
.6753 0 TD
(+)Tj
/F7 1 Tf
9.9626 0 0 9.9626 119.7921 480.4723 Tm
[(,)-298.1(calc)-8.4(ium;)-305.5(DAG,)-305.1(diacylg)-10.1(lycerol;)-310.6(DGL,)-304.5(diacylg)-10.1(lycerol)-308.4(lipase;)-305.5(EA,)-303.3(etha)-7.8(nolamine;)-309.5(FAAH,)-304.9(fatt)-8.6(y)-300.2(acid)]TJ
-4.3248 -1.3031 TD
[(ami)-6.8(de)-298(hydr)-8(olase;)-305.1(HP)-7.6(A,)-303(hypothala)-9.9(micÖpitui)-11.7(taryÖad)-9.1(renoco)-10.5(rtical;)-307.3(HPG,)-303.7(hypotha)-12.3(lamicÖ)-8.7(pituitaryÖgo)-14.6(nadal;)]TJ
0 -1.2974 TD
[(mG)-7.2(luR,)-300.2(metabo)-12.3(tropic)-308.4(glutam)-8.7(ate)-303.7(recepto)-9.7(r;)-300.4(NAP)-7.2(E,)-298.5(N-ara)-9.7(chidonoy)-11.7(l)-300.2(phospha)-10.3(tidylethano)-12.6(lamine;)-304.2(NAP)-7.2(E-PLD,)]TJ
T*
[(N-arach)-12.3(idonoyl)-303.7(ph)-7(osphati)-9.9(dylethano)-11.6(lamine)-302.1(ph)-7(ospholipas)-10.5(e)-302.4(D)0(;)-302.2(NMDR)-6.8(,)-298.1(N-m)-7.2(ethyl-D-)-9.3(aspartate)-311.1(recepto)-9.7(r;)-300.4(PE,)]TJ
0 -1.3031 TD
[(phosph)-11.3(atidyletha)-12.1(nolamine;)-309.5(TRPC,)-309(transient)-310.3(recepto)-9.7(r)-298.3(pot)-9(ential)-300.9(ca)-7.2(tion)-302.2(cha)-7.2(nnel.)]TJ
/F5 1 Tf
-1.7015 32.641 TD
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23231.5(11)]TJ
ET

endstream
endobj
115 0 obj
<</ColorSpace/DeviceGray/Subtype/Image/Height 384/Filter/DCTDecode/Type/XObject/Width 627/Length 48042/BitsPerComponent 8>>stream
ˇÿˇÓ Adobe dÄ    ˇ€ C 		



ˇ¿ Äs ˇƒ “            	
 s !1AQa"qÅ2ë°±B#¡R—·3b$rÇÒ%C4Sí¢≤cs¬5D'ì£≥6Tdt√“‚&É	
ÑîEF§¥V”U(Ú„Ûƒ‘‰ÙeuÖï•µ≈’ÂıfvÜñ¶∂∆÷Êˆ7GWgwáóß∑«◊Á˜8HXhxàò®∏»ÿË¯)9IYiyâô©π…ŸÈ˘*:JZjzäö™∫ ⁄Í˙ˇ⁄   ? ıNlŸ≥fÕõ ?û∫Ê≠°˛XÍ∫ûìs%ù¸ZzS√OPªâVª|J≈~úÁ˛z¸ÃÛtöﬁ≤∂êjûZä◊ W◊∞⁄^àQÕ‘w1*\†çÊUbªü£ Z˛d˘´Àz&ª™˛î’ı..î¢√RÛ¢Ÿ:ÎSŒ∞«.cçû5F27¿@ß\Ëﬂë^p∏Ûî'µø‘„÷5m
Ók›R«tı!∏G_Ñ´∆„ÓﬂÙœœªÌKUº“Ì4ãiÆ⁄ ˆ˜I1]ª¡/‘è∑
CW^èH†ÏƒboÁ%ÁödÚñØeeqc§Í∫’≈ùú1‹†ñ‚+k)˛±Jî™/1–1 d£Ú€ÛBˇ Õ∫•ÂÖˆôô5º"™˝aç‹Uræù≈¥—A 4ßÔ#ÁÈÀ:lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lÛ}øÊ∑ùd¸ªÚ¯h5hÔg◊·∂∏Û+¨"÷h[RxÃ!√ô)È˛Ô˚±”—¸€˘ÉsÁ≠Q4çSX‘ØmºÕ=åöC⁄,ö4zR\Òs%—åzNë÷ú\ûÇõ‡õ<yñO—~rΩÛ°j∫Æµ-úz1≥ıÙ®-E·¥K;üI9≈tiPÕ'^‘…ˇ ÊüÊ§ﬁHkuÜ ÷{yÔ%éI›%1€”í«1\>ı˚n1–∂¯\?9oÓºﬂ•yb”EÆøkm™Èór‹*(”eÄÀ<í®À4L•5®nº©\èÈ_ùzŒôÂ?-J⁄÷”P∑íYµM^Ù¬è ºxZKs
ÀE‰ﬁö“Äs∏ƒÂ„G"ÖÄ$TTxé∏ÏŸ≥fÕõ6lŸ≥fÕõ
|◊Âm#Õ:˙&Æè%Ö√DÚ¨n—±0»≤•w˚h0üÕﬁLÚF±-ﬁΩ'ßsw¶M§=n5≥öEñ@F¸ê|XÜΩ'ÂÊªö∫ï«÷†—Ó÷{Xx»”ƒçáN$J¥c÷¢∏Üêˇ ó∫>≥©Îö\Ÿ‹_«Ò¡ã˙¨n"Q¿8BFÙÎëÉ˘˘3`œiñÛŸFÜ‚CµÏÅ¶∂ä•ñ5vØ¬Ωâ…mØÂ7Âˇ ◊b‘ÏÌxƒ∑?_Üﬁ[Íû±∂6åÎ%(ö0Ωp√ÀóSÚ’¸ó˙]¥ÇÈ†pI<“N`¥VÊ∂∂˛£7ßsÀÇ˜…6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥f»_Ê«ûu&yr€S∞∑∂∏∏πø∂∞ˆS∫ñ+ÍI(ä≠*OÜF!¸ŸÛåÒiz]ûü¢Í~g◊'∫w‘5õMK[(—Êñkïå∑0œ«”Q^á◊ø6¸”•⁄Ëñóö¶áØj“]«#kWæÜõYê(óQ£si˘rà]´ùÀÆ°´hVó˙Üû˙UÏ }{tóÉTÒë	WFß%n‡çÜfÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ≤&üï˛RO,ÿyhC7Ë≠6ı5XÃŒ\\$ÊÂK=y0ıö1–¥?/ymu$±qÈŸı;·,ºè÷.Hi‚?
Ù†Èëiˇ .ˇ (Ó<Œ5∑0õ÷ò_!x‚—ÓT˙ÇÂ≠ûëí£ó.>¯gÊ"yŒÛ«s|Ì4Îm-ìMeu$%¨€…Ü^qñ∏û„∑¸õÚ<¡têOıÎ[ã[õ[„<Üxçî?WÜ4zÌä™…—´æ¯ã˛H~^5ç•è‘Ê[kXæ´"%Ã .mΩc?’Ó∏∞ı£ı[ï'àâ*"ÖDUF¿∞/6lŸ≥fÕõ6lŸ≥f»wôº„yku%¶õË®ÑÑûÊ`ÕÒö’T°H€‚5Ìë35√Hg,“3©GvfsPiSZ≠	?<Ifø•séew!\§˚ÚÀì◊Ó‚fT€˝◊P+E Ú‹…€Œ>Ãï‰EXö∞Z‹â#l^ŒÚÓ¡Ω[;âmX}òî˛Ëì∑&à¸-∑˘◊&˛]ÛuæßK{µ[-C`∞≤m÷&†Â∏;u…lŸ≥fÕõ6lŸ≥fÕõ6lŸ≥f»wÊóíµ?7h6v:e‹WñZçÆ£∑Q4Òj≈¬4jÀ»1•wÈëŸ,º˚9”5ñ◊4Ào6Ëì\~ç∏∂”Ÿ,Z“Ó5I†ûﬂ’‰X≤r¨
’?.<Ôu¢Z√'ô·’uıÅ©€ÍˆKq•›óÊ’U‘«Ëtàá;lz‰üÚ˜ ‡ˇ 'Èﬁ]˙„ﬂ}EY~∞„à<›üä%[ÑiÀä-MëfÕõ6lŸ≥fÕõ6lŸ≥fÕõ6lŸ◊¸Ÿob'µµ¨◊ÍáèBPıdÒÆŸæ‘//k5‘ç~c©π
¢E48ÒT#}È\±‚ì™À∆:Õp¿T≤Sµ;Å_£2îQPGÍï„)‚\Çw#ó-ó«ls˙&Ú*£5†<XTÖ©oÑ“¶òo§˘´T∞InVÓ’x±é·ã∞≥ÑêÑq]´QìçÃ:v≥Ω£2…§∂Úé%zæ±ÈÜY≥fÕõ6lŸ≥fÕõ6GºÈ≠6üß%º,—‹ﬁñDïOàÉîépΩ2 ˙ºí:EiY™8Úﬁø3›∫e´K,‘ÇZ`é‘ nÔƒ"÷ùÈéÇ9‰,œuk@ii’¡Ï® Z∑ÀÜ÷ÍxCG3N°ïe˚OàÍ@Òﬂí92'®–L£‚éú]9πÂPvˆ Féû§{ß#˚™.√cˆËwÎQéiû9ñXøt– HBüp?Ætœ.kV“aº<D¶©2°%CÆ∆ïÏzècÜY≥fÕë-WÛ «[º—ÌÙ}[T∫”ƒ_[}>‘M”‘E,]7*kà Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Up.°˘√aß"=˜ñº¡n≤Ωääê*i˚ﬂR”ÛbﬁÚ›n-<ØÊ‡zÒë,TÉCC˛ÌÒ≈øÂf?˝J^cˇ §ˇ ™πøÂf?˝J^cˇ §ˇ ™πøÂf?˝J^cˇ §ˇ ™πøÂf?˝J^cˇ §ˇ ™πøÂeø˝J^cˇ §ˇ ™πøÂf?˝J^cˇ §ˇ ™πøÂf?˝J^cˇ §ˇ ™∏_/ÁfçÔ‘•–5ÿÓ˘ÙZ…CrjqﬁwÆ Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ Us Ã˙îº«ˇ H+ˇ UsÃ∆ üóòˆˇ óˇ ™π%–5ªwE≤÷l5ï¸)qn]J?îÙ>8?6lŸ∞ØÃz»“¥Û*qkôGoªBh;(‹Á2ﬁi§ëk!îÛëïG¶ŒÏ«ïE <Å≠;eÀszV¨≈UbBxÚ¶ËùI‹‘Ïqè™¥ÈRÖ*»•[nú®å@?Ü)"Om≈¶é·ZüH6à_µ≤ö◊Ω\|dÑI,d‰h€”¶„Ø˚x∆R 	)"3}ß‚õ∂ˇ gf≈¨Ôf±ºÇÚÿÚ∫ÖΩ:±‘Qª∆‰S˝ΩÛ®Èzå:éüÏ;$À^5´ôM;©¡Y≥fÕõ6léÎ_ò^R—u6”5π˘#IûmnÆ
«!`ÖåH£ó•Olˇ +g»ﬂÚ’uˇ pÌC˛…Û ŸÚ7¸µ]‹;Pˇ ≤|ﬂÚ∂|çˇ -W_˜‘?Ïü+˛V◊ëøÂ™Î˛·⁄á˝ì·ßí|√'òºØc≠Hãº:¢Q≈eeMü‚™äÉﬂ?0Vpñr5MòÊœ™@+∞?oÈê„•èh‘Ä¢B*ÉPÌ∏±[Idà‹˙±Ü≥ôHïπ0~#ê¯I∫‚ûhƒ&Xd8UxdeR\9+∂Êå§oQJ`hÓ%∑£zä~&∏‡R *≥ÇÙ√EªèZ—'{®ÄªÖ$xv(]V•X+~ÀSâåj∏+Í¶:éNH!Hâ˛ﬁg"!W¢”s∞©¯ytß∏ÌíOÀ©Wwˆ≈ŸΩTéàÚF%´Ú†¶Np/Èm3ÙüË°w	‘˝#plÉ©òD_P•y´\õ6C|©O˘X>xˇ å∫o˝A.L≥fÕõ6lŸ≥g<¸ËÉñçaqZzWi˛ºg˛i¡?ï“FﬁQçT’£û`‡v%πSÓ9-®˜Õ_ûjå’˘ÊÆjè|µ4ÈúOÛ/Cœm!^HfØJ)UÎÚ¶wuee¶™¬†éÑßöË$uBzr ~ºµee§;Ç7/6lŸ≥f VVØ;ºŸ±≤vﬂ#˙≤˘Kslüñæ\VïÖåUÄ#lñ˝r”˝ˇ ¸ˇ \ﬂ\¥ˇ «ˇ ø◊Ω’ÙÎ;9ÓÊù6Ò¥≤q`OR∆ÄÕÚ«ú|±Êù=o¸ø©A®€0ò\Zˆë∆áŸÄ8qêüÃ%f∫±ÁXR9x›|;≥ïSN‡9m◊Ë»«6-È)5^ »FƒíIˆ›z„¥…û'πıî£HÖ ùExR£®ß⁄®?ÀÆ-9≈ƒm<…ºÒÄ’nUúÇÛ-Osé∂‘uY˘Gp@±+E
¥<O&ü®ÈÜ3,:ûì=ı∫µï‘\Öƒu	ÀçkΩ@óun∏í 	™–±©*xÆ›9˚^¯’P!i9€c˚Fû9-¸πû@∫Ö¨¨+Í$ËÄÙıèAAµWØéL§ë#FíF	ŒÏh íIÌï±MM¨ëH°„ëeeaPAF;6lŸ≥dCDˇ …ùÊØ˘Ä“‚Wy/Õõ6“t´-*¬;%)mvE$±¨édmŒˇ iémSL¥‘¨ﬁ÷ÈIF°VåÆ7WS‚CÂÚ.±§wﬁ/"*ÀË∏SJ:ì◊•0öŸ˛ØpmôeyS	iYYy+q4„⁄£√/V±ñµ!˝FôiVmïT’ÇØ∑â˙p≠±·q3⁄pÜGå¨~3Ä¯[·`Ù∂‘“(&PÔ3ê.$çG&à(eìç8Tnå#^’ÎÅ$1ÿÃ∑!„@€»É£¢P©zP’ÎMÎµkÜvÎÎE… OQKö±eêx˛œN’√ø(≈v<Ÿƒ™ËcóÎ€ïà®°_Í*ÌùX÷Xû6ØR≠ƒï4"õ2êGÃg*—øÁ|©•y“ÛÃ1^ﬁ‹Zﬁ¿ÒÀc=ƒ˛¢ Œ¨n£í9ô~8πoûKÂX˘;˝Òwˇ qC˛´Âˇ  ±Ú˚‚Ô˛‚:á˝W ˇ ïc‰Ô˜≈ﬂ˝ƒu˙ØÖüó˙MéìÁO;YX´≠∫Mß2â%íf´Yä’ÂgsÙúûÊÕõ6lŸ≥f»7Á'ï£îHn£,p¡ìı∂¸•#¸7pk∑Ø¸ãLõfÕõ6lµ˚C8ˇ Ê‘<”Í
÷{hŸâÈPY>ÖŒ√¢Œ.4{¬î€ƒ·OP¶rﬂÃ{mÁÛ_HMgÀ≥˘ö—t;¶[+x‰∆ˇ [Ñ	JHÒÄ)UØæ«®yØ…ñÚﬁü˙OÛGöm4˝M÷•ñ˜¸'ëm‚ó˜J◊óH√ÙÏ+É5üÃø9ZÍ˙éÅm™Fu,€€•› h˜∑ã®ﬂÀ¨»‚ÿ2Z≈B£bZ¶Ω0Wôˇ 2¸ÈX‹±ã z}Œïoks©YMuo-Ù LñWì°Ah±†ñ ö÷¥`›sÛKÃZ	÷‡øÜ“{∑—Ïı?,≠∑)#ö‚ÂÖ¨ê˜ä∑RFUÖ*çÅØ<’˘ßu®y∫¬¬ˇ M≥ì…÷ˆw.ÚZI/◊%ñ»\K~ÙzqrW£(-∏›˛g¸ ◊ñ.{-N€MkΩ"[Í0i˜ZΩ”K*ñ+:AAØEâçiJbñûtÛÔö5L—Æ¨¥S´yjzÊÍKgªhÊyUq)í5‡y˛÷‡{Ù)∂Û/úº—y‰õ«‘a”o†÷µ'S∑Üí∫±∂ªIdReRÒH±é(ﬂdö‘”¶Û∆£cyy¢hˆˆvz∆∑Êªù&÷Ï¬∆$T¥é‚[©ëXz≤Ò¯Gƒ†öW`r}Âh¸·›⁄yí[kﬂBE•≤òZ‚&Zì=øƒ±»ç∑¬‹[®¶Ê∆À_IÈ◊â˝Yœø+|ßÂ{øÀØ.‹]ËˆW2Xƒeö[hùÿ”´3)'%?‡è&’áNˇ §XÊúﬂ‡è&’áNˇ §XÊúFÛÚˇ …wVì€6âcœƒdé⁄u•IS√b+∂#‰üÀ&y&ÀÍﬁ]”cµfP≥›ëŒÊjwñf´∑ ¥ˆ…6k⁄%æ±bmÂ<]O(§≤‘#q‹hr{†kZ|4û’Ω/ÖKnSÅR¸ r_¯ß∑6^´B¥/#qíS…§SF≠6⁄ò›FŒeü‘û!W"UﬁÅO*±4‰?g!Ü Â≈$§FÂ$~!AÊ*¨)==∆˘ØÇ€$0$Õ˚Í[»Æ˝JÄ»daƒ!ówﬂ«G}{k?_Ùb~0„ˆ¿4†®l52zÏ±R·eB6$mPk◊~¥ÏpÁ…n#ÛZíºöky"V‹
UË ﬁõ◊'zÌº∑:&°o
zìMm4q«P93F@;nNA|Ø‰ØÃ´?,Èíy¡¨§∑≤∑âÏˇ GY…ËîâT≈Œø
qØ|3ˇ 
~c‘Ùﬂ˜≥Õ˛¸∆ˇ ©ÈøÓgÖ^k”2¥?+Í˙Ã~u3I¶Ÿ‹]§-¶ZvÜ&ê)#±„ùMûIÙÎY‰5íXcw SvPNÿ#6D4O¸ôﬁiˇ ò'˛%wí¸Ÿ≥fÕõ#zÁîíÍfª∞+Àí”+r„#RÄ‘ÅΩ¿»ïÓóØññ94Ÿ§òÉ‡ºπWm•çüû\ˆW÷ê˙7±˙SÑâùsßP*√jÌÑz€ŸƒˆR:s∫÷8¡`Œ®‹à˛_PüûíÚ‹∫›zq√2pGî?!l›)¿Ò¯vn˚WaÉ|£cy´\]XŸÀîY&âù[ÖC(#bHûŸ”|≥Âà¥hﬁI$ıÔ¶⁄i¿†‚ £∑øéfÕõ6Cº´ˇ ìœÒóMˇ ®!ìŸ≥fÕõ6lŸ¸Ÿˇ î:_¯œ¸O	(ù+RZÏ.# |„5˝Y>Õõ6lŸc®Œg˘ÀnE÷ósQ≈íXÇ”zÇ≠_∆ô8¸æ∫˙œì¥«,Œ…§≈∫÷6)O£é
ìÀvèÊ»| eìÎpX…ß,;zf9eIãπr¨`u¿˛lÚuáôõFkπ•áÙ&•≠oÈq¯Â∂Â≈ê?	ÁΩ7¿ÔÂÍﬂÎwŒó≠_Ë7ó•∂™l.71«¥l¬dóÑ®§™»îj}[¸¨∂‘&ûK=sR”°gü¨¨2G7◊ Öjd7	1Yx3)ë(∆ª·fµ‰xu_;˘B =X4O&!û-RGOJ@!H‡µçC¥è≈’]À®ßJ◊$…‰]9u4ﬂâΩ_5≈7£·§Kπ∂S›xµO*ÔÑwìöo¨≤È⁄÷£§º⁄mæè™µõƒ≠ymiß	vx‹«"©#út48Hüï˙ıßútk}/Uø∞”¥,ç.z´iÂx√,R#£˛ËVº6"µÆIÂNôo¢Ëzvì©^i∑€ﬂ€j(bñygùd[á∏ıQ“C0ù˘|=ˆ¶-˘c£ﬁZ_DnÓ†ªπ’Nπg®B»≥⁄^÷0–û%xÒN%\¿êp” æSèA[…•æπ’uMJQ6°©]≤˙ícUH¬E"Ï™ä”áπ±ìP»ß°R?ä~Pä~X˘dxXB>Â…vlŸ≥fÕêçw WV˜w¶£\«#¥ç	
œ±Ø%©^KΩ)‘doSøyC,≈≈¬âG…
H‘ Ï;`Üiç¢â"kz,N êP"î8S´¿Ö≠Ê Do≠O¶EH¯‘Z©#˝¨BYÏ‰1LEYG Taƒq‡∆•jÌ˜‚˛YáQæI≠m≠≈ƒñdîUaÀè>&ú®nπ—|ùÂÀ≠2).oÿŸÄN ÜÄ÷ïßRz”$ô≥f»œÊw˛K4ˇ €&˜˛°ﬂ¥_¯„ÿÃ<_ÒÉ3dCDˇ …ùÊü˘Ä“‚Wy/Õõ6lŸ≥f¬Ø2i¢˜Mê*rñ ](*€¬Ó|+úÉÃ—⁄¨6∑≤2÷ë9Ú™x˝AD?j¶=à•0¶ìØﬁ[rµ±ë≠Æ´H!we^Uœ‚¥‹Ó3§~[yZÛMﬂ^B`gOJ§KªVGaS«ëU†ˆ…ŒlŸ≥f»wïÚ`˘„˛2Èøı2cõ6lŸ≥fÕõ!ﬂõ?ÚáMˇ ‡ˇ âå#¸üØËÕO˛3≈ˇ 9–Qµ}∞∫fYu€≠;ÍåëC!sSCˆzäÒs<h«Ïö”1FÌ¨¨¶πX˝vâyÎJ¸»a‘Ïv∆È◊ç{c”EË4ÀÀ“≠iπ ÉA≥»Tt8',t?,Ö˛nZºµor+[[Ö&ÇøäSs€zbøìóû∑ñß∂$ìkr‡T◊·ëCä¬µ¬?Ãœ:˘∑Àøòz4öc5∆Ée¶\j>`“ëC<∂©<p…4[2@%ıÉÒ FüÃã;wÕZ≠’Î\˘gO“4≠B≈a
·æ∂nb•4≈P
ötÈÅ.<?GZk'X—E¶£¶Èík6∂pﬂ[›-≈ºL”‘äæú®Ã9≠ÓìjûÜ¬khÕõIıùÛ[H≥Xò≈”´˙ˇ kµ0é◊ÛoTö∆¬Y|Øqo}Êâ|≠ß…q	ñÒZ^i•„»[E
Ó≈™iJ
öb◊õ©m¶‹˙˙-«¯ÉN‘¨Ù≠KAéHﬁTñ˝îA$2URX‰V‰åx◊zÒ ·∑î<Ûq≠köœóıM-¥ùoEK=∏ônbx.√42$®ÄÜR6>#|ñfÕõ6llø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6lŸ≥f (Ñ‘®Øç0áÕZDwoqRe!§eÍ h	4Ìú≥Ã6q≥⁄]3ÀBdVx≈VÄ£U◊ÁÑ∞jsiqn…,‘eRÒ©ßf<MCÏŒì˘Q¢]€-≈¸—¥I$b4‰
ÛbC3 ¿
^˘–ÛfÕõ#?ôﬂ˘-¸”ˇ lõﬂ˙á|:—„èaˇ 0ÒƒÕëˇ &wöÊIˇ â]‰ø6lŸ≥bR›⁄C*E,—«,°ö8›Ç≥,`*	©
˛Ë'Ç‚ÁÇEö	T<R∆C#+
ÜVF=ôTUà u'¶≤‘,o¢ylÁKà£íH„!Äñ1»Üù—‘©˜¬Â˝R‘nΩ;îπíŒÍ3{k∏ID¢7™í)˜…:Ä 
(¿≥fÕõ6lŸÚØ˛L<∆]7˛†ÜLsfÕõ6lŸ≥d7Ûk˛PÈ„<Ò<!¸®û}Vπ∏ëa∑ÜTyfs≈V3RO`2oª¢…"EÙ,àdçE´ .•«˘ ƒ‚æ«#:~©eõµ=fV0Ë◊êAmk©»•-‰ïÇ¢Åçˆ'n¸…¶€Œ– öÚXá+Åg‹zK±¨Ö*ﬂÏä±Ï∏ÕzÆõÂK˚K	“ÚÔR¥ö+híY\ØäÒß⁄¶_ìµ/(iˆóíãkΩ*“5i®íA"†Z:ı°#·#f˝ö·›µıÖ—qkqÊ:zÇ6∆§ÅZtØ˜b¯SÊ›<ÍX‘≠Trë†gâi_é:H¥›2˘5©µõ€¿-‘"T]∑hèﬂˆ_'~S∏∏¸√≥Û1ñ#em•\È≤Z∞%ŸÓ'äPﬂÀ«åDÖ[˛D¥yœKãQD–ı¯-a–Ì˝>mb-§í‡D @GÖgó·O‰¯qh?)nu=X”µç#À⁄◊Ù˘¥¯Ót;b'i& ⁄GHJ&ﬂ‹ä◊ªb∞yœ˙ù¬ÕÆÀ•[%∂É{°€Edn%-%⁄ƒ¢wy(üπ˚ Txú3’|áÆ¶õÂÕÍ‹yè 0¨1-«1iuñÎosï”ü »¸O« C˘_≠\œuÆjW6©Ê-[X“ı=E`ı¥V⁄SØ•m	`€Ä5vQV= ¶Ht'ﬁÿ˛cyãÕ2\FˆöÕ•Ö¥6Í‘F≥-_ÜçÍmLïÊÕõ6llø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6lŸ≥fÕôÄ`UÖAÿÉ–åÜj?óêj.x=ÉLHWí7§
ÀB+µiíãM#K≥Å`µ¥ÜW¢"(Î^ù}^lŸ≥f»œÊw˛K4ˇ €&˜˛°ﬂ¥_¯„ÿÃ<_ÒÉ3dCDˇ …ùÊü˘Ä“‚Wy/Õõ6lŸÛüín¸√≠Ë◊–ﬁµî:l7ÒJasÃo#ç+aƒ¯Ür¡˘cÁ{([OÄœygß~Ü¥∑∂Y%µÇY‡˝)" çÍ˙mìpªrn#Æ_~Jy„Q“N‘uànÏ÷	.⁄ÊÌã§vÍ±ŸÕ“)Îz’ÁÌÜO˘GÊH4[Ë,n†[ùJYﬁˆﬂÎ7iG%ˇ ÷¢Da»#G2r·Ò∏8à¸®¸¬K€IóY∑⁄ˆ“˛ˆ·f∏Iö[x,‡ïâI=Tµïh‘˚uØQñﬂìhãJû-k“øû‹[¥ÕsxÈ˚›>K{üÖôÄı.LRä∏mL£˛\˛`€yìM’nuJ;ŸÆÔm÷ÓÒ—"ô˘¢N1´5(95‘*vŒ±õ6lŸ≤Â@Êû}Â”kˇ HKì,Ÿ≥fÕõ6lŸ¸‡ùì —ƒ™ûÍ5$ˆ‚ˆˇ Å¬ˇ À[œ(_⁄›ƒ%∂∫∏í)‚5£°çü<Ω_QÚwó5˚kã^c4"5âb≥µ∏ï†EZTÊ%ùﬁä™O∂√|£Áﬂ-y∂÷4≤ì˝*[eûÎMïIhëï	çÕ=&*%NAXı Ç-‚X†çaâ>Ãq®E%ZèX›«eÊo1À|ˆñ÷Ãmçúƒƒì¡Æå(ÙF¯˛cØ4˚+°I·V?|.=7%QæP√~∏Üõ¢i:_´˙>÷;_Zû±åPπÃÊÆ€˚‡Ï¬ù®;‚l‚p3˘Oœµj§6w%[ﬁﬁ_ª˝÷ﬂÜw•` MTäÇ:sfÕõ6lŸ≥fÕõ/˜oÚ?´"î˘,¸∑ˇ 01~¨ófÕõ6l„¶É˘ñö››‰7S—◊Ã≥ﬁEÍF≈·ÉÙk"›ºÕ)å⁄¨î¨f>∏JÛøÁ©{•«o˙Ê°ao™EÇ!e
\\\èNÍyÃ´Ë≈ÉïzıÆ:˜˛VÓ°bÌ5OJhÊ¥∑ç!µäa1é›Ωk®¢n5û9}&VØWÆ+ÊkÔŒßkù&+õÀ	Ì£]¨vÒ˙∞<qÀ˚∞Æí1q*Twß\[E‘?9[Q]5ÌnÏt∏÷ ‹]K¨Æ£’EöH⁄çQËí~>Fæ˚byãÛﬁ“¡È˜ìIn7é⁄€ö]M ‚y(Ù„ïëﬁïÓ)ì ﬂ˘ÊÁQ÷£Û$2≠¥2 ”Êí(°V§‰®àX¸*ßõÿıgõ6lŸ¸Œˇ …oÊü˚dﬁˇ ‘;·÷ãˇ {˘áã˛ 0flàhü˘3º”ˇ 0O¸JÔ%˘≥fÕõ6lÿC‰Õ~Ô\”.ÓÆ£é9 ‘oÏêGZÌ.§Å‘üà¨`ü|>Õõ6lŸ≥f»wïÚ`˘„˛2Èøı2cõ6˘üXø≥}:√NÙ÷˚Tù°éy‘ºq$q4≤9U*Y∏ß¬µ=pºZy‹S˛vcˇ nÒˇ U;‹yô.Ÿº’ßãò”‘í‹⁄F%XÈ^lÜÁêZoZ`Ö∑Û≥™≤Îˆ¨¨+>†Ç*˝ˇ Lø™˘ﬂ˛Øˆﬂ˜ˇ Ø¯¡úåÕ¯ä”÷U—}@sIä˝b¥$R∏„oÁ`@:˝∞Æ¬∫xﬂ˛K·_ò|£Ê]z⁄+mC_ã—â˝UXÏB’®@&≥7J‚V˙_ô<£†œ-Æ•m{eß§∑RYIiÈ4™yL≤±V 'âﬂÆÿw≠y; ˛cí¬˚V±2€í
ºëÌ…fDîF ≤*»°¿p@aQïÂˇ #˘cÀ“	4ã3l·Y*dë˛Hëæ€7Qm›Óp∆mkEáWÉEñ˙’Ó¢iÌ¨¿öHíºùS©QCæ!®˘gC‘fí{ÀQ,Úƒ÷ÚI…‘òÿTÒ t;£zñ÷pC◊TpÖ%∏êrv?
Ï~'c∑â8ælﬁ˘Œ?74~Ø≠ƒªP[]Å”∆6>€ï˚≤K˘eÊe’¥%¥ôø”¥"êªF6ç˛·CÔìŸ≥fÕõ6lŸ≥ce˛Ì˛GıdOÚèˇ %üñˇ Ê/’íÏŸ≥fÕôïYJ∞H°pAÕAõ
ºΩØ«¨«~ÈAıÎù=É0nFŸ¯Ë≠0◊6lŸ≥fÕëüÃˇ ¸ñ˛iˇ ∂MÔ˝CæhøÒ«∞ˇ òxø‚f»Üâˇ ì;Õ?Û§ˇ ƒÆÚ_õ6lŸ≥fÕêˇ  ﬂ¯‡Í?ˆ€÷?Ó£>L3fÕõ6lŸ≤Â_¸ò>xˇ å∫o˝AòÊÕë5ˇ  EÂo˘ä∫ˇ ®)pÿv»µ‰;ùST◊u0∆^Eöƒ!74v	©∫cŒ(Ã¢åî‹¥'ˇ á|›amîPπ—“$o´€ﬁ®π[°fä•eñD"∏V,Å¯‘Éƒ≠F‘≠?0¨‰ΩºΩ{Ÿ#í⁄›.g∑πX◊◊2Z£%¨I!R¨}N-¬&ZûL¿ä-gÂ?8Æ¨⁄≠.bñlörÀy EµMRYíÑ•l‰ß∆_≠-Ä"ÚœÊ=ˆ°ms©€N!µ’,µ†{†Î™óQŒ»¬vib_RG¡»Wäô#¸º“0-#sÊ+ÛZƒgÅ”÷ Ωy"ïÆ&h’‹© QMêdóÕﬂÚäk_Ûsˇ &[m?ﬁ_¯√¸@bπ∆¸Õ´ikˇ 9AÂHûÚí-Ê⁄H⁄E≥Œd1FEvy+‘ÁdƒÓ≠-nÌ⁄∏R‚›Ë^T2û$0®;l@#¨<ﬂß∑öeÚç›“KÊ(Ìﬁ¸¨qºqõS"¨fØ∑©≈«%B|v≠2DüoûQV±;À+[ÎIm.ì‘Çt1»áj´{˛¨‚ÛG´˘Õ(Òb=·vŸn-ÿ“Ñ˜¯0Æv›W≤’Ùÿ5'Âo:’k≥–´ƒ∏76lŸ≥fÕõ6llø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6lŸ≥fÕëÀ˜üÃ_ˆﬂ‘ˇ ‰ˆKÛfÕõ6lŸ¸Œˇ …oÊü˚dﬁˇ ‘;·÷ãˇ {˘áã˛ 0flàhü˘3º”ˇ 0O¸JÔ%˘≥fÕõ6lŸ¸≠ˇ é£ˇ mΩc˛Í3‰√6lŸ≥fÕõ!ﬁUˇ …ÉÁè¯À¶ˇ ‘…élŸÛ_¸§~Vˇ ò´Ø˙ÇóªdSÛ\’tÕ}g:∆•8Ü’ÌmÕ‹±¢,“˙#Ì ´«˝ñ\~cj∫çåØ¶Mcß‹∂ùÎCct≤õÁ∏{YûOB"Wó’Áá”*T÷çVT>óÁˇ 0Gß€OÈ«®À®õ;yÍ¸°wßZœ¿•ÇDÓÚÛ„–å	w˘©Æﬁk¶ÈÚ[Aïá©{|Èg6§÷3C4o!h€·Õ¬ˆZQ∞]èÊ∂ØxJ…éöès2‹^´`Î•“	π?WUWoO‚jq€y◊ìÓn.¸ß£]‹»eπ∏≤∑ñiI©wh¡-^ı'Êﬂ˘E5Ø˘Åπˇ ì-Ü÷üÔß¸aè˛ 1LÛWú¸≤≥Œ]˘x¥r¨W´i© ®g¥ÜM‘”ÏÜ∑PŸÈ\rÓ¥?FCuÕv‡µıÙWV∫Nó°9Ç}f‚ﬂÎrõä ë≠SÑhŒ™ÌSSQ∞ˇ à5&ñxGú-ñÔr/Ë–~)fkt˚ﬂé≤°_Üæ=0NçÊÌDnÊΩèV“&∏éŒÂ÷“KõY¶*"/ñÂsP’Ök∏ÆMXu¶˘ªÀû`”§w1’≠¶•JøÅˇ %∫6s/)˘ö˚…∫‘÷öÑN-d`ó÷∆ºëáIPt;¡ñw'Ü‚ûC*áéE5§Tq˘≥fÕõ6lŸ±≤ˇ vˇ #˙≤'˘Gˇ íœÀÛÍ…vlŸ≥fÕõ6D.?ﬁ1€Rˇ ìŸ.Õõ6lŸ≥dgÛ;ˇ %øöÌì{ˇ PÔáZ/¸qÏ?Ê/¯Ä¡ô≤!¢‰ŒÛO¸¿i?Ò+ºóÊÕõ6lŸ≥d;Ú∞É†Í?ˆ€÷?Ó£6LsfÕõ6lŸ≤Â_¸ò>xˇ å∫o˝AòÊÕëo6 GÂ_˘ä∫ˇ ®)q˛f◊†–tKçNhÃ¬M"Ñ%ÂûUÇ$ÂCƒ4í('∞ﬂ#Wüô?¢y˛ôÇ€ïî”A©:≠dHŸ8+ùO)x≤»£•EF+/ÊNñæa∫”£”Ó$ãNÇ˛KÀıT¨riÚDíGWõ3ä6ﬁ˝»t_ôæ^í$k[KÀÖ_˜®Aoıg–§îíÖÑÎ«˜|Ö> xÔçãÛLóQí“=:·¶(ÅÏ÷%_[kômöÑ[5π¯ΩJwÈæ*øòﬁTë†ì¨W∞}g÷kzÇDOqÈº`¥¨¸!~àWê„ZÌç?ö~UéŒŒÍo^ÓŸÇ´¨`§j»Üjá(ÒÚïÓôéÁoÖ®yÊ‡Gïu†zãê‰Sa≠ß˚√kˇ cˇ àPÇ:åÑÍ˛Oπ∫¸„Ú˜öTKıK˙⁄g
=!#»¢$-ZÇÀ3ûü≥ìjvﬂªÇ<2¨i76±Í6È˜ñã™]-ÚMßäS*O$RG!^Q¥ë‘0Æƒ©l#µÚﬁÉm3ÕñuœTÀ∞H€ª¿aª{≈X$i¢ÛêÆ«ÏÄ;aÜç°ﬁHü£m¨Ô¨¨'ΩMCVΩ‘ƒI!à£†ÜÑôKÍ?_àö±…•ˆ´•ÿ+5ı‰V‰‘“GU;oˆIØ·Öy”…”:∆ö¥õß&*?‡òÖûuÚùßôlí˜Më˙"	ïÅISØ¶Ã*?’=æYÚ/ùn¸ª|tçP2È∆Bí$ÄÛ∂êù»À_¥>ëÔŸ—’‘:»¿`j=9y≥fÕõ6lÿŸªë˝Y¸£ˇ …gÂø˘Åãıdª6lŸ≥fÕõ"?óÔ?òøÌø©…ÏófÕõ6lŸ≤3˘üˇ íﬂÕ?ˆ…Ωˇ ®w√≠˛8ˆÛ¸@`ÃŸ—?Úgyß˛`4ü¯ïﬁKÛfÕõ6÷ıxtù6[ŸQ•+≈!Å)ŒYd`ëƒï˝ßv
0≤/ké∑zŒ≠p≥ic`ˇ W∂å7E‰£’êØÛ3o¸£¶6„N–≠Æ‚≥π÷Ó°ªúÇﬁMBDë’A,QÜ Ω0&è¢˘1aË⁄ºÇâ¶ê%Æ¢Ó≤N‰œ9ë™‰ø6ßçppÚ›•›™Mg¨Í98ÀÃØ #®+œ‘çî¸à8Ì3P’,ıa¢k≠ÃìDf”µOK÷X»«*
™ úî¸;05 P·ˆlŸ≥fÕêÔ*ˇ ‰¡Û«¸e”Íd«6lä˘Ÿ≈≠˛Å™Œ
ÿX›Kı…Ç≥ñ{i"Gp†—9∞‰›|©˘ßÚˇ R±ö¬˚U≥ö“u)4FZr}ôwA®;·Ÿ˛QMmqﬁ©Ùó|ç’›’‰í‹HY5&RkTDPüÀJıƒd“ø'dÅ‚óUILÀpóR…}+I9∫hﬁVïâ¯õ‘Ç76¡öw¸™]>ﬁX-ı+v˙¡Âq$∑RHÚ?÷>µ…Ÿè⁄3|gÓÈã≈y˘W¶⁄™Í6k|Ú˙Õ7÷y=Y'≠q˛Úf4˜¿P⁄˛PCvópjê£FºR4ΩîFD–áX|b9CWn£}Ò¥ﬂ…¯≈±∫4ˆ”<‚ÂØ\À!ê°uëøi§õPt˘‘˜ÃqÚŒ°°jV:~£Â˝Â¥÷ˆ∂ñ‰…,í ÖUWv?!ﬂ%÷÷Ú≠¨»J#PÓ§ á€|Ü™⁄ àyj 8Äª Zú©…∑›â=Èí*Ût/óf^ELoîß%oﬁ®‚ÎU‰Üªä‡˚8ÃVpEÍ<º"Eı%<ù®£v=œé-ö¥‹ˆŒoØ˘Û[÷uS¢˘JgsOVÍ º∏r*“rr©uË«vÌõEÚ^á›º^jµº[Î≥¬+â•FµíSR"¬Ã¡»zÑrÌæŸ-oÀ%2”Í⁄ïÀ_ü⁄»ﬁ©‰CÀÚ}{ ∫õ≈(6:É Óö+¸ò}8UmúÌûTàY˘∂¡x]ÿ∞‡.6™Ú‹0˜È”¿ÊÚü‰—¶˝´ñz∑‰zÚ∂j–´ø
ˇ ¿ÁaGWPËC# UÅ® Ù ÂÊÕõ6lŸ±≤ˇ vˇ #˙≤'˘Gˇ íœÀÛÍ…vlŸ≥f¿˙é°ißXO}x‚;kd2JÁ¿x‰Ùπ¬*˘ﬂTÑOo-∂É—¢ÇxÂœ¯∫í√¸´ û8üË_Ã-ˇ Ág¥ˇ ∏_˝ú‡'…^u“íÌ-<œnÌ‘◊≥”V·π=?“’Ë0∆-#Û9QﬂÃvs"Ó–∂öT>›-ÕG—ÉÙçjÓk…tΩRÿZjê†ò€‘Çxâ„Í¬‰)Ÿ∂eaU€® ìåŸ≥fÕëüÃÔ¸ñ˛iˇ ∂MÔ˝CæhøÒ«∞ˇ òxø‚f»éâˇ ì;Õ?Û§ˇ ƒÆÚ]õ6lŸ≤=ÁGéﬁ”Nøûñ“√P∑ûÈú–E≈≠–ˇ t“>¬π!‹á ∫Ôîuô¸¡™‹¡ig®Zk0€Ø≠x‰=õZ$ãH‘#‰d‰Ñ0‚‹´ë›;Ú]ÉZ—Óß‘K-§J∑7–» ∏l™¿ãkíßù92∑≈^#:ëÙ[≠…⁄.çvQÆ¥Î8-¶h…(^$
Jí’ûµ"MÊ}Œ%qìﬁÃ›„Å`x*◊íe«?Õõ6lŸ≤Â_¸ò>xˇ å∫o˝AòÊÕõ+Ç(˚≥pOÂvn	¸£Ó∆O%¥ºÛ≤«jZIÅUF‰ísáyì\‘|„Ê8≠¥ıo´ÚÙ¥˚≤7˚RΩ<iS‡3´˘{Dµ–Ù®l ¯ô>)• ríCˆúˇ l1‰}æ·Ö˙ﬁ©uß€G-ΩÑ∫ãºÜ3ø ·}7~D±U„T◊ø—Ö÷>`Û£Ç◊L[i—¬$◊l‚(Å@’t„ªÒMøÀÕ;N◊|πf-≠„˝9cR ´È€›£π$◊ì,/i›YGÛ`¡oÊ∑ê]õõxX}ù(GŒ‹Is¥ú¸à˛V¿r~ôÛ-åñÒ“¨˘47WHÓnK≈í +
ÒÓœRê`ó‘uΩ>ŸíÚ≈gxä$WpË»ánO,l¥¯î+ˆoË:›ˆ¶˜is•O¶ãrÇ7ûîóëêõ~œ¶:ÔøOœÃ≠Z{m-IZì˝Yx÷ºH´S‹Ï>ú$”¸©.ò∑ﬁ\Kœ—∫û®÷wQ^Úu˙ÃP¢-ÃHÖ`ﬂ
µh¿˜'Û<~`”ºøßjöÑW◊:¢ºz5ù∫4óMx“â#h£ìr∞Só⁄¢Å\?‘¸—ÊÀM"‚Î¸;*∫BÃ•'Üy¯¨°Äjrƒ”¶Èœ‰â~∫/m‡◊&éŸ‰ª‘n¯‹‹ﬁ$pG<íCÜ§JÖ*°æ2'rÀô≠ıØ*ã´´7F∏ä€åì4~ÑÔk:+)ó˜/È¸ ûù6o=hz>≤ü§Ù·$ZòPdã–úz€to›–H:ﬂ¶%˘}ÊçwJhÙΩR∆ÚM1ç!ú€ÃÕ?L´:˘üF@Y•ëBä±0O∞ˇ Ä√'Ü‚ÁÇEñT<r!¨¨*#®#õ6lŸ±≤ˇ vˇ #˙≤'˘Gˇ íœÀÛÍ…vlŸ≥f»ˇ úÄ0i^ß™˛î≥˙œ*“ûßÓ˙≈ﬁü]≤AúõFµÛ‰ó’Ì‡º¥ûcZ÷´/9âôßoVXñv{i≈ˆ#äG@	C~h_ãç^ˆŒkkÎ€S◊’√•√K˙,¢°A(à[µ¿´q^K'Mâ#§˘F«Ã÷˙Œ±&π*\	c≤”C√	·â£…7ƒ	¯ç|0Gòãè2yc–„ıÉsp$≠9}WÍØÍ“ΩΩOJøFH≥fÕõ6F3øÚ[˘ß˛Ÿ7øı¯u¢ˇ «√˛a‚ˇ àõ":'˛LÔ4ˇ Ãìˇ ª…vlŸ≥f tI£ëC£ÇÆ¨*;A¬.j⁄täöF¨b”ñº4Î»E FEä@ÒJ®Ωïô©–P`±mÊëˇ K3Û¥ì˛ 0õ öœöµÌ>ÊÌß≤∂6˜◊∂<ºØQgrˆ·ÎÎØ€Ù˘S∂\Xy≤X˝8ı{h	 ¥©dY¯◊pºÁe©Ò*pNè°ZÈû¥´$∑W∑<M›ı√sö^5‚	 *™Ú<Q QÿaélŸ≥fÕêÔ*ˇ ‰¡Û«¸e”Íd«6lŸ≥fŒE˘üÁoØL˙ü!6êø«]˝Y˝Å˛Jüº‰ã»O˝f/n„ˇ rW+G ◊”åÓ#˝€ﬂló1ùçIÿf
ƒVî˘Ât>„∂A|˜Êè4i˝Ñ61JtÈ„ã”˙µ∞∫í‚ÊK•äHòµKÍu©#Ï”¸ØÛ∑ôuò-¥›wOñ+ÿm=kã˘cí/TÑ∑en&4åÚ|*v·”: bH9—u‘–ÔÆ4ƒ”/•˙î◊wWn•øòHX∑í¨ïˆË|rl.#˝€F–Dj(ƒäé;ÔQæŸ{˛=2˘ú¨5Ø-»ËL"ÊçNïıc4√?9õ-nk≠'TîZh/WsW∏ûÓÂu´ò¯¨ÄÛQŒ¶ÄÄc⁄VÖ‰è,jñöÆè;µå_Z∑ºñ·å≤Y<°"•O]"ú≠ƒrÂ∞©…¨˙¨Öﬁ∑l⁄u∫†ªñFcÕ9g]ﬂîíπ%@ﬂ‚¶Ù¬
„ÛE±ûC°≈˙&Fû‚÷‚UuoƒÔ:ƒˆ∑™—∆ÆÒQLòe]_Íz§W:ïÂ•ùﬁùyH"õ…$)
!¯m˘≠s^Fß	Ót<,i4w3ﬁ€$æ7¨ãopˆÛ	aâDà√˜ÚØ≈óèZP0éœÕé±g-‰Me¶ªZΩ‰o{Ò[Xn"ñ2∞»’˙√Nå
Ì¸T `ÌA∏“ÁÚıÀŒQlÏÆ"÷K^4ëô]b*Â]ŸXÚF%˚dØ √ZyADhπ%V$©¿ÉQÜ˘≥fÕõ/˜oÚ?´"î˘,¸∑ˇ 01~¨ófÕõ6lB˛¬”P≤ö Ú!5µ¬îñ6Ó∏‹:a5§^o”kk˚çb—-Ófï≠ÓÇéã5Tê”ˆ«˜O◊º—J˛â∂Øá◊˝P¬˝ÕZﬁÆ∑çk§D¢∆Ú{	}K∫VKv‡Âi|$Ù¡≤_y∏£¥õA'ÏΩn5Òj[ì˜cÙç‚π5MRuª’•OK‘çxE<πzP©%©]Ÿò’è» oõ6lŸ≤3˘ùˇ íﬂÕ?ˆ…Ωˇ ®w√≠˛8ˆÛ¸@`ÃŸ—?Úgyß˛`4ü¯ïﬁK≥fÕõ6lŸL©
hƒliZñAˇ (Ùè8ÈZ.©oÊÅ‹>≠=†∑R°°ö·§ıMYˇ ºwfQŸh˘9Õõ6lŸ≥f»wïÚ`˘„˛2Èøı2cõ6lŸ≤˘óÁÅ¶@⁄>ü'˚êùis*ıÜ6øÀ`v¯d»VÇ÷Ÿ¸’¨ØßmmMiÿU,”ê|?cÔ¡~c¸Ÿ∑o-…yÂ˜Mm:Ex∑aX‚ê2¨|è®ËõVù∆G˘çÁyu}&ÍCó÷∞˙L|M3;Ú˝À,k…QòSΩrK˘}ÁÀØ4›_G%àÖ-’^9cft‚∆úùΩA◊lô∑S˙±È%6≠=Ú/ÊÔ?Èﬁ\æµ¥ª∑û‡›/0Ò
£òM√ë„\íµç∏∑ÜÓ⁄[kï[L≠–æÍ»√ã)`kÕ+MΩÜ.m“X-§äkt;íNÖhT≠;|∫a'ôœˆ~Y‘$–⁄«R◊ï§í√÷â‡_LIå4ÇIj8WíZÌÖ:ÆçÊﬂ0y	<≈omôÌÈr÷∂<ùÒ£DÀU ¯Wa^∏FñO0Z\Œ÷£WK•ÅuÕÀË‹%≈∞«yjÃP|h´…y-
ÏkPn˚M∞ªõU“,t…<πh∂–Æµ©‹2KX%vu∑∑∂Y'âûb¥zè≤iBJå—Ë>V“|œiÊgÇÍ ∆y-ıG[;hﬁ“‚h˛â^(‚pÇ°O√EÂ ¥Ïa÷Ù?/ôØu{fQt∑2ÍI$©ıbQ•
dÁVìãÖAÒmêCO1\X˘n“ÿ$"ÓÓÚc"'( û·‰XºWÑo∫ˇ 1„€:≤Ë:*†Aß€QTÓb¸I\wËM˛X-ø‰DÛNDºÔ˘yg©√ı›&ﬁ(uñçDTùGÏÏ(¿˜Ëpá»}õG∏>Æ[Í¯DÔ≥[=i≈πo¬ø9ÿÅÆ„¶lŸ≥f∆À˝€¸èÍ»üÂ˛K?-ˇ Ã_´%Ÿ≥fÕõ6ll¶QòÇôxüL1!KSjê	æŸœ?%5P“µ˚≠_I:CIÆ_4P¥ÜFf2“_ÿOÖ\V˝™W:.lŸ≥fÕõ#?ôˇ ˘-¸”ˇ lõﬂ˙á|:—„èaˇ 0ÒƒÕúﬁ]~˚J¸–Û∂–ÔıÅ.ü•Û6?W§|ZÍú˝y†˚U⁄ïÈá„Õk˛§ùs˛Âˇ ˆWõ¸y≠‘ìÆ‹ø˛ Ûè5Ø˙íuœªOˇ ≤ºﬂ„Õk˛§ùs˛Âˇ ˆWèÚöuo0MÊ®Ÿ…ß˛è‘~´me8åO_UÇZJbyPí“±7Jd∑9dûP\^ImúïäË⁄ÃÀp”4,∑Èb·#ã˜M/>QnCw¶èÛ”ÀÔÂ◊‘d≥∏¥øôV u%C∫x˘KÖñ∆BHm∂¥¸‰–}ìT¥π”¬ÍÈ™Ã™ÍœâÑ÷éÚ®Ñ¯Ìæ“?5|Ø™ﬁi∂VÈyÊ¨ëMcˆÔº3,Æ≥o˜X[v,›™æ#Øø9t!sæõ◊.∑⁄\¥±Iòdû[gûƒ˙ºe∑ë@H≈a¸ÏÚLìCn‘… äg0g[zÕ"ñE‰]¡;û˘7œ±y£W÷-m≠%∑≤”£≥ñ÷y’£y“Ò√àÿ
%5ﬁΩ≤YåöTÜ&~E#RÏKµT—T'ÿg(–?Á$<ù¨˘™ˇ GK[€[+y5‰÷∑+ÕÃ/´C≤F†o N?,ï €Ú/¸µ]ˇ ‹7Qˇ ≤|ﬂÚ∂¸ãˇ -W˜‘Ïü7¸≠ø"ˇ ÀUﬂ˝√u˚'¬ˇ ÀΩoO÷ºÂÁk˝=§{WõOUibñ%l‘›Ã±∏˚≥†fÕõ6G|ÌÊÿ<ª•ôè®N
Ÿ¿OS›€¸ï˛ÃÊ^IÚΩ◊ôµW‘uFy,¢~w2…RgêÔ¿Êˆ€:GõÁæ≤ÚΩŸ“Ì› «¡-Br_Mè˝ÿ˚|PüÄuœ6yõ ﬁi‘‚áR”tòåj°R⁄≈
Àq?'y°S$—â7©€ˆv»,v¥´ 2.‡¨Ä>"8©Æ€∑è\ö˘pÎ(5¥S,Ó&ñ€’8X£<µ&á¶ŸÈœ+XjZóÏ¨µKè≠j'Á‰^ßë rj‚(*z·∞ ëQêøÃç{F“÷Ã…ßA{´TÕ`nSîpÑ 4¨›zÏu?,‰œ8›yèÎM?Í´m∆∑≈‚f=S‚U<ª¸∞ùº˝´hb”ÙÀ];Î›b~ssrûú%vªZıÌ◊&ƒÔ˝2®;ÊüNC<¡‰k§ø:◊ñ.û®	y!äHO⁄•~À∏oÑ˚dnÔÕZ•¶©q˛)—Ó⁄Ò ˙…∑B“Esh≈‡∫Å®ƒ†ù’XTT`;œ2˘.“œT≤ÚÃ7”\kê¨:≠’◊©√”*C»}r$y∏HÀAÉÚ≈†–ou€Ä˙ó-¥V
ÜˆD£@ ‡Ã6†ˇ }% ŒãÂ*Èæ^±Ùmˇ {q!Âqt¬è!Ì„EÖq}wF˝+πäÚ}>ÚŒe∏¥ª∑#í∏¯Y]©":¨¨;ÌCCãYkV7ó◊÷ñéˆ¡ïg∑ên.+©_∑Ô≈∆’u+ø∑|É~c˘#ÎÈ&±ß(ë°70˝Ú(˚C¸µCﬂ~W˘ÂπG†ÍRñW¯tÈ‹÷î›Ù|?wÜuŸ≥f∆…˝€|èÍŒ}˘[Êﬂ*⁄~]˘z⁄ÎZ∞∑πä %ñnaGSNå¨¿ÉÛ…O¯ﬂ…ı”È.˘Ø7¯ﬂ…ı”È.˘Øª¸¡ÚE≠¨◊Æÿ8Ü6î«‘Ï!Wû‰”lK…?ò˛LÛ≠ôπÚÓ•Ÿåqjjó◊˝˚Q◊ÁJxíÊ»b˛l˘TÍÿ2›G4rMº±„ìÍ∑+kp»Ï¡HäWª”ÏÉÉ≠2<ïy£6Øc™√wf±˙´È∞W`cíUd·FdÖ»Náß~by'Pó—∂÷-öqrlL- W˙ ®cJµjÉ€¶y˜…â¶Î6w%ÁKuXeV-<¡ù’ò#†¯bwüòûQ∑’b“WPäÁQ{µ≤ö⁄›“GÇFWjŒ¯zd„ã≈Áø&Jˆâ∑dœ|≈,‘OeunS}»m©è–<·°k˜˙≠ûï8π:<±¡u<eZ#$à$¢:ì^=ﬂ∞ØÆXi&ƒ^3/È§≤∑**=Yôy√‡;‡—4'`Î˜åﬁ¨Œ>Òõ’è˘«ﬁ23˘ü,_Ú≠¸”ÒØ¸ro{è˘g|<—ø„ècˇ 0Òƒ¬o1˘ûﬂAé9nm.'äR‹Dƒ»∆ã£HéÓ›Ç)¬*›5ﬂÊ'ô.Z	mZ]7G´ŒeJõ≥≈¬ñæúõÊÕõ∂∞≤∂ñ‚[x)n‰ıÆù)í@™ú‹éßä(©Ï1|(ˇ 	ywÙH“>§ü£ñ‡]ãzΩ=qqı†ıØ*˙ˇ _√	OÂÂÀSñé
Ñh¯Ó
pa(°_Sé¬‚@6€ë¶/s˘Y‰+´è¨M•+KÍº‰âgPdíDï…Up2BèƒärÎäÿ˘G≤Û%ñµ
4≠8iZM†E„o`^ío#Ú†roáz}£Ñ÷ì>XãV’Ôu⁄çæ©"ºz|ä#∑Ä,≥MDX¯‘óπrOzÙÆZ~Wy
“ûéíïè…‰öF-©2dv&èù¸)”<∑‰œ-yl‹ùœÍ≠v#…,•ñ+É+øEbF√≥`D“t∏ı95D¥Ö5)£Àx®¢gçMB3Å»®=¡y≥d7 ü˘0|Òˇ tﬂ˙Ç2Õõ6‘µM6¬{Î∑ÙÌ‡RÓ›˝Ä…;„ú:G’|ÛÊ≤I(%˚'Ì-Ω≤üÌ˙XÁf”tÀ-/OÜ¬—=8#Z"ç˝…>‰ÓqpTö6s˚Ø ñéMZÔN’$èP‘Q“%ëGÑ≥,Œà}Fèëﬁ∏ÛÚ„ŒCÀ⁄Vùg´"ﬁYœ3Ã¬Y£ç"ôÅFS’Ω;)Æ‘…GòºÖ¢˘é{[çJYD÷®±4ë0OYA©Y*nU;PÓw…1®E«aO”¸„ÊΩAóSµÄ\Kë'T,èƒ±·ÒmúœÛ*MKÃ>YÚØôgîÈ≥ô]^◊ã…!¯∑ƒPÒ~ —∫Ìë-&_;Èöq};YΩ{ì∞Å⁄‹OÈ,BOP≥ÒJö5*I•zuˇ  ]7T≥Ú·õUöKñ∫1Ω≥Œ]•¢'ÌÍnæ°ø˘5°Oly©iˆMnóó1[Ω‘ûç≤ ·í^	ZT”+O’t≠J›Ót˚∏ÆÌ„bè,.(©èèÜ˛∆S£qøXã◊ÉÉ´sàq˝‚PûKÒÆ„mMÄˆƒ£≥≤ÜB—[≈7⁄(ä§¸»∏´ÂÀÓ b	€+ıÀmV]6‡Ë”Cm´Uûx˝H…FÁÈH6<u®˚5‰7¡ñÚ¥±)ëV9¬ØØ∏ì“ëî1B¬ï•v4‹oã©P(⁄ŒO˘õÂ®\ùj≈J⁄\8˙ .¬)IŸ≈:+~Û…øÂ◊õNΩ§ònû∫ùï‚¥‘˝âh<z|ñfÕõ-}'¶Áâß›ê œ,yjÔÚÁÀ∑7zEî˜X¬eñKxùÿÒ˝¶e$‰ß¸Â˙±Èˇ Ùã¸”õ¸Â˙±Èˇ Ùã¸—â‹˘…∑Ú€æâbdhÿ•¥*¿0°‚¡j˝Fo)y# ûQ”Öáótÿt¯ ÃkY$#ˆ§ë™Ó}ÿ·Êlà[~VyFŸnﬁ;j__^Î≠H,bÈÿ›ãﬂL LH†S˘p¢…-(E∑È[”eË}]Ì«†9ä{xõ”- (.Y~ 1Æ*ﬂìös_A7È{Ô©€ﬁËÏ?rcı—aRc≠}Kpy}†	PiãÈ?ï÷zgô¥B	ãXyM{+dêÚöYôœß$¥UO‹«$ÅHﬂ„o§õL¸õºˇ \jû§WMÅ›Ù{{FhöIÁòñï£V†7$äñj˛’¥¸ëÚÏV±√qys"Ô$§¬Ö€Î˜ê±çÀZ '≠	Ôæy»:î!ªé“Ó‚ÔÎ^ä÷„”¯"µåCkÈ¢}à¿µIÍrOëˇ 9yB”Õ⁄u•ËçÏÌ/‚Ωπ∂ö?U&Hï«¶A n\Ô”ˇ  ≠¸∏Î˛”Î„ıxˇ ¶o˘Uﬂó?ı-Èˇ Ùéü”7¸™ÔÀü˙ñÙˇ ˙GOÈëﬂÃ_À ⁄˘Ãó6˛_∞ä‚.ÚHeX2∫¿ÂYM6 Ù…|ZÓô•Ë∫{_H—+Z∆¸÷)dP™ã»≥"∞^ΩÒø„ü*qÁ˙A8˝CÙΩxø˚√ÀáØˆ~œ/ß!øô∑07òÙ∆ÇKy¥,“F≥<íˇ ∫Kz—<IˆëΩË√Ø,Z√k˘çÊX!RëGßi
äXπ 5ﬂVbI˙NMsfÕõ6lÿåóvÒ†r‡Ü<Vù»ÎäG*Hºê‘vlŸ≥fÕõ6Cº´ˇ ìœÒóMˇ ®!ìŸ≥g ¸◊ÛCﬁÍ#C¥b÷÷å»]˝IÕ Zº+J1…ë|Æ4-L√˝»]“K∂Ó>ˇ ÿw˜ÆH≥fÕõ6Z÷ª{„nm≠ÆaxnbKà_ÌG*áSM˜V®¬<€yëºªÈymä]#!Ù·aÜ%Íë7¬™’ß—∂Ú™ÎiÂ˚D◊X>®âKáïH'â,:∑r=ŒíI©¬ùwÀV„YãÁìÍˆéÓFÔò:Ò·!F^I‚¶†·¸´ªô-lñ}vÊ;Õ2Œ}>¬{ORÑ3™ß9`2∫<™fÿW∂√—ˇ /#“µK;¯ıYÊ˝≠î4ír/≤®cÒ…PWà („∂Ú‹´jv⁄Nìq©›W–∂BÔƒUç<æ ÚØõÙœ1ŸMsjéØﬁÑ—J ej*YHe58_o˘ã•ÕÁÚ“⁄J$$	rhñ%,À¿¸\h¶çﬂÂCíé4_·òu»˛≥ÖÂ…µ/8Õ»∆ﬁ4’ç∞.$ä'gñ!ˆöf¯∆·+÷Écí9cY#`Ò8í)YXT2ë±t8€´H/,Êµ∏A,©Ic=’∂9≈—ØºìÁ €∫€∑_˜ı¨üƒè¯aù⁄⁄‚õxÓ pÃ°„q–´
ÉäfÕçó˚∑˘’ë? ?¸ñ~[ˇ òøVK≥fÕõ6lŸNËÇ¨h<NX äç∆lŸ≥fÕõ6F3ˇ Ú[˘ß˛Ÿ7øı˘ÛÏ◊Ç«À™üX6Q√]EñQÈ˛Ì·ôeê2|*‘7˝®„˙ZÁó‘}~çµ}N|ΩoÓÈœè√«Ï˚W ô+Z˘Å‰≤äˇ “’mﬂÎÀm#àeb∫$A:∆à‰YÄ¯Å⁄á%z˛LÔ4”∂ü§ÌÙ›‰√6lŸ≥cdí8◊îåzTöa6±Ê+kX¯g2®1∆ ◊v®™.›z‰FmVÓkÜûF‹Ï®6UA—TvÏ<∆ÒÖY€∏√Îo0€…@ﬂy€—π j^«Æ^lŸ≥fÕêÔ*ˇ ‰¡Û«¸e”Íd«6l(Ûn∏∫&ÅwP%E·ny_d~˘ -47’5÷‘nk%Ωì	Yü~sΩJW‹nÁËŒ¬‚ánò‹Ÿ≤&˙øÈçNX_VóG”m'öﬁÌÄ[õπ-]c∏ï›ëÃvÒ»·W©jP`k0•ñ±i˙Àk∫CÕ7Òœ¬I-æµ¡bû•Ø9cWç™√ïA⁄ô6qCïöπÅßM≥O]ÛW,-kNÿÊÚÚJŒ’,$û⁄Á’ıÔë–GmÈ®eıC«‘Ëº~ú ÂBwÎLF‚Í+[YÆ&<bÖIä—PTüª"÷ﬂòZ÷Ù˘>Ø$—¬Ànˆ
øæ3cUe`‡o‡+\,¥◊µ{©i÷VZ<
’ÙÌî CVe,®ïoá ⁄^^XÍm©€,WW«kâÓaF∏ëv¯>∞ºj:5>ä`≠{Ão÷uç5<™f∑ÖxùB›˝4d`‡±î5yE√nIQ]∫ÁG·$Ï›±å)VïÅ¨†ÉÖ∫EŒØ%÷ßo®Z-º6◊<tÀàË#û’„WSNLC∆≈ë˚TTaùH»'Ê∆å.4®5TΩ≥qæÒJÉ”Ô√ -`›˘zK5ìNìÇˇ ∆)*È¯Ú9Õõ/˜oÚ?´"î˘,¸∑ˇ 01~¨ófÕõ6lÿ
˚W≤≥à…3—:+
M”ä¯ù≤!}Ê[õõä≠R›OÓìøÕΩ”MÛ"pTv‚√≠z;ÉVµîàW€++(e5°ÀÕõ6lŸ¸Œß¸´è4◊ßËõﬂ˙á|ÄyæH¨'≤]B˝$Üˆ…g”÷·	˙úÇ(‘º,'á„¨uN+±;ıÎúì˝˙ﬂ‹◊øOÊÈ◊ ?öV÷ÚﬂÈÎ5≤‹zÒº
.!ê€L	sÎ¡√aU,‰˚3eÁÔ1Z∑”4xó“RàÿP™Ã‰ <X‰Á6lŸ≥`F+/n/ƒí¶ù4€µm ]‹˙ÊY©F!U˘ j Zˇ J)€àÕ-√˛—D⁄çΩ*F€Pú1ìÀZ0Ö≠˝W`J∏bd¶ﬂ$◊c∂–t)mê…+/◊ÿCÒîì∏€lë∆ÅPxäUçI˘úvlŸ≥fÕêÔ*ˇ ‰¡Û«¸e”Íd«6lÂ?ù©{´)Zâõôø÷j¢}¿7ﬂíè!iCLÚ≈¢IÆWÎSWØ)@ ±N#$%âÎô@$xeîﬁãæáU“¶ºk(oÌ•ΩO∑lìF“≠<P1n˛ºÚ“ÿj≤ ˙m∆´¶›Ks4mc)éÊ›Øhn°ï±z÷Ú:âÜ™›∂¶Ë≤…ÜèßÈ2Ëû\”Ó#πùÆŸÕ”¬ﬁ™F®≠)„Í—ûIªqzâãXü¨›Ú¬ívÈò”∂VyãCìZ”£≤éÂÌ
‹€‹„$HæÑÇOÄ©jçªxÌêÎoÀ-hÿ¨⁄ƒ7»R;’1ÜKt∫[¿ûì≥}S'⁄€ã”†¶H<•‰[O.ﬁÍë‹5ƒ∑¨3 B—¿°B'>"B~Í≈zPíIrD—=7]HE5Ò…?0|ùic™i±Ë3E°[$πDSÈœ)ûÍ‰ZëCJr®ØÖjQ&â®ﬁÈ≥i∂w˜ROFñ≠Gtñ@9Z>Gè6raFîQÇuÕ3Rñ∆[KõÀ´[à–£‹*	3(·ÍKM∫±≠	≠0~ÉÚ˘∑MΩnk30µÅ¶©$q$á‚!}8˝2ıÔ ü>∏X”~¯‹-ûÀTˇ ŸﬁEtñ-gÇÓ≈ÿ¸Róç·ö5vPZßÏú2¿ZÂäﬂhZç°å∂ÚZ”‚„UﬂÊ3ö˛Nﬁ¥^dö‹∞wlv=ﬁ2q˙Ïπ≥ce˛Ì˛GıdOÚèˇ %üñˇ Ê/’íÏŸ≥fÕÅZA0¨‹®]◊ÔéÎ˙5’Â‰sG**ï™πaFﬂÏ–æ¡Ây‰Ufπ@Ø^ö≥÷ï‹Wáq”ˇ ÑÌD.À,°ËJó RÉ∫ÒÇq=Hº0%›ƒEñN>Ö±®≠wÁ!Ï£%Ò´* «ìw P}ÏŸ≥fÕëüÃˇ ¸ñ˛iˇ ∂MÔ˝CæGº›»ÿh0£\⁄b∂ÜX“·Ÿï>(£6óí9Q¸•@Ôí®k˛ï}iΩO©}[è÷Rûß©O_ó’ˇ ΩÙ˛*”çv„ﬂ
º˘†C{mwqÆ«§≈o‚≤»—Ò£Ú•%çy ¬ÖÅªTc¸ª<3~ey¢HdYcm?H+" A7{Ç6…ñlŸ≥fƒ¢â∆∆0MY I&§”ƒÂΩ∑-πïR)µ+ZıÆ9#Çﬁ6‚h*Ó›7ÍÃNs5yæi5¶ª“Êdé⁄!m™vwë™ﬂ	¶’È–W'ûV∂’ —`˝)p◊7“VIùÄr‹.›Ä√lŸ≥fÕõ6Cº´ˇ ìœÒóMˇ ®!ìŸ≥Öy‡Õ®˘˙ÓﬁÄ≥O¥j*¥UÎ„ÒÌ¢˝ïW‰6ÜVaëo>j∆l4ÊY⁄∆Í;ÀùA-∂ñxl°}U f-Ω7(¨6¬õFÚŒ™$–Ì¸≠h˙ïº´õ>@™¨R6∑ºÙ‚ï\:©PEjiﬁb’`ÚÑ“ò⁄ˇ V¥æóFµ3mıôí‰€C,¨)Ùi
¯1qd∂≤I´y´P∂ø,‡ÕX√U*Ì†ñ>
ì’ã{ìÜ˛X’oÆ÷ÓœP+-Âã†˙ÏQ¥Q]A2ñÜdF'ã|,éΩ)¶‘√ÃÿOÁ0K†˘~„RÇ‹›º<WÜ¸WõÍIM¯/zoÖ˙'û-n|úæe‘‚6qrd1≠\H¡∏)ä¥$9ÈáöF≥ßÎ:|ZéûÊKYπqfRÑb¨;‘ëﬂ6k7mo•i-ëœ{ïÌ„rhñV%åªefeX…ëj;)Ír3ˇ +-˝(‰mb‚9e†[w¥≥	∂˙Õ+Z®Çár¿é¯¢yÎÃ∆∆ÚÚ‚[´x,,˛πq[X9oS“çß"≤˙åiÊﬂ3O£ÍöâöxüHX‰Ω∂ö⁄⁄61:„-ƒ∞§®eR€t…~âp⁄æöÎ™[¡,ˆ∑†GXú†íà‰Á¿îqU©‚j+Ü∂√jûå$P©™≈ÑA]˛ –dK ˛@}Ã:Ü¨˙è÷£ΩY[˙|6í_S˜ç…ÉÒË6¡⁄ˆèyg£ﬁ…ÂK[kMZn?ºDTrú™·X¸!©“ª`è&è2/D<«C©s}Í•Ω>_>*u¶a-Õ∂ïÊ˚ÅyMSA∂ô§±J›j<Q^C˚?Ô1„L: ñüVû¶ÉÉo˛ƒÁ¸´V>s≥‚•ÇE1cNÄ∆EO”∂w<Ÿ±≤ˇ vˇ #˙≤'˘Gˇ íœÀÛÍ…vlŸ≥f¿‚Ÿ—ÿ´U]ãﬂ≥^¥˙rﬁ`®'©5€ËÔèÜå±©gsVc¸<@¸ŸÁkÎ0p±t{;Xπâæ Û3Ø(~kíü+]_ﬁÈ1_j,SÚ&4 ÅèÒzaælŸ≥fÕëüÃÔ¸ñ˛iˇ ∂MÔ˝Cæy≥BÛ6´£hﬂ¢bäxaÜp∏Ä3Pô%FdE Èê«lùó¸üÓ¯˛◊⁄˛üé@?4Ó¶éÓ¬‘^Ÿ¬óÉ–[këπei&2G/ÓV©ZRªÔÉ¸Øeke˘èÊã{Xñ√J„cäÇ^öô…∂lŸ≥fÕÖ˙÷Æöm∑ æ≠√Ü0≈ZWà©'¸ëúÀ_Û^≥©J∂BK‘ùPâh€¥«¢Ú€ÚwË˚o2ÿG:)âÑ—€≥–“w ´{ê‚s†j>d∑∑∫ìOµâÆµAƒGl£j∏®ga^(?i©∂XGzñ¿^ ≥\íY⁄5‡Ç¶°Tö(€}FlŸ≥fÕêÔ*ˇ ‰¡Û«¸e”Íd«6l·:íò2•ıà jàÏƒÏ§V?#ù©˙„r◊®¬˝oDáVÇ8ﬁG∂∫∑êOc}	[yñ†:TARUîÏ H8\ˆüòÉo6≠a≥|"Ú÷“AyJuUñY F ¯∞ˆ»›¶±c™Îóøóö$RŸ€hV—›⁄k≈˝Ek˚kòŸ–˜o	$π-R≈óäÍ⁄Œy$ºÚñ≠q™¿ÏÖ ]YJ“≤≥4/,Å=._ÜQ«}≤O†È∑–=Ê°©2˛í‘ﬁ9'Ü6fä‚N@Öæ◊RÕA…â4òmõíØƒ‰*ÆÏƒ– 7$ú!ΩÛ]Ö∆î”Ë≤€_Õ5‘V’πD≤œ'¶º~.#s∑\áÎfáY'@π∏ÇÓ—ÁªÜÙ•∫ƒ∞.õ¡ûZãê‘¯¡ZoLwÁùGÀûX∞∑—m`é⁄H£ªµπH›¬[ÃXîû2Úõ’FG¯œ∂˘=∞—ÙÌGÀ∞¥ˆ#Mí¯çFx≠œß,wí“FòH°XKÀˆ˙ˆ;b‡®)æØ´RÅﬁ Ï:±€∫Úﬁõk_≠˘ãSÉê°ıo¬Ú∑ƒªÌÖ-/íœ ﬁn‘jvjﬂußè√æJ|æ4,R”I∫éxÍ”9ıΩiùÂbÔ$åIfwcS\4*jqπjh}ªÂ≥=hAÖ>g÷f—¥iØmÏf‘Æ˘$6ñ6‡óñiõÑjHÇr?”·Zúa•Ÿ⁄œw{∫C}©4sj.å_ú±ƒ±à”·UZ- Ò¶¯2á	<Û©~çÚ•Ù’ÂO´∆võ‡¸ìêÔ…}8æ£®j$|Dê!ﬂs!Ê}∂3≠fÕçó˚∑˘’ë? ?¸ñ~[ˇ òøVK≥fÕõ6l©j6˙}£‹‹¡v
ª≥1Ëæsˇ 1~ajrEı}>ÖÓß©/∏¯ôÿ}ï^Ù˜¬ø)izuŒøgi®Vdq, ÑÄØ2( 2ˇ (V$(˙sÆ*™®UUEÄ/6lŸ≥f»œÊ}Â[˘¶üıiΩˇ ®w»ßûÁΩ]+Eé!q⁄G17AŸßPãWí0	+’ÉuÈ◊%ﬂ·;C“Á}O©˝[ü÷ÊÁÈzæØ•Àó⁄˝ûké’»«ÊíLu(x¿≤!µ$)Gsp»‰}Yô&á”FW µkÜ>QøÉP¸¡Û%‰ñ)¥›!ï\QÄ&Ôbrsõ6lŸ≥dGÛ
ﬁ´€ﬁ®ˇ G∑∑R°∏ë ü≥˝ÙŒqßﬂ©’5(‘y†âR£‚X√Lµ˘Slf©#ÖÜ8kıíÍÒqØ A¢ëMÎÀ¶v-3À÷6◊Rí!˙Ves8y. ÖvZÙmõ6lŸ≥f»wïÚ`˘„˛2Èøı2cõ6q_Õ]*[4˝z5„˙,—∏z±ÄØ„æ Ÿ”¥=^-_Hµ‘# âêzÉ˘d:üp’¡Ÿk◊!>lÛ&™∫¨⁄~ütl‚µX˝icçZWíEqed®À—MIÍ)ÖÎÁ/1k)Èµã]πEñmn(¡ÜŒ≈â;©4©HSπ<©ƒ•h∫VÖ˘èa•Èp≠µçØñ¶H£Û,ƒ˝¶f%ôé‰ö‰‹”c÷£ÆlÿÖÌ§7∂Ws‘¡s√/A„"ï4#°°»«óˇ ,¥ù*∆Ó›/n&ûÊXf[∆‡è€–P
’û£z‰SÀSZj>eª–-gíÿ˙wÀ7‘tÂ"8YVXΩTHöµÔíõ;œ,˘k\M"ÓˆKçZˇ —â9@±≈UoF$X!çYâ'ƒùÚS©Íö]¥∑ó≤,V–äÚ;÷Ω ©=Ürü1˛fÎîèô ¬Õè)ºÔ]∑aˆk‡ø~ ±Úõıcıó∂h—˛&∏ºoLëJ◊„‰ˇ ÜO-Èdr0Y™Úµ¿éÂ≠CqÂO≠ƒßÌr¶ª¸µÛuîkutÑsY,‰¿¡_∞«oÂ«Ë_ò~`—Ê˙ΩÒ{€xœÇ‚´2S˘]æ*˚6um]”u´1ya í:ÒuË»›x≤ˆ9Û'Ê˜ì<ΩÊÌ+ ∑∑!ı]Jeän$zvã >õ\1˚&F¢™ıﬁ¶É$´™]6º⁄jiW?TÜ?R}VOM-π∞"åı%oÊ*¥_≠FóLKñüR∫‘ÓÆÊ3Õqt¬Ç†*«H8£U qQøSRp√-‰Haid`±†,Ã∆ä ÍI=qœ<yûo3j–i˙j¥∂ë0é“1±öf¯y–˝ÀÌæuo'yr?/ËPXT4˚…u €îØˆè»}ëÏ0Î6llø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6lŸ≥dGœÕw¥ë-πÁ€~ls∂ÍsÎ'≤k˝BIW’ôbHmiˆSë©cÙ◊Ó¿˙ç‹÷ã‘R‚	∞∏®5@Onﬁ9‹¨ÊiÌ ô¿,jÏh(&ï≈sfÕõ6lå˛gˇ ‰∑ÛO˝≤oÍÚÁƒ—§∂—Ù´÷∂›∆ÚÀ\R.!Ã∑⁄òá⁄ÑSlË?ßt.ˇ H√√Íﬁø/^:z<∏zïÂ¸ˇ .ï€ üöè`5ÎHÓ„wI¨§éEH·ï›üÇ,nRBvÊ§nTS∏<Ú’≠µØÊ?ô≠ÌbH èN“p∆°G+ΩÇçÄ…¶lŸ≥fÕòÄATà8Cy‰O)›‹âtÙYñ§<LÒ}£S˝€/\fï‰/-È∑ü\äöÂ[úR\;KÈüÚ€n›ÚCõ6lŸ≥fÕêÔ*ˇ ‰¡Û«¸e”Íd«6l"Ûüñ"Ûåˆµ	u2Ÿ z,†í›rè,˘èRÚé´6ü®DÎj“{kOçl$è«·ˇ Çÿ,ıF÷;ªVki>Ãàj6ÿècÏquß!SA„úû{óªªπªqF∫ûYTQá¿\¨AÙ’j:W¶y⁄ ÎÛCWÛü´⁄y{OdΩπàoPEr8•ê|«B0£D∫’¸”´?öıÀÅpÜ)!”lZ%QWïF*G©È∆#ê4$Ô∞Œç‰1u≠46†&ûa/sb%,Lë˝ï‰ÉJtÓrx~» ÕõÇ∆¬9Âûh‚∏ûûºÍäÆÙ˛f≠Ù·v°‰Ì˚\∂◊/!/dÊ çƒ’®ÿî˝ìú≥Œ>cºÛ.∏-≠C=îrzVÎ˚lO}æ'Ì^Ÿ6Úˆâ‰ﬂ'•÷µU÷‰i<àEˆ4Í;sÔá>n∫±æ“¥’˙ …£_ﬂ¡Ï–êÒI¯‘ÄIB#˜ß| ˙Áö°ø∂≥:CΩö…,´'—HŸÄ∑Ù€~acß2´«s¸¶Ü>GQ
Î6pmßYÍ2E`ÉÏ"zQºëFj~ÁiŸ˚4€Ûítﬂ0⁄±eÍ(?qvıˇ ô?Ãg#–5=C >dhÓî∆˝Bø~“ü˚JpŒ˚˛qãÚˆÛPãXµæ’-oΩÆ}gÎ"‰À/!"ª˙Î%~-˙ÔùÄöÆÊ¶õü„åFÎæf—4hÀ^Œ»™¿ø≠ÚAø“vŒaÊ/9k~jπ]/NÖ““S≈-#¯•ñác!ºGŸŒNºÉ˘}ÑÉP‘À´»¥¯ñ?≤ßªÌÙ∫ÕsfÕçó˚∑˘’ë? ?¸ñ~[ˇ òøVK≥fÕõ6lFÚŒ“ˆ›ÌÆ‚Y‡ìgâ¿e?A»úˇ ï∫#›ò.Æ≠‹*™ À∆µ‚C´TW¶˛Xÿ¡›˝ÏöÄÑÜéED‰A`	®ˆ…¶lŸ≥fÕõ#?ôˇ ˘-¸”ˇ lõﬂ˙á|â˘⁄~Ë∞ô&”TÛπçmú"∞∏&›ô‚¨Vùre˛—=/Kúú>•ıoÔdØ£Ízº´ÀØ>˝{doÛ+—]f…ûIæ≤ˆÏ4”ú~≠p≤ı¶_^≈U∏Úu„R;–èÚÃ“M˘èÊi%ÖÌ‰m;H-ÖK)≠ﬁƒ°eØ»‰◊6lŸ≥fÕõºùÊùsM∫ª∏â"x5Î%XÍAK;© F5ÓÀNÊÕõ6lŸ≥d; ø˘0|Òˇ tﬂ˙Ç1Õõ6Gº€‰ù+Ãp7Ó/£^0^ ´ZÒa∑%ˆ˚≥ñ]i~uÚM€œë-âÆb¯Ì‰ΩE;ˆ@|ÓÕYÔ¥˘,ZÀÜßtÜ('à÷Ã(d`ﬂÑ^Mﬂ
nn ∞±í‡(X-"$-)≤
*Ä(@0ï=MÚGúúøJy˙ˆ¨O√!¥õrh)ø‘aˇ Çnµ¶È∂QŸYCn(Ç4˝·4cªíh:~ÆŸ—<ëß= ]H
\ÍL'`ÊÑ!Ü:{F+Op◊X‘WM“ÓØ›¢⁄2‚4i¢FΩwv!FO0˚Ù§"õ	!äX≠‹Ã≤5–à≤∆K30J7ˆ≈ˇ ƒ:zÿ‹›]¨∂Mg0∑π∂ëC %~&4Qê9ì‘^<I≠pVü®Z_⁄ãõVbÅö9#ëY$éD4x‰F ´)Ì¸0G#„Ñﬁuºíœ zîÒ∑^öö”yMΩËŸŒˇ ,,9ÍÜ®™Æ˙]£=≤êIıú0SƒuŸN[j:∆ãkm6è•~ì[€ØØ51…5Â‘ÍÃKH¨
™qfP Ï#≥π◊ ∑ãMhtœ0Ÿ›æ≠•Ã°cW∑xë&xJä4°ŸI@w#ì‰[™&ª™-ùvá÷å∏O˜ÿú«ÎÒ¶’ÁÀ¸¨!ºÉIíkÀ)Ñë˘kEö."’ç∫Iq2$ç%√Úà∫Y È^E™z'®\i:<Ô†;Ÿ_Z†Ω‘t¿X€‹[r´-]EYGèøàÆ˛rÈ©ßa®  ‹ƒ–…N§ƒASOì·˜ï<◊£[y;LóUΩéﬁDç¢Ï∞â )£ëŸ|0ß˘∑£¬JÈ∂≤›∑gì˜)Ì÷Æ~Ïç\y„œÏçöØ}ÑV1±aÛì‚#Øà¡⁄7Â6Ω®Mıùj©£ûNz◊Û5*øI9“Ù+Ë∫=: é¿	goäWßÛ1˝]0◊6lŸ±≤ˇ vˇ #˙≤'˘Gˇ íœÀÛÍ…vlŸ≥fÕõ6h∫Ìû∞óèjÆ¢∆Ó{Ω@≤€∑+BjµËp«6lŸ≥fÕëüÃˇ ¸ñ˛iˇ ∂MÔ˝CæDº˜.óéà˙ÑêƒÎ`ôŒòÀvpÖŸ‚öë∑Ç—é˘1ˇ Ëè≠ıìÈ˝KÎï˙µœ˜^Ø£ ûùº€è⁄ÔJdÅ¢âò≥"ñ#â$x¯|≤%°è˘	˛j˙Üì∑˚+ºóÊÕõ6lÿQ¨y√ ˙4ûû©™[ZÀµbyòÂ∏%XO-ˇ ïß˘yˇ WÎ_¯#˝2/˘y˘É‰≠?FæÜ˜W∑∑ñ]_Tû4êêLs_K$n0ˆ…TôﬂóÛ ±EØZ3±†J§öÙ‰ñ)bñ5ñ'Y"pHe`zG\vlŸ≥fÕêÔ*ˇ ‰¡Û«¸e”Íd«6lŸ≤ù‘£Ä ¬å§T{ú£Õ⁄fómÊπŒÕm=¢îYrX∏ Ò4T∞Ò»_úc∏’NÚΩ©X÷Ób∑b‰±ª“˛B,è˛«∂y˙[}GÛ#O—-íö_ï≠cÄF†YÊA3™"â7€„#æ^≥rmÏ$ë@vbëÄ‹äë#ÖnEHjq'pv√W¸Õ”ı(íﬂT“Ñr$êÀi;FÒ2Ç∆¿++Pë≥t4¡˘ä˘¥3
IıãV∑M}çÃÖÓ ”‡òH`f%ô›˝?ÖœJû°Fyå◊R[Y≈æ‘-577IÕWX££#Å…ƒt°ØË+É·Û=∫ﬁ[√{±áQ’ˇ JµÍ…≈ª€$\ëΩhù¿&DE ï©C≠Õ60[»∂∂œq©jzï”•ÇÒéb	-ì4•V>P™‰w@…6õwwyí‹ÿIßQ¯≈ÔHÀƒƒFŒ´Ò≈Ω+ﬂ
¸˚h◊>P‘£UÊ—∆%_úlëÚPr˘3}ZΩ˝õÌ%Ã*ÒIè!Û£◊&◊T‘¨ÀùZ}&Õú ˆRA‘ìR˛àrçbjT7 29¢«~L˙ÎÎ´ßÙ2GuyRﬁ‹Z®cåèÈ«o⁄dä8˙n«ë4ïiÆØ®∫6≤—O,∞¥÷:å
bYÑEVX‰àñÙÂ^Aæ è
Äº€•-∞º’ƒ∂£Ó#E÷¨5o˜édãeìù”ê/√ˆX6¬õÑê‹h˙˛πrXi– –∆∞√¢‚˝mø{‚hm’†V£på5|F¯;ÛC ⁄ﬁµå∫jâ≈πuí⁄™≠Ò”˜Ä±8–ä·%óÂ°sßÈƒµ¬H„_Q√ów"µ∑?|îiï˛R±*“[µÏã˚W-…k˛†‚üÜJmÌ≠≠¢[ƒêƒøf8‘*èê¶lŸ≥fÕçó˚∑˘’ë? ?¸ñ~[ˇ òøVK≥fÕõ6lŸ≤#˘o˛Û˘ã˛€˙ó¸û…vlŸ≥fÕõ#?ôˇ ˘-¸”ˇ lõﬂ˙á|o†h˙ûïßæ°l∑,ñë∆ÇBJ®eRJ≠h™(√‚éÒ˝)‘Â‰GDˇ …ùÊü˘Ä“‚Wy.Õõ6lÿOÊãÎ˚m>(tÔÜ˛˛‚+;y∏áM^bßcÈ∆¨¿§SË˙õ§[zQq,KO;|SL‰’§ñCÒ;±5$‰x~di”µıΩÖ§∑:ÖΩ¯”mmã*â]ñUê‘,_πîr=––™\¸…‘txÁπªÚ‰Èimßœ™LÔq
 ±€ß•øƒ¬èäÑoá>\ÛûïÊ-SW”ÏTIñ∂æ•»ex‰7qô8≠?ê
„"¥_Û§K√H÷T{E†éµC0í1_ÖeD~j6‰Ó’íÊÕõ6lŸÚØ˛L<∆]7˛†ÜLsfÕõ6yÉFÚÂı≈´Ínê‹Ü¿˛Ø¢Ú
ÚÙ∂#öí+«9∆©aÂ'~g[Î:úWñ⁄MÆõ$∞ÍS	Ó-‰Ω∏sP8Z+t*9qŸº+ÑZgñıÌ84Îb4èÃI&†ÃCÇ{«z2ñZG¬Dö=èYwëÏmµ]n¯«wkdè;IEö1)í ı†z3û˚u¶Ÿ2’|èÂ{ÿf-•¿'e~.ä#<‹…N5ﬂ«9ıú)™My`¸†‘e”!—ΩxIí·~™P]	Ì‘ìÊévu#çkπ4_XMÙE√]\C+ãÎ5µÅ)	íYÆFí÷Òb2GÒ®„¬¥Âˆq+˚;àt€}.fä;e∞≥óUûC’í)'Ù¯,|§rIj1@_¥‹´íMb√\˙ﬂò.4ÿ¶µ‘ı=V⁄+V∑êèZ⁄Œ-«p·F,\.1˛kŸ√Zjùzm1©ˇ ÉjbO}˘ß$M&§—∏*¿¿hAÿÉ`_-˘oŒ0Î∂R⁄i˜ÛC*∞ñXﬁ8¬ÉGÊÃ °SJgxñ5ñ'â˛À©V˘Cú‰iêZ¥6û`KÎyÌlŒôıÀ8^[k€8…Ùâ0§ÕÉïYOÎˆó<´¢µŒ´m©à.¢”¨‹÷≥j"∫π∫æ`eõ“PûújïUÄöÙ©Êgi<’g¿.ﬁŒ¬Êˇ J±qDöˆ6TØ#∑8—˛∂ÊN[è0jﬁi~i“˝m‘É~·!5- b™œƒ™—‘ä˘‰ì…ów∑ûS“.ØôöÓkHûWu‚ÃJ…îÙ,78sõ6lŸ≥fÕõ/˜oÚ?´"î˘,¸∑ˇ 01~¨ófÕõ6l-Û´6ô¶¥÷˝bÚY#∑≥ÄíÊô¬'"¢Çy1Ï†‡o%È“/≠≠3j˙ãèﬁ‹\‡	‹¨0◊ÑI^Äo‚Iﬂµ;OÀ].¯YﬁŸEÀF&~6ÛH©,¢IdçY#J£|N¿lq4˛UÍ*Y⁄[,ä≤‹K∂ñ›¯∆‰ïë“2AYTÚß≈]´áﬁSÚeÌúw˙|muºR†e-Ä2≤êC
ç¸r¨~∑¢Î0ÈRœ%ﬁó~ÆtÈgnr¡,cõ@“â—í¨ÖâaƒÇNŸ!Õõ6lŸ¸Œˇ …oÊü˚dﬁˇ ‘;·÷ãˇ {˘áã˛ 0flàhü˘3º”ˇ 0O¸JÔ%˘≥fÕõ	|Ÿcs¶«qßUØÙÈ„Ω∑Ä71Üº·'˛-çôGπ+I÷¥Õb–Àc??Ÿñ3MwI#?næ0Å+<© ∑kÂ”Æ-£TéÓ—ñ9åà≈ñwb≠ÍKÒ∏‰‡‘;ToÉ/¸Ö°_Èíi∑&·‡ö∆}6W31ë°∫eyòªTÛfJÚ¡⁄óÙΩ/S‘µxã-∆§∂‚Ò§zßHÃq–≥ù∫+ƒÛòÌ&∞ê…§hÕ,í]°)Óﬁ3
«~ÿâÀ≤ör†‹÷ílŸ≥fÕõ!ﬁUˇ …ÉÁè¯À¶ˇ ‘…élŸ≥aoôu)Ùœ/Í:Ö∫Üû÷ﬁIb	^j§Ø 7‚_lÉ€[˘vﬁ˙[MKKÉU‘^Q
jWÌ◊77j>6tëI∑ä§z|*8Ù^ïß_AÂ]OQ“ÁGãÀÒÈ≥jëYªâ˛¨ñ“•H~”zR´D?d‘¥[ΩGZíTæÛ+h◊PF.n4K†súƒsµƒSôú'€‡ )–ì&yö;õ˚≠Æ-ÔZŸZ[{˚8˝$ê#Ñö)¢O2Û‹0 ¿ó„VWïcUïË@ f•OSLi†h∂óWWV÷QEqyµÃä¢Æ	©ÿìRSπﬂ YyÀVëO[#û/´Å4è/• ‹C	rLhßu
E—õBÚ}ñì:œÎÀw$1àm}^!b@(J¢_Q«€ê¸M„áŸ≥fÕõ Í˙-Ü´q›+Ö˝Kkàò«42Péq»¥*hi‡F∆£
…m9d’ıõÌ^Õò7‘n¬hjAo-"¯´qíP  @6 fÕõ zæ∞uñ⁄•Œì¶Ky&ù¶€X|772¿‹%öIëdtEu ¶¬¨w†myq†›Ÿ'ÈG’4[…bµqy"Ω’¥◊[ø©EgI[·*ˇ $iQìŸ≥f∆À˝€¸èÍ»üÂ˛K?-ˇ Ã_´%Ÿ≥fÕõ|Â£Nµ‘#âß˝wÏëG^f(…YJ®˚Ecv`ΩÈ„áV◊6˜VÒ‹€H≥[Ã°‚ïeeaPAG©˘3M‘uŸ5õÜ-uı1gm·§øJ=}o≤ÍFŸ≥¸ô≥*…™ﬂ}r ó	mir[¡∏é$Â˙“2”—‰Só∂¿d˜I∞vïeßâ=QgV‚R8ñÙê'*oJ”	5oCSÛvëc∆˙3>•xÍE#/€¬ç±¯§ıY©‡µ….lŸ≥f»œÊw˛K4ˇ €&˜˛°ﬂ¥_¯„ÿÃ<_ÒÉ3dCDˇ …ùÊü˘Ä“‚Wy/Õõ6lŸ∞∫˜Àöıœ÷ÆÙ˚yÆ©ƒŒÒ©êØÅzr#lK¸#Âü˙∂[ˇ ¿â˛[˘{Eº—o‰ª≥é‚HıçVﬁ@\à‚øô#@Zø
(
£∞…Sy; ¨
æïlÍ~“¥j ~`‘6ä(¢çbâ8êDPTÄ–c≥fÕõ6láyWˇ &û?„.õˇ PC&9≥fÕâ]⁄[^ZÕiuÕmpç∏™∫8‚ √¿ÉLã≈¢˘◊LèÍ:]Õçˆüq≥ìQò¿†Të‚™ÃEQ[∆ßr y7Î≤jwçs©kÊ“{»–F∞≈≈ÇGo[Ç£9m…%∑'•#7–ÿ≠≈πÛNï¨I™[L≥,öz\›ŸI4j®.!sÛ
EH˜…6ái®ﬁÎ“Î˜vœß[skca'+zé≤Mq:°`¨Ê4UZ‘æÊÇKõ6lŸ≥`}GQ≤”lfæΩîCkÚíFÌΩ  TíI†rvC˛+◊˙√À«N·œ÷2[	ÈO˘e2zïˇ 'Øµv√Õ3S≤‘ÏbΩ≤ì’∑î-B§%YYXVV2ëPv8+6lŸ≥f»V´†…i<ﬂX—ˇ Oh‚y5EÑ†ª∂ûBdïH—¨äÚUñå≠†/NÚ‰∑˙™^æòtç8OÙ–œ ñÊÍÊ˝«5*C%πR¿ty¶lŸ≥ce˛Ì˛GıdOÚèˇ %üñˇ Ê/’íÏŸ≥fÕõ.|óß≥L˙}›Êê”∑9EÑ∆8ÀV•ÑN$âK~—U¿ﬂ‡{öˇ  Q≠¸Ωx?ÍÜ˘KC’µàµf∫Û>∞≠e™^X√ÈÕ˛ÍﬁN)Z¬j‘ÍrCí•ç˘KÊ-f·(AçÓ#PkÔQ∞˙iöNù•€}^¬Ü2≈ﬁïfw=^GbYÿ˜f$‡ºŸ≥fÕëüÃÔ¸ñ˛iˇ ∂MÔ˝CæhøÒ«∞ˇ òxø‚f»Üâˇ ì;Õ?Û§ˇ ƒÆÚ_õ6lŸ≥f ~|”°z!∫Wµiúˇ ÚP˘´¸;™1i©¶\~ô‘^ïôãân^GàÉ‘viE{ÁAÕõ6lŸ≥f»wïÚ`˘„˛2Èøı2cõ6y´ÃSÈÇK%ãÎ˜K,øXπ%m≠≠‡ Õsp¿èÅ9®PXöT
êV'ÛD1Z‹ÿyÜ”[ñu&+9 H°πÎ O1àS≈õê…&Å≠Zkz=Æ´h`∫NAÅ—îït`*9#©SÓ0'öuk˚[h4‘W‘u	÷⁄›Â¢àqi%û@
í±≈5+Ò˘ÜH‰µI„Ûf£•& ˜1∆ÉêbC=ã≈#o≤)BAj‰ü ˙’Œ´ß;^B ‘-&{[Ë”ó¶eéáúE®Lr#+≠{ﬂ
|≈ÆI•€¿ñ÷ÊÔQæóÍˆ’‚≠'Â§z¢!gjtÈR@¬TπÛÅ≥]Vﬂ\“Ø"î(éÿ¬—Z;C,w"i~Jûüg$µ±¶•ÏQº-…‚ûﬁJsäh\«,mMâWR*6=FÿaëıÛïµƒ≤Æïay™¡˙r›⁄§b@ê·$ï‚p"ç¬ªÌÉÙMN÷`íKBÈ,È›ZNç»G.∆€©°®Ï{Wr;Á`±Ÿi˜ÛFe≤”o‡ªΩU-Uâ/©≈k»DÓ≤‡µÌëxÙœ>¡±o≠Ÿ‹h…$ìNfπê√qo+Œ•^Ç'°vÿÔÒdó…ö-[Rä£N‘ÔﬁÎN¨&(„24†ñHﬁA‚ó|í‡_\“4{u∏‘Ó„¥Ö€Ç4Üúöï†N√¡<7«<≤√*áéD!ïïÖAucÛfÕëm7ÛHøÛd˛ZéíÚôD¨”f∑ 8ŸãªTdß6l	™j⁄nïjnµÑ∂Éê@Ó~”∑ŸEvcŸTT·eóû<ªwuØ´5¨◊T˙®º∂∏¥ñ≠x„VcO≥Z˚aˆ6_Óﬂ‰VDˇ (ˇ ÚY˘o˛`b˝Y.Õõ6lŸ≥f=3ü˛Nk∂⁄ŒùÊ+õhn!åk˙è˚”à‘ÀR =◊£x≥†fÕõ6lŸ≤3˘üˇ íﬂÕ?ˆ…Ωˇ ®w√≠˛8ˆÛ¸@`ÃŸ—?Úgyß˛`4ü¯ïﬁKÛfÕõ6 ì_—b◊!–dºçuãàÓ"xF¡Y¿p=üõº∑w$—√®A ûäDPÔk+˙düå*∏©\ö÷éÌ
•˝ª5 ˙ñÍ≤°2%r@ƒ(§‘`k_3Ëóz∏“≠nV{ñ¥˙˙¥_FT√»JµCÒ©Æ&˛qÚ ›An5◊I‰YíEhUm∏}IA(îıóÌ5}$ —ÿ®û´∆%NB>!πëZÖ‚¿◊¿„tçgO’≠‰π∞ì÷Ç9•∑2óÖ 7˚KQ±õ¶´¶>¢˙b]D⁄åQâ•≥WS*∆OÏÄÚ
OsÇ≥f»oï¸Ñ<{K¶ˇ ‘‰À6lã˘ÀO‘L÷˙ï§R‹√3Zﬂ[[7>îÕ¨÷˛ß¬“C$J‹⁄ÍhwIªÚˆùwys¢ZÍ:˜ò'hÈo=¨êò¶ÙBUÂñ#∑WU˝·˚álõy_HüI–≠lnfıÓóú∑Sç4“4≤Òˇ 'õû>ÿŒÇ‹¡k"ÍV÷ùú¶ÊÕ.•X£òh§äJêxHí‰>…°ÌL%¥î@>±oÂ}V}]ïb]Kë-õô&í.+ZZµ;dóÀ⁄d⁄Fùq.•r≤^›Õ%Ó£8%aY$•V>f¢8—B≠{
ÂXyœ ZÖ⁄⁄XÎ6w7OQ1œ3Ò4< ?ÜyÔBk‰≤‘⁄Kﬂ®˝bõ8[å≤Z^¬`∏Ù∑_ﬁ*êÀæÙ nFÆ£‰∆∏µΩi.u‰çÌa”Ö§¢gu!æ;sQóÖIEÔæI|ù§]i˙dÛ^D-Ôı;©µÀunkìëH√èURFƒ‘‡œ2A}?óuH,Èm'K^¡ΩVçÇQødÚÔêËÌ<Õ®Xi∑^TªÜﬂNÜ⁄ÌÌÀ≤"pPdähïH.≤F´B#cZòh_œÁI⁄‡#‹⁄ÿº¨ˆ«˜£\Û≥ÖÅÎ*A…õ√ó∏…ñl#ˇ y?Î&ÁÙ=Ø™Xπí,[ü.có-ÎJ·ÊD1ÙÔ7^È÷ÀÂ◊~QÀ ÍfÚ8•P¨çAEaR+øæ’Ùù+^Úﬁüßk∫Ï)™ZÑ3ﬁ[À
ì0^¸Y~/à`ù{TìBÚjˇ Ö¯^.ú!Ä≤÷Ï≈ ≤£r8Ú¶£©Í^_≥Ω‘Ìç•Ù»L∞êS£≠≈æ%Ê†7∏≠0€¸¡˙`Ëó£F
uOIæ©ÃÄæßmŒﬂ*‰S ⁄ˆ∑°ËÀú•ímRÊi$≥¥âÕÿ∑©uÄ0¢µwÏ(+Ç°ÛîÌu	ıt+ÿu	«˙E“is¨¨>€à¡ﬂèsÖ˛pÛ˛∑µÑﬁSµ˙öWÇÈ^	Y„∏Rº-Âåhôπÿd˛2Õó\Å…||vsÔ8O¨ØúA≥àI=∂üÈ$¢ Ëe∫)®M, $í8tw˜8¨ìjzÕû≥ôÌõ†ÿ∆Uç¿J\√Ë¨≤\Prhû)pe}Ω»…/ìÁ‘Ó<´§O™é:åñêµ–©'ô@I$”s‘˚·¨ø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ1 
ûô≥ceñ8£yeqQÇŒÏ@UP*I'†ÖÜ©¶Í14∫}‹7ë)‚“A"J†“¥%	¡8ÖÂ˝ïîi%‹Èoí$1¥å4í∞H–˚Lƒ <qä˙eåë[)äŸÔ%ê√‚ÜY[î≤6‰«‚f˚Ò˜˙Öéüh˜w”«mk=IÂ`àºò*’é€±ƒ.Ø¨≠Zπù!k©D·ÿ)íVÇ%z±
M=±|Ÿ≥f»œÊw˛K4ˇ €&˜˛°ﬂ¥_¯„ÿÃ<_ÒÉ3dCDˇ …ùÊü˘Ä“‚Wy/Õõ6lŸÛ/Â4zˆø>∑.πykw+,pãp™±Z˝ZKwÖkSWı‰nuÿûõW
G‰=ì⁄ºwí	ÃP√%µúVÈ›P$H√5(,˛0«Õ™w«ˇ  ã∞˝‹…®¨—zf;àmRë∫=”±âeyJ,ü\¯ìë_áﬂyOÚv?/ùJC™=‰öçîˆLã∑Dê≈ì‚îÆ‚Ω˜$‰s üí:“ij6˙E¡óç¥6≈<fî,fA¡9IıÀâØ≈ZÜ¡±Œ;È©j±ùbCr©√ÎB›î[o´¨dñ,b(ZÑ|>˘–ºüÂ≥ÂÌÙ{Nó”œpœ+m7¥•câKUÂ@+áx…¢I°xûº$Rç≈äµP—îÇ∏ŒS†Œ8˘CFÛ^°¨«y}sgg-’¬Àº√s˙‘2G,äEG9|ÚT?)¸í?›ø˜‘Ï£7¸™è%æoÓ'®ˇ ŸFo˘UJˇ |ﬁˇ ‹OQˇ ≤å/¸ª—t˝Œ^v∞∞YŸ&”ŸVYeù™÷jOÔ&i˝''˘≥fÕÖæf‘ß”<ª©Í03⁄ZÕ4^©§|—)r?f£lÁÉQÚÆè{=Ü≠ß⁄Í∑ç$6ÛÍ≥2]›Oqqπy£xˇ w	$‡ƒS`£$>SK˝/Ã2ÈoÖçƒ\E¶«0ï#í	cFö‹„Ç[˚∂ß^õúKÛ·€SµµñﬂÎ∂vˆ7zê”X3Guqn§k"®oQb¥ú(I mÖÁWΩÛZ]h∞Ë∞Ãñ)i)û‚9ÌmÁKÉRˆí≤,ê…9Æƒ¸∫‰ª…W∑WæW∞ûÍ≠M≈„7D eH—¨¶õU’CûÊÕÑzóí|≥®›5’≈£%√ûR…m4÷∆FÒì–x˘üvÆ⁄ŸÈzMêÜ⁄8¨¨„ﬁä4èRv‹ûÁÆ/’µ¬∑ï&@hZ6+·Q\¨jˆ∫Mãﬁ\áecäóú≤À#é8◊ª;«l%˝#˘ÑO÷?DÈÀoˆæ§◊í}gç>…q	Ñ=}¯ˇ ïﬂ Û
ﬁh:•ç¨í‹[§¡¥Á&T4ˆÄnk«jÉ‘TdSIÛöº—Â/0á∞h.èNû%í‹ ÔÂ§ßòd;ÈΩ:Éë}Zvé˙;ù:-9l‚›Œõ-∞ä·-bå´≈ û8¿yùÍ~/Ñ®›∫dã»vìùv9“(òƒó_[Ωµå≈	ävI!∑j§!ﬁ9Ö!Mnjw=Ú◊ÊûªÊ›Wå⁄¨éìóV±H"nJ7C»Ì◊%yÛßÊüïØlmg≥íÁÎïbË ºT0S@ﬂi™›6˘‚^s–uª….≠ÌÙvie<QàZH¯N'*\2D˛ß·44nô∫ÚÊ≠s|ºluOJIc≥y4˘x€√" ∞ö‹)ÕG⁄ÌAÓTáÃ2˛]i∞~ï¥ñÊ„RÙ¬ƒ^%ôa≤Ç;~rÂïË49’#pÒ´äÄ¿]≈qÿ_≠hZ~±nê›áWÖ˝[kò]¢û #úR!¶Ñèq±€!Ú\O(mWTæ÷ éA,6óèÅJê…… é/*=NY#∆…˝€|èÍŒ[˘mÂfÔ»ZÃl’lañ &KHVƒ«√ˆP…lÔOõíˇ Åº¡ˇ Sæ≥ˇ ßŸ&o7ò?Íw÷‡4Ô˚$¿⁄üÂ˜òÓ¥€ªdÛÆ¨Ô<2F©"ÿ%–®V”ó˜¶¯óÂÂ◊ò<ë†ãcÃó„ïQºüÔ5∞_ÿÄø)©˛≥S¡FOr?ÁÕ˚]ÚΩŒùbc˙”<G‰¨2˝^tò√)Pƒ$¢>±ÿÙ9Õ/|Ö˘ù}•s41*^‹\=ûìÚ⁄…lÚ√[‹Ω›úz¢’—¯#)<ORF]˛]˘Ω-o¶ÇSs}-ŸøYog4FÚmÑ@∑òB≤qÿ(&çPpûÎÚœÛitssW≤Ÿæü$Í34v& ÚI§_D™ãÅ$mÂ≥|=®0”»>FÛˆüØ[ﬁkJ±ÿ[›,Îmıø¨Ñv∞ñﬁ·‚™Ç´$¨Ñ)5¶Áz·ªÂ;Îq÷tË≠ÊùwM6©4˜	k2œwm5úåä!V∑Ü7E1r≠7•p√N¸π¸√π÷.óWoCF∫ªµöˆﬁﬂPò$¬9Ówà/"WéH«˚”|^◊ÚÔŒø‚Ω˚PÑ^&ùug9‘§‘%vÜ-$ÇH≥.Õ+Ûı:ö¯ÁaÕõ6lå˛g‰∑ÛO˝≤oÍÎEˇ é=á¸√≈ˇ 36DtO¸ôﬁiˇ ò'˛%wíÏŸ≥fÕõ6l	y™ÈˆuÃ¿Èèâ»&õ(©À”5K=J€Î6åZ.Láê*j¶ácÇ≥fÕõ6lŸÚØ˛L<∆]7˛†ÜLsfÕõ<œêLã$2©IcaUeaFRPFE¢–|„§Eñâ®Y‹ÈëêG©≈+M#aÀß™lº◊óã3–¸º÷7Wïı…ø÷.’cöÏ†ç$$§FpçKπ$ìV'lÑ˛ey∫D}V(t+ªëÂh‚æìZ¥ª∑∑ñ’ÂâõîK)%ˇ wP T´VÑdòysÃ˜»–Í~bi4ŸB÷KTµù„#‚I'Á/⁄ÓbT>dñ⁄ﬁkx≠≠„X†Ö8¢QETQEP< ¶lŸ≥üÍ◊v˜öÜØ®jê√uç{Öçù„q¥ä∞≈3‹∏‡¸§c'%M(“§·bÎ⁄3±‘¥ª¢kz{	.B°Ü⁄xÒ√ËMƒ ê ìÉ$®nõV≥_8€‹õ+;˚{Sz˙M‰W≠hâŒY£Ij?x´!eÒ"ùÚ.ïßã®u˚o:¡s…$vÚ+9d,Ò\®ï&yy;-8äQGçg~N¥ªXı=JÊµ˝1xo!¥îqñ8Ñ1¬û®—‹CÃé’°‹a¶∑®æõ£ﬁÍ	\=§/2¿µ´îRxÏ	¸3ûÀy™~eË2E`±ÿ6üvØ#<ñó
—pë8ûI»
ÏrGÆk≤y/ 6ø˚ê∫âa≥ı§c<Å7yπïÅÒﬂ<£>ô®ÈqÎˆ∫rX\Í»≥]—dvZªÄ•«Ú±Í7√Ãw¶È◊íA%›¥WZø´lÚ¢πéNúêêxüqê◊—<˙2WR[æ>^i}SÈò}:z?W5¯˝Oãü„€KÂ]7 ûiøÛ∆ß©ü™»eÙ≠Rﬁπ î%K)«·VM#]^≤≥æÙ·ø¥%nl•táŸt‰>~fÕõ66_Óﬂ‰VDˇ (ˇ ÚY˘o˛`b˝Y.Õõ6lŸ≥fÕõ6lŸ≥fÕëüÃÔ¸ñ˛iˇ ∂MÔ˝CæhøÒ«∞ˇ òxø‚f»éâˇ ì;Õ?Û§ˇ ƒÆÚ]õ6lŸ≥f»ª˘Öf˙Ñ÷6W…6≤zw3ÿ∞˚\[ß–”z·t÷ó	X'YñÖπ+roüèΩpì5ilu”d‰–Õ'®‹5>≠{Ø\Ë≥fÕõ6láyWˇ &û?„.õˇ PC&9≥fÕõ∏NﬁY+«Ç3r•iAZ”8Õ≠ıÂ’¨s5‹ÚÆO?©$r4é°ÑÉâ¯˝ï'áT’u#~k‹ÍwÓı,„âÓV5oN—Ü Ä∏c•˘É[’ñ[€˚óyΩY`ÅTò“8 DE o›éÁ:OÂ‰˜íhÚ≈4ÜX-Ê1Zªø7T‚§∆’¯®Ñ¸<â4…FGıﬂ=yDøé ˙I9û&ybC"[´˝ñòÆÍÂÓvÕ•˘ÛÀZ¶£ı;íÚdäfFH•tØ$çÿdS∂«∑|êa©Â€∂øóU—Æ÷ÀPû5éÍ9¢ıÌnuÙÃ±Üçπ%hm±Æ‘FﬂÀzÕÂ‰>bøÜÊ+Y∞ÿY¬–@“°¨rL]ÂíBùUjÈP2Ië_Û ∫VÆmÆ≠ÊfF·&£XR@7Ft%˘∑ŸÎ∑é]«ÊüîR‰[€K5Û‘Z÷uç
ÚıèW∑√S]©\ï¡4s¬ìDyG"áFÒ*:Â™«Q@D&î w8ImÊ?-krù0è].ëöπÅ÷®“úÃ-*àÊU®Ø·Í®PE ÿ–Ÿ≥agòºπ¶yÉN:~¢Æ–sYT∆Â]>À>}Fë•Yi:eæõbÜ;KTƒ§ñ4,jI¬ﬂ8j:Ö≠Ö≠∂ù'°}™]≈aŸ¬V¨ÚÒÖä¢7Ó‘»M¢yÍ )ÜôuuÆ]ƒ“X≥‹3ÍS£22›$µâ•PŒ™Ãî‚¬Äñ˘S‘Ó¨.-uúOe$k]Ö^å§Ò%»Jß≠ìÉêw"ΩÚMõ/˜oÚ?´"î˘,¸∑ˇ 01~¨ófÕõ#à„y$ ,@Íh+∂rK’?3//µçZ˛Í€À9äÀLÖÃbAB≈N≈v$ıØ∂JWGÛïßı¥´ô¸√£m>ôw 7qì∫ò'o∂wWﬂ¿·ú_ò^Wë}a„ªåU¥˘bí+Ø¥Whú+‘‘çá|éÍqÛÃ™Òa
ûFUw†ÏÓC}<~ÉÅ”Õ>cI÷hÔIE }^H÷HÕ7$Ï≤TÙ˚Y.“ºÁ¶\Ÿ¥∫É.ù4Hdôfn)≈I¯ñCE"õë‘w¿∑ûqπ‘cÙ<£m˙NÍBÎıŸC«e©vîèﬁo—c≠|póQ¸µÛE¿íÒ|·®Oá4åR;c278ˇ vΩ©øΩz`ø Ø9jZıÖÌÜ≥O”ZL∆ñ«ö‘ÖfnUVû2sõ6lå˛g‰∑ÛO˝≤oÍÎEˇ é=á¸√≈ˇ 36DtO¸ôﬁiˇ ò'˛%wíÏŸ≥fÕõ ?õûjóJ“#“Ì•Ê§<äJ¥p-9êF‡±<G”úLàØÂ”µ∫π¥ôg∂s©—á‚ÓprgÂ≠nÁ[◊≠-a@öß"AH%¡'‹ö}Ÿ‹≥fÕõ6lŸÚØ˛L<∆]7˛†ÜLsfÕëçSÛ# ñIl∑-}wC€Ÿ°òÜºKè›©ˇ YÜGÁ¸È”„ë◊Ùk¢
yÓ åÙ˝•Ïª¸Ò1˘œßœèÙhò∏+"•‹hv;±O’ëΩ2‚ãkàbA$j—@¶¢4˝îø€ÙÖñ?ÀﬂÕ∏‰dÅè¸7Í#º∫ÂÙ{vmçeZèô‘~:Â≈Ωºz%ƒ–πssy4íÇ „"qÑ®ßo›W˘€S∞”ºØ®Õ{s¨o√…0∑Â,äV4Y	Z37MÛÖﬂ˘áB{;ê5[Vï„`Iî1bWâ®§ë∂%£Î⁄Zu¨M©Z°àU2ÄTF‰'⁄5≠)ævˇ À≠V√QÚïì⁄^ExaSÔﬂX*‡◊ã∑P‹H<OLíÊ»«Ê!∫_/¨ê»4πÑ‹‘Ldï ˆxPÚŒ?Ê+˚$”ﬁŸ%âúÕI∞‰ú_‘bBÙ°]ÎÅ|ø®[≈=«´qp≤Ÿ‚SøƒMz√:wÂ∏∏m^Â‘≥Y•™äâ?t‰™“:–í†—º6…ﬁ†mÖÖ…∫ORÿDÊxÈ^IƒÚZ{åÊ\Ûµù‘?ó<·ò√|.¢∑-ƒ∫À&›» P∆^†w#√ÚÔû≠˙6®eΩfΩ˙È◊ã	ÊA√ó’Ä@%%Ä„Ètﬁ^Û•Ω∂°•_›≈´-Œ†˜£YYÖƒë¿Ø';S$mTTOHl:·ÁôºÎÂªΩOC”‰øhÙ€…ßˇ ºíÃèJ—zåLRÖg?6cÑVõ÷ã•Ë∫iπùØo'πéÍÌ#ı§ÜﬁﬁVÙÈ»që‰NÀzn«|;ª¸„”"ÈiwD‘ÛYﬁﬁà¨ç\/π¸ÔÖJã{+J≤œ{0>H?™˛gi:Ìí⁄Mc<R∆Èqkye5ºÚCs	Â∆é…œãlA+Pz‡Ø.˘¶Ó˙Si¶i˙(÷Y›Â≤gF¥üVx§É’RFÂù˘CM¨¢I⁄Ó˛ÚSs®ﬁ∏
fùî)!F»™™™ä:(z·¶llø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6llà$çêíµEE6ŒÂ=x˛[yØQÚ˛µ…tiÿ…ﬂï†˝‹¶ÄñV_Ö©–Áh≤’tÀÂew»*˜NØ∑Ÿmâÿ·üt€CEóÎqﬁzFíF 0<à⁄õû;¯gûºÃ5_-ÎÀi§Í7ñ⁄|Î’¨k<§ môj«‚‚T¯ÌJ‰ÀNÚóÊñ≥lóíÍèb≠OG’ï£bß~E`|éLºç‰€8u	öˆÿ\ΩèÓ‰ñ‚ì;‹1úóÁ¸µÿäW:+40BŒiQÇÃz ‰‰?Õˇ ö\—4óö“ÓF˛Uˇ DµÇEzì˚nÀÀä/sÑüëzÌ¶ì}≠]ß´»Ø£Dúà~#e´9ß∂tÏŸ≥dgÛ;ˇ %øöÌì{ˇ PÔáZ/¸qÏ?Ê/¯Ä¡ô≤!¢‰ŒÛO¸¿i?Ò+ºóÊÕõ6lŸ¡?5µ!{Á;®“@ÒŸ$v $õäáìÔë˚FËKÈ;∆O™†ê:r†ÈáóüòæPÚß´®_Ÿﬁ›kW1UçbHò‘à˘≤6Ù¯òıË6œDhz¥:∆çe™¡ê√}w≈2ëVEØb+ÉsfÕõ6láyWˇ &û?„.õˇ PC&9≥g ÛœúuwS}Gg}< l“8+ﬁ‹tuÁ˚0%"˚ˆ√ÕÚ∑KÇ›Z"˛jºâXÏ„ˇ %c2u°g≠|KlÙm…xŸX[€ö>úH¶É†$
öb≥i⁄}»XÓm!ö:É∆H—≈~D‰vQ∫Z≈«È:U:q‚CëJv¶iÛ˙˛A¸›î
ÇÅ’∂tˇ çp√Àu,µ?„<òe§yT‘aæ‘4≠Ny.•¬Ê›ï…¡Ââ∑¢∞"âÑﬁq–u≠TÚõ˘íÌ.¥ë®:¥FyÓbP±j§´»íÅ∑¥¿≤…Â	t‚àèÚ∞ódîÕeë†ƒ8∆¨{=é\∑~[3¥ﬁú?Vnm1BDâ79M[ú|Z.ä™IÄÿPÂyOÕö¶ëÊØ1-€,ñS€ÈfE6óU`ê;2€ïH‰cˆ‘
xmìè˘Zûjé d——ò}ßhØ _π£z}¯˛tj‡”Í@˜¥‰ˇ …ú®˛mﬂ_ÿœe>üb—O#Z~‚Çü∫É∏˜¿ã=Âﬁób4]nŒ¡ﬁ¬&Y•U·,+p.˘BZ6´ô#π˝ú´µ{;(Æu?0¡®,^≤K•«{rzLe1ª^˝Ïà$Z“5®	ÚŒ±Ê˝6 Ó=KgµöfëÍS¥™Ñ“!…ö4eX¿•ìW¸›º¥ªÉÍ∑ÍC"k8 $≤8¥íRπŒÙ}œ3€˘.Œ÷ò‰ÖÆ^¿sHDKVwWUg@Än}˙d÷RÚ[}>];ÕÈ£Z•µºk§ÀX¯˙qDíÜå¿Õ»∑™j∫úk®‹ŸC«LÛ.ô`õ[«5Ã±à¯ø L…),%í•Ö+N«#ÚˆôÁN∑øí˙Œ‚ÊÍgΩ∂H◊Í»L›
ÊÑöoC]â¿ï-d‘|ê˜íÕmuy™Ax%ı:≈#zqë˚;DOΩs≤€˘G ñË"Õ¿z∂Á∏‰≠º
 Xc l(™6˚∞&°°ËZÄ+}ß€\í8üV$c∆µ•HÆB|◊˘_’ÎARL_iN≈ïÈΩm‰cŒ)?ó‚°>pWÂüû.o§]Tôßô„2È∑íy*'˜ëKˇ «„‹{Éù66_Óﬂ‰VDˇ (ˇ ÚY˘o˛`b˝Y.Õõ6lä˛`y7O◊Ù¡r–3Ízq˙ÕìEA$ç«Ë›%„ƒÉÇ¥ÀMBTÇg≥:t“*óîe„´GT®mˆ¡Z¢=‘w*∆ ™,µÎÿvŒ)Áø/µ˛ïÍÑ?§tûe~‘ì4Ï>⁄˝9—¸´Ê˝#SÚı≠–∏DuÑ,—±°W@ñõ˝%ÚÈYm¶º^%.•/BcPyoøŸ8ÌN£(1´KØë@ıÿêr'Â˛üÊo7œ}´X=Ωéò©¢PF/&4î»Yh%S√‹¸©ù!B¢Ä@† l /6lŸ¸Œˇ …oÊü˚dﬁˇ ‘;·÷ãˇ {˘áã˛ 0flàhü˘3º”ˇ 0O¸JÔ%˘≥fÕõ6yÀœ§åı™ÀI˚¯.≤íª7H
üû¯ˆ	MºÜ`‡+ÉÛ…áê|ÖÂ›r‚…5kÀõò¶é∞√Ç(«ßWÙçk'*8É€=õ6lŸ≥f»wïÚ`˘„˛2Èøı2cõ#_ò∫‘∫OîÓ‰Å ^]q¥¥`hDìûá˙†ñ˙2˘K°D◊Z¡ZEk˛„¥·Mî(wÏ‹SË9“X’è∂V2~F	xû-¡∏ùˆ<MŸ»t†~£f^_W˜Qs∏$—®Ä3í€ÓA&øN%˘]ÂüÒ'ÂèöZ]V5õÃÔsitÒ¡¡l⁄püÑπ2lCÓWcÖ?ó˙ïŒ•ÂxÆ.$éIy‚Gâ}51,Ñ¬≈9?Òê‘'æuOÀÔIt˚‰ç˝ÏfíBAVë¢å0®·ƒ\êjz>ï´€˝KT¥Ü˙—ò1Ç·â…NÕFÓ;‡>gÚøóm⁄˚”“≠cwªx◊—OÖ»€%z
%6È\O@ÚÁó=(&∏“‡ê«=YDBGxƒúäÒjÇ≈jΩ3–^â§hñ≠i§YCß€3ô+dX‘± `¥©€©¡|ﬂ˘èﬂõõ¯úJÚË€Ÿ\\ñ—ç‰´ö/¬§Ó{∫Á
Û%√õ;hg¯Ænò4Œ¿37¶9ΩZüÔ¬Mó§é=H√E˝¸D™ï„àÉ ¥€·cﬂ;_íÆÆ&ÚÙªÛh^XîÚ,x+üOë=¯∑l4ΩKπ-&éŒe∑∫u"áOP#⁄·UÂO
‡#Âç5¥Î+ ”D4Ù⁄\√+EpÉè§©CÒÅÒv?v6o+È-cad¢h#”?ﬁ`öHÊé®Qøz&‰¨yr≠pΩΩ≠áô¨≠˝“÷¡”KéßåìM-njÏjÚD4&ßì˚-Êõà÷ÁGT~:∑◊¢6Ò≤Ó∑Qø¶ .\ëNùÈãX˘cJ±º˙’∏óí¥ØO,èMp≈¶h£bU9ñ5ßâ¶ÊÕèè√ÓŒ5Áã9<πÊ˘/,‘™áMf–∞uz\ƒ€6Á˝ñvªKòn≠a∫ÅÉ√:,ë∞‹q»Ωé+çó˚∑˘’ë? ?¸ñ~[ˇ òøVK≥fÕõ6lB[InRÂ”˜Òä+ÇFﬁ{W!>p”-Ïık{àH_≠πgÑˆÅàË›˝Ú1Â≠ 3a•B}8fôÀ◊˜íπm…≤°WËŒ√1¡
CÒé5ã‡PcÛfÕõ6lå˛g‰∑ÛO˝≤oÍÎEˇ é=á¸√≈ˇ 36D4O¸ôﬁiˇ ò'˛%wí¸Ÿ≥fÕõ<˘˘ßß˛åÛ’ÂWÑä%‰Mπà…πˇ )>[‰cj{bWàÉ’∂&üíØ$∫µºcãzW8Ó#öë˛…ÛΩÊÕõ6lŸ≤Â_¸ò>xˇ å∫o˝AòÊŒs˘≈#ë†¡QÈõô¶`F‰«	C˛Ã·óÂí∆æE“ﬁ1ƒÃ≤Ã˛%ûg$ü|ìfÃ=∫‰VÚÀ_“í5’ÕÇ^	
‹ZΩ“¨FW`«’∑Ê"23⁄Z‰KŒ≥\h⁄ﬁπÂ´#Èøü†∂J≠ Kóu±‘@˛[fIèmâÒ91÷¥ü!Ÿ•Öæ¢±[?Ç¡ci#∏í;p8†REQ◊®Ò√MRÚı¬Ωñè<5≥†ñŒ0cx˘nD¡\ØR7√:ü§w¬Ú7ñf‘dΩ∏∂3	»÷≤9kP±c'•”ïO»v¢Ú/ï†ΩéÍﬁ”–2∫⁄ƒ≈`2!\«¸√àˆÒ|I=sf ë#ñ!ìÏJ•ùh¬á!Ú™4ôÁV‘/ß∏∂∑[FîÖ‘<åí-LÑÖ¶¡qó?ï:/÷RÛK∏û∆·W"‚"$P•x9V†¶‘ø%ö6ïó¶•§r<™åÃdê¸LŒ≈òÌ∞;”cˆ‚7ﬂ(q#sÅÔÙ˝:˙‹€^A‘Ü1L°◊í˝ñ Ù#±‡}?C—ÙÁy,l‚ÇY Y%QYGE.’j{Vò:ß6lŸk∂„c„úÁÛy_Ë/«˜í}n"˝¯îFß £%ˇ ñ◊O‰]Ê ∫€,uÇë˛íLlø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6lŸ≥fŒY˘”≠›h˜M›™¨íUë„a…xö∞/B•w_Äè|Öy/ÕöŒßÊ]2¡cE˝·wÙñí≤´s†.ƒ-Væg¢3fÕõ6lŸ¸Œˇ …oÊü˚dﬁˇ ‘;·÷ãˇ {˘áã˛ 0flàhü˘3º”ˇ 0O¸JÔ%˘≥fÕõ6F¸ı‰ç?ÕöX∑ôΩÎzΩÖ‡1πÇ?iˆó¯Á	’ø.ºˇ §4Çm&[®PÌq`}u`Møºˇ Ö€—ø+º˜¨Õ˛è}6⁄A…Ô/æ´ Üëo'*TÄ@Œ£ÂO"~ÅÛîQ⁄¨´¶Èˆ!cπ`Ø,õIÃ¯‘Ú€:&lŸ≥fÕõ!ﬁUˇ …ÉÁè¯À¶ˇ ‘…élÁﬂúVï”t≠Báçù‡IiD∏Fé¥ÔÒÒ¡?ï◊+7ì·∑ 	,&û’’k’dgRAÒW%D
ÿGÁãòÙªx-‰x?H_ZXœq+$p‹ÃFFPx±_Ñ7bkë€O2∫i0Èoó!ıÓÑ∞[iûì¨14QÓóDé7£+!ˇ óπ¡æU–l?J\€]€C+˘vtóH£ôEÑó÷°Æ Åõãp^Gá%V†¿n•¨¡Æﬂﬂ≈l˜3=Ó°o{2¿” âdÀı;øu¬Õ/>ÖΩ€unß◊ØI◊ıkHtª—}kënÖæ¥ﬁ≥¨S≈#≤ÉÈK™¸®X–ÉIùÆ£ey%¬[J${YWÓt‰¶åuS–ç∆Õõ6l±ÚÆ9ïYIdu†©»fäæyv‘>øÃ˘~í}]§hÃLø—ƒh  µı9~8€ÙÛÈÛÌ≥Z£.Ø#så€òx˛ı]vêÕœÏ”€∂Ÿ4 1:Ê∑ûq◊ÓumBkõÀU∂r∂ñˆv∂Ú´(πñ⁄í…2 ﬁ´wêPq„∑⁄Í§:˜ò.!∏ûÀ\Ω∫Ùù~®∆ ŒHfÖÅq Dâ÷":≠]™:åúË˙ë‘¥kA£5Â¥WöÖ2†bµÔJ‡º‹NlŸ≤”≠sÕÌEJÿ[–aiqw'ZèXà„Èø¶s°˘7M˝ÂM&ƒßÜ÷!"‘ö9Pœπˇ (ú9∆À˝€¸èÍ»üÂ˛K?-ˇ Ã_´%Ÿ≥fÕõ6lÊû˙lóZÜÒë¥î3 
æ&;“ÑÌêü…=)Æ¸‹n ÉúDΩG?ﬁq©€ç<s–Y≥fÕõ6lå˛gˇ ‰∑ÛO˝≤oÍÎEˇ é=á¸√≈ˇ 36D4O¸ôﬁiˇ ò'˛%wí¸Ÿ≥fÕõ6l§Î:~≠o-≈Ñû¨Pœ5¨ç≈ñì[H—J¥`>À°¡π≥fÕõ6lŸÚØ˛L<∆]7˛†ÜLsaoôtHuÕ
˜JîÒ[∏ä,ùx8¯ë«˙ÆŒS˘uÆK§˘Ük@óR™‹!ÿE®€’@ßÑ´ÉÏæ9÷ªfƒ/llÔÌ&≥ºâfµùxKVÑuÌ∏ Ó‹∆_≈¨Ë˙dØuÊ¡o¶ƒUVÍÓ“9nUM î:¨í7Ï÷"ƒûá+G’¸≥¢⁄E[ÎX.ÂÊ⁄Ü£mq≠q=	íy‰@ú–||GEÈÜ∑˛\ä}HjvwsÈzÅ
ó3Z˙|n> œäË¸kµ9ï¶2€ÀêG©¶ß}wq©ﬂ¬Z…rTGnx∑£Jë´2Ï\Ç‘⁄¥≈µ-;ŸÍZœSÅJ€^∆*¡NÊ9°eàû®ﬂE¯C◊ØØ5≠CC‘4Àã;Õ:8d˙ËF6Wk-G;iOÚëÒ#|KÔ◊
0?e©„L¢§MÈõÅ⁄Ω=Ìıçå^≠Ìƒv–‘RWTZû’b7≈mÁäH“hùeäE‰éÑ2êw0ÿÉë>˘wÃZ≈•™h◊ÀlÒ3â!wí,Ù·78Åj«CÙ5»˜õÌ/ñÊk{Ô™^jâ¢i7:°Ÿ˙i+…E~RIWâk‚^ã∏!≤K>h◊⁄^ò∂is?◊ö)†-nÓ™,/33Dô+ƒ¸;TÏf˙_ûZ“ÁE–uh&:§€≈{p≈*∑'$ï©Â˚G±Ìè’|•´›ÍW7∫mÚi±›?© ∂öÓë®ú´/E•@¬≠O»^p}*Í+}Yn§0HêY‹‹ﬁõy°	ä^ÖR£¶]=√Âh≠ÌOôõ”Kñ”œßg
ƒ•»_\7¿¸tßÌm„õOªÛ‹∑sÀ5ó£mqwjˆ—IÈß©È‹∆h≈π˙j$‹u&ò]¢/Ê4I7O=’&ıµ°0@DrqàBÅ∏v•bïd˜6ld◊[€Àu;à‡ÅZI§=rb~@g“°∏ÛüùVYêà/%∑∞ﬁ;b7Åroı≥πf∆À˝€¸èÍ»üÂ˛K?-ˇ Ã_´%Ÿ≥fÕõ6l≠Ëöf∑ßIßjPâÌ%ß©$WâØQ∏˙0ñ¸πÂM.{ŸÙ!ÑÃ‚µÅÉ*…¬RÄû,?haÊlŸ≥fÕõ#?ôﬂ˘-¸”ˇ lõﬂ˙á|:—„èaˇ 0ÒƒÕëˇ &wöÊIˇ â]‰ø6lŸ≥fÕõ!ﬂïÇö•ÔÆk˜Qõ&9≥fÕõ6lŸÚØ˛L<∆]7˛†ÜHıΩb€H”§Ωù^^%cÜﬁ! YeëÇGjH´;„∂%ﬂû^⁄K£&ë)Ÿ∑≠ åPóJ·Cî"ß±√O/k±ÎO)Å≠/-‰0_X»C<3(©e¯YJ∞da≥) öﬁQ‚eÛ™™¶≥:Ñ†éÈ)˚Q˛◊µÏ·∑ê¸›˙f◊Ù}ÙÄÎVh¨x´E∏è±Æ‹¿Ëﬁƒd¨Çläyµßˆê?’ØI∏˙¯˝êﬂª2ã_TƒΩ{WiÚyéÓÊhıxQt(„·(ΩH—ÊÇXjÌ Fí6*€0! ˚]ü‰πo(i¶rÌ…Ë4õπ∂∏∂'˛xpÎæ3ß*r©P§ä–w¶Z2	3 N‡TTèñqui/ıR}bq}÷YRa7aF{àJà˛ èNÇ?år;5^œÖú≤ÿião©C8◊ˆ˜5ê˙"(“w2Ó¬OÜîJÔ\ÏºÅbi¯¨Œ™dé£Ì“¨‰súﬂKqß˛gæ£u¨'Ë‘SÍ⁄°∏ñTç‚™¬ÒFí"¸º#moúo¸ôÊ[¨g’•¥Ù•G0∂üc≈îÚÁ8ÒfÓ)í›L∂”4{-:—Ã∂÷∞¨p»Hb»ÕU€~ª`‡[â#n’»ÜìÂﬂ4«Á+≠CPºIÙW3˙P]˘âL ¿√”OH*Î≈|˘ØÍ_∞∂ª”l¢rÚïû‡¿“à@Z≠V*?∆vÆiñV◊–YkZÜóæ∑,1»Lë£O›=Jr‰~Xl›r≤‘Å◊,∞Ì◊+ë ÕñFsÃø5«rÌÂ˚BdµÜD˝(—¸Fi∂1Y∆v%©Ã|áéLø/º®˙î”^ u}@âoòPÑ†¢B¶É·å√T˜…Nllø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6lŸ≥fÕëÀz}_ÃTˇ ´˛•ˇ '≤_õ6lŸ≥f»œÊw˛K4ˇ €&˜˛°ﬂ¥_¯„ÿÃ<_ÒÉ3dCDˇ …ùÊü˘Ä“‚Wy/Õõ6lŸ≥`McSãJ“Æı)¢ñhl°y‰äÁ+,jYÇ-G#A”9ﬂ‰'ùt_3h:π“ƒÌ:≠ı√À,F4+}u-ÃJ¨v,"u,;W:~lŸ≥fÕõ6Cº´ˇ ìœÒóMˇ ®!Üﬁm≤æû¬ﬁÊ¬!sw¶‹≈{°‚¬*áçY∂Vdf‚OÌS VˆæHdGæÛ ÅΩ9tüKÍ7 êº"x‡·p“lÅˆ<∏ä 6…üí¥˘bé˚Q{#¶≈®À≥”ôB<6÷Ò,âlÆ ú∏˛»!zÉíFUe*¿"Ñ¡8Áú¸ü{Â}I5ç¥Z9ñﬁxÖMå≠ˆë◊ˆ≠§Ë:®riÂ:⁄k–yÇ€jÒ/+ãJÏ¿mÍ¿«Ì∆~ıËrEC\©Èzv©hlıu∏∑‰Æâ]U—îÜGS—îÇ0µº°ßLê≈}w®Z¿j∂óWNæı≤é&`)“BÿzM~]ÜB¸—‰=GXÛÈk=B±¿ì˙L˜1º^∏˝€Ü G π¯÷õïzëu'T”ß˙Â≠Âµäƒˆ‘æÒ¨´1»§FãIá*.¸}ˆ0‘|Ö£j7èsw=ƒ≤Ω~&ÙäÔE^p±‚+@+Ö∫üÂVì>ü<~•y¶] ºb‘-Ωö#Py#$Q∞;SÌOÃó˙∂°£\«¨JWNé(ßö·y‹KË $ıC∆cPÔ—æ2µ7X¥◊!êiÌwaß&§n‚ç¶ù÷Jîí3D„èƒY _ÊTtø1¯Ø°ãPº∏y˛∞ˆ˜ñÄBè#´Õıvi@âü”´øÿB›I¡æ\÷|Â•Î˙ñ%”L∫múQ€Àxë»*¿’1‡√ü√Joù˘oZSÆÿ–	4qÎ”à%Oé5î÷•™réÁ6lŸ≥~º¿€9ˇ ü|¸mΩ}#Hõ”ñ?áP‘ìBªzP“ºß5ß˘?Îbˇ ó@{Vá[’‡0œ'L”õsΩk,ﬁ3=O_≥ÛÆt|Ÿ±≤ˇ vˇ #˙≤'˘Gˇ íœÀÛÍ…vlŸ≥fÕõππ∂µ∑íÊÊUÇﬁ/4“®à¢•ôé¿ﬂ!ï:ﬁç®GÊ8Ï/ÌÓ‹kwÛïÇTêà•ò˙nBìΩ>ﬂ'y≥fÕõ6lå˛g‰∑ÛO˝≤oÍÎEˇ é=á¸√≈ˇ 36D4O¸ôﬁiˇ ò'˛%wí¸Ÿ≥`kXãKµILmqq<ãù§eDìLˇ eë l1;ˆ¬©,º˚w∆Q™ÿÈuï¨v≠wƒ◊jÃÚ√»”Ø¿1£GÛı?Â%µ>ˇ £Ï„7Ë>ˇ ‘…kˇ pﬂ˚9Ã⁄/üJü2Zêv5”€˛í0õ ñ˙ÔîÙ£•hZÂ≠≠ãM-À'Ë‡X…;ór[ÎΩxè v√ü–˛}ˇ ©í◊˛·øˆsõÙ?üøÍdµˇ ∏o˝úÂÆëÁ–Í«Ãvå†ÇPÈ¥WqQs]Vü≠_¶¢öNµp^ ≠%•ÃZﬁ·SÌÖÂÒ$ä%ªn	°°ﬁlŸ≥d; ø˘0|Òˇ tﬂ˙Ç1Õ≈kZ
¯˜Õõ)ï]J8¨e"†É‘ú£ÕﬂóW∫L√UÚËï≠bó÷[X?ﬁãF5%Ìøû:˝®È”•FÿcÂÃ´{’ÇÀZx„∫íãm~üΩ¡©|"ìm—∂ØOùÇßÆ«√Ñ˙üù<ü•\Mm©Î∂s€*ΩÃr»ƒÆ9!ì≤Üä·¥R√4QÕ¨∞ °‚ïeeaUeaPAÏMn-⁄w∑YQßçU‰à0.™ı‚Ãµ®CBqLè˘ÎF÷µçÍöE¬€‹˙ä“#±Eí1P»]AeÍ—LÂm2ˇ MÚ˝•ûßvo/bJKpK1,IjUæ#ƒ û†dZÚwòÓºˇ aÆA~±È∞zfE.˛™,kFâP≤ÔRN’=v…ùÕ≈º/ñeFùΩ8ïÿ)w°<PÒ54ÀR∞æ˙«‘ÁY˛´<ñ∑!kTû*ç´Oâj0C:F¶G`®Ä≥±ÿ I?!Ä¢ÛÅ6ç∑£o&è7KPY†nn#Z84›œûÿ8äu˙sfÕõ0Õ<–¡œ;‚åñG!UTnYòÏ ˜ŒcÊœÃ[çMˇ Fy’KkÜÙæ≥?Yπb‘)jõ2©Ô!Ì“É|=Ú?Â¨ZyáR÷¢F‘"bˆñHyCm^ç·$ΩÀûùºrõ6llø›ø»˛¨â˛Qˇ ‰≥Úﬂ¸¿≈˙≤]õ6b@ì@7$·~m[∆'H”.ıKP/°Gn‰~ÌÁí/PîÄØæ*∫Ó≤F˛]º˛2Ÿü˘üó˙sXˇ ©zÛ˛FŸˇ ’|Ø”ö«˝K◊üÚ6œ˛´„&’ı9°xeÚ›‹ëH•$ç§≤* ¬ÖH3Ó»gÂgíÚ˜N‘m4Ô/^;j7í\º¶K>B*ëı˙C√Û©…øÈÕc˛•Îœ˘gˇ UÚøNkı/^»€?˙ØõÙÊ±ˇ RıÁ¸ç≥ˇ ™˘_ßu™”¸;yOVÀ˛´‚öômÆoFüum>õ®0fä⁄ÌU}UO¥bë‚íùHV®FÊÕëüÃÔ¸ñ˛iˇ ∂MÔ˝CæhøÒ«∞ˇ òxø‚f»n•Âè9EÊΩC\Ú˛ßao£mko4÷≤Œ m§2¥s√≥z˝À˙áÊÔ˝^t?˚á]Ÿ^_‘6ˇ ÍÒ°ˇ ‹>Î˛ Û}GÛo˛Ø˝√ÓøÏØ(ÿ~nûöŒÜ?Ì›tÏo±∂Û<>s“èôØ¨ØZﬁ;Ív“€û∞ÛÂÍM8f1r„–”ñy÷€XπÚÆßäÃ∫îêënc<\Ó9*5Sã≤T)®°Œ{¶9È⁄Ç]È˙UÂæçku0ä&êµåíŸôJ[LÕ*=ºWzêÃªoÆ˛gΩÅö‚»ØcÇﬁImí ç°ïaı§çãr˙‘e•˝÷„·é˝+˘¨Ep◊	:ml‡…2V[≥»z7xqà%®)ªqﬂY¸ Ω≥Ωví˛ﬁ÷´KbÎmWsD5Í≥∆Wi¨›Ö•NT7ﬂô6–IV◊0 av”Ì‡µäH¸m,ìÀ+ÜYπw*ábP©{˘ï=ç‰ãk|∞‹√%™ﬁGlÇ˘†≠‡Åç∏<QŸ˝tå2´VÉ±«Â•◊üR˝4Ωrï”-t€qì¬±™Lëƒ¶3),Ú∑€%π5{Ñ"ÜKÁì°àx˝oÙµ∑°Z÷ÉóØN;ˇ qÍ{dã6lŸ≤ÂC_Ã<˚K¶ˇ ‘‰À6lŸ≥d'Œññ:±ö˜LÙÏı9GÔë¡6◊Rì ËﬂÂÆ˛5»ÜëÊø1˘RÒtç^⁄i≠÷úlÊpgTV“sœ€‡'olÈ:6ø§kvﬂY”ß®⁄XËVX€Ø#?ûAbo9üÃO:CÂ˚}.{Wb›NY–Ü6tH£ê:ÒÍ	WßËÉJΩ>I’|Às•XyCÜ}6kIˇ G}fIûcuuP~%∑eDX…*µﬁµ¬ãˇ 1˘≥P–¥}GS’ÂÇaÂÿÔµ:ÀPM.˛û∫í∆Í∞›H≈"wPßcˆ≥X"≈ÁØ5Î±yñÊŒÍ*XÍ∫ùÎ:CŒxÁ¨Ôdk˚®MFö‚ˆ7^j6öŒóßkßÃVöMæ≠ml5’≠n^“uoV+∫	b˙–C¬ËÉUz≥´yªÙ^π±®i⁄/ö|¬ñölV≥44€[	√¶{à›ò“ª
tØµ≠B¬+Ô.∂©®]4~h:~òdæKY$àX≈|mÓµ)§H™ÔN?ºmêavÉÊGWì@“ı/2‹[Èﬂßµù9ÆÌu
ô°∂∂Y`ÅØ¬∆f£µ–1`]N’ı;ﬂ.õç{QΩ“ÙÔ:À¶iöØ÷ùC⁄ãWóëõ§íE9xZ‘®+í#¨Í7ûb:Eˆ≠sc§]˘´T∂∏ªÜf∑p∂∂qKmh.=4w-ÇRÄ‰ﬂDñ’ºü|ñ∫€yÇﬁ}zåå$p"Êæã ?Ωh~¡ì´S8‹]˘GÚªE¥Ü2|±Êª}XUae™ô≠§ôv7àå„z	˛l7◊|…Áãü3yñxÔSNóH÷!¥∞˙∆∞∂V–€°à∆&”ÃL'[±!<ãT‘°\5≤Ûnßç›≠ﬁØ"ÍcœÀß√Ã=o©µ‰d[™÷æëÖè√¸∏å˜ö‘:v≥¨?òu!πÛT⁄%Â√‹VﬂO”>ª¡û?,(#ü≥À∑gÍ◊öå∫ØóÙØ1j•Æ≠Â¯b‘—ö‚‘&dª∑éÈÉ=5ç∏1<y{‰√…1‹ŸyõÕz$öÖ›ıéü%åñf˙vπñ?¨€ëDèÒÒ,µ ù∞ﬂÃ^t—¥*A)7Ï	ä∆4ß¿∂Ùç j{W9·7~`^—SÍæË§ã7Î#
5Ã†–m˛Ætü*˘'JÚÚc≠÷•*ÒüPîQÜﬂ≤G∂ >ö‰á6lŸ±≤ˇ vˇ #˙≤'˘Gˇ íœÀÛÍ…vlŸÛƒÆtÎ+ J√™_[X›0%O°+VEˆ’x}9!é4ç8‘$h¢(† l  bÛ∂•¶˘ÆKfπÙ≠-$µç4»‡I¶∫é·ûoâ„ìè1È!ãóò Ï^?9Ó%0ÈVÛJ"7SàÔÉFê‚î®êEºÍ&£†˘∑À‘?8•{igih.ü’.¶ºÙ·UT∏5üî\£í∂áå|O*ı¶7K¸◊æ‘u-3JH‡YdöŸ.ncì‘fñ9÷HYƒYﬂ· ∞ÿÔçáÛWZ≤º‘-Ø¨‡πW’Ôl4´Ø\A%µÃPü≠˛ÌΩ$A8˝‡ÂS±£∂¸ﬂ‘nÙπ5}5ç'˙™$˜e•é…Ô¶;B‘N“6˝∫Éå¥¸·ùe›iQC$løYˇ K®eî@Q-yDÜi©t•£¢”«|7Á]Ã—…6äæ¥Ê7∂Ü;Æ|·í&î^ê§§!O√˛VJºôÁY|«w™[Àd∂/ß∫¨&r≤
\¢à√~Ô¢;S°°?Œ6Q›yrıãàg≥çÆÌ.ç+ˆ‡…ÄöRÖwÒéÃŸùº©ÊN™[çäëR+∑ÔzbøÚ≤˝JﬁaÙb?Í¶_¸¨Éˇ R∑òÈ’L$Û∑úÔ5'köMüïuÛw®X\€[Ü≤
æ§—2'#Íl*›s†ÈQ…ógäVDÇ5u=C åõ6lŸ≥a~π£C™⁄,M#€‹@‚{;∏øºÜd,ã]éƒÇßb	ÆéÎŒê˙}ùÛ(na∏kpˇ 8û9
}ÿÒ®˘ÆüÒ≈ÇøÛ?Íé_È4’ñ˙LıK7È4’ñ˙LıK/Ùèö?ÍÕ˝&˙•ï˙GÕıfá˛ì˝RÀ˝#Êè˙≥Cˇ IÉ˛©c[QÛe_≥ ˆÇæÙÑÂi∫%˚jCW÷Áé{Ë’£≤∑Ä2€€#˝æè'ëÈÒH‘€` ≠O3fÕõ ◊>\¸¿±Ûf∑´˘~ÎI6z¡∂fÜ˛;ñë⁄	°Ö’HjW·˘…˛˛ÚÔ¸äæˇ ™ô∏~røºªˇ "ØøÍ¶núüÔÔ.ˇ »´Ô˙©õáÁ'˚˚ÀøÚ*˚˛™f·˘…˛˛ÚÔ¸äæˇ ™ô∏~røºªˇ "ØøÍ¶büúΩ¶ÚÔ¸äæˇ ™òX–45ã6≥‘óÀW07@–ﬂrSJrFrV˜9ÉÚßÛF⁄‡]Zj⁄EΩ“‹\¢ﬁâQ{#7:HæŒJmtüÕÿ9H_À-w0Aut-ÔQÊ1Øg„'P6é©ÂüÃ}Y`]Rœ w‚Ÿ˝X’•‹‹˘ìõû'+UÚøÊ.¨÷Ô©ŸyJ˘Ì[ù≥]Z]ÃcoÊÁè—ãO†˛fœ}¸÷˛VñˆŸ(.^⁄Ò•HÂŸ—ø ≠‹w¿	‰ÔÕ-:Ú”Àˇ ·_/À{R˜VW·€¨úygãL[HÚØÊnó§iö\#Àr√§"-úí√xŒÆàS’Ø=§`ÕV'æÚ«Ê-˝≠Õ≠ıóîÆ≠Ø$]√5•‹â,ä "≥êÃ 	ﬂl*’?.|ˇ ®^i≥Iï£µ”⁄Â€N[Kü´\∏=ıcÂCE%Ú∑Ê$∫LZ;ŸyI¥®xz6ivm””<ìå\¯Ø∏†«]˘oÛ"ÓŒÊ Ê” s⁄^πñÚﬁ[[∑éY*Ú!z3|#sæÿ"ﬂI¸’∑µKKtÚƒ6ëßßºp^§JîßÅ¯ÅÌLMÙ?Ã˜≤é¡‡Ú≥ÿ¬#ZµΩ·âDD¯°~#ÅPWmªb7~W¸ƒº‘†’.¨º•q®€
[ﬁÀitÛ«˛§åÂáﬂåó >óT¥∫î$‘«ÙÊ≥∫3÷3…™[ïTÓ7¡cF¸“On!Ú∞∑πiÊ´ﬁpë¶5ë§^tbÁÌWÆ≤Ú∑ÊçÑZ}ùóîÌÏ†êO¨6óqƒí´s*+–8aP›sjÁÒ‹}NÔÀ∫u’ﬂs}oﬂÆÎ¢élÁ†ÿ√¶F‚¸¢¸¬"YÓ¥I‚-ŒhYoˇ |Áˆ¶ì‘Ê„⁄π2∂≤¸‹µÅ-Ìèñ†Ç1∆8£ÇıQGÄQ ·˘Õ˛˛ÚÁ¸äæˇ ™ô∏~r˜õÀøÚ*˚˛™eî¸‰Ì7óiˇ ØøÍ¶WŒO˜˜ó‰U˜˝TÕ√Ûì˝˝Âﬂ˘}ˇ U3p¸‰ˇ yw˛E_’LßãÛïïó÷ÚË®•}+Ô˙©á>H–.|ΩÂ#Dπô..4˚h‡ñh¡TvABTÈáy≥`kJMSNíÕ•häº7”úR∆¡„ëkµU‘∏Sô5ãΩgF∫íÊ1Csß«ıò&‹éh™∆D≠*Uóo◊óÕZdó\…Â˝RKà* ù¥Èß-õãUØzcÃö4jR?.jH¨ŒÃ´¶8§5r@^≠M¸qá_–KH«ÀÅiúI3~ãjª©™ª|;∞&†ú|~e“#ï¶èÀöíJ‰3»∫kÜ%@ ív†ÀóÃ˙L±ºr˘wSí9C	Q¥◊!Ñî/»ø*
¯„ø≈zm)˙T°‹è—“/Â¯~[c_Ã⁄K¥l˛]‘ô¢V&:kí≤«öÌ≥Sj„dÛç"ìÀzîà•YQ¥« 4`ÄGUÌ·äCÊ›>ê¡†j±ú…3&ù"Ûs±f†>Á.ÛÙßôáËÛe6õ¢_ØÕu≈&∏@j`ä5, è—Ÿ©µ@ƒ† ¿fÕõ6lˇŸ

endstream
endobj
119 0 obj
<</Length 13718>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 62.022 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(modulate)-588.5(expression)-587.8(of)-590.2(cannabinoid)-587.5(receptors)-590.4(and)]TJ
0 -1.1847 TD
[(thus)-476.4(inîuence)-482.1(the)-478.9(ECS)-476.4(activity.)-479.2(Studies)-481.6(have)-475.6(found)]TJ
0 -1.1795 TD
-.0001 Tc
[(variations)-438.1(in)-440.7(endocannabinoid)-441(activity)-438.7(in)-440.7(female)-435.5(ro-)]TJ
0 -1.1847 TD
0 Tc
[(dents)-303.9(across)-307.2(the)-303(estrous)-305(cycle,)-304(which)-300.9(suggests)-308(that)-300.7(go-)]TJ
0 -1.1795 TD
[(nadal)-479.2(h)-17.4(o)-22.5(r)-18.8(m)-20.9(o)-17.3(n)-22.9(e)-18.5(s)-499.9(p)-18(o)-17.3(s)-24(s)-18.8(i)-19.4(b)-17.3(l)-24.2(e)-494.5(h)-22.5(a)-18.2(v)-23.1(e)-494.5(a)-23.4(n)-498.8(a)-18.2(c)-18.5(t)-23.9(i)-19.4(v)-17.9(a)-18.2(t)-23.9(i)-19.4(n)-17.7(g)-499(e)-18.5(f)-19.4(f)-24.6(e)-18.5(c)-18.5(t)]TJ
0 -1.1847 TD
[(o)-17.3(n)-395.3(EC)-8(S.)]TJ
8.2191 0 0 7.3052 98.9291 637.9652 Tm
[(20)-7.7(3,2)-10.4(04)]TJ
10.959 0 0 10.959 128.6362 633.0896 Tm
[(For)-380.1(exa)-8.5(mple,)-381(a)-380.4(study)-386.4(has)-380.3(showed)-385.6(that)]TJ
-6.0785 -1.1795 TD
[(CB1)-309.9(recep)-9.7(tor)-308.4(mRNA)-308.8(le)-6.5(vels)-312.3(were)-310.1(lowes)-7.1(t)-303.3(and)-312.6(AEA)-309.2(lev-)]TJ
T*
[(el)-6.5(s)-412(wer)-7(e)-411.7(hig)-8.1(hest)-414.9(in)-419.9(the)-416.8(pitui)-10.7(tary)-420.3(gland)-416.8(dur)-8.3(ing)-417.1(estr)-7.7(us)]TJ
0 -1.1847 TD
[(in)-306.1(femal)-8.1(e)-303.1(rats)-7.4(.)]TJ
8.2191 0 0 7.3052 124.8378 599.1306 Tm
[(20)-7.7(3)]TJ
10.959 0 0 10.959 72.9637 581.329 Tm
-.0001 Tc
[(Estradiol)-543.5(administration)-545.5(was)-539.7(considerably)-540.5(associ-)]TJ
-.9984 -1.1847 TD
0 Tc
[(ated)-404.6(with)-407.9(decreased)-404.1(CB1)-408.2(mRNA)-402(expression)-406.7(in)-404.3(OVX)]TJ
0 -1.1795 TD
[(females)-324.9(than)-320.4(in)-326.8(nontreated)-322.1(OVX)-324.5(females.)-324.1(Second,)-325(the)]TJ
0 -1.1847 TD
[(m)10.2(o)0(s)20.8(t)-303.3(su)20.1(bs)20.8(ta)19.9(nt)20.5(ia)19.3(l)-303.5(a)0(l)19.7(t)0(e)19.6(r)0(a)19.8(t)0(i)18.8(o)13.7(ns)-295.2(of)-295.4(en)20.6(do)16.4(c)12.5(a)0(n)21(n)0(a)21(b)0(i)20.2(n)0(o)16.7(i)11.7(ds)-295.5(oc)21(cu)20.3(r)]TJ
0 -1.1795 TD
[(across)-302(the)-303(estrous)-305(cycle,)-304(suggesting)-302.8(that)-300.7(there)-304.1(are)-298.8(pos-)]TJ
0 -1.1847 TD
[(sible)-289.6(relationships)-291.9(between)-286(gon)-6.4(adal)-285.6(hormones)-286.5(and)-286.8(the)]TJ
0 -1.1795 TD
[(ECS)-222.9(function.)-223.7(For)-224.9(example,)-223.9(Bradshaw)-225.6(et)-218.3(al)-223.5(investigated)]TJ
T*
[(sex)-402.3(and)-400.6(cycle)-397.8(diff)-8.9(erences)-403.7(in)-399.2(endocannabinoid)-410.8(release)]TJ
0 -1.1847 TD
[(in)-254.3(several)-259.3(brain)-257(areas)-258.2(of)-259.2(the)-251.2(rat,)-256.8(such)-259(as)-254.3(hypothalamu)-9.7(s,)]TJ
0 -1.1795 TD
[(pituit)-8.8(ary,)-271.6(and)-276.4(midbrain.)]TJ
8.2191 0 0 7.3052 167.4141 469.644 Tm
(205)Tj
10.959 0 0 10.959 182.211 464.7684 Tm
[(Although)-276.8(there)-273.1(was)-275.7(no)-273(dif-)]TJ
-10.9671 -1.1847 TD
[(ference)-264.6(in)-254.3(AEA)-252.3(pro)-7.6(duction)-257(in)-254.3(the)-256.4(hyp)-6.8(othalamus)-259.8(or)-253.4(pi-)]TJ
0 -1.1795 TD
[(tuitar)-8.5(y)-255.9(between)-260.1(males)-261.1(and)-255.7(females)-9.3(,)-252.8(f)0(e)-6.9(male)-257.8(rats)-260.9(showed)]TJ
0 -1.1847 TD
[(signiìcan)-9.8(tly)-293.6(highe)-7.8(r)-293(2-AG)-296.5(levels)-303.3(compared)-298.4(with)-299.3(males.)]TJ
.9984 -1.1795 TD
[(Both)-230.9(2-AG)-229.3(and)-229.9(AEA)-226.4(reached)-231.6(their)-232.5(maximal)-228(levels)-230.9(in)]TJ
-.9984 -1.1847 TD
[(the)-251.2(pituitary)-250(during)-249.5(early)-247.8(proestrus,)-253.2(whereas)-245.5(AEA)-252.3(pro-)]TJ
0 -1.1795 TD
[(duction)-303.6(was)-306.8(highest)-304(in)-300.9(the)-308.1(hypothalamus)-302.7(during)-301.3(dies-)]TJ
0 -1.1847 TD
[(trus.)-378.9(It)-373.8(is)-379.6(interesting)-375(to)-377.5(note)-372.4(peak)-378(levels)-375.7(of)-378.1(AEA)-376.4(and)]TJ
0 -1.1795 TD
[(2-AG)-296.5(in)-295.7(the)-292.6(midbrain)-294.6(during)-301.3(late)-291.8(proestrus.)-299.7(Although)]TJ
T*
[(the)-390.9(physiological)-383.1(implications)-385.7(of)-388.5(these)-392.1(cyclic)-386.1(îuctua-)]TJ
0 -1.1847 TD
[(tions)-340.3(remain)-341.2(obscure,)-344(the)-339.2(most)-339.6(substantial)-342.7(alterations)]TJ
0 -1.1795 TD
[(occur)-458.6(during)-456.5(the)-453(transition)-459(from)-454.1(anestrus)-458.1(to)-455.1(estrus,)]TJ
0 -1.1847 TD
[(suggesting)-297.6(that)-300.7(the)-297.8(ECS)-295.3(may)-300.2(play)-295.6(a)-302.8(role)-296.1(in)-300.9(the)-297.8(regula-)]TJ
0 -1.1795 TD
[(tion)-393.9(of)-393.7(gonadal)-390.3(hormones.)-394.4(Third,)-395.2(gonadal)-390.3(hormones)]TJ
0 -1.1847 TD
-.0001 Tc
[(may)-403.8(regulate)-406.6(the)-406.5(activity)-407.6(of)-404.1(endocannabinoid-related)]TJ
0 -1.1795 TD
0 Tc
[(degraded)-239.3(enzymes)-234.5(and)-235(further)-238.3(inîuence)-238.9(the)-235.7(ECS)-233.3(activ-)]TJ
0 -1.1847 TD
[(ity.)-236.4(For)-240.4(instance,)-240.1(evidence)-235.2(shows)-238.6(that)-238.6(as)-238.8(FAAH)-237.8(activity)]TJ
0 -1.1795 TD
[(increases)-317.4(around)-315.1(blastocyst)-318(implantatio)6.5(n,)-317(AEA)-319.5(within)]TJ
T*
[(womenês)-470.9(uteruses)-474.2(decreases.)]TJ
8.2191 0 0 7.3052 189.9212 236.4661 Tm
(206)Tj
10.959 0 0 10.959 206.9291 231.6472 Tm
[(The)-472.1(FAAH)-470.6(gene)-471.1(se-)]TJ
-13.2226 -1.1847 TD
[(quence)-352.2(covers)-353.1(an)-351.5(estrogen)-353.4(response)-353.5(factor,)-348.3(and)-354(when)]TJ
0 -1.1795 TD
[(activated,)-336.4(the)-334(FAAH)-330.9(gene)-336.6(is)-333(upregulated)-336.4(and)-333.3(thus)-331.6(af-)]TJ
0 -1.1847 TD
[(fects)-301(estrogen)-301.6(production.)]TJ
8.2191 0 0 7.3052 176.0881 197.6315 Tm
(207)Tj
10.959 0 0 10.959 72.9637 179.8298 Tm
[(As)-423.4(mentioned)-415.2(previously,)-421(ECS)-419.5(is)-415.8(regulated)-419.4(by)-418.1(the)]TJ
-.9984 -1.1847 TD
[(HPA)-412.1(and)-410.9(HPG)-411.8(axes,)-414.6(which)-409.6(may)-414(affect)-412.9(its)-408.7(receptors,)]TJ
0 -1.1795 TD
[(cannabinoids,)-424.6(and)-421.3(related)-419.6(enzymes.)-425.2(Conversely,)-423.6(ECS)]TJ
0 -1.1847 TD
[(can)-313.2(overwhelmingly)-313.5(inîuence)-316.5(endocrine)-314.6(activities,)-311.1(in-)]TJ
0 -1.1795 TD
[(cluding)-428.6(hypothalamic)-428(releasing)-430.8(factors,)-429.2(pituitary)-425.9(ste-)]TJ
0 -1.1847 TD
[(roids,)-339.9(and)-343.7(peripheral)-339.9(hormones.)]TJ
8.2191 0 0 7.3052 205.285 119.9055 Tm
(73,208,209)Tj
10.959 0 0 10.959 244.1196 115.0299 Tm
[(The)-342.7(ultimate)]TJ
-16.6162 -1.1795 TD
[(outcome)-222.5(is)-224.4(to)-222.3(affect)-221.5(the)-220.2(effectiveness)-227.4(of)-222.9(ECS)-217.7(as)-223.3(a)-225.2(poten-)]TJ
T*
[(tial)-318.5(drug)-315.9(target)-318(for)-319.4(HAND.)-312.4(However,)-319.2(in)-316.4(these)-314.5(studies,)]TJ
0 -1.1847 TD
[(evaluating)-370(the)-370.2(interactions)-371.9(among)-371.5(ECS)-372.9(and)-369.5(the)-370.2(HPA)]TJ
0 -1.1795 TD
[(and)-204(HPG)-204.8(axes)-203.2(may)-207.1(be)-201.4(limited)-206.3(in)-202.6(the)-204.7(clinical)-206.7(application)]TJ
22.9068 57.9085 TD
[(because)-262.6(it)-260.5(is)-260.6(not)-260.7(possible)-255.9(to)-263.7(achieve)-257.9(rapid)-263.2(assays)-255.7(aimed)]TJ
0 -1.1847 TD
[(at)-202.5(observing)-200(whether)-203.2(there)-200.7(are)-200.5(alterations)-203.6(in)-202.6(the)-199.5(expres-)]TJ
0 -1.1795 TD
[(sion)-280.1(of)-274.7(certain)-274.8(genes)-277.8(or)-274.1(relevant)-276.9(metabolic)-271.5(enzymes)-275.9(or)]TJ
0 -1.1847 TD
[(receptors)-368(or)-362(the)-359.9(levels)-365.4(of)-362.6(endogenous)-361(molecules.)-359.4(It)-363.4(is)]TJ
0 -1.1795 TD
[(more)-236(easily)-230.9(used)-228.6(in)-233.6(clinical)-232.6(applications)-231.7(with)-226.9(the)-230.5(devel-)]TJ
0 -1.1847 TD
[(opment)-302.6(of)-300.5(molecular)-297.7(detection)-300(technology.)]TJ
1.0036 -1.1795 TD
[(For)-359.4(example,)-358.4(liquid)-359.7(chromatograph)5.5(yÖtandem)-359.9(mass)]TJ
-1.0036 -1.1795 TD
[(spectrometry)-228.9(\(LC-MS/MS\),)-233.1(the)-225.4(simultaneous)-228.7(quantita-)]TJ
0 -1.1847 TD
[(tion)-362.8(of)-357.4(a)-359.7(variety)-357.2(of)-357.5(endogenous)-361(hormones)-353.7(and)-359.2(endo-)]TJ
0 -1.1795 TD
[(cannabinoids)-409.8(that)-409.3(are)-412.6(used)-409.7(to)-408.5(evaluate)-411.1(the)-411.6(functions)]TJ
0 -1.1847 TD
[(of)-336.8(the)-339.2(three)-335.2(systems)-339.5(and)-333.3(interaction)-337.6(among)-335.2(them)-334.2(has)]TJ
0 -1.1795 TD
[(been)-449.8(achieved.)]TJ
8.2191 0 0 7.3052 378.7652 560.2959 Tm
(175,178)Tj
10.959 0 0 10.959 409.0959 555.4203 Tm
[(Although)-442.4(the)-447.8(concentrations)-447.6(of)]TJ
-8.7634 -1.1847 TD
-.0001 Tc
[(hormones)-296.9(and)-292(endocannabinoids)-294.3(have)-294.6(been)-294.7(suggested)]TJ
0 -1.1795 TD
0 Tc
[(to)-449.9(evaluate)-442.2(the)-447.8(activities)-446.3(and)-447.1(the)-442.6(interactions)-444.4(of)-450.6(the)]TJ
0 -1.1847 TD
[(HPA)-303.4(and)-302.3(HPG)-303.1(axes)-306.7(and)-302.3(ECS,)-299.8(these)-304.1(biomarkers)-305.1(based)]TJ
0 -1.1795 TD
[(on)-309.2(the)-303(hormone)-303.9(concentrations)-307.9(have)-304.9(a)-307.9(deìciency)-304.3(that)]TJ
T*
[(is)-457.2(susceptible)-457.2(to)-460.3(external)-453.1(interference.)]TJ
8.2191 0 0 7.3052 485.518 495.4959 Tm
(144)Tj
10.959 0 0 10.959 502.3557 490.677 Tm
[(A)-456.3(previous)]TJ
-17.2732 -1.1847 TD
[(study)-458.8(suggested)-460.3(that)-455.9(the)-458.2(ratios)-457.9(between)-456.7(endogenous)]TJ
0 -1.1795 TD
[(steroids)-288.1(are)-283.2(regarded)-281.5(as)-285.4(biomarkers)-284.4(to)-279.2(evaluate)-287(the)-282.3(in-)]TJ
0 -1.1847 TD
[(teraction)-300.5(between)-301.5(the)-297.8(HPA)-298.3(and)-302.3(HPG)-297.9(axes.)]TJ
8.2191 0 0 7.3052 502.5826 456.6613 Tm
(210)Tj
10.959 0 0 10.959 324.0566 438.8597 Tm
[(The)-296.2(ratio)-299.4(biomarkers)-299.9(are)-298.8(relatively)-294.8(stable)-296.9(since)-299.9(they)]TJ
-1.0036 -1.1847 TD
[(can)-209.7(counteract)-203.9(external)-204.8(inîuences.)-205.3(Thus,)-205.1(the)-204.7(multicate-)]TJ
0 -1.1795 TD
[(gory)-232.4(biomarkers)-232.7(\(e.g.,)-234.5(steroid)-233.1(concentrations)-230.3(in)-233.6(combi-)]TJ
0 -1.1847 TD
[(nation)-476.4(with)-475.2(ratio)-475.3(biomarkers\))-474.3(could)-473.7(provide)-474.6(clearer)]TJ
0 -1.1795 TD
[(and)-555.8(more)-551.5(comprehensive)-550.8(details)-554.9(on)-552.3(the)-551.3(HPA)-551.7(and)]TJ
0 -1.1847 TD
[(HPG)-277.3(axes,)-274.9(ECS,)-273.9(and)-276.4(their)-273.9(interactions)-273.7(than)-273.8(single)-271.7(bio-)]TJ
0 -1.1795 TD
[(markers.)-405.6(Indeed,)-403.8(our)-400.8(research)-401.2(group)-400.5(has)-401(utilized)-403.1(the)]TJ
T*
[(concentrations)-602.8(of)-605.8(glucocorticoids,)-600.9(gonadal)-602.4(steroids,)]TJ
0 -1.1847 TD
[(endocannabinoids,)-480.7(and)-483.3(ratio)-480.5(biomarkers)-481(to)-475.8(evaluate)]TJ
0 -1.1795 TD
-.0001 Tc
[(the)-391(interactions)-387.6(within)-388.2(a)-390.8(neuroendocrine)-388.1(system)-388(and)]TJ
0 -1.1847 TD
0 Tc
[(among)-350.8(the)-344.3(three)-345.5(systems)-349.9(in)-347.4(human)-345.7(and)-348.8(animal)-346.2(stud-)]TJ
0 -1.1795 TD
(ies.)Tj
8.2191 0 0 7.3052 326.8912 301.2661 Tm
(175,176,178,211)Tj
10.959 0 0 10.959 384.5479 296.3904 Tm
[(For)-452.5(example,)-451.6(the)-453(ratio)-454.6(of)-450.6(cortisol)-453.2(to)]TJ
-6.5234 -1.1847 TD
[(AEA)-366.1(was)-368.8(used)-368.3(to)-367.1(assess)-365.6(the)-365(interaction)-368.6(between)-363.6(ECS)]TJ
0 -1.1795 TD
[(and)-483.3(the)-478.9(HPA)-479.3(axis,)-482.7(and)-483.3(the)-478.8(ratio)-480.5(of)-481.6(testosterone)-479.4(to)]TJ
0 -1.1847 TD
[(AEA)-459.2(was)-456.8(considered)-452.7(to)-460.3(evaluate)-452.5(the)-458.2(interaction)-456.6(be-)]TJ
0 -1.1795 TD
[(tween)-301.9(ECS)-300.5(and)-297.1(the)-303(HPG)-297.9(axis)-297.1(among)-299(patients.)]TJ
8.2191 0 0 7.3052 516.3589 249.4488 Tm
(175,178)Tj
/F5 1 Tf
10.4607 0 0 10.4607 313.0582 218.6645 Tm
[(Conclusions)-304.1(and)-298.4(Perspectives)]TJ
/F6 1 Tf
10.959 0 0 10.959 313.0582 205.6818 Tm
[(We)-255.9(review)-254.3(how)-252.7(ECS)-254(contributes)-248.5(to)-253.3(HIV-1)-253.3(disease)-254.5(pro-)]TJ
T*
[(gression)-349.1(and)-348.8(how)-345.8(it)-348.5(can)-344.2(be)-351.4(used)-347.6(as)-347.5(a)-349.3(therapeutic)-342.6(tar-)]TJ
0 -1.1847 TD
[(get)-360.4(to)-362(reduce)-358.8(HAND)-359.6(pathophysiolog)5.9(y.)-358.6(The)-363.4(ECS)-357.4(may)]TJ
0 -1.1795 TD
[(be)-392.8(ideally)-394(suited)-390.8(to)-393(modulate)-391.9(the)-390.9(pathophysiology)-389.7(of)]TJ
T*
[(HAND.)-343.4(Direct)-342.8(activation)-344.6(of)-341.9(presynaptic)-342.4(CB1)-346.1(or)-341.4(a)-344.1(re-)]TJ
0 -1.1847 TD
[(du)15.7(c)12.5(t)0(i)18.8(o)0(n)-345.4(i)0(n)-347.5(c)0(a)20.1(n)0(n)21.5(a)0(b)16.2(i)11.7(no)21.9(id)-347.8(m)10.2(e)0(t)19.6(a)12.8(bo)17.1(l)12(i)11.7(sm)-350.1(a)12.8(t)0(t)19.4(e)0(n)20.6(u)0(a)20.6(t)0(e)19.6(s)-360.2(HA)24.4(ND)]TJ
0 -1.1795 TD
[(ex)14.9(c)12.5(i)11.7(to)20.8(to)20.8(xi)19.3(ci)19(ty)20.2(.)-366.6(T)0(h)17.2(e)-365.1(ac)20.1(ti)18.8(va)20.7(ti)18.8(on)-355.8(of)-357.4(CB)18.1(2)-364.2(o)0(n)-360.9(i)11.7(m)10.2(m)10.2(u)13(ne)-362.2(c)12.5(e)0(l)19.3(l)12(s)]TJ
0 -1.1847 TD
[(ca)14.9(n)-312.6(r)0(e)19.5(d)0(u)15.7(c)12.5(e)-318.6(c)12.5(hr)15.6(o)13.7(n)0(i)19.8(c)-318.6(ne)20.7(ur)20.1(oi)20.2(nî)21.8(am)17.8(m)10.2(a)12.8(ti)18.8(on)-309.2(a)12.8(s)0(s)19.3(o)0(c)21(i)11.7(at)19.9(ed)-310.7(wi)21.3(t)12.3(h)]TJ
0 -1.1795 TD
[(H)-5.6(AND.)-239.5(More)-7.8(ove)-7.3(r,)-235.4(enh)-7.1(anc)-7.9(ed)-238.3(can)-7.9(nabin)-7.6(oi)-5.6(d)-235.3(recep)-9.7(tor)-241.1(ex-)]TJ
0 -1.1847 TD
[(pre)-8.8(ss)-6.6(ion)-261.3(in)-259.5(HAND)-261.4(may)-258.8(inc)-9.1(rease)-263.7(the)-261.6(ECS)-264.3(sensi)-10.5(tivi)-8.1(ty)-259.1(to)]TJ
0 -1.1795 TD
[(H)-5.6(IV.)-335(Howev)-8.4(er,)-336.7(ta)-5.9(rgeti)-10.6(ng)-335.7(cert)-7.4(ain)-334.6(el)-6.5(emen)-8.4(ts)-332.4(of)-336.8(ECS)-336.7(has)]TJ
0 -1.1847 TD
[(some)-308.4(dra)-8.5(wbacks)-8.8(.)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(12)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
123 0 obj
<</Length 15112>>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 70.7527 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(Particularly,)-288.7(the)-292.6(psychoactive)-297(effects)-292.4(caused)-291.3(by)-293.9(acti-)]TJ
-1.0036 -1.1847 TD
[(vating)-265.1(CB1)-258.2(are)-262.5(of)-259.2(particular)-263.4(concern.)-261(There)-261.1(are)-262.5(several)]TJ
0 -1.1795 TD
[(limitations)-248.9(to)-248.2(the)-246.1(use)-252(of)-248.8(CB1)-247.8(agonists,)-244.5(including)-248.4(motor)]TJ
0 -1.1847 TD
[(impairment)-397.5(and)-395.4(diminished)-394.4(the)-396.1(short-term)-393.5(memory.)]TJ
0 -1.1795 TD
[(MAGL)-313.6(and)-317.8(FAAH)-310.3(inhibitors)-313.5(may)-315.7(be)-315.2(used)-316.5(to)-310.2(increase)]TJ
0 -1.1847 TD
[(endogenous)-350.7(generation)-343.3(of)-352.3(agonists)-343.5(to)-346.4(prevent)-350.8(the)-344.4(de-)]TJ
0 -1.1795 TD
[(sensitization)-510.3(of)-512.6(cannabinoid)-509.9(receptors)-507.6(that)-507.6(happens)]TJ
T*
[(during)-627.2(persistent)-620.7(activation.)-623.2(Because)-619.3(patients)-624.1(with)]TJ
0 -1.1847 TD
[(HAND)-432.1(may)-434.7(not)-431.4(be)-434.2(able)-430.1(to)-434.4(receive)-430.4(preventive)-432.5(treat-)]TJ
0 -1.1795 TD
[(ment,)-458(understanding)-449.7(the)-458.2(disease)-451.1(duration,)-455.9(especially)]TJ
0 -1.1847 TD
-.0001 Tc
[(alterations)-343.3(in)-342.4(neuroinîammation,)-341.5(is)-343.5(crucial)-342.7(to)-341.4(under-)]TJ
0 -1.1795 TD
0 Tc
[(stand)-458.8(the)-453(importance)-450(of)-455.7(excitotoxicity)-455.7(and)-452.3(neuroin-)]TJ
0 -1.1847 TD
[(îammatory)-297.8(targets.)]TJ
1.0036 -1.1795 TD
[(In)-310.7(addition,)-316.8(due)-313.2(to)-310.2(the)-313.3(reciprocal)-314.6(inhibition)-312.9(of)-310.9(ECS)]TJ
-1.0036 -1.1847 TD
[(by)-531.9(the)-530.6(HPA)-531(and)-535.1(HPG)-530.7(axes,)-533.6(indirect)-531.9(regulation)-530.3(of)]TJ
0 -1.1795 TD
[(ECS)-497.1(by)-500.8(modulating)-495.6(hormone-rela)6.5(ted)-500.2(receptors)-497.3(may)]TJ
T*
[(be)-304.9(a)-302.8(potential)-305.4(strategy)-303(affecting)-302.4(the)-308.1(ECS)-300.5(and)-307.5(may)-300.2(also)]TJ
0 -1.1847 TD
[(alleviate)-203.9(the)-204.7(progression)-201.5(of)-202.3(HAND.)-203.7(Collectively,)-199.1(several)]TJ
0 -1.1795 TD
[(promising)-204.4(targets)-207.5(in)-202.6(ECS)-202.2(to)-206.8(suppress)-204.8(the)-204.7(neuronal)-202.3(inju-)]TJ
0 -1.1847 TD
[(ries)-251.4(that)-249(underlie)-251.5(HAND)-245.8(have)-253.2(been)-248(discussed.)-249(CB2)-253(ag-)]TJ
0 -1.1795 TD
-.0001 Tc
[(onists)-364.4(inhibiting)-365.4(neuroinîammation)-368.1(were)-361.9(better)-364.3(than)]TJ
0 -1.1847 TD
0 Tc
[(nonselective)-448.4(drugs)-448.6(that)-445.6(activate)-448.4(both)-443.2(CB1)-449.6(and)-447.1(CB2,)]TJ
0 -1.1795 TD
[(with)-361.4(psychoactive)-359.1(side)-364.4(effects.)-358.9(MAGL)-360.2(inhibitors)-360(have)]TJ
0 -1.1847 TD
[(become)-214.7(promising)-214.8(reagents)-214.6(because)-216(of)-217.8(inhibiting)-210.1(gluta-)]TJ
0 -1.1795 TD
[(mate)-350.6(release)-342.6(by)-350.8(enhancing)-344.2(endogenous)-345.5(production)-347.4(of)]TJ
0 -1.1847 TD
[(2-AG)-389.6(through)-384.2(CB1,)-392(and)-385(hindering)-392.4(immune)-384.4(function)]TJ
0 -1.1795 TD
.0091 Tc
[(through)-458.3(C)-2.2(B2)-458.6(in)-463.8(CNS.)-460.9(A)-462.7(C)2.9(B2-selecti)-5.1(ve)-459.5(agonist)-459.7(a)-4(nd)]TJ
T*
.0114 Tc
[(MAGL)-337(in)4(hib)4.4(i)2.4(to)4.4(r)-343.7(a)3.5(re)-338.2(we)3.2(ll)-343.9(t)3(o)-.7(le)3.2(ra)3.5(t)3(e)-2(d)-337.7(a)-1.7(n)4(d)-342.9(a)3.5(r)-2.2(e)-343.4(c)3.2(u)3.7(r)-2.2(r)2.9(e)3.2(nt)3(ly)]TJ
0 -1.1847 TD
0 Tc
[(be)21(in)19.8(g)-302.5(s)12.2(t)12.3(u)0(d)15.7(i)11.7(ed)-290(f)11.6(o)0(r)-289.6(o)13.7(th)20.8(er)-290.9(i)11.7(n)0(d)16(i)11.7(c)12.5(a)0(t)19.9(i)0(o)20.2(n)0(s)-290(t)12.3(ha)21.3(n)-302.2(H)0(A)24.4(N)0(D)19.5(,)-299.3(wh)23.3(ic)19(h)]TJ
0 -1.1795 TD
[(m)10.2(a)0(y)-279.3(s)0(l)19.1(o)0(w)-281.8(t)12.3(he)-279.1(pr)20.1(og)21.6(re)19.5(ss)19.3(i)11.7(o)0(n)-283.3(o)13.7(f)-293.6(H)0(A)24.4(N)0(D)19.5(.)]TJ
/F5 1 Tf
10.4607 0 0 10.4607 59.7543 294.3495 Tm
[(Human)-301.3(and)-298.4(Animal)-304.8(Rights)]TJ
0 -1.2357 TD
[(and)-303.8(Informed)-295.1(Consent)]TJ
/F6 1 Tf
10.959 0 0 10.959 59.7543 268.4409 Tm
[(There)-468.1(have)-465.3(been)-465.3(no)-464.4(animal)-465.2(or)-465.5(human)-464.7(studies)-466.6(con-)]TJ
0 -1.1795 TD
[(ducted)-384.1(by)-381.9(any)-379.8(of)-383.3(the)-380.6(authors)-380.8(for)-381.4(the)-380.6(purpose)-386.2(of)-378.1(this)]TJ
T*
(article.)Tj
/F5 1 Tf
10.4607 0 0 10.4607 59.7543 218.6645 Tm
(Acknowledgment)Tj
/F6 1 Tf
10.959 0 0 10.959 59.7543 205.6818 Tm
[(The)-228.9(ìgures)-223.3(in)-223.3(this)-224.3(article)-229.6(were)-222.2(created)-227.8(using)-221.2(BioRender)]TJ
T*
(\(https://biorender.com\).)Tj
/F5 1 Tf
10.4607 0 0 10.4607 59.7543 166.8472 Tm
[(Authorsê)-303.8(Contributions)]TJ
/F6 1 Tf
10.959 0 0 10.959 59.7543 153.9212 Tm
[(L.C.:)-280(Conceptualization,)-278.2(writingÑoriginal)-275.6(draft)-279.4(prepa-)]TJ
0 -1.1847 TD
.0097 Tc
[(rati)-4.5(on,)-450(a)-3.4(nd)-453.2(writingÑreview)-446.2(editi)-4.5(n)2.3(g.)-450(Z.S.,)-450(X)2.9(.G.,)-450(and)]TJ
0 -1.1795 TD
.0112 Tc
[(Y.W.:)-277.8(W)1.5(rit)2.8(i)2.2(ng)3.6(Ñr)2.7(ev)3.6(iew)-274(e)-2.2(d)3.5(i)2.2(tin)3.8(g)-1.6(.)-277.8(J)2.1(.Y.:)-277.8(Fu)3.5(nd)3.5(ing)-275.7(a)-1.9(c)3(q)3.9(uis)2.7(i)-3(-)]TJ
0 -1.1847 TD
.0094 Tc
[(tion)-442.8(and)-443.2(r).9(eviewing.)-439.9(H)-1.4(.D.:)-439.9(Funding)-443.1(a)1.5(cquisition,)-439.9(a)-3.7(nd)]TJ
0 -1.1795 TD
[(wri)-4.9(t).9(ingÑreviewing)-298.3(a)-3.8(nd)-303.6(edi)-4.9(t).9(ing.)]TJ
/F5 1 Tf
10.4607 0 0 10.4607 59.7543 76.1953 Tm
0 Tc
[(Author)-303.3(Disclosure)-299.8(Statement)]TJ
/F6 1 Tf
10.959 0 0 10.959 59.7543 63.2126 Tm
[(The)-301.4(authors)-298(declare)-300.5(no)-298.9(conîicts)-301.6(of)-300.5(interest.)]TJ
/F5 1 Tf
10.4607 0 0 10.4607 310.8472 698.2297 Tm
[(Funding)-301.1(Information)]TJ
/F6 1 Tf
10.959 0 0 10.959 310.8472 685.2471 Tm
[(This)-284.8(work)-287.6(was)-286.1(supported)-288.5(by)-288.7(the)-287.4(National)-284.6(Natural)-287.7(Sci-)]TJ
T*
[(ence)-202.7(Foundation)-201.1(of)-202.3(China)-203(\(31800952\))-194.8(and)-204(the)-204.7(Program)]TJ
0 -1.1847 TD
[(for)-257.3(New)-263.1(Century)-255.6(Excellent)-264.1(Talents)-257.5(in)-259.5(University,)-260.1(Min-)]TJ
0 -1.1795 TD
[(istry)-300.6(of)-295.4(Education,)-302.3(China)-296.1(\(NCET-08-0122\).)]TJ
/F5 1 Tf
10.4607 0 0 10.4607 310.8472 620.1636 Tm
(References)Tj
/F7 1 Tf
7.4718 0 0 7.4718 318.3306 610.1857 Tm
[(1.)-499.4(Heaton)-307.2(RK,)-301.7(Franklin)-309.3(DR,)-300.5(Ellis)-303.2(RJ,)-304.1(et)-301(al.)-301.4(HIV-associated)-311.9(neurocogn)-12.2(itive)]TJ
1.2064 -1.1988 TD
[(disorders)-307.3(before)-311.5(and)-296.3(during)-307.4(the)-302.9(era)-300(of)-306.1(combination)-305.2(an)-8.5(tiretroviral)-309.8(ther-)]TJ
T*
[(apy:)-304.7(Differences)-309.7(in)-304(rates,)-304.1(nature,)-304.2(and)-303.9(predictors.)-313(J)-296.1(Neurov)-11.3(irol)-302.8(2010;)]TJ
T*
[(17\(1\):3Ö16;)-309.8(doi:)-307.2(10.1007/s13365-)-14.7(010-0006-1)]TJ
-1.2064 -1.2064 TD
[(2.)-499.4(Bhaskar)-11.6(an)-296.8(K,)-301.5(Mussini)-301.8(C,)-300.9(Antinori)-306.3(A,)-299.2(et)-301(al.)-293.8(Chang)-9.4(es)-296.3(in)-304(the)-295.3(inciden)-9.6(ce)-297.4(and)]TJ
1.2064 -1.1988 TD
[(predictors)-312.7(of)-298.6(hum)-8.9(an)-296.8(immunodeìcien)-12.7(cy)-306.6(virus-associated)-310.6(dementia)-310.1(in)]TJ
T*
[(the)-302.9(era)-300(of)-306.1(highly)-301.3(active)-305.9(antiretrovi)-12.8(ral)-297.8(therapy.)-308.4(Ann)-302.7(Neurol)-306.8(2008;63\(2\):)]TJ
T*
[(213Ö221;)-310(doi:)-299.6(10.1002/a)-13.2(na.21225)]TJ
-1.2064 -1.1988 TD
[(3.)-499.4(Heaton)-246.5(RK,)-248.5(Clifford)-256.1(DB,)-244.9(Franklin)-248.6(DR,)-247.4(et)-240.3(al.)-248.3(HIV-associated)-258.8(neurocognitive)]TJ
1.2064 -1.1988 TD
[(disorders)-307.3(persi)-10.3(st)-299.7(in)-304(the)-295.3(era)-307.6(of)-298.6(pote)-9.9(nt)-294.5(an)-8.5(tiretroviral)-309.8(therapy:)-308.4(CHARTER)]TJ
T*
[(Study.)-304.3(Neuro)-12.2(logy)-296.6(2010;75)-13.3(\(23\):2087Ö2096;)-310.9(doi:)-299.6(10.1)-10.6(212/WNL)]TJ
0 -1.2064 TD
[(.0b013e318200)-14.7(d727)]TJ
-1.2064 -1.1988 TD
[(4.)-499.4(Gates)-307.1(TM,)-302.7(Cysique)-306.8(LA.)-301.7(The)-302.8(chronicity)-307.1(of)-306.1(HIV)-304(infection)-305.4(should)-306.1(drive)-305.7(the)]TJ
1.2064 -1.1988 TD
[(research)-307.2(strategy)-312.5(of)-298.6(NeuroHIV)-308.6(treatment)-309.6(studies:)-303.8(A)-306.5(critical)-300.7(review)-10.5(.)]TJ
T*
[(CNS)-301.3(Drugs)-311.1(2016;30\(1\):53Ö69;)-309.6(doi:)-307.2(10.1007/s4026)-14.8(3-015-0302-7)]TJ
-1.2064 -1.1988 TD
[(5.)-499.4(Saylor)-309.8(D,)-300.3(Dickens)-304.1(AM,)-301.5(Sacktor)-308.5(N,)-300.3(et)-308.6(al.)-301.4(HIV-associated)-311.9(neurocognitive)]TJ
1.2064 -1.1988 TD
[(disorderÑ)-13.4(Pathogenesis)-309.7(and)-296.3(prospect)-13.9(s)-295.5(for)-310.4(treatment.)-309.9(Nat)-295.8(Rev)-303.5(Neurol)]TJ
0 -1.2064 TD
[(2016;12\(4\):23)-15.8(4Ö248;)-305.7(doi:)-299.6(10.1038/nr)-12.8(neurol.2016.27)]TJ
-1.2064 -1.1988 TD
[(6.)-499.4(Zenebe)-301.6(Y,)-303.9(Necho)-308.7(M,)-298.5(Yimam)-304.6(W,)-303(et)-301(al.)-301.4(Worldwid)-12.1(e)-296.7(occurrence)-313(of)-298.6(HIV-)]TJ
1.2064 -1.1988 TD
[(associated)-309.9(neurocogn)-12.2(itive)-297.3(diso)-10.6(rders)-304.3(and)-296.3(its)-306(associated)-309.9(factors:)-306.7(A)-306.5(sys-)]TJ
T*
[(tematic)-305.2(review)-306.4(and)-303.9(meta-analysis.)-309.8(Front)-303.1(Psyc)-10.4(hiatry)-298.9(2022;13)-13.3(:814362;)]TJ
T*
[(doi:)-307.2(10.3389/fpsyt.2022)-18.7(.814362)]TJ
-1.2064 -1.1988 TD
[(7.)-499.4(Heaton)-307.2(RK,)-301.7(Marcott)-12.6(e)-296.7(TD,)-304.5(Mindt)-302.5(MR,)-306.2(et)-301(al.)-301.4(The)-302.8(impact)-307.3(of)-298.6(HIV-associated)]TJ
1.2064 -1.1988 TD
[(neuropsych)-14.1(ological)-304.1(impairment)-306.3(on)-303.1(everyday)-304.2(functio)-13.5(ning.)-300.5(J)-303.7(Int)-300.7(Neuro-)]TJ
0 -1.2064 TD
[(psychol)-311.5(Soc)-298.5(2004;10\(3\):31)-15.8(7Ö331;)-305.7(doi:)-299.6(10.1017/s)-13.7(1355617704102130)]TJ
-1.2064 -1.1988 TD
[(8.)-499.4(Laverick)-310.8(R,)-296.3(Haddo)-10.9(w)-295.3(L)0(,)-306.2(Daskalopoulo)-14.6(u)-293.6(M)0(,)-306.1(e)0(t)-301(al.)-301.4(Self-repo)-12.3(rted)-297.1(decline)]TJ
1.2064 -1.1988 TD
[(in)-304(everyday)-304.2(function,)-311.6(cognitive)-307.1(symptoms,)-310.2(and)-303.9(cognitive)-307.1(function)-303.7(in)]TJ
T*
[(people)-308(with)-300.1(HIV.)-304.3(J)-303.7(Acquir)-307.3(Immune)-298.3(Deìc)-305.1(Syndr)-308.2(2017;76\(3\):e74Öe8)-16.6(3;)]TJ
T*
[(doi:)-307.2(10.1097/qai.000000)-17.1(0000001468)]TJ
-1.2064 -1.1988 TD
[(9.)-499.4(Matsuda)-304.9(LA,)-309.2(Lolait)-304.2(SJ,)-300.6(Brownstein)-309.7(MJ,)-306.3(et)-301(al.)-301.4(Structure)-306.6(of)-306.1(a)-294.9(can)-9.2(nabinoid)]TJ
1.2064 -1.2064 TD
[(receptor)-308.2(and)-303.9(functional)-308.9(expression)-311.1(of)-298.6(the)-302.9(cloned)-302.7(cDNA.)-308.2(Nature)-306.1(1990;)]TJ
0 -1.1988 TD
[(346\(6284)-11.2(\):561Ö564;)-302.5(doi:)-307.2(10.1038/3465)-15.3(61a0)]TJ
-1.7072 -1.1988 TD
[(10.)-497.8(Mun)-9.5(ro)-297.9(S,)-300.4(Thomas)-307.6(KL,)-304(Abu-Shaar)-306.1(M.)-306.1(Molecular)-303.3(cha)-9.2(racterization)-307.3(of)-306.2(a)]TJ
1.7148 -1.1988 TD
[(peri)-10.8(pheral)-300(receptor)-308.2(for)-302.8(cannab)-9.6(inoids.)-299.7(Nature)-306.1(1993;36)-13.3(5\(6441\):61Ö65;)]TJ
T*
[(doi:)-307.2(10.1038/3)-12.6(65061a0)]TJ
-1.7148 -1.1988 TD
[(11.)-497.8(Devane)-309.2(WA,)-298.5(Hanus)-309.3(L,)-298.6(Breuer)-309.1(A,)-299.2(et)-301(al.)-309(Isolation)-307.2(and)-296.3(structure)-317.1(of)-298.6(a)-302.5(brain)]TJ
1.7148 -1.1988 TD
[(const)-11.7(ituent)-303.5(that)-305.4(binds)-302.6(to)-305.5(the)-295.3(can)-9.2(nabinoid)-300.3(receptor.)-316.1(Science)-303.6(1992;)]TJ
0 -1.2064 TD
[(258)-10.3(\(5090\):1946Ö1949;)-315.3(doi:)-299.6(10.1126/sc)-14.4(ience.1470919)]TJ
-1.7148 -1.1988 TD
[(12.)-497.8(Mecho)-11(ulam)-300.5(R,)-303.9(Benshabat)-307.2(S,)-300.4(Hanus)-309.3(L,)-298.6(et)-301(al.)-301.4(Iden)-8.4(tiìcation)-304.6(of)-306.1(an)-296.8(endog-)]TJ
1.7148 -1.1988 TD
[(enous)-308.8(2-monoglyceri)-13.9(de,)-296.5(present)-307(in)-304(canine)-306.4(gut,)-300.1(that)-305.4(binds)-302.6(to)-305.5(canna-)]TJ
T*
[(binoid)-307(receptors.)-315.7(Biochem)-302.6(Pharmaco)-12(l)-294.5(1995;50\()-13.1(1\):83Ö90;)-304.1(doi:)-307.2(10.1016/)]TJ
T*
[(000)-10.3(6-2952\(95\)00109-D)]TJ
-1.7148 -1.1988 TD
[(13.)-497.8(Cravatt)-310.5(BF,)-300.5(Demar)-9.9(est)-300.5(K,)-301.5(Patricelli)-307.2(MP,)-306.2(et)-301(al.)-301.4(Supersensitivity)-310.2(to)-305.5(ananda-)]TJ
1.7148 -1.2064 TD
[(mide)-250.9(and)-243.2(enhanced)-249.3(endogenous)-249.9(cannabin)-10.2(oid)-238.6(sign)-9.6(aling)-242.9(in)-243.3(mice)-244.5(lacking)]TJ
0 -1.1988 TD
[(fatty)-310.8(acid)-301.3(amide)-303.1(hydrola)-11.1(se.)-296.5(Pro)-9.7(c)-296.6(Natl)-302(Acad)-305.7(Sci)-307(U)-295.9(S)-300.1(A)-306.5(2001;98\(16\):)]TJ
T*
[(937)-10.3(1Ö9376;)-304.1(doi:)-299.6(10.1)-10.6(073/pnas.161191698)]TJ
-1.7148 -1.1988 TD
[(14.)-497.8(Dinh)-310.1(TP,)-300.5(Carpenter)-307.8(D,)-300.3(Leslie)-304.3(FM,)-305.1(et)-301(al.)-301.4(Brain)-305.1(monoglycerid)-13.5(e)-296.7(lipase)-307.2(par-)]TJ
1.7148 -1.1988 TD
[(tici)-9.8(pating)-301.1(in)-304(endocannabinoid)-309.4(inactivati)-11.7(on.)-303.4(Proc)-298.7(Natl)-302(Acad)-305.7(Sci)-307(U)-295.9(S)-307.7(A)]TJ
T*
[(200)-10.3(2;99\(16\):10819Ö1082)-16.1(4;)-302.2(doi:)-299.6(10.1073/p)-13.7(nas.152334899)]TJ
-1.7148 -1.1988 TD
[(15.)-497.8(Hilla)-10.1(rd)-299.7(CJ,)-301.1(Beat)-9.4(ka)-297.4(M,)-306.1(Sarvaideo)-305.7(J.)-304(Endocannabinoid)-312.9(signaling)-305.6(and)-296.3(the)]TJ
1.7148 -1.2064 TD
[(hypothal)-13(amic-pituitary-adren)-17.3(al)-301.2(axis.)-305.9(Compr)-303.7(Physiol)-302.6(2017;7\(1)-13(\):1Ö15;)]TJ
0 -1.1988 TD
[(doi:)-307.2(10.1002/cphy.c1)-18(60005)]TJ
-1.7148 -1.1988 TD
[(16.)-497.8(Di)-306.3(Marzo)-304.7(V.)-298.1(Targ)-9.4(eting)-303.4(the)-295.3(endocann)-11(abinoid)-306(system:)-304.5(To)-305.4(enhance)-302.9(or)]TJ
1.7148 -1.1988 TD
[(redu)-9.9(ce?)-304.5(Nat)-295.8(Re)-8.5(v)-294.9(Drug)-303.9(Discov)-310.8(2008;7\(5\):438Ö455;)-315.5(doi:)-299.6(10.1038/)]TJ
T*
[(nrd25)-10(53)]TJ
-1.7148 -1.1988 TD
[(17.)-497.8(Padwa)-277.8(H,)-281(Huang)-273.7(D,)-277.6(Mooney)-276(L,)-275.9(et)-278.2(al.)-271.1(Medical)-280.3(conditions)-281.3(of)-275.8(primary)-275.4(care)]TJ
1.7148 -1.2064 TD
[(pat)-10.4(ients)-301.1(with)-300.1(docu)-10.8(mented)-304.8(cannabis)-303.7(use)-301.6(and)-303.9(cannabis)-303.7(use)-309.2(disorder)-307.8(in)]TJ
0 -1.1988 TD
[(ele)-7.8(ctronic)-243.4(health)-249.3(records:)-249.9(A)-245.8(case)-242.9(control)-248(study)-253.9(from)-243.8(an)-243.7(academic)-250.4(health)]TJ
T*
[(sy)-9.6(stem)-302.2(in)-296.4(a)-302.5(medical)-310(marijuana)-301(state.)-311.7(Subst)-301.2(Abuse)-304.1(Tre)-9.2(at)-299.2(Prev)-300.1(Policy)]TJ
T*
[(202)-10.3(2;17\(1\):36;)-309.3(doi:)-299.6(10.1186/s)-13.7(13011-022-00467-)-13.8(1)]TJ
-1.7148 -1.1988 TD
[(18.)-497.8(Rober)-10(ts)-299.7(BZ,)-303.4(Minassian)-304.1(A,)-306.8(Halberstadt)-312.3(AL,)-301.7(et)-301(al.)-301.4(HIV)-304(transgenic)-308.9(rats)]TJ
1.7148 -1.1988 TD
[(dem)-9.5(onstrate)-307.7(impaired)-305.5(sensorimotor)-311.6(gating)-303.6(but)-305(are)-300(insensiti)-11.5(ve)-295.7(to)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23231.5(13)]TJ
ET

endstream
endobj
128 0 obj
<</Length 20151>>stream
/GS1 gs
BT
/F7 1 Tf
7.4718 0 0 7.4718 78.633 700.2707 Tm
0 0 0 rg
0 Tc
0 Tw
[(cannabinoid)-309.5(\()]TJ
/F4 1 Tf
5.7741 0 TD
(D)Tj
/F7 1 Tf
5.6038 0 0 4.9805 126.7653 703.5588 Tm
(9)Tj
7.4718 0 0 7.4718 129.5999 700.2707 Tm
[(-tetrahydrocann)-15.9(abinol\)-induced)-314.1(deìcits.)-303.2(Int)-300.7(J)-303.7(Neuro-)]TJ
-6.8212 -1.2064 TD
[(psychopharmac)-15.5(ol)-299.9(2021;24\(11\):894Ö90)-17.7(6;)-302.2(doi:)-299.6(10.1093/i)-12.8(jnp/pyab053)]TJ
-1.7224 -1.1988 TD
[(19.)-505.4(Towe)-305.6(SL,)-302.8(Meade)-298.3(CS,)-305.1(Cloak)-306(CC,)-305.5(et)-301(al.)-301.4(Reciprocal)-311.2(inîuences)-309.1(of)-298.6(HIV)-304(and)]TJ
1.7224 -1.1988 TD
[(cannabinoids)-309.1(on)-303.1(the)-302.9(brain)-299.2(and)-303.9(cognitive)-307.1(function.)-311.6(J)-296.1(Neuroi)-10.9(mmune)]TJ
T*
[(Pharmacol)-306.6(2020;15\(4\):76)-15.8(5Ö779;)-298.1(doi:)-307.2(10.1007/s1148)-14.8(1-020-09921-y)]TJ
-1.7224 -1.1988 TD
[(20.)-505.4(Izzo)-303.3(AA,)-302.2(Borrelli)-304.2(F,)-302.8(Capasso)-310.2(R,)-296.3(et)-301(al.)-309(Non-psychotropic)-315.7(plant)-299.2(canna)-10.1(bi-)]TJ
1.7224 -1.1988 TD
[(noids:)-301.1(New)-307.8(therapeutic)-307.8(opportunities)-315.6(from)-304.5(an)-296.8(ancient)-310.7(herb.)-302.7(Trends)]TJ
0 -1.2064 TD
[(Pharmacol)-306.6(Sci)-299.4(200)-10.3(9;30\(10\):515Ö527;)-309.6(doi:)-307.2(10.1016/j.tips.20)-17.3(09.07.006)]TJ
-1.7224 -1.1988 TD
[(21.)-505.4(Canet)-306.6(G,)-296.2(Dias)-304.9(C,)-300.9(Gabelle)-308.4(A,)-299.2(et)-301(al.)-309(HIV)-296.4(neuro)-10(infection)-305.4(and)-303.9(Alzheimerês)]TJ
1.7224 -1.1988 TD
[(disease:)-301.6(Simil)-9.3(arities)-301.1(and)-303.9(potential)-308.3(links?)-304.2(Front)-303.1(Cell)-306.2(Neurosci)-307(2018;12:)]TJ
T*
[(307;)-298.9(doi:)-307.2(10.3389/fnc)-14.1(el.2018.00307)]TJ
-1.7224 -1.1988 TD
[(22.)-505.4(Hill)-299.4(MN,)-302.6(McLaug)-11.7(hlin)-297(RJ,)-304.1(Morrish)-304.6(AC,)-303.9(et)-301(al.)-309(Suppression)-306.9(of)-306.1(amygdalar)]TJ
1.7224 -1.1988 TD
[(endocannabinoid)-309.4(signaling)-305.6(by)-305.4(stress)-303.9(contributes)-312.8(to)-305.5(activation)-306.7(of)-298.6(the)]TJ
T*
[(hypothalamic)-13(ÖpituitaryÖadrenal)-309.4(axis.)-305.9(Neuropsycho)-14.1(pharmacology)-308(2009;)]TJ
0 -1.2064 TD
[(34\(13\):2733Ö27)-14.7(45;)-300.5(doi:)-299.6(10.1)-10.6(038/npp.2009.114)]TJ
-1.7224 -1.1988 TD
[(23.)-505.4(Evanson)-223.4(NK,)-214.6(Tasker)-222.7(JG,)-220.5(Hill)-215.9(MN,)-219.2(et)-217.5(al.)-218(Fast)-221.9(feedback)-220.1(inhibition)-221.8(of)-222.7(the)-219.4(HPA)]TJ
1.7224 -1.1988 TD
[(axis)-298(by)-305.4(glucocortico)-15.8(ids)-301.2(is)-301.7(mediated)-307.7(by)-297.8(endocann)-11(abinoid)-306(signaling.)]TJ
T*
[(Endocrinology)-310.8(2010;151)-11.7(\(10\):4811Ö4819;)-310.9(doi:)-299.6(10.1)-10.6(210/en.2010-0285)]TJ
-1.7224 -1.1988 TD
[(24.)-505.4(Totorikaguena)-313.2(L,)-298.6(Olabarrieta)-306.9(E,)-308(Lolicato)-302.6(F,)-302.8(et)-301(al.)-301.4(The)-302.8(endocann)-11(abinoid)]TJ
1.7224 -1.1988 TD
[(system)-213.1(modulates)-211.3(the)-211.8(ovarian)-212.1(physiology)-212.9(and)-212.9(its)-207.3(activation)-215.7(can)-206.5(improve)]TJ
0 -1.2064 TD
[(in)-296.4(vitro)-307.4(oocyte)-307.1(maturation.)-312.3(J)-296.1(Cell)-306.2(Physiol)-302.5(2020;23)-13.3(5\(10\):7580Ö7591;)]TJ
0 -1.1988 TD
[(doi:)-299.6(10.1002)-13.3(/jcp.29663)]TJ
-1.7224 -1.1988 TD
[(25.)-505.4(Nomenclature)-307.5(and)-303.9(research)-307.2(case)-303.5(deìnitions)-310(for)-302.8(neurologic)-311.1(manifesta-)]TJ
1.7224 -1.1988 TD
[(tions)-260.1(of)-260.6(hum)-8.9(an)-258.9(immunodeìcien)-12.7(cy)-261.1(virus-type)-265.7(1)-263.9(\(HIV-1\))-265.4(infection.)-267.7(Report)]TJ
T*
[(of)-298.6(a)-294.9(Working)-302(Group)-295.1(of)-298.6(the)-295.3(Amer)-9.7(ican)-296.1(Academy)-303(of)-298.6(Neurology)-301.3(AIDS)-298.3(Task)]TJ
T*
[(Force.)-306.3(Neurology)-308.9(1991;41\(6\):778Ö)-15(785;)-298.9(doi:)-307.2(10.1212/wnl.41.6.)-17.7(778)]TJ
-1.7224 -1.2064 TD
[(26.)-505.4(Antinori)-207.6(A,)-208.2(Arend)-9.5(t)-201.5(G)0(,)-205.1(Becke)-10(r)-201.5(JT,)-209.6(et)-209.9(al.)-202.8(Update)-10.6(d)-204.3(research)-216.2(nosology)-210.1(for)-211.8(HIV-)]TJ
1.7224 -1.1988 TD
[(associated)-226.4(neurocogn)-12.2(itive)-221.4(disorders.)-224.1(Neurol)-10.9(ogy)-222.1(2007;69\(18\):1789Ö17)-16.1(99;)]TJ
T*
[(doi:)-299.6(10.1212)-13.3(/01.WNL.0000287431)-18.1(.88658.8b)]TJ
-1.7224 -1.1988 TD
[(27.)-505.4(Dore)-302.8(GJ,)-304(McDonald)-307.4(A,)-299.2(Li)-304.6(Y,)-303.9(et)-301(al.)-301.4(Marked)-304.2(improvem)-10.8(ent)-295.3(in)-304(survival)-307(fol-)]TJ
1.7224 -1.1988 TD
[(lowing)-271.4(AIDS)-275.5(dem)-9.5(entia)-270.2(complex)-284.6(in)-266.1(the)-280.1(era)-269.6(of)-275.8(highly)-278.6(active)-275.6(antiretrovi)-12.8(ral)]TJ
T*
[(therapy.)-308.4(AIDS)-298.3(2003;17)-13.3(\(10\):1539Ö1545;)-310.9(doi:)-299.6(10.1)-10.6(097/00002030-)]TJ
T*
(200307040-00015)Tj
-1.7224 -1.2064 TD
[(28.)-505.4(Robertson)-309.4(KR,)-301.7(Smurzynski)-306.7(M,)-306.1(Parsons)-305.7(TD,)-304.5(et)-301(al.)-301.4(The)-302.8(prevalence)-308.9(and)-303.9(in-)]TJ
1.7224 -1.1988 TD
[(cidence)-306.5(of)-298.6(neuro)-10(cognitive)-307.1(impairment)-306.2(in)-296.4(the)-302.9(HAART)-306.3(era.)-307.9(AIDS)-298.3(2007;)]TJ
T*
[(21\(14\):1915Ö19)-14.7(21;)-300.5(doi:)-299.6(10.1)-10.6(097/QAD.0b013e32828e)-16.2(4e27)]TJ
-1.7224 -1.1988 TD
[(29.)-505.4(Avalos)-300.5(CR,)-308.6(Abreu)-301.2(CM,)-303.2(Queen)-308.2(SE,)-304.6(et)-301(al.)-301.4(Brain)-305.1(macrophages)-309.6(in)-296.4(simian)]TJ
1.7224 -1.1988 TD
[(immunodeìcien)-12.7(cy)-299(virus-infected,)-316(antiretroviral-suppressed)-320.5(macaques:)]TJ
T*
[(A)-298.9(functional)-308.9(latent)-304.8(reservoir.)-313.1(mBio)-299.2(2017;8\(4\))-12.8(:e01186-17;)-302.6(doi:)-307.2(10.1128/)]TJ
0 -1.2064 TD
(mBio.01186-17)Tj
-1.7224 -1.1988 TD
[(30.)-505.4(Simioni)-304.9(S,)-300.4(Cavassini)-311.1(M,)-298.5(Annoni)-308.6(J-M,)-300.2(et)-301(al.)-301.4(Cognitive)-311.1(dysfunction)-305.2(in)-304(HIV)]TJ
1.7224 -1.1988 TD
[(patients)-303.9(despite)-306.5(long-standi)-12.2(ng)-299.7(suppression)-309.8(of)-306.1(viremia.)-305.8(AIDS)-298.3(2010;)]TJ
T*
[(24\(9\):1243Ö125)-14.7(0;)-294.6(doi:)-307.2(10.1097/QA)-13.1(D.0b013e3283354a7b)]TJ
-1.7224 -1.1988 TD
[(31.)-505.4(Tozzi)-299.9(V,)-305.7(Balestra)-306.8(P,)-303.9(Galgani)-302.6(S,)-300.4(et)-301(al.)-301.4(Positive)-309.9(and)-303.9(sustained)-304.5(effects)-311.8(of)]TJ
1.7224 -1.1988 TD
[(highly)-301.3(active)-305.9(antiretrovi)-12.8(ral)-297.8(therapy)-308.1(on)-303.1(HIV-1-associated)-311.8(neurocogn)-12.2(itive)]TJ
T*
[(impairment.)-306.5(AIDS)-305.9(1999;13\(14\):1889Ö1)-17.7(897;)-298.9(doi:)-307.2(10.1097/00002)-13.7(030-)]TJ
0 -1.2064 TD
(199910010-00011)Tj
-1.7224 -1.1988 TD
[(32.)-505.4(Spudich)-275.3(S,)-277.6(Gisslen)-279.8(M,)-275.7(Hagberg)-280.5(L,)-275.9(et)-270.6(al.)-278.7(Central)-279.1(nervous)-274.2(sy)-9.6(stem)-271.8(immune)]TJ
1.7224 -1.1988 TD
[(activation)-306.7(characteri)-13.6(zes)-301.8(primary)-305.7(human)-305.7(immunodeìciency)-311.8(virus)-302.7(1)]TJ
T*
[(infection)-305.4(even)-306(in)-296.4(particip)-12.1(ants)-300.7(with)-300.1(mini)-8.4(mal)-302.8(cerebrospinal)-308.8(îuid)-302.9(viral)]TJ
T*
[(burden.)-307.5(J)-296.1(Infect)-307.1(Dis)-305.8(2011;204\(5\):753Ö76)-17.7(0;)-294.6(doi:)-307.2(10.1093/infdis/jir)-17.3(387)]TJ
-1.7224 -1.1988 TD
[(33.)-505.4(Letendre)-303.1(S.)-308(Validation)-302.8(of)-306.1(the)-302.9(CNS)-301.3(penetration-effect)-15.8(iveness)-303.8(rank)-303.6(for)]TJ
1.7224 -1.2064 TD
[(quantifying)-306.8(antiretrovi)-12.8(ral)-297.8(penetra)-10.5(tion)-298.4(into)-306(the)-302.9(central)-305.5(nervous)]TJ
0 -1.1988 TD
[(system.)-304.5(Arch)-305.8(Neurol)-306.8(2008;65Ö70\(1\):6)-15(5;)-302.2(doi:)-299.6(10.1001/a)-13.2(rchneurol.2007.31)]TJ
-1.7224 -1.1988 TD
[(34.)-505.4(Woods)-304.8(SP,)-300.5(Moore)-306.3(DJ,)-308.1(Weber)-300.5(E,)-300.4(et)-301(al.)-309(Cognitive)-303.5(neuropsych)-14.1(ology)-301.9(of)]TJ
1.7224 -1.1988 TD
[(HIV-associated)-311.9(neurocogniti)-13.8(ve)-295.7(disorders.)-315.2(Neuropsychol)-308.6(Rev)-303.5(2009;19\(2\):)]TJ
T*
[(152Ö168;)-302.4(doi:)-307.2(10.1007/s1106)-14.8(5-009-9102-5)]TJ
-1.7224 -1.1988 TD
[(35.)-505.4(Kaul)-304.2(M,)-298.5(Garden)-308.9(GA,)-299.2(Lipton)-308(SA.)-303.4(Pathways)-309.3(to)-297.9(neuro)-10(nal)-295.5(in)-8.1(jury)-304.2(and)-296.3(apo-)]TJ
1.7224 -1.1988 TD
[(ptosis)-302.8(in)-304(HIV-associated)-311.9(dementia.)-310.4(Nature)-306.1(2001;410\(6831\):988Ö)-16.1(994;)]TJ
0 -1.2064 TD
[(doi:)-299.6(10.1038)-13.3(/35073667)]TJ
-1.7224 -1.1988 TD
[(36.)-505.4(Honeycutt)-305.7(JB,)-309.3(Wahl)-302.3(A,)-299.2(Baker)-307.8(C,)-300.9(et)-301(al.)-301.4(Macrop)-11.1(hages)-299.1(sustain)-304.2(HIV)-304(repli)-9.4(ca-)]TJ
1.7224 -1.1988 TD
[(tion)-298.4(in)-304(vivo)-305.5(independently)-306.5(of)-306.1(T)-300.1(cells.)-302.1(J)-303.7(Clin)-299.7(Invest)-307.7(2016;126\(4\):1353Ö)]TJ
T*
[(1366;)-304.9(doi:)-299.6(10.1)-10.6(172/jci84456)]TJ
-1.7224 -1.1988 TD
[(37.)-505.4(Fischer-Smith)-313(SCAT.)-304.7(CNS)-301.3(invasion)-307.5(by)-297.8(CD)-8.8(14)]TJ
/F8 1 Tf
5.6038 0 0 4.9805 213.959 138.6708 Tm
(+)Tj
/F7 1 Tf
7.4718 0 0 7.4718 217.9275 135.3826 Tm
[(/CD)-9.6(16)]TJ
/F8 1 Tf
5.6038 0 0 4.9805 238.2235 138.6708 Tm
(+)Tj
/F7 1 Tf
7.4718 0 0 7.4718 244.4598 135.3826 Tm
[(peripheral)-310.8(blood-)]TJ
-22.1936 -1.1988 TD
[(derived)-306(monocytes)-310.3(in)-296.4(HIV)-304(dementia:)-310.4(Perivascular)-305.3(accumu)-12.7(lation)-303.7(and)]TJ
0 -1.2064 TD
[(reservoir)-305.3(of)-306.1(HIV)-296.4(in)-8.1(fection.)-305.1(J)-303.7(Neurovirol)-306.5(2001;7\(6\):528Ö5)-15(41;)-300.5(doi:)]TJ
0 -1.1988 TD
[(10.1080/13550)-13.7(2801753248114)]TJ
-1.7224 -1.1988 TD
[(38.)-505.4(Bagasra)-304.1(O,)-299.7(La)-9(vi)-293.6(E,)-308(Bobroski)-308.7(L,)-298.6(et)-301(al.)-301.4(Cellular)-305.9(reservo)-14(irs)-298.4(of)-306.2(HIV-1)-303.9(in)-296.4(the)]TJ
1.7224 -1.1988 TD
[(central)-214.4(nervous)-213.5(system)-213.1(of)-207.5(infected)-216.3(individuals.)-211.1(AIDS)-214.8(1996;10\(6\):573Ö)-15(586;)]TJ
T*
[(doi:)-299.6(10.1097)-13.3(/00002030-199606000-00)-18.6(002)]TJ
-1.7224 -1.1988 TD
[(39.)-505.4(Minagar)-303(A,)-299.2(Shaps)-11.8(hak)-299.3(P,)-303.9(Fujimura)-305.4(R,)-303.9(et)-301(al.)-301.4(The)-302.8(role)-304.9(of)-298.6(macrophage/)]TJ
1.7224 -1.1988 TD
[(microglia)-304.7(and)-303.9(astrocytes)-308.5(in)-304(the)-302.9(pathogenesis)-309.1(of)-298.6(thr)-10.4(ee)-297.5(neurologic)]TJ
33.5976 85.2005 TD
[(disorders:)-315.2(HIV-associated)-311.9(dementia,)-302.8(Alzhei)-8.5(mer)-302.6(disease,)-301.7(and)-303.9(multiple)]TJ
0 -1.2064 TD
[(sclerosis.)-310.8(J)-303.7(Neurol)-306.8(Sci)-299.4(2002;202)-11.7(\(1Ö2\):13Ö23;)-303(doi:)-307.2(10.1016/s0022)-14.8(-)]TJ
0 -1.1988 TD
[(510x\(02\))-11.4(00207-1)]TJ
-1.7224 -1.1988 TD
[(40.)-505.4(Emory)-306.2(JF,)-303(Seserko)-305.7(LA,)-309.2(Marzinke)-303.2(MA.)-301.5(Developm)-9.8(ent)-302.9(and)-296.3(bioana)-11(lytical)]TJ
1.7224 -1.1988 TD
[(valida)-9(tion)-298.4(of)-306.1(a)-294.9(liqu)-9.7(id)-301.6(chromatographic-tandem)-317.8(mass)-303.3(spectrometri)-16.4(c)]TJ
T*
[(\(LC-MS/MS\))-310.3(method)-309.3(for)-302.8(the)-302.9(quantiìcation)-310.4(of)-298.6(the)-302.9(CCR5)-303.8(antago)-11.5(nist)]TJ
T*
[(maraviro)-11.2(c)-296.6(i)0(n)-304(human)-305.7(plasma.)-301.2(Clin)-307.3(Chim)-302.7(Acta)-302.9(2014;431)-11.7(:198Ö205;)]TJ
0 -1.2064 TD
[(doi:)-307.2(10.1016/j.cca.2014.)-20.3(02.008)]TJ
-1.7224 -1.1988 TD
[(41.)-505.4(Ipp)-285.9(H,)-281(Zemlin)-284.3(A.)-284(The)-280(para)-9.4(dox)-282.8(of)-283.4(the)-280.1(immune)-283.1(respon)-11.3(se)-281.1(in)-281.3(HIV)-281.2(infection:)]TJ
1.7224 -1.1988 TD
[(When)-307.3(inîammation)-303.9(becomes)-311.8(harmful.)-304.3(Clin)-307.3(Chim)-302.8(Acta)-302.9(2013;416:96Ö9)-15.5(9;)]TJ
T*
[(doi:)-307.2(10.1016/j.cca.2012.)-20.3(11.025)]TJ
-1.7224 -1.1988 TD
[(42.)-505.4(Ponch)-9.9(el)-295.3(F,)-302.8(Cuthbert)-313.3(RJ,)-296.5(Goe)]TJ
13.0506 .0076 TD
(®)Tj
.3946 -.0076 TD
[(b)-303(V)0(.)-298.1(IL-7)-304.5(and)-303.9(lymphopenia.)-305.5(Clin)-307.3(Chim)-302.8(Acta)]TJ
-11.7227 -1.1988 TD
[(2011;412)-11.7(\(1Ö2\):7Ö16;)-304.6(doi:)-307.2(10.1016/j.cca.2)-17.3(010.09.002)]TJ
-1.7224 -1.1988 TD
[(43.)-505.4(Wallet)-304.1(C,)-308.4(De)-300.8(Rovere)-298.7(M,)-306.1(Van)-298.7(Assc)-10.4(he)-298.6(J,)-304(et)-301(al.)-301.4(Microglial)-304(cells:)-309.7(The)-302.8(main)]TJ
1.7224 -1.2064 TD
[(HIV-1)-303.9(reservoir)-312.9(in)-296.4(the)-302.9(brain.)-307.1(Front)-303.1(Cell)-306.2(Infect)-299.5(Mic)-9.2(robiol)-300(2019;9:3)-13.6(62;)]TJ
0 -1.1988 TD
[(doi:)-307.2(10.3389/fcimb.20)-16.6(19.00362)]TJ
-1.7224 -1.1988 TD
[(44.)-505.4(Gong)-305(Y,)-303.9(Zhi)-298.4(K,)-301.5(Nagesh)-310.8(PKB,)-299.4(et)-301(al.)-301.4(An)-300.8(elvite)-9.7(gravir)-303(nanoformulation)]TJ
1.7224 -1.1988 TD
[(crosses)-313.2(the)-295.3(bloodÖbr)-12.8(ain)-303.1(barrier)-306.7(and)-296.3(suppresses)-311.9(HIV-1)-303.9(replicati)-12(on)]TJ
T*
[(in)-304(microglia.)-305(Viruse)-10.5(s)-295.5(2020;12)-13.3(\(5\):564;)-304.7(doi:)-299.6(10.3)-10.6(390/v12050564)]TJ
-1.7224 -1.1988 TD
[(45.)-505.4(Clifford)-309.2(DB,)-305.6(Ances)-301.9(BM.)-303.8(HIV-associated)-311.9(neurocogn)-12.2(itive)-297.3(diso)-10.6(rder.)]TJ
1.7224 -1.2064 TD
[(Lancet)-305(Infect)-307.1(Dis)-305.8(2013;13\(11\):976Ö986)-16.1(;)-296.2(doi:)-307.2(10.1016/s1473)-14.9(-)]TJ
0 -1.1988 TD
[(3099\(13\)7026)-13.6(9-x)]TJ
-1.7224 -1.1988 TD
[(46.)-505.4(McCutch)-12.2(an)-296.8(JA,)-307(Marquie-Beck)-308.9(JA,)-299.4(FitzSi)-10.3(mons)-304.3(CA,)-303.9(et)-301(al.)-301.4(Role)-300.8(of)-306.1(obesity,)]TJ
1.7224 -1.1988 TD
[(metabo)-10.5(lic)-301.4(variables,)-302.3(an)-8.5(d)-295.4(diabete)-10.1(s)-295.5(i)0(n)-304(HIV-associated)-311.9(neurocogn)-12.2(itive)]TJ
T*
[(disorder.)-308(Neurol)-10.9(ogy)-298(2012;78\()-13.1(7\):485Ö492;)-308.4(doi:)-299.6(10.1212/W)-13.4(NL)]TJ
T*
[(.0b013e31)-13.6(82478d64)]TJ
-1.7224 -1.2064 TD
[(47.)-505.4(Nighti)-9.5(ngale)-298.2(S,)-300.4(Winst)-11.2(on)-295.5(A,)-306.8(Letendre)-303.1(S,)-308(et)-301(al.)-301.4(Controversies)-309.1(in)-304(HIV-)]TJ
1.7224 -1.1988 TD
[(associated)-309.9(neurocogn)-12.2(itive)-304.8(disorders.)-307.6(Lancet)-305(Neurol)-306.8(2014;13\(11\):)]TJ
T*
[(1139Ö)-9.5(1151;)-304.9(doi:)-299.6(10.1016/s1474)-14.8(-4422\(14\)70137)-13.5(-1)]TJ
-1.7224 -1.1988 TD
[(48.)-505.4(Kraft-Ter)-13.4(ry)-302.6(SD,)-296.9(Buch)-309.1(SJ,)-300.6(Fox)-305.1(HS,)-300.4(et)-301(al.)-301.4(A)-306.5(coat)-305.2(of)-298.6(many)-300.9(colors:)-310(Neuroim-)]TJ
1.7224 -1.1988 TD
[(mune)-305.6(crosstalk)-309.7(in)-304(human)-298.1(imm)-9.5(unodeìciency)-309.8(virus)-302.7(infection.)-305.7(Neuron)]TJ
T*
[(2009;64\(1\):13)-15.8(3Ö145;)-305.7(doi:)-299.6(10.1016/j.ne)-13.4(uron.2009.09.)-15.5(042)]TJ
-1.7224 -1.1988 TD
[(49.)-505.4(Gonza)]TJ
3.991 .0303 TD
(¥)Tj
.3794 -.0303 TD
[(lez-Sca)-10.3(rano)-298.8(F,)-302.8(Martö)]TJ
7.9517 .0152 TD
(¥)Tj
.2656 -.0152 TD
(n-Garcö)Tj
2.7163 .0152 TD
(¥)Tj
.2656 -.0152 TD
[(a)-294.9(J)0(.)-304(The)-302.8(neuropatho)-12.4(genesis)-299.1(of)-306.2(AIDS.)]TJ
-13.8473 -1.2064 TD
[(Nat)-303.3(Rev)-303.5(Immunol)-309(2005;5\(1\):69Ö81;)-311.2(doi:)-307.2(10.1038/nri1527)]TJ
-1.7224 -1.1988 TD
[(50.)-505.4(William)-9.6(s)-242.4(KC,)-245.5(Corey)-252.7(S,)-247.3(Westmorela)-13.6(nd)-244.2(SV,)-249.2(et)-240.3(al.)-248.3(Perivascula)-12.7(r)-239.5(m)0(a)-8.3(crophages)]TJ
1.7224 -1.1988 TD
[(are)-307.6(the)-295.3(pri)-10(mary)-303.3(cell)-302.2(type)-302.9(productively)-314.3(infected)-299.8(by)-305.4(simian)-302.9(immunodeì-)]TJ
T*
[(ciency)-270.7(virus)-264.8(in)-266.1(the)-264.9(brains)-268.5(of)-260.6(ma)-8.3(caques.)-270.7(J)-258.2(Exp)-266.5(Med)-268.1(2001;193\(8\):905Ö91)-17.7(6;)]TJ
T*
[(doi:)-307.2(10.1084/jem.193)-15.9(.8.905)]TJ
-1.7224 -1.1988 TD
[(51.)-505.4(Aksenov)-308(MY,)-306.2(Aksenova)-307(MV,)-300.4(Mactutus)-309.1(CF,)-299.9(et)-301(al.)-301.4(D1/NM)-9.8(DA)-303.1(receptors)]TJ
1.7224 -1.2064 TD
[(and)-303.9(concurrent)-310.2(methamph)-10.7(etamine)]TJ
/F8 1 Tf
14.9778 0 TD
(+)Tj
/F7 1 Tf
.7208 0 TD
[(HIV-1)-303.9(Tat)-303.4(neuroto)-12(xicity.)]TJ
-15.6986 -1.1988 TD
[(J)-303.7(Neuroimmune)-310.5(Pharmacol)-306.6(2012;7\(3\):)-13.1(599Ö608;)-302.4(doi:)-307.2(10.1007/s11481-)]TJ
T*
(012-9362-3)Tj
-1.7224 -1.1988 TD
[(52.)-505.4(Congote)-297.3(LF.)-297.7(Monitoring)-297.6(in)-8.1(sulin-like)-294.4(growth)-297.8(factors)-298.8(in)-296.4(HIV)-296.4(infection)-297.8(and)]TJ
1.7224 -1.1988 TD
[(AIDS.)-306.2(Clin)-299.7(Chim)-310.3(Acta)-302.9(2005;361\(1Ö2\):30Ö53;)-314.7(doi:)-307.2(10.1016/j.cccn.2005)]TJ
T*
(.05.001)Tj
-1.7224 -1.1988 TD
[(53.)-505.4(Longordo)-306.7(F,)-302.8(Feligioni)-307(M,)-306.1(Chiaramonte)-309.8(G,)-296.2(et)-308.6(al.)-301.4(The)-302.8(human)-298.1(immunode-)]TJ
1.7224 -1.2064 TD
[(ìciency)-312.2(virus-1)-302.6(protein)-303(transact)-13(ivator)-306.5(of)-298.6(transcri)-12.6(ption)-297.9(up-r)-10.6(egulates)]TJ
0 -1.1988 TD
(N-methyl-)Tj
5.3796 0 0 5.3796 360.8503 278.8157 Tm
(D)Tj
7.4718 0 0 7.4718 364.3653 278.8157 Tm
[(-aspartate)-307.2(receptor)-308.2(function)-311.3(by)-297.8(acti)-10.2(ng)-299.7(at)-299.2(metabotropi)-15(c)]TJ
-4.6436 -1.1988 TD
[(glutamate)-310.8(receptor)-308.2(1)-301.9(receptors)-307.8(coexisting)-304.9(on)-303.1(hum)-8.9(an)-296.8(and)-303.9(rat)-303.5(brain)]TJ
T*
[(norad)-10(renergic)-301.6(neurones.)-300.9(J)-303.7(Pharmacol)-306.6(Exp)-296.9(Ther)-299.5(2006;317)-11.7(\(3\):1097Ö1105;)]TJ
T*
[(doi:)-307.2(10.1124/jpet.105.)-18.3(099630)]TJ
-1.7224 -1.1988 TD
[(54.)-505.4(Neri)-303.7(E,)-300.4(Musant)-12.4(e)-296.7(V)0(,)-298.1(Pittalug)-12.2(a)-302.5(A)0(.)-299.2(Effects)-307.7(of)-298.6(the)-302.9(HIV-1)-303.9(Viral)-306(Protein)]TJ
1.7224 -1.2064 TD
[(Tat)-303.4(on)-303.1(Central)-309.5(Neurotransmission:)-315.2(Role)-300.8(of)-306.1(Group)-302.7(1)-301.9(Metabotropic)]TJ
0 -1.1988 TD
[(Glutamat)-12.2(e)-296.7(Recep)-9.5(tors.)-302(In:)-304.3(Neuroinîammat)-14.4(ion)-301.8(in)-296.4(Neuronal)-307.7(Death)]TJ
T*
[(and)-266(Repair.)-260.6(\(Baget)-11.1(ta)-261.3(G,)-258.2(Corasaniti)-265.7(MT,)-264.8(Lipton)-270(SA.)-257.9(eds.\))-265.4(Elsevier:)-264.2(Calabri)-11.4(a,)]TJ
T*
[(Italy;)-306.8(2007;)-304.9(pp.)-302.8(339Ö356.)]TJ
-1.7224 -1.1988 TD
[(55.)-505.4(Jain)-303.3(KK.)-306.8(Evaluation)-303.7(of)-306.1(memantine)-306.5(for)-302.8(neuroprotection)-315.7(in)-296.4(dem)-9.5(entia.)]TJ
1.7224 -1.1988 TD
[(Expert)-306.2(Opin)-307(Investig)-300.6(Drugs)-311.1(2005;9\(6\):1397Ö1406)-16.1(;)-296.2(doi:)-307.2(10.1517/)]TJ
T*
[(1354378)-11.4(4.9.6.1397)]TJ
-1.7224 -1.2064 TD
[(56.)-505.4(Lipton)-308(SA.)-303.4(Neuronal)-307.7(injury)-304.7(associated)-309.9(with)-300.1(HIV-1)-303.9(and)-303.9(potential)-308.3(treat-)]TJ
1.7224 -1.1988 TD
[(ment)-304.5(with)-300.1(calcium)-12.2(-channel)-302.3(and)-303.9(NMDA)-301.9(antagonis)-11.6(ts.)-300(Dev)-299.9(Neuros)-11.8(ci)]TJ
T*
[(1994;16\(3Ö)-12.2(4\):145Ö151;)-308.4(doi:)-307.2(10.1159/000112101)]TJ
-1.7224 -1.1988 TD
[(57.)-505.4(Sonti)-287.5(S,)-277.6(Sharma)-283.2(AL,)-278.9(Tyagi)-279.4(M.)-283.3(HIV-1)-281.1(persistence)-291.5(in)-273.7(the)-280.1(CNS:)-286.4(Mechanisms)]TJ
1.7224 -1.1988 TD
[(of)-306.1(latency,)-303.9(pathogenesis)-309.1(and)-303.9(an)-304.4(update)-304.3(on)-303.1(eradication)-308(strategies.)]TJ
T*
[(Virus)-305.6(Res)-304(2021;303:198)-14.7(523;)-298.9(doi:)-307.2(10.1016/j.virusres.2)-20.8(021.198523)]TJ
-1.7224 -1.2064 TD
[(58.)-505.4(Lopardo)-311.3(GD,)-300.3(Bissio)-310.5(E,)-300.4(Iannella)-302.1(MC,)-303.2(et)-301(al.)-301.4(Good)-306(neuro)-10(cognitive)-307.1(perfor-)]TJ
1.7224 -1.1988 TD
[(mance)-269.6(measured)-268.9(by)-259.9(the)-264.9(international)-269(HIV)-266(dementia)-264.5(scale)-264.2(in)-258.5(early)-270.7(HIV-1)]TJ
T*
[(infection.)-313.3(J)-296.1(Acquir)-307.3(Immune)-305.9(Deìc)-305.1(Syndr)-300.6(200)-10.3(9;52\(4\):488Ö492;)-311.2(doi:)]TJ
T*
[(10.1097/QA)-13.1(I.0b013e3181b0)-14.5(6348)]TJ
-1.7224 -1.1988 TD
[(59.)-505.4(Cysique)-306.8(LAJ,)-309.5(Maruff)-301.5(P,)-303.9(Brew)-305.7(BJ.)-301.7(Variable)-305.3(beneìt)-306.7(in)-296.4(neuro)-10(psychological)]TJ
1.7224 -1.1988 TD
[(function)-311.3(in)-296.4(HIV-in)-10.1(fected)-299.3(HAART)-10.3(-treated)-302.7(patients.)-311.7(Neurology)-308.9(2006;)]TJ
T*
[(66\(9\):144)-12.8(7Ö1450;)-304.1(doi:)-299.6(10.1)-10.6(212/01.wnl.000021047)-16.6(7.63851.d3)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(14)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
132 0 obj
<</Length 20939>>stream
/GS1 gs
BT
/F7 1 Tf
7.4718 0 0 7.4718 63.496 700.2707 Tm
0 0 0 rg
0 Tc
0 Tw
[(60.)-505.4(Chatter)-11.6(ji)-298.3(T,)-300.4(Singh)-304.5(S,)-300.4(Sen)-302.8(M,)-306.1(et)-301(al.)-301.4(Proton)-302(NMR)-302.5(metabo)-10.5(lic)-301.4(proìling)]TJ
1.7224 -1.2064 TD
[(of)-306.1(CSF)-303.8(reveals)-298(distinct)-311(differentiation)-316.1(of)-298.6(meningitis)-303.8(fr)-9.2(om)-295.3(negative)]TJ
0 -1.1988 TD
[(controls.)-308.6(Clin)-307.3(Chim)-302.8(Acta)-302.9(2017;469:42Ö5)-15.5(2;)-302.2(doi:)-299.6(10.1016/j.cca.2)-17.3(017)]TJ
T*
(.03.015)Tj
-1.7224 -1.1988 TD
[(61.)-505.4(Gupta)-273.6(S,)-270(Knight)-271.9(AG,)-276.4(Losso)-270.2(BY,)-271.3(et)-270.6(al.)-271.1(Brain)-267.1(inju)-9.7(ry)-264.7(caused)-278(by)-267.5(HIV)-273.6(protease)]TJ
1.7224 -1.1988 TD
[(inhibitors)-12.6(:)-296.2(Role)-300.8(of)-306.1(lipodystrophy)-309.6(an)-8.5(d)-295.4(insulin)-308.1(resistance.)-305.7(Ant)-9.2(iviral)-301.7(Res)]TJ
T*
[(2012;95\(1\):19)-15.8(Ö29;)-301.3(doi:)-299.6(10.1)-10.6(016/j.antiviral.2012.0)-18.7(4.010)]TJ
-1.7224 -1.2064 TD
[(62.)-505.4(Martinez-)-10.6(Arroyo)-305.4(O,)-299.7(Gruevska)-306.3(A,)-306.8(Victor)-303.4(VM,)-300.4(et)-301(al.)-309(Mitophagy)-303.6(in)-304(human)]TJ
1.7224 -1.1988 TD
[(astrocytes)-308.5(treated)-308.8(with)-307.7(the)-295.3(an)-8.5(tiretroviral)-309.8(drug)-299.3(Efavire)-10.9(nz:)-296(Lac)-9.7(k)-298.3(o)0(f)]TJ
T*
[(evidence)-305.6(or)-305.5(evidence)-305.6(of)-298.6(the)-302.9(lack.)-304.6(Antiviral)-310.9(Res)-296.4(2019;16)-13.3(8:36Ö50;)]TJ
T*
[(doi:)-307.2(10.1016/j.antiviral.20)-18.7(19.04.015)]TJ
-1.7224 -1.1988 TD
[(63.)-505.4(Pistell)-304.2(PJ,)-304.1(Gupta)-304(S,)-308(Knight)-302.3(AG,)-299.2(et)-308.6(al.)-301.4(Metabolic)-305.1(and)-303.9(neurologic)-303.5(conse-)]TJ
1.7224 -1.1988 TD
[(quences)-304.5(of)-306.1(chronic)-309.3(lopinavir/ritonavir)-309.5(administra)-14.1(tion)-298.4(to)-305.5(C57BL/6)-304.3(mice)-9.3(.)]TJ
T*
[(Antiviral)-310.9(Res)-296.4(2010;88\()-13.1(3\):334Ö342;)-308.4(doi:)-299.6(10.1016/j.ant)-15.9(iviral.2010.10.00)-16.5(6)]TJ
-1.7224 -1.2064 TD
[(64.)-505.4(Chu)-307.8(L,)-298.6(Wu)-300.5(Y,)-303.9(Duan)-306.3(C,)-300.9(et)-301(al.)-301.4(Simultaneo)-12.2(us)-300.8(quantitation)-310.4(of)-298.6(zidovudi)-11.4(ne,)]TJ
1.7224 -1.1988 TD
[(efavirenz,)-311.1(lopinavir)-300.9(and)-303.9(ritonavi)-11.1(r)-300.2(i)0(n)-296.4(hum)-8.9(an)-296.8(hair)-307.3(by)-297.8(liquid)]TJ
T*
[(chromatogr)-13.5(aphy-atmospheric)-315.9(pressure)-302.4(chemic)-11.9(al)-301.2(ionization-tandem)]TJ
T*
[(mass)-303.3(spectrometry.)-316.4(J)-303.7(Chromatogr)-305.8(B)-301.2(Analyt)-305.2(Techn)-9.5(ol)-299.9(Biomed)-307.1(Life)-302.7(Sci)]TJ
T*
[(2018;109)-11.7(7Ö1098:54Ö63;)-306.2(doi:)-307.2(10.1016/j.jchromb.)-20.5(2018.08.031)]TJ
-1.7224 -1.1988 TD
[(65.)-505.4(Wu)-224.6(Y,)-228(Yang)-223(J,)-228.1(Duan)-230.4(C,)-225(et)-225.1(al.)-225.6(Simultaneo)-12.2(us)-224.9(determination)-233.4(of)-222.7(antiretrov)-14.2(iral)]TJ
1.7224 -1.2064 TD
[(drugs)-306.5(in)-304(human)-298.1(hair)-307.3(with)-300.1(liquid)-303.7(chromato)-14.9(graphy-electrospray)]TJ
0 -1.1988 TD
[(ionization)-11.6(-tandem)-304.6(mass)-303.3(spectrometry.)-316.4(J)-296.1(Chromatog)-13.2(r)-300.2(B)-301.2(Analyt)-305.2(Technol)]TJ
T*
[(Biomed)-284.3(Life)-287.5(Sci)-276.7(2018;108)-11.7(3:209Ö221;)-285.9(doi:)-284.5(10.1016/j.jchromb)-20.2(.2018.03.021)]TJ
-1.7224 -1.1988 TD
[(66.)-505.4(Mucke)-307.4(L,)-298.6(Selkoe)-308.1(DJ.)-300.5(Neurotoxicity)-312.1(of)-306.1(amyloid-protein:)-310(Synapt)-11.3(ic)-302.8(and)]TJ
1.7224 -1.1988 TD
[(network)-306.7(dysfunctio)-14.9(n.)-298.1(Cold)-304(Spring)-306.3(Harb)-306.2(Perspect)-305.9(Med)-298.5(201)-10.3(2;2\(7\):)]TJ
T*
[(a006338;)-308.3(doi:)-307.2(10.1101/cshperspect)-18.1(.a006338)]TJ
-1.7224 -1.2064 TD
[(67.)-505.4(Gaoni)-308.3(Y,)-296.3(Mechoulam)-311.5(R.)-303.9(Isolation,)-307.5(structure,)-309.8(and)-303.9(partial)-306.9(synthesis)-304.6(of)-306.1(an)]TJ
1.7224 -1.1988 TD
[(active)-305.9(constituent)-307.7(of)-306.1(hashish.)-306.3(J)-303.7(A)0(m)-300.6(Chem)-304.9(Soc)-298.5(1964;86\()-13.1(8\):1646Ö1647;)]TJ
T*
[(doi:)-307.2(10.1021/ja01062a)-15.5(046)]TJ
-1.7224 -1.1988 TD
[(68.)-505.4(Shao)-245.7(ZH,)-237.4(Yin)-243.5(J,)-243.3(Chapman)-242.9(K,)-240.8(et)-240.3(al.)-240.7(High-resol)-12.5(ution)-243.1(crystal)-244.1(structure)-248.8(of)-245.4(the)]TJ
1.7224 -1.1988 TD
[(human)-305.7(CB1)-304.3(cannabinoid)-309.5(receptor.)-308.5(Nature)-306.1(2016;540\(7634\):60)-16.9(2Ö606;)]TJ
T*
[(doi:)-307.2(10.1038/nature20613)]TJ
-1.7224 -1.1988 TD
[(69.)-505.4(Hua)-307.8(T,)-300.4(Vemuri)-300.9(K,)-301.5(Pu)-308.9(MC,)-303.2(et)-301(al.)-301.4(Crystal)-308.8(Structure)-306.5(of)-306.1(the)-302.9(Human)-303.8(Canna-)]TJ
1.7224 -1.2064 TD
[(binoid)-307(Receptor)-304.1(CB1.)-304.6(Cell)-306.2(2016;167\(3\):750.e1)-19.6(4Ö762.e14;)-303.5(doi:)-307.2(10.1016/)]TJ
0 -1.1988 TD
[(j.cell.2016.10)-16.4(.004)]TJ
-1.7224 -1.1988 TD
[(70.)-505.4(Zou)-300.9(SL,)-302.8(Kuma)-11.3(r)-300.2(U)0(.)-303.7(Cannabinoid)-305.9(receptors)-307.8(and)-303.9(the)-302.9(endocannabinoi)-14(d)]TJ
1.7224 -1.1988 TD
[(system:)-296.9(Signali)-10.5(ng)-292.1(and)-288.7(function)-303.7(in)-288.9(the)-295.3(central)-297.9(nervous)-296.9(system.)-296.9(Int)-293.1(J)-288.5(Mol)]TJ
T*
[(Sci)-307(2018;19\(3\):833;)-310.4(doi:)-307.2(10.3390/ijms19030833)]TJ
-1.7224 -1.1988 TD
[(71.)-505.4(Pandey)-307.3(R,)-303.9(Mousawy)-301.7(K,)-301.5(Nagark)-10.8(atti)-302.1(M,)-298.5(et)-301(al.)-309(Endocannabinoids)-312.4(and)-303.9(im-)]TJ
1.7224 -1.2064 TD
[(mune)-305.6(regulation.)-308.7(Pharmacol)-306.6(Res)-304(2009;60\(2\):85Ö9)-15(2;)-302.2(doi:)-299.6(10.1016/j.phr)-16.4(s)]TJ
0 -1.1988 TD
(.2009.03.019)Tj
-1.7224 -1.1988 TD
[(72.)-505.4(Patel)-298.8(S,)-300.4(Hillard)-302.1(CJ.)-301.1(Pharmaco)-12(logical)-298.7(evalua)-9.4(tion)-298.4(of)-298.6(cannabinoid)-301.9(receptor)]TJ
1.7224 -1.1988 TD
[(ligands)-279.9(in)-273.7(a)-272.2(mous)-11.8(e)-273.9(model)-279(of)-275.8(anxiety:)-277.8(Further)-277.8(evidence)-282.8(for)-280.1(an)-274.1(anxiolytic)]TJ
T*
[(role)-251.8(for)-249.7(endogenous)-249.9(cannab)-9.6(inoid)-246.8(signaling.)-252.8(J)-243(Pha)-8.7(rmacol)-244.8(Ex)-9(p)-242.3(Ther)-246.4(2006;)]TJ
T*
[(318\(1\):304Ö311)-14.7(;)-296.2(doi:)-307.2(10.1124/jpet.)-15.2(106.101287)]TJ
-1.7224 -1.1988 TD
[(73.)-505.4(Lo)]TJ
2.3218 .0303 TD
(¥)Tj
.4097 -.0303 TD
[(pez)-301.7(HH.)-311.3(CannabinoidÖhormo)-14.1(ne)-298.6(interactions)-307.6(in)-304(the)-302.9(regulation)-308.4(of)]TJ
-1.0091 -1.2064 TD
[(motivational)-311.6(processes.)-306.2(Horm)-307.1(Behav)-302(2010;58)-13.3(\(1\):100Ö110;)-308.2(doi:)-299.6(10.1)-10.6(016/)]TJ
0 -1.1988 TD
[(j.yhbeh)-10.6(.2009.10.005)]TJ
-1.7224 -1.1988 TD
[(74.)-505.4(Croxford)-291.1(JL.)-283.7(Therapeutic)-292.5(potential)-285.5(of)-283.4(cannabinoids)-286.3(in)-281.3(CN)-8.8(S)-277.3(disease.)-286.5(CNS)]TJ
1.7224 -1.1988 TD
[(Drugs)-303.5(2003;17\()-13.1(3\):179Ö202;)-308.4(doi:)-299.6(10.2165/0)-12.6(0023210-20031703)-15.1(0-00004)]TJ
-1.7224 -1.1988 TD
[(75.)-505.4(Okamoto)-309.8(Y,)-303.9(Morishita)-302.2(J,)-304(Tsuboi)-308.4(K,)-301.5(et)-301(al.)-301.4(Molecula)-10.7(r)-300.2(characterization)-309(of)-306.1(a)]TJ
1.7224 -1.1988 TD
[(phosphol)-11.6(ipase)-301(D)-300(generating)-311.3(anandamide)-304.5(and)-303.9(its)-298.4(cong)-9.8(eners.)-303.5(J)-296.1(Bio)-9.3(l)]TJ
0 -1.2064 TD
[(Chem)-304.9(2004;279\(7\):5298Ö5)-17.7(305;)-298.9(doi:)-307.2(10.1074/jbc.M30)-17.5(6642200)]TJ
-1.7224 -1.1988 TD
[(76.)-505.4(Alger)-304.5(BE,)-305.7(Kim)-301.5(J.)-304(Supply)-305.5(and)-296.3(dem)-9.5(and)-296.3(for)-302.8(endocann)-11(abinoids.)-305.9(Trends)]TJ
1.7224 -1.1988 TD
[(Neurosci)-307(2011;34\()-13.1(6\):304Ö315;)-308.4(doi:)-299.6(10.1016/j.t)-15(ins.2011.03.003)]TJ
-1.7224 -1.1988 TD
[(77.)-505.4(Kano)-307.5(M,)-298.5(Ohno-Shosaku)-312.6(T,)-300.4(Hashimotod)-15.1(ani)-295.5(Y,)-303.9(et)-301(al.)-301.4(Endoca)-10.6(nnabinoid-)]TJ
1.7224 -1.1988 TD
[(mediated)-307.7(control)-308.7(of)-298.6(synap)-10(tic)-299.5(transmission)-14.3(.)-296.2(Physi)-10.3(ol)-299.9(Rev)-303.5(2009;89\(1\):)]TJ
T*
[(309Ö380;)-310(doi:)-299.6(10.1152/p)-13.7(hysrev.00019.2008)]TJ
-1.7224 -1.1988 TD
[(78.)-505.4(Fezza)-305.8(F,)-302.8(Bari)-303.2(M,)-298.5(Florio)-307.1(R,)-303.9(et)-301(al.)-301.4(Endocannabinoids,)-312.7(related)-303.2(compo)-12.5(unds)]TJ
1.7224 -1.2064 TD
[(and)-303.9(their)-305.8(metabolic)-304.4(routes.)-308.1(Molecules)-307.9(2014;19\(11\):1)-15.8(7078Ö17106;)]TJ
0 -1.1988 TD
[(doi:)-307.2(10.3390/molecules1)-16.4(91117078)]TJ
-1.7224 -1.1988 TD
[(79.)-505.4(Maccarrone)-314.2(M.)-298.5(Endocannab)-13(inoids:)-299.7(Friends)-307.2(and)-303.9(foes)-306.5(of)-298.6(reproducti)-15(on.)]TJ
1.7224 -1.1988 TD
[(Prog)-307.5(Lipid)-302.2(Res)-304(2009;48\(6\):344Ö354)-17.7(;)-296.2(doi:)-307.2(10.1016/j.plipres.2)-17.8(009.07.001)]TJ
-1.7224 -1.1988 TD
[(80.)-505.4(Cravatt)-310.5(BF,)-300.5(Giang)-304.9(DK,)-305.6(Mayìeld)-302.1(SP,)-300.5(et)-301(al.)-309(Molecular)-303.3(characteri)-13.6(zation)-303(of)]TJ
1.7224 -1.1988 TD
[(an)-304.4(enzyme)-301.4(that)-305.4(degrades)-308.8(neuromodulatory)-316.5(fatty-acid)-302.6(am)-8.2(ides.)-302.3(Nature)]TJ
0 -1.2064 TD
[(1996;384)-11.7(\(6604\):83Ö87;)-306.6(doi:)-307.2(10.1038/38408)-13.7(3a0)]TJ
-1.7224 -1.1988 TD
[(81.)-505.4(Kathuria)-306.1(S,)-300.4(Gaeta)-10.7(ni)-296.4(S,)-308(Fegley)-299.5(D,)-300.3(et)-301(al.)-309(Modulation)-308.5(of)-298.6(anxiety)-307.8(through)]TJ
1.7224 -1.1988 TD
[(blockade)-309.4(of)-298.6(anand)-8.9(amide)-303.1(hydrolysis.)-308.5(Nat)-303.3(Med)-306.1(2002;9\(1\):76Ö81;)]TJ
T*
[(doi:)-307.2(10.1038/nm803)]TJ
-1.7224 -1.1988 TD
[(82.)-505.4(Freund)-306.7(TF,)-299.4(Katona)-310.8(I,)-302.4(Piomelli)-305.9(D.)-300.3(Role)-300.8(of)-298.6(endog)-9.4(enous)-301.2(cannab)-9.6(inoids)-299.5(in)]TJ
1.7224 -1.1988 TD
[(synaptic)-309.5(signaling.)-305.9(Physiol)-302.5(Re)-8.5(v)-294.9(2003;83\()-13.1(3\):1017Ö1066;)-305.2(doi:)-307.2(10.1152/)]TJ
T*
[(physrev.00004)-14.8(.2003)]TJ
31.8828 85.2005 TD
[(83.)-497.8(Iann)-9(otti)-300.8(FA,)-305.8(Di)-298.7(Marzo)-304.7(V,)-298.1(Petrosi)-13(no)-295.5(S.)-308(Endocannabinoids)-312.4(and)]TJ
1.7148 -1.2064 TD
[(end)-9.8(ocannabinoid-related)-316(mediators:)-309.2(Targets,)-302.6(metabo)-10.6(lism)-302(and)-303.9(role)-297.3(in)]TJ
0 -1.1988 TD
[(neuro)-10(logical)-306.3(disorders.)-307.6(Prog)-307.5(Lipid)-302.2(Res)-304(2016;62:107Ö128;)-316.1(doi:)-299.6(10.1016/)]TJ
T*
[(j.pl)-9.8(ipres.2016.02.002)]TJ
-1.7148 -1.1988 TD
[(84.)-497.8(Ueda)-310.4(N,)-300.3(Tsuboi)-308.4(K,)-301.5(Uyama)-305.6(T.)-300.4(N-acylethano)-12.1(lamine)-304.1(metabolism)-304.9(with)-300.1(spe-)]TJ
1.7148 -1.1988 TD
[(cial)-308.1(reference)-307.5(to)-297.9(N-acylet)-11.5(hanolamine-hydrol)-14.8(yzing)-298.7(acid)-308.9(amidase)]TJ
T*
-.0163 Tc
[(\(N)-16.3(A)6.9(A)3.5(A)-16.3(\))11.3(.)-297.3(P)-1.3(r)-16.3(o)12.1(g)-298.9(L)-16.3(i)13(p)-.6(i)-16.3(d)-287.6(Re)-16.3(s)-289.8(2010)-16.3(;)7.8(49\(4\):2)-16.3(9)9.7(9).5(Ö)-16.3(3)14.9(15)-16.3(;)-288.1(d)-.6(o)-16.3(i)10.1(:)-297.3(1).5(0)-16.3(.)7.8(1016)-16.3(/)7.2(j)2.7(.plip)-16.3(r)10.3(e)-16.3(s)13.7(.)-1.4(201)-16.3(0)9.7(.)-1.4(02)]TJ
0 -1.2064 TD
-.0149 Tc
[(.0)-14.9(0)11.1(3)]TJ
-1.7148 -1.1988 TD
0 Tc
[(85.)-497.8(Su)-9.5(giura)-297.5(T,)-308(Kishimoto)-308.9(S,)-300.4(Oka)-300.9(S,)-300.4(et)-301(al.)-309(Biochemistry,)-312.1(pharmacology)-308(and)]TJ
1.7148 -1.1988 TD
[(ph)-9(ysiology)-302.6(of)-306.1(2-arachidonoylglycer)-17.7(ol,)-300.1(an)-304.4(endogenous)-303.1(can)-9.2(nabinoid)-300.3(re-)]TJ
T*
[(ce)-9(ptor)-301.7(ligand.)-303.4(Prog)-307.5(Lipid)-302.2(Res)-304(2006;45\(5\):405Ö)-15(446;)-298.9(doi:)-307.2(10.1016/j.plip)-14.5(res)]TJ
T*
[(.200)-10.6(6.03.003)]TJ
-1.7148 -1.1988 TD
[(86.)-497.8(Everar)-11.6(d)-295.4(A)0(,)-306.8(Plovier)-302.7(H,)-303.7(Rastelli)-303.2(M,)-306.1(et)-301(al.)-301.4(Intestinal)-303.6(epithel)-12.1(ial)]TJ
1.7148 -1.1988 TD
[(N-acylp)-13.5(hosphatidylethanol)-15(amine)-297.9(phospho)-13(lipase)-299.6(D)-300(links)-304.7(dietary)-304.8(fat)-304.1(to)]TJ
0 -1.2064 TD
[(metabo)-10.5(lic)-301.4(adaptations)-313.5(in)-296.4(obesity)-306.4(and)-303.9(steatosis.)-307.2(Nat)-303.3(Commu)-11(n)-297.8(2019;)]TJ
0 -1.1988 TD
[(10\(1)-10(\):457;)-299(doi:)-307.2(10.1038/s4146)-14.8(7-018-08051-7)]TJ
-1.7148 -1.1988 TD
[(87.)-497.8(Cas)-10.8(tillo)-301.4(Pablo)-306.1(E,)-300.4(Younts)-304.8(Thomas)-307.6(J,)-304(Cha)]TJ
17.5196 .0303 TD
(¥)Tj
.387 -.0303 TD
[(vez)-301.2(Andre)]TJ
3.8545 .0303 TD
(¥)Tj
.4021 -.0303 TD
[(s)-295.5(E)0(,)-308(e)0(t)-301(al.)-301.4(Endocanna-)]TJ
-20.4484 -1.1988 TD
[(binoid)-307(signaling)-305.6(and)-303.9(synaptic)-309.5(function.)-304(Neuro)-12.2(n)-297.8(2012;76\(1\):70Ö8)-15(1;)]TJ
T*
[(doi:)-307.2(10.1016/j.ne)-13.4(uron.2012.09.020)]TJ
-1.7148 -1.1988 TD
[(88.)-497.8(La)-9(prairie)-301(RB,)-301.7(Baghe)-8.9(r)-300.2(AM,)-301.5(Kelly)-301.7(MEM,)-305(et)-301(al.)-301.4(Cannabid)-11.7(iol)-298.5(is)-301.7(a)-302.5(negative)-302.3(al-)]TJ
1.7148 -1.2064 TD
[(loster)-12.8(ic)-295.2(modu)-11.8(lator)-299.9(of)-306.1(the)-302.9(cannabinoid)-301.9(CB)-10(1)-294.3(receptor.)-316.1(Br)-297.9(J)-303.7(Pharmacol)]TJ
0 -1.1988 TD
[(201)-10.3(5;172\(20\):4790Ö4805)-16.1(;)-296.2(doi:)-307.2(10.1111/bph.1325)-16.5(0)]TJ
-1.7148 -1.1988 TD
[(89.)-497.8(Mecho)-11(ulam)-201.9(R,)-212.9(Parker)-208.2(LA.)-203(The)-211.8(Endocannabinoid)-214.2(System)-210.2(and)-205.3(the)-211.8(Brain.)-206.7(In:)]TJ
1.7148 -1.1988 TD
[(Annua)-11.2(l)-287(Review)-294.7(of)-291(Psy)-9.7(chology,)-297.2(Vol.)-294.5(64.)-293(\(Fiske)-296.1(ST.)-289.4(ed.\))-296.2(Annual)-298.1(Reviewers:)]TJ
T*
[(Cal)-9.9(ifornia;)-301.3(2013;)-304.9(pp.)-302.8(21Ö47)-9.5(.)]TJ
-1.7148 -1.1988 TD
[(90.)-497.8(P)15(e)0(r)25.3(t)18.5(w)15.8(e)0(e)-274.7(R)15(G)15.2(.)-281(P)15(h)0(a)29.4(r)0(m)32(a)0(c)23.1(o)17.5(l)16.5(o)17.5(gy)-269.9(of)-275.8(c)14.5(a)16.2(n)20.9(n)0(a)29.4(b)15.7(in)29.8(oi)26.4(d)-280.2(C)0(B)28(1)-286.7(a)16.2(n)0(d)-274.5(C)18.1(B)17.4(2)-286.7(re)32.9(c)14.5(e)0(p)30.1(t)0(o)28.4(r)0(s)26.5(.)-281(P)15(h)0(a)29.4(r)0(-)]TJ
1.7148 -1.2064 TD
-.0164 Tc
[(m)-16.4(a)13.3(co)-16.4(l)-285.9(T)-16.4(h)7.9(e)-16.4(r)-287(1997;7)-16.4(4)9.6(\(2\):12)-16.4(9)9.6(Ö)-16.4(1)14.8(80;)-305(doi)-16.4(:)-288.5(10)-16.4(.)7.7(1016)-16.4(/)14.7(s)-16.4(0)8.4(163-)-16.4(7)14.1(2)-16.4(5)9.6(8).4(\(97)-16.4(\))8.2(8200)-16.4(1)9.6(-)-16.4(3)]TJ
-1.7148 -1.1988 TD
0 Tc
[(91.)-497.8(Ryb)-9.7(erg)-302.9(E,)-300.4(Larsson)-308(N,)-300.3(Sjo)]TJ
11.4193 .0152 TD
(®)Tj
.4173 -.0152 TD
[(gren)-297.2(S,)-308(et)-301(al.)-301.4(The)-302.8(orphan)-300.2(receptor)-308.2(GPR55)-308.1(is)-301.7(a)]TJ
-10.1218 -1.1988 TD
[(novel)-309.2(cannabinoid)-309.5(receptor.)-308.5(Br)-297.9(J)-303.7(Pharmacol)-306.6(2007;152)-11.7(\(7\):1092Ö1101;)]TJ
T*
[(doi:)-307.2(10.1038/sj.bjp.0)-19.3(707460)]TJ
-1.7148 -1.1988 TD
[(92.)-497.8(McH)-10.5(ugh)-297.5(D,)-307.9(Page)-297.8(J,)-304(Dunn)-301.6(E,)-300.4(et)-301(al.)]TJ
/F4 1 Tf
15.8731 0 TD
(D)Tj
/F7 1 Tf
5.6038 0 0 4.9805 438.1794 434.5511 Tm
(9)Tj
7.4718 0 0 7.4718 441.014 431.2629 Tm
[(-Tetrahydrocann)-15.8(abinol)-298.9(and)]TJ
-15.2054 -1.1988 TD
[(N-arach)-10.6(idonyl)-302.3(glycine)-308.5(are)-300(full)-303.4(agonists)-306.1(at)-306.8(GPR18)-300.5(receptors)-307.8(and)-303.9(induce)]TJ
T*
[(mig)-9.8(ration)-301.7(in)-304(human)-298.1(endome)-9.9(trial)-300.8(HEC-1B)-309.9(cells.)-302.1(Br)-305.5(J)-296.1(Pha)-8.7(rmacol)-305.5(2012;)]TJ
0 -1.2064 TD
[(165)-10.3(\(8\):2414Ö2424;)-312.5(doi:)-299.6(10.1111/j.14)-15(76-5381.2011.01497.x)]TJ
-1.7148 -1.1988 TD
[(93.)-497.8(Buzn)-10.4(ikov)-301.3(GA,)-299.2(Nikitina)-311.2(LA,)-301.7(Bezuglov)-302.5(VV,)-307.6(et)-301(al.)-301.4(A)-298.9(putati)-11(ve)-295.7(èpre-nerv)-12.3(ousê)]TJ
1.7148 -1.1988 TD
[(end)-9.8(ocannabinoid)-307.2(system)-304.2(in)-304(early)-301.1(echinoderm)-311.3(development.)-308.4(Dev)]TJ
T*
[(Neuro)-12.2(sci)-302.4(2010;32\(1\):1Ö18;)-311.2(doi:)-307.2(10.1159/000235758)]TJ
-1.7148 -1.1988 TD
[(94.)-497.8(OêSul)-11.9(livan)-300.7(SE.)-304.6(An)-300.8(update)-304.3(on)-303.1(PPAR)-299.4(activation)-314.3(by)-297.8(cannab)-9.6(inoids.)-299.7(Br)-305.5(J)]TJ
1.7148 -1.1988 TD
[(Pha)-8.7(rmacol)-305.5(2016;173\(12\):1899)-16.9(Ö1910;)-305.7(doi:)-299.6(10.1111/bp)-13.2(h.13497)]TJ
-1.7148 -1.2064 TD
[(95.)-497.8(Godl)-11(ewski)-304.3(G,)-296.2(Offer)-10.8(ta)]TJ
9.9852 .0379 TD
(¥)Tj
.3794 -.0379 TD
[(ler)-307.2(L,)-298.6(Wagn)-9.7(er)-301(JA,)-299.4(et)-301(al.)-301.4(Recep)-9.5(tors)-301.8(for)]TJ
-8.6498 -1.1988 TD
[(acy)-9.7(lethanolamidesÑGPR55)-311.7(and)-303.9(GPR119)-10.5(.)-296.2(Prostagla)-12.2(ndins)-305(Other)-303.1(Lipid)]TJ
T*
[(Medi)-8.8(at)-208.2(2009;89\(3Ö)-12.2(4\):105Ö111;)-217.4(doi:)-208.6(10.1016/j.pr)-14.5(ostaglandins.2009.0)-16.9(7.001)]TJ
-1.7148 -1.1988 TD
[(96.)-497.8(Smith)-10.7(-Dijak)-229.6(AI,)-229.6(Sepers)-229.2(MD,)-226.8(Raymon)-10.5(d)-227.1(LA.)-225.8(Alterations)-232.2(in)-228.1(synap)-10(tic)-223.6(function)]TJ
1.7148 -1.1988 TD
[(an)-8.5(d)-219.5(plasticity)-233.3(in)-220.6(Huntington)-230.3(disease.)-233.4(J)-220.2(Neurochem)-229.7(2019;150)-11.7(\(4\):346Ö365;)]TJ
T*
[(doi:)-307.2(10.1111/jn)-12.3(c.14723)]TJ
-1.7148 -1.1988 TD
[(97.)-497.8(Do)-9.4(ng)-223.8(X-X,)-228.4(Wang)-222.1(Y,)-228.1(Qin)-224.1(Z-H.)-231.3(Molecular)-235(mechanisms)-233(of)-222.7(excitotox)-13.8(icity)-224.7(and)]TJ
1.7148 -1.2064 TD
[(their)-305.8(relevance)-309.4(to)-297.9(pat)-10.4(hogenesis)-306.3(of)-298.6(neurodegener)-12.4(ative)-305.2(diseases.)-301.2(Acta)]TJ
0 -1.1988 TD
[(Pha)-8.7(rmacol)-305.5(Sin)-300.6(2009;30\(4\):379Ö)-15(387;)-298.9(doi:)-307.2(10.1038/aps.200)-15.3(9.24)]TJ
-1.7148 -1.1988 TD
[(98.)-497.8(Ma)-8.9(rsicano)-206.7(G,)-205.1(Goodenough)-209.3(S,)-201.8(Monory)-211.2(K,)-202.9(et)-202.3(al.)-202.8(CB1)-205.6(cannabinoid)-210.9(receptors)]TJ
1.7148 -1.1988 TD
[(an)-8.5(d)-249.9(on-demand)-253.9(defense)-258.6(against)-254.7(excitotoxicity.)-261.6(Science)-258.1(2003;302)-11.7(\(5642\):)]TJ
T*
[(84Ö88)-9.5(;)-296.2(doi:)-307.2(10.1126/scie)-13.8(nce.1088208)]TJ
-1.7148 -1.1988 TD
[(99.)-497.8(Mon)-9.5(ory)-300.4(K,)-301.5(Massa)-303(F,)-302.8(Egertova)]TJ
13.43 .0303 TD
(¥)Tj
.6829 -.0303 TD
[(M,)-306.1(et)-301(al.)-301.4(The)-302.8(endocannabinoid)-309.4(system)]TJ
-12.398 -1.2064 TD
[(contro)-14.2(ls)-301.7(key)-301.6(epileptogenic)-307.3(circuits)-308(in)-304(the)-302.9(hippocampus.)-306.8(Neuro)-12.3(n)-297.8(2006;)]TJ
0 -1.1988 TD
[(51\(4)-10(\):455Ö466;)-302.5(doi:)-307.2(10.1016/j.ne)-13.4(uron.2006.07.006)]TJ
-2.2156 -1.1988 TD
[(100.)-503.8(Romigi)-302.2(A,)-306.8(Bari)-303.2(M,)-298.5(Placidi)-306.3(F,)-302.8(et)-301(al.)-301.4(Cerebrospinal)-312.8(îuid)-302.9(levels)-300.9(of)-306.2(the)]TJ
2.2307 -1.1988 TD
[(endocannabinoi)-14(d)-295.4(anand)-8.9(amide)-303.1(are)-300(reduced)-306.7(in)-304(patients)-303.9(with)-300.1(untreat)-12.3(ed)]TJ
T*
[(newly)-276.3(diagnosed)-279.3(tempo)-11.5(ral)-275.1(lobe)-277.4(epilepsy.)-280.9(Epilepsia)-279.2(2010;51)-13.3(\(5\):768Ö772;)]TJ
T*
[(doi:)-299.6(10.1)-10.6(111/j.1528-1167.2009.0)-19(2334.x)]TJ
-2.2307 -1.1988 TD
[(101.)-503.8(Sugaya)-262.3(Y,)-266(Yamazaki)-263.4(M,)-260.6(Uchig)-10.6(ashima)-257.8(M,)-268.1(et)-255.5(al.)-263.5(Crucial)-269.2(roles)-266.5(of)-260.6(the)-264.9(endo-)]TJ
2.2307 -1.2064 TD
[(cannabinoid)-271.6(2-arachidonoylglycer)-17.7(ol)-254.3(in)-266.1(the)-257.3(supp)-11.4(ression)-260.4(of)-268.2(epileptic)-267(sei-)]TJ
0 -1.1988 TD
[(zures.)-266.1(Cell)-260.7(Rep)-266(2016;16\(5\):1405Ö141)-16.1(5;)-264.2(doi:)-261.7(10.1016/j.celr)-15.1(ep.2016.06.083)]TJ
-2.2307 -1.1988 TD
[(102.)-503.8(Xu)-300.7(C,)-300.9(Hermes)-310.5(DJ,)-300.5(Nwanguma)-308.3(B,)-301.5(et)-301(al.)-301.4(Endoca)-10.6(nnabinoids)-301.8(exert)-310.9(CB)-298.3(1)]TJ
2.2307 -1.1988 TD
[(receptor-medi)-14.4(ated)-299.5(neuroprotective)-315.9(effects)-304.3(in)-304(models)-301.4(of)-306.1(neuronal)]TJ
T*
[(damage)-305.4(induced)-302.2(by)-305.4(HIV-1)-303.9(Tat)-303.4(protein.)-303.3(Mol)-302.2(Cell)-306.2(Neurosci)-307(2017;83:)]TJ
T*
[(92Ö102;)-304.1(doi:)-307.2(10.1016/j.mcn.201)-17.9(7.07.003)]TJ
-2.2307 -1.2064 TD
[(103.)-503.8(Wu)-300.5(MM,)-300.8(Zhang)-310.1(XW,)-302.5(Asher)-305.5(MJ,)-298.7(et)-301(al.)-301.4(Drugg)-9.9(able)-301.4(targets)-302.4(of)-306.1(the)-302.9(endo-)]TJ
2.2307 -1.1988 TD
[(cannabinoid)-309.5(system:)-304.5(Implicatio)-12.6(ns)-297.4(for)-302.8(the)-302.9(treatment)-309.6(of)-306.1(HIV-associated)]TJ
T*
[(neurocognitive)-309.5(disorder.)-308(Brain)-305.1(Res)-304(2019;172)-11.7(4:146467;)-307.9(doi:)-299.6(10.1016/)]TJ
T*
[(j.brainres.201)-15.1(9.146467)]TJ
-2.2307 -1.1988 TD
[(104.)-503.8(Ranganathan)-306(M,)-306.1(DêSouza)-304.5(DC.)-305(The)-302.8(acute)-298.4(effects)-311.8(of)-298.6(canna)-10.1(binoids)-299(on)]TJ
2.2307 -1.1988 TD
[(memory)-304.4(in)-304(humans:)-305.6(A)-298.9(review.)-306.7(Psychopharma)-15.4(cology)-302.6(2006;188\(4\):)]TJ
T*
[(425Ö444;)-310(doi:)-299.6(10.1007/s0021)-14.9(3-006-0508-y)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23231.5(15)]TJ
ET

endstream
endobj
136 0 obj
<</Length 20330>>stream
/GS1 gs
BT
/F7 1 Tf
7.4718 0 0 7.4718 62.022 700.2707 Tm
0 0 0 rg
0 Tc
0 Tw
[(105.)-503.8(Broyd)-305.2(SJ,)-308.2(van)-295.9(Hell)-309.1(HH,)-303.7(Beale)-300.5(C,)-300.9(et)-301(al.)-301.4(Acute)-310(and)-303.9(chronic)-301.7(effects)-311.8(of)-298.6(can-)]TJ
2.2307 -1.2064 TD
[(nabinoids)-307.5(on)-303.1(human)-305.7(cognitionÑA)-311.5(systematic)-306.8(review.)-306.7(Biol)-303.8(Psychiatry)]TJ
0 -1.1988 TD
[(2016;79\(7\):55)-15.8(7Ö567;)-305.7(doi:)-299.6(10.1016/j.biopsych)-18.2(.2015.12.)-13.9(002)]TJ
-2.2307 -1.1988 TD
[(106.)-503.8(Fischer)-209.7(B,)-202.9(Russell)-207.5(C,)-209.8(Sabioni)-204.5(P,)-205.3(et)-202.3(al.)-210.4(Lower-risk)-208.3(cannabis)-212.7(use)-202.9(guidelines:)-210.8(A)]TJ
2.2307 -1.1988 TD
[(comprehensi)-15(ve)-250.2(update)-251.2(of)-253(evidence)-260.1(and)-250.8(recommendations)-17.7(.)-250.7(A)0(m)-247.5(J)-250.6(Publi)-9.8(c)]TJ
T*
[(Health)-308.1(2017;107\(8\):e1Öe1)-16.6(2;)-294.6(doi:)-307.2(10.2105/ajph.20)-15.5(17.303818)]TJ
-2.2307 -1.1988 TD
[(107.)-503.8(Volkow)-308.9(ND,)-304.5(Swanson)-299.7(JM,)-306.3(Evins)-306.8(AE,)-303.4(et)-301(al.)-301.4(Effects)-307.7(of)-298.6(cannab)-9.6(is)-301.7(use)-301.6(on)]TJ
2.2307 -1.2064 TD
[(human)-305.7(behavior,)-304.7(inc)-8.8(luding)-301.8(cognition,)-307.2(motivation,)-314.3(and)-296.3(psych)-11.7(osis:)-299.3(A)-306.5(re-)]TJ
0 -1.1988 TD
[(view.)-301.7(JAMA)-304.5(Psyc)-10.4(hiatry)-298.9(2016;73)-13.3(\(3\):292;)-304.7(doi:)-299.6(10.1)-10.6(001/jamapsychiatry)]TJ
T*
(.2015.3278)Tj
-2.2307 -1.1988 TD
[(108.)-503.8(Sena)-301.8(Laura)-298.4(A,)-299.2(Chandel)-302.3(Navdeep)-298.7(S.)-292.8(Physi)-10.3(ological)-296.5(roles)-304.5(of)-298.6(mitochondrial)]TJ
2.2307 -1.1988 TD
[(reactive)-311(oxygen)-305.5(species.)-303.3(Mol)-302.2(Cell)-306.2(2012;48\(2\):158Ö)-15(167;)-298.9(doi:)-307.2(10.1016/)]TJ
T*
[(j.molcel.20)-14.4(12.09.025)]TJ
-2.2307 -1.1988 TD
[(109.)-503.8(Zhao)-304.1(S-C,)-306.6(Ma)-297.2(L-S,)-304.3(Chu)-307.8(Z-H,)-299.6(et)-301(al.)-301.4(Regulat)-10.1(ion)-301.8(of)-298.6(microg)-12.5(lial)-298.4(activation)]TJ
2.2307 -1.2064 TD
[(in)-304(stroke.)-305.3(Acta)-302.9(Pharmaco)-12(l)-302.1(Sin)-300.6(2017;38\(4\):445Ö458)-17.7(;)-296.2(doi:)-307.2(10.1038/aps)]TJ
0 -1.1988 TD
(.2016.162)Tj
-2.2307 -1.1988 TD
[(110.)-503.8(Nagatsu)-271.2(T,)-262.5(Sawada)-265.8(M.)-260.6(Inîammatory)-272.1(process)-267.7(in)-258.5(Parkins)-13.6(ons)-257.2(disease:)-271.3(Role)]TJ
2.2307 -1.1988 TD
[(for)-302.8(cytokines.)-312.2(Curr)-306.9(Pharm)-302.9(Des)-300.4(2005;11\()-13.1(8\):999Ö1016;)-306.8(doi:)-307.2(10.2174/)]TJ
T*
[(1381612)-11.4(053381620)]TJ
-2.2307 -1.1988 TD
[(111.)-503.8(Tuttolom)-13.8(ondo)-300.4(A,)-299.2(Di)-306.3(Raimondo)-307.4(D,)-300.3(di)-301.6(Sciacca)-306.4(R,)-303.9(et)-301(al.)-301.4(Inîammatory)-310.1(cy-)]TJ
2.2307 -1.2064 TD
[(tokines)-308.8(in)-296.4(acute)-306(ischem)-10.8(ic)-302.8(stroke.)-305.3(Curr)-306.9(Pharm)-302.9(Des)-300.4(2008;14\(33\):3)-15.8(574Ö)]TJ
0 -1.1988 TD
[(3589;)-304.9(doi:)-307.2(10.2174/13816)-13.7(1208786848739)]TJ
-2.2307 -1.1988 TD
[(112.)-503.8(Goran)-10.5(tla)-237.1(S,)-239.7(Makarov)-239(E,)-239.7(Roy)-235.5(D,)-239.6(et)-240.3(al.)-240.7(Immunoregulation)-247(of)-237.9(a)-241.8(CB2)-236(receptor)]TJ
2.2307 -1.1988 TD
[(agonist)-306.5(in)-304(a)-294.9(muri)-9.9(ne)-298.6(model)-301.8(of)-306.1(neuroAIDS.)-308.6(J)-303.7(Neuroimmune)-310.5(Pharmacol)]TJ
T*
[(2010;5\(3\))-12.8(:456Ö468;)-302.7(doi:)-307.2(10.1007/s1148)-14.8(1-010-9225-8)]TJ
-2.2307 -1.1988 TD
[(113.)-503.8(Han)-304.4(KH,)-301.5(Lim)-306.2(S,)-300.4(Ryu)-303.8(J,)-304(et)-301(al.)-301.4(CB1)-304.3(and)-303.9(CB2)-304.3(cannabinoid)-301.9(receptors)-315.4(differ-)]TJ
2.2307 -1.2064 TD
[(entiall)-9.5(y)-298.3(regulate)-303.3(the)-302.9(productio)-15.2(n)-297.8(o)0(f)-298.6(reactive)-311(oxygen)-305.5(species)-303(by)-305.4(macro-)]TJ
0 -1.1988 TD
[(phages.)-306.5(Cardiovasc)-313.2(Res)-304(2009;84\(3\):378Ö386;)-313.9(doi:)-307.2(10.1093/cvr/cvp240)]TJ
-2.2307 -1.1988 TD
[(114.)-503.8(DêAloi)-10(a)-219.1(A)0(,)-230.9(Molteni)-231.9(L,)-222.8(Gull)-10.1(o)-225.3(F)0(,)-226.9(e)0(t)-225.1(al.)-225.6(Palmitoylet)-13.8(hanolamide)-226.4(modul)-10.4(ation)-229.2(of)]TJ
2.2307 -1.1988 TD
[(microgl)-11.1(ia)-301.2(activation:)-307(Characterizatio)-15.1(n)-297.8(o)0(f)-298.6(mecha)-11.6(nisms)-297.2(of)-306.1(action)-305.7(and)-303.9(im-)]TJ
T*
[(plication)-310.1(for)-302.8(its)-306(neuroprotective)-308.3(effects.)-312.1(Int)-300.7(J)-303.7(Mol)-302.2(Sci)-299.4(2021;22\(6\):30)-15.8(54;)]TJ
T*
[(doi:)-307.2(10.3390/ijms22)-14.6(063054)]TJ
-2.2307 -1.1988 TD
[(115.)-503.8(Pacher)-310.3(P,)-296.3(Ba)]TJ
7.0337 .0303 TD
(¥)Tj
.387 -.0303 TD
[(tkai)-300.3(S,)-308(Kunos)-305.7(G.)-296.2(The)-302.8(endocann)-11(abinoid)-306(system)-304.2(as)-302.1(an)]TJ
-5.1899 -1.2064 TD
[(emergin)-9.9(g)-297.8(target)-302.9(of)-306.1(pharmacothera)-14.1(py.)-298.1(Pharmaco)-12(l)-294.5(R)0(e)-8.5(v)-294.9(2006;58\()-13.1(3\):)]TJ
0 -1.1988 TD
[(389Ö4)-9.5(62;)-300.5(doi:)-299.6(10.1)-10.6(124/pr.58.3.2)]TJ
-2.2307 -1.1988 TD
[(116.)-503.8(Ramirez)-305.9(BG.)-301.5(Prevent)-11.2(ion)-301.8(of)-298.6(Alzhei)-8.5(merês)-302.5(disease)-301.4(pat)-10.4(hology)-303.8(by)-297.8(canna)-10.1(bi-)]TJ
2.2307 -1.1988 TD
[(noids:)-308.7(Neuroprotection)-310.4(med)-9.5(iated)-298.1(by)-305.4(blockade)-309.4(of)-298.6(microgl)-11.1(ial)-299.8(activation.)]TJ
T*
[(J)-303.7(Neurosci)-307(2005;25\(8\):1904Ö19)-17.7(13;)-300.5(doi:)-307.2(10.1523/jneurosci.4)-18(540-04.2005)]TJ
-2.2307 -1.1988 TD
[(117.)-503.8(Garcö)]TJ
4.0973 .0152 TD
(¥)Tj
.2656 -.0152 TD
[(a-Arencibia)-302.9(M,)-306.1(Gonza)]TJ
8.5739 .0304 TD
(¥)Tj
.387 -.0304 TD
[(lez)-300.8(S,)-300.4(de)-303.8(Lago)-304.6(E,)-300.4(et)-301(al.)-301.4(Evaluation)-311.3(of)-298.6(the)]TJ
-11.093 -1.2064 TD
[(neuro)-10(protective)-305.9(effect)-304.7(of)-306.1(cannabinoids)-309.1(in)-296.4(a)-302.5(rat)-303.5(model)-301.8(of)-306.1(Parkinsonês)]TJ
0 -1.1988 TD
[(disease:)-309.2(Importance)-312(of)-298.6(antioxida)-11.2(nt)-294.5(an)-8.5(d)-295.4(cannab)-9.6(inoid)-299.9(receptor-)]TJ
T*
[(independ)-10.1(ent)-302.9(properties.)-305.5(Brain)-305.1(Res)-304(2007;1134\(1\):162)-18.5(Ö170;)-299.7(doi:)-307.2(10.1016/)]TJ
T*
[(j.brainre)-12.5(s.2006.11.063)]TJ
-2.2307 -1.1988 TD
[(118.)-503.8(Palazuelos)-307.9(J,)-304(Aguado)-302.4(T,)-308(Pazos)-297.9(MR,)-306.2(et)-301(al.)-301.4(Microglial)-311.5(CB2)-304.3(cannabinoid)]TJ
2.2307 -1.1988 TD
[(receptors)-307.8(are)-307.6(neuroprotective)-315.9(in)-296.4(Huntingtonês)-313.6(disease)-301.4(excitotox)-13.8(icity.)]TJ
T*
[(Brain)-305.1(2009;132)-11.7(\(11\):3152Ö3164;)-310.9(doi:)-299.6(10.1)-10.6(093/brain/awp239)]TJ
-2.2307 -1.2064 TD
[(119.)-503.8(Pertwee)-306.4(RG.)-303.9(Pharmaco)-12(logy)-296.6(of)-306.1(cannabinoid)-309.5(receptor)-308.2(ligands.)-303(Curr)-306.9(Med)]TJ
2.2307 -1.1988 TD
[(Chem)-304.9(1999;6\(8\):)-13.1(635Ö664.)]TJ
-2.2307 -1.1988 TD
[(120.)-503.8(Zayyad)-307.8(Z,)-298.1(Spudich)-313.2(S.)-300.4(Neuropathogenesis)-313.7(of)-298.6(HIV:)-304.3(From)-306.2(initial)-303.2(neuro)-10(in-)]TJ
2.2307 -1.1988 TD
[(vasion)-223.5(to)-229.6(HIV-associated)-228.4(neurocogn)-12.2(itive)-221.4(disorder)-231.9(\(HAND\).)-223.5(Curr)-223.4(HIV/AIDS)]TJ
T*
[(Rep)-303.9(2015;12\(1\):16Ö2)-15(4;)-302.2(doi:)-299.6(10.1007/s)-13.7(11904-014-0255-3)]TJ
-2.2307 -1.1988 TD
[(121.)-503.8(Centonze)-305.9(D,)-307.9(Finazzi-Agro)]TJ
12.398 .0303 TD
(`)Tj
.7132 -.0303 TD
[(A,)-299.2(Bernardi)-309.6(G,)-303.7(et)-301(al.)-301.4(The)-302.8(endocannabinoi)-14(d)]TJ
-10.8805 -1.2064 TD
[(system)-311.8(in)-296.4(targeting)-305.3(inîammato)-15(ry)-302.6(neurodegenerative)-310.1(diseases.)-308.8(Trends)]TJ
0 -1.1988 TD
[(Pharmaco)-12(l)-294.5(Sci)-307(2007;28\(4\):180Ö)-15(187;)-298.9(doi:)-307.2(10.1016/j.tips.20)-17.3(07.02.004)]TJ
-2.2307 -1.1988 TD
[(122.)-503.8(Bari)-303.2(M,)-306.1(Rapino)-300.4(C,)-308.4(Mozetic)-305.8(P,)-296.3(et)-301(al.)-301.4(The)-302.8(endocann)-11(abinoid)-306(system)-304.2(in)]TJ
2.2307 -1.1988 TD
[(gp120-media)-12.8(ted)-247.3(insults)-258.3(and)-250.8(HIV-associated)-258.8(dementia.)-257.2(Exp)-251.3(Neurol)-253.7(2010;)]TJ
T*
[(224\(1\):74)-12.8(Ö84;)-301.3(doi:)-299.6(10.1)-10.6(016/j.expneurol.201)-16.9(0.03.025)]TJ
-2.2307 -1.1988 TD
[(123.)-503.8(William)-9.6(s)-212(JC,)-217.6(Appelberg)-220.3(S,)-216.9(Goldberger)-219.8(BA,)-213.5(et)-217.5(al.)]TJ
/F4 1 Tf
21.45 0 TD
(D)Tj
/F7 1 Tf
5.6038 0 0 4.9805 227.2818 192.4724 Tm
(9)Tj
7.4718 0 0 7.4718 230.1732 189.1842 Tm
[(-Tetrahydrocanna)-14.9(binol)]TJ
-20.2739 -1.1988 TD
[(treatment)-309.6(during)-307.4(human)-305.7(monocyte)-303.1(different)-12.4(iation)-303.7(reduces)-306.8(macro-)]TJ
0 -1.2064 TD
[(phage)-208(susceptibility)-215.3(to)-206.9(HIV-1)-205.2(infection.)-207(J)-205.1(Neuroimmune)-211.9(Pharmacol)-207.9(2014;)]TJ
0 -1.1988 TD
[(9\(3\):369Ö3)-13.6(79;)-300.5(doi:)-299.6(10.1)-10.6(007/s11481-014-9)-14.3(527-3)]TJ
-2.2307 -1.1988 TD
[(124.)-503.8(Wu)-285.3(Y,)-288.7(Costantino)-290.4(CM,)-288(Gupta)-288.8(A,)-284(et)-278.2(al.)-286.3(Cannabino)-11.9(id)-278.9(receptor)-293(2-mediated)]TJ
2.2307 -1.1988 TD
[(attenuation)-267.5(of)-260.6(CXCR4-tropic)-271.9(HIV)-258.5(infection)-259.8(in)-258.5(prima)-10.7(ry)-257.1(CD4)]TJ
/F8 1 Tf
5.6038 0 0 4.9805 257.5558 147.6283 Tm
(+)Tj
/F7 1 Tf
7.4718 0 0 7.4718 263.4519 144.3401 Tm
[(T)-262.2(cells.)-264.1(PLoS)]TJ
-24.7278 -1.1988 TD
[(One)-302.1(2012;7\(3\))-12.8(:e33961;)-304.3(doi:)-307.2(10.1371/journal.pone)-17.5(.0033961)]TJ
-2.2307 -1.1988 TD
[(125.)-503.8(Raborn)-306.1(ES,)-304.6(Jamerson)-308.6(M,)-298.5(Marciano)-11.2(-Cabral)-302.5(F,)-302.8(et)-301(al.)-301.4(Cannabino)-11.9(id)-301.6(inhibits)]TJ
2.2307 -1.2064 TD
[(HIV-1)-303.9(Tat-sti)-11.5(mulated)-305.1(adhesion)-302.5(of)-306.1(human)-298.1(mon)-8.9(ocyte-like)-303.8(cells)-309.4(to)-297.9(extra-)]TJ
0 -1.1988 TD
[(cellular)-309.5(matrix)-301(proteins.)-310.4(Life)-302.7(Sci)-307(2014;104\(1Ö2\):15Ö23;)-314.7(doi:)-307.2(10.1016/)]TJ
T*
[(j.lfs.2014.0)-14.8(4.008)]TJ
-2.2307 -1.1988 TD
[(126.)-503.8(Goodwin)-306(RD,)-308.1(Pacek)-299(LR,)-306.4(Copeland)-305.2(J,)-304(et)-301(al.)-301.4(Trends)-306.1(in)-304(daily)-301.7(cannabis)-303.7(use)]TJ
2.2307 -1.1988 TD
[(among)-237.4(cigarette)-234.7(sm)-8.8(okers:)-232.7(United)-240.3(States,)-232.5(2002Ö)-9.5(2014.)-229(Am)-232.3(J)-235.4(Public)-238.1(Health)]TJ
T*
[(2018;108)-11.7(\(1\):137Ö142;)-308.2(doi:)-307.2(10.2105/ajph.2017.30405)-19.6(0)]TJ
31.3669 84.0017 TD
[(127)-10.3(.)-501.1(Terranova)-306.2(J-P,)-305.6(Michaud)-303.3(J-C,)-302.6(Le)-299.1(Fur)-304.5(G,)-303.7(et)-301(al.)-301.4(Inhibition)-312.8(of)-298.6(long-term)-308.6(po-)]TJ
2.2383 -1.2064 TD
[(tentiation)-307.4(in)-296.4(rat)-303.5(hippoca)-12.1(mpal)-302.3(slices)-301.4(by)-305.4(anandamide)-304.5(and)-303.9(WIN55212-2:)]TJ
0 -1.1988 TD
[(Reversal)-305.7(by)-297.8(SR14171)-11.4(6)-165.3(A)0(,)-299.2(a)-302.5(selective)-306.7(antagonis)-11.6(t)-300.2(o)0(f)-298.6(CB1)-304.3(cannabin)-10.2(oid)]TJ
T*
[(receptors.)-308.1(Naunyn)-303(Schmiedeber)-12.7(gs)-297.4(Arch)-305.8(Pharmaco)-12(l)-294.5(1995;35)-13.3(2\(5\):576Ö)]TJ
T*
[(579;)-298.9(doi:)-307.2(10.1007/bf001693)-16.5(93)]TJ
-2.2383 -1.1988 TD
[(128)-10.3(.)-501.1(Esposito)-304.7(G,)-303.7(Ligresti)-306.4(A,)-299.2(Izzo)-303.3(AA,)-302.2(et)-301(al.)-309(The)-295.2(endocann)-11(abinoid)-306(system)-304.2(pro-)]TJ
2.2383 -1.1988 TD
[(tects)-305.5(rat)-303.5(glioma)-301.1(cells)-301.8(against)-307.8(HIV-1)-303.9(Tat)-303.4(protein-induc)-14.6(ed)-296.2(cytotoxicity)-16.6(Ñ)]TJ
0 -1.2064 TD
[(Mechanism)-302.4(and)-303.9(regulation)-12.5(.)-296.2(J)-303.7(Biol)-303.8(Chem)-304.9(2002;277\(52\):50348Ö)-16.1(50354;)]TJ
0 -1.1988 TD
[(doi:)-299.6(10.1074/jbc.M20)-17.5(7170200)]TJ
-2.2383 -1.1988 TD
[(129)-10.3(.)-501.1(Maccarrone)-306.6(M,)-298.5(Piccirill)-14.1(i)-294.5(S)0(,)-308(Battista)-302.7(N,)-300.3(et)-308.6(al.)-301.4(Enhanced)-305.8(anandamide)-304.5(deg-)]TJ
2.2383 -1.1988 TD
[(radation)-300.3(is)-301.7(asso)-11(ciated)-298.8(with)-307.7(neuronal)-305.5(apoptosis)-306.6(induced)-309.8(by)-297.8(the)-302.9(HIV-)-9.6(1)]TJ
T*
[(coat)-290(glycoprotein)-296.8(gp120)-292.4(in)-281.3(the)-287.7(rat)-295.9(neocortex.)-294(J)-288.5(Neurochem)-290.4(2004;89\(5\):)]TJ
T*
[(1293Ö1300;)-306.8(doi:)-299.6(10.1)-10.6(111/j.1471Ö4159.2004.)-19.9(02430.x)]TJ
-2.2383 -1.1988 TD
[(130)-10.3(.)-501.1(Kramer)-303.7(S,)-300.4(Buontempo)-310.1(P,)-303.9(Agrawal)-301.2(S,)-308(et)-301(al.)-301.4(Imaging-based)-307(assay)-303.1(for)]TJ
2.2383 -1.2064 TD
[(identiìcation)-305.4(and)-303.9(characteri)-13.6(zation)-303(of)-298.6(inhibitor)-13.1(s)-295.5(o)0(f)-306.2(CXCR4-tropic)-309.9(HIV-1)]TJ
0 -1.1988 TD
[(envelope-dependent)-313.1(cell-cell)-302.5(fusion.)-304.3(SLA)-9.6(S)-300.1(Discov)-303.3(2011;16\(6\):668Ö)-15(675;)]TJ
T*
[(doi:)-299.6(10.1177/1)-12.6(087057111403480)]TJ
-2.2383 -1.1988 TD
[(131)-10.3(.)-501.1(X)0(u)-300.7(C)0(,)-300.9(Yadav-Sam)-10.7(udrala)-301.7(BJ,)-301.7(Xu)-300.7(C,)-308.4(et)-301(al.)-301.4(Inhibitory)-303.8(neuro)-10(transmission)-310.2(is)]TJ
2.2383 -1.1988 TD
[(sex-dependently)-305.1(affe)-9.7(cted)-301.1(by)-305.4(Tat)-303.4(expression)-303.5(in)-304(transgenic)-308.9(mice)-305.3(and)]TJ
T*
[(suppressed)-281.5(by)-275.1(the)-272.5(fatty)-280.5(acid)-278.6(amide)-280.3(hydrolase)-277(enzyme)-278.6(inhibitor)-278.6(PF384)-9.5(5)]TJ
0 -1.2064 TD
[(via)-300.2(cannabinoid)-309.5(type-1)-302.8(receptor)-308.2(mechanisms)-13(.)-296.2(Cells)-305.8(2022;11\(5\):857;)]TJ
0 -1.1988 TD
[(doi:)-299.6(10.3390/cel)-14.3(ls11050857)]TJ
-2.2383 -1.1988 TD
[(132)-10.3(.)-501.1(Yadav-Samudrala)-312.4(BJ,)-301.7(Fitting)-304.6(S.)-300.4(Mini-review:)-309.7(The)-302.8(therapeutic)-307.8(role)-304.9(of)]TJ
2.2383 -1.1988 TD
[(cannabinoids)-248.4(in)-243.3(neuroHIV.)-246(Neuros)-11.8(ci)-242.1(Lett)-247(2021;750:135717;)-252.9(doi:)-246.5(10.1016/)]TJ
T*
[(j.neulet.2021.13571)-17(7)]TJ
-2.2383 -1.1988 TD
[(133)-10.3(.)-501.1(Starr)-304.4(A,)-299.2(Jordan-Sciutto)-315.2(KL,)-304(Mironets)-305.4(E.)-300.4(Confou)-12.3(nd,)-297.6(cause,)-309.2(or)-305.5(cure:)-299.7(The)]TJ
2.2383 -1.2064 TD
[(effect)-259.2(of)-253(cannab)-9.6(inoids)-253.9(on)-257.6(HIV-asso)-13.1(ciated)-253.3(neuro)-10(logical)-260.8(sequelae.)-255.1(Vi)-8.1(ruses)]TJ
0 -1.1988 TD
[(2021;13\(7\):1242;)-308.8(doi:)-307.2(10.3390/v1307)-14.3(1242)]TJ
-2.2383 -1.1988 TD
[(134)-10.3(.)-501.1(Lowe)-265.9(H,)-265.8(Toya)-11(ng)-261.8(N,)-270(Steele)-267.5(B,)-271.2(et)-270.6(al.)-263.5(The)-272.4(current)-271.9(and)-266(potential)-270.3(appli)-10.5(cation)]TJ
2.2383 -1.1988 TD
[(of)-298.6(medicinal)-310.5(cannabis)-303.7(products)-306.7(in)-304(dentistry.)-311.8(Dent)-299.4(J)-303.7(\(Basel\))-306.3(2021;9\(9\):)]TJ
T*
[(106;)-298.9(doi:)-307.2(10.3390/dj909010)-15.3(6)]TJ
-2.2383 -1.1988 TD
[(135)-10.3(.)-501.1(Skalski)-300.9(LM,)-300.9(Towe)-298(SL,)-302.8(Sikkema)-297.5(KJ,)-301.7(et)-301(al.)-301.4(The)-295.2(impact)-299.7(of)-306.1(marijuana)-301(use)-301.6(on)]TJ
2.2383 -1.1988 TD
[(memory)-304.5(in)-296.4(HIV-)-9.6(infected)-307.4(patients:)-304.2(A)-298.9(compr)-11.4(ehensive)-299.3(review)-306.4(of)-306.1(the)-295.3(HIV)]TJ
0 -1.2064 TD
[(and)-296.3(ma)-8.3(rijuana)-300.3(literature)-12.7(s.)-303.3(Curr)-299.3(Drug)-303.9(Abuse)-304.1(Re)-8.5(v)-294.9(2017;9\(2)-13.1(\):126Ö141;)]TJ
0 -1.1988 TD
[(doi:)-299.6(10.2174/1)-12.6(874473709666160502)-16.3(124503)]TJ
-2.2383 -1.1988 TD
[(136)-10.3(.)-501.1(Skalski)-300.9(LM,)-308.5(Towe)-298.1(SL,)-302.8(Sikkema)-312.7(KJ,)-301.7(et)-301(al.)-301.4(Memory)-305.1(impairm)-10.9(ent)-295.3(in)-304(HIV-)]TJ
2.2383 -1.1988 TD
[(infected)-307.4(individuals)-301.9(with)-307.7(early)-301.1(and)-303.9(late)-298.6(in)-8.1(itiation)-306.6(of)-298.6(regular)-302.5(ma)-8.3(rijuana)]TJ
T*
[(use.)-256.3(AIDS)-260.4(Behav)-256.4(201)-10.3(7;22\(5\):1596Ö1605;)-270(doi:)-261.7(10.1007/s10461-)-14.7(017-1898-z)]TJ
-2.2383 -1.1988 TD
[(137)-10.3(.)-501.1(Whiting)-302.4(PF,)-303(Wolff)-301.3(RF,)-303(Deshpande)-310.6(S,)-300.4(et)-301(al.)-301.4(Cannabi)-12.3(noids)-300.8(for)-302.8(medical)]TJ
2.2383 -1.2064 TD
[(use:)-301.9(A)-298.9(systematic)-314.4(review)-298.8(and)-303.9(meta-analysis)-13.6(.)-296.2(JAMA)-304.5(2015;313)-11.7(\(24\):2456Ö)]TJ
0 -1.1988 TD
[(2473;)-304.9(doi:)-299.6(10.1001/jama.2)-16.4(015.6358)]TJ
-2.2383 -1.1988 TD
[(138)-10.3(.)-501.1(Lutge)-272.7(EE,)-274.2(Gra)-10.8(y)-268(A)0(,)-276.4(Siegfried)-279.2(N.)-277.6(The)-272.5(medical)-279.6(use)-278.8(of)-268.2(can)-9.2(nabis)-271.8(for)-280.1(reducing)]TJ
2.2383 -1.1988 TD
[(morbidity)-302.5(and)-303.9(mortali)-11.8(ty)-302.6(in)-296.4(patients)-311.5(with)-300.1(HIV/AIDS.)-307.5(Cochrane)-306.9(Database)]TJ
T*
[(Syst)-298.8(Rev)-303.5(2013;4:CD0)-14.8(05175;)-303.3(doi:)-299.6(10.1)-10.6(002/14651858.CD)-14.9(005175.pub3)]TJ
-2.2383 -1.1988 TD
[(139)-10.3(.)-501.1(Brunet)-302.6(L,)-306.2(Moodie)-300.2(EEM,)-306.9(Rollet)-303.7(K,)-301.5(et)-301(al.)-301.4(Marijuana)-309.2(smoking)-307.3(does)-301.1(not)-307.4(ac-)]TJ
2.2383 -1.1988 TD
[(celerate)-305.2(progression)-309.4(of)-298.6(liver)-304.9(disease)-308.9(in)-296.4(HIVÖ)-8.9(hepatitis)-302.5(C)-300.6(coinfec)-12.9(tion:)]TJ
0 -1.2064 TD
[(A)-298.9(longitudinal)-309.6(cohort)-302.5(analysis.)-310.2(Clin)-299.7(Infect)-307.1(Dis)-305.8(2013;57\(5\):663Ö)-15(670;)]TJ
0 -1.1988 TD
[(doi:)-299.6(10.1093/ci)-13.5(d/cit378)]TJ
-2.2383 -1.1988 TD
[(140)-10.3(.)-501.1(Cristiani)-305.5(SA.)-303.4(Marijuana)-309.2(use)-301.6(and)-303.9(cognitive)-307.1(function)-303.7(in)-304(HIV-infected)-309.4(peo-)]TJ
2.2383 -1.1988 TD
[(ple.)-302.7(J)-296.1(Neurop)-11.7(sychiatry)-309.1(Clin)-299.7(Neurosci)-307(2004;16\(3\):33)-15.8(0Ö335;)-305.7(doi:)-299.6(10.1176/)]TJ
T*
[(appi.neuropsych.1)-17.3(6.3.330)]TJ
-2.2383 -1.1988 TD
[(141)-10.3(.)-501.1(Parrish)-303.7(C,)-300.9(Whitney)-305.1(BM,)-303.8(Nance)-302.4(RM,)-306.2(et)-301(al.)-301.4(Substance)-311.2(use)-301.6(and)-303.9(HIV)-304(stage)]TJ
2.2383 -1.2064 TD
[(at)-299.2(entry)-302(into)-306(care)-300.7(am)-8.2(ong)-297.4(people)-308(with)-300.1(HIV.)-304.3(Arch)-305.8(Public)-306.4(Health)-300.5(2021;)]TJ
0 -1.1988 TD
[(79\(1\):153;)-309(doi:)-299.6(10.1186/s136)-16.5(90-021-00677-2)]TJ
-2.2383 -1.1988 TD
[(142)-10.3(.)-501.1(Raymond)-305.9(HF,)-302.8(Fuster-RuizdeApod)-16.8(aca)-302.2(MJ,)-298.7(Castro-Gr)-15.3(anell)-302.5(V,)-298.1(et)-301(al.)-301.4(Preva-)]TJ
2.2383 -1.1988 TD
[(lence)-291.1(and)-296.3(patterns)-301.9(of)-291(illicit)-294(drug)-299.3(use)-294(in)-296.4(people)-292.8(living)-294.6(with)-300.1(HIV)-288.8(in)-296.4(Spain:)]TJ
T*
[(A)-298.9(cross-sectional)-315.6(study.)-307.3(PLoS)-300.4(One)-302.1(2019;14\(6\):e02)-16.6(11252;)-303.3(doi:)-307.2(10.1371/)]TJ
T*
(journal.pone.0211252)Tj
-2.2383 -1.1988 TD
[(143)-10.3(.)-501.1(Zapanti)-300.2(E,)-300.4(Ter)-9.3(zidis)-297.7(K,)-309.1(Chrousos)-306.7(G.)-303.7(Dysfunction)-309.8(of)-298.6(the)-302.9(hypothal)-13(amic-)]TJ
2.2383 -1.2064 TD
[(pituitary-adrenal)-309.4(axis)-305.6(in)-304(HIV)-296.4(infect)-11.2(ion)-301.8(and)-296.3(disease.)-309.2(Hormone)-11.6(s)-295.5(\(Athe)-9.7(ns\))]TJ
0 -1.1988 TD
[(2008;7\(3\):205Ö216;)-315.5(doi:)-299.6(10.14310)-11.7(/horm.2002.1200)]TJ
-2.2383 -1.1988 TD
[(144)-10.3(.)-501.1(Oyola)-304.8(MG,)-298.5(Handa)-302.9(RJ.)-304.1(Hypot)-11.5(halamicÖpituitaryÖa)-16.5(drenal)-300(and)-303.9(hypotha-)]TJ
2.2383 -1.1988 TD
[(lamicÖpituitaryÖgo)-16.2(nadal)-301.6(axes:)-300.4(Sex)-305.8(differences)-305.1(in)-304(regulation)-308.4(of)-298.6(stress)]TJ
T*
[(responsivity.)-310.1(Stress)-308.6(2017;20\(5\):476Ö494;)-313.9(doi:)-307.2(10.1080/10253890.)-16.7(2017)]TJ
T*
(.1369523)Tj
-2.2383 -1.2064 TD
[(145)-10.3(.)-501.1(Chrousos)-306.7(GP,)-303.9(Zapanti)-307.8(ED.)-296.9(Hypot)-11.5(halamic-pituitary-ad)-17.5(renal)-300.5(axis)-305.6(in)-296.4(HIV)]TJ
2.2383 -1.1988 TD
[(infection)-305.4(and)-303.9(disease.)-301.6(Endoc)-11.6(rinol)-297.1(Metab)-309.4(Clin)-299.7(North)-308.2(Am)-300.6(2014;43\(3\):)]TJ
T*
[(791Ö806;)-302.4(doi:)-307.2(10.1016/j.ecl.2014.)-20.1(06.002)]TJ
-2.2383 -1.1988 TD
[(146)-10.3(.)-501.1(Morena)-264(M,)-268.1(Patel)-268.4(S,)-270(Bains)-270(JS,)-262.7(et)-270.6(al.)-263.5(Neurob)-11.7(iological)-264.8(in)-8.1(teractions)-269.1(between)]TJ
2.2383 -1.1988 TD
[(stress)-303.9(and)-303.9(the)-302.9(endocannabinoid)-309.4(system.)-304.5(Neuro)-12.2(psychopharmacology)]TJ
T*
[(2015;41\(1\):80Ö102;)-315.5(doi:)-299.6(10.1038/npp)-15.1(.2015.166)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(16)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
140 0 obj
<</Length 20417>>stream
/GS1 gs
BT
/F7 1 Tf
7.4718 0 0 7.4718 59.7543 700.2707 Tm
0 0 0 rg
0 Tc
0 Tw
[(147.)-503.8(Christ)-13.3(eff)-299(N,)-300.3(Gherbi)-308.6(N,)-300.3(Mammes)-308.5(O,)-299.7(et)-301(al.)-301.4(Serum)-304.5(cortis)-12.7(ol)-299.9(and)-303.9(DHEA)-299.6(con-)]TJ
2.2307 -1.2064 TD
[(ce)-9(ntrations)-307.5(during)-299.8(HIV)-304(infection.)-313.3(Psychoneuroendocr)-17.4(inology)-302.5(1997;22:)]TJ
0 -1.1988 TD
[(S11Ö)-9.3(S18;)-304.7(doi:)-299.6(1016/S0306-4)-14.8(530\(97\)00015-2)]TJ
-2.2307 -1.1988 TD
[(148.)-503.8(La)-9(ird)-298.3(GM,)-306(Bullen)-306.5(CK,)-298.6(Rosenblo)-11.2(om)-302.9(DIS,)-303.2(et)-301(al.)-301.4(Ex)-297.4(vivo)-305.5(analysis)-309.9(identiìes)]TJ
2.2307 -1.1988 TD
[(effectiv)-14(e)-251.2(HIV-1)-265.9(latencyÖreversing)-270.1(drug)-261.4(combinations.)-267.1(J)-258.2(Clin)-261.8(Invest)-254.6(2015;)]TJ
T*
[(125\()-10.1(5\):1901Ö1912;)-305.2(doi:)-307.2(10.1172/jci80)-14.1(142)]TJ
-2.2307 -1.1988 TD
[(149.)-503.8(Ram)-8.4(esh)-298.2(G,)-303.7(MacLean)-309.7(AG,)-299.2(Philipp)-308(MT.)-302.7(Cytokines)-308.4(and)-303.9(chemokines)-309.6(at)]TJ
2.2307 -1.2064 TD
[(the)-302.9(cro)-10.3(ssroads)-302.7(of)-306.1(neuroinîammation,)-314.2(neurodegener)-12.4(ation,)-305.4(and)-296.3(neuro)-10(-)]TJ
0 -1.1988 TD
[(pat)-10.4(hic)-297.1(pain.)-302.8(Medi)-8.8(ators)-300.8(Inîamm)-309.9(2013;2013:1Ö20;)-310.1(doi:)-307.2(10.1155/2013/)]TJ
T*
(480739)Tj
-2.2307 -1.1988 TD
[(150.)-503.8(Pari)-9.7(s)-212(JJ,)-213.2(Liere)-211.8(P,)-212.9(Kim)-218(S,)-209.3(et)-209.9(al.)-218(Pregnane)-215.6(steroidoge)-12.8(nesis)-212.9(is)-210.6(altered)-219.7(by)-206.8(HIV-)-9.6(1)]TJ
2.2307 -1.1988 TD
[(Tat)-280.7(and)-273.6(morphine:)-279.8(Physiologi)-12.5(cal)-271.5(allopregnan)-10.9(olone)-277.5(is)-271.3(protective)-283.1(against)]TJ
T*
[(neuro)-10(toxic)-302.1(and)-303.9(psychomotor)-311(effects.)-312.1(Neurobiol)-302.7(Stress)-308.6(2020;12:1002)-14.7(11;)]TJ
T*
[(doi:)-307.2(10.1016/j.yn)-15(str.2020.100211)]TJ
-2.2307 -1.2064 TD
[(151.)-503.8(Raber)-307.2(J,)-304(Toggas)-307.8(SM,)-302.7(Lee)-299.9(S,)-300.4(et)-301(al.)-301.4(Central)-309.5(nervous)-304.5(system)-304.2(expr)-9.4(ession)-301.7(of)]TJ
2.2307 -1.1988 TD
[(HIV-)-9.6(1)-218.4(Gp120)-222.2(activates)-225.3(the)-219.4(hypothalamic-pituit)-17.5(ary-adrenal)-222.9(axis:)-222.4(Evidence)]TJ
T*
[(for)-295.2(involvement)-300.3(of)-291(NMDA)-294.3(receptors)-300.2(and)-288.7(nitric)-296.7(oxide)-289.8(synthase.)-298.1(Vi)-8.1(rology)]TJ
T*
[(1996;22)-13.3(6\(2\):362Ö373;)-306.6(doi:)-307.2(10.1006/viro.199)-16.9(6.0664)]TJ
-2.2307 -1.1988 TD
[(152.)-503.8(Co)-10(sta)-215.3(A,)-223.3(Nappi)-220.8(RE,)-217.1(Polatti)-222.7(F,)-219.3(et)-217.5(al.)-225.6(Stimulating)-223.3(effect)-221.2(of)-222.7(HIV-1)-220.4(coat)-221.7(protein)]TJ
2.2307 -1.1988 TD
[(gp)-9(120)-291(on)-303.1(corticotropin-releasing)-313.3(hormone)-301.9(and)-296.3(arginine)-303(vasopressin)-303.1(in)]TJ
0 -1.2064 TD
[(the)-302.9(rat)-303.5(hypothal)-13(amus:)-301.8(Involvement)-307.9(of)-306.1(nitric)-304.3(oxide.)-305.3(Exp)-304.5(Neurol)-299.2(2000;)]TJ
0 -1.1988 TD
[(166\()-10.1(2\):376Ö384;)-308.4(doi:)-299.6(10.1006)-13.3(/exnr.2000.7502)]TJ
-2.2307 -1.1988 TD
[(153.)-503.8(Sal)-9.4(ahuddin)-225.8(MF,)-221.6(Mahdi)-229(F,)-219.3(Sulochana)-228.5(SP,)-224.7(et)-225.1(al.)-225.6(HIV-1)-228(Tat)-220(protein)-227.1(prom)-10.7(otes)]TJ
2.2307 -1.1988 TD
[(neuro)-10(endocrine)-309.7(dysfunction)-305.2(concurrent)-310.1(with)-307.7(the)-302.9(potentiation)-312.2(of)-298.6(oxy-)]TJ
T*
[(codo)-10.8(neês)-298.4(psych)-11.7(omotor)-306.9(effects)-304.3(in)-304(female)-301.7(mice.)-305.5(Viruses)-306(2021;13\(5\):813;)]TJ
T*
[(doi:)-307.2(10.3390/v1305)-14.3(0813)]TJ
-2.2307 -1.2064 TD
[(154.)-503.8(Sal)-9.4(ahuddin)-301.7(MF,)-305.1(Qrareya)-301.6(AN,)-303.3(Mahdi)-304.9(F,)-302.8(et)-301(al.)-301.4(Combin)-11.7(ed)-296.2(HIV-1)-303.9(Tat)-303.4(and)]TJ
2.2307 -1.1988 TD
[(oxyco)-11(done)-303.4(activate)-301.6(the)-302.9(hypothal)-13(amic-pituitary-adren)-17.3(al)-301.2(and)-296.3(-go)-8.7(nadal)]TJ
T*
[(axes)-269.8(and)-258.4(prom)-10.7(ote)-260.8(psychomotor)-15.1(,)-258.3(affective,)-271.3(and)-258.4(cogn)-9.8(itive)-259.3(dysfunctio)-14.9(n)-259.9(i)0(n)]TJ
T*
[(female)-309.3(mice.)-305.5(Horm)-299.5(Behav)-309.6(2020;119:104649;)-313.6(doi:)-299.6(10.1)-10.6(016/j.yhbeh.2019)]TJ
T*
[(.104)-10.6(649)]TJ
-2.2307 -1.1988 TD
[(155.)-503.8(Ma)-8.9(rtelli)-263.2(M,)-260.6(Zingaretti)-266(L,)-260.7(Salvio)-262.8(G,)-258.2(et)-263(al.)-263.5(Inîuence)-264(of)-260.6(work)-261.8(on)-265.2(andropause)]TJ
2.2307 -1.1988 TD
[(an)-8.5(d)-295.4(menopaus)-13.1(e:)-297(A)-298.9(systematic)-314.4(review.)-306.7(Int)-300.7(J)-303.7(Environ)-303.6(Res)-304(Public)-306.4(Health)]TJ
0 -1.2064 TD
[(2021;18)-13.3(\(19\):10074;)-307.4(doi:)-307.2(10.3390/ijerph18191007)-17.7(4)]TJ
-2.2307 -1.1988 TD
[(156.)-503.8(OêKe)-9.9(lly)-234.9(AC,)-235.6(Michos)-236(ED,)-236.2(Shufelt)-240.1(CL,)-235(et)-232.7(al.)-233.2(Pregnanc)-10.6(y)-230.1(and)-235.6(reproductive)-242.4(risk)]TJ
2.2307 -1.1988 TD
[(factors)-314(for)-302.8(cardiovascular)-308.9(disease)-308.9(in)-304(women.)-305.3(Circ)-304.2(Res)-296.4(2022;13)-13.3(0\(4\):652Ö)]TJ
T*
[(672;)-306.5(doi:)-307.2(10.1161/circresaha.12)-20.1(1.319895)]TJ
-2.2307 -1.1988 TD
[(157.)-503.8(Bhasin)-309.8(S,)-300.4(Brito)-306.1(JP,)-304.1(Cunningham)-307.1(GR,)-303.9(et)-301(al.)-301.4(Testosteron)-15.1(e)-296.7(therapy)-308.1(in)-296.4(men)]TJ
2.2307 -1.1988 TD
[(wit)-9.9(h)-297.8(hypogonadism:)-312.9(An)-300.8(Endocrine)-305.5(Society)-312.2(clinical)-300.3(practice)-311.3(guideline.)]TJ
0 -1.2064 TD
[(J)-303.7(Clin)-307.3(Endocrinol)-308.7(Metab)-301.8(2018;103\(5\):1715Ö1)-17.7(744;)-298.9(doi:)-307.2(10.1210/jc.20)-15.7(18-)]TJ
0 -1.1988 TD
(00229)Tj
-2.2307 -1.1988 TD
[(158.)-503.8(Gh)-9.4(arakhanian)-257.6(S,)-254.9(De)-255.3(Wit)-260.1(S.)-254.9(Hypogonadi)-13.5(sm)-251.6(in)-258.5(HIV)-250.9(in)-8.1(fection:)-259.6(Time)-255.7(to)-260(ìne-)]TJ
2.2307 -1.1988 TD
[(tu)-9.6(ne)-298.6(clinical)-307.9(monitoring)-304.5(of)-306.1(persons)-306.8(with)-300.1(HIV?)-303.6(AIDS)-305.9(2022;36\(8\):1197Ö)]TJ
T*
[(1199;)-304.9(doi:)-307.2(10.1097/qa)-12.7(d.0000000000003256)]TJ
-2.2307 -1.1988 TD
[(159.)-503.8(Moreno)-12.3(-Pe)]TJ
6.4342 .0303 TD
(¥)Tj
.4021 -.0303 TD
[(rez)-298.9(O,)-299.7(Pico)]TJ
4.0669 .0303 TD
(¥)Tj
.7208 -.0303 TD
[(Alfonso)-307(AM,)-301.5(Portilla)-304.8(J.)-304(Hypogonadis)-13.1(m,)-297.8(erectile)]TJ
-9.3934 -1.1988 TD
[(dy)-9.5(sfunction)-303.2(and)-303.9(endothelia)-10.8(l)-294.5(dysfu)-11.7(nction)-301(among)-305.7(HIV-infected)-309.4(men)]TJ
0 -1.2064 TD
[([in)-303.8(Spanish].)-308.3(Med)-306.1(Clö)]TJ
8.3463 .0228 TD
(¥)Tj
.2656 -.0228 TD
[(n)-297.8(2009;132)-11.7(\(8\):311Ö321;)-308.2(doi:)-299.6(10.1)-10.6(016/j.med-)]TJ
-8.6119 -1.1988 TD
[(cli.2008)-14.5(.07.018)]TJ
-2.2307 -1.1988 TD
[(160.)-503.8(De)-308.4(Vincentis)-304.2(S,)-300.4(Decaroli)-307.4(MC,)-303.2(Fanelli)-307.7(F,)-295.2(et)-308.6(al.)-301.4(Health)-300.5(status)-307.9(is)-301.7(related)-303.2(to)]TJ
2.2307 -1.1988 TD
[(testos)-13.8(terone,)-214.9(estrone)-214.2(and)-212.9(body)-219.2(fat:)-213.4(Moving)-213.9(to)-214.4(functio)-13.5(nal)-212(hypogonadism)]TJ
T*
[(in)-304(adult)-302.7(men)-307.8(with)-300.1(HIV.)-304.3(Eur)-302.1(J)-303.7(Endocrinol)-308.7(2021;184\(1\):107Ö12)-17.7(2;)]TJ
T*
[(doi:)-307.2(10.1530/eje-)-13.5(20-0855)]TJ
-2.2307 -1.2064 TD
[(161.)-503.8(Qrar)-11.1(eya)-298.2(AN,)-303.3(Mahdi)-304.9(F,)-302.8(Kaufman)-305.5(MJ,)-298.7(et)-308.6(al.)-301.4(Age-related)-302.8(neuro)-10(endocrine,)]TJ
2.2307 -1.1988 TD
[(cogn)-9.8(itive,)-305.1(and)-296.3(beha)-8.8(vioral)-300.8(co-morbidities)-314.2(are)-300(promot)-12.7(ed)-296.2(by)-305.4(HIV-1)-303.9(Tat)]TJ
T*
[(expr)-9.4(ession)-301.7(in)-304(male)-303.6(mice.)-305.5(Aging)-303.3(2022;14\(13\):5345Ö53)-16.1(65;)-300.5(doi:)-307.2(10.18632/)]TJ
T*
[(ag)-8.5(ing.204166)]TJ
-2.2307 -1.1988 TD
.0226 Tc
[(1)-6.1(6)-6.1(2)1.5(.)-508.8(C)-4.8(ru)-5.5(m)-305.3(N)-4.3(F,)-303.9(Fu)-5.5(r)-4.4(t)-4.4(e)-.9(k)-306.1(K)2.1(J)-8(,)-303.9(Ols)-7.3(o)2.1(n)-305.6(P)-.3(E)-4.4(,)-303.9(et)-307.9(al)-6.4(.)-296.4(A)-306.7(r)-4.4(e)-.9(vi)-6.4(ew)-303.1(o)-5.5(f)-301(hyp)-7.2(o)2.1(g)-9.6(o)2.1(na)-6.8(di)-6.4(sm)-305.3(a)-6.8(n)-2.1(d)]TJ
2.337 -1.1988 TD
.0245 Tc
[(erecti)-4.5(le)-302.5(d)-5.3(y)-.7(sfuncti)-4.5(o)4(n)-303.7(a)-4.9(mong)-296.1(H)-5.8(I)3.1(V)-7.7(-).2(infec)-6.5(t)-2.5(ed)-301.2(men)-303.7(d)-5.3(uri)-4.5(n)-.2(g)-303.7(t)5.1(h)-7.7(e)-295(p)-5.3(r)-2.5(e-)-303.3(and)]TJ
T*
.0241 Tc
[(po)-4(st-H)-6.2(AART)-306.4(e).6(ras)-5.8(:)-302.4(Dia)-5.3(gno)-4(si)-4.9(s,)-302.4(p)-5.7(a)2.3(th)]TJ
14.6743 0 TD
.0255 Tc
[(ogene)-5.6(s)3.2(is,)-301(a)-3.9(nd)-300.2(manage)-5.6(ment.)-301(A)-.3(ID)6.2(S)]TJ
-14.6743 -1.2064 TD
.0291 Tc
[(P)6.2(a)-.3(t)9.7(i).1(e)5.6(n)4.4(t)-301.4(C)1.7(a)7.3(r)2.1(e)-297.9(STD)9.8(S)-301.4(2)8(005)8(;1)8(9\()6.6(10\))6.6(:)6.1(655)8(Ö6)8(71;)-289.9(doi)7.7(:)-297.4(10)8(.1)8(089)8(/a)7.3(pc)5.7(.)6.1(200)8(5.)]TJ
0 -1.1988 TD
.0287 Tc
[(1)7.6(9)0(.)5.7(655)]TJ
-2.337 -1.1988 TD
0 Tc
[(163.)-503.8(Cu)-10(-Uvin)-281.8(S,)-285.2(Wright)-283.4(DJ,)-285.4(Anderson)-289.4(D,)-285.2(et)-285.8(al.)-278.7(Hormonal)-289.2(levels)-285.8(among)-290.5(HIV-1-)]TJ
2.2307 -1.1988 TD
[(seropos)-14.3(itive)-266.9(women)-274.6(compare)-11.2(d)-265(with)-277.4(high-risk)-276.3(HIV-seronegative)-276.3(women)]TJ
T*
[(during)-307.4(the)-302.9(menstrual)-311.4(cycle.)-307(J)-296.1(Womens)-312(Health)-300.5(Gend)-305.6(Based)-300.1(Med)-306.1(2000;)]TJ
T*
[(9\(8\):857Ö8)-13.6(63;)-300.5(doi:)-307.2(10.1089/15246)-13.7(0900750020883)]TJ
-2.2307 -1.2064 TD
[(164.)-503.8(Szotek)-310.8(EL,)-302.8(Narasipura)-308.7(SD,)-304.5(Al-Harthi)-307.1(L.)-298.6(17)]TJ
/F9 1 Tf
19.1434 0 TD
(b)Tj
/F7 1 Tf
.5539 0 TD
[(-Estradiol)-310.8(inhibits)-306.5(HIV-1)-303.9(by)]TJ
-17.4665 -1.1988 TD
[(in)-8.1(ducing)-303.8(a)-294.9(complex)-307.3(formation)-306.1(between)]TJ
/F9 1 Tf
17.0113 0 TD
(b)Tj
/F7 1 Tf
.5539 0 TD
[(-catenin)-304.6(and)-296.3(estrogen)-307.1(recep-)]TJ
-17.5652 -1.1988 TD
[(to)-9.6(r)]TJ
/F9 1 Tf
1.472 0 TD
(a)Tj
/F7 1 Tf
.7815 0 TD
[(on)-280.4(the)-287.7(HIV)-281.2(promoter)-291(to)-282.7(suppress)-288.8(HIV)-281.2(transcri)-12.6(ption.)-283.1(Virology)-284(2013;)]TJ
-2.2535 -1.1988 TD
[(443\()-10.1(2\):375Ö383;)-308.4(doi:)-299.6(10.1016)-13.3(/j.virol.2013.05.027)]TJ
31.3745 81.604 TD
[(165.)-503.8(Periyasamy)-311.5(P,)-296.3(Thang)-8.9(araj)-302.1(A,)-299.2(Guo)-306.5(M-L,)-302.4(et)-301(al.)-301.4(Epigeneti)-10.6(c)-296.6(promot)-12.7(er)-301(DNA)]TJ
2.2307 -1.2064 TD
[(methylation)-307.2(of)-306.1(miR-124)-300.6(prom)-10.7(otes)-298.3(HIV-1)-303.9(Tat-m)-10.7(ediated)-298.4(microg)-12.5(lial)-298.4(acti-)]TJ
0 -1.1988 TD
[(vation)-304.1(via)-300.2(MECP2-ST)-12(AT3)-301.5(axis.)-305.9(J)-296.1(Neuros)-11.8(ci)-295.2(2018;38)-13.3(\(23\):5367Ö5383;)]TJ
T*
[(doi:)-299.6(10.1)-10.6(523/jneurosci.3474-1)-17.6(7.2018)]TJ
-2.2307 -1.1988 TD
[(166.)-503.8(Shanmugam)-304.9(S,)-308(Patel)-298.8(D,)-300.3(Guindo)-10.6(n)-297.8(J)0(,)-304(e)0(t)-301(al.)-301.4(Gene)-306.9(expression)-303.5(of)-306.2(endocan-)]TJ
2.2307 -1.1988 TD
[(nabinoid)-307.9(system)-304.2(in)-304(HIV-1-related)-305.1(neuro)-10(pathic)-299.9(pain)-302.6(model.)-309.7(Biochim)]TJ
T*
[(Biophys)-308.6(Acta)-302.9(Mol)-302.2(Basis)-305.6(Dis)-298.2(2020;186)-11.7(6\(10\):165891;)-311.7(doi:)-299.6(10.1)-10.6(016/)]TJ
0 -1.2064 TD
[(j.bbadis.2020.1658)-17.7(91)]TJ
-2.2307 -1.1988 TD
[(167.)-503.8(Silverman)-304.1(MN,)-302.6(Pearce)-309.2(BD,)-298.1(Biron)-311.3(CA,)-296.3(et)-308.6(al.)-301.4(Immune)-305.9(modulation)-307.9(of)-298.6(the)]TJ
2.2307 -1.1988 TD
[(hypothalamic)-13(-pituitary-adrenal)-310.9(\(HPA\))-306.1(axis)-305.6(during)-299.8(viral)-303.1(infection.)-313.3(Viral)]TJ
T*
[(Immunol)-309(2005;18\(1\):41Ö78;)-309.6(doi:)-307.2(10.1089/vim.2005)-14.9(.18.41)]TJ
-2.2307 -1.1988 TD
[(168.)-503.8(Fekete)-220.6(EM,)-219.2(Ant)-9.2(oni)-218.3(MH,)-222.6(Lopez)-218.4(C,)-225(et)-217.5(al.)-218(Stress)-225.1(bufferin)-12.7(g)-214.3(effects)-228.4(of)-215.1(oxytocin)]TJ
2.2307 -1.1988 TD
[(on)-303.1(HIV)-304(status)-300.3(in)-304(low-income)-309.8(ethnic)-304.1(minority)-305.5(women)-9.1(.)-296.2(Psychon)-11.9(euroen-)]TJ
T*
[(docrinology)-312.2(2011;36\(6\):881Ö890;)-313.9(doi:)-307.2(10.1016/j.psyneuen.20)-19.9(10.12.003)]TJ
-2.2307 -1.2064 TD
[(169.)-503.8(Cole)-305.3(SW.)-299.6(Psychosoc)-15.6(ial)-299.8(inîuences)-309.1(on)-295.5(HIV-)-9.6(1)-294.3(disease)-308.9(progression)-13.5(:)-296.2(Neural,)]TJ
2.2307 -1.1988 TD
[(endocrine,)-310(and)-303.9(virologic)-300.7(mechani)-12.2(sms.)-304.6(Psychosom)-304.9(Med)-306.1(2008;70\(5\):)]TJ
T*
[(562Ö568;)-310(doi:)-299.6(10.1097/PSY.0b)-16.8(013e3181773bbd)]TJ
-2.2307 -1.1988 TD
[(170.)-503.8(Leserman)-306.4(J,)-304(Petitto)-306(JM,)-298.7(Gu)-308.8(H,)-296.2(et)-308.6(al.)-301.4(Progression)-310(to)-297.9(AIDS,)-306.2(a)-302.5(clinical)-300.3(AIDS)]TJ
2.2307 -1.1988 TD
[(condition)-304.5(and)-303.9(mortality:)-314.7(Psychosocial)-307.8(and)-303.9(physiological)-313.7(predictors.)]TJ
T*
[(Psychol)-304.6(Med)-306.1(2002;32\(6\):1059Ö10)-17.7(73;)-300.5(doi:)-299.6(10.1)-10.6(017/S0033291702)-14.3(005949)]TJ
-2.2307 -1.2064 TD
[(171.)-503.8(Ironson)-214.2(G,)-212.7(OêCleirigh)-218.1(C,)-217.4(Kumar)-212.9(M,)-215(et)-209.9(al.)-218(Psychosocial)-216.8(and)-212.9(neuro)-10(hormonal)]TJ
2.2307 -1.1988 TD
[(predictors)-259.6(of)-245.5(HIV)-250.9(disease)-248.2(progressi)-13.8(on)-250(\(CD4)-249.7(cells)-248.7(and)-250.8(viral)-250(load\):)-252.9(A)-245.8(4)-248.7(year)]TJ
T*
[(prospective)-308.2(study.)-307.3(AIDS)-305.9(Behav)-302(2015;19\(8\):13)-15.8(88Ö1397;)-302.4(doi:)-307.2(10.1007/)]TJ
T*
[(s10461-014-)-12.4(0877-x)]TJ
-2.2307 -1.1988 TD
[(172.)-503.8(de)-303.8(la)-301.2(Torre)-299.6(B,)-301.5(vonKrogh)-313.3(G,)-303.7(Svensson)-300.6(M,)-306.1(et)-301(al.)-301.4(Blood)-302.4(cor)-10.3(tisol)-302.3(and)-303.9(dehy-)]TJ
2.2307 -1.1988 TD
[(droepiandroste)-15.1(rone)-300.6(sulphate)-304.9(\(DHEA)-11(S\))-299.9(levels)-300.9(and)-303.9(CD4)-303.1(T)-300.1(cell)-302.2(counts)-305.4(in)]TJ
0 -1.2064 TD
[(HIV)-304(infection.)-305.7(Clin)-299.7(Ex)-9(p)-295.4(Rheum)-9.8(atol)-303.2(1997;15\(1\):87Ö90.)]TJ
-2.2307 -1.1988 TD
[(173.)-503.8(Wen)-290.2(Y,)-296.3(Ding)-294.9(HB,)-293.9(Chen)-290(W,)-295.4(et)-293.4(al.)-293.9(Correlation)-300.3(of)-298.6(baseline)-294.7(hormonal)-298.8(disor-)]TJ
2.2307 -1.1988 TD
[(ders)-300(with)-307.7(immunologic)-12.1(al)-301.2(failure)-299.9(and)-303.9(mortality)-306.9(in)-304(male)-303.6(HIV)-304(patients)]TJ
T*
[(during)-307.4(follow-up.)-307.2(Medicine)-306.7(2016;95\(52\):e57)-15(32;)-300.5(doi:)-299.6(10.1)-10.6(097/MD)]TJ
T*
[(.00000000000057)-15.5(32)]TJ
-2.2307 -1.1988 TD
[(174.)-503.8(Palermo)-260.2(M,)-260.6(Shackleton)-269.6(CHL,)-257.7(Mantero)-260.7(F,)-264.9(et)-255.4(al.)-255.9(Uri)-10.5(nary)-258(free)-261.2(cortisone)-263.5(and)]TJ
2.2307 -1.1988 TD
[(the)-302.9(assessment)-310.2(of)-298.6(11)-300.3(beta-hydr)-13.2(oxysteroid)-305.7(dehydrogenas)-16.9(e)-296.7(activity)-310.5(in)]TJ
0 -1.2064 TD
[(man.)-306.4(Clin)-299.7(Endocrinol)-308.7(1996;45\(5\):60)-15.8(5Ö611;)-298.1(doi:)-307.2(10.1046/j.13)-15(65Ö2265)]TJ
0 -1.1988 TD
(.1996.00853.x)Tj
-2.2307 -1.1988 TD
[(175.)-503.8(Wu)-300.5(Y,)-303.9(Wu)-300.5(Y,)-303.9(Deng)-304.6(J,)-296.4(et)-308.6(al.)-301.4(Screening)-303.4(and)-303.9(identiìcation)-313(of)-298.6(salivary)-304.1(bio-)]TJ
2.2307 -1.1988 TD
[(markers)-307.9(for)-302.8(assessing)-304(the)-302.9(effects)-311.8(of)-298.6(exogenou)-11(s)-295.5(testoster)-15.5(one)-296.3(adminis-)]TJ
T*
[(tration)-306(on)-303.1(HPG)-303.5(and)-303.9(HPA)-299(axes)-307.7(and)-296.3(ECS.)-309.3(Steroids)-304.9(2020;158)-11.7(:108604;)]TJ
T*
[(doi:)-299.6(10.1)-10.6(016/j.steroids.2020.1086)-22.4(04)]TJ
-2.2307 -1.2064 TD
[(176.)-503.8(Chu)-300.2(L,)-298.6(Li)-8.7(u)-293.6(W)0(,)-303(Deng)-304.6(J,)-296.4(et)-301(al.)-301.4(Age-rela)-9.9(ted)-300.5(changes)-301.7(in)-304(endogenous)-303.1(gluco-)]TJ
2.2307 -1.1988 TD
[(corticoids,)-313.1(gonadal)-301.2(steroid)-12.3(s,)-295.8(endocann)-11(abinoids)-305.6(and)-303.9(their)-305.8(ratios)-299.4(in)]TJ
T*
[(plasma)-300.9(and)-303.9(hair)-307.3(from)-304.5(the)-302.9(male)-296(C57BL/6)-311.9(mice.)-305.5(Gen)-298.6(Comp)-307(Endocrinol)]TJ
T*
[(2021;301:113651)-17.4(;)-296.2(doi:)-307.2(10.1016/j.ygcen.2)-17.1(020.113651)]TJ
-2.2307 -1.1988 TD
[(177.)-503.8(Chu)-300.2(L,)-306.2(Li)-297(N,)-307.9(Deng)-297.1(J,)-304(et)-301(al.)-301.4(LC-APCI)]TJ
/F8 1 Tf
16.5257 0 TD
(+)Tj
/F7 1 Tf
.7208 0 TD
[(-MS/MS)-303.7(method)-309.3(for)-302.8(the)-302.9(analysis)-302.3(of)]TJ
-15.0158 -1.1988 TD
[(ten)-287.7(hormo)-10.9(nes)-290.6(and)-288.7(two)-297.3(endocannabinoi)-14(ds)-287.4(in)-288.9(plasma)-300.9(and)-288.7(hair)-292.2(from)-296.9(the)]TJ
T*
[(mice)-305.2(with)-300.1(different)-308.3(gut)-299.8(microbio)-14(ta.)-299.5(J)-303.7(Pharm)-302.9(Biomed)-307.1(Anal)-298.5(2020;185)-11.7(:)]TJ
0 -1.2064 TD
[(113223;)-309.2(doi:)-299.6(10.1016/j.j)-14.5(pba.2020.113223)]TJ
-2.2307 -1.1988 TD
[(178.)-503.8(Chu)-231.9(L,)-230.3(Liu)-234(S,)-232.1(Wu)-232.2(Y,)-228.1(et)-232.7(al.)-233.2(Hair)-229.5(levels)-232.6(of)-237.9(steroid,)-232.7(endocann)-11(abinoid,)-230.4(and)-235.6(the)]TJ
2.2307 -1.1988 TD
[(ratio)-307.4(biomarkers)-303.8(predi)-10.3(ct)-300.9(viral)-303.1(suppression)-309.8(among)-305.7(people)-300.4(living)-309.8(with)]TJ
T*
[(HIV/AIDS)-307.3(in)-296.4(China.)-309.9(Clin)-299.7(Chim)-302.8(Acta)-302.9(2022;53)-13.3(5:143Ö152;)-308.7(doi:)-299.6(10.1016/)]TJ
T*
(j.cca.2022.08.023)Tj
-2.2307 -1.1988 TD
[(179.)-503.8(Wang)-305.6(W,)-303(Wu)-300.5(Y,)-303.9(Chu)-300.2(L,)-306.2(et)-301(al.)-301.4(Detection)-309.1(of)-298.6(endocannabinoi)-14.1(ds)-302.5(and)-296.3(gl)-8.1(u-)]TJ
2.2307 -1.2064 TD
[(cocorticoids)-235.3(in)-228.1(hair)-223.9(of)-222.7(peopl)-11.3(e)-220.8(living)-226.4(with)-224.3(HIV)-228.1(by)-229.6(high)-224.4(performance)-235.6(liquid)]TJ
0 -1.1988 TD
[(chromatogr)-13.5(aphy)-298.8(tandem)-303(ma)-8.3(ss)-302.6(spectrometry.)-308.8(Chin)-303(J)-303.7(Appl)-304.2(Chem)-304.9(2021;)]TJ
7.4718 0 0 7.4718 327.5149 216.0566 Tm
[(38\(11\):1521Ö15)-14.7(30.)]TJ
-2.2307 -1.1988 TD
[(180.)-503.8(G)-22.7(o)-20.5(r)-19.4(z)-20.7(a)-21.8(l)-21.4(k)-17.6(a)-325.3(B)-20.5(B)-20.5(,)-319(D)-19.3(a)-21.8(n)-24.7(g)-320.6(S)-19.4(S)-19.4(.)-319(M)-25(i)-21.4(n)-17.1(i)-21.4(r)-19.4(e)-23.5(v)-21.8(i)-21.4(e)-16(w)-22.2(:)-319(E)-19.4(n)-24.7(d)-22.2(o)-20.5(c)-23.4(a)-14.2(n)-24.7(n)-17.1(a)-21.8(b)-22.2(i)-21.4(n)-17.1(o)-28.1(i)-13.8(d)-22.2(s)-325.8(a)-21.8(n)-17.1(d)-318.2(g)-24.7(o)-20.5(-)]TJ
2.2307 -1.1988 TD
.019 Tc
[(nad)-3.2(a)-2.8(l)-298.3(h)-5.6(orm)-5.4(o)-1.5(ne)-4.5(s)-3.3(:)-300(Bid)-3.2(i)-2.4(rec)-4.4(t)-.4(ion)-5.7(a)-2.8(l)-298.3(i)-2.4(nt)]TJ
14.5453 0 TD
.0198 Tc
[(er)-7.2(a)5.6(c)-3.6(tions)-298.4(i)-1.6(n)-300.8(p)-2.4(hysiology)-301.3(a)-2(nd)-305.9(be-)]TJ
-14.5453 -1.1988 TD
.0209 Tc
[(havior.)-305.6(E)1.5(ndocrino)-7.2(l)7.1(o)-7.2(gy)-300.2(2012;153\()6(3\):1016Ö)5(1024;)-298.1(doi:)-305.6(10)7.4(.1210/e)5(n)]TJ
T*
(.2011-1643)Tj
-2.2307 -1.2064 TD
0 Tc
[(181.)-503.8(Pagotto)-209.9(U,)-212.7(Stalla)-208.6(GnK,)-212.3(Lutz)-214.8(B,)-202.9(et)-209.9(al.)-210.4(Requirement)-215.3(of)-207.5(cannab)-9.6(inoid)-208.8(receptor)]TJ
2.2307 -1.1988 TD
[(type)-302.9(1)-301.9(for)-302.8(the)-302.9(basal)-306.8(modulation)-307.9(of)-298.6(hypothala)-12(mic-pituitary-adre)-16.3(nal)-295.5(axis)]TJ
T*
[(function.)-311.6(Endocrinology)-310.8(2007;148\(4\):1574Ö1)-17.7(581;)-298.9(doi:)-307.2(10.1210/en.2005-)]TJ
T*
(1649)Tj
-2.2307 -1.1988 TD
[(182.)-503.8(Hillard)-302.1(CJ,)-308.7(Cullinan)-304.6(WE,)-299.6(Rademach)-10.3(er)-301(DJ,)-300.5(et)-301(al.)-309(Endocannabinoid)]TJ
2.2307 -1.1988 TD
[(signaling)-305.6(negatively)-303.3(modul)-10.4(ates)-299.6(stress-indu)-14.9(ced)-296.9(acti)-10.2(vation)-304.1(of)-298.6(the)]TJ
0 -1.2064 TD
[(hypothalamic)-13(-pituitary-adrenal)-310.9(axis.)-305.9(Endocrinology)-310.8(2004;145)-11.7(\(12\):)]TJ
0 -1.1988 TD
[(5431Ö5438;)-306.8(doi:)-307.2(10.1210/en.2004-06)-16.5(38)]TJ
-2.2307 -1.1988 TD
[(183.)-503.8(Atsak)-251.1(P,)-243.2(Hauer)-252.2(D,)-247.2(Campolongo)-258.4(P,)-243.2(et)-247.9(al.)-248.3(Glucocorti)-15.5(coids)-246.5(interact)-256.7(with)-247(the)]TJ
2.2307 -1.1988 TD
[(hippocampal)-306.9(endocann)-11(abinoid)-306(system)-304.2(in)-304(impairing)-300.1(retriev)-12.1(al)-301.2(of)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23231.5(17)]TJ
ET

endstream
endobj
144 0 obj
<</Length 20122>>stream
0 0 0 rg
/GS1 gs
1 i 
q 1 0 0 1 313.058 418.394 cm 0 0 m
.113 1.02 l
.671 3.658 2.352 5.338 4.989 5.896 c
6.009 6.009 l
6.009 4.989 l
5.159 4.932 l
3.117 4.572 1.438 2.893 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 546.236 424.403 cm 0 0 m
1.02 -.113 l
3.373 -.558 5.512 -2.505 5.839 -4.932 c
5.953 -6.009 l
4.932 -6.009 l
4.876 -5.159 l
4.586 -3.116 2.856 -1.44 .85 -1.077 c
0 -1.02 l
f*
Q
319.068 423.383 227.168 1.0205 re
f
q 1 0 0 1 319.068 374.57 cm 0 0 m
-1.02 .113 l
-3.474 .397 -5.449 2.568 -5.896 4.932 c
-6.009 5.953 l
-4.989 5.953 l
-4.932 5.102 l
-4.57 3.097 -2.893 1.367 -.85 1.077 c
0 1.02 l
f*
Q
q 1 0 0 1 552.189 380.523 cm 0 0 m
-.113 -1.02 l
-.244 -3.151 -2.802 -5.709 -4.932 -5.839 c
-5.953 -5.953 l
-5.953 -4.932 l
-5.102 -4.876 l
-3.097 -4.541 -1.371 -2.883 -1.077 -.85 c
-1.02 0 l
f*
Q
319.068 374.57 227.168 1.0205 re
f
313.058 380.523 1.0205 37.871 re
f
551.168 380.523 1.0204 37.871 re
f
q 1 0 0 1 313.058 345.373 cm 0 0 m
.113 1.02 l
.671 3.658 2.352 5.338 4.989 5.896 c
6.009 5.953 l
6.009 4.989 l
5.159 4.932 l
3.117 4.572 1.438 2.893 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 546.236 351.326 cm 0 0 m
1.02 -.057 l
3.385 -.504 5.556 -2.478 5.839 -4.932 c
5.953 -5.953 l
4.932 -5.953 l
4.876 -5.102 l
4.613 -3.125 2.783 -1.327 .85 -1.02 c
0 -.964 l
f*
Q
319.068 350.362 227.168 .96378 re
f
q 1 0 0 1 319.068 73.871 cm 0 0 m
-1.02 .057 l
-3.657 .614 -5.338 2.295 -5.896 4.932 c
-6.009 5.953 l
-4.989 5.953 l
-4.932 5.102 l
-4.597 3.129 -2.84 1.336 -.85 1.02 c
0 .964 l
f*
Q
q 1 0 0 1 552.189 79.824 cm 0 0 m
-.113 -1.02 l
-.397 -3.474 -2.568 -5.449 -4.932 -5.896 c
-5.953 -5.953 l
-5.953 -4.989 l
-5.102 -4.932 l
-3.106 -4.532 -1.363 -2.916 -1.077 -.85 c
-1.02 0 l
f*
Q
319.068 73.871 227.168 .96375 re
f
313.058 79.824 1.0205 265.55 re
f
551.168 79.824 1.0204 265.55 re
f
BT
/F7 1 Tf
7.4718 0 0 7.4718 78.6897 700.2707 Tm
0 Tc
0 Tw
[(contextu)-12.2(al)-301.2(fear)-297.3(memo)-9.4(ry.)-302.9(Proc)-306.3(Natl)-302(Acad)-305.7(Sci)-299.4(U)-303.4(S)-300.1(A)-298.9(2012;109)-11.7(\(9\):3504Ö)]TJ
0 -1.2064 TD
[(3509;)-304.9(doi:)-307.2(10.1073/pnas.120074)-19.9(2109)]TJ
-2.2307 -1.1988 TD
[(184.)-503.8(Haller)-304.8(J,)-304(Varga)-302(B,)-301.5(Ledent)-305.6(C,)-300.9(et)-308.6(al.)-301.4(Context-dependent)-309.7(effects)-311.9(of)-298.6(CB1)]TJ
2.2307 -1.1988 TD
[(cannab)-9.6(inoid)-299.9(gene)-301.3(disruption)-312.8(on)-303.1(anxiety-like)-302.2(an)-8.5(d)-295.4(socia)-10.8(l)-294.5(beha)-8.8(viour)-300.9(in)]TJ
T*
[(mice.)-305.5(Eur)-302.1(J)-303.7(Neurosci)-307(2004;19\(7\):19)-15.8(06Ö1912;)-302.4(doi:)-307.2(10.1111/j.1460-9568)]TJ
T*
[(.2004.03293.)-16.6(x)]TJ
-2.2307 -1.1988 TD
[(185.)-503.8(Ganon-)-9.6(Elazar)-299(E,)-308(Akirav)-302.3(I.)-302.4(Cannabinoid)-305.9(receptor)-308.2(activation)-306.7(in)-304(the)-302.9(baso-)]TJ
2.2307 -1.2064 TD
[(lateral)-308.2(amygdala)-304.7(blocks)-309.6(the)-302.9(effects)-304.3(of)-298.6(stress)-311.5(on)-303.1(the)-302.9(conditioning)-306.9(and)]TJ
0 -1.1988 TD
[(extinction)-248.9(of)-237.9(inhibitory)-250.7(avoidance.)-247(J)-235.4(Neurosci)-246.3(2009;29\(36\):1107)-18.6(8Ö11088;)]TJ
T*
[(doi:)-307.2(10.1523/jneurosci.1)-18(223-09.2009)]TJ
-2.2307 -1.1988 TD
[(186.)-503.8(Wang)-305.6(M,)-298.5(Hill)-306.9(MN,)-302.6(Zhang)-302.6(L,)-298.6(et)-308.6(al.)-301.4(Acute)-302.4(restraint)-305.3(stress)-311.5(enhances)-302.5(hip-)]TJ
2.2307 -1.1988 TD
[(pocampa)-12.3(l)-294.5(endocann)-11(abinoid)-306(function)-303.7(via)-300.2(gluco)-11.8(corticoid)-305.6(receptor)-308.2(acti-)]TJ
T*
[(vation.)-304.4(J)-303.7(Psychopharma)-15.4(col)-300.5(2011;26\(1\):56Ö7)-15(0;)-302.2(doi:)-299.6(10.1177/0)-12.6(269881)]TJ
T*
[(1114096)-11.4(06)]TJ
-2.2307 -1.2064 TD
[(187.)-503.8(Hill)-306.9(MN,)-302.6(McLaughlin)-308.7(RJ,)-296.5(Pan)-304.6(B,)-301.5(et)-301(al.)-301.4(Rec)-9.2(ruitment)-301.9(of)-306.1(prefrontal)-311.2(cortical)]TJ
2.2307 -1.1988 TD
[(endocann)-11(abinoid)-306(signaling)-305.6(by)-297.8(glucocortico)-15.8(ids)-301.2(contributes)-312.8(to)-297.9(term)-11(ina-)]TJ
T*
[(tion)-306(of)-298.6(the)-302.9(stress)-311.5(response.)-307.9(J)-296.1(Neuros)-11.8(ci)-302.8(2011;31\(29\):10506Ö1)-16.1(0515;)]TJ
T*
[(doi:)-307.2(10.1523/jneurosci.0)-18(496-11.2011)]TJ
-2.2307 -1.1988 TD
[(188.)-503.8(Rober)-10(ts)-299.7(CJ,)-301.1(Stuhr)-308.3(KL,)-303.9(Hutz)-303.4(MJ,)-298.7(et)-308.6(al.)-301.4(Endocannabinoid)-312.9(signaling)-305.6(in)-296.4(hy-)]TJ
2.2307 -1.1988 TD
[(potha)-10(lamicÖpituitaryÖadrenoc)-20.5(ortical)-306.7(axis)-298(recovery)-305.9(follow)-12.2(ing)-298.3(stress:)]TJ
0 -1.2064 TD
[(Effects)-307.7(of)-306.1(indirect)-304.6(agonists)-306.1(and)-303.9(comparison)-311.8(of)-298.6(male)-303.6(and)-303.9(female)-301.7(mice.)]TJ
0 -1.1988 TD
[(Pharmaco)-12(l)-294.5(Bio)-9.3(chem)-300.9(Behav)-302(2014;117)-11.7(:17Ö24;)-306(doi:)-299.6(10.1016/j.pb)-17.3(b.2013)]TJ
T*
(.11.026)Tj
-2.2307 -1.1988 TD
[(189.)-503.8(Hill)-306.9(MN,)-302.6(McLaughlin)-308.7(RJ,)-296.5(Bingh)-9.7(am)-296.6(B,)-301.5(et)-308.6(al.)-301.4(Endogenous)-306.5(cannabin)-10.2(oid)]TJ
2.2307 -1.1988 TD
[(signaling)-222.1(is)-210.6(essential)-215.6(for)-219.4(stress)-220.5(adaptation.)-215.6(Proc)-215.3(Natl)-218.5(Acad)-214.7(Sci)-216(U)-212.4(S)-216.6(A)-207.9(2010;)]TJ
T*
[(107\(20\):9)-12.8(406Ö9411;)-308.4(doi:)-299.6(10.1073/pnas)-14.2(.0914661107)]TJ
-2.2307 -1.2064 TD
[(190.)-503.8(Hill)-223.5(MN,)-226.8(Tasker)-230.3(JG.)-228.1(Endocannabinoid)-229.4(sign)-9.6(aling,)-220.4(glucoc)-12.5(orticoid-mediated)]TJ
2.2307 -1.1988 TD
[(negative)-309.9(feedback,)-303.8(and)-303.9(regulation)-308.4(of)-298.6(the)-302.9(hypothal)-13(amic-pituitary-)]TJ
T*
[(adrenal)-306.7(axis.)-305.9(Neuroscience)-311.2(2012;204:5Ö16;)-311.7(doi:)-307.2(10.1016/j.neuroscience)]TJ
T*
[(.2011.12.)-13.9(030)]TJ
-2.2307 -1.1988 TD
[(191.)-503.8(Cota)-309.2(D,)-300.3(Steiner)-303.2(M-A,)-303(Marsica)-11.1(no)-295.5(G,)-303.7(et)-301(al.)-301.4(Requirem)-11.1(ent)-302.9(of)-298.6(canna)-10.1(binoid)]TJ
2.2307 -1.1988 TD
[(receptor)-308.2(type)-302.9(1)-301.9(for)-302.8(the)-302.9(basal)-306.8(modulation)-307.9(of)-306.1(hypothalamic-pituita)-16.6(ry-)]TJ
T*
[(adrenal)-306.7(axis)-305.6(function.)-304(Endoc)-11.6(rinology)-306.7(2007;148\(4\):1574Ö15)-16.1(81;)]TJ
0 -1.2064 TD
[(doi:)-307.2(10.1210/en.2005-16)-16.5(49)]TJ
-2.2307 -1.1988 TD
[(192.)-503.8(Romero)-245.1(EM,)-249.6(Fernandez)-247.9(B,)-240.8(Sagredo)-250.2(O,)-239(et)-247.9(al.)-240.7(Antinociceptive,)-253.6(behavioural)]TJ
2.2307 -1.1988 TD
[(and)-303.9(neuroendocri)-13.5(ne)-298.6(effects)-304.3(of)-306.1(CP)-300.7(55,940)-303.3(in)-304(young)-305.2(rats.)-303.3(Brain)-305.1(Res)-304(Dev)]TJ
T*
[(Brain)-305.1(Res)-304(2002;136\(2\):85Ö)-15(92;)-300.5(doi:)-307.2(10.1016/S0165-380)-16.1(6\(02\)00306-1)]TJ
-2.2307 -1.1988 TD
[(193.)-503.8(Lammert)-310(S,)-300.4(Harrison)-308.9(K,)-301.5(Tosun)-304.6(N,)-300.3(et)-301(al.)-309(Menstrual)-304.4(cycle)-306.7(in)-296.4(women)-305(who)]TJ
2.2307 -1.1988 TD
[(co-use)-309.1(marijuana)-308.6(and)-296.3(tobacco)-14.8(.)-296.2(J)-303.7(Addict)-301.5(Med)-306.1(2018;12\(3\):207Ö)-15(211;)]TJ
0 -1.2064 TD
[(doi:)-307.2(10.1097/adm.0000)-15.7(000000000387)]TJ
-2.2307 -1.1988 TD
[(194.)-503.8(Martö)]TJ
4.1276 .0228 TD
(¥)Tj
.2656 -.0228 TD
(nez-Pen)Tj
2.9516 .0152 TD
()Tj
.4173 -.0152 TD
[(a)-294.9(AA,)-302.2(Petrik)-306.5(JJ,)-304.2(Hardy)-308.7(DB,)-298.1(et)-301(al.)-309(Delta-9-)]TJ
-5.5313 -1.1988 TD
[(tetrahydr)-13.2(ocannabinol)-307.8(increases)-308.7(vascular)-301.5(end)-9.8(othelial)-303.1(growth)-305.4(factor)]TJ
T*
[(\(VEGF\))-308.1(secretion)-304.5(through)-305.6(a)-302.5(cyclooxyg)-14.7(enase-dependent)-308.4(mechanism)]TJ
T*
[(in)-304(rat)-303.5(granulosa)-303.3(cells.)-309.7(Reprod)-305.4(Toxicol)-306(2022;111:59Ö67;)-310.1(doi:)-307.2(10.1016/)]TJ
T*
[(j.reprotox.2)-16.2(022.05.004)]TJ
-2.2307 -1.1988 TD
[(195.)-503.8(Grant)-229.5(KS,)-229.8(Petroff)-229.5(R,)-228(Isoherranen)-230.8(N,)-232(et)-225.1(al.)-225.6(Cannabis)-231.9(use)-225.7(during)-231.6(pregnancy)-12.4(:)]TJ
2.2307 -1.2064 TD
[(Pharmaco)-12(kinetics)-302.8(and)-303.9(effects)-304.3(on)-303.1(child)-302.8(develop)-11.1(ment.)-304.8(Pharmacol)-306.6(Ther)]TJ
0 -1.1988 TD
[(2018;182)-11.7(:133Ö151;)-302.7(doi:)-307.2(10.1016/j.phar)-15.4(mthera.2017.08.0)-16.6(14)]TJ
-2.2307 -1.1988 TD
[(196.)-503.8(Rettor)-11.5(i)-294.5(V)0(,)-305.7(D)0(e)-300.8(Laurentiis)-310.8(A,)-299.2(Fernandez-S)-10.8(olari)-301.8(J.)-304(Alcohol)-301.8(and)-303.9(endocanna-)]TJ
2.2307 -1.1988 TD
[(binoids)-10.6(:)-296.2(Neuroendo)-12.2(crine)-302.2(interactions)-307.6(in)-304(the)-302.9(reproductive)-310.7(axis.)-305.9(Exp)]TJ
T*
[(Neurol)-306.8(2010;224)-11.7(\(1\):15Ö22;)-303.8(doi:)-307.2(10.1016/j.expneuro)-18.3(l.2010.03.019)]TJ
-2.2307 -1.1988 TD
[(197.)-503.8(Scorticati)-308.3(C,)-293.3(Ferna)]TJ
9.3782 .0303 TD
(¥)Tj
.387 -.0303 TD
[(ndez-Solari)-300(J,)-296.4(De)-293.2(Laurentiis)-303.2(A,)-299.2(et)-293.4(al.)-293.9(The)-302.8(inhibitory)-296.2(ef-)]TJ
-7.5344 -1.2064 TD
[(fect)-306.6(of)-298.6(anand)-8.9(amide)-303.1(on)-303.1(luteinizing)-304.5(hormone-rele)-12(asing)-304.5(hormone)-301.9(secre-)]TJ
0 -1.1988 TD
[(tion)-306(is)-301.7(reversed)-304.9(by)-305.4(estrogen.)-307.4(Proc)-306.3(Natl)-302(Acad)-305.7(Sci)-299.4(U)-303.4(S)-300.1(A)-298.9(2004;101)-11.7(\(32\):)]TJ
T*
[(11891Ö11)-12.2(896;)-298.9(doi:)-307.2(10.1073/pnas.040436)-19.9(6101)]TJ
-2.2307 -1.1988 TD
[(198.)-503.8(Scorticati)-255.2(C,)-240.2(Mohn)-246.6(C,)-247.7(De)-240.1(Laurentiis)-250.1(A,)-246.1(et)-240.3(al.)-240.7(The)-242.1(effect)-251.6(of)-245.4(anandamide)-243.8(on)]TJ
2.2307 -1.1988 TD
[(prolactin)-308.1(secretion)-312.1(is)-301.7(modulated)-302.3(by)-305.4(estrogen.)-307.4(Proc)-306.3(Natl)-302(Acad)-305.7(Sci)-299.4(U)-303.4(S)-300.1(A)]TJ
T*
[(2003;100)-11.7(\(4\):2134Ö2139;)-312.5(doi:)-299.6(10.1073/p)-13.7(nas.0437924100)]TJ
-2.2307 -1.1988 TD
[(199.)-503.8(Cui)-304.5(N,)-300.3(Wang)-305.6(LN,)-302.8(Wang)-305.6(W,)-303(et)-301(al.)-301.4(The)-302.8(correlation)-311.4(of)-298.6(anandam)-9.6(ide)-302.4(with)]TJ
2.2307 -1.2064 TD
[(gonadotroph)-13.1(in)-304(and)-296.3(sex)-308.7(steroid)-300.7(hormo)-10.9(nes)-298.2(during)-307.4(the)-302.9(menstrual)-303.8(cycle)-10.8(.)]TJ
0 -1.1988 TD
[(Iran)-307.3(J)-296.1(Basic)-306.7(Med)-306.1(Sci)-299.4(2017;20\(11\):1268)-18.5(Ö1274;)-298.1(doi:)-307.2(10.22038)-11.7(/ijbms.2017)]TJ
T*
(.9488)Tj
-2.2307 -1.1988 TD
[(200.)-503.8(Berghui)-10.6(s)-295.5(P)0(,)-303.9(Rajnicek)-303.3(AM,)-309.1(Morozov)-307.8(YM,)-298.6(et)-301(al.)-301.4(Hard)-10.3(wiring)-300.7(the)-302.9(brain:)]TJ
2.2307 -1.1988 TD
[(Endoca)-10.6(nnabinoids)-301.8(shape)-304.3(neuro)-10(nal)-303.1(connectivity.)-307.2(Science)-311.2(2007;)]TJ
T*
[(316\(5828)-11.2(\):1212Ö1216;)-306.8(doi:)-307.2(10.1126/science.1)-15.9(137406)]TJ
-2.2307 -1.2064 TD
[(201.)-503.8(Chevaleyr)-11.6(e)-296.7(V)0(,)-305.7(Castillo)-304.7(PE.)-300.5(Heterosynapt)-14.5(ic)-302.8(LTD)-299.1(of)-306.1(hippocampal)]TJ
2.2307 -1.1988 TD
[(GABAerg)-10.7(ic)-302.8(synapses:)-306.1(A)-298.9(novel)-301.6(role)-304.9(of)-306.1(endocannabinoid)-13.5(s)-295.5(i)0(n)-304(regulating)]TJ
T*
[(excitabili)-11.2(ty.)-302.9(Neuron)-302.5(2003;38\(3\):46)-15.8(1Ö472;)-305.7(doi:)-299.6(10.1016/s)-13.7(0896Ös6273\(03\))]TJ
T*
[(00235Ö00)-12.2(236)]TJ
-2.2307 -1.1988 TD
[(202.)-503.8(Fitzjohn)-308.7(SM,)-302.7(Collingridge)-310.7(GL.)-298.6(Endo)-10.9(cannabinoids.)-309.4(Neuron)-302.5(2004;43\(6\):)]TJ
2.2307 -1.1988 TD
[(762Ö7)-9.5(64;)-300.5(doi:)-299.6(10.1)-10.6(016/j.neuron.2004.09)-18(.004)]TJ
31.3669 84.0017 TD
[(203)-10.3(.)-501.1(Gonza)]TJ
4.4994 .0303 TD
(¥)Tj
.387 -.0303 TD
[(lez)-300.8(S,)-300.4(Bisogno)-306.3(T,)-300.4(Wenger)-304.8(T,)-308(et)-301(al.)-301.4(Sex)-298.2(steroid)-308.3(inîuence)-309.5(on)]TJ
-2.6481 -1.2064 TD
[(cannabinoid)-301.9(CB)-10(1)-294.3(receptor)-308.2(mRNA)-304.9(and)-303.9(endocann)-11(abinoid)-298.4(levels)-308.5(in)-296.4(the)]TJ
0 -1.1988 TD
[(anterior)-306.8(pituitary)-304.7(gland.)-304.7(Biochem)-310.2(Biophys)-301(Re)-8.5(s)-295.5(Commu)-11(n)-297.8(2000;270)-11.7(\(1\):)]TJ
T*
[(260Ö266;)-302.4(doi:)-307.2(10.1006/bbrc.2000.)-19.8(2406)]TJ
-2.2383 -1.1988 TD
[(204)-10.3(.)-501.1(Minney)-303.9(SM,)-302.7(Lo)]TJ
8.0276 .0303 TD
(¥)Tj
.4173 -.0303 TD
[(pez)-301.7(HH.)-303.7(Adolescent)-310.4(cannabinoid)-309.5(treatment)-309.6(negatively)]TJ
-6.2066 -1.1988 TD
[(affects)-264.6(reproductive)-265.2(behavior)-266.4(in)-258.5(female)-263.8(rats.)-265.4(Pharmacol)-261(Biochem)-264.7(Behav)]TJ
T*
[(2013;112:82Ö88;)-310.1(doi:)-307.2(10.1016/j.pbb.2013)-18.1(.09.015)]TJ
-2.2383 -1.2064 TD
[(205)-10.3(.)-501.1(Bradshaw)-303.9(HB,)-301.5(Rimm)-9.6(erman)-303.6(N,)-300.3(Krey)-301.1(JF,)-303(et)-301(al.)-301.4(Sex)-305.8(and)-303.9(hormonal)-306.4(cycle)]TJ
2.2383 -1.1988 TD
[(differences)-305.1(in)-304(rat)-303.5(brain)-299.2(levels)-308.5(of)-298.6(pain-rela)-10.9(ted)-300.5(cannabimime)-11(tic)-299.5(lipid)-306(me-)]TJ
T*
[(diators.)-230.9(Am)-224.7(J)-220.2(Physiol)-226.7(Regul)-226.8(Integr)-231.8(Comp)-223.6(Physi)-10.3(ol)-224(2006;291\(2\):R349ÖR35)-18(8;)]TJ
T*
[(doi:)-299.6(10.1152/ajpre)-14(gu.00933.2005)]TJ
-2.2383 -1.1988 TD
[(206)-10.3(.)-501.1(Fonseca)-302.2(BM,)-303.8(Correia-da-Si)-13.8(lva)-300.2(G,)-303.7(Teixeira)-307.1(NA.)-295.8(Anandami)-12.3(de)-296.2(restri)-11.8(cts)]TJ
2.2383 -1.1988 TD
[(uterine)-304.3(stromal)-308.7(differentiation)-308.5(and)-303.9(is)-301.7(critical)-308.3(for)-302.8(complete)-307.5(decidualiza-)]TJ
T*
[(tion.)-298.7(Mol)-302.2(Cell)-306.2(Endocrinol)-308.7(2015;411)-11.7(\(C\):167Ö176;)-306.9(doi:)-307.2(10.1016/j.mce)]TJ
0 -1.2064 TD
(.2015.04.024)Tj
-2.2383 -1.1988 TD
[(207)-10.3(.)-501.1(Waleh)-303.1(NS,)-296.9(Cravatt)-310.5(BF,)-300.5(Apte-Deshp)-15(ande)-297.1(A,)-306.8(et)-301(al.)-301.4(Transcriptional)-315.8(regula-)]TJ
2.2383 -1.1988 TD
[(tion)-230.2(of)-222.7(the)-227(mous)-11.8(e)-220.8(fatty)-235(acid)-225.4(am)-8.2(ide)-226.5(hydrolase)-231.5(gene.)-233.3(Gene)-231.1(2002;291\(1Ö2\):)]TJ
T*
[(203Ö210;)-302.4(doi:)-307.2(10.1016/s0378-1)-14.7(119\(02\)00598-x)]TJ
-2.2383 -1.1988 TD
[(208)-10.3(.)-501.1(Murphy)-304.1(LL,)-301.1(Mun)]TJ
8.7105 .0076 TD
()Tj
.4097 -.0076 TD
[(oz)-306.7(RM,)-298.6(Adrian)-309.8(BA,)-296.9(et)-301(al.)-309(Function)-305.4(of)-298.6(canna)-10.1(binoid)]TJ
-6.8819 -1.1988 TD
[(receptors)-307.8(in)-296.4(the)-302.9(neuro)-10(endocrine)-302.1(regul)-10.9(ation)-297.5(of)-306.1(hormone)-309.5(secretion.)]TJ
0 -1.2064 TD
[(Neurobiol)-302.7(Dis)-305.8(1998;5\(6\):432Ö4)-15(46;)-300.5(doi:)-307.2(10.1006/nbdi.1998.022)-18.1(4)]TJ
-2.2383 -1.1988 TD
[(209)-10.3(.)-501.1(Brown)-304.6(TT,)-297(Do)-9.4(bs)-302.5(AS.)-295.8(Endo)-10.9(crine)-302.2(effects)-304.3(of)-306.1(marijuana.)-308.9(J)-296.1(Clin)-307.3(Pharmacol)]TJ
2.2383 -1.1988 TD
[(2002;42\(S1\):90SÖ9)-15.8(6S;)-298.8(doi:)-307.2(10.1002/j.1552Ö46)-16.9(04.2002.tb06008.x)]TJ
-2.2383 -1.1988 TD
[(210)-10.3(.)-501.1(Sollberger)-306.6(S,)-300.4(Ehlert)-302.4(U.)-303.7(How)-308.2(to)-297.9(use)-301.6(and)-303.9(interpret)-307(hormo)-10.9(ne)-298.6(ratios.)-307.3(Psy-)]TJ
2.2383 -1.1988 TD
[(choneuroendocrin)-15.7(ology)-301.9(2016;63:385Ö397;)-316.1(doi:)-299.6(10.1016)-13.3(/j.psyneuen)]TJ
T*
(.2015.09.031)Tj
-2.2383 -1.2064 TD
[(211)-10.3(.)-501.1(Chu)-300.2(LX,)-305.7(Huang)-304(Y,)-303.9(Xu)-300.7(YH,)-303.9(et)-301(al.)-301.4(An)-300.8(LC-APCI)-303.4(plus)-306.5(-MS/MS-based)-311.2(method)]TJ
2.2383 -1.1988 TD
[(for)-249.7(determinin)-12.3(g)-244.7(the)-257.3(concentration)-264.2(of)-245.4(neuro)-10(steroids)-254.7(in)-250.9(the)-257.4(brain)-253.7(of)-253(male)]TJ
T*
[(mice)-297.7(with)-307.7(different)-308.3(gut)-299.8(microbiota.)-313.5(J)-296.1(Neuros)-11.8(ci)-302.8(Methods)-302(2021;360)-11.7(:)]TJ
T*
[(109268;)-301.6(doi:)-307.2(10.1016/j.jneu)-14.9(meth.2021.109268)]TJ
/F5 1 Tf
-1.2975 -3.9531 TD
[(Cite)-278.9(this)-290.9(article)-284.3(as:)]TJ
/F7 1 Tf
8.4905 0 TD
[(Chu)-285(L,)-283.5(Shu)-284.6(Z,)-282.9(Gu)-286(X,)-280.5(Wu)-285.3(Y,)-281.2(Yang)-283.7(J,)-281.2(Deng)-289.5(H)-280.7(\(2023\))]TJ
-8.4905 -1.1988 TD
[(The)-295.2(endocann)-11(abinoid)-306(system)-304.2(as)-302.1(a)-302.5(potential)-308.3(therapeutic)-307.8(target)-302.9(for)]TJ
T*
[(HIV-1-associated)-289(neuro)-10(cognitive)-284.3(disorder,)]TJ
/F13 1 Tf
17.7017 0 TD
[(Cannabis)-288.3(and)-288(Cannabinoid)]TJ
-17.7017 -1.1988 TD
(Research)Tj
/F7 1 Tf
3.8621 0 TD
[(X:X,)-303(1Ö19,)-307.3(DOI:)-302.5(10.1089/can.2)-14.5(022.0267.)]TJ
/F5 1 Tf
8.9663 0 0 8.9663 393.1652 337.4361 Tm
[(Abbreviations)-336.5(Used)]TJ
/F7 1 Tf
7.4718 0 0 7.4718 362.0409 325.1338 Tm
(2-AG)Tj
/F12 1 Tf
2.2307 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(2-ara)-9.8(chidonoyl)-340.6(glycerol)]TJ
-3.6572 -1.1988 TD
(2-AGE)Tj
/F12 1 Tf
2.7239 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(2-ara)-9.8(chidonoyl)-340.6(glyceryl)-336.1(ether)]TJ
-3.2475 -1.1988 TD
(2-OG)Tj
/F12 1 Tf
2.3142 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(2-oleo)-9.9(ylglycerol)]TJ
-2.3142 -1.1988 TD
(AA)Tj
/F12 1 Tf
1.3809 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(arachi)-11.1(donic)-332.3(acid)]TJ
-3.3765 -1.1988 TD
(ACEA)Tj
/F12 1 Tf
2.4432 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(arachi)-11.1(donyl-2)]TJ
/F8 1 Tf
5.6831 0 TD
(¢)Tj
/F7 1 Tf
.2504 0 TD
[(-chloroethyla)-17.1(mide)]TJ
-9.3479 -1.1988 TD
(ACPA)Tj
/F12 1 Tf
2.4811 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(arachi)-11.1(donyl-cyclopropylami)-18.4(de)]TJ
-3.4144 -1.2064 TD
(ACTH)Tj
/F12 1 Tf
2.4811 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(adreno)-10.8(corticotropic)-342.9(hormo)-10.9(ne)]TJ
-2.7998 -1.1988 TD
(AEA)Tj
/F12 1 Tf
1.8665 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(N-arach)-10.5(idonylethanolamine)]TJ
-2.3521 -1.1988 TD
(AG)Tj
/F12 1 Tf
1.4189 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(Noladin)-341(ether)]TJ
-3.2019 -1.1988 TD
(Ca)Tj
5.6038 0 0 4.9805 369.6377 247.748 Tm
(2)Tj
/F8 1 Tf
.6778 0 TD
(+)Tj
/F12 1 Tf
7.4718 0 0 7.4718 378.7086 244.4597 Tm
(º)Tj
/F7 1 Tf
.9333 0 TD
(calcium)Tj
-2.7315 -1.1988 TD
(CB1)Tj
/F12 1 Tf
1.7982 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(canna)-10.1(binoid)-337.3(receptor)-338.6(type)-340.8(1)]TJ
-2.7315 -1.1988 TD
(CB2)Tj
/F12 1 Tf
1.7982 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(canna)-10.1(binoid)-337.3(receptor)-338.6(type)-340.8(2)]TJ
-2.8226 -1.2064 TD
(CNS)Tj
/F12 1 Tf
1.8893 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(centra)-10.9(l)-332.5(nervous)-334.9(sy)-9.6(stem)]TJ
-2.686 -1.1988 TD
(CRF)Tj
/F12 1 Tf
1.7527 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(corticotro)-17.8(pin)-333.9(releasing)-339.4(factor)]TJ
-3.0123 -1.1988 TD
(DAG)Tj
/F12 1 Tf
2.079 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(diacylglycer)-15.2(ol)]TJ
-3.4827 -1.1988 TD
(DAGL)Tj
/F12 1 Tf
2.5494 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(1,2-dia)-10.9(cylglycerol)-340.7(lipase)]TJ
/F4 1 Tf
10.3039 0 TD
(a)Tj
/F7 1 Tf
.5539 0 TD
(/)Tj
/F4 1 Tf
.3338 0 TD
(b)Tj
/F7 1 Tf
-14.0673 -1.1988 TD
(DGL)Tj
/F12 1 Tf
1.9424 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(diacylglycer)-15.2(ol)-330.2(lipase)]TJ
-2.2004 -1.1988 TD
(EA)Tj
/F12 1 Tf
1.2671 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(ethanola)-10.9(mine)]TJ
-2.6556 -1.2064 TD
(ECS)Tj
/F12 1 Tf
1.7224 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(endocann)-11(abinoid)-336.3(system)]TJ
-3.4372 -1.1988 TD
(FAAH)Tj
/F12 1 Tf
2.5039 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(fatty)-341.2(acid)-339.3(amide)-333.4(hydrola)-11.1(se)]TJ
-3.7482 -1.1988 TD
(gp120)Tj
/F12 1 Tf
2.815 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(glycopr)-12.7(otein)-337.2(120)]TJ
-4.3477 -1.1988 TD
(GPR119)Tj
/F12 1 Tf
3.4144 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(G-protein-co)-16.1(upled)-337.6(receptor)-338.6(119)]TJ
-3.8317 -1.1988 TD
(GPR55)Tj
/F12 1 Tf
2.8984 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(G-protein-co)-16.1(upled)-337.6(receptor)-338.6(55)]TJ
-2.2839 -1.1988 TD
(GR)Tj
/F12 1 Tf
1.3506 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(glucocor)-14.5(ticoid)-333.3(receptor)]TJ
-3.0123 -1.1988 TD
(HAD)Tj
/F12 1 Tf
2.079 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(HIV-asso)-13.1(ciated)-336.7(dementia)]TJ
-3.6648 -1.2064 TD
(HAND)Tj
/F12 1 Tf
2.7315 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(HIV-asso)-13.1(ciated)-336.7(neurocognitive)-347.5(disorders)]TJ
-2.8833 -1.1988 TD
(HPA)Tj
/F12 1 Tf
1.95 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(hypothal)-13(amicÖpituitaryÖadrenoco)-19.6(rtical)]TJ
-2.9288 -1.1988 TD
(HPG)Tj
/F12 1 Tf
1.9955 0 TD
(º)Tj
/F7 1 Tf
.9333 0 TD
[(hypothal)-13(amicÖpituitaryÖgonad)-18(al)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(18)Tj
44.153 0 TD
[(CHU)-307.8(ET)-299.4(AL.)]TJ
ET

endstream
endobj
148 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 1141>>stream
hﬁ\ë{LSw«Ô-‹;˛ê´<.ê^”{7ueº0
©¨‡VpTô`°Fy§-XÆºV*
ÇÉ≠ÄºV@b6√õDƒ!7≥»6"nÏW˜c….¸πú‰˚«9'ÁÛ=Á†à9AQ‘˛ÃI¡iÅ‡0?>34‚àWÇœEwâ≥pªDô(‘¥wó›>XˆœÉ7a z7PXUÏ5◊X#U¥3nææÓN€Íπ£ﬁNåª´´Îéz2¸¯4âîe)U“%#LçKS§ß).™§ÒŒ_.gI≤DïíQHïREÊv2Lë¶í∆±uFí≈D:ãÿ€ù ˆzzy:y˘∏;ˇﬂ&Ç≤ÅÏG	0GÑ(ä""ŸÕ.áò#o!gêf‰Ù(™DG9÷Á2gÑÕéòi∂í	ÿG<1eø ’	¢º(
äXñ∑◊¶∆È{ÉÛm©â{öú∫m´…ä¨ÁSΩ‰a⁄≈/
ZB.<Òö~ãì_◊ˆàªß¯Ë√ŸN©s9]~¸j†˛≤≈*ûﬂ¶ù)|©ùÀË?o()uXi~¸√:˜Æ∫Gﬁ∆3 ¬Pbë6OBœáìzCCôëZ˛Ù‰—†SÔ–|ú0˘€]ÆX5<Î◊íƒï—î¡=P èª≠ŒÕvΩ§KÒ/ƒ⁄ORπ≠‡&	I•Ø€)*D=4®◊¿Xﬂ®”}I¿„Õ9rﬂV¶U•*πÓ”â+‡Ïﬂ 8Æ∆˝¸váI¡±º+¯4ò≈ﬁﬂíì o^XxD›oçÖà?tÑVQÈ-wÈ‚÷≤z}≠6WHç"!GLì¸%∞Xw∑ÂÁ◊”Õ˜± IÕ
@:Aﬂ˝ìﬁ¿j¶ø∂¶Ö&L±¨ãXòÉ]ÀL∫*ß†?¥ÖÓƒ¡øósì=sΩÏ.ü∆Ò≤æ —™ÅM”êÙﬂJ&!öÈB^ö¸ê/XñE◊ç|çÅ&î&ÙÚ≥îÿÏè(q|CØöŒm’›—7XÄ ÿg6‹á‚Ë
ËﬂeF=ÄÌÃx›ın^X#˝dA˚Rﬁb√¯èKTo{F<ML 3ª;†»ı'èß©·ÜƒòtùJóMGB#ˆ∑∞ÚÊ≤oZ∏ø#¬¬$ÏÕ&¿4ÊÉCÍﬂs+ÿ	øö‘ò/Óº•∆Äãiä465KËˆKç)©Jer1/•.„&o’4ÿ’¯l~ú´óùœ‘eË‘ÙYµÃ¢∫±ÚV}{#˜U∞1\ îmøßz„„⁄∏¬Ë‹»¯õFM$tÉf=Ë	—n¿xoph#l⁄”˘BÚyÎ1ƒ¯–⁄Q3∂ÃÊÄÕü4=X¸mêÑ¨a˙˘#™™≤∏∏Ç6,c%Ö˘%T«b°ú÷·Â∑Ùù˙Nã \{° $˜túq ò™&≤1ª/g∞ÿbcylcXˆ]d;”¨jÏ‚~€›—ﬂ›°…´Â5Ma’YÒ’1‘ÅÄ`oqGÏ®úH´UIπ±2ô(Nb¯J≈#Lµ∂¶dÚ? ØÀ˛E

endstream
endobj
150 0 obj
<</Filter/FlateDecode/Length 266>>stream
hﬁTê=oƒ Üw~Ö«´:ê‰>rïPñk+eËáökwé8)RC!C˛}‰ÆÍÄ1Ô∂˘©~¨çˆ¿ﬂ›®Ù–i”:ú∆Ÿ)Ñˆ⁄@^@´ï_O1™AZ‡dnñ…„Põn!ˇ†À…ª6œ˘ˆ>ª˛ÊZt⁄Ù∞9Áü_öŸ⁄–x»†™†≈éÒ”ã¥Ør@‡—˜œãE(‚9_ø[ú¨TË§Èƒn[Å()†iˇﬂ±"9.ù˙ñé%eñ—∆ƒæà9må|´bw’'ª8‰$:Ï£ír« 8Ät	<(ãµÂıÒÙ\®/åÌ÷´öù£1ƒŸ∆fCõ⁄‡m¸v¥°´∞ÿØ  í4Ç.

endstream
endobj
153 0 obj
<</Length 4420>>stream
0 0 0 rg
/GS1 gs
1 i 
q 1 0 0 1 59.754 699.364 cm 0 0 m
.113 1.02 l
.602 3.474 2.462 5.394 4.932 5.896 c
6.009 5.953 l
6.009 4.989 l
5.159 4.876 l
3.116 4.586 1.44 2.856 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 292.875 705.316 cm 0 0 m
1.077 -.057 l
3.26 -.362 5.72 -2.708 5.896 -4.932 c
6.009 -5.953 l
4.989 -5.953 l
4.932 -5.102 l
4.639 -3.07 2.912 -1.411 .907 -1.077 c
0 -.964 l
f*
Q
65.764 704.353 227.112 .96381 re
f
q 1 0 0 1 65.764 598.167 cm 0 0 m
-1.02 .113 l
-3.628 .574 -5.318 2.396 -5.896 4.932 c
-6.009 6.009 l
-4.989 6.009 l
-4.932 5.102 l
-4.433 2.979 -3.016 1.504 -.85 1.077 c
0 1.021 l
f*
Q
q 1 0 0 1 298.885 604.176 cm 0 0 m
-.113 -1.077 l
-.461 -3.485 -2.551 -5.502 -4.932 -5.896 c
-6.009 -6.009 l
-6.009 -4.989 l
-5.102 -4.932 l
-2.98 -4.455 -1.512 -3.081 -1.077 -.907 c
-1.02 0 l
f*
Q
65.764 598.167 227.112 1.0205 re
f
59.754 604.176 1.0205 95.187 re
f
297.865 604.176 1.0204 95.187 re
f
q 1 0 0 1 310.847 699.364 cm 0 0 m
.057 1.02 l
.538 3.471 2.447 5.45 4.932 5.896 c
5.953 5.953 l
5.953 4.989 l
5.102 4.876 l
3.084 4.573 1.38 2.869 1.077 .85 c
.964 0 l
f*
Q
q 1 0 0 1 543.968 705.316 cm 0 0 m
1.02 -.057 l
3.505 -.503 5.415 -2.482 5.896 -4.932 c
5.953 -5.953 l
4.989 -5.953 l
4.876 -5.102 l
4.573 -3.084 2.869 -1.38 .85 -1.077 c
0 -.964 l
f*
Q
316.8 704.353 227.168 .96381 re
f
q 1 0 0 1 316.8 598.223 cm 0 0 m
-1.02 .113 l
-3.461 .431 -5.457 2.552 -5.896 4.932 c
-5.953 6.009 l
-4.989 6.009 l
-4.876 5.102 l
-4.541 3.097 -2.882 1.371 -.85 1.077 c
0 1.02 l
f*
Q
q 1 0 0 1 549.921 604.233 cm 0 0 m
-.057 -1.077 l
-.504 -3.442 -2.479 -5.612 -4.932 -5.896 c
-5.953 -6.009 l
-5.953 -4.989 l
-5.102 -4.932 l
-3.07 -4.639 -1.411 -2.912 -1.077 -.907 c
-.964 0 l
f*
Q
316.8 598.223 227.168 1.0205 re
f
310.847 604.233 .96378 95.131 re
f
548.957 604.233 .96375 95.131 re
f
BT
/F5 1 Tf
8.9663 0 0 8.9663 125.2346 691.4266 Tm
0 Tc
0 Tw
[(Abbreviations)-304.9(Used)-305.8(\(Cont.\))]TJ
/F7 1 Tf
7.4718 0 0 7.4718 115.6535 679.1243 Tm
(LH)Tj
/F12 1 Tf
1.2823 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(luteinizing)-342.4(hormone)]TJ
-3.6268 -1.1988 TD
(MAGL)Tj
/F12 1 Tf
2.686 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(monoacylglycer)-16.1(ol)-330.2(lipas)-10.5(e)]TJ
-3.8848 -1.1988 TD
(mGluR)Tj
/F12 1 Tf
2.944 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(metabo)-10.5(tropic)-338.9(glutamate)-341.2(receptor)]TJ
-3.7331 -1.1988 TD
(mRNA)Tj
/F12 1 Tf
2.7922 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(messenger)-345.1(RNA)]TJ
-3.6268 -1.2064 TD
(NADA)Tj
/F12 1 Tf
2.686 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(N-arach)-10.5(idonoyl-dopamine)]TJ
-3.3916 -1.1988 TD
(NAPE)Tj
/F12 1 Tf
2.4508 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(N-arach)-10.5(idonoyl)-338(phosphatidylethano)-15.8(lamine)]TJ
-5.3492 -1.1988 TD
(NAPE-PLD)Tj
/F12 1 Tf
4.4084 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(N-arach)-10.5(idonoyl)-338(phosphatidylethano)-15.8(lamine)]TJ
.8346 -1.1988 TD
[(phospholipase)-343(D)]TJ
-4.5905 -1.1988 TD
(NMDR)Tj
/F12 1 Tf
2.815 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
(N-methyl-)Tj
5.3796 0 0 5.3796 163.4456 607.4077 Tm
(D)Tj
7.4718 0 0 7.4718 166.9606 607.4077 Tm
[(-aspartate)-307.2(receptor)]TJ
25.0768 11.442 TD
(OEA)Tj
/F12 1 Tf
1.95 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(N-oleoylethano)-14.8(lamine)]TJ
-2.906 -1.1988 TD
(OVX)Tj
/F12 1 Tf
1.9652 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
(ovariectomized)Tj
-2.1245 -1.1988 TD
(PE)Tj
/F12 1 Tf
1.1837 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(phosphatidylet)-15.3(hanolamine)]TJ
-2.7315 -1.1988 TD
(PEA)Tj
/F12 1 Tf
1.7907 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(N-palmitoyleth)-13.1(anolamine)]TJ
-3.5965 -1.1988 TD
(PLWH)Tj
/F12 1 Tf
2.6556 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(people)-338.4(living)-340.2(with)-330.5(HIV/AI)-10.6(DS)]TJ
-2.8453 -1.1988 TD
(PVN)Tj
/F12 1 Tf
1.9045 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(paraventricul)-15.4(ar)-329.6(nucleus)]TJ
-2.815 -1.2064 TD
(ROS)Tj
/F12 1 Tf
1.8741 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(reactive)-341.3(oxygen)-335.9(species)]TJ
-2.3977 -1.1988 TD
(Tat)Tj
/F12 1 Tf
1.4568 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(transactivator)-349.8(of)-336.5(transcription)]TJ
-2.815 -1.1988 TD
(THC)Tj
/F12 1 Tf
1.8741 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(tetrahydr)-13.2(ocannabinol)]TJ
-3.2323 -1.1988 TD
(TRPC)Tj
/F12 1 Tf
2.2914 0 TD
(º)Tj
/F7 1 Tf
.9409 0 TD
[(transient)-340.9(receptor)-338.6(pote)-9.9(ntial)-336.3(cation)-336.1(channel)]TJ
/F5 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(ECS)-308.2(AS)-303.5(A)-299.6(POTE)-9.6(NTIAL)-306.4(THERAPE)-12.8(UTIC)-303.7(TARGE)-10.5(T)-301.2(FOR)-300.2(HAND)-23231.5(19)]TJ
ET

endstream
endobj
157 0 obj
<</Filter[/ASCII85Decode/FlateDecode]/Length 428>>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#s<Xl5FH@[<=!#6V)uDBXnIr.F>oRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0I<jlL.oXisZ;SYU[/7#<&37rclQKqeJe#,UF7Rgb1
VNWFKf>nDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j<etJICj7e7nPMb=O6S7UOH<
PO7r\I.Hu&e0d&E<.')fERr/l+*W,)q^D*ai5<uuLX.7g/>$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
158 0 obj
<</Filter/FlateDecode/Length 276>>stream
hﬁTëMo√ ÜÔ¸
;Ì@ívTìP.›*Â∞-›Óúi!à$á˛˚»:Ì ~1ˆcl¯°yjúùÅøáQ∑8Cgù	8çK–gÏ≠É≤cıºû“ÆÂÅSr{ùf◊ç %„t9Õ·
õcY‹w¿ﬂÇ¡`]õS˘˘EévÒ˛t3P◊`∞c¸¢¸´x ˚sûÆ°JÁr-=úº“îÎd’’ ˜¢tÊˇ{»ÁN_T`9≤(™cÕ‰nõ4“òı3iÒò4ñ†§…0bØîÌ/3óê¢§ ëi§…i"óπØ‚wôU≠¨úü'yk_/!–d“∏Sˇ±sÎˆ#~Ù±—∏ÿè  dÜÄ

endstream
endobj
160 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 1499>>stream
hﬁ\ìP”u«øõ|ø}=kÙ√o¡>∂œ¨ŒÆ§5ïD≤:¡–2B¨0~å¡Äˆ{ÃÕ¡`nìÒc„ª…€Ä¡`0ÇRä¢iVhôñŸï˝ÓºÆªÙ∫ÎÓ3˙‘]ì?ªÁÓuÔ{ûÁÓ˘uáH‚Á°ºÌ9Ø‰º¥>KRø{OÜd≥DöQV.z˘NhMp‚kÓ~ã±Ûo”“Ô$r$£·˚úk(Í~ÇÀ·Ñ&£¬ôô‚¥;‹∞ÃçÀL_f∆2∑§	7ä≈‚en\f∫0K¢(Ø4⁄ w4¬óÂ
µR°.”VJD¬¨∫:°ZVU≠’’ïöJu˝gæZ°≠¨HƒÖÂ·Î¢¬Ñ'ë-O‰º∏iSF⁄fq˙÷;jKZ¶8#°û'T˙&—ˇg"8	#Ó%à«‚iÇ»Êªb7á(‰Eëúÿ¡%HÇ!$ƒ˜úrŒ‹ı\˚ä‰˚W\N'©ìæ‡·Mº]hi)çŸK·Ø˛›Gûßx®=˛ f“vÆòüÉ(Ù(z≠Bœ£Ì∑œU„Uù0ÍtÕ∂‡|?’´»=∞Ábn∆ª—ΩÎ–÷≈´A˜˜€¿qöáæ\r/=Ã`eU^≥ö[JR
k±ATÇ;RSx6Œí¯Q ¶º–¥˘ÍSªu.S”æ"‹ñr‡È¶˝MUç•ZsQãUôÇŸ—iËÍ8ï⁄sü	˛tı•8)tÊü•Æ«◊Î>ÁJÌ>Ÿ∏ËLTNäøÅhF˛éLcˆñ#,DD—ö¿'WJSÉ”Ÿ;uzß‰fWó√Ïº∑0wˇπÒö·H¨7ú8:;{ÏÌ§Ùid∂©€‘ÜÊßÊ/@ºX¡òÃ°ô[”hÂ¬Yÿ›ÒD¿∞’⁄mµ¶Ìf	ùSÉ)|ø˛¸kÈfî:÷ÍrXJjf~RÅn‹Â™Í—–jÃ0¶Œ˜º{	˛2w=Ä∏¸+ ìoólﬁˇ»35ÇVG– –˝ùm]p∞P}ËxÎﬂT¶\:˙G≤16¬ˆ“7/ˇÈQ–Á◊c^¶Û´°≈§∑ œÅ~E˜0
e^I1(UN]]Ë[üÑS˝#—£`,‹ A÷‚vÈy˚Z˝ÙPkÌP)x#ßRZwHû»‡ßù(æ<˜ÌÙ’Kû©ñV32}ç™™Ç∆¡±¡H¥Un©ˇå0ıô lOòÖhÑ<Ìk◊UN˘Î{†OGçEÉ¿∂5ÎÏ0{»L}œ¡~0Òı‹Ù‰!Q\ã8å\Æ4ZÄµıHÑÖÅœÉãÅ≠é*¸jp†ﬁzPÀ4Y;E¥É
˝L~›{xB“Ç=∞GCÜá¢°#Äu™µB5^!«´ò√ZS˙‹˜pßÔíŒwÜ˛Ò,¢QÚI‡g^kÄ∆,cñ!ã~·@ó2Ü?ˇlÚn¢fÊ√ë…pÒ„©?~‚ﬂ⁄˜Qfmy£æJ∞•t«„¯A˛÷©mø&ßôΩußØ°ßÊø;ﬁ;Ω>ßú:Z˘,l«´◊Ó’“áõöf¿kDhíÒû%˝≠ßT@˘jYa1Ï—íë—X¢[w{≥Ã¨ï„dµ–mMLÙru_Ò}‚üÔõ;=0Fèº>‡ı⁄öºêµ{Z=lóªÀÎˆy∫€ÇV›c1˙å†"ÁEê˜6"ÕÃç€_]?°ÕüÅ“˘–$bh`t"¨W˜ñÕ“˛Æ.ê?,ãñ÷º©S÷	*dÊ9ø¯=ÈåL0+ıÍ‘¸Z•¢¢F:p\%∞ª≠ç6cs£©›HW =-‡mC7„€ºíöDÎõŸmπ⁄ß»<J]Á¥ê◊®&”ˆÀ¡˘ÎÛ”1h
ëjÕõ5F–dÛûÒ¬èQ‰∂ã‰]DäüôñÔÏ7Ïø–_⁄Õ«T†∂®®®
u‰‘X_¿<¨!ﬂ;ÛºxÉSDG®ã◊~EwÕ›†g>LèÒc≠Ü∞çF<|®Õ‚≤“Ó&ÁA#ˇ•ƒø≠+/‚˜0ˇ	0 ^“£„

endstream
endobj
163 0 obj
<</Subtype/Type1C/Length 419>>stream
  NCEKEG+AdvPSMP10 ¯ã˚¬˙q˘∂Õ‘ã¯6 
AdvPSMP10     B     d ÊK˜·¯à˜]¯ºØ^5ô˚ObLQYuªÃ˜ π˜·˜ñ˚ûyáÇhgb∞–z˜ ˜∑=3˚K˜	u}“G˚]˚[1,®9‹ÕƒøÂ∑GöîA¿πûÀ¿ì¯º˜ô¯áï∫†ﬂµµóó£ïûßª}Ebo˚=gè{}ê`åhÆìúçèô∏kúVX/Y˚+3miõ∑g˚ ˚EÜvÄ]yh◊ö´ì™éúØ˜D]¥≤±Ë˜Ë˜.ÃnΩ=ªˆ≥∏◊—⁄Kª:Ufypo]]l1Ñi¯Iø˜—¨ñî∑πî®Ñ_ù†Vê˚ê˚!QBg5fqìuü∑∑˜Òà˜!˜@≠˜Àûâ `w|wsbØm\a[18$É˜;ÖÁt’∏~rüi{wÅ~~yy`äU

endstream
endobj
166 0 obj
<</Filter/FlateDecode/Length 215>>stream
hﬁTP1n√0‹ı
é	2»ˆlx®ã⁄u“]ñhW@M	¥<¯˜ë'E¿#w§lª◊él ˘…N˜`¥d∑≤Fp≤e∆Í∞wı¨<»(Ó∑%‡‹—Ë†ÆÖ¸ä√%á∑≤:Gêg6»ñ&8\ Îw$˙’˚_úë–4`p≤}W˛CÕ2Î˛»ÀÊ™‹óªµ3∏x•ëMı†õ; ôˇ≥ábıèbqﬂ,äó∂qwgì*ÛL†WÊ._ú#$sK¯|äw>y•7 ¢diÙ

endstream
endobj
167 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 259>>stream
hﬁbd`ab`ddÚsvıvı“vL)0q6q57âäˇê·+ˇÙÎ›œi¨W¯o<Ï˛>GàÅâëëô◊Ÿ I102Ãclg`VË¯œ¿¬»»—øÜÔWÕwÂÔãE'NZ6wÂféÖ+Áoô"5°}RCAØ±œofπÇö∫Æ©ÜÖÌK´‰VULØõ÷¿·{≤.yâÙ¥˛I˙Î÷goó/\[8ßy
«œ©lìt/ú_“›*œ˜s⁄OÁÔ∑EgÕÎû?ø¢ªV˛œk∂⁄äÓÚÚy›≥‰º˙&:"S#ˇÁ%[Df&H€w†cZKªÀKÁwOñˇ±õmÚ|†ô• 3 u£o

endstream
endobj
168 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 565/BitsPerComponent 8>>stream
8;Z\4Mj8oK%.cZl&,WRAqe2O9!QTB)a#V#7jjZKb7?MEji;5br'"sbe>X[$HqMD)9
5J<YqoY%g?@#DLNR0l&eYfr)rr?Q3ETFBG>3gl>bJQ9/1\\n?f=?>>tQ).7sLUC/G
\>Y_P>C[cF,LXT@gPg!c.4hIoe/\Tt+KJ[LZN8K2$#YL9(6/gpk4#prXQGQ%01:Vi
A3:Um.H#hPUS!@R=W/Ia3XD=AVp=?.@I!V$m'!_!((=229%SMS938dH9:jS^hd>b1
8QW74It+lb(B/@:l`Rt*^Z="S+4pB_Dn\X\YoTC=$ep,F=0@RK8>jtm#Pm[n?-oM;
op7&qPciJ`n'ol[_4@pu\0kWRlLJNR"C6:aQfb?Hmr+&Ejnq1#hS<BjpoVe8ZSQTX
"##N=qSegXR*n72U"Pb!>_Qami0NVbY.93V`7D*W&#eQiJsZs_)JE1VDf)4"$NlaP
cpA_gK5-L0"8P*&F'pCHCnWt20Mj!L-C$518%9@8RbAQf+O].`W-#Rl^&KWm*F03$
JN/Tr$`T+sEtF,"/A\lB)P.ab%_i)GTL,,Y~>
endstream
endobj
63 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 526/BitsPerComponent 8>>stream
8;Z\76'B,>#g<64aEP4^CbZ3HA)lB41n@D%#*9)p8*%W&>S#)^T?fmZ(]PJAJWMAe
i(I2ij#LIskU)9E;Xl3'j0\lYT)%0*S&o-75f:cPAAl$u\J-"rq:14!qtj.9C9K;&
rF92O)T/-[d0K)Y'Grjj,quQRAc&R-7P<@G(Zdc0$Qnh\YjQmqZhqu]ntkg@6QdT#
R*aR&=9ZMIR39LlOF>ARmaDH&'g\nbVcB]&!S%U8E@pc#G6q>j:_-4K(\8B.QEK[7
d+"opo-c92+ks.W?`L<0hJ5KLco@5@i5eO=TgpUm&FCBi71nL_7(a'$ME$3qAREJ7
-3s!(j$cGhT"U\.CfGWM;TE.nj(C;UiG:7oE1;0BiF-a:;cHeh5fJmNqdHS'M5/0f
bHDFJ@(s"-`"F^fM@.(Pkg%eJpE;Iip$7Ac^N%c>\d&:&MLq/)/qa'<4A$L+'U=*b
39M.J4]!rT^0nilf\9CNbBi5mQ]]`$H$NK]M@[)rDP&3+r3Sds]]dCK!0'NpQ2~>
endstream
endobj
71 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 552/BitsPerComponent 8>>stream
8;Z]"8X@7J#Xl6'"h@CCQaCQ:<<4#E0e3b;r@3H%W4jtt&qp;F6]c4+%DO'>hZ)AO
C2%ghjq>`tUTr^/XaP+^@2?jfbgqsCfA*=/Ekc$J4O;SE)QdRGJ*k\g\;1?GL?p0e
*fK\mI8i?C>O]@o5[C<ciF/g-AbbT^Yue`k<D2\G*75%)cY(L:/:R?u*7;jtOrAsq
kkYc*mf2Ue8Lk0+'haQ-o.O-P_7%.VC4#3#>QCPtb5Is=fli$BBq-nDC^8AT?-FV'
\P-mF0\ircM>N]K0OO!40'KUHcEc<c=tlMkp,um^2'N?\CTLR3Ag)5&IaC5Gr\@f8
bZ\q2!jt5K:On[CIt'k$Kj`bKPUkG]1Z6%L5aq9PYj54To_Vnp4FT+)0HmJ/,R:dr
iBiOn]@bHkiV%:T!+fU\;$&q9mu%<`F\8rq7_;b+_D%lW2e;TpNQ/T><r;#k[8oc8
+(-IsC%WgreQT&:m)#oHc9AV2H[8uj)[Q&`n$`*ERJ7)JWF2HRr"i)oI@8B?rT4&!
JP5n<FIqNP2[8;\!+(@re,~>
endstream
endobj
82 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 564/BitsPerComponent 8>>stream
8;Z\6$aRYm#itt$b]Wbg'8+/R9#tYB@6/6=ESX%pQfYW2;/dHPI=cNIHao2NM,8VY
ENbT&++lhE")R?odZ)E41l[)?U']sr;SW\lokk12cNCL+a3$4hp@96bolWWYQbi!W
QSnQ#fIK,&)UH@M_+VaNlRYk"g?5&4?%[.>3cH0l><"")=>2+%@RPKq/\-TIHo1:<
?5P3AZHjLFpE5ch(Hj-dCIl3d#aVF26a]XjkJ;56fhI9FFlF@L4mb/CCNLX?JV@m5
O#>R*#C2#55BMgm9rV=J.AQgrdr;I,X`Q!4[<gJDSE4sEO*WQ_nod351AOC5>jZ<f
.bd;jlPfHj)SmDo_`jYu^,,\&K)(r",W_u(9=kN9lH)pK-`FKWHd;/Qd^[?u(]IYF
(<O[Ppj9s8Z#/,")TDiH,W0bM&C[%$F>R`i$aj2LjB#`/Dl<eoJ+es_jkV63-p\`H
eBS4^WY6r83G@[^Lp/GJV4Y2WN`8[W%I9cAOVT/+`lm0D$d*9UmTT?U<;#T:%nDC<
`fQWl=;,qV-@<O8,kLG^j(lD=T)eqtjurD~>
endstream
endobj
89 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 499/BitsPerComponent 8>>stream
8;Z\6M[k@^%.+#o@"2h2Je%W0<&C"K@OC%+Xr\=r2^STrYTM^inr9d13J-%M^D[m9
e\Z1QII"oEEnE48dta=\EXY?hPp%D8ed_duFc(3S_PG0KAb/bUrZ6*WY6lIGe!SQe
a@f+Z>@H0fVe7h;ac'8p>;VKY`&a6X;+V=f;sQ:TR*e36.tfc8C#X5?7!]>C*i(Zg
;6Q@`+]f51ei;!_5D5@W+33+!01@+C,Z$U6jE]i5Gf?m;aO-O?l(qSi*PfjfiF4>.
P-&I-ntK:a*doChTjG_aj/$FAj1B+5gn`>3m@/B$L97/Thg7YnUbB8<Y-#Gc.Q,ci
_s]U&*0F8reVQO%=O8E+BU#du+1?nCi$GImX`DV0YTSA`0sTL]pDA0=i4O/Aa6QC-
N]Pi9'n7""?$\c'3KIV?"L".fp"IEj&AUskqL75N=`f[H\%`8oBJEOj<''H@k$;X5
Hp_XTSae5S'!"0b^tGi]q?#RLoCr^o+>c_F~>
endstream
endobj
93 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 819/BitsPerComponent 8>>stream
8;Z\7!Kr'X%-0YK&-(TQr$UA^'$qgJ"OKn*F,dl>.P/2)#SuqH45i*0\b+SAqhm*<
2iRb+jc51Ob'2ga(MTD:F-C`&@*`4K;8Q4r=r'dfhUEq]i;6E0iRpWnX(OZJ\3k[=
Uc.Wa[_@3]QYEQ-0R6CI-$C.QW/ajh+4R6dL.JV=MmnCKaHBn+@XUWher+i?UGQHk
Bq4Rde?8,jW_<cl*OboC%3^-Q&C<pU1mf)a]Nss2_F7e3nJ]>O^LI.;iR_LtA82qg
fTLj6p!ETuESFYQCnMBp)qF[gM%a<BlU:c<GE[7?67ImN2ie$PU2c*Z8R(0*2L]c\
?NGp5"p=T=%Cc&9`rQ4a#\r`MK7sm$aA<?\?L9XQeS'[=mkFq7O_t2scS@/.!f"c^
Du]n=#/%)X)4nK=V!a@>inb(jn1s^+iYT->d[>K'$mtd]C*YKbnjF$l*.^]QB]Pm<
%OHCWPt.E3"r"4QGYpsT72&4h5t"HWJ_-j!'OKi<2\2KC6d@J\A%*!T.P`S,\8[8Z
d)ZiNnil(Xc/B'a+Xb-<3L1&0f*k\.lRrr#+(S[k)MnQA'[d":9dbL1o#gP0\YDqK
M:\m-iW[E=+V]c6/JNKLQlShk,u1hAnl")DjPR*X$c:":PfsE&)A>TC?H`d5PW-9o
haIg/MB8A.\NnPL>j(3HQ#TWcBP*NAZe)/:6KNXVP(b7tk/e#nodc>EW'g4#ei7oa
OnX()Nm1,kfm(a3Z:;gSGAEGA.(oCESmIJ%]l,P]^Q-="`^[0d`&Z0Lo'=5WGUZal
`Wpc,c^/l>#PF#T'Rp2b!e']u~>
endstream
endobj
98 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 578/BitsPerComponent 8>>stream
8;Z]">B[n<#Xl$!%C2ORUksB@N$N4"5N]>4CWkoO!f<:-f!*cAoZK0Z5'F"&jo>>i
);u[f"N%m5ET[6(q%rHM5p)H")Hlb=DC;p2[:fmt5-iLq])sks>Wp%iNGrJ3=.!nm
6dO@BKiX*[>j$t`E1I"7&ST3X%?12&f[h*i:ZI!_)e%ZGo``0c!Nd'NKtkKkcEBlM
^T%kji3cu4<?.*-V>9jK>HSO428Z=%/E2#%>FDsR.r9=9XS@*W/;NGOPs<W/09Hp3
>^c1j<,5`1(5[&OYhugB2$2ulC:m:#<"8d+Mq+u,cRG=/pm>7UGk+M6:SWmJg4$4f
S_kea6F_YLkkAgRVGU-08RrFe'JK4*UD`rVEgY%eRl#^f1LM>fpclT[GP0+L52#\;
#qbdEO$Crd2=e:\rmCZ'MjaJ/g,JH*82R:4ElO0rTAd'WE7Ab3]>/u-rEEOsN5i;g
#pC(A6#Y&*0fidHA&d:qU[!>E?!L^j6mLta&d@`0MD$B<\hX54X%&ptDa0r*E9?b:
$*MZX-?l(C86/O/AW?=A)K"4*'Me'0q#3I[`ub-3hZ,<+S[/~>
endstream
endobj
102 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 531/BitsPerComponent 8>>stream
8;Z\7$a.B$#g<0"aE?@8Fj85:6;"^7'i!uI-=@cZ;N]!D<eAfClPH)gfM<>[h`JBH
FZ2hMa1#\MN)$pU@hs;o-fjfn5mc$Oi-7ZYgg6<SFa_*F3%baORKjWH[*,_(ON^Qo
Z]r&%"WR9L&/Q#SK58D!E#BWb(LnOY1FB>0=ajK?(sS15Y:YoPCpgP1R3?Ie2:Run
>Rk,pqepM&VuKm!G;UBG+QYKQ-0)4Cs%;E5_1a:iTl<g;f-jNF0POVg6[K3-4tS<k
2Fj1YIlGV9?_oi/)]NjSj*B?:,tP@F"g![c(un_C,J8^Ur1%eI]^,npE%)&.CVgoN
h>$]aIJPuJ\9BcXC,(sa:D-oaf(_#@2CLUt0pCDhRX19s[O.?T@d8/me-l"n/P#Hp
"D\$#8]?CZ5;928;O7Nc^)IIr"[C#`=;)76Jqi9*XWamS$)NQ=KB)2la$ja\huN`+
FQ]&%l.=5AAH*6=pKF5'1%Y/tNg8'#Y*R7!3&Qc.!uS3<f-YTIZA%VLa*dS>!7p&+Sc~>
endstream
endobj
106 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 554/BitsPerComponent 8>>stream
8;Z\6;0E'c#i#5`d-L>;[S?u=&4QIPI-dr06BXX1[FZ2\':?Q1'$/\-g@of(q7rn9
`^Hf5OaYt8S`"fdNDH;>ouQ@YYO.jKHIKnn3'rFT*5R#do>`flAFmaMDCjQoPqbUd
3QD$nTr0"/@Z(iILgu,BYa2Xl6QilO29,lR[Km@o#,dEaB_&^)?SZJ"3A)cnL%@Qr
B^_/d-T8jOobmft'#*B-NXeEO'AsWD\J[>nGKei'$=qj,n'BQFc=l.O@O]mS]_:G>
Naa:WirRt$><ee^emfWM"BmZ/:)oI7(d.k9[31oarp)NJoHf0&"r]8/[s\a($-<2(
i(2iOX:NX!\-cc=iG@7""A*C:DJC_olH]Wg32?I-n)]8bkSMg?J5=O_S`K!mCU-2j
_nK*dkiH^T4-l-"-O<d6Meh&q#2\H=>\7K^)62W_2\*N>P`,O(DB[lt*fWeNqlP*:
2rom4CYl.U9,\.08S!2LOqTSk0a:+n?\":p%9U=%CV^q_'b4U*lb-Q=d@Ru$X@?]i
o,PI+gf,rDn[6u/f[g+8Y(eS~>
endstream
endobj
110 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 584/BitsPerComponent 8>>stream
8;Z\7m;g,f#itqkOOn40g@IRq%lL0]&a![X;8h9jOYB#.A$e7T^42V^+6tj0Yro&p
obpK@4osPZ,W]Wp'5N8242Qs-/\Ber*.8d^bQJL?U%Q;9GU'-]T=`c9Roh;l9S,J*
b`+;%\B'TiF6';lXDT7Q$qDH2J_uH&d]86U)TZ6dZ1MZK.NIi.L&1A,bAi'5Jif@;
eImmnU)"$l`=[.s.H:<fKa]q"f-\59TN.lV$ZH-7$n_YgS];(-7#f<\/.Hu?dBlaI
s*tK"X6dC@&c1^kmtaZS&UIhQiu!."3[_/0QO;J[Z^Lqs;JUC7b3PQIY/L&YNpD8s
-F-hE$%ol/hhcit^Ii^j2QkCAG"/f-*t])T9TRRnB!p#4#5Fk""fAmk+Ke6lk:J+j
9r.",\<^WZ9/$0^rW7AW(9<:%7=kPa,?7KibJ<8hVI"_[J;1I:RtRCT#:(f6rA56U
?AGqQM+-5_$R@qHctNJ">onh*XkL\)Q/DN;;f9(I%MR[WCE-+r0XE/mg;,,J5"jsm
V(9Q+G?1%"<bUi=KR8Bf@[6Sk28FY)$QT[*8cZI@fOL!@g=H=u"aIc~>
endstream
endobj
114 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 661/BitsPerComponent 8>>stream
8;Z]!l`l*c%#+)hIcuQ9dLY_Me5\jW,f.OV+(f+d#L(4K!Pq[J(l6:iIdUDi^TbSD
a2ff=RTIY+rNi(VdlrBf3GYQ%[*)k-"MdUudun_l"sCja1aK@X<04[RX?![W;'!8j
m>qIO,1%A:YdtAf$V_kI1P&6*jl4ik9*I0naW"W)fkLEXNERm%NE-2b4$@1H$O>89
9ZgIT>rcbOA>r%#-T&$K3OdQ@X<s,FBREN.7m,#iEFOI;Cu)]9HT*N^7mbL#(=5qV
/=<,#9"`?jg/F^3qnsX*d:^..osc?^rnb&oC<EVG!>_uG.@Y<Eh1?Q;r]S:3c<AM#
f-/uL/Jf!^-;W,KKg.+&ep,9IE(R4r$8EIOCE?If?<n^YL9<U$hT*2A=+lM^B'O6K
3T\b/3F>_]W9dBUPd@45Njn:bc'-TTlft\]]/@Y*?QO.6eKOR?($a?18??J6MTE@f
qR,_A+JLB"_AY>,`q6Lm?1f$C9@p/BR!VT#F_:4sDMh36m2gD$O6U2Ni*.Bh?(0eC
p.4Z9WIh(InO\e5g1u%2I(3C&D/3&GP*9u:JE'e5##BqX>O=<7lfp]-hO(gjiA11]
C[q]8*E@j629I@N:ebU4c;3(_*/6U[?TR"sqm]/Tn3\-MD*@<Ze+LZr8,NericsqY~>
endstream
endobj
120 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 548/BitsPerComponent 8>>stream
8;Z]"CN>%]%"u1k"a-BEai%S4G:iVVq?'G=$.tQX'`ncLa%#D4>^$$o#1l'4cgCM6
p\/C`X<6s'J?R+Nq%I1Db;DV7YIL$:,8eEM@69lE^<fQK*gFTCb$S.jC3:ZcdbrKR
0]0nnTiHm`C5>>#[*dN4FQRWb<u>.]EIgZG]D^p#E/gM/b-.t(6*AR$&_L>td*/XG
+=H`I=DC.)b99Zpp@7gh"'/NjCBYQ'(96Rf._j%j)QBod_b=a69Y^f3m*gV7J<`IZ
>U!Np,!X9<(-:(dNKPfhd>arlBn\K]]\M4qc;kVHi.=%+[C)S"Ane\'?SoO^rdL2'
M!"]IhK[,nQSlpWWTb8oF*71]FGT3T-<GK<CJ6;FEg:q$(0QqR,scD(lL[@0na"U4
)EAFIV$L.(UDiN?Y1*0VZ5/>1cZH=1FeBC2o3@j0:^tbh:2s!s9MI-HT-^$\QT3hT
&X0aE]\*=R0:37nH)j?P`I"KOMoRe?8s5$W+7>Q.YF#-f`[<>P,7A7nb;XIV>9qIo
LY.COfON?Y"oqVaKRj~>
endstream
endobj
124 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 801/BitsPerComponent 8>>stream
8;Z\7;/ug`#ikn#j>rjbQ%4I\[(FeJjl<asUR6]?QMHG*:_N*-Dk[*gh,mljf,n_(
+kN.Z*b>%!EUe2>)VgG?TT8`HkLa>ccVIp2!lnr0,e2JM_)Ktt!PC8=!a*$KI;QZI
;#Act-go=B!Q'i0_'#honHQNNHFIG4GJt\DP\WMgjKN`\$S4hm!>P?'>JR&eV@#:9
_e%18SsjEJAO!(MUga^s<bD"okXf+3C^+b=6=Urjc(3R/OV-@!\OLU\mu3s&#!Z8j
"P!jd-:UYV7%>q:+@.[0JpJm;>aBSb7*<ia8/>i`:TWR4!L;%7V&feJ*U,TW'UM^^
`[M;uhkq_CO#20k.F0uZau53TI9bt?&1d9APbI,.`Y0gAC$0agG,,r-=ZVsUXjVKI
a^XMF'-[J^H0u42'V"0@jjuq\+pMm]GhaA&Z-%\7Ut=/?ifU-O/i]:Q9^gR6<T&\6
KULm9$Yn:uNc)iU&aIp,<f^Z'bpLihH$BG`Q_9:"?^V0M<\P9<-cRmDL9*6:gS`Z5
EoakM7+P6sq/e!sAg\LNcfeYtGgWqj__qN`$L^9Alg%I+?NeXaf/hNU@5Ml+6]t&;
'-?Q`Tn9>:1I[%TOVEQ$dB/LB;%7%jrgf#l#K*`!F)9[-h[Kr4++%:$PmK*<Gm5AN
@^LNJCuU<!(8L!bqn([DCSDim2s"C@+n`Kr"%4P#-s)@tgb(!p--S$gMg0(e]>^V!
#?N$Gbiea?4u8Me<M?:neIl*>rY(I?g5)M2;3et6n(]I=P>d7CTp/A"9DXQ"*floo
!7%hmdf~>
endstream
endobj
129 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 1073/BitsPerComponent 8>>stream
8;Z\6=`sj$%.jENkj,U:M&%I6=<?s#$Dj<8fWm(XAH(.1.pdTSra.<Bqcb.G\!^K2
M(t^^PiB8t)dQd:\ae.YY-bnoDd7*N]4\?`SEh6*HL+UkLN/=/[u^(>QjIgVcI'$W
5q1/R/]\TdO6^X.lr78Z)J`"K1g[k[R<2CadX$s,(1[I&G:T.3EOV"keFZW`!sDF$
.K?ehccl*j`Jh2Bi`D9iTh4l6:P<(R4ju(Pj[^'-&QilQ+^8r=_t8TO7+"gnKTFB@
H=T7',P7P:Gc9']cF<=0LY-g"DL^nYl2:^CU?Y7L9TAJ;P^)WGpsoUoX;0$`PHp4?
&84^]B>JUa=8KXHSI6dtR">WNW[@.D_3u<Q?-5CL3o>CN%HJ>F*7eULb/D7bolWmP
[3u>RIUl#r]>mbKRa]^%3k:XQY$\m$Q[XA:OV_!\UENNtDDg3_^=3<+@AWImb\IkD
Ea/19`<CK[HhK>&%bh8G]&,2V\lRtq]goGE-f\1o<fjYk:9(;FEFE59nLi_odp/u2
<*]YBS+03#bZBTN"9L'6%MgKnqEmuB-OSPsWsR_4*,5&`%ZD\[m%[Ij/X,:-l+<P3
h4k?55<C2Qq1L8o%B<o5#ocRo8VhH9+_XVdocn08T3A&8,ol6[W7f"%QL=T8VdX[J
@3fDIQ"g\hj_6;!q1/ubB*Zc4=Um=`<^1YnX,F;Y1ObhRg>UjW!j?"qqX.oq_4t[J
3R0BIiR*62#,K/i@E]4P1#RU-`6Atchm_/=ZD>1s=!\L42\D$u8m3Xj[U868SWq$X
?mptNW$2j(.EpgD0YFuS_(E#G<1=I&KL1*64fUdn[[QT(^:Ri\F!_bu39HujVUJnZ
B=IR`fm<8e>]tUNj#sPDk(%Fc'fb=??Lc5*^pK(Z,"rdX\5GDJXl4`D>i*sIV^e7[
66.Y`W1iJm0=&^8,Q=R[cosWA0c<h^UPAr'@[p0ALmeSTN,?=i>dd\K;YF/][M?[J
dju];Fh,bfc67UmW&8o0mabA14RX'mn4)iRqdCBE$8@*W$WIUE%kVoNR$Q!<V?Yg+
pU>V;:$Z]tOnE)W~>
endstream
endobj
133 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 1083/BitsPerComponent 8>>stream
8;Z\6D0"qr#h8f+aE9PG]cSB$rEbukMC-eDCkS*c=Z,3FraW("FhRNT-pR$@Xm^G'
T:`8-5M"Maj4jD(q"_6D?JiY35`SX1VZZ_qjST[E3$^j;qJ*9+(8*rZ*Ni&jEB=1M
nuR@LNb?//Wq8,Op:XH,cBdWN_Q8qG?"<t,dd+gc!qs3JT!g5SiLeo`ghr@=&hmg4
VGLVQf6.'APbH)n$dfnWhbjoZlR87Mgo!<`L.G0>rBm7s2U3Hqb!$Cu$NiEOWT[?d
kHJ;WYc1*\!5K/FTLh8DNV)"pdAUcIYGCq$Y%0!Z)1or@JVZb/@<mW-'OF(mk6/b/
lq2CkAGMTiaq^'8)"al*^.H;.56,WTnBo1N5!g$r2J-IL?J%(8,RTLT]./a2]d-B_
[<K>7(sA;@hN5U$1YJnk+<OT0P3<!jRMnMu.PF.U4%!BAd4tulC/Z6k[?Es:_<bVd
M^Hb==&Z9&K?h@oL6qFBJf5qo?o[4;IFQ"?7C?QPg]ZA-O9F2X"_D;g)GS:,`IF9e
d-]:?qYbG$99IUaIRN#\f@<HN`LAqUa1Y99QfDg+\%JV\?f@#]cF3V$;=(C+o77^(
ACUn@d.;BtX*_qn_GjMAf2HLZUU;\R&Fb&eh&F&+Ir=FJN<DtfB-Ra=U:Wk`qkZr;
hFG2_WmDmPZmAFf9S6)A&a6)[07$cj>s_Rc)u!$>On<OD7)^IKl9aorjOfhCZaVi`
]K(r6VT+O`,O,k.3*rIsFn4OYimDYVHa_/5c8LUNiI.t3(L_)7bjoS)`lksC=>$*'
3Aa&!Jd&b4mCBgIpDb<fA(sXnO\c[K5ls08gC<?6GYrG]P]8_0'PO/qUDIgrZ8@Ar
;)MX"Q$o*\rp1iB:V\<HLsh`SWf?m,M^?*u&n#1_5lPN/*'6ee@TiE+9=625(3\*J
*,S/:]<i`t(0NjJ1+4[o\TO,UdqgqlRnogq1#.2b\B74S*/;!\O0N,ao9?ZS:3eF<
e?W*>UTLTsP]RQ2CW/n@Mi]]=KrEgEXu4;qaRb(,*D*Of.CI;N90+i;mV%a:2H2Vn
a_f+@/\O_0TCl@U=C2.1HZ^8H~>
endstream
endobj
137 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 1066/BitsPerComponent 8>>stream
8;Z\6>B8aX%-.:>aQms&(_=cblt2HLIRMX3Z)n63JtOnaj-^KT/rP4/:TjYT2iROR
aS/cokP*$CNT9PKnb>'b`3TO?9kZL4o_XG!PLoLiJYPS(J3[brGUFO>bo%g1,#aQl
Yg=V!Np@S3gnUg`1=9tT[hp,8efbIAD3VFiPnfr]'8.@2a:JG(^gO0-C4J2(%aoA#
'2$53R=b8%ijXp7M8phS_EgD^]M;KfVK#8f9-qsAN7h+;-j-plM.=*:"D:AD&`#VU
-;NSfU@^2d[o1Fq4-WB^q>m^S'M#VTL7kpn%ucmd`sH0oX(Kpj[qEF"aQ+oUpNo`5
r/C%B14C:='(rG>V\HD_@@=.Z?o>jt@$kU:Br,7;TO.<!HHpWhbbB>7KES?[j9-uZ
T.gn;ZK%fRIo0o/rXtV?G%bdZ'Ig&1K4`/Fe7<%<`/=kW05]#U;V=U[h1_\s<bYRf
.\42EBG@lk-%7,cHZF-m^EMeg8p;D#?_'714UM>Zh>i,0]>EGAa[2[tme@tZ=gI9r
Z?ilsN%JH@[JQp/-'#U&n3<\hC'_A/h+m=<<"6!+gcP(5pf8?\Wn\H'p`%C*2ZhC[
P//lhmEpYgY'QG"Z>IPF8S#4</[Qr@@QoLWaJcZ50WO'J/f?XFI%u,b?41b)`XW*;
HFp9\a>e`7.KaC=%4'N1J4>f+E,V[NX*f5j7H<>tEh8i-e!Y1lO6Ia!%.YT3;[/L[
GF/3q+^XrkD]IJ![/(gb'9BWoZ+OZ-[=*iY7!>!>Q]9it:6FE>,KL@_Y]_:gl629c
0,19I=V'__B3`h!k=P+.G(%?>_NuOMgP2@u^\hlVPH:kf=Uc]Ebb##MW,u#g8-N:$
BQg[rZcO]SG2^4RN7[;M3`YAen8B(jWh,WY,M6I_TT[QpL[Bt6"LJGQ7pV5e=clO\
gT0%S`fri]am==bU1BJ`CA=ftBlKT-Fll"&Ud5ZSOlL/##2P\!66_`LZL)@.[J5Su
BE.]7j!EaFN)b9B41Ud]mpU7+e:WpT;6o6aT<+qE7eOVR;.&Fm+=S2=mlmB6)1QXR
%02C06Bh~>
endstream
endobj
141 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 1019/BitsPerComponent 8>>stream
8;Z\5>B]<d#\<rSA378up,nFuPkHI&ZJ#sR2W6A!6frH=ET1s2^\t2aT6!&#^$qU^
no?t)RW[NJZ+]sPDHE>iXm`G%N#-_pq^sP7?L]heB\'VbnJronLVi<QmrB`<NXuAr
=e//.p8jL5SR:NlaSejgcsnnP2?^1:)`Q&KA$K.%$[D(@dr0;_otjjf(c=-7R4Rk)
\E'.o00La'TF$%.SOjK81!Liia"f=Lis:nf-eT=LpibMQUB$Un$^"#CH:Ot$gYB]q
WrocF$`I3nWmS=l*kL,VXHXju8(;*mLEbC>0_?(E3'H^p>P8c,Xg=n:Ao"t]"N+?B
cM6<M&gK9Q+MFn5mF5CV.j"QO+1MXC:FCojZn1Uk[jorB?;h"RX<8MZe05*OVH-sU
pQmlTUaACV]J2us!%mV]og%[qMIKUCaM78Tg5IW14>N+K#q4j5M6@jqMZ_qTe9`J(
0dj-?U1L0@/$5]C,Knl!Q'f`U&*,`<,YJ8K7&?>A-fY:t[MRMpUINXnr@VQk,$%MK
N-U*ps*Y`]7WXRc8Ho5p>L@(&A.(aW=8Ys;g)NN7..(^h.1)J<\%i]S[AP[JPX;L:
I\n>#B=p>Smlf8l=@uYFm&F=7qg]LP<m@`k;l6AiW5t'c?km6:GAL\mRFW7T,Bf_t
+oQ(G-W=YiZ>*eW6qZGra=ETTf/*``p-lKFFi\_s=6!CJb,\J>Ke_Htg)XVFZIT5`
kTJFtnBpgaolN'OEZSqAf4u14a@?ck6t@iGc]A[7$[]&c.k5o0NN;o<dIjf]T@D5t
4?E+/_%<:t@SKQS@SNY7ol.h=-"=JfUe3[OSS]O0l(<fo)03M/EieM8Y>B9YR+&i'
I?bf=nP@g1hG\(@V`_"TK]+#+F7cjL"Y[NEiM.Xs"(AbGrF5nY8%RX/.T*S)O2<7@
VS1+\r+iWl&9pZoar5LZk[FkK_(04Km?j#?Jjig.n='%^i%Ii]",Teu'TcsE-4$r]
JaJ(].lApPc[!fWIX1o%!1t@84T~>
endstream
endobj
145 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 1037/BitsPerComponent 8>>stream
8;Z\6;3!.]#ikn#j>q4gNK$LPR2N!)pX,pCF`nB&N"'q0Xs_C6*j_Kb_mA7nRIsdJ
pQsdkk]59>YH>"QIo8RZCB["(4'mJGfD?Y-X#),jnPpV7P%0,#_;2dg5%$$%R`+!O
?a+X!c2G/k&RXM3dr".Q7&;OM'"3htE%1!Sf-/&EF)Yd/(9)u<WYB#;/eW-&A*:1T
^d#8^#.l'%C@eB66Q?M(]s8X"UuubkBG:sAaI7?mNLP6D;g<HTE=L,X^]NjR)3ZUq
,#d5%]5dF6T(C2un#f&_$49''WC7H$g$A^d0CFq75H<;0<^Go'FkJej89uLOK"dn\
`nKF"mP)f?V;mRp(/IX;cBdB8jZlU<mI[AMS"(#-BI'F1/k)p_[;;.^[UEkuWAgkk
Yt(5Ka9P;alK*%EmDR\3,Z^0N2"dgoEN;XH>XY&2*TLbJK*$+tOdE:807pnS,a!FV
Eg/O$[o^P2KI_IJau9s]@<$c7#\-@I*KB9p/5=6Y]t;<g^s(P71bn0uU!<o.Re/sd
$+g`PM'lqjA>=RjQsj*2MDJ[%JQNCP^D22q@O5A]gOr*-"I(o%KQ(+Tl&$f#c.BDt
(fB[5!"r#SW;L,_lPiD./VQcKY,LopHXWi<A8Kh!$qo_=cP0LY\3uVRYdpU6J^mas
]#BnAJL,@+YTXN[S6Eh34;8)3QcJ`+>WPuga&7Y$E(r>^UQHWsCQ@c'0sIBZ"VK2%
2EC%&N#=!F]]XsU?%KC_Z&:,j8t(#R[N#MCEtAJGaPgPqmQ@9lRWJ,*7pAJ'8"l[E
W/!!8BfDI)2!Nl+FVG@c[_YsO5ptEs<*k`fb+Q3:2FhW^.E;EH7Ar=:HSEe$*5TR@
po3[3Xd-S]*I*g+m^oUO89!u\QJu'd7E,3[a.PVqYLHWiA*m4pE[%&pe1N[j-JW<;
D@(=KU$+IONYep-Alg5a.He58A)'G[5Z[Y7mdY]G[qijD+DWN&DH`6Z6>0D0,qmki
FYCB+"`)"<n2qpCA&R#5_Ln6KA\E7aJ(JoCJ*YtlVl7FC~>
endstream
endobj
154 0 obj
<</ColorSpace 156 0 R/Height 99/Filter[/ASCII85Decode/FlateDecode]/Width 76/Length 221/BitsPerComponent 8>>stream
8;Z\t>7Q9>$j;"Y$g'LP)OCT]a[0##URDc]$Gi5)"'U<f0YosH="Ze4\p1-rgV1C/
J):,2qho$2TU;BUbKl-@Y3#*BG-sHoP-t/+bHL$c_H.O9q]!8\=GU:![9T@"n`[""
>*/'HF#;2e)RHE5`MlaNY48I(*M'IKQ3f-mR`8fBY@=g#4uV#u@jQ.(=koPE/)TAu
Xmc39zz!!(qQGROSbc?Bp~>
endstream
endobj
173 0 obj
<</Metadata 22 0 R/Type/Catalog/PageLabels 169 0 R/Pages 171 0 R>>
endobj
195 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 2452>>stream
hﬁdUiTWÆÍ5é¶à&E∞K´ZìåÄk≥∫ƒê#ãëU∂àÄ Õ¢@öMª•A¢@#"õ¨≤ÔÇÄKXåKîs4íÄÀ®ôâ&ìƒ€Ã√3Û$?ÊÃ©sÓ©ÛΩwÔª˜~˜{ODÈÈP"ëà›∫iÛñMN´ù¬í>Ú
∑s∂≥û_XÆÂD⁄eã±Œ_¶◊ÚÔ4¯@ˆ‚¬eë-°tD¢ÑÃF©•ÉÉ’öy+{eÌ÷H≠,,,^Yô‘),6$\Íôüæ7^Í+ﬂ+N3ì:EGKÂ{vG$ƒKÂ·Ò·Ú§ypõ<6!<î¨KCí•ﬁfû!ªc»ôçlççΩïŸˇ¶Iâ»G1µÑ¢8äZ©Gôà(3eIQ÷:îE9ÎS4Â©G˘Rî1©ó“£ƒ‘î	ÂCR?ãÃD©¢Q∑Ë¢Œr?ùJùﬂu7ÈzÎfËNÈŸÈ≈È]•hg∫á˛	-F.hÍCœ≈oãSƒù‚ˇË€ÈÀıOÈ?ü˚ïô3c`#\fm·ÿ¥òŸÜ∞pñaÎıïf∞púV#féÅ≈póhlÈÿ{&00:2 ®iOØÄÈ˝∆‘kÌ¿ìù¿û4,E8v÷ñ∆ñGø¥•·4
ût≈vãªää:ó™QQXqÄ&‰<v4b"&’lÓô·úØ8x˝ne˜†–—\;0.yÏ~…•úœﬂ™ÎºtY2€|öo
‹^b…mv9t0L ∆ëÕ◊T™€∏;É1[∂˚á⁄»JoMﬂàZgÔ≥.6ÈH~™¿ƒkõ@üUDÓ»ÙÂ∞âÕS0€g3∞¸b∫‚åP˚≠ëo?È»·lé%XéC¿K rÍJYiÉ¿‹$…Ât_»ù‰‡≠M◊Ö+£›·5	†–{nÁ˘ëmjÒŒŸ5˚†ó VlAy]~'f36ÿX%‡çk¨∞,èó«…OS≠óˆmŒPıÛ‹≤ó∂⁄’?„vÖœ369kÀæ¥Ç<≥∂ÿ W„®3¯˘ü´≥∂b¢fW¬"6ﬂe2√’qÎÏìùóF)∑ìæãøk5FÿŒw_åN@Õ—«/Úê∂ó€’ò◊⁄<¬›FO—3ËoúÆˇ{’‘“|§≤8∫≤@¶œåÅá!dãAW˘0Á>_ê◊º±œ°◊i)∏‡!ﬁ$)!úéﬁQÀé[ÚJ}+ÙN–mÏ=Fx≈K[ƒxM«PÓ…
U5wˇ€ösCB{[≈»…óqÁCõ˘∂]Óß,9á≠Ÿ	}2B_M~7=ˆﬁzœ s˘Åº£ÑØW1/£õ ¶ÿ
Îrªì^E˚ıa	J´Mæì¯CÍ’òﬂr˝|Òï™±±˚í—§ÅOõ¯é ˜2SŒ≈5;ÀüƒµcÛKNæép˛‡ì {¡1¶›gÿÑˆoˆÕÅ”‘S˝”s/Ë,[√jF$]Õ›wæ8êvöoxFóG¯î9sxïπ=÷5ù‹z°¬ttÀﬁO$^AüÆ˜ÿZQ∆327ÌW‡ÛØπ¬w¿1
≠é!(Ê˘xô‡â8πCÚ⁄•Jî2ïp'n⁄∆ç∞A!Ñëj∑A?˚"∂ÿ‡ëî∏õØYKW6ù‰f4>Q¬A1˛ ã<0#q∫ËÚ”ï·∫é>˜¶Ae7*{˚$x—6ÎH÷·,>"="j']5¯Õ˜Â˜UdÿØ¡rvß“[…ˇÜ
o‘z)˛Kt@˜>l¿8œˆ^»9˚D˚Ôî–ãÃ9≥%Íbıq˛ÇÊl€7’ΩŸ∆ÿÎü]mCiÇÚ∏™®H¬`ôvıÔlf|tV0gÁ˛≈s·°Í“çß\_CVfÖPıÑ.â(
‰∆Uò∆≈´üô¿öâaMI≠¿DhóÕ˙≤∏^)nKÙ´˚Ä√ﬁ5≈vy6}lnéµ\h‡’®p"§lV^íhoä±¡\.õ¶J?ú¡˚§ÌŸ…≠∫˙ËQﬂÕªó:√¸ãuf^Z¶Ñ*¬Yízyµ‰≈"\+l·Äﬂ¿DËOL¡ÍÊ®¶ºáO˛ÅNÕ⁄Œ≠sÌxpXò—:zÊ∆∑‹TÖS ÈÑ C≠€„ß≈„√’eπ9•¸±È¬qÖë‹.ø¥=ªÖ‡–Iíõ˘µ9AL
*ÄÁÏuuó∫ôó¢wZâ∫vµΩG*{€À0?≥
^ªzÆ°∑^P£ïØ›∂„Ty4øœåñ˜\S\ÊÆOñˆ	√g+o˝"¡∞íU®Rr”˘@EËﬁ nCıÔüèﬂi›®Ú3Û2“%Ã52o–è4yöÇbæΩ¥ÂÃ ˜U≠˜f◊ºK≤ãˆ—1r^ûñt‡≥}%Ùj<jSI7S≈ógﬂgCbc¬w◊ÌÌÓ≠kl:Tq¡#ÖèÁ˘1xÈKb9¢Ós ≈Q4¨F‰*Ï7£±1¬±ezä")˝ ôjv>°Yﬂ˘# É¸/ÇnT™.-–Õ%Mmgπ/Í¸\‹J~q©∫å$›™ijÏ·∆Í˝\E˘§.ÆâŒ<À'*ˆÔOŸßØDív∂m·ÏÉ√Ñ√(˚kz%R´˝=ˇË@9‰DAﬂÆii=«]Øı!®'xèÃ¨/⁄:˙Ñ'ÚƒÔ-˝”∫¥9,^µ“Ñc˘‚o∞^á%ﬂÅ+õ˛Çﬂ[±?¥Xo4ˆu›Ï‰?˘Ù^ÎÙ˝ya_ñÑ=™Faßá„&8–›ipÅ5fˇ¿zN€£ΩvJî}õ∆R®wlëÄA [DÊ∞àHh†}òª€≥ŸfuÄ˚˙?$T¨*.!*|UD·<çÍb˛Rqw˚(w¢X•,@,Vg KÁ|∂G∏∆ì“s”+P˛Æ<?7‚ÁŸV√Óo;Ø„ÄΩqÂ°†˙:¥ﬂ™Iˇ√ÍÑ“&IcMU_oWjzzÜ.ãÒ◊xsòvq≥˘∏s«èQ¬xbEj§$*>¡;»Á‘…}<ÉOŒho≥Ôõﬂ¿…‚-%Åu±ºº∫˝≥≥\Gs·ÁÂÇÚ	ù´HW%r˛©ç„D¡Ç«x,3Zï6ï	@
•"'ìèJè"™tèπ'@9¡;≈ÿ˙ûœÉÉC-ï‰æ*t¶_ eórpT¬Hãâ+∏Õ•“Ç≠⁄T≥h=>íîûJ^≠¨ÆÃNEÔ:8bƒHèÕÔuùÛ§è¶Á ëd+ÂdÒ)ë˚b‚?ì'À3írÍﬂ1j,*;◊Û≈PˇΩÎ‡N^ãi#rÌnƒöÃË¨OÌ#’e¥g6 †‘à—éΩ©˝ï˝Ø  ¨6

endstream
endobj
189 0 obj
<</Filter/FlateDecode/Length 311>>stream
hﬁTQÀN√0º˚+ˆXƒ¡âI\ê¢H–
©¢-w◊ﬁîHƒ±úÙ–øg◊.E‚èΩ≥ì±\m÷ﬂœ ﬂ„h∑8C◊{qO—"ÿ{(∏ﬁŒó]ZÌ`HjﬁûßáçÔFh!?Ëpö„œÍ∂∏˘∆ﬁa±+˜üDlO!|„Ä~Ü⁄vBÆ^Lx5Ç‰∂?nw*ÌÀÀ‡—·å≈h¸°QÆÖf˘–z˜ˇLË‹qËÏóâ"ﬂ,
µnEsW&LÖ∞…¯ëp]$LÖ∞ŒXÊÑ©ösQ\˛ÍÁqM≈¢UùnV¨\›3ë[	¡*Ã˚®·∫ Éö5tn—¨°¸Ÿñ~b+‹≤Ãﬁg?ŸG¿ÔrM”ûb§†”„•<9…ﬁ„ı}√88˛ƒè  Ôïﬂ

endstream
endobj
174 0 obj
<</Filter/FlateDecode/Length 745>>stream
HâúTMs”0Ω˚WË®Ã4äVﬂ:˝†îz(–·`51ìÿ≠ÌŒ¸oVR⁄iÅ„â#KOoﬂæ]ÈÆ “êÇÎ1 »‘z`ﬁi“á‚ä¥∏ü~QÃŒ.Å,ú0F1Ø!¡¡3Æ|ﬂ8I~∏Å!”¬'†‘¿¨êâK‡p„ñÉ3Øƒ√ 6Ü±Üyê	bw∆Ï	£-0pôÂXæ’sG ±≈∑÷é	≠IΩNSÎ"Ç9Y•Ä+_Ï¿*∑à8Œs\
ó †ÅÅ£CZ1%] JcÆ¬Ê¨.+Òº,fßÄåÂMaô∑\$∫ÌPjè˚%±J3ŒAër˝‘›≤éØÔ≈5}{⁄…TJ†uµ}Öc°ò¶]üg/ﬁ«ŒÌC5yñ≠⁄˘‰K˘™` (s
L(ÂHyåîC]%JNÎn‚H0K«.YZ’uÜ»`†qŸyI˚±©W!C,øJÃ|féAT–n\f19˙0tõY’∑´¶,ùî≈]ÅMÇìÊ$Q;–±l,F1;_9Ó–‚d≠»÷bßz·|ÆﬁvåﬁZ≠∞7%&†¨èÊ^”rsÂÿŒÙ§ùwhB[}m⁄Æâöπ§ó?á1¨„ò§’ê¿˘ËªnÌÿT´ÑF3êØØn√-IyËhŸã≤ÍaÃ`OobΩ"ë¶/œ?La˙l∫∫©∆ê£cƒ7a”wu∑hõ±πOR£S«Õ–ı±Æ1ƒÏTÊ¨=ÛFòîÙv¯ê≥ˆÇâ‹O◊Ùu≥ôLˆ∆è&F«CF_,”î£Gâ—2e¡%"√y•#~Ky(¸ñGìÚÜW[”ô“‚Ãî˛ K{ïXºgî⁄ïˆy⁄EL“†®ÀÂfè0hçbGè⁄UÉ@Âcsﬁö]1õˆ64QMtÊlüx‘ï‹£ˇ_åË^ùªb>•”ôZÏjØÉgLpıœ2Iº¢cÒvˆ^<C˛0 -≠sõ
endstream
endobj
199 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 3595>>stream
hﬁlVyTg∂oê™j 8Zÿt%U1Ç» ‚é≤à (
B≥à¨“-‡¬.Hw∫A3Ï Çà»¢≤	*∏Å‚äâhîqâq4ìDç…åôwõπxﬁT˚^˛yÁù>ßNü˚›Ô˜}˜ﬁﬂ˝}◊@dd(200òπﬁ}ïóªáçkTöoÄc§£}åsT§ùõ~È3k†˚‘ƒÌ±¯S£ø˝{:aS!g⁄°Oß∫ˇIdh`†Ãoë˝yÒb[˝◊È„w°≠Ã¡ﬁﬁ˛„◊IÊï-Ûﬂ≠PF'*dkì‰…©)…© Ë(;ôkBÇ,5.vªR!KçVDß¶Èç~©… hπ∞.ã‹-€dÁ/XÔ$¡«√iÅìÌÇEvˇ˜¢"·'ähS—,ëh6)≤%DéF"7±»õ˘S¢$ë»EUd$¢Dúh≠H) ’àNâ~102XiPbpÕp™a™°∆&ÖM:4iƒ»ƒhãQ∫Q±—S£qÇ"ûDÒ…ìQ‰y ò˙åZC)®ªbkq¥¯≤±ëÒ„”∆?M6ôÏ2y›‰Æ…oßXLŸ=•Àƒ¿dô…nì&S#S”#¶è&>–ãËâIo∆W0ôé;m¸X*9˜∞˜ó÷∑bØÅ€¯j&pπ/J‘$∆Äh~y9˜/“ˇÁ00)¨>“°9ΩÎÁhÃ\~|fj Põ◊√Ã¿1Ósr»Ó,ö„*)Æ
C÷ﬂNÔ⁄#Ã®˛ç.á<›uôR«v±Å1—ÅQy˚¡8äÅ„qƒw|à#hh∑fpŸ2¥¬<zkæEX∆¬‚ß¿C(xz¬|tÂUH17ZW‡l¥äwı€;
÷`€yoêß!«,«9úF¢Î“cH¬'√Ññ§u3òÜj-u˝Ò˙˘_ˇÜR0^˙≠ú\cB∏^«N4±[#yı
O7¥¿ãVJÊStÁIFŸ9∫Îπpâﬂû˘¬{xyØ•ûÔ¸F˙ ÂrŒ.ä‘(Æâö¶°£óŸ;≠IQ^Èõy_4∏IﬁΩù¥.DΩÃ«ÁXu
OÎBÃ`˛ê.∫iËK°jBFXAŒß–çˆÃjË9‹Y∆ºòTE®‰QRúM—∫îqé¡ì¯3Q“tL{ö≥Àëk<◊$z˚˘ÆJÊìë$2NèÏ~ÃÇ˚˚ˇ”GâWÇ€˘ˆ0Ø*voˆó™LæÍW
©ÿ:n…dj24…Es
ùº¸ƒk√æ@ZäÛøG‹@ˆÓ_¿ ;|∑fƒ«sEdÌ√Îﬂ [ﬁ®=¨©Uã—e¬áYµ„Ê7E¸am≈¡RÆ≠Í‰±ˆN[êÔ⁄∏‡@û–ﬂu\TQX?qÑÄ$‘Î.o(¨‡„ë∂iπ‘Òë,õwO`Úw˛WºπbÍN[À‡êÙ±˜K¥E3+74‹ÿxk3±ÄŸ€w^√ü?q˙B7º∑7n£tkÏˆ@ÆH≈ïG ‚∑ÁÚA5QÕ}“Ó¶Só8˙US´>Æ>¶˝≠‰EÀÕ!ÒËHÔ/©ló¡\ä_»p:Nˇq˜÷∂ú‡¥Íú‡‰m€íÃ„°Y°EâÍΩÍt≠÷Ë|ò—¶’ûj>Cï[òÀ)3ì2"ÿı	˝C_wú(,∞õá;Ã‡©ÆK¸†z{G Ω)Ët‘%˝f∫YÁÆÃ%t%`1â1„ŒÜíÒ¡ôÄ?ì˝‡J4 …tÉEyWŸ≈≤ns-Y&ØÿR!?ÉZ°;ìï∞%/îEvÈ˜¿¬‹üÄ…`ovVﬂ&Duäoı2∑·"!æ= &82üﬁÆ©<Œ”˜Fäô¬é´ÖK$`–<< ﬂ<ˇ
)L	ˇn’%Æﬂka#2Ï
∑Ç<lQƒW-nºüπ¢ÿØ@^√ÔﬁıeqO/–≈ÍÊ1®‘¿¥	«Œ:W°ÀZ¿	4$=˜ÆÿB#¬'XvP!∏Ã'ÈÎ„∆:3Kp {úEf'àcqö„SƒÚÌ(Lˇˆlˆû!ê©Dıé5µN,ÓƒÖ8ïjﬁÍ§„?ŒÔÊ´ò æz’Ps^àÁÓ∏3Û¡Y8Ëî‡)∞w∏SÅ%PA—¯Íè’qgäŒ1H!Øé¬Ï#`âY∫ô†Än˝HaórØbØbﬂNs\Díñ›5”-®RØÎE[íÜ¥q÷¨»ÿˇ)ó*ï+ïªóõ ˜=NæÎØkaó√…m˙2~NVBi…Ûí˜≈ WÎÿ`”∞Ù>VJ`
˘jö7øix!,X[/·Ë{i·™^˛¿ïêmÀŒ:uª√l˝'! n&ø(∂/u‡Td¬£®ÁÚQî¡óÙ¸‡L“áˇwc0Õ–√pL3ÇÈ6áTEBPL9_Ñ¶ÃÔW-ê∆ô~÷≥ø˘IXùy˝ó˜<ˆ1/ÖdQ’aıˆá±£˝ó¯ûé˙´#“ë‰°ì‹È∞5áÁ±vkÚCy∞ë1≈Âı⁄v¨7∆gıñ»% }=‚>Ç>KﬁRüÿUÁ\∑®vSY∫Ï…¨¶Ùóic{nÓÏ≠S◊Ío/Ωπ´?≤çÎYUm….v/»Äg}Ó`Ôùâ_ÔΩÇ˜%È›mLZÁ£¥1|^º‚u¿Mú“«;∂«‘ıJO∂µé‹»»j‚NM‘…™]XtòÎÑîı∑>`$Áü&∑)"§·1I´÷y’◊À9zl(©Îoò1Qç3`ù@«Å"&Óxg.‡Ò˚;à‚t4⁄NÃ§–$‹©Kÿ0s∫ô}XgiÈ˙Ú;ì∞GÈí∂tœÛ"rÔÛ¥G ßã°SÇKIHÍOœ’má3à7ø¡ÖkR3‚∏fk‚H€Â⁄Ï√™òæÄBW$}q˙Úa˜w◊.‘wµÒ≈di0üë«UgœI—Ú:ìßŒSÂs	πÒ©1l‹Œ∫Æk7Îû¥‚ÃaT~™xÚ–◊¬Î∂·‰P⁄Uå`“K‡aÆ∆˘-≥´7ßD$Ò*hÿ∂nLô¶T[ ıïu∂ˆ∞£'}W8 ∑¨ﬂﬁ÷ùÀ´˛¢.-ì“Ë¢≥ÉiLÆ2π ñuıÌ≈?Q_∫˙ÑÌ>æ?ˇ0ﬂQ˛ïú≈u÷h,ºèÛ~õ◊.ñÈÖE°õ>Ã`≠äjﬂµµa=ã∆≥mp±ÜG€ü¨@|ÎzÛïÆò<‰A K™⁄U◊•∫îêÂ&[ù≠ ·∂Â≈&Ü≥ﬁëóæ;uÛﬁ˘ˆ8y)ØÕ˚2'_*$363⁄Ú‚£MR0ıÖ©ËÄ..¯~ÇÛ^€¿íëeı∏Ùôë˚ÉXÔñ[xı{¶ª§i¯6{Ø∆'F4:`ØôŒÙ-Y£˙Îª.©):P…c‚`⁄ŒÉ;ÿ∞†¨ÿ(~õ|˜:?i∆:4∫3aJ—q∫zx√<–ˆh€8îêÖ~ÑäÏIç8±ÜE”9ñ¬5d/¨¡tË¸—Óº6Å¥àvﬂXw8ÅKD1°ËªõuáΩˇ†Íú0˜‘ç˝,E[∞d≤‘{ds€sv YÔÿ´^ı]:s"E^.Ñ´…Õì“q7Ù∫ŸKñk*KJπÊÚcM›Ï’Üp/{'VÆwÁ&'ÔœVräÏÙ={wâU–ÆW(¸‚ÃtôBR3©±ÒLp¸ém≠q˝[Oû·{’âÌ¡¨–q˙2Ÿ~∞Êëù˝0∑‡Kb(ÙÅ;ËEZ°eˆÓÏÙú4sïUüÒ‡èò+¸∑ÇN≤RSu∞Çk,=⁄“≈4D¨Á±Y∞wQï⁄Í‚rÓDyc„iv‡h§èuÇΩáKèëy±ây˚R8EfZz∆N±äºò‹Ó≈.
ﬂü∆ë#2§6\ªy˝)8EVi™J Ù)8qÜlÿÊÕc£`?C¡Ïïw-á∆ß≥…˛Ø	°6ˇª3˙u*,Ê†#:Ä·<∞Äô0˝¨+À¢5_àÃ7ÕÆÓ1~æÎ∂ﬂz~ø˘·}}Sa0#@–íÒÁ√, Ò<¡ﬁÊ'ôáÚÊX^ı«A[µõºÑ)"Ñ)’îiˇ¬ù-ÎlÎeø>Â∑|QT¿⁄Ì≠=B?ï©À*Ñ~*¸áÜ¨–ThÀ∏Ûeù-ClmÖJU¡É•ÕŸØ…dC¸›S˘d¡öë≈öPwa„∆ˆF&Ω„Íæ€,»FÔ˛»´G£˚Ì⁄ƒæıç“∆˙ÍéûﬁΩŸ\”ÔDu‚ñ™çó{ŒÁ’∫˛' ®Œﬁ)MÕÿ∑5lC]m≤0åz¶cÏı¨∆P ≥*¥9âK=÷≥gÄ=”qË´:^Qîô´Nc√ˆÊaïΩÄÑ¢√tu∫LÅ/ÿGf©r‰qäº‘§vì≤wîá¡ﬁM°Õ}ü__ûª–R'4¯WûHHUèÍ“m°qKÖΩ‡9ëIÄ AÎtô:ëﬁòûëì/î3ø+ø3˚ÃZHó–`^Æw∂–;[ê∞≤‚lŸπ“˙·g}ixe»9\!ÅY$Ã’£XìëòÌüÎø?@†hﬁP÷ïÃ°`í†	Ña9!˚Ú¸ıCπWÚ.»a´Ññ}•Gw∆˝∏µ,%œΩ¨h¨l¨hÜÏä‘ä‘*≈Ä£Ví∏Jag,&∑-ÕRd+≤RÑ#≤≥3èÖ<ì–sÈÅ÷L≥5˚§E˘Ö˘\¶bg™2[ô•»À8–é3$ù%CµóŒúªA@¬Câf¨«˝˚ìÚcRÑë°†)∑#øŸ
$t‹Gez	Fu‘PSﬂçÊ∫Â‹ƒk°ÈñQM¡k´›ÿÂæ{¢C¯–Ëi⁄‚§ò°˚¿¸GÄ √B'‡

endstream
endobj
198 0 obj
<</Filter/FlateDecode/Length 308>>stream
hﬁTëMo√ ÜÔ¸
;Ì °i“H(á∂™‘√>¥vªp∫HA$=ÙﬂœÑ∂”Ñó?∆±˘ˆ∞;∏n˛sƒ	⁄ŒŸÄ„p	°¡sÁ ì`;3›NÛ◊Ù⁄'¯x'ÏÆ@)∆?Ërú¬˚’≥x˛,ÜŒùaq >ø»8^ºˇ¡›Í,∂åo_¥’=èÿüw∫z9ü≥€√É≈—kÉAª3ÇíÎTï◊ÄŒ˛øcÀD4≠˘÷Å©<£H!hc™§•»™®	V˚çê5£∑ËıùM©“3≤ö3ê&√í^ÍdÏ»»ó§ÛAöåÜÙJ$cC∆JF£ò“L±¢"!E,´àHôê""eD QﬁL%≈ˇçCx¥Œ\B†ÆŒìöõ€÷9|”>v).ˆ+¿ 5)ë˚

endstream
endobj
175 0 obj
<</Filter/FlateDecode/Length 968>>stream
HâtUÀí€6ºÔWË8J≠`‡π9Yª÷>‰UR.;àÑ$ÿ"∞ÄÎ’‰úŒ@zï‘∫t 6gzf∫¡èﬁ∫ıFnV√Ìé∑ÎøvÔoZVµº[mÒ◊∞¶‚+…+÷÷jU+‹Àfµo@ﬁ6Î›Á≈T#öåùóR4å◊ï@¥`ÇWÑ˛⁄î®e-‹Oˆ4È≤pg‹ÒY¢Î∂˙OZ˛∑º}9oµU¨ÎTÉäq’âåˇâ¿Øﬁ÷+æ⁄n6R∞∂í’j#ôËwá‹^Ô„z”A
∫Oô ´∑¢‡∑´gBµ3›9Æ7ä5¸‰Üüg¥,Ëöµ\!°åΩ3ë6ôıF¥í)HßºD ƒ©Ô	¬∑x”π<®¡∫¸@Ôv0ı…zGOVÅ?î8z?Ó-gÜ%†v…ìÜ‰LÇ¥AœAyI‹aªÉ~∏‹“)NÙöŒC0è«w9◊õíT\%Ì9'£Úìœ•oJ…ÿ$πïº>˙¡jù+Á8Y8¯0∆eìcb·5‹ø˚cCX:Fﬂ[|Éré≈;3_∫›˚£≥…>Êp
È6˙0‰Óµ`Bé\!‹ø˛ÌÓ”öˆ∆f‘•pÎ2à„·	[Gä?ûQmÔ≠Pp“3M{c\YcB3“ :ƒF wö‘D]TÛ?±\—wy]ãEëﬂ(˜Á)\L·,ıM6G%ÏÁSlΩB"∞DHI0OΩM>Âò5<Ÿ>ä≥ZDbÙ8jÇpÍ`»£Óà¬5äjEoVÿ÷ÃãâÂY_±5Tz:ï‡?òÅRg0˝Ÿ:SÇQÚÁ.<´Å∆¡ñ©ΩqÉÔµsyn5ËΩuûdåTÜ¢ÒìÀ¸8ŒÛÕØøóq÷‰•‡Y’Ù).*"Ft{?\ä:8?.É\:˜Dπê)Ó.Ejnß‚Øä]:ig™ŸÑYœ´a÷æ8º$Ä≠Sìªb6`.3o9Iû[*j¥1˜°ºÈ)UÖV-dÃîÚ∞1îÑ§√—–[‚Ä∂*K|LÊKb_¢,›o©º{L∂>éŸ,æÖòŒór!(≤U?≈∏lØÔüå+·—◊$Á¶AƒÉ&Ω‡›yÚG„6/)¿D0}d6æÃ£"fπ∑ùë«˛\o¡în¨h˙b8îB<”ÀﬂòBèñä<âwÂîo<)C0p]sá…—=:ﬂÆ`Ù'¸‚ôôD,ƒX$AﬂDN™º Ä:§Â6õücK–ÅPgﬁπà~
°\ﬁÿØBúZ˘≈˘Øhê’ø Ø%Î
endstream
endobj
176 0 obj
<</Filter/FlateDecode/Length 858>>stream
HâlUÀé€6›Á+º§ÅHE=F›ù&AÄ	ÇvÄ.ö.â3&*ìIç„˛F˚¡ΩáWöG0+S‰}úsÓ√∑üﬁTªBñı–7ª€Î7
}Ù˚‚™¨ÖªﬂıU]*ÒÒ›Ák:MŸãìN÷∏K\Te+˛00k…,lòÊT)≈d„∏ƒàOYb\B@‡+AÓpÈ≈8[gG=√§&Ì&<4d}
Ü^˜≈@ˆõ%ƒø∞<ÎÓ#_J1z7◊"8À¿Øè·<Œ,¡ü÷wüÃXÏˇ∫]â´JI&ûÏÏªñH1íéA%[Xá§ù¯Oè:ë@R“S ◊∂#˚S»¢5‚dÈ`]Eh˝Nítc0]C:˝˙ÀÔ8*:íÿmŒ¥ ‹u3ÀLà≈*u·ﬁ˚%$¶qxãÀAúM˛•«≥ùgé‘?ìæÉ1ÁnA D 8ô†«dΩãOR<ı¿7ìŒLÿr ç‡Ç(™BÆÃ@U¿îïRU_Æ2ˆsìÉu´G-"I’«òÃ1æÕèX∆yôr—8‚≥<áÀ…ßÉF»AÃ˙h©rπ%N6-6i@V§c°ß`úQôöBRrœpÚØ‚„ów_˜Ù)´¯ïÍ#CßÑ9U=à‚1WAeC$º”GG€#˙áùThÑ˛éÚC2)7ôÄèÓâWÛXi∫FÁNú÷Êjî€OÔÎ·∫˚±.7ö O¨ûQ]’;ÓU⁄7&¸3ÃZ¸º∆RBI©v« s´ÄÊ†s„S0¬£C»çGL∂Ó)êﬂWbA˝ë∂;è
e0ß¬úqCír”+ï7Ça3)fõL`¶:-¡∞q+ñ»Û™˝ÀÚÌ∆d6F∆≥uÕBc«ïˆ≥ô?èÌÇΩ∆≈∆ÙÖv1Aº=È+:Ä◊>$}¸Ì¸y6”}Ó†˛•ë√ÜzQA£mn⁄(^‡¯ÍÏ¨£∂%G¶kH†≠ÍO≠˘õâÀúxw∆äJ¡’–n5ΩÕÇ4Õ6¢uÉ]r‘æm	N(çùå∆¬@–¸åZFjÙ¨É±πÛÅ≠qÙ”¬∂ÛJ∂n@6ó∫¡ˇ¬∫º»Qby∂}{∏DÎg…[Ìqmi∑'∂∂–bÊù™≤‘jk∫«ËÙw/éË≠Ô›ˇ bå¿é
endstream
endobj
177 0 obj
<</Filter/FlateDecode/Length 858>>stream
HâlTÀé‹6ºÔWÃëX≤DΩ}3÷±◊>2»%Å£·Œë»ÅDŸªˇ·N)ÕnÇΩ5˚≈bu±ﬂÓí"≠äÆ⁄%y*ª¶‹>›˝-ºÈ˜IQÁi+ze≠:ö}ígi%¨3'F$"ìÓı’ªâÁ2ÌD£jê‰ˆôòb}ç¨”“˚X_gôƒl˜Î‰€7†Q.∆}“§•–^›`Ê1VTByøFÏ¢ºûÈØ—˝·„Ôü"∫NËßﬁxÁ›”>È28=ßl‹"xô‹>i—¡‚•ﬂﬂÓ2PdE	∞zaFá˚Kç£Ú¿Ñí=’<ªﬁ @ ,”F¸4ƒ%Öø0áœ\!U§ç•π8jZJ?±CÅ¸„3,÷~‡Z‘‰Ä&Œ‘®X˘≤¿óKdqYÆ1¢.EúKI~e,Ã√\n‡Õ8.Vøº˝e¯ΩÜTï≤Bœ√PÀúÊ¨-®ÓÑ0∞…å0”GZ9.1óËªˇìf”;Z§˝·Î_4;<bTk}∏àNm¡[i)(a◊:PB€~“jé!π1⁄¿àÑòhÅÈEõ¨l°ÜÎDËzû»˚*Ù{kˆYd$æ⁄8óZ®”	œv´åÌ;˙9>cOóyÊg‡}“Áe¿‘ÇJÍÇzyåÍh#=,+"=®ÄorÀô3kƒ%EåÓ¥Pú≠∏5™Í[£÷≈M£√P’âd“√¶¡„˛ØÊh úÂ	cÏjü»í‚Ω:Ø…j+¨7jÄª ‡û˝ÑkŒœ<Sè´,[DCT ø◊—∑æ5ˆoe4mO±]#‘0ﬂ®a–?¯ë‰8_U_'wû0∂ v»ñ|H®Ω	|∞Wπ~2~÷∆ùﬁ“<TªÈUcd¢xpEﬁY∂îDB≤/Êòº%≥N$ì+Ç"kHFË€q£ƒ—fƒ>32À◊Òá?‚Ó˙H«J	ín˛/ÙÇ'“™Ò	Â˝gπå«ˇOÓﬁŸ>n≥a°ºÁ∏Ú>¨EE,¬n:πÀbÕA˝£„~#ü¢;ØS÷ÈùÅ05ù5ñ$*õb˚„kx±¨ª®-Yì’càr€®-Ì∫Ì⁄—Ã±‚ı¶ß∞›rpoo„™˘MÇ0"ãÚÄªzçÅ€ô≠öêÉBÍbï€˜›ø ®ø»W
endstream
endobj
203 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 6330>>stream
hﬁTW	X◊⁄j2„Rl’±0”Œ†ó∫ØàZ•
¢ AŸAˆ$Ñ-lÅ$B≤Bÿ˜vDd+"∏[≠˚Rkµ^ØµˆˆVÔm{¬=Ù˛⁄˚?œˇà2ÛÂ{ø˜€èg $éçç±wÁÁ{\?_ÍëÍ}`udî”zßU÷Y(ÀG3ÊB
˝G1ˆÜÿô¿¸Åˆ#äò≈ôdcS€—‚∞⁄Ÿy’2Îπz‚\3qÆõ8ù&ŒçÀ÷¨Zµj‚\3qÆspâ‡áE:¯äE…ë	"˜ƒp~íÄüö±¬¡%>ﬁ!)Êht≤»!)Rôîj}∏/âüéﬁ;Ñâ¸V¯¢'H:…∏ÆuZΩÃ…Ÿy≥ÉÎ:Ñ∏⁄i˝_mXªj≈ˇgƒ±Aˇ8<üƒyo&g˛TŒÚ)úµS9[9úˆúÑIúg/Úg
áÀâ·Ë8√ú_l>¥YdÛôçóM°Õ‡$ﬁ§ÙI˝ìgOéü\7eˆîÑ)eSqWsõ∏øÛ¸xW±˘ÿ1Ï>ﬂáóNù>5cÍ»¥O¶uMˇ`:˙£üŒËxoÈ{∫˜†≠Ω≠ìÌËÃπ3Cg^xﬁ˚∫‹>h¸‡áYªgùõıf6;˚ÔsË9ys^õ	qgÆœ‹ g~(˝ù›.ªõˆÓˆ~ˆa„.∂∂‡æÂ’ÿT"∂~|·KZìπÍ±ïÑc»¬M[˙ﬂæÎ{˜‰I»€Öå*Å∏Æ_Ë([‡π7˜Ì–P…/óÀ4®#Éëdø„€∑J.bTâƒU√¬ÉÅ“{˜Jﬁˇyô±}1@àì$âVÆS1Ìlsj4ñòòFπW+nÙ›!Ø˘wá“∂Î¡0\D,~∂¨€I∞˝X˜À3Z‹¿Öª√up7©¬†˚∏,\bï6É∏yÇ5pÒ[:]ƒ˝≈˘"‹ ∑ìpª/\ÔËDW's¡íwW¡j‡F⁄æsâ$QFR¶^¶a:§Êî£d$_êFó$rØVﬂÍ}Lﬁ:pÚ(mª-≈ºÏ\ ÊŸÆÑho®Ôl5∆≈âí‚¢í[[04∂ú·¡¯?qGy∂g;6ìÄÀ¸‡.Ë◊ûáŒ`)¯tÏ¡ä/¿gp	£å%^5¬≈p>t¡OWØÂ#	‡– ñ¸ù±=kô3∑	[•cıwIKv ≈;›3ag
∏˝jÖ?9N`;YŸj9-¿ê*‡@x&‰‰˚Qp/ÃK∏?¸‹sÈ˘ÎÊÎk}c„iüMui‹ì¶æÛ_S˜˙ú÷{:{π0˚}|¿ì-S1„@qi/éÔ∂ÿ-5ıUÂxMuI}3˘pﬂËZ≈˚‚HR<ü	Ò¨I„ûhÏÈ°Ü{„º\vGÆJ`¥â\ME£∂û∫p;jÂíC~Æ>aÊz!#”…T2V*œ…QÂH‘πe9∏§ÙT iÍ.π6‹Ûø∫∂“Jı0ÿE.µ,«¿è·íepŒ•;1˜|vbMÿ&]æÊ&y€<H¿ ﬁM0È´üÆøƒ≠û^n$@6œÙ´Á¬ìºHxëk®Î.È•¿§aœµ€Cw8Ìk´Ja§zôJ JÚ§9™<ïD-EÊdóı•û¶Œøi:ﬂè_9kΩL~ÁÒŒŒÃä§ëÓè¡OD`^_ª“‹UŸcl”≤mvaÚ√íl|^$\πêO¬[
¶ÇœﬂÇÔv<uHKïÁ•–ıƒ´æMw'm¸Ã˘–œ`ÜÈx£¶ö)≠Ô(Î¶gﬂ±…ƒ¯,^~à‚êÙ ﬁÃª—†5‹†@<o3‹ß¿∞˘põ.◊Ó~ÒO ÏÚ€#k
≠9≈q›ÏÙy‡WQÃ—î(AfûíöúD:<˜˙˝9‡^S_xûŸuí>›jj–™∫‚ÊfÚ©€çetn1xÓËoATåÄqÌÙnøOûÎ∫Dè?!<ˆü}=“~ˆLÛ8‚N∞πıo+•qÓ6à:ˇﬁ÷ﬂ™´’∆:ÊÎÆƒú≥.Ÿk∏çWäÎŒ3ÄyÊOP;æOg∆?õ‡Ã5i™de2ìô#â¶ú›{y…¸¸!cpÀ*"V$äçiµµ’7t¥'7ƒ3„[˛Ø∂‚ˇ¨≠$À≥ &#Ÿz$€ÄdEH6v¢˙ÕfÍÂ”!3'O0Í"%	‹+’∑˙˛[¿†dl˝\3Ê°Õ6ƒøÏpæ^`[º‘Üè◊∆¨…f˜HÌ˘ —åm”…äkØïˆñ˜V‡ ÜW∑∑∆Ø4¢4B*Ûî·|,¥–ì◊˙¥ıomœ≠ôVXp+1RÒ‰‰Útjt]l‹N¡b>Ô	´f7í„ã±ç,ªû•˘@à}s√hb.µuùªI˛≤µq9◊	‡èµïki≠°^›@ΩÈˆﬁÌt$⁄0ácà∞Ω‰8Gÿ&„!Ææãúëf˘ÿI,>‰w¿ëBaòÊ o∞Ï%*˙ÕÄs9d^”¨gáŸS≤Q{w›&
äP§·Q∏ÿ¿Ì†Ó≥≠ô©Íhº_v∑√}c4¡«±˙¸ı‰¯BlÉÃjØ ‰b¿ˆó∆ãòá_Ç‰è—˜ù°/{≠hÑ≥)8i—£.1hi}±I”K›ºò√`ûÓ^ΩÄÑÎ÷A∏wGlıC‰|{Kÿ@dG§Gg§·¬ælu(˙Xi:#6≤uÉ$ÿˇ{°c]Kôf‡õ»sì(d´®Â ù◊\X‘J?‰›míßî1•©≈)Ü–fµùrHÒu#9Ó√Á=FˆÆ!«ÁcŒ2Ÿ*9Õ∑§bÜ÷öµÌ∏Ì+KûÂëFqM’Öè{Úyàõq˚[/c7[c—h∆Vie⁄ÔI‡˛/Ïï&wó¡˚%Ú<$
È*jêÚöãäZ¸√Z)øí)M”¶¬ëØ⁄∆‹¿u|ﬁ?ÂZ˘Nr*…IÀ•sS‚Ÿ
˙m [Ä#S ,ˇÈA,úŸ¿òµÚäeßΩ.v[ù˝·^‘52a X?Ç'OÎ Æ2¨Y’÷I~è]Rk.Îë◊ûç%†®¿2ƒSÆWl$Q∞ÔÙ⁄áZ⁄ç|Ï)‚‰dÕ/'ôbÇSÖsFúæ#A ¯ZüO‰]≠€§ïiûëñ≈Ë˚öß:⁄v)ù;!≠˘û¥,¿ûÎµO≠Z´&¥≤»Ò÷,pFﬂ∆–`µZb‰Ûæeır'æ∆6Ïó“π>âG|∆D;ìæΩ∫£øq•Ê H4JûÈuè¥¥Ì;ã8YGƒqb˘‰≈*4¶∞$ç+jŒì˚ﬁ†˛∆
\f÷*˛ñ;!`À!Œ⁄7⁄V‹÷rxÏ2wùN©U˛&ˇcß¸ó∂•7√≠Ã/ÄÈñ.‹»ÁΩíjÚ•pn6å∞ìœgCÿhyh∫dãFI∂s”%Î
Œ®zéı©ø+›vÖ<ê<ﬁ ≠·•eÄ´Ê©«óqÁ)Ygπï4∏6neùÀÁ›V÷Áhé‡j~Q–
™îÿ¯ãäÒyÉ˘µ≤⁄$º*πP±ÉÑlï2@O+Ñ9>JÑôg∆v´ìçä!\Ÿ¨<Û	‘ÖòeÎx-∑’≤à˜∫p@›J´˚JGãP^]≥|Ä∂T¢≥‡fË˝¿Ë ‹¡¥ÿÅxp.¬œòî£˙<	çá£¿‚Ë˜ºhBÌ˚ﬁΩìQo∞?=QÀ˜˙¸µVgnî…&r£¡å≠÷J5œI∞ªü^¢™>V^hˇ≥Ò◊¿\Ú´§”-ts¯~£+µi—\d‘kiùÆVc¶ûﬁ:9pˆÊhèXÅNìÉ º∆¶W)ZQâ∞%…îf:z.a ÙfF~Ø˝¸˜‰e·@òânå
0Ï†‡Òâ‹Un¯´ßX≥	îõ±-Z©Ÿ±∂™î†⁄j	ËÚÍ8ïÚ0Wïè©Òµ‡éaÊ¢ΩÜ÷Í+’Õ‘É;·ê„óë¿§&≈ Q∂'-À-«	Ÿ5EO~'nå-9BAb´ÛR»}p=öy>ÌBÓ>ºÌì†∑W≤Ëπ.∞tΩ.’æXQ.kî·ÚÜvŸ)
ÿø|ˆ+‡.?ΩÂ≥•'∞Ûyæc‰—ã¶]ûï®
Ω,/-
ÇΩòOuOÂ•g…X5Œ¯9ÖıŸLØ‡Ä¬C·çÜ∑±_ﬂl¨ƒÎJkﬂQW«Ûx[dy´¨ÑOö±ÂZYÒ7§%Ô6ˆ∞B&™dJ2ãìä≠çw,ƒöcR>Ôé¢V¢â¿’ÒE°+…ÌtÇÔ¡˝=Ø¡z§a◊kkPùî±«rC˛jbpöŸÂÚ:¶ˇBˆ%Í∆Õ⁄3ÉÃÖ+Uœ¡4Ú)ˆCQ_Q≠Ó≠/Ω¨F@µc;≠@)®ÑÛ¥ÚÙ˝qã∂¡Éá‡,ºÄ∑lﬂæH∫ìŸ_§ø£C%U¿«.≥≤fóã–Ò)L∏	˜‡≠ºá ¸W†k∫—˝≤‘µUd◊ˆY5
Pà•Í‹lÔ,W_Ë
I§q/pŸ6¯g<ëÁù|‡&?∏=Û# Ö~≤Ü
ı˜*üè]ëóKùG‡ÆQË:›‘ÿ0
÷èW4`á†„-Ë7◊£ÁOA˚∞øÓzÀw˝-"?ˆ	j
üÎR è‹ºw‡Öﬂ˜7ˇ’>X€<p©∫¯æµ9§Û±2Mû(XêÍ¸u‘ÖÿY¶„Ü+Vû*>vWVö€Á—È{⁄eÿi-¸»gR|bd|éèµaàQ√–+ä˙⁄.ù∫ıÂ˝´K∂7ÜU« •^r‹⁄¸«8VëdE≤‰C¸Ω~K¢‹C<y"nWÔZ	 ê/%π=ªŒØ<·ﬁπØåWK”Hho-á5÷ÏË4c+µ2›3|ÑôäJ LÙ‡ﬂ:.‹Îæb,æÖ¸6Z.WBêóöÇ'£‰jóW°:éAeå˛pH^f7˛	/!∑∞^¬àxAäÌ
œfïù±ø§—XÖ7UV á.<»¿`8†È†œ≤≥îÒJNUΩ÷u·ËÍ‘ù3Ê`(P?&«pÏqëÊ7= ∏≠¸é°∑©ËÌÿÔp´ ˚MZ§¯å¸√∂(ÛÁÂY/zÀÁ'â<óÕÀVH®q˘ º∞·ºûË∫*%¡ê@˘H‹#ixz∂DíMä”´ äuZﬂb®3ñ·∆ír]55‘æÉ…¿Rƒ;ﬁi¯Åta| È˘Âæ;-gN4ı–ömviû[R+-ßv¸D§£mBH≈á7ù®´>Y≈‘ü©≠-¡mÔÄeñ≈∏ÇEeÔÕ:Ã‚…ÿu∂êı$«œa¬ë°<kΩÉiˇFW∞È´pê‰(ÂôÃ&¢∏™Õ`¶æªÂÜÊ2~–’È`bWµú…/.(.'ms,$òLÑâìÑP>ÀOÊ◊#7∫:s¯-åLØQj©í∫∫⁄•>ßÑ)Àå-£Tº(ÔåÉåõå€V“·Å#òuÈFˇ≈~Ì%eCD\7J-◊ú#-?bQ∑ÃÉ,ûÑ›Uhî$¸3$'eS#Tˇ6(\øÓxR“§≠ÔaÆtq=∞ãµJÎ‘8\yâã¢2£)è¡t‡¯¨{DoftÉ¨}ˇ7"&**3å˙|À(¯H≈Äj0´∏¢ØV´ı5‰#∑—]Œﬂè∆Ñ%yÌ&!˜Ó"0≥ıV’„k4‹
æ%F;™ò,V!¶ˆ˚™|©oÀz([Hü∑∏ÇDu.˜6‰πÀ{XZr±-zy—}Ù V¢”4∞NÎ·©ûóú)≠¡+K*å&™ΩYú^ÕÚ«∫bΩV_§◊UFiIfubiLaÑ"Z|4¡ÔHÊ!y
.O…Oå#S1€fK8åb˝Ÿ@%^ïkàEﬁ›Í¯‰ÓÓ;<êŒd¶≈	√≥TyEbCvijcrWÆ(=">-œ í¶ßê>«ØxÄ)÷ò„ˇx˚Û¶/&&ZEâ´´À*´Kå≤¢∫†Çz˛˜sÄ”)i◊2îÜì°¬ÊO¯~∂%""X≈à}¸®ß∑ó©w!˙õïyçåYRôCz,sŸjƒ\c6’—ÂUı⁄”⁄{äÁö∞˝ôˆ	vb`Üœ–&ø/¢é•¡K,B‚ù(G˘la>JL!Ê.cΩ¥J»1&û∑V°ªN)÷fÓÆÓ¶n∂Ü93pÊ!c˜#Wc∂3@Y⁄âÊ∫Ü¶ñî:æ@îí hô0uºù0a{¥rÌ◊$¯Ê¯ÀÃeTØ^$√vÀYœ?UÏûPa˛SÖÄüåT‘ãöòÖpqmP(!b´
ˆ±!4#OñdeãÖíXû≠îÀsHQ}Z©^Ø÷”ı5◊v˛ÇW´˚æ"¡kÈüsPÜ€^û†Y((èÓéÈt”“[˙ŒV’46û<Q[r´oƒ`àî+ƒŒ(äd©ÒÈÇÑàîî¨LqNã[‚∞àüå@2¸äB√∫ì„ÒÿVÊfM3ëïﬁÑO'cÖZÕq•7∞ôeÃà€µÕß˝q+/È‹ˇ X~≈b$^®∏Dÿ5V[∞õO¿‹•π¿2{¨€"≠\}ì~ÿœáF∂&
%Ÿ©tRf¢81?ó“H≈ã$ôB&^ú*NÕ∆ø≈Ç“ÂÀPOπà|∫áÑ·òáîu∑öv‘Ñ†µπAÇ5∂Ù4ù§ÆöBw0p;ÇTxY%bMÿ$qç±*ï±¿H∑vw◊vQ◊É\∏sÕÕﬂ7aòb©ù0çUm5ÌßÄ—Õ»41üN H…JÀ¬ø¡Ç”K•»éÛy⁄¸=÷ÿ∫+ªÂ%¡ÑÌ˚ÛãÃ‘r≤±á∫Ÿ¥À™ó\ˆß˛;†ÿ‚G¨Ñs∂Cg8˘)∫>~¸O0ÌXfÆ¸æœ‰ƒ/óB~Ïƒk£ﬂè`‡ûøzô±}>≥ºO|ÉN˜Õµ&Uô∫¿É˜∑∫uœƒÖ±	€äÚÔ!	>ƒJÂ¶ºÊ6ÄÈˇ K…ü›_¡…ítEÆò^πé®m:U◊F›ΩÍç∂À)æ;ù¢£*ÍS€o-F('ö–Pó´oìñÏfaıÒZ:øà+ÀÃQ≤îL•8û≠ñhR5GQ§è√π®I. óﬁÜ\‡Hˇ÷ÀÖÎ0Wñ›Çå¡ûÉaBö.í«S.øÔÅi7.›÷õ)¨gl=–f˝Ü 6X`Z∞$`"†ruæª5†Órv"\&DEaÕµ=ÿh][≥â™0≤ŸÂåñ’´åº⁄PZSC¢¢â	ÒıO†ë ª‡1Q–ê{YZá“Ü0j•∑˜Á€æäπ,`Œ&7ãÇ…êAîw–≈¥@¡=Zº[óMgUûN¢û<|uÀøk[+\^ﬂOˆòöO~Ÿ·]C€¬Ÿ`®ãêö∏Úú‰º$J[˛-øc•˙¢⁄º—˛òó]Ë·∆›ÑÒ≠m˘Ï„mÈøV\Æ6TZN˘YBpúQ$”û%¡,K) Á+Ûcî‚›≈r€ˆÊ`±1ëYG©†êÜó†∞õ«—ı;S…œ‰ïI T´∏ôÂ6¢['˜« ÁBÿÕ¶Z}e3›\YWU_âªbZ∂Z”®7ÈÏõtfm∫◊4[íPˇÜªÑºrmnf`äG‹ÍËçâw¬~K∫ùŸW®?Ø≈M0TàùóÈ‰ı>g‡‘”ê€g‡fﬁ(XrÃÏx–tIo÷°MË¯òßUïõêw]™S‰Lw·ØMŸÖˆ P¿	˚-Íﬂ∏ê
Ò(«®•ËY“£§oD≥Ok¥ó!5tw≠:ÿgúÄ”N¿È°L>ıœÓ∑ßÊüZ“9há ‘ ∞oyR3b0ûEê'-â®Ωı9Ü®üÇ≈vÌ_6t÷ö∫zK5W¨fÔb˝
ùB/éMãOKÿ˜⁄.›¨÷˜Z_
±πQ÷¯~dó$ÁGG ïy…p!ÿk¬¸ıJCMGuW˝â∫ˆ˚p™]•@*U‡BÏø˛rÚ. µITög0ú∆ﬂΩŸewkäu*ìÚF‰Üú∫ÕÆΩ»”fœQd)rd©‚hQpzR\:û!ëI3IëYd.+’‘hË≤·∫7¡∫[¿πı;”p”®^?å÷ÀÀáÄ&rD\Ô»¥‘m‘b¥dìO¿úß`[f3xQm9À§Úd!YûπëçRª≤&Ó®π¥¸n}€± ⁄oÇs÷√Ÿ∫,;îWﬁSy∫Ï$é¶_ŸDf5®Ÿ˝À=Ë[∞ô⁄“¡{R6Tm¢´çµïÕ‘`Gú†û—K«åzÉF_¨1®Ké••π—-ﬁÖë˘Gƒaq~¡i˛≤$úMU„…‰¿?Û˚.<ÀÛí)<≠ÕN`¬<QªπJÇ≥h}˛≤Hƒ¿ÃSŒ˙*¨çÓù•‚Øipï¥º√dö,Y∂43ﬂæ4-Æ8Å
SDfF∆˚âè»ìpY≤BNf∆˛ZmÜ¸Oåx∂WÀN`¸é6ıƒfÉü„=,ÎØ¨£kÀÎ [©ŒÈ¬JfºÛíÀ˜O@kâGà°q'4j2«∆≠˛∏Ü>Äƒ9‚  =∂ä

endstream
endobj
202 0 obj
<</Filter/FlateDecode/Length 309>>stream
hﬁTë=o√ Üw~≈ç©:ÄâIb	yh¢H˙°&ÌN‡úZ™1¬Œêﬂ√∏©: /˜p«∑á›¡∑#∑ÿ€#é–¥ﬁE˙k¥gº¥
	Æµ„ºõf€ô úÃ«€0bwMZ3˛Ná√o∞ÿØ≈◊Ë0∂˛ãSÒÒI¬Ò¬7vËGP◊‡∞a|˚l¬ãÈx≤˝iß[@ê”æò/Ó¡Xå∆_¥T5Ë™¨Ω˚∆Tvú˚e"ÀëB–¬¥r´ÒÜÃZä¢L¨2/â+ëπ™Âû≥¨sÊ+¥‹§†*gﬁêKZ‚Â9[ Ç∏4ì@LBäP")B…$d1”´dYgÀ*Y™Â¸IΩ≈¸û¸ÇÙÌ‘ã{Ì5F*Ó‘∞©Ü©z≠«{OCR±“`? ≥<ì«

endstream
endobj
178 0 obj
<</Filter/FlateDecode/Length 931>>stream
HâTUÀé€8ºœW¯HëV§ﬁõSÄAê…π¨±ó$F¢m≤Ë•‰Ã˙Ô∑äîg&'∑…ÓÆÍfukˇ˘!´Û¶Ìı.SπÓ€j∑|¯*f{^f}ﬁà—ÌlÉYTâìYfZπÉπ.v‰øN¸∏·Wµ‚””?ô‚QïW¬Õ+≥ñÆüÛÿäè◊∞ûò^“°Àz‹S/Ã÷ Ö	ñQ¡˛{uâTà∞™«ÈÍÔ÷0ô‡tËDbÉ¯ıdÔlÇülÎÖ?–R∞Ï<˙Å$aÊŸ¸p3ÎTy-‹(øÔ??lMYî*µfq«Ÿ»¨»‰Ê£Ã™Z”y¶’∞~%Æﬂ4qıˇπ¡≠∑úwPˇ^—QÀ4ç8:ªƒ`ÿó‡œ~e≤≈ÏREíë∏•Œz–ãAU¢¥ëi¿UúÕçwµX&ˇÃCñ<˙Áç„‡èsÇv´˚e_´|¿há	.¿…≤P@aÀh°∆_i7Èu B„˙¬Z;¢»c“?>÷;¥Ìê≤˜E—§ÏŸ€≥è/≠Dó?7Á29WyØuπ+í/eñ¯$ΩX¸‡–∑ë†∫˛¶≈,äÂli#ØÇ˙uã£•$¥ºèÁl(Ÿj±µïWÓ±≠®H,∑eµÁËﬁE≠G∑ò∏õ[N¡ˆ≤z¶fŸFˇ∑v~…tﬁ3ú‹ËÁ€D:–ﬁz2≥ü7sF≥ﬂß Z°AÔ≠Q£xÖ€tún«•@Ùoù∆!ûªE˜ä››ÆëæÆ–›æŒª∂Ïw˚ÛÉxö◊‡«kLπˇâÕKÜæÓÔ	hæƒw:Ô´é·_≈£].éÆä<Ï·`á®&‡5ŒË©â…qPëÈ!Zò≤’_.ò)›÷ú”`≤W)™ÆjSÔ.èwt´—áÎÖVâtú{Zï8ôÈpøè"Ì9ú‘˜œÂ¬€R\lX¸ÃaÉdÒ¶TÊ´M8•o€æ&~ñZÈ›~ ììay•Ó˙È	`(Œ%ô\D f¨◊¨<nET´Ê–«YB≠◊∞è].ï<’ox˛(ô≤ñ¨”Iç†DÅR†≤· Bﬁ\Ã‘<ñ‰–äo«*éÎ7˘.©Ûˆ¶≈EB3qÁvõTxPYàU*éÕ@≥g◊≥ì«_Lí‘qÃ“ñÌ≈3hrq¡skx)>≥\È\"YÅn©öèXÀM¶ 	±¬Ñ€œJ≈Õ∫ﬁ—´;Ï@¨zª≤â„rß[æê;J|Aî¿*⁄˝/¿ ` ƒ
endstream
endobj
207 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 4734>>stream
hﬁlWPŸ÷êÓcXõ¶}›à.¢(´dQ	î Aë00‰h Üù¡¥í$+àQWWD]0†∞ãqÎ€=√ªXÔø„˙ÍØøﬁ_T55Áﬁs˙;˜~ﬂ9ßU8j™ qÌz˚u÷zkÇ‚ú‹åLÇ∑õ-S.ÃQ–*ä9S5–Rî˜ØÒÒ‡5“fú3{Â,é™äJlfù÷≤ÂÀ+üF_û¶ãµñ.]˙Âi§µ&(2 XÀ51&6xWå÷Üà¿HQT§h[lpêæ÷öp-QËéêÿ-QpL∞(NitE∆‚u≠ÄD-w}Wl¡ª#ûuF∆FãçÕÙˇ/Jé
˛„&q¶MÁhÕ·¨‚p÷9ªT9)*útgá#·pr8û8QéáÀ˘«ñ#‚trÓqÜ9™pU¨U∂®‰´ºV’RçPP˝}íÁ§ÆIØ‘f´Ö™Ò=!#në≥…•‰:2è¨%€»«\uÆ7ñ€ÃÁôÛéÚ>™[®;™'™W©ûl=Y<˘–‰„ìœOÓü¢?eÔîS©©ﬁS˜OSõ∂b⁄ñiÖ”nNÎÁõwÒ´¯0}„Ù=”{g3VœùqmÊ‘ô[gfÕ<;Û√L4k⁄,≠Y^≥ˆÕ:8´t¢ãèﬁÒ_éØ¢2÷FÕèsæzPpÏÏ‡TÛ¯®<∆Ì(S[DÂ"OÚ∏Éfﬂ2cÓêÎﬂª¡7`-ªã@ºc÷Q4ç∫5‹≥•‡…O†û06dˇÇÀËd+D∂nàZØãwÍB≈∏ÂàÊr#h9ÜºB”		-8JÿpA∑å»·.F¸k;z`.!#o"≠[Mz0ï»„Ç^qáãÙ‚	˜5Ã$¯ÉHù:~Æ&U=[ò)»∞ä“;a‘Í‡
e?Ùp˘†öA5Wkjé©		EÌÿQ’¿ÚQto'«C	kù¯J˝@>æêBÇ≈h
äd—NŸöﬂ–0Ô)!ÕÅèÊ∞˚l®-⁄»≠◊6XÈÒ,`˝’WYÏû°Òlú±$ëˆÍ[ nb‡|?Öø∆ jóqªŒåºÖ©¬óŒoê÷ªàÌ~ÃÒçDu›Ö∫ÎÙ€éÆ6E+êkmK∏s˘~m'©∏˙ûÿæ2ˆâÕ≥ø±≤ò'„’∂^ª#⁄ÙÕ^øA$
a™Ïâ≤„ùïÈ«'}<V≠≥gΩ7\ ü=	Z*e›§;÷!5z£Ku±cTÃ◊ Î±;K∫ãπËÃÑ!·Wê5ÖB.%„Ç!Dó÷…èóù“Ã#%°π°°B¥#Q¨g(‘CnC∑âº™⁄ºS4P◊úMY#ÈZ˜Â¥”Ê2y+∂%‚ÎØ«˜”0˜√k¯ÊÒ∂kû«ŸÍ@Ô#ûtLjÆ$Ö≠ÜïHïGb4ÆK%ãs≥£ŸÂôk√‹7ÛÏÏ}u–l!≤C``ŒcPÖ©0k≈0‚Æu›ŒH»b‡‹{lEı˛JYi.ÈMßÙΩ˝ïÀ ˜8¬úØÍ¨øD?æ‰™ØÔÈ`â3ΩÜ![A?ÊT„ƒ=båÑ&≈ØD7NV¿je®∑Ûr·‚'+aÃx˚ »AØÓıL˜QÛÒWÑOÏ—,ƒ5Z?ﬂıÑÎ@(ÛµQf^›∑ÛÿüZªV0£¢+AB[OosF™h£ÜN∏{8˚∫&∞ñe^ç“€º´-ÁæﬂõL™<˜∏¥˛¿›√?◊u^‡ı¸t˛=h¡|˘_Hi öé&=0^Ô≈Íˆ&&èL_Ó‚¥}«ñxœΩªrƒíµ‘ÀV4)%gw÷n6(÷'¬ô^Ì}ÌÒÀKΩ˜Y>LÇ◊TsÂ±∆Êÿö°¢ËÌ!J~£?’˛ÀÜµ¬˚¢’™Áã∞V÷DÕ≈Z˘†˛ow>2Ñ(p£$’9]ÚéˆãöÁØù∫pG¯–£q7ª&«Ñ2Uƒ—ÍñÇ&˙Vn}®ß–W‰ªôÒrJt:∏Y-hF~ˇOPX´pÉ√‘∆åÕk6—~‚˙ˆ∑˝OG+K≤≥è∞ß'4©ÿÄÕÈ.4“E*ü`%¯aΩhÄ)|?¢çt◊≈⁄S∆ÜI”ã6¿AAt–è€hƒ.Döaﬁπµ˚∆Ÿ⁄ÎçlπQ“›BøÖE∞Ò`:≤B"4Ÿ† ‰,ö
f}WÛkØ∞¸NÖ9ÑP˜PÒíDI„&ƒ<¸Ô≥	ÒyBà“;T/xµi;rZSF	:XÏ◊á6¯ieTvÌŸÏ4®>,;sñm¨ØÏËæ∑ºd_åt∑∫˝ZØí∏%§Üip-6¢ù˜ÌfG6QyEïy-ÙËıùvÓﬁKYs“NÌ˘z(hÈB≥∞e·1“ºDñ_™®£íB‹3‹id∫¯üò≠Îˇ˘ÆûKOÆg+˙âÇX˜R3„î¥QÅ6N…Â…mπ¸Àˇà°eµwÂ‹¢·€O∑zÿü~j¸TÖ†2ËxÖπÏlPáf“÷˚vofG®ï˚;hp¯MÊ≤»n¡<‰∫Sö'f¯v
sÖÄBE
u*üM3PdC…∑|†1
›pË:±p| ˝õ‰è)F‡/
â÷√‰Cf∆Ì¡7i›X}≥;ÈIMJ¸EK,háX¥ ˘h7-Îvezá£?“cÉ≈ßY˛ÿÉqÍ≥…(¸CËÁ—qC‘àÜ†ëÀGÉ_ó∆M-	ókﬂã]—%2ÈÎà›Âß˜û§Å7zlXÖá!_ñ∆!oﬂáh4L¸A"πB 9pö@3‚`í81&1Z3çHæÒ≈‘‘™¯›ê‰Ét\W„9πM"—T4¥À$fM¢ç¶ÑLº+æ˘qaHÄó∂bŒ<%K°Ì‡«†&∆l9∫≤∆∏^T—}A/	S‡Q√Àcœ™ÒäŸADX¬?ÇÅ¥rA-˜q÷3&Oz“™c’9KMCØ	úﬂr‘HjÀñ^∆‰‰ÜˇÿÔ=§âv¬+BÔ≥	F¶	p˜D∂HÄ¥PÚáà∞Ñπ0í¡˜≠πh#õ≥éÇÔÓ‚-4ZbÅ0É¿&XpÑÀèUN%ôUVï[C?ª_}·€–Xz˛¶FÏÖıLS†Cô1ΩﬁmﬂﬁmJ∂Ï/VV˛◊=˛Àñ⁄{hGƒ»$`IkéMπ±í€ñˆ„|Z·‚m%Ñ-Ñ6r@vË[|’·(c2Ôc
≥≤äŸ¡®_£∆bx®©øaÕù{∏/Äyw±√úØêøÇÏxBÂ4áîÈóöª‰«Û~#Skíoã_%ﬂ?ÔY √™´∫z}Tx)˛lX”‡X™O;€Ô€„«é8~¡›Fø∏l¥ ŸSü5 ˘v∏µ∆4ı«ﬂ¶¡·ÿßw.WŸŒÍ7ú∏%<€xÂ≈ÕéÑ¥r¶™ü(âî€–Ë[#Ì%w6Åj ;⁄¥}£–∆c´ÅìÎ—Í ,◊UºÖÄ˚Ÿk`˘7'Êr—ˆO∏ôÈÄ 02
∆pb>È⁄m–]f€ã≈|._∞LüD$zneí`Å˘ï0$z9¶œãIà∆Ù‚C‘iºÅO’#Úﬁ¸>Ã£mä6î?Cü∏µπ‚§zgö`ô∫G»ÏO|îh9º,%ó°ó±Fq+3l±=˝v‚p¸Jx%¯ûÑ’ »ág4–vx€‡1°C.E"ˇ§Ñ@Õ2±)°A‘n º—s¨óWƒ{Ú1Ë6\/k:™,ãÂAÂ€]F–B?˙4†Öb≈∑ƒBrråˆåÒKÙ√/ç;◊*ÍZéÇ$ÑMtÁ^ß°»òòñG*xä6‚“ƒ+xï√ùPüh'îCg	R£µåØÚ
≤ˇå=PMfΩêü◊!“Ï«±f*|©¸{«˛(øÓ∫OÂ„è8±¶<æ•btRov|@∫éŒI¢@¶Ãô®l8Wxñ~'Õ∑
frëìtû=RÆÔ¥˛˝Áãßé·Ê{»ë"≥NJZ€Ñ&Á®=πô9ôL@j@†=Ì\”˝
TJﬁHX˛·òI˘Kº%aÃÚ¿ûÚöØF›•Å™œaËòæG”,\C›√Y	\3"G&¨®"YA^>”[zµÌ:˝∫”lö‰n©oÔ—v3ôÕ9íõü/‰k)<•2DaÈ^¥ﬁ⁄üAÌ˝çß0È¸…Ùår∂¨è(åÒ)ÙP÷S§Ç"›◊∫†sª´$ø£Q,˜¶PõÑ{JÏ›hI#uùÖ»XäãÎò.®u∑^Æ¡ôÌ7%I…I…Ö3B≈Æ—ƒ~*57='ù±Kvt¶óx?˛˝œÀè∆zœ˚∏≤y“î!ﬂ] qîÏà¥∞T¯k 0»Õ5∆,’A:øÍ¬¬_.óù`ío©;É2hÀ0E¬JoQ7ùz¸˝Æ »-Or∞–PÉzRØ·>8z˚AMI÷æB¶‡q()˙–N:¿/mgîº—Fkk€7aåô°HÜR›“ñº∆ÇÃ±¬ü-bﬂ3¶4R”˙ô!·ÛÔ`ÍÉKM5¨l3â¶oÿ∫Ã…´¥|'#∂!¢O˜§v”7Ôü9œû=SŸjBC†©IRV
„öËÍÜ≥zj7˙áo∑mÛê≥˚3§i)Bæd ˜¥R.-<P»ú+ioπF?≠µ≥`—âQeô^1Ø≈.,|wJ4ï"éMÒ$p˜4∆ä√ân˚∏)&Ì⁄USﬂX^UwB\µ¿ùhuÆG~˙4{¶Ω¯Ê+°b£·ÑÒ2Éc¢ò∏ò–åÄXçwqé(’7ïU◊÷≈Uá±|c0¬wkÙŸ{Ï»éNXÅR¿m+NÅ#l!¥I<¨LMJéKO¬2√hp„ﬁ ﬁU?†Ò⁄…bô¸@”^‘⁄~ôÓkp[≈¢3œ·"WûWºøêiìüjÓ¢Ô6∫-aQÕshÊÇ˘‚6;ütqüü…ìê◊‚ºZÏËæ˛>Qlô=D¨"eÅ≤@œØ'¶|EÒ˛|ÊÇº£ı?'Vˇü≥]ÈÍÎÉá˜¨GÑô(U∫•¡	≈n
ij-F∆h…G=<„Ò`Ê n_ñ|@,+Ÿ@}jùø©8òõ;=˙s¨„ÕJ—!oj‰2rKÌ’»»øûÉËæCìÕ7Ö:á∞¯-OÒ[d>2Øç¬\Ú
ïíì_kªAøÏ2”√í[≠Ô∞˘ã‰Ús
ÖJÈ(É*Œíù≤3≤∆ÏoÆùçÒj∂§øCÍÊ∏w-x±à¡KßŒce$LWKÀI Ncú‚ΩC\ËE>OﬂÁ /cΩg}‹ãî∫IKÚQäÚ\Ú…"i±¨ÄÈ-h?˚]„íŸß\ÈûΩ“›¥≥{ÄùXyòoaÊ˘JΩ]∞óaK%ﬂp!ıDﬂçÁ˜¸⁄ÃN∞’ë•-¬¶„u;ì“è2Â=DI¥°7=ﬂﬁﬁbSÎ÷—ùlOLµxõ0`W∏ÉüO©<
ZßºTÙSÀ,m†ÆÀˇ™(&∂¸dj+›pÏ‡¡6ªè»NKïƒ–ﬁI7X(ÇY}h†§)(CtÅL IŒJgìúiÛà[/X(3DM\¸uÊˇ˘≈Æ”åå<`éJŒ©‹ˆ.!ﬂ≤;Ç√D1LÇã"Å¯û\Ç™í}S3î]$≥%≠%πc1T	¸_™‹™É∑>"!©‰bqgA7n#.E[J‹Ô£d¡#ñ‚F§5 NvIÛ‹„çCd\HÌJÏ∂Ñ,¡“˝êÏëÏë°¥ÔÓLÎLªlπæû\Ÿe"KÙÒè*GkÂ5ÚZΩ$Bu4ÚRº#ë‰¡rH#ÙH€˘I—…¢‰H,ù‰c)U	«¨?	¯∆?*„XO∏2d{≥ÑY9{≥w3qæ°1	—‚àTÒﬁ
+A≈˛∂‚ˆÊóŒﬂ¬Ûπ ~Ëìz®9=$s˚ÓnOm˙©Ùzm8-‡£oJ5sÓ¢FYQu¥∫¸ÑCÉ‡ Ñ⁄z(ñp≈—Ò±‚(ÅN	¯°óJ˜	„QEj®‚˛rÏˆÀ3Õi)LuQ*⁄\‰K£9ñfË6Ík•¸ÍBÙ!¢ö˚Àâæ±Ü ¨=≈ÃÁŸ£„Îπe€=
\iØ§ù¡¨oP¨ìç0Ó´õ{4SN
á∏ß +∆7P¿GÛàüHCòG(Kˆ&l2¸b˛ﬂ¶äÍ∏Ïpâú.»ﬂó^∆fîÕ¨†œU4ˆÊ≤[…0IÊÓ:-ıè…lAl“1Ìd'Sñˇ´ä>™Æ¨ÍXm\ETÑ862™<Ê8é_mëëJ[YL-ÀW∏|Aı/K%™ˇ-´|ö≠Ë¢˛GÄ ÷K©ö

endstream
endobj
206 0 obj
<</Filter/FlateDecode/Length 317>>stream
hﬁTQÀnÉ0ºÛ{L’∂	Iê,§&Q§˙PìˆnÃí"cr»ﬂw”T=`ç«3;Àn∫;ÓèÆ!}Ω=·MÎÍÄC°¬KÎ@*®[;Œ∑È¥ùÒêí˘tFÏéÆÈAÎ$}ß«a7X÷è‚“◊Pch›g˘ÒIƒÈÍ˝7vËFPñPcì§ªg„_Láê≤Ìè;ﬂ<ÇöÓrÓkº±åª hŸî†´e	ËÍˇo…::™∆~ôêD•P˚]ôËºf,Ú=·ôµr…8è8#\÷»L6õIˇ¥!ÃaÑ∑§ßÃπ˙Í7+Fk≈5Uä] Œ™Hp∑ìG";±Ñ◊—BòöaE!bG\£»ò‡¯√V»9>ÚﬂÛJÓÉ¥◊h∆”ﬁ¶QÚ[á˜’˙ﬁÛÃ¯K~ rKñ´

endstream
endobj
179 0 obj
<</Filter/FlateDecode/Length 917>>stream
HâtTMo€8ΩÎWR`ƒ¨¯!ë:6uªi–ªµ∑=ƒ=®2c3∞•TrRÙÏˇﬁ7îÌ€,xŒ«õ7√.Ø3/µ™ï(pú4E©Ö.kiΩ±BY/k£çXÓ≥ô,TUãeõ›ê˙'ü©J÷dÚØÀÎL≤.ÎÑpµ3“9ƒ[Yîï„¯b
}›Á !rü√U”,iº1¬Jß=íÕ·wﬂ!Ø•¢u>≥@”Ù#∂,tÿïó%›°}ï;ÈÈ”íçñ¬–\LV˜‘qﬂ·§√c»Q%ïSên˚aü®b¶§ru9—Ëo·aôir‘∑˝¶Éd)‚##òóu{hÎ0 Ω"¶Åh∫z˜y÷¿V”8ˆmräÕ!pe∆‚≤˚–%ÏClû∞÷M,Vtıä˚eiæ kº¢m3Bp%øÖ]U¥l¬–.ågk€ß^s:÷U»≥¢€j‹,ºuÒÇEŒáû%ÔÍ≈*Æ#ôÄ (Â=›á\(¢øœ1ñvπ“ÿ u¶[ÃzÃU|;=m&Ñ
ÀëöE»v“+¥£Büseqyâ@Ù†DÍwìﬂ|G«#≤"ÊT”üyœ1_∏W‡Ø°a™.¯ˆ÷°Œâ`âa˙˛„„`F0ÁπYÁ ¿X–‹√‹NÕËì=·†©e°°Qÿ ÿq„ﬁÛ˚’Ä˝»’xö'/‹GÆÂ\˙)Èn
Stü≤[“ŸäÒ=›–(•ﬂ˜◊ZÉµ+__?Ì†ΩHÎÎ©¸üıµ%V¥“3¸∂ü:8`zkûÈ'O∫Ü'≤è'±J⁄ÓNMƒkQ≈)œ@ÛÎ˘ô”õeˆ=S"äë+Òa…åÆƒ>+-¢¥:kvgçu“’öSÃ˘˛EtYë
¸ÙPØÖwBjÌƒî,>àõØÖXgﬂ≈‘F%˛ì¥›'˝>≥ò£
[–EˆŒÂ2{˘?ùXﬁfÿ6SË‰jee}yƒ1BÈJ•<˜ëTæºÀ{:„ìÔQ¨¥¥A¯©jìz~CÛÄüêßUÛá"ﬁ8˝K∫ˆt94ë∑∫@©‘tkÍ}hÜ."åg≤€∞¥hcË⁄pë@ ∏h∑}ø„[%'Pñ]∆~◊ob€$õ?≈MâÃ”D¬˙ËÜûﬁtõÿÖ0ƒn√Iˇã˛q3N‘Ò‚wÈﬂ‰1∆x¯y1—´Ëc”›#ëÙı6vf\¸+¿ °éáì
endstream
endobj
211 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 301>>stream
hﬁbd`ab`ddsvıvq◊vL)ÆÃââ˝êÊ˚Ì˙{˚ØÛø⁄Xœ_Ï˛~]$√	Wå<Úâ›lååL¨ä	Ô¯æ˜Ò˝ÿÛΩ˚«J—ﬂıøCæ7˛n?ÙΩ˝{„°ﬂçﬂÎŸÅr?Êﬂ!˙ßı{´/˚◊ﬂ—Äƒâ u/˝i(:cv¡∫∆âµS&6W˝f¯›"—\π™j∆læü´¸°!⁄∂¥yu∆ –JΩÅQÆ›ø-è9_∞¸Œ=Û¿°›{z÷ıÃÁàaÎÃØ.,.MH¥üú∫›ÔÚ“Ôº´6ûπ˚] n≤3«üXG—ﬂ¡ﬂı~Î~BΩÔ`˙∑P$ıÄ0Xn≥ÿwõÔ≤@h¢À˛∂B8ó„0 ìVòã

endstream
endobj
210 0 obj
<</Filter/FlateDecode/Length 238>>stream
hﬁTê=oƒ Üw~Ö«´:êp:DH◊k+eËáökwNä‘ r»ê_ —U@Øm^˚¡¸‹>∂ŒF‡Ô‰uáÎ·Ï“=é÷A-¿X˜®‹zRx2wÎqj›‡°iˇH≈9“
áÁ˚€Í¯$ÎF8\ÍœØîËñ~pB°)¡‡¿¯˘EÖW5!l˚À]÷Ä J\ÔÉΩ¡9(ç§‹à–à^B£îtÊç›mé~–ﬂäÿˆ≤™ƒÉdÕã>>%≠D—'ëµ⁄ÙI≤‘owÊŒ˘ªWHΩ%˛≤ìÇô≠√Î⁄Çô'ˆ+¿  òpˇ

endstream
endobj
180 0 obj
<</Filter/FlateDecode/Length 644>>stream
Hâ§î›N€0«Ôyä\ûJ≈ã;±/+™†iÕÆ∆.LÍ£‘FIä‘ÁÿÔ8N
C¢∞MΩh¸qæ~Á\^û¬≤î%)˛8…πâP§<K(-àbî%Âˆÿ¨|8…â*29‹?sF8ï
Ôr"Öí·Ó¯bˆ≥”,ÕàÇ+}Á[›œNiF$¯6ÄﬂÑˇúP8´m≥éõÁÊ…4˛qk\6·†›pF	É+£[tCq◊Yw∑¨*k\e¬≤¿£[X˘]_›ç>|wˆ	œ√g€Ÿ~;õ«‡Æ≠≥]ì C~á¥>ØwïÓ≠wÛ…ÛçvwXÀê∂”dˆ≥<J0ƒófÔƒ∞<W,<7è∫‘f=C~L…4§Aﬂ¡¯òÍaÕt»≥™cΩú°µicîço££lÄ>—k§ú†√¸Oÿ€ÒvGä√áÂ©|„¯î$i!ãHÔ¨¡æb…)T∫	Sq≥Î[:rëÒ÷î%∏~ÃUAYz‚H≤¨m;≤§∞ÿ¸j¨Ó'ãuhÊ
Kﬂ=⁄>Ü
îûe¥™±>ÚÎ€N¬îpm÷vLê£ó7–Âpâ¨bﬂÇ’á–)Ã/Õ≥Åú8NN¢	ÁÚC∫[Ó∂⁄≈Å∞p∫˜€˝8⁄Û·F»ˇ(9Óãó˙}ÌnQÈµŸéA˜!hd?K· ˝UêQ≥]îZï⁄é<s§˚!ûµP∞8»˘;<)…Ç…_œÒã¢kﬂòÆÔx∏‹ﬂ€®ª¸U±ä≈¨™⁄˚&#^(ÔÎÓÆ±U\qX›Ùı<æ b[Ùáœ6Ñˆ!≥ÿè±ò=wıÕÒ˝t¡öîõ#äú§í™@$˘-¿ x7°
endstream
endobj
181 0 obj
<</Filter/FlateDecode/Length 610>>stream
HâTSÕn‘0æÔS‰Ë≠∫Æc«v‹•€ä¢∂ ‚‡&Ó∆%k'UºO…ÿŒ™TæÃœ73ﬂ¸˝Y7è´ìKYîEÛ∞XIVﬁ"
äô†¥êJx—ÏWﬂP”õ—¨7¨,qçÙ<ı>å†ÜK‘z7{?OÎM…1G¶Àûôü≥ÜÁ®÷X°…Ø7T)ÄLΩM·@ø}¯Å◊ﬂõ˜´f≤*6WeUÕÍùu]Ä¬Pó°b®à1≠¡åOﬁu∆µ‡ç6@Q.†»iDq ˆn∂˝^ä)“—H ∂5nwúÛTËcøM≤Ù÷<È0Ìçõ¢•®»ô8z¥u†v]FHtmtp÷Ì¢^ÓÆµ@»ƒúíÅ÷{?‰Íˇl÷~g[}íøƒeZÚPÅÄÁ∆t Ö⁄ngù1!≤)	(ı¬∏Ó<l éQ0†®`£iÑΩ—„îA√üù˝e‚¬hßÁ„<¯C»¶ƒî0öoµ{LΩ1¢Ä?-	Q‚8ÅBÁΩu:jÑ£ãÕ^€·4oT!X .¥√¯f4Ûrÿt3n]™&·ŒM'∑à¿_ÚäísL≠ÛÕùkÁÙ}:∫ÃËyq8oì©”'8O⁄> ±è≤ñ*˜Ò≈Û>/ÂËkdÃ‚ÍoÁ˝Ω	—J@{±SBY rrYÁ/“≠–ﬂWü≤S¶æ—!û8∞Ñ3Áb"-_[¶òò÷†_πv9Û%¸…Ìá´8?™Ä,∂$µ:iµ[óÒ`)î¬ora∆3¯TB∞4…Ed~ØR™ 6¥™”$Q…_4´‚ü  ∑ˇ™
endstream
endobj
194 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 1367>>stream
hﬁ,TÀ´%G>wòÍZå‹†p≤Q1ÅdE\à´dTåÇÑ0≥≤I&3Ø‹{Êú~VWuWUÍŸ]›’ès'É:yò0†õ»∏qQíÖ$$KˇÁéwÎÄıu˜¢∫ÍÎ_ı˜}øÉ≈˘sãÉÉÉ√ü]¸·O/^|ÊŸWé^∏˙Ì˝Ã„ß_˝“„„Ÿ?ˇÛ‚√è¿_˚‰ÀÍk—ª_ŸøÅˇ_∆Ö≈”ãÁWQ†Yú[¸Î‡{Á˛t˛~Ù¬·È◊wø⁄}±ÃQM„$›‰qô‡ØÒqµ™è9‰5ÿFˆÆŸ6S;µCÁ˚æwC€ßúÏ$Ë"œ∑l¨f2Cﬂ OÚèØ‹ÕÓ¶m=íôL’DG¶hå`¨Ù∂o∫∂kç∆aÓÊvn&ªµ≥9±˜VºNÍ§J¶LAëÊ)≠.JT°—úmx"bÎççõUøvœxk∫9&m6M¢A™ëäR$<eIùU˛ÂÙÜ\~}]ﬁ=qi˜‰Â›ìgÁwÇUtˆèˇ^¸Ù<˚˛Ó—ÚM(‡˝O«¶˜«ÄäT)â¬ªÁ]p»‡£o
.wﬂÿ˝xxi∑8˝Ò2Oã≈xÉW‰®zÉﬁ¢∑¯/≈uÄ°<RG˙»¨Ï∫Ÿ¥±€¯ÿ'æËë«Òt >Í¯(1(ØΩﬁˇëﬁ)Âánr≥õ˝=…ªWõ„f•ë)laKáAS5‘rÀÅã—™F5∫m\o;≥ßòÂ$ﬂõ®∫… ∫§òê™™jÃyT 2!G’•«#Î†ÿÓ¬Ó£ÔÚú˝∞(˘C˘ÙÎ∫-Ár,∆|,∫ºÕöÃ$*ë â6,ﬁˇPíñ¿~kÈ€ﬁˆ⁄+/º0<ú≈3O˚ „ª“Â]Í∑n÷˝MAE(|˘©rUﬁ¶5NÀ°$Ørñqƒ± ãRgŸZ•.˜π/G*ú´mΩe3õ¯$&†°§óﬁåv≤c„õŒu »£áœ-3îYÜ7÷Ÿàïº@†Ä‚—Á¸:ø∆n–õ4„ÀX>ãÙVàNæ≠ﬁÔÉ˜‡ﬂ°‡‡MÔ≈[t6–±ÿ»¿ú; Y›—'Õ‰7t}Ø’0ı'Jπm{bOÙ,¨Ïe/<–¬ÜôŒ’Ã-™»ÔœTÎ§KªJMnr;è”8Õ›ËÜf f“^vaw‰3{ÒTŒŸ$ËP[ÿ<Ä»L':\&"»G	/y•ä´îÄw~ætmg{$QA«sº•]›„@Å,2•ÕÃZ«{sÊ"9Ã!',Â	Õ«Üƒ≈ç‡Ò©Le2ï©(D…KÜÆI≈ –ëµ¢äi÷≤ûy˙h[9Î0…%Û∑˝¶[∑Îv•êYôï^…ï»≈mp+»B*i@0QésîáÅ2íU)M8H£=ïÍƒ&MÏRwÌ-~zU·’®'3¥C”É√'v/?¸Œí"Z∞$0lÿJB»n€çIu,jâB—$8éBNYà"¨9jèö„∂âF	¬é0	©I∏BBJVH§ê.-	®mxªôìΩÍ‘˝q4ì±¬Itﬁw,a)ç´uhU9.Í™ÆˆCøaBÓ%—Øõ◊—Ø™´2S/©óÚ≤º$ÆÅ_¿◊‡k[(>î‰˝ l°˛ù˛=h†˛≠yO¯`¥`5}ßyw}BÈCb{⁄—ÅÌ˝—k®Ö‚õÎ)4‹ÅåïÊmƒﬁÀ-BWV[£TcÕæ^Lp$3ÃPSYbà&
)PDyî-bíêÎ(´”∫`8¯	8"—Î`»ª÷É˜âm†h ùá∂°"ã¨ë$‘QÖõ!ZVòT°’û˛{˘? úÌ<c

endstream
endobj
182 0 obj
<</ColorSpace/DeviceGray/Subtype/Image/Height 150/Filter/DCTDecode/Type/XObject/Width 150/Length 11753/BitsPerComponent 8>>stream
ˇÿˇÓ Adobe dÄ    ˇ€ C 		



ˇ¿  ñ ñ ˇƒ “            	
 s !1AQa"qÅ2ë°±B#¡R—·3b$rÇÒ%C4Sí¢≤cs¬5D'ì£≥6Tdt√“‚&É	
ÑîEF§¥V”U(Ú„Ûƒ‘‰ÙeuÖï•µ≈’ÂıfvÜñ¶∂∆÷Êˆ7GWgwáóß∑«◊Á˜8HXhxàò®∏»ÿË¯)9IYiyâô©π…ŸÈ˘*:JZjzäö™∫ ⁄Í˙ˇ⁄   ? ‰@Ú7ü?1¸”´iZ±ıy¨ñKôÓ‚tBû∞éã¿HkVŒÖˇ Bó˘◊ˇ Só˝&]ˇ ’,ﬂÙ)ùı1Ÿ“eﬂ˝RŒy˘ë‰/>˛[ÎöfüÆk?Xñ˝ÒKâ›B¨únb=ÎûŒ¸Œ¸›ÚÔÂ∂ó¶ﬁÎñ˜WjaÑZ*;DKsxˆœ?~vˇ ŒM˘GŒæCüB– ‘Ïµ. ï'ïcâB∆’a 9Y∑˘a.áˇ 9ÂÎ»kü"\&¢˛cñﬁÍæLAÁô§CÍ=MïáÏ‰cÚÁÚüÛ#œæZ‘<¡§kiûù+√2\‹‹,Ö£âe<B+äqnÁ˛U~]~`˛eœ®√°ÎB›¥ƒâÁ˙›ÃËò∞^<O‰5ŒŸÆyØ˛VßóÌˇ (º±,ˆ>l–}/Øjlbµ—ãıi¯KI)Á#Ujõé¥Œ˛CÛÚ~hèÀÉ¨ˇ π£0ÉÎYüÍ‹ö^º©Œú…Îù€ üô_êZky'œfÎU÷Æ%mN;ù<ãàDÅ!{ÜÖ˘Åâiá?Ù:_ñ?ım’ˇ ‰Tı[8‰ÁÁfô‰ˇ ÃMcÃ:„_ﬁió‹Gmo:¥∑	*≤H™(™F«=˘œÊ˚1ˇ Œ7Í^f“Lˆ∂˙Ñ”[s>ú ¶Ó5ﬂÉªÛøÂø‰wÊèü¸¥æ`—ıÿ`≥i§∑›]\¨ú¢•MSîˇ –•˛uˇ ‘«eˇ IóıK7˝
_Á_˝Lv_Ùôwˇ T≥ôZygŒáœ◊æB:≥~ó#L˝boC÷˙ÃqÚÂN\k˛NuO˘√ü¸ô˛iˇ ò?Í.<å~m~u˛jÈôûf”4ﬂ2›€XZj≈mnÖ8¢+QTUzGÚ√ÛªÛ_T¸∆Ú÷ù®yöÚ‚∆ÔRµÜÊ)≈„yT2üá°/ˇ ú—ˇ îÔ ﬂÛﬂıs§ˇ ŒQ~]y«Œ˛[Ú˝Øñ4Û=ùƒí‹ í(¯£D »˛‰=ÚÎŒ«õ.<•ßiÊ0Z¥…=ó©ïkrD£õ0OÑèÊŒÖÂè»?;ysÃÔü4ì¥ÈV}vY&ÜT[U˚e£ÜFëá≤äÁz—7Át=˚CÚï¸QqµÇ⁄ÌDó«È)%„Íh£Æˇ Œ)˛VyÔ»˜˛cóÃ˙a”“˙+Uµ&XeÊciKˇ tÔJssÅË÷øô?ú~eèÚÒÂMÎzâfÇH¢o´ã£Í|Rê¥ØıßÂwÂ}§ZVëÊo9iøÊ:ìQ’%`˜®gçºlc'—‚ªv¬/œmGÚªÿ|Â≥˘π¥«˝“√pÚq"A5(?{ZTÁÜ3⁄øñ⁄¸„úñﬂJ“4´˝j$ûˆ/FÂ‚$bŒO∆˝éHÁ!4m/Eˇ ú}÷Ù≠*›-4˚HÌ£∂∂éºQ~∑†≠|r%ˇ 8˘}waˇ 8…ÆﬂY –]⁄Æ´5ºÀˆíH‡‰å+‹\Ûø˝Á7˝MóøzÕ9‹øÁø2¸˘Êœ7k6ûc÷Æ5;k}<KS*ØÎ"Úz2iˇ ≠e{ˇ Åˇ ®Ëˇ ˛pÁˇ &öÊO˙ãè _úüóﬁ|æ¸‘ÛMÂóó5;õIıﬁà≠'x›Kl  Ñ}± èÀœ>Ÿ˛fyZÓÔÀzùΩ¨•§ìO-úËàã*ñff@ πŒçˇ 9£ˇ )ﬂïøÊ	øÍ ÁÆ°˛Ê?ıGÍœüzÁûıÔ#˛xyß_–åK®G©j0©ù=D„,Ã·®…Vß˘Àˇ 9Áè)›ÿ~Ñ{˝VâÌ‰∏≥”&edØ·"rZÇ)úö\—<…•€Î}Œõq$I7q<.…ÍÅ»+Ö$TÛÈ∂qÔ-ycÚ…ﬁw‘<œcÊ;HuÎñπéÒ.5(
´œ'9ó”$!◊Ë…Á¸¨ÔÀ˙ötü˙N∑ˇ öÛ…øÛíWæ^ÛOÁÜÉçÙéõuoaiq5ú…*¸wR+®t,q|Ì_Ù'ˇ ìøÔ≠C˛íè¸”ú∑˛qÀE∏Ú'ÊñπyÊKy|ø°õ[õK+˝QZ÷	Î1ò—fò"32!`‹
Áfˇ úèø±‘?!u˚€àÓ¨ÁKfÜ‚Y#u˙‹[´© èñBø ≠Ó.Á¸¡omMq2j—√`≥ª¥UUíN¿góˇ ÂX˛d‘≠´“«¸—ù˜˛pÛ ^j—<ÁÆO¨Ë˜∫l2È¡#ñÓﬁXUõ◊C≈Lä†öâZÎY^ˇ ‡F?Í:<â˛X~m_˛YyªY’m4ÿı'ΩI-Z)]£
=a' T7ÚgQˇ °ﬁÛ˝J∂øÙì/¸—õ˛á{Ãı*⁄ˇ “LøÛFrﬂÕèÕÌCÛ;ÃN£w¶G¶∂ü∑X‚vê0iy‘ñNπÎoœ?Œ-CÚ«D—Ø¨Ù»µ&‘eh%ë£0’CW<˚˘ª˘;ßßêÛoÙú¶˚ÃR¡®K§˙kÈB⁄ëıZ5íºàèù#|Îﬂì^hõ ﬂÛãqyäÍ].ÎÑ∑v*ÆRÍOÑ∞©”tHˇ Á ≠d¸ƒ‘ÂmÎÀ$ŸCß€q´n>∂ù¯,“Ò†≥¢~A˛|j?ô˜zÃöT:`“„Å—¢ï§Êf.<Ç“ú3Õ~P¸¥≥¸≈¸ÌÛ/óÓÔüOà\ÍWB‚$Y±]P-®°ÁÄ‰¸û±_œa˘j5Mëπ[“^ö˙îka=xWèSN∏/œïˆñˇ ú^[–-/‰‘cñ[≥<®±∞2]„E-∑ÓÛ”?üøûzèÂ|∫*YÈPÍCU[ÇÊiZ>Åéî‚≠Z˙ôˇ úªΩmCÚw@Ω*ÓµY⁄55
d¥ï®>Uƒ5–ËK-≈7˙Ö¶ﬂÙ|ô…ˇ *?Á%µèÀø)Øó-t(/‚YÂ∏˙ƒ≥<mYi∑Vq…è˝˜òˇ ÍUµˇ §ôÊåﬂÙ;ﬁcˇ ©R◊˛íeˇ ö3êZ~bﬁ ÃΩ¸¡˙Ç}gÎÉT˙á&Ù˘}j7Ù˘“¥˜¶{[ÛsÛ'À?ñö5û´©È}Ìœ’Q-í ¡∏4úè>;| ˇ Ërˇ .?ÍUΩˇ Åµˇ ö≥®ysÛC ˙ÔÂ}ÔÊ;≈ßŸEu3Ÿ∫CÎ0¥Ø <>.;oú∆/˘ÃÀ©$DVΩò(<m{ö6z=·∑∏D2ƒ≤-9(uJè|Ò¸‰‰Wôº∫öÔùÓu{y¥õÕI§áNè’Êãu3≈p¯ÌÙgZ¸ûÚÕ◊öÁ#Úı§…ŒßıºSKRäÕu&ÌƒLäh:‹Ûè˙|ˇ óû`çµçGÃ¨o-Ø4˙,1•¬ãEY‹°¢,h:a?ÛÖûÜ¶2ÈÒñÎ√Î+Z|ì!ˇ öÛéæk¸∑ÚÁ¯í˚Zµ∫çÓ‘•Ø¨≤ñî3V¨´∑¡æ˘6¸Æˇ ú•Úwî|è§hZÜÖ{y®ÈËÎ-Ï~ÅÊ^WpC;˚/M~≥†\~tj–~oË≤&ô£˘p$W:mÂMÃáMcw!C(˛5ê*‘ıÎèÛ,G˛rt€ÀÂÉ˙y[í]O‚2õÍÙ˝SÏ˝\÷æ#&ëﬂÛè>fÚönumsV¥’,Ê≤{XÌ£±Wi#p‘ïBÏåÓÊﬁ¢cSOOà„˜tƒøGiˇ ÚÀ¸ˇ Lﬂ£¥ˇ ˘eã˛EØÙœ:‹Œb˛]C<ê∑ïØKDÏÑÖµ•T”˘≥Æˇ ç|Ωˇ *«˛VË≥˙?ÙwÈO©ã÷Ù¯zú?óó”û}ˇ úx‘/ø1<ıØi{∏ìÃ˙]Ö¥óvZ£®¢ò\,bDI9nV£∂Lº¡Êœ˘ƒΩ[Ω—u=∆-COô≠Ó£])ú	—ÄeåÉúæoÃ-+W¸Á—ºΩ‰ã…mˇ -ı+ª+iÙïÌ¨•YôVÈ‘ÖR≤yToù´œ√˛q£Úˇ P¥≥Û'ót˚[´∏Õ≈∏ãNıj™‹kX–”qÇG¸Âè‰ò•≈Aı;è˘£:3⁄˘WœX¥ñÚŒ-WC‘¢ÜÚn‚‰å¨°„cçç|ÊæwÛÁìtK=GÚü…r6èÁb˙æãeg€≈Õ“âìÑ 4ÂŒ•´å¸£¸ß◊&—Ó.?7¥¯5œ1≈w]6ˆ˝„øñ;UD*â-_äây∑ıﬂ'ò?öûL¸øä _3]IlöÉHñ¶8dö¶ •ÎÈÉO∂:Á:◊ˇ Á#ˇ Á|√b,5…N•de◊:|“«Õj∏≤QSúWÕ?êæhÛ÷ΩwÊøÀù&’|ï™2…£ÖíA¡E'Ó´'ÔQ˙è|§~Dˇ ŒPh⁄T⁄Fì4ñ:]¡s=îîIô#Ú@Ù<îPÁ^ˇ ú]¸®ÛØê"Û˘ö÷;c®5©µÙÊén^êóù}2‘ß1◊"_Ûç˛{Ûûπ˘≈Ê=3X÷Ôu:⁄ﬁÒ†¥∏ô‰â.„E*¨HR@Œªˇ 9¨Í⁄/ÂΩ©i7íÿjFÍ›Ãr'+ò’∏∞‹UI„Ø*˛x˛b€˘üH∏÷<€™>ìÌºöÇ5ƒ≤∑YT 
TÚ+∑|Ë_üﬂÛë?¶µ-ˇ .|«®Z[EÀ®,µ†ió”$<∂ÆEW˛qSÛÆ·E«ËÀwıÄìôº∑©ÂΩO«ÔÖ6◊üõÕ©›˛W6±vfJhÎ£˝l˝T7≠>çyz|7ßÖ3”˛Jó˛q£»∫ÕÓß†yáOµ‘/†ªi5-T»áÅÒ.;Õ?ìÛèö¨W^}◊é´ ªõW7Ú«lÌp¿++1⁄ô÷¸πˇ 8≈Âù˜Ã>O÷lø≈ZL/y°”Qyœ◊aR~ÂùñOåÑçè»ﬁc¸ø¸÷”o5/Œm^–Îö{˝[GVúi‰¿…Ã“8Laˇ xzêr;˘O˘KÂã-KQŒK	¥)‚Q£Õ®À%ÇI7?çQÍú»MÈû†—ø5%tm"ÀI∞ÛfóçÑ1€[#^#é%Ä≥1'a‘‰kŒﬁDÚnπe®˛k˘*#´˘ (æ±¢ﬂŸÃ˜ΩÕ®ß1?+«˛V⁄ˇ ŒJkÍöèúu∏¸ø¶Ú¯lEç©æîΩC'AÒ`[¸û˘–|Ê?+â≤wõIñ[ ∆”Ù√€r@2§¥n"¥\a£˛Gyí3mßŸysTP≈mî≠Oí√Ê¯¥/%yÜùÆ≈‰}2√í⁄Œ∞≈q
¥å_”JÆ“rbO Á—?6øÁ"µ˚MGOº]s…∆Ï%Œµißƒ∞ãx•vòƒêè‚!¿€q∂˘Èœ-˘◊ ^fÀ⁄ΩÆ™-xãìi*ÀÈÛØ\I•xögö2ıøÀoÀ(eÛÂ.Øh<Âyx÷ö¢ãÅ|¬ﬁNrL2ô?}oM∫dCYÛ¸‰ÔÊìﬁ∆„Jª‘¸Ω´"?´mß YQ$•$ç˚Iÿ‰?@¸òÛ‰ZÓù'ò¸Ø©Z˘y.ambÍhdä8¨ƒÄœ#…A¡V>D∑l3¸˝Úˇ Âè©h…˘qw›¥—J⁄âÇÈÆ¬»Du,œ«jÁ∑o¸€Âü-hö}◊ò5;m.ﬁté(e∫ëbVOó[Ωsï≈iˇ 8º<„7ú”_∞:Î\ã˘n?IÇoUdÂÈÛ·OP©Ö7ÛÖ^Gû‚Yõ^‘√JÏ‰oJ±Ø˚Ô#v∫‘˛jÛüÛéwq•øñ¥÷{(µò´ıÊM0£fX™Ê ‡˘bæyˇ úCÚoó|õ≠Î÷˙ﬁ£5∆óe=‹QH ‡Õe¬µ;dÚÚO ﬁ~–µM[X’Á”Æ4Àïé°hB∏ÙƒïoP◊√'^Y’Êˇ úï∏ü@Û:.âoÂ≈v“Èï/# }"ØÎ˙ÇÄ
Ìáiˇ 8_˘vÚòSÃ∫ÉJ+X¡∂,)◊nŒõ˘AÂçg 0Í>QDWÚ¶á"≈£ﬂÃ◊.§∏Ê·üç#	Õ¡hª”€ŒF˛eÍB¸º{Õ)Ñz∆•:ÿÿÃE}"ÍŒÚÄv™¢5ÓFx˙˛˚PªñÚ˙‚K´πÿº◊;I#±ÍYòíN%“√*À¥r°™HÑ´;Ç7:—ˇ 2_W÷¥82ÁøÛ/ïÙ¢ ∂F‡¨ä≤RØœÌ…Jô™F‹Ü{ß…˙'ÂÂÁí^P∂µ∑ÚÊµn√ùÇ,^¢ Ü6,@ÂÍPyn\‡^gúŒ1…U¶π˛(˜ÉT4hæ•AßËzoÎ^^gòÆÂ∫’5+´¥Ñ¥◊2…;«,»≈ç:ös”Ûéˇ û~j:óñ/nÙ{{m§Åµ'$°bäITíÕÈ‘∞¶zWÃË˙÷Ö®ËÛﬂG:ï¥÷í»í'5Y„1ñZí*gˇ °8¸¥Ù’^ˇ ¡⁄Õ∆5ˇ ;|Õ˘ã•⁄˘zÎJ∑Ü‰À∂ÇWv‡çÂ…òRá√&Òˇ Œ5yz?…I|5Û™Õ¢ãˆ∞+ßÍÖY∏√ù9-:◊=ãûmÛwÂ˝œÂgü5Œ˚ªƒ’,VÍY?BƒÜ)i®n£÷bÀj~Û•h>cèÛèÚÉRû £˛õÇÛOåL¬M®—s<xTw¶pŸ?Áµÿ„wˇ [*ZüUì∞Ø˚Û9«‰OÁóÂv±´^]È≤jb˛∑TäEà©çÀTÚV≠r[ˇ 8ÎÆGØˇ ŒHﬁÎëB–G©çJÌ c»†òó
XZr¶{S87¸‰÷µ˘e©∂ì‰O5_Õ¶ﬂ]Úæ≥’aH¨§ä&∫J’£ñÆ:Rªgìº˘˘mÊ%^§Z¨+-çœ≈ßjˆÕÍŸ›FEC√2¸&£z«ÜEsg§Áø0Ôl¸œu‰ã©KÈ⁄úr]X#£∫Öy8_$@ìÓ£;'Áœ‰ ¸œõIª¥‘#“ÔÙÂñ)gí#/©ê ø/ÿ`H˘ú‚ÛáˆF«ÛÉ]±g5Æùs	p(”∫ÖjΩ2Cˇ 9ˇ 9ß]X˘£Ú–h”%‘r«o˙K÷S1K‹Ω>5‹-:Áô¸π£æ∑Ê3FID©]Ah≥0,œ"∆Å÷ú≤m˘œ˘3{˘a}¶Z›jëÍgSäYU¢â¢	È2≠&j◊ñt_˘¬O˘Nuˇ ˚f˙àè=èú√ÛÛ…ﬂòûiÚÓùi‰mA¥˝BœVÍE∫í–¥>ìØqÓﬂg8¸Ø¸î¸Â≤Ûùù«üı÷¸Æ©0º”ÆÔ§æâÿƒ¬"mÊç∆N$Wß\Ùfô§ÈzU¢ŸÈvpX⁄),∂ˆ—§1Ç∆§Ñ@´πŒ5˘ˇ ˘s˘ΩÊΩoL∏Ú>™˙}åØ‰k}-†yBA+Õ˜9Àºì‰ç7ÚJÍÎT¸‹”lı?XAm¶,1G®ïö3Í9+*Ø
©Í2-ÊÔÀØ8˘fÚOÕm&X¥ø*jw…u¶õ9⁄ﬁ·lØ•ı!å≈^”`†ÈûÁäDñ4ëQ¿e#∏"£>p˛r˘™o4~gyáVw-]…®&†An}Äˇ bï≈<ç˘µØ˘bŒMÍuÔ*\ìıø.Í#‘∑jıhâ´C'p…ﬂzíI˘q‰/=u˘k™Æü´…ª˘7YëcõóÚŸ›7ÓÊ
«óâŒmÊ,yáÀöÉi⁄Óùq¶ﬁßXn#d$x©;0˜gbˇ úCÚf´™~e≈Ê5âóJ–¢ô¶π"à”ODë›®ÂèÄ„;Ø¸ÂØòµÚ¬	t€˘Ù˚ÎçJ£ö⁄WÜB¢9]á$*iÔëœ+ˇ ŒH˛@Ëñ÷”[È≤⁄Í∆›"Ωº∑”¢Idn*dÂ"êÕ…≈MNÁ|‰õˇ ñæe◊Ü∑˘¡` ˇ jí-Ì©íN7^îÆ∞Ø(hhyˆÂùÚ?Àæ_ó˛q√\÷‰”-_Y¥MR[]M†å‹≈$0Úâ„òØ®¨å*§èLÚˆØÊZí'÷5+≠I·akπ§ú†cR»ZïˆœF~VËwﬂÛè˜”˘£ÛÇÈzÂ≤ÿÿù=æ≥'¨Yg¯◊˜t^wÆt¥ˇ úΩ¸°uëïµDº€˝t,˘¸[;fxõÛ[˛rÛwD¸»Ûë¶kÔoßÿﬂÕ¨f	5j—≥§‚zwÊ¸ÂN£Âôºœc{u>ÅK$⁄Ç€Yzj∞W’&±◊·°Æÿˇ '~gŒS˘∫7∫Ú˝Â÷ßgm*≈s$6ˆTV 7 5˝úÏÛñFÛõºπÂÎ.Èìjw◊R…rêÒ™+D 'ë^ß|£u˘_Êˇ %Ëüñ˝ƒ7⁄Œüeo•†óñ9bπ±âVTfèÜÒ8 —≥≠⁄⁄Cieù∞)ºk*Ibääöì@:ú˘{¨C4ΩÙÇ&ä‚Tîºï»j˝8, –ç¡kûôˇ úfo=y˛[≠'ÕöÔê4Ë œ≠›;≠"ä⁄g˝‚2˝£Fÿqû≠—t=C”¢”t{(l, ä⁄›h=Ë;ûÁ<Ìˇ 9M•˘ãœ◊∫gó¸ôkshJ˙ı•©Rm¶ùÍ˛Ø"¢¨ÅËæF?Á"ø(|ç‰Ô ÌT“4qßÎS›[A}/´3±Âm#»•]›G∆ùÜvü _,Ëûfˇ úÚﬁâÆ[Õ2Ó∆?¨[ñt¬RÎÒ!VecúüÛÀö˛M}OA¸∂”Ó,ø-æ†ÚﬂE
≈4Uñ6˙„'Á7ÿ—æXKˇ 8©˘W‰?;h˛`∏Û>î∫å÷W%≥fèä∫9a˚ßJ‘é˘¸Âπ¸ı}.÷ÃÆc–¢ªa¶zÒ€¢˙Å(˛ÓΩs≠/‰◊Â≤Œ8?ö◊FQØ…ÂÔÆ=Ô≠=L˛êìü|>⁄ÉN4√Ô…˘»çwŒ>n÷4Ø46ôßXÿ€ºñ“ß(§Yñ0••ïÅ¯I;gõÀ>VÛß¸‰∂ª•kZá’Ù;À˚È˙	¢å|ÓúepÈFe=;†yGÚ√D¸∏ªÚßòb}Ú;ò•öKÀcpÓº¯∞j9mÁ◊u}KÚ>h¥o àGô4ÕYMÊ£qp≠~bù¶®–ƒ´T£oÑWˇ ÛñﬂùZz#ﬂË66â!¢4ˆwQ#zÚä‰∂˚ Õ‰œ+Z˛w˘fãˇ :Îâ’÷ü"ôÏ√j†IqÈ√¨°Tø√W4Ô\Îﬂîò∑gÚnõ{ÊI-tˇ 2]º©6ñ° )3§tÇV2éH†˚Áóˇ Á*ø)ÊÚøõÂÛMàS°˘ÜrÏä@ho\ë
ˇ ,úY‘¸«m¯_\Îîˇ Ûé~wÛ’‹77VÚhﬁ\®3jW(U§N‚ﬁ6°êüÊ˚#«∂{è >Q–|£Â˚]B∂⁄}¢—´;⁄Iˆùé‰‰WÛKÛV/)õM'Oµû˚\‘eä bâ⁄HepØs<úJ/©U={Ìó˘W˘}‰Ô*›kó∫∑6∑w¨À⁄•≈≈Ã7/Í)ròïhX»’Æq∏u˝cÛáÃ˛N¸À∑ñt…&º∞‘ G≤y'ÇOB43]#nQ Õ@*i^ÿ+Úˇ Ûä˜Àøöñïíÿ$ÈRMgm™L’ù°éôß,$ó€d¡üõ?ù˙«¸¨´Àç4ÿ]˘kÃ€X^^GYgT‘¡?ß"IÈÜUoÜ™hp≥Õ∞Îˇ Ûèì[Èøñ⁄|⁄ÕÆº≠s®Ω¸2]¥r[êëÑ6¬†á5Â\gï.|œ˘ˇ y7ó1ÙŸtm7HèÙÖî÷KjÔ9aküYH·!4∏ÃmrO6\~D≠ˇ ¬N<∏∑a[ÎﬂT3%∑3'/O‘‡›}:W∂∫ˇ ú"ıÓfü¸]«’v~?Q≠9i˝˛C?5øÁø¿>HΩÛ?¯ãÙá’˙Ø’}.^¥´€ı^îÂ^ô«<õÂÔÒõ4ç◊˙∑È[∏l˛±«üY¬r„UÂJÙÆzR-{˛ÖñTÚœ£˛(ˇ 0ø˙◊/©z<°√Ö.9t≠j3≠˛v~NüÕ-#J≥˝+˙+Í=«?G◊ÁÍ ^4Á)éÛèöÂN˛Ri◊W˝5˙+=7è?´˙îQ©“^?f¥ﬂ<ªÂﬂ>>ŒLË>h˙üËˇ ØjÉÍæß´«—âb˚|Rµ·^ôÈ_Õ? }_]Ûeóù¥ﬂ0ù*M–dmñ·&ÙI™‹‹&· ÓÜô≈‚ˇ ú∂Úúwü\OÀk∫Ø#pí¬%Øè1m πÎT]_C”µUè—]B÷°<ä	£Y8Ú≠9Rπ¬u/Œø;Kˇ 9#i˘{AkÂ¯/)Ñq÷i‘⁄zﬂºëÀPr?∞w}oN˝'£_Èæß•ıÎi≠ΩZr„Í°NT⁄¥ÂûbıG¸‚·Ùi˛*>k¯Î˛˙Q€˛^9Û˙œµ)ó˛8ˇ °ó‡©ˇ Ü?GπèØÛ˙Ô?K˜óß∆ﬁï˙≈yrÌë_Ãˇ ˘≈??ëı/42}{Ùxà˝WÍûó?VdãÌ˙ØJsØL‰ñ˘1º≠ˇ mk˙àL˙_úÁÛ∑Û{˛UéáßÍü¢ˇ J}zË⁄˙^∑°∆ë≥ÚØ	+ˆi”<ci˘ìˇ !V˜ÛÍÒ¸5_—ﬁØ¸ΩF˛ü´«Ò„ÙgÛüúÂ¸¯â|≠˘uqu§j⁄,Õ}}=Ûµ§oÉU{vôòÛëMq˘€¢j∫¸‚‡—ıi≈Œßaù›¬ªHD∏å3p´‚sï~S~by*OÀt¸∏M9«ùıá∏≤”5oBWÆV›Õ¿oY8≠GlóysU”ˇ $ï¥OÕXèòı]bE∫”.`Uø@ø∫(^Ô“d¯≈h¢òoˇ 9õ´jVWÚ‘∫}‹ˆm%‰¡ö	"W—¿ä‡,ˇ ŒV~W[y/F–ıÌ7Q‘n,¨Ì‡º2¡Òº–∆™œYe´|B†ë\ë˘3˛rÚ_^ÛVó£È]ö€Sæ∏Xm. “0í7F.éY~`d∑ÛGÛÛ…óz≈æçØZﬁ‹Oyl.T⁄«ë˙lÌúëÔT=∞Âgüˇ )ˇ 2ß‘`–º∏ê6òë<ÊÓ ’«Åíø`◊9¸‰¸‰ñµØ-‹yCÀã®È∫∂ô®¨o2Ö∑ãÖØ©™4R„ZPq»_íøÁ4¸·¢ÿy”M’Ì#:ài`∏ûÊ·náhâgX‹◊‡˛nô◊|ÖÁ’¸ô6ﬂóû|öÎUÛ©v∑v◊vån`Xn ¡¥ì¥Nxòê:ÁÊüÂ˜ëd“óÕ∫Töì_âçôéﬁé.ÎÎ2qØ1”<£˘ë˘IÁè!È„Œ√PÇ€N÷Æ∏⁄%Ñ“«:•–kà’¿H¿WpÔùO»?Ûîøó:WÂˆëÂﬂ2XÍZùÂ•∏ä˘ûn#ë√≠eñ≠€®ŒOÁﬂÃø&Îúö?õÙ;	l¥->[	&µ≈áÍ≤Ûê¨q±Jë”|Îæmõ_ˇ úÇû€R¸∂‘&—≠tk}E/Êí—§í‡áå†∂3P÷¥Œá˘ˇ ˘IÊoÃ/(h∫Fç=¨Wz} œp˜nÍÑZ3ƒ™HI‰›∆p»?Á4#ä·˛ìYc¥ö~¢D}ˇ s‡π◊ºπ˘ìˇ 8±ÂRÍÛBΩµ”u	’†∫ñ+{“Ãº√2ö∆√Ì-v√1˛zŒ9˘ìIóH◊5®/ÙŸä¥∂“€ﬁqbåI„;0ÆF4œ3ˇ ŒÈzç∂•`lmÔ¨ÂYÌß[{˛I$gí∞™PF˘üÛ3˛q_Õ◊÷◊^aΩµ‘ÓÌó“∂ík{⁄™ñÂƒqçG⁄Õˇ 9Q˘yÊˇ :˘{@∂Ú∂ú⁄å∂óRÀ:,ëG≈ ™z…ﬂ√4?ïíP¸∫“5o?hñ71Z⁄√™‹H&î˝m„√z,ı%Î∏€4è5ˇ Œh˙ù∂©¶5ïÆ°g ñ⁄·-Ô˘#ØFB2˘ÁÂ˝_ÛüÃñ^a¸¥∑>`—Ï,≈Ö›‘l∂·.VGî«∆‰¬«‡ïM@¶˘ÃÆ4ﬂŒœ…ê.Î[◊Ó˘«%ºû∑’˛*ZqıÙ’œëø!4ü#i>oÛæìiÍpZÀ}® ≥»“››B%veà±´∑&;S<˜ÁoŒø0Ëæiø”?-º¡5èí-ôWFµ∂^1$f5iâì‘ﬁRÁ‚Œ€ˇ 8Û°iô^Tˇ yÍŸ5Ô2Yj/ok©‹◊’é+uéXêp(¥Gëòmﬂ#ÛúÔGî?‘æ˝pg ÛÊgû¸…§[Ë˙Ê≥=ˆôj»ˆˆ≤p‡çB8®;+û£¸æ¸∫¸ê¥¸î—<·Á–!¥éMGQïfrZI}5%c$ÓƒÜ_˛]ˇ Œ?Îﬂñ`Û7îtK;àmloçµÍ-¬ûÅ!SU4=3Œﬂì÷üû≥ŸjGÚ—ÓV—eèÙó’‰∑åzúOß_\Ç~ÙœZ	Ö§"ÔΩ5ık◊ï.û¯ÆxKÚÚøÀò~{◊Ùœ0˙ˇ V¥ÇKò~≠ âπ˝aSrU∂£Ï7ÛèÛåˆWR⁄^yÑ[]@≈&ÇmZŸ$FUïÄ èïkˇ 8Ûˇ 8Àws≠ØòE≈ÃÃ#Üµkgwv4
™†íIÏ3êŒD˛Vy[ÚÔÕzáóÖ«°{Ø?÷dûk7Bh)ûî¸˘Û∑ÊGï4=„»⁄sj7W3<wà∂íﬁqçcO∑]˚úcÚèÊØê¥œ-˘ßRÄÎ7Vˆ◊ZÆógq7q]DÅÂFÄóí>He+QúßÛ#˛qÎÚWCÚÓ≥ç4ﬁo∂∑-ßËÊ˙)ndúÄcAj´Íπ`jÛëy;ÛkÛWÚóOõBµ∞]9/e7¶-NŒEïã(èíÛ1û?ªÎÖ?ôú˛s¸≈Ç¬1}WÜö“=∑’¢1 7*≥WÏı≠–¸°Û∑ÂgóºπÊO2ÿ≈o•Ñ“E£m´46·x∑&4ß#PFyÚ◊ÚOMø¸ãA”¨5œÀ…ÆDqk0ñãÍ¸ŸñÒƒ@ö´_£%ﬂòsÛ‰Gò‡Ú'Â‚$öU‰1ÍùÙfÍ·ÆÆ°`¨¶=àÖ(¥Îú˜Û/X¸Ú¸≈m=º≈Â{ÍÈ¢Qmım2Í/Ô∏ÛÂUjˇ v)Üˇ úøñøîﬁYÚï©ycS^bûx"‘,˛ª√F≠¥º°AÕ
»†o”¶vœ ›~X˘ã˛qˇ CÚóô|¡ck≈îIyoıÎ{{Ñ1ÕÍÄCµTÚQ‘aÑáÚì…üîcÚœñº…c4XÍCöÖºÛ<≥@√äÒ`MH  3Ã_ìﬂòüõ>T±‘°Ú6î⁄çΩ‘±ΩÎ≠î◊úÑãÏ‘◊%˙_¸ÂÁˆ≠q%æïß[ÍéSCkßÀ3¢÷ïeçòÅ]∑«Aˇ 9O˘Á%ıŒölÌJ≈H÷√Í2z˛±ï#Ù˝.|˘|_fï√O˘√ü¸ô˛iˇ ò?Í.<‰_û˘7º›ˇ m;è¯û¸ùˇ …≠Â˚kYˇ …ÂŒœˇ 9£ˇ )ﬂïøÊ	øÍ Áj¸Ú¸„º¸∞—4{Îm2=LÍ2¥íJ—p	jÇ™ıÆr´ç?.¨W˛rﬁc®ﬂÎ°n‰–$_Jé±˚∆Q8,Ã"Á@xoúcV¸‚ª‘8 ¸ m.8Ó!ûﬁ—¢V(MºKß¸\+ˆs∞è,«ˇ 9•]˘ÎQùºª6Çíi±ÿ€®∫IV$˙œ®]ÃEI3q•;gñr˘'˘gm˘çÁ&Úı≈˚È—≠§∑_Xé1)¨Lã«âeÎœ=ô<Ú¶ø$‰gÙœ¯j‹¥~∑Ó=oV‚ßó|iÍ˛‰o4˛h‹˛d~mys_∏””Mí)Ï-=‰2Ç#∫ÁÀì*ıı<3Ëxü˛r˛q˛√»z1ÛLÃ∑ÛjZëâ≠^çPN≤ÃH`ÏM8S¶˛]ˇ Œ$i>mÚNèÊI|«=§öù∏ù≠ñŸPíEzxg:Ûˇ ‰ıüïø6Ùø"E©…u†ˆH◊Õ£ß◊%Ù…É«Ø\Î:ñ™ﬂÛå,öNôÛ2yî©%π?T0õo›ÖPûØ.^•{cı?ÁaO:ÈÛ1MÊSı),ÆZ¨!«÷yáC)cT„Jg¥¸»∏ˇ ïù{˘Öı˙«◊©˙?‘<9}j7Ù˝JVûÙŒ≥ˇ 8sˇ ì?Õ?Û'˝E«Üˇ ò_Ûâ>sÛ7û5œ0ZÎ:t⁄•‰∑0≈/ØÕVF®∆2+Ú8üëÁ<ÈÂﬂ9ËöÌŒµ¶Õo•ﬁ¡w4Q˙¸Ÿ!ê9UÂ w8]ˇ 9£ˇ )ﬂïøÊ	øÍ ‰ó˛sc˛Q*ˇ ÃdøÚddÀﬂÛâ~Ûñ¥ÕV0ÿ•ñ•k‹6“µ…(í†uV
’CvŒ{™~OÎZwÊ¨?ó_[>ß<–@∑ãÍ}\5ƒk"ìUÁ∞já¸∆¸™Û/Â◊ôtÔ-ﬁjêœ6©LíZ4´âehG0 ÜµOôÍ?˘«ˇ »=cÚ‚ÔZõ\ª±‘ìRéÅ`WbÜÂâıQzÛ3Ö~w˛C˘£…	©˘⁄mR’¨Øı9+{S*L¢Ì‰ïA™™–CCÑﬂÚ§º„?Â#~c>µi;X3Œg*≥˙°^‰+◊;˜¸·Ω•¨øïw2Ko"Í”ÒvU,)$nEsøgüˇ Á4ˇ ÚXÈüˆ◊ã˛°ÊŒs˘'Á Xˇ 1F∑ “NñÛâ¬À0Ñ-8®-^π Úæº4ø6h˙›Ô©sù{mu*É FH%Y
©c÷ãµs’sŒg˛\ŒG≠ÂΩFR6RÎj‘ØŒCáøëüëæcÚoòu-o]‘≠uKN◊çµ∫dhŸÂYA"U
>M∞|_üûFÃôºÑ4Å®≈|4Ê∫ÙÌ˝Êeáó⁄Â«ìW•s…ﬁN¥¸ƒˇ Íü‡€±©~ÛÎcK^ß£Í˛ﬂßxÛß”ìo™ŒXÀoô>Îˇ ˙ßõÍüÛñÚ€ÊO∫ˇ ˛©‰œVüô¶tÔÒ˝Ì·æ‚>•˙T]sÙΩM¯zë˝ûYÓ_Ã˘Uﬂ£tˇ ˘X£>©»˝GÙØß√‘‚9z~ß~=sÃıØ¸‰kwÌ‰€Õi<§n$>_[yıAaÃ˝X[˙qîÙΩ.<8ÌNôÕuOÃØ˘XQ}zˆÛ¸{ÍEË˙¢ÎÙá©¿z4¨|ÎÈ”è∂wﬂÀ¯¥TÚı˙˛tÕo/ùÃétÛ!z-˝1Ëà>≤´'¨s„ƒ}™˜Œ{ıO˘À˘mÛ'›ˇ TÛÆˇ ŒLE|ﬂÛè∫"jìøiø]í„ü38∂Sù∑"ı≠FI?'W Èˇ 8Á¢Øôﬁ÷O/ãi~æ˜Ô1OÆIN~†]πS®Îú£Û8…Ø#~E‹‹C‰ﬂ´†ù|∏'6_‰ﬁ±o™£GÍ˙~ü-ÎJgHˇ úiáÛ^8ıˇ Ò¸˙îÃM∑Ëˇ “BqAI}_O◊Tˇ &¥Œç˘áˇ *ÁÙ<?„ﬂ—ˇ ¢}u˙øÈNè÷87>¶‹¯r˙+ê?œÚ”ˇ Œ9Í´Â∑µè@0€}AÌﬁa÷„˛Ô”µk–g¸≤èÚM$5ÑÛ∫#˘∏«®}JKÆ"Ï1á˝á5Ïˇ fÉÂû˙§Ú€›7˝SœbŒ5A˘«òuÁãçRm(ÿ(±]@\àÑû™Pß¨äµ·^ù≥†'¸®_Òƒú?Aˇ å˛π˚ z?]˙Á™:˛ﬂ©Í”ﬁπˇŸ

endstream
endobj
212 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 1243>>stream
hﬁåR}LSWØ}}ES™‡^ìı±˜ûN∞FÖ∂|Xf4 _¢ä¢›¢ïvR ⁄Ç6Ü∏LaÇñ˘òn»∂¡8çõìaŸ4*hÕ¿≈ÄƒèM‚ús"õú«Ï≤èd˙◊rnŒÕ=˜ﬁs~øﬂ94≈((ö¶#s“2ñ,¥ÕJuV⁄í3”2«£Q2OÀQ—˘«·—ØTP1	ˆDÏâRUDR
ön¸$ÕS∫◊˚%C—L…îl±Ã&>Ÿ¯óèóRùûu.iy¿Áwï˙§Ï≤"è∑‹„u¯]ŒXIJ-)ëñçˇıIÀ\>ó∑íDπJ*]~wëCr˚$á‰˜:úÆRáw£‰yK≤∫À<˛@πkyT"•fIé2gú«+πI_≈:ü€Èvx›._ÏHP41jE) LS)*]Ae”‘RÜZÆ§8¬ùb(5AΩNµ”J⁄O∑—cä≈≈f≈;äÀäae¢≤J˘ëÚ	#0ã«nkÒ"Yê≠{6w™Zsé√(áv`0*¿§ÉÏ»@˙±Ã@ª–£c?ò!l˝h&RÁëÕÜyÛH–(ê4≤Úπ‚µ”U˛ık∂⁄˘ÆûˇÁâ≥Êä0√∏Ë™kWO¸
˝ã≈˛”{˘‡Òîï∂ˇöÆæáF∏›˚PπgF∞tÁ &OX[zbÁ„5wÀØƒ~T?8x¶wPú·N∞üÌ…„`/˚Ù€¸ÑÑtªEƒΩ¨6[÷C≥+)go[~24/◊ç4ãMı≠ª˜}dÒuÓN‚âõ|Ô• §ee€Ì’"Fm¡©5≠ıÊÍü=˝ywªdW4¨ø“‘∞´˛ÄpV][≥≠v;Ô›z‡ê-j≠Fúòd«jÅ‹#L¨JÍDèÊDå@Ó·d¢å˙VLn≠l‚∂%9Ûyœ≈∏u>p¶`Aì®≠ÇFn§T†˝TIR™PèöU†dì\¿Y±£ñÌ-O9πÄGS
N¡åÈ√H0ıúÓnÉ3/é™9àﬁù—¯èñL|£p∆Uå Ëz∫aB2”+‚ê7A˘†N<À<l∏08Ã?Ì4œÆµÖù∫úcáÇ]◊üOè,2ãÿÇªjò¥Ê:F/Ãt,ıµ•ï’^“Ö‰˝Vˆ&4Ù˜i¥êÏ∞≥ã$8≈µ´} hæˇH^Fùà√!8≠~ttË¡œV'	¯$√j–Êu¢*kÒÜ¨°gsŒ±,>yE—“‚éÚÿˇ‰>©ËÜ£r+˜ÇÍÊ{0`HÑ4ã+ÔB≈∏Â˛|à˛r)iÄ¥äàÆA}&¥Éö“aÃ4ñœRA6µ•œuÉ'¢C$ƒ@L
LAì%mmFôX˚ò`∆ñqÚ≠Ï»Õ;¿V!uÏ˚´6Z¬j!ú‹Jr∫Ls¿ºó|n:oú^4-˛≤g†BºP]®:ø)Wüñ¸∂mÆµ˝nç`e1≤a 4¸#P∂3ò“ñ÷(ŒmV≠m\ÚÒy}˜wüûø÷U<ø^–‚◊ê0O¶#Œ¥rü±ÒuG Ô46ÛddÅ∫ _X_}ËîÜ~?;M≠-îΩÚ~Ú˙;≠ ©≈?Ì‡æT£Êõ–›Ë˘‚Í1!K¶	r_íos
0 l]Äƒ

endstream
endobj
213 0 obj
<</Subtype/Type1C/Filter/FlateDecode/Length 3569>>stream
hﬁlWyXS◊∂√9Ç•ûrzœ°jùZ-´ﬁ*¢TD¿ë0©IeÛÏL∏@&'dê1†Vƒ™≈ÈVΩh¡©ıVmmıÆCWÏ˜v|}Ôæ˜}˜€‰‰ÏµWˆ˙≠ı[øâµ•ƒ¬¬Ç]‰9o°Áúè=TI~K\‹ßNvwôÏnﬁ‡DŒB¸¿N∂~?8¯öÇŸ∞ÓΩù8LrîXZXGx∆ƒ¶∆G¨]ó‡|‘˘3gUÃjµs`™&A•q^Ω&&>6&~UÇZ5…Ÿ#2“9¿l¨qPk‘ÒIÊóK'Nr^L¢úÁ™5ìúc’—™àËµì˛ˇe$dIl-%ˆñGJÚÅD2R"ÕH&ZJ&K$S,$Ó÷í9Ní(K…líƒZ¬ê˜AíjIó‰¢‰°‰ç≈dãÕÌñåeîe©Â-+ôU∏UÜ’´~+¥∂±ûh=›züıJN©©$™Ç˙É^@ß—˚Ë7å/≥çyhÛëMêÕu[€Ò∂kmãlÀá–Cæí2‰Í–èÜ*áVΩk7‹n∂ù¡ÓâΩª˝j˚=ˆﬂ⁄ﬂ2-ìbÜ@5ËÀzπz¢#)pÂw¯ﬁµ©|=„7?pÄ˘
9é~ÂâÂ9t`Ø=˙ﬁÉï
ÚGØ>îÓuá·z˚°„å—º‘ˆz∞>8Ç““ﬁ ã@;JÀ‡áET0#ã…Û¥kåΩNT>}	ÂÌ]a(ïœ¿GŸTÉc≤…Û#êRR¨ˇÌY√·†Ko˘lîoÚçEI˙*)∫ÖNvljfà—≥∂⁄P^u0ΩL£IKâ4y%IïúrdÉ|çsˆ©ﬂ\$ø%Á…öF>”n§¿¶˛¯+W‹yÖ‹¸ÄXı*æl=UuÿxÏ"ñ5s<–zÊß∏ Á	~æT4#m;Œ&>üpôÉ	◊z˛l¡≈È!üπs¥•Á≤‚fmtX¥8.>í/[GUÈ®Ï‚~®ÙõÏ≤⁄S_sí˛ÈYZË›ÜO—âÛ]RUí HEKæl'∫´ºnöEmÄK»‡NHg	°Pi®‘W®w*»£¥—yQë
40Rq¬ œbΩ
;®¬ öÇFÿûπu¬x›Ïy9ø†äíx!Ö…·≥IW8∞{˘F¨ÏYQ-î©◊Ï	Á¢”µπ¬1PS†%à(«≥iÌVç0/À;"8»∆œ'déP†◊≥O¿‰ä,˚ŸèpËÃ≈· (^K√{`ŒGlv™“ïq(ò˙YÁ≈Oaƒ˛≈;ãÑsG{Í/pO.˚#çñã<]Öwâ¥˚ÔDñ‹Ú˝w"oãiˇ9uN¢‰∞˝òCu“∏}–ç
°1˜≠˘ˆ r(}˚ í˜∑’Ìmt ß˜™˜DÇÔc¢\
÷b˘E6Eò¿·ÇQ0¬2∞"üﬁÁ:≥”j}µ7yeŸT#ê≈è17ÉÀ(p–[RR+Hayül{ggﬁidØzœÆz¸RÒ*ÍKª˘ÛÅìé£∑0`Î¶ÂÇq-ªÛ»…ƒ0Íühã≥¥.wF{åWÈ
cyÈnq§8î≈
ÿM8÷^5·◊`Ñ
Z∫ªOfÑª†oB=îø€¶•0MºYWÅn¢3„C7ŒÂ–≠ÄÜ ˆ‡€€öùV'©‚∏≈%û¶¢∫¢Z‘ªt/\ÌK|Ã˝˜ä˝ÊH<˚›ÿ∑nFx"⁄‡„†õªL6–E≥Ìœ≠A7FÍàaqBêjjîfÁÆ4~£ö⁄\RªπÜ˚i†f‚WJFö€'É_öÃ†TInzc3YJ≤@„«&ßçwöØS.ù“õpuC?~$:…ó–A$]t9\⁄÷;¿6ˇ.…‘è#”FÇ˛.?N√H—≤ÒóCw™oêè›8lÁ^
æ0\œ∞Œª±ÌüØ´õ◊>∑Î'ÿk˙Äjt¡«ÙH›ª\xmﬁ˙^’•%ﬂ;°^IÖæu£•]f\O“[™Â’pæ;ÿŸ"‘‘Zz›)mÎk¯_-*ü¡m›¢åÎÿ¬“„Ö≠‹øn+?tˆÙG˚ıQ˘ª	)w7◊±quWSz8}˝·ãüüB´6aBCx√M≈ô˙Î`—”ííU óû§Ù	JÉáÃtœq.ΩÅ Q	/æjù≠òÊ0&pYÈA5)PÀåÉRàm2e¨ÅXrC®êAAnç#Ì∫O"ß$œ2#w+¶√
oÂ+iH –I·ÿ$Ft:˙¢ÏJ—EÇ—√ÇC„~1…ÂÌ4ò·¢— ‰†ôö8'céìñŒπñ¯ Ò˛X—^NÿbiÎ™ôë„C6≤.%ı%>/ì—‡ev˛T‹'√(x	†è
§ë¬˘—!IëI*bù|"©.¶-`æ|)´p ◊„3Í,˝>oÓ-ØØ0SÆRU•nˆyÖ”Â$§£2he Y|üZF#É¡QKcÇìCâ'çQ”}Üîpà|ÎMé∂1“æZôŸdr)†≈è≈ü®c&Ø5¢m.cö`zNIs≈apñÌè˝Ö•Ÿ—aº~U]◊Z‘Ã≠€ÛI∞"ã¡˘Ê£ïbaÎóœoüi©Ø‚ÛÈ]^T+Ωµ>Ø±A°lb7ÁÂlﬂ»ßáÕ‡VÜ‘\x√Î\A˙ÙX≥kÛVÂF-t· ëÔÜÓw∏◊`—≥`¥˚+¥w[¨Ú› h·¶í6öÊ∞%≈˚¯{ïWå◊9∞¯fZ‚{>ì—r∂ØÒFíêª/o_ëBö%é:œf«}ïN∫é’Ã˚‡‘Â¿û©œÃ¨J]SÉJs8j‘húà£¸ıÆÚΩÂ‰B‚îA%ã=Z¶9iYÀ4áåãStéz4Ü>>◊y¶öDWËBµ–πµyÕu
Ò9£4Ìg3Ú≤∂gÛ3ìΩCº8§óæ	ª¸ÙıùsÀÑ¬L]ZñB*.-õøÁoªä◊¢`N∆aüÁ¯·¿X‡øÔ,ﬂ[ g◊SY±k3Áq„‹/¿D°†ÅΩπßÌŸlèôü'òßπL$îlƒ·áòJÔ?9R∫uÀ~^Ç⁄ì∑;íS´≤¢£ï*”œCÁ•∫fÚeHL*Ÿ.]C¡	¢æπ”…–î|˙ÓC¥t≈8¢$ÿt∑vV˘_“8rŒÚ1æ¡•|ööä©øêyñ˚∫Wﬂ‹*45º 
%∞lZnÍ∂t˛Àxø59§~$·æ˝¡´ª]À;2u©
iüô¸ÌÙ]Ò=æºªÛ*˜¢vÊTÎç–Ã¿ó(≠]ª>'-ÜèIKàœåµ—¬u“Õp∞21AiJ`*≈lïæ¨¢2Ω,11-91QüRA0ÿ∂
’lçÓõ‚∫õìm{œ(ƒ@•…ï¡˜s‘ÒQ|b¸⁄¨UZpÃb´˜(Ø»8êò@N'Èì…ÈN¨|´4B0›yV‡™á∆8®%∫§§¸i¸Ω2“S≥3aÃ≠ô4•πÀ˛aéßì.)0ÓÁªKOù˛ñªsr!âÁk#\`JÕØª :⁄æ·4/DâÄ«åpÇo¥<ºbC&ER3R≥bl¥Ù7I+Zp3C÷,â¥tÓ˜T(]†÷≠˚¥S¥æ¿PPƒ_*Î1^·^÷Œt}⁄IÊ–B˛∫(|ië˝‹ÅˇsÙ9Ïp∏^0vÚœËÑCQ‚Ç”p¬O`òêﬂƒéüıÏ~=dä|øÌ]—aÊ‰±f
bkÑ#˘¥ˇÒë◊H©ΩzD®˜·¥WË‡æXÂ≥Œ|√ßDÔBt¡~
c[\®/(ÊÔñ_˝Jp∏œghÈ±–x3ŸÃ¿‚bÖôHfø‚)˙ÔsRxâÀ€ßqc–n6˙‚»«caHˇπvcïêOø∂Œÿû∫-ìüÔßÚ&º[˘Àø¿Ò £◊wŒ.ı)
≥tÈô
2gﬁ#¯î“ù°`?ª∏„‹enœÆøÂÌ⁄›÷-∫-ú˜ ‡E§–⁄ÁT]¨R*§S[+Ÿ‰c≠YÌ‹ãoœﬁø“¯◊¡˚PDyó¢ıX„cMZv	_⁄Hïh‘≈a‹§%~Û¸[¬ÔF	◊bé≈,S¨\ªzV∏™ƒG&Óq/≈^÷u∫™ªô†›´+‚˘ƒ“#9u‹ëä;¬÷‘ˆÏ‘‹xnEJ√z·/ç¯ó7åÙ∫∏\L`ïxöNŸû≤-ÉW&≠ö«}≤·÷oT*ÒÉ~çº–ˆtõπsL•⁄Ë‹˙ºÜfÖ4WO¬bS’LqB≠§…w*5$uU÷≥éúÃhJÈ@k8E&≠ÚJ≥Ò∏w∆ˇÑ≤›•gˆwi(^Z≤‚ÄˇS,óü§a
qDªauäÜr£Y≤€2:ìœ
ïÚP˙c<ò≤$mEvòYº⁄3çÈ›”·†\öPnˆ<≥q.j©ØÈÔ¡æÚxŸ¡“ÛU]ŸèˆÚ≥4z@ÃÄ,";ü£mJlJ\j4Òîz$Ω:ÈÁ`+ófô=yô¸©¬ç˘[∂+∂i∑a–lX£—D«F¶i6È◊»ã
Îˆ7ªtˆ‰„£·w9g[¸6Cï≠ﬁhv∏ÈhVcV-:¬πtâA&⁄6bo>]Za®(1èwœ‰∫c˛¶Çv-ùíêJÓ√g°w≠ScÚ5ä	Xuò˘Ò–ΩüõNd¶óÛıTib∞~5áé˛S–Aà¸≥s˛ªŸfûøç’[7ïo'2˙Ë∞¢PŒ7<-&R[ù‰?KëÙÁ±Æ£pàUâ>ç‰œÅf∏∏å˝/ £q0O

endstream
endobj
192 0 obj
<</Filter/FlateDecode/Length 319>>stream
hﬁTQÀnÉ0º˚+ˆò™l“D≤8$U§˙PìÊNÃí"cr»ﬂw”T=`è«;≥ÀXn˜œ{ﬂé ﬂcÔ8B”˙:‚–_£C8„•ıêÂP∑núO”Í∫*Ä$Ò·6åÿÌ}”ÉµB~–Â0∆,v˙Q=Ä|ã5∆÷_`qÃ>ODÆ!|cá~e	56Bn_™Zuíe‹ÒÚÈúÕç˚áP9åïø ÿ|UÇ]õ–◊ˇÔÑIäs„æ™(¨>S•RzS
k≤	”&l°&Lõ∞´ÇpÆ2]
ÚõïÎ_üdõZÊ’§"LÑc±%B≥Ω^¶~‹√h¬&I¡ì$Ü%W&ç¬Àã$!,ÏíMü±d”µû›Ó6*õ'N3r¸B˜\›5Fä|z∆)YŒ¥ıxÈ–éê?Ò#¿ ‚&ò`

endstream
endobj
214 0 obj
<</Keywords(HIV-associated neurocognitive disorders,endocannabinoid system,cannabinoid receptors,N-arachidonylethanolamine,2-arachidonoylglycerol)/Creator(Arbortext Advanced Print Publisher 9.0.114/W)/ModDate(D:20230218211152-08'00')/CreationDate(D:20230206070128+05'30')/Producer(Acrobat Distiller 8.1.0 \(Windows\); modified using iText 4.2.0 by 1T3XT)/Subject(Cannabis and Cannabinoid Research 0.0)/Author(Liuxi Chu, Zheng Shu, Xinpei Gu, Yan Wu, Jin Yang, and Huihua Deng)/Title(The Endocannabinoid System as a Potential Therapeutic Target for HIV-1-Associated Neurocognitive Disorder)>>
endobj
21 0 obj
<</Filter/FlateDecode/Type/ObjStm/Length 4356/First 732/N 82>>stream
xúÌ\[S€H∑˝+˝8SßBﬂ$µtÍ´©‚öar„ ô0ì‚¡ÿ4¡6c&ÃØˇ÷ﬁ›≤dI∆Ü¬√)«Hñ•æ¨Ω˜⁄ón«%-\,íTXãC&"mÖs¬ôX∏L§q,R%¥äpûmS-R'tlµ»p=U8j”Ld±0≤Dkï»2a‹ßï∆≈‘äVYCÕ	´-]q¬F∆‚†Fµ÷ùƒ81¬f:¬âë1xJß"≤	NåQb0\çú¬Õmî°cmkz_«R7qî¶8—"éyë¿}a∆qÜôaZ"1∏¨m&K#ååHÙ¨#+GF E—PÒÄ”néùuòElÑã®†Â9'¬•º√ø4"¿Pê4˙MêuF§V—ú$ËRHSCêã4ÉtRÖ±$±»úF?QÇ r™¨¶ÓïJ◊1“¯&¡≥äÊØ5&´uÔtã5öÍüN	ˆ˜•2ﬂ∆gâIÖ#(	gzƒD$™ÃÃ‘$)Äq$ÜUAà"ÖiÇM0]ùz*é $¡ÈEìH#(
ÙJdî†QƒIBó"íhíbdŒ“–#çKh⁄%1ù—¨S†•Iñ.√5Õ™»Yc®Ï˛#ènŒfw◊π<∆ÕÂﬁx4ì[ΩiŒ'«≈0üæ:{#π;Íè≈ËB~*Fõ£iQ~˛Âjj∑Á£ŸÙ3•ƒ!¥Ö@
áSy|y3<ÉÊ–'ﬂ—AÔ"óá˘t|3ÈÁS¥p0˜èÚô¯,vˆÑ<ŒøŒÑ‹‚∂≠p‹«˝Sπ˚uˆ˙h÷õÂxıK-ˇÚè◊ˆbBú:€K^ˇÂ…á≥øÚ>}R¿ä¸U\ﬂûåØ∑∆_?+6whZfN1¿	&D BÕé©7°‰ª|PÙö7{¬x<˛Gé≥Å(Ãí†tä÷‘u˙ŸÖ}9„áöíﬁÒ»»E˛4#Â≥à¨ÉœVJÙÙ§ΩÊÊG∞ìO˚4ËW&ì€óΩ	FÛìú^˜˙π¸≥‹Ó]ˇöó4©DÕÚ·ÔòçdØ∏ ·[“J§tïZõ◊≥ÒDÓ]ı.¶Ú§l¡˙'ﬂ˜Üπ|øΩ˚fwˇ6∑GQ™åã¯ª-”+f∂qô>ï˚≥ﬁU—ﬂ]\úõ~¿Iñ4uèß(RØÇ6©Î^jûM˜±†Jó§*Ò‚ÍÜ††iº¶>Zø}| ˘6˘:H8ı|Ω(·ÏHx•å‡/_ñå÷@9ÚîyØ-pxˆÙ^±ÇohDÊUÊ§@0ˆ0≈ÎûÈìI!LÙÅ˚÷È,
Œz¡˘®&äó>π‡ÓuPèÚ∏âH_Çı|”Ñ2äΩp”Û1^à9ﬂˇ {Ä@ú»^Ç@÷{”>JÏΩâÿ'? ˚Jü ƒFÍeâa›i4ç!…º1,8tÌ'˘‹îı 9 w’/Akèæ	ø˜Z˚c-¬=£´Géã|ﬂObhU}û⁄€SEÂô‹˝wõ–b¬S œõè]îüy>ÛY]¿†˙‹”Â˚‘0LÄ5M÷ß7ãG‰ö™ú˜º9ç1;Ìì®GæIu8˘Òpüﬁ?]Œf◊”ˇïÚ¨£•A>ŸËèá?£˚≤T˜∂}Ò@qﬂrk<¡]‹Æ:n˝ŸÁƒnƒ†!ù©e©‘önd`K£‘FÊígÀxÇÚ@-˙!Û#2À˚<jSˆTt}∆µÓõ{˛“æ\(bµ ø}æBÏ}qet™oø0–◊Ä⁄ÜÿW«Ñ]Å˝∑/X”¡ÓÖÅ˛ M7A”£P_‘ÙË˘
‰]„Ø2⁄e”r—ãÖøk¯ÕÄ∑Ñü€I˛¯ÖhgQîX>Ít˝NËı≤Úk+g’\êP≠âmŸì#y&9ï9ñá2óŸóóã+Q«JÖéV-UT+Q-¨Tº››•ïä«I|ûˆå=€ÿØV+^—˙˜+√+‚ò~öDK,úV~Ü<Ñ˘
ÂNq~ûC<P≥œâì€"5íjxòÍ¶6ê9≠∞ÀKYPFåÈè)5√¥ßßMÌˆ%%“∫x°p´„∑v»º©Ω¥ê¸¬¥∑s‘h¯≥‹Gò˚5@Ioã~~¯zKòò¢VvJßÌeÍΩb2ùëcl≠£‘≈|˝∫cI¨ZÂ^∂†-ﬂˆ™>ÉŸ%"|ïŸ”U™99ΩÍM/ÎúKÂ˚πŒQÅ¨≠mí$ê €”¶ô∆Ó>3ù…[hÒ{ﬂLv≤Ü©&jÖ©&ï©FYcQÒWo™nêŒ]Øa™qRö™RêÒrS5~ñÀ§	Ù“§≠ mq∂”)o'·˘é?é
\À)‚+s·ÚA∫ñ´$ÎºŒÙ:ÆÛ¡ÍWîfòh&¨´∑c\uN{|¢$Âs⁄èb-Ì	¢ÒE÷µE•MEau[T€©µ`’2sßçxÌmÍ›ÅVãÃ4R⁄≈[[™—˝zêuËÅÈ–É˙b‘Ÿ‹®c(lJØÄ]6&”R‘1§ﬂxH—v¥€I4ºQ©°ï>{Æie:◊JÁ÷—®ˇ}ﬂPoYY‘éöîèÚøozìYæ@øNªNk´eÅ+"%O±hljU1/|¸´¨¶©¨L√^bpÒ …`>¨y’úVD“6“®Ì{ªÇºN≤IZç¨ïhêu<∑⁄¯~≤éÕ˝¶ÔÈ!ˆ·c‰©õà◊Ë¥∫è∂CÜ∂»AÄå(ÔoÜ”œä∑Ràêí;˛‰M1†®Sp‹®À≤W"N[ﬁP‰ï…˝„ì„ü¢≥°~Æ=©}ŸZxﬂGNÈê*Õfa7Å/8–ˆQå¬1]÷©ö~.¨≤T˝˙ïﬁDÍw·≥)À![Çh'®O¸Biw7{Õ:;≠ '°FÔB˚.ÃŒÖ˛]ó˜Htÿõ‰”ˇyhû<˝⁄|}1Ç6Uz'uR@3ƒÍ$NÛ˛R>≠6ÒXﬁa∫§ÚÒ"7]Ã'˛ƒ”Ω7rLZdî&-2z≥u‡y4â˜∂˜2hêz`√Íˆç.ÜUû˛&<¡U\∆åZ(Ÿ(é4Ô1¶s:¶È1cÃÙA|Ea¶S‡õd≈m¸\øÌMOÊ˝‹≤¢ .*OÉ›UT6ëU`›éªc€Ü’peØz%¥ù`Hi«π±◊¢I ªRc¨ﬁQƒÈŒ %o∂Í öBA¥KŒÄ˚–D>G&.Ô¢≥ú«Ì&~4∏7éÿ°ÿÚ5ow¯™~¶:¿ﬂÚ‡+√Ô@ª¿œZ~‘o8´ÅÕ√KÇåﬁñÛr
DI[t–H“ûÆw	ò^–\M<âbJ¯ù .°ÑâvûZv/Öµ	;ë§Ú~%%ÿIõU[-X<¯ª?íé'ﬁ"ÿ´îﬂ$
:r[÷«˜–NyÃí+eÊ˛ﬂ—/'‡Ë®]õußxÂhª_üU¬n'a˜ﬂ¢∞∑ô©
˝0ñ2∂*W‹;ÿeØUtt/U˘¨Õñ¿@˚p Œ{W”\éØ√…«ÌCÉ0¸ºws5·kÈì‰÷ÎÍ´£wBm(Éﬁ	-è6˝„≠\πVT9õ äø œg»ñ{rG√|RLø‘Cy’»gµíﬂ™¥©Ób$_…u≈kã§ŸXAÅ|jVOÓ´‰ÀK	Ñ‰àÎ∏}ÆàKÔ∏d4îÚJN‰µºëÚ\˛*˜ÂÔÚÚÓ˙2Q‹/7Â{y(∂‰Ÿ_çGÚù<î€k‘ñ≤x&ı2∞k@“t*]ï%˙•Lö∆è/√√˘ô
§rò,Àœ±&æ%∑1Ò]·¡Ü¬‘ﬂ#Êñ\9Ü«"M‰Ô%d`x·K»P¨/¿vH•=y]˜ÄÙ-ªªªG¯Äé f{«ceœ¨:Og[›^ ‰ö5/–,}E•Ø ”!nçôÙ™∑wç5·5r¥	¢à2ã"áMü}¸î U!KéîÆ:pµè\»ìîlÕœÿ%ll|Ïp§œT*„ÁÒˆ%5Ê{«eIˇπsf\*¿„ì'(c+˙	^*¨ˇ™@Ì]ÀP7°B§(S_æÅ*›…†:É`w˚P§ò.Y%ı;®÷G(ÿ¥Û=uˆœ
ª+ﬂ kê÷x M¸:z ?@W_À=9ªú‰9,˝Vû#Á	u‚Û‚6ó”‚kiÛ”¸ø Û+…∂)G˙˚7üå°ÕﬂåâÈÚ5•Lï|∆◊!Ö⁄èï§–(8w(z-p(ñ}-®ŒŸâ9]î {
	¿cÃ¯Œëıê÷–¨8Ü◊àd û◊ûebà˛-1‰V$˝ûÅ}ïw¥[ì˙˘’
ˆ±≠ZéÒÖEˆŸ	µùüªÿıªäÆ¸´≈EÓ1jyÍÇ›PlË„C≈
¶˘hÃ“8¥˘¶˚Î’ÂŸáR˙©)R	À… ˝z”≥ÖÂ"Ò‹gdÙéπﬁL—+‚ÈHœSâ?£œ‡7äjâG¸®À±+ó™ZmI˚®ö¢[éOœ¥¿⁄[èuçgéMÎÒ)E“`BG ∫+HÀ®GΩÑü.!^cµij7ÅPÆs®·-nÖA-'P¡À“>˙„·∞˝Û—ƒ öZïQAAÔJs" G≤)oF€–˝c6+∂1‹FCÛ6≈¶GÏˆV~™Ÿ€^∞≥ø(‚![€Ç]˝sbFÉk¨1Ÿy„˙ÄÎ√¬Ìâ¸M˛…±‡ó|Ê£AÓÔ˜7ÂCËãúwp˝özÌE6€ÑZÊUc<¯¿∞ƒ¶◊Zb[ŒxË5Ä+ñí_§˙)∞¬|!‡*πP˛ã\¬Ö˙â¸cQL"≥íÍ‰KhFç-°Æîˇ“Ó∏Rº^€¸ÈHkVS®nSh«—Œûóqî˙Ω<ÌJÔ¯∑›M
m≠©yüu‘Mb—;‚Á($*·#HZ≠ıÊ_ßœW5))f§¿ç!kπû…§H?[«=RE~3U˛æ2,è¸\Íü£ r^Q±æåÂ√ƒ≤ÿ∆Í<1s¿*,\ﬁ*√PÙl@ﬁ‘+ùsQ,Ùj5D˜4oC˘Äf≈¥ö¯@õ>9ôÓŒ˛Î ïÎ
5A4
X1uàn˛ÕQ$Y!ÒÙ5sÚ,(˙9l´ÄºÖ¡ Ç)√ﬁ¡ﬁn`a w0¥ø`É¡∂…òﬂ¿~∫¯ X˘°∑Ûc/‚WXÓoï—¿∫˛ÅµïYt0z&&Å@%ΩÏ˘ˆ˛!0Ñ'œØax˘tV‡¡O∞œ?@ÊΩ˛2˝äØk\‹G∞ﬁ?âÛˇO
‹¥ò ¡<1ù˛	û—≈§á—.Â˙Yq5»WáµF≠øê◊‹Ú‘6ˇŒ\°EÍæ!®Òdñ¸\JOŒÙ∂ího÷≈˙ı ‚{ Á'A¶ﬂã˘mM[∫| Ì˜ök≠0ÕıçôïuU¢o€~"Ìao√—›∞€E47∑òªÆ E8µÓzÈ<w}DÒÓeæö	≈ˇÂAìQM“b‘…‡⁄À |}u3Ö~Â=®Å§'Vo©1∫∂◊xE¯ÁúipCM‰5Z@‹ˇäÀÚäˇ3Ω|ë?ZôÏZûrór^¥±ÜÁ∆ÍRõ}€˚ƒ≠ˇ»Üï√¿®Ã8ÑÅçŸ~lhdÇW07œ'ãª#:IUõ¿¡ZK‰bù,"∑∏¨◊§T˙O/T§◊Ÿêtü≥}ã)›Ä;∂19œô≠ÊO∆Éº.Û‰	 zÌŸÚ`Ù	lG¨9 ÛUÂfÜ´ﬁ∫b)≈"Á\´Ã.MßYˇEûÔê*(Íòı |˙o»•˛Æ»xœ¶W%/uœ÷¯oGZ´SïÄ}»]H
˜Ï‰’è¨÷¨Úg°‰ªÃè!èod'≠RM-=	Ea;/	óÆÍÒ)à≠<P-Ÿ¯/S1ÑŸ
endstream
endobj
215 0 obj
<</Info 214 0 R/Filter/FlateDecode/Type/XRef/W[1 3 2]/Index[0 216]/ID [<d64e8aeeeee2aa76152fcfd66c9b96c6><733f2930ed502d93b65b090c11300c47>]/Root 173 0 R/Length 639/Size 216>>stream
xú5‘YHTQ«ÒÛøsœqLÕu∆•,5s◊q4[›mµ≤çê6⁄Ë•íñá
Û-"– ZL|È°¨ßíÇﬁz®^L*Ç (≥§(4≤`öﬂè„ÀáÀ˜ÓπpÁÃUJ©pXît(Â(ÂSJTíö)˝:#P≈C7”æAåØÖ)OaÚAìıeòz&‹Ç±Á`‹{Ë›—L¿uF+ÃˇZË]˙ÓßC∞»OyW—sH£]Ù,—n:K™ËM:K€Ë ,”tÜÂÜ£è`E=Nﬂ¿`.ΩHﬂ¬ zzâÚÌÖËm:mﬂ∞à™⁄)zfØ-µ¥ë∂–%‘°Qÿ_ˇõ±ÎKËZDÀË*Íäz0`WjjDcáêÌkÈ
ZN£®W‘Á£¯]úŸÛMÁà¯2–›Âp¿Nch¨»d¶ﬁ{∂«—π‚O¢«tŸOƒ9’é>7ÀˆDö$ŒùÙÑ1€ìiä8ﬂÔ£'„Tx|}vZC}‘/ûëwX„±”Tö&n‘ zzèÌÈ4ÉŒ∑·¶ôA;ùO3≈Ì≈È2Ÿ?m_@ä˚Òzﬁc€≥h∂Ë #ËÅ”∂Á–E¢{v£óÖmØ§π¢_Œæ√≈¢_OŸÎ<ö/z¨	wÖnÿ^@E¡i‘_gü=È≥◊≈¥TÙØf[*hPÙT!ÓönÜø˚Ì4D´h5]*¶'ﬂ‘?Å€è6;G·ÆÏuÿáÛoÆÇ˝•p∞€ÓπúÆ§ÀË&ZOƒ‘5⁄ïõiõòOù∂‘âxÖ›™€mi¢Õb∂‚˚`ö&m_M◊à9ìÖæ/—ˆutΩòﬁÌËùÁmo•≈\≈∑À\·Yı¬±8Y†¯%¸SLâö
endstream
endobj
startxref
457671
%%EOF
